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Grape (Vitis vinifera) is one of the most cultivated fruit crops in the world, with an 
annual production of ~64 million metric tons in 2010 (OIV, 2011). During wine making the 
extract ability of grape (poly)phenols typically reaches only 30–40%, depending upon grape 
variety, vineyard location and the technological parameters during the wine making process 
including destemming, crushing, maceration and pressing (Kammerer et al. 2004). Therefore, 
grape pomace potentially constitutes a very abundant and relatively inexpensive source of a 
wide range of (poly)phenols including monomeric and oligomeric flavan-3-ols 
(proanthocyanidins) as well as anthocyanins (glucosides, acetylated glucosides and 
coumarylic glucosides) (Louli et al. 2004). Moreover, pomace has also been evaluated as a 
potential source of antioxidant (poly)phenols which could be used as nutraceuticals or food 
additives. Epidemiological studies have shown an inverse correlation between the 
consumption of (poly)phenol-enriched diets and a reduced risk of CVD (Mennen et al. 2004; 
He et al. 2007). (Poly)phenolic compounds are known to have some health benefits such as a 
chemopreventive role toward cardiovascular, cancer, and degenerative diseases related to the 
antioxidant activity conferred by (poly)phenols involving different processes and also 
different compounds (Huang et al. 2005). 
Hypertension is the most important of cardiovascular risk factors worldwide. 
According to the World Health Organization 2013 data, hypertension accounted for 
approximately 9.4 million deaths a year, contributing to 45% of deaths due to heart disease 
and 51% of deaths due to stroke. The prevalence of hypertensive people under 25 years of age 
is low but steadily increases to ~40 % in 65 year olds and 90% at 85 years of age. It is 
estimated that by 2030, more than 23 million people will die annually from cardiovascular 
diseases (CVDs). The importance of oxidative stress, vascular inflammation and endothelial 
dysfunction has to be highlighted in the development of CVDs. The knowledge of the process 
has provided new perspectives to elaborate novel pharmaceutical or dietary strategies to 
control the development of vascular diseases. 
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Following this observation, Perrin & Fils society was willing to investigate wine by-
products associated with the production of their wines at the Château de Beaucastel located in 
the Rhône Valley, appellation of Châteauneuf-du-Pape. In the first instance, the aims of our 
work was to characterize and select grape pomace (poly)phenolic extracts from different 
Rhône Valley grape varieties in order to develop food supplements preventing high blood 
pressure. Thereafter, grape pomace (poly)phenolic extracts will be associated with a common 
anti-hypertensive drug, verapamil, and will be further developed as a drug molecule 
“activator” of verapamil. 
In the first part, different classes of phenolic compounds will be underlined also as 
their antioxidant capacities, their biological activities and their bioavailabilities. Their 
presence and content in grapes and wines will also be included in the discussion. Then, the 
current state of knowledge about high blood pressure will be presented. 
In the second part, materials and methods used in grapes and grape pomaces 
characterisation and in vivo study will be presented. 
In the third part, grape and their respective grape pomace samples were characterized 
for their phenolic contents (total phenol contents, tannin and anthocyanin contents - total and 
individuals; quantification of monomeric and oligomeric proanthocyanidins as well as some 
anthocyanins [glucosides, acetylated glucosides and coumarylic glucosides]) and for their 
degree of polymerization by HPLC-PDA-Fluo-MS method. The in vitro antioxidant capacities 
of all the extracts were evaluated by four different analytical methods: ABTS
•+
, DPPH, FRAP 
and ORAC. Ratio of initial phenolic compounds from grape to pomace was estimated. 
Correlation between antioxidant potential and phenolic composition was assessed. Grape 
pomace samples were selected for the in vivo study. This work was done at the Institut des 
Sciences de la Vigne et du Vin (ISVV), University of Bordeaux 2 Victor Segalen, supervised 
by Pr. Pierre-Louis TEISSEDRE. 
In the fourth part, in vivo activities of grape pomace extracts and grape pomace 
extracts alone or in association with verapamil were investigated using a spontaneous 
hypertensive rat (SHR) model. Different experimental groups were made, blood pressure was 
follow and the effect of grape pomace on hypertension was determined. Some extracts were 
chosen for bioavailability studies in which urine, faeces, plasma and tissues (liver, heart and 
kidneys) were collected and analysed for metabolites by HPLC-PDA-MS
n
 and GC-MS. This 
work was carried out in collaboration with the Centre de Pharmacologie et d’Innovation dans 
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le Diabète (CPID), University of Montpellier I supervised by Pr. Gérard CROS and with the 
Plant products and Human Nutrition Group, University of Glasgow, supervised by Pr. Alan 
CROZIER.  
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Le raisin de vigne (Vitis vinifera) est l’un des fruits les plus cultivés dans le monde 
avec une production annuelle de 64 million de tonnes en 2010 (OIV 2011). Leur composition 
en polyphénols et l’extractibilité qui est loin d’être complète et n’atteint approximativement 
que 30-40%, en fonction de la variété, du terroir et des paramètres technologiques de 
vinification incluant le foulage, la macération et le pressurage (Kammerer et al. 2004). Suite à 
la vinification, les marcs sont produits en quantités abondantes et constitues une source peu 
coûteuse de polyphénols comprenant les monomères et oligomères de flavan-3-ols 
(proanthocyanidines) et des anthocyanes (glycosylées, acétylées et coumaroylées) (Louli et al. 
2004). Plusieurs études ont démontré leurs richesses en antioxydants phénoliques qui 
pourraient être incluses dans les formulations nutraceutiques et compléments alimentaires dû 
à leurs effets bénéfiques tel que les maladies cardiovasculaires, le cancer et les maladies 
dégénératives (Huang et al. 2005) 
En effet, l’hypertension artérielle (HTA) constitue l’un des problèmes majeurs de 
santé publique dans les pays développés et émergents. Il s’agit de la plus fréquente des 
affections cardio-vasculaires. Chez les personnes de 20 ans, le pourcentage d’hypertendus est 
très faible mais augmente ensuite régulièrement pour atteindre 40 % à 65 ans et 90 % à 85 
ans. Selon l’OMS, le nombre d’individus hypertendus est en perpétuelle croissance et le 
nombre de décès dû aux maladies cardiovasculaires est estimé à 23 millions d’ici 2030. 
D’après une étude épidémiologique Mona Lisa établie entre 2005 et 2007 en France (Wagner 
et al. 2011), il a été démontré que 47% des hommes et 35% des femmes de 35 à 74 ans sont 
concernés par l’HTA qui se définit par une pression artérielle systolique supérieure à 140 mm 
Hg et/ou une pression diastolique supérieure à 90 mm Hg. 
Suite à cette observation, la société Perrin&Fils, propriétaire du château de Beaucastel, 
situé en Vallée du Rhône dans l’appellation Châteauneuf-du-Pape est désireuse de valoriser 
les sous-produits de marc de raisin issus de l’élaboration de leur vins. L’objectif principal est 
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de procéder au développement d’extraits phénoliques de marcs issus des différents cépages 
caractéristiques de la Vallée du Rhône en tant que complément alimentaire préventif de 
l’hypertension artérielle. Un deuxième volet réside dans la mise en évidence de l’effet des 
extraits phénoliques de marcs issu de différents cépages en association avec le vérapamil en 
tant qu’extrait de raisin à portée thérapeutique agissant comme « activateur » du vérapamil 
dans la lutte contre l’hypertension artérielle. 
Le premier chapitre de ce mémoire sera consacré à l’étude bibliographique. Les 
différentes classes de composés phénoliques seront présentées. La biodisponibilité des 
polyphénols, les métabolites générés ainsi que leurs effets potentiels sur la santé seront 
discutés. La présence de polyphénols dans les raisins et les vins seront aussi abordée dans 
cette étude bibliographique. L’état des connaissances actuelles concernant l’hypertension sera 
aussi étudiée.  
Le deuxième chapitre traite des matériels et méthodes utilisés pour la caractérisation 
des raisins et des marcs de raisins ainsi que pour les expériences in vivo évaluant le potentiel 
et la biodisponibilité des extraits de marcs sur modèle de rat SHR. 
Le troisième chapitre portera sur la caractérisation chimique des extraits phénoliques 
des pépins et pellicules des raisins et de leurs marcs respectifs ainsi qu’à l’évaluation de leurs 
activités antioxydantes. Dans un premier temps, le contenu en polyphénols des extraits a été 
dosé de façon globale (composés phénoliques totaux, tanins totaux et anthocyanes totales) et 
individuelles par HPLC-UV-Fluo-MS (tanins monomériques et condensés, degrés de 
polymérisation, anthocyanes glycosylées, acétylées et coumaroylées). Par la suite, l’activité 
antioxydante a été appréciée en utilisant quatre tests différents d’activités antioxydantes : 
ABTS
•+
, DPPH, FRAP et ORAC. Les ratios entre la quantité de polyphénols issus des raisins 
et la quantité finale retrouvée dans les marcs ont été estimés et la corrélation entre le contenu 
en composés phénoliques et l’activité antioxydante a été établie. Ce travail a été effectué à 
l’Institut des Sciences de la Vigne et du Vin (ISVV), Université Bordeaux 2 Victor Segalen, 
sous la direction du Pr. Pierre-Louis TEISSEDRE.  
Le quatrième chapitre est dédié aux résultats des études in vivo sur un modèle de rat 
hypertendus (SHR, Spontaneously Hypertensive Rat). Différents groupes expérimentaux ont 
été mis en place et les extraits de pépins et pellicules de raisins et de marcs ont été administrés 
seuls ou en association avec le vérapamil aux SHR. La pression artérielle a été suivie et l’effet 
des extraits sur l’hypertension a été apprécié. Trois extraits ont été choisis afin d’étudier leur 
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biodisponibilité. Les urines, fèces, plasmas et organes (foie, reins et cœur) ont été récoltés. 
Les métabolites ont été identifiés et quantifiés par HPLC-UV-MS
n
 et GC-MS. Les 
expériences in vivo ont été effectuées en collaboration avec le Centre de pharmacologie et 
d’Innovation dans le Diabète (CPID), Université Montpellier I sous la direction du Pr. Gérard 
CROS. Les études de la biodisponibilité des polyphénols avec l’analyse de leurs métabolites 
ont été effectuées en collaboration avec l’Université de Glasgow dans le groupe « Plant 
products and Human Nutrition » sous la direction du Pr. Alan CROZIER. 
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I. Phenolic compounds and classification 
Phenolic compounds or (poly)phenols are the most abundant and ubiquitous secondary 
metabolites present in the plant kingdom with more than 8000 phenolic structures currently 
known. These compounds play an important role in plant growth and reproduction, providing 
protection against biotic and abiotic stress such as pathogen and insect attack, UV radiation 
and wounding (Weisshaar et al. 1998; Winkel-Shirley 2002). (Poly)phenols are widely 
distributed in the human diet mainly in plant-derived food and beverages (fruits, vegetables, 
nuts, seeds, herbs, spices, tea and red wine) and can influence multiple sensorial properties 
such as flavor and color, and contribute to the aroma and taste e.g., astringency and bitterness 
(Bautista-Ortín et al. 2013). Indeed, dietary intake of (poly)phenols has been estimated to be 
about 1g/day (Scalbert et al. 2000). Their intake is 10 times greater than that of vitamin C and 
100 times that of vitamin E or the carotenoids (Scalbert et al. 2005). As a result, phenolic 
compounds are currently receiving much attention because of their beneficial health effect 
related to their antioxidant (Halliwell 1994; Landrault et al. 2001; Dröge 2002), anti-
inflamatory (Delmas et al. 2005; Castilla et al. 2006), cardio-protective (Stoclet et al. 2004; 
Zern et al. 2005), cancer chemo-preventive (Castillo-Pichardo et al. 2009; Nichols et al. 2010) 
and neuro-protective properties (Halliwell 2001; Shukitt-Hale et al. 2006; Aquilano et al. 
2008).  
In the oenological field, a considerable number of studies on grape and wine phenolics 
have been published because of their complexity and importance in wine quality. Recently 
and from the clue of the “French paradox”, interest are focused on the bioactive phenolic 
compounds in grape and wine and their role in beneficial health effects. The French paradox 
was based on epidemiological studies and showed a lower incidence of coronary heart disease 
in France despite high levels of saturated fat in the traditional French diet. A moderate daily 
consumption of red wine has been proposed to be responsible for this effect (Renaud et al. 
1992). Another epidemiological study has revealed that individuals who habitually drink 
moderate amounts of wine experience a reduction in all-cause mortality, particularly those 
link to cardiovascular mortality, when compared with individuals who abstain or drink 
alcohol in excess (Morten et al. 1995; German et al. 2000). Some investigators believe that 
(poly)phenol therapeutic effects may actually be enhanced in wine, perhaps due to additive 
effects with the alcohol component of wine and/or to an increased bioavailability of wine 
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(poly)phenols as a result of the fermentation process. However, some authors argue that the 
average moderate wine drinkers are more likely to exercise, to be health conscious and to be 
of higher educational and socioeconomic class (Lindberg et al. 2008). Beside wines, there is 
also a large body of evidence that supports the health benefits derived from grapes, grape 
juices, grape seed/skin extracts and even grape by-products (Fitzpatrick et al. 1993; Bagchi et 
al. 2000; Castilla et al. 2006; Pérez-Jiménez et al. 2008). Although the chemical constituents 
of grapes and wines vary to some degree, similar therapeutic effects have been reported. 
(Poly)phenols vary structurally from simple molecules such as phenolic acids with a 
C6 ring structure to highly polymerized compounds such as tannins. Originating from the 
shikimic pathway and sharing at least one aromatic ring structure with one or more hydroxyl 
groups, phenolic compounds represent a large and diverse group of molecules including two 
main families: the flavonoids based on a common C6-C3-C6 skeleton and the non-flavonoids. 
The majority of (poly)phenols have a sugar residue linked to the carbon skeleton. Glucose is a 
common sugar residue including different monosaccharides, disaccharides, or 
oligosaccharides. Other compounds including amines, organic acids, carboxylic acids, lipids, 
and other (poly)phenols may also be linked to the basic (poly)phenolic structure (Bravo 
1998). Phenolic compounds can be classified by their sources of origin, biological function 
and chemical structure. To simplify, classification will be done according to the number and 
arrangement of their carbon atoms (Crozier et al. 2006) (Figure1). 
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Figure 1: Structural skeleton of phenolic and (poly)phenolic compounds 
 
I.1. Flavonoids 
Flavonoids are the major constituents with more than 4000 compounds having been 
characterized (Bravo 1998; Harborne et al. 2000). They share a common flavan core 
consisting of fifteen carbons with 2 aromatic rings (A and B), bounded by 3 carbon atoms 
which form an oxygenated heterocycle (ring C) (Figure 2). 
 
 
 
Figure 2: Flavonoid ring structure and numbering system 
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The flavonoid skeleton C6-C3-C6 can have numerous substituents and occurs naturally 
as glyscosides rather than aglycones. Due to differences in the oxidation state and substitution 
on ring C, flavonoids can be further divided into different sub-groups comprising flavones, 
flavonols, flavan-3-ols, isoflavones, flavanones and anthocyanins (Figure 3). 
In grapes, flavonoid compounds constitute a significant portion of the phenolic 
material. Concentration of phenolic compounds differs extensively according to grape 
varieties, locations, viticultural and oenological practices and also the age of the wine (Makris 
et al. 2006). 
 
Figure 3: Structure of the flavonoid skeleton 
 
I.1.1. Flavonols 
Flavonols are the most widespread throughout the plant kingdom with the exception of 
algae and fungi. They can be found accumulated in the outer and aerial tissues (skins and 
leaves) with their biosynthesis being stimulated by light. Noticeable differences in 
concentration exist, depending on exposure to sunlight. Seasonal changes, exposure to 
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sunlight and varietal differences contribute to noticeable differences in flavonols 
concentration within fruits from the same tree and even between different sides of the same 
fruit (Hertog et al. 1992; Hertog et al. 1993b; Price et al. 1995; Crozier et al. 1997). As an 
example, Crozier et al (1997) found that cherry tomatoes have markedly higher flavonol 
content than either the traditional or beef varieties, with the Spanish-grown cherry tomatoes 
having higher content than the English one. Sizeable variations in flavonol content were also 
observed for lettuce with the commonly consumed small “round” lettuce which contained 
only 11 µg/g fresh weight compared to the outer leaves of “Lollo Rosso”, a red variety of 
lettuce which contained 911 µg/g fresh weight. 
The main representatives are quercetin, kaempferol, myricetin and isorhamnetin 
(Figure 4). They are characterized by the presence of a double bond between atoms C2 and C3 
and a hydroxyl group in C3. They are typically found as O-glycosides with conjugation 
occurring at the 5, 7, 3’, 4’ and 5’ positions. The associated sugar moiety is very often glucose 
or rhamnose, but other sugars may also be involved such as galactose, arabinose, xylose and 
glucuronic acid. The 3-hydroxyl group can be glycosylated as well. Indeed, the most common 
flavonol aglycones, quercetin and kaempferol, alone have at least 279 and 347 different 
glycosidic combination respectively (Valant-Vetschera et al. 2005; Williams 2005; Tsao et al. 
2009).  
 
 
Figure 4: The principal flavonols of grapes 
 
In Vitis vinifera grapes, flavonols are yellow pigments mainly located in the vacuoles 
of the epidermal tissues. The principal are quercetin, kaempferol, and myricetin. They are 
primarily present in glycoside forms such as glucoside and glucuronide. Recently, also 
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isorhamnetin, laricitrin and syringetin were identified in grapes (Ribéreau-Gayon et al. 2006; 
Castillo-Muñoz et al. 2007; Jeffery et al. 2008; Hsu et al. 2009) (Figure 4). A recent study 
have reported for the first time the presence of quercetin-glucuronide-glucoside and 
malylonated kaempferol-glucoside based on their MSn fragmentation profile in Sercial and 
Tinta Negra grape skins (white and red varieties respectively) (Perestrelo et al. 2012). In red 
wines, the concentration of flavonols ranges from approximately 50 to 200 mg/L and is 
primarily presented as quercetin glycosides. Levels in white wines, where fermentation takes 
place without grape solids, ranged from 1 to 3 mg/L according to grape varieties. Only 
quercetin, kaempferol and isorhamnetin have been detected. The flavonoids myricetin, 
laricitrin and syringetin were missing in all white varieties. This is due to the absence of the 
enzyme flavonoid 3,5-hydroxylase expression in white grape varieties (Mattivi et al. 2006; 
Jeffery et al. 2008).  
I.1.2. Flavones 
Flavones are much less common than flavonols in fruits and vegetables. The only 
important edible sources of flavones detected are celery (Apium graveolens), parsley 
(Petroselinum hortense) and some herbs. Apigenin and luteolin are the most widespread 
flavone aglycones. They structure are similar structurally to flavanols with a double bond 
between C2 and C3, but lack a hydroxyl group at C3 (Figure 5).  
 
Figure 5: The flavone aglycones apigenin, luteolin and the polymethoxylated 
flavones tangeretin and nobiletin structure 
 
A wide range of substitution including hydroxylation, methylation, O- and C- 
alkylation and glycosylation is possible. Glycosylation occur mostly at position C5 and C7 and 
methylation and acylation on hydroxyl groups of ring B. Polymethoxylated flavones such as 
tangeritin and nobiletin are found in citrus species. 
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In the leaves of Vitis vinifera, apigenin-8-C-glucoside, luteolin, as well as the 7-O-
glucosides of apigenin and luteolin have been identified (Monagas et al. 2005). Data on grape 
flavones are scarce and there are not presented in significant amounts except for luteolin 
(Alarcón-Flores et al. 2013). 
I.1.3. Isoflavones 
Isoflavones are found almost exclusively within the leguminous plants with substantial 
quantities of daidzein and genistein in soybean. Isoflavones are isomers of flavones, 
displaying the aromatic ring B in the C3 position rather than the C2 position (Figure 6). They 
occur predominantly as β-glucosides or as acetyl-β-glucosides and malonyl-β-glucosides and 
are therefore polar, water soluble compounds. Isoflavones are structurally similar to 
estrogens. Although they are not steroids, they have hydroxyl groups in C7 and C4’ position in 
a configuration analogous to estrogens. This confers pseudo-hormonal properties and they are 
consequently classified as phytoestrogens. 
 
 
Figure 6: The isoflavone aglycones daidzein and genistein structure 
 
A recent publication identified the presence of genistein and daidzein in grapes by a 
dehydration technique, an approach used to make dry and sweet wine in which the majority of 
phenolic compounds are concentrated. A control of temperature and weight loss intensity 
during the postharvest dehydration can help to increase the concentration of isoflavones 
especially for the daidzein which rose from 150 µg/kg DW to 1434 µg/kg DW in Grechetto 
white wine grape variety (De Sanctis et al. 2012). 
I.1.4. Flavanones 
Flavanones are found in tomatoes and certain aromatic plants such as mint but they are 
present in high concentrations only in citrus fruit (Manach et al. 2003). The structural features 
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of flavanones are basically the same as those of flavones. They are characterized by the 
absence of Δ2,3 double bond and the presence of a chiral center at C2 (Figure 7).  
 
Figure 7: The flavanone aglycones naringenin, hesperetin and eriodictyol 
 
In planta, flavanones occur predominantly as the S- or ()-enantiomer with the C-ring 
attached to the B-ring at C2 in the α-configuration (Crozier et al. 2009). Flavanones can be 
hydroxylated, methylated and/or glycosylated. Representative aglycones of this group are 
naringenin in grapefruits, hesperetin in oranges and eriodictyol in lemons. The most common 
flavanone glycosides are hesperetin-7-O-rutinoside (hesperidin) and narigenin-7-O-rutinoside 
(narirutin) in citrus peel. Flavanone rutinosides are tasteless. In contrast, flavanone 
neohesperidoside conjugates such as hesperetin-7-O-neohesperidoside (neohesperidin) from 
bitter orange (Citrus aurantium) and naringenin-7-O-neohesperidoside (naringin) from 
grapefruit peel (Citrus paradisi) are intensely bitter.  
Flavanones are present in very low quantities in grapes and wine. Only 0.05 
mg/100mL of wine were found for hesperetin and 0.75 mg/100mL of wine for naringin 
(Jandera et al. 2005). However, recent advances in equipment performance allowed Perestrelo 
et al. (2012) to identify in Sercial and Tinta Negra V.vinifera grape skins, the presence of 
naringenin, a naringenin hexose derivative and an eriodictyol-glucoside based on their MS
n
 
fragmentation.  
I.1.5. Flavanonols 
Flavanonols can be considered as flavanones with a hydroxyl group on C3 position. 
There are often referred to as dihydroflavonols (Figure 8). A well-known flavanonol is 
taxifolin or dihydroquercetin in citrus fruit.  
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Among the flavanonols found in the Vitis vinifera grapes, astilbin (dihydroquercetin-3-
O-rhamnoside) and engeletin (dihydrokaempferol-3-O-rhamnoside) were firstly identified in 
skins and in wines from white grapes by Trousdale and Singleton (1983). Astilbin has also 
been found in grape pomaces (Lu et al. 1999), in grape stems (Souquet et al. 2000), and in red 
wines (Vitrac et al. 2001; Landrault et al. 2002). Both astilbin and engeletin have also been 
found in white wines (Baderschneider et al. 2001; Chamkha et al. 2003). Other flavanonols 
such as dihydromyricetin-3-O-rhamnoside, dihydrokaempferol, dihydroquercetin, 
dihydrokaempferol-3-O-glucoside, dihydroquercetin-3-O-glucoside, dihydroquercetin-3_-O-
glucoside, and dihydroquercertin-3-O-xyloside have been reported in red and white wines 
(Baderschneider et al. 2001; Vitrac et al. 2001). Taxifolin-pentoside and taxifolin-deoxy 
hexoside have recently been evidenced (Perestrelo et al. 2012; Flamini 2013).  
 
 
Figure 8: Flavanonols astilbin, engeletin and taxifolin structure 
 
I.1.6. Flavan-3-ols 
Flavan-3-ols are the most complex subclass of flavonoids ranging from monomeric 
form to the oligomeric and polymeric forms. Unlike flavones, flavonols, isoflavones and 
anthocyanidins, which are planar molecules, flavan-3-ols, proanthocyanidins and flavanones 
have a saturated C3 element in the heterocyclic C-ring, and thus non-planar. The two chiral 
centres at C2 and C3 of the monomeric flavan-3-ol produce four isomers for each level of B-
ring hydroxylation. (+)-catechin and ()-epicatechin are widespread in nature whereas ()-
catechin and (+)-epicatechin are comparatively rare (Aron et al. 2008; Crozier et al. 2009) 
(Figure 9).  
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Figure 9: Flavan-3-ols structure 
 
Another important feature of the flavan-3-ols is their ability to form polymers, which 
are often referred to as procyanidins, proanthocyanidins or even condensed tannins as 
opposed to hydrolysable tannins (gallotannins and ellagitannins). Oligomeric and polymeric 
proanthocyanidins have an additional chiral center at C4 in the upper and lower units and their 
structures vary in the nature of their constitutive sub-units, mean degree of polymerization 
(mDP) and linkage position. Proanthocyanidins usually contain up to 50 units of monomeric 
flavan-3-ol with a molecular weight between 500 and 3000 Da (Chung et al. 1998) and the 
polymerization most often occurs via a carbon-carbon bond. Type B proanthocyanidins are 
dimers resulting from the condensation of two units of flavan-3-ols linked by a C4-C8 or C4-C6 
bond (Figure 10). The four most common B-type proanthocyanidin dimers are the B1, B2, B3 
and B4. Type A proanthocyanidins are dimers that, in addition to the C4-C8 or C4-C6 
interflavan bond, also have an ether bond between the C5 or C7 carbons of the upper units. 
Two main groups of proanthocyanidins are distinguished depending on the nature of the 
liberated anthocyanidin in acidic conditions. Procyanidins which are composed of (+)-
catechin and (-)-epicatechin releases cyanidins and prodelphinidins and those composed of 
(+)-gallocatechin and (-)-epigallocatechin liberates delphinidins. 
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Figure 10: Type-B procyanidin structures and C4-C8/C4-C6 interflavan bonds 
 
The content of proanthocyanidins in grape berries depends on climatic and 
geographical factors, cultural practices and stages of ripeness. They are mainly localize in the 
solid part of grape bunches (skins, seeds, stems). In the berry skins, they are found as a free 
form in the vacuolar sap or bound to proteins and polysaccharides in the internal face of the 
tonoplast and to the cell wall respectively (Amrani et al. 1994). Grape seeds are composed by 
an outer integument including a soft outer parenchymatous layer covered by a cuticle and an 
inner layer of hard, lignified, brown cells (hard, brown “hull”). The endosperm constitutes the 
white soft tissue inside the inner integument. The majority of both monomeric and polymeric 
flavan-3-ols are localized in the outer seed coat with 2 to 5 times more than the endosperm 
which is mainly constituted of monomeric flavan-3-ols. A considerable amount of 
proanthocyanidins can also be found in seed hull (Thorngate et al. 1994). 
The flavan-3-ol monomeric units found in grapes are (+)-catechin, ()-epicatechin, 
(+)-gallocatechin and ()-epigallocatechin (Tsai Su et al. 1969). Moreover, ()-epicatechin-3-
O-gallate, (+)-gallocatechin, ()-epigallocatechin, (+)-gallocatechin-3-O-gallate have also 
been identified in grapes (Figure 9). 
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Grape seed proanthocyanidins comprise only procyanidins whereas grape skin 
proanthocyanidins include both procyanidins and prodelphinidins (Prieur et al. 1994; Souquet 
et al. 1996). Skin proanthocyanidins have a higher mean degree of polymerization (mDP) and 
a lower proportion of galloylated sub-units than seed ones.  
During red wine-making, grape proanthocyanidins are extracted from seeds and skins 
and concentration depend on the original grape profile but also on the extraction and 
winemaking techniques employed. The concentration of flavan-3-ols in red wines ranges from 
approximately 500 to 3000 mg/L and in white wines, between 100 to 300 mg/L. 
Proanthocyanidins are of great importance to sensory red wine quality due to their astringent 
and bitter properties (Gawel 1998; Peleg et al. 1999) and their role in the long-term colour 
stability via some chemical reactions with anthocyanins (copigmentation and/or condensation) 
(Somers 1971; Vivar-Quintana et al. 1999). Molecular size of proanthocyanidins reflected in 
the mDP affects their relative bitterness and astringency (Robichaud et al. 1990; Gawel 1998; 
Peleg et al. 1999; Vidal et al. 2003; Cheynier et al. 2006). Indeed, monomers are more bitter 
than astringent whereas the reverse is true for large molecular weight derivatives. 
I.1.7. Anthocyanins 
Anthocyanins are a unique subgroup of flavonoids that give plants distinctive colors 
ranging from pink, red, blue to purple pigments. They are involved in the protection of plant 
from excessive light and also have an important role in attracting pollinating insects. 
Anthocyanidins have a structure based on the flavylium cation (2-phenylbenzopyrylium). The 
most common are pelargonidin, cyanidin, delphinidin, peonidin, petunidin and malvidin. 
According to pH, they exist in different chemical forms, both colored and uncolored. They 
show colors from red (in very acidic conditions) to purple-blue (in intermediate pH 
conditions) and yellow-green (in alkaline conditions). The color can also be affected by 
acylation or methylation at the hydroxyl groups of ring A and B and glycosylation pattern 
(sugars or acylated sugars). In their unconjugated form, anthocyanidins are unstable. 
Degradation is prevented by glycosylation, generally with glucose at C3 postion of the ring C 
and esterification with various organic acids such as citric and malic acids. Indeed, 
glycosylated molecules, generally known as anthocyanins, are stabilized by the formation of 
complexes with other flavonoids.  
In grapes, anthocyanins are only localized in the grape skins except for “teinturier” 
grape varieties in which they can be found in the flesh (Amrani et al. 1994). Anthocyanin 
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concentrations in grapes vary not only with the ripening process (Pérez-Magariño et al. 2006) 
but also depend on climatic (Mori et al. 2007) and water stress condition (Roby et al. 2004; 
Koundouras et al. 2006), temperature (Mori et al. 2007), input of nutrients and plant growth 
regulators (Delgado et al. 2004), terroir and grape varieties (Vivas de Gaulejac et al. 2001). 
Anthocyanins firstly appear approximately three weeks before the first ripening stage in 
which berries change colour (véraison) (Darné 1991) and concentration increases 
substantially through full ripeness (maturity stage).  
The structures for common anthocyanins in Vitis vinifera grapes and wines were 
determined in 1959 and malvidin-3-O-gucoside was found to be the major anthocyanins 
present along with its acylated form (Ribéreau-Gayon 1959). Moreover, Ribéreau-Gayon also 
showed that anthocyanins in V. vinifera differed in structure than those found in non-vinifera 
species such as V. riparia and V. rupestris. Vitis vinifera contained exclusively 
monoglucoside anthocyanins whereas non-vinifera species have also 3,5-diglucosides. 
Principal anthocyanins of Vitis vinifera are delphinidin (Dp), cyanidin (Cy), petunidin (Pt), 
peonidin (Pn) and malvidin (Mv) and are present in the berry skin as 3-O-monoglucoside, 3-
O-acetylmonoglucoside and 3-O-(6-O-p-coumaroyl)monoglucoside. The Mv-3-O-(6-O-
caffeoyl)monoglucoside is also often present. More recently, pelargonidin (Pg) 3-O-
monoglucoside was found in grape (He et al. 2010) (Figure 11).  
 
Figure 11: The principal monomer anthocyanins of grape 
Indeed, among the five principal anthocyanins, malvidin is the dominant molecule in 
all grape varieties, varying from 90% (Grenache) to less than 50% (Sangiovese) whereas the 
quantity of acylated monoglucoside is highly variable according to grape variety. The 
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concentration of anthocyanins varies between 350 and 500 mg/L in red wine from Vitis 
vinifera varieties. 
The wine anthocyanins composition depends on the original grape profiles but also on 
the extraction and winemaking techniques used. Maceration, which allows the diffusion of 
anthocyanins and other phenolic compounds from the solid part of the grape to the must, can 
occur before fermentation, as in the case of thermovinification, or during the alcoholic 
fermentation using crushed (traditional vinification) or whole (carbonic maceration) grapes. 
After reaching a maximum level after a few days of fermentation, the concentration of 
anthocyanins decreases as a consequence of their adsorption on yeast cell walls, precipitation 
in the form of colloidal material together with tartaric salts and elimination during filtration 
and fining. Hydrolysis reactions, as well as condensation reactions with other phenols during 
winemaking, also modify the anthocyanin composition of wines. 
It has been demonstrated that in acidic or neutral medium, four different anthocyanin 
structures exist in equilibrium: the flavyluim cation A
+
 (red), the quinoidal base AO (blue), 
the carbinol pseudo-base AOH (colorless), and the chalcone C (pale yellow) (Brouillard et al. 
1978) (Figure 12).  
 
Figure 12: Structural transformation of anthocyanins according to Brouillard et 
al. (1978) 
27 
 
 
In a young red wine (pH ~ 3.5) approximately 12.2 % of free anthocyanins are in the 
red flavylium form, 45.2% in carbinol pseudo-base form, 27.6% in chalcone form and 15.0% 
in quinoidal base form (Glories 1984) (Figure 13). 
 
Figure 13: The distribution of the different form of anthocyanins according to 
pH. A
+
, Flavylium form; AOH, carbinol pseudo-form; AO, quinoidal base form; C; 
chalcone form. 
However wine anthocyanins, and thus color, can be stabilized by copigmentation or 
through their conversion into more stable pigments by different condensation reactions that 
occur during the winemaking process. Copigmentation consists of the hydrophobic interaction 
of the colored form of anthocyanins (flavylium cation and quinoidal base) with another 
molecule or copigment (intermolecular copigmentation) or with an aromatic residue linked to 
the pigment (intramolecular copigmentation). The complex is stabilized by hydrogen bonding 
and hydrophobic interaction (Brouillard et al. 1994). This interaction is responsible for a 
bathochromic shift in absorbance (anthocyanins change from red to more blue) and a 
hyperchromic effect, in which the intensity of the anthocyanins color is fortified (Robinson et 
al. 1933; Asen et al. 1975). According to Boulton (2001), copigmentation can account for 
between 30 to 50% of the color of young wines . 
Moreover anthocyanins can undergo reactions such as oxidation, hydrolysis and 
condensation reactions with other matrix compounds and form new molecules with different 
chromatic characteristics. As a result, reactions of anthocyanins with monomers, oligomers 
and polymers of flavan-3-ol shift the wine from purple-red to brick-red hue, and the formation 
of stable structures (i.e. pyroanthocyanins) formed by reaction between anthocyanins and 
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acetaldehyde, pyruvic acid, vinylphenols, vinylcatechol, vinylguaiacol or vinyl(epi)catechin 
shift the wine toward orange hue (Somers 1971; Timberlake et al. 1976; Fulcrand et al. 1998; 
Hayasaka et al. 2002; Asenstorfer et al. 2003; Alcalde-Eon et al. 2007; Marquez et al. 2012). 
Indeed, more than hundred structures derivate from these reactions were identified in wines 
(Vivar-Quintana et al. 1999; Marquez et al. 2012; Flamini 2013).  
The direct reaction between free anthocyanins and certain yeast by-products, such as 
pyruvic acid, acetaldehyde and vinylphenols can lead to the formation of stabilized pigments, 
the pyranoanthocyanins (Asenstorfer et al. 2003; Marquez et al. 2012). They constitute one of 
the most important classes of anthocyanin-derived pigments occurring naturally in red wine 
(Mateus et al. 2001). Resulting from cycloaddition, pyroanthocyanins have an additional 
pyran ring between the C4 position of the C ring and the hydroxyl group on the C5 position of 
the A ring. Pyranoanthocyanin structures can be formed through the reaction of an 
anthocyanin molecule with a compound containing a polarizable double-bound. Thus, 
compared to the free anthocyanins, pyranoanthocyanins have two heteroaromatic rings, and 
they have a dynamic equilibrium among different flavylium cation forms. These new 
pigments are mainly formed from grape anthocyanins during the fermentation of must and 
later during the maturation and aging of red wines (Schwarz et al. 2003; Freitas et al. 2011). 
To date, a great number of pyranoanthocyanins have been identified from red wines, 
especially in the aged red wines, including carboxy-pyranoanthocyanins (A type vitisins), B 
type vitisins, methylpyranoanthocyanins, hydroxyphenyl-pyranoanthocyanins (pinotins), 
flavanyl-pyranoanthocyanins, and their second generated pigments, such as flavanyl/phenyl-
vinylpyranoanthocyanins (portisins), pyranone-anthocyanins (oxovitisins), pyranoanthocyanin 
dimers and others (Ribéreau-Gayon et al. 2006; Freitas et al. 2011). Some structures are 
presented in Figure 14. Such pyranoanthocyanins are highly stable and resistant to sulfur 
dioxide bleaching and oxidative degradation, therefore they can significantly contribute to the 
color stability of red wines (Fulcrand et al. 1998; Boido et al. 2006; Freitas et al. 2011). 
However, most pyranoanthocyanins possess yellow to orange color and contribute to the 
tawny color shift associated with red wine aging, except for the newly found A type portisins, 
which are blue (Bakker et al. 1997; Pozo-Bayón et al. 2004; Rentzsch et al. 2007).  
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Figure 14: Type A vitisins, type B vitisins, pinotin A and portisin structure 
I.2. Non-flavonoids 
The main non-flavonoid are the phenolic acids which can be further divided into two 
main groups, benzoic acid and cinnamic acid derivatives based on C6-C1 and C6-C3 backbones 
and the polyphenolic C6-C2-C6 stilbenes (Figure 1). Non-flavonoids are structurally simpler 
than the flavonoids.  
I.2.1. Phenolic acids 
Phenolic acids are one of the other main phenolic classes of the plant kingdom. These 
compounds exist predominantly as hydroxybenzoic and hydroxycinnamic acid derivatives. 
The average concentration of phenolic acids ranged from 100 to 200 mg/L and 10 to 20 mg/L 
in red and white wine respectively (Ribéreau-Gayon et al. 2006; Chira et al. 2008). 
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I.2.1.a. Hydroxybenzoic acids 
Hydroxybenzoic acids are characterized by a C6-C1 skeleton and the most commonly 
found is the gallic acid. It can be considered as the most important since it is the precursor of 
all hydrolyzable tannins. Indeed, gallic acid and hexahydroxydiphenic and its derivative (e.g., 
ellagic acid) compose the base unit. These acids are usually esterified with D-glucose. These 
hydrolysable tannins are known as gallotannins (hydrolysable to gallic acid) and ellagitannins 
(hydrolysable to ellagic acid). Hydrolyzable tannins are not found in V. vinfera, but can be 
found in other fruits such as raspberries or muscadine grapes. 
The most common derivatives found in wine are gallic acid, gentisic acid, p-
hydroxybenzoic acid, protocatechuic acid, syringic acid, salicylic acid, and vanillic acid 
(Figure 15). In wine, the different hydroxybenzoic acids can be mainly found in their free 
form (Salagoïty-Auguste et al. 1984; Fernandez de Simon et al. 1992; Garcia-Viguera et al. 
1995; Vanhoenacker et al. 2001; Pozo-Bayón et al. 2003). Gallic acid is found in a high 
concentration in wine. It not only originates from the grapes itself but gallic acid is also 
formed by hydrolysis of hydrolyzable and condensed tannins, i.e. the gallic acid esters of 
flavan-3-ols. Moreover, several hydroxybenzoic acid derivatives have also been identified in 
red and white wine (Riesling wine) such as ethyl vanillate, ethyl p-hydroxybenzoate, ethyl p-
hydroxyphenylacetate, ethyl protocatechuate, methyl ester of protocatechuic and vanillic 
acids, glucose ester of vanillic acid, protocatechuic acid-glucoside and p-hydroxybenzoyl 
glucoside (Güntert et al. 1986; Baderschneider et al. 2001; Perestrelo et al. 2012). 
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Figure 15: The benzoic acids and hydroxycinamic acids structure 
 
I.2.1.b. Hydroxycinnamic acids 
Hydroxycinnamic acids possess a C6-C3 structure and formally belong to the group of 
phenylpropanoids. In grapes, they are located in the vacuoles of the skins and pulp cells in the 
form of tartaric esters (Ribéreau-Gayon 1965). The compounds present in wine mainly 
derived from the hydroxycinnamic acids are caffeic acid, p-coumaric acid, ferulic acid, and 
sinapic acid (Figure 15). These derivatives can be present in cis- and trans-configured forms, 
while the trans forms are more stable and therefore more prevalent (Singleton et al. 1978). 
The concentration levels of hydroxycinnamic acid derivatives in wine depend on many 
factors like grape variety, growing conditions, climate, etc. Among the hydroxycinnamic 
acids, caftaric acid predominates with up to 50% of total hydroxycinnamic acids in both red 
and white grapes and wines from Vitis vinifera. Other important substances are the tartaric 
esters of p-coumaric acid and ferulic acid, glucose derivatives of caffeic, sinapic, trans-p-
coumaric, trans-ferulic and cinnamic acids (Somers et al. 1987). Other compounds with 
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phenylpropanoid structure can be found in wine, such as p-hydroxyphenylpropionic acid and 
2-hydroxy-3-phenylpropionic acid (Gómez-Cordovés et al. 1997; Baltenweck-Guyot et al. 
2000; Baderschneider et al. 2001) Concentrations of some hydroxycinnamic acids are given in 
Table 1. Perestrelo et al., (2012) have recently identified but did not quantified novel 
hydroxycinnamic acids in grapes: the caftaric acid vanilloyl pentoside and the p-coumaric 
acid-erythroside. 
I.2.2. Stilbenes 
Stilbenes are phytoalexins structurally characterized by a C6-C2-C6 skeleton with 
microbial inhibitory activity and are produce by plants as a defense response to some 
exogenous stimuli such as UV radiation, fungal, bacterial and viral pathogen attacks 
(Langcake et al. 1977; Jeandet et al. 1991; Korhammer et al. 1995). 
 
Figure 16: Structures of Stilbenes and their derivatives 
One of the most extensively studied stilbene is resveratrol (3,5,4’-trihydroxystilbene) 
which exists in both cis and trans forms as well as conjugated derivatives, including cis and 
trans piceid (i.e. trans-resveratrol-3-O-glucoside). Cis-resveratrol is known to be produced by 
UV irradiation of the trans-isomer (Goldberg et al. 1995; Jeandet et al. 1995a; Trela et al. 
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1996). Stilbenes can also occur in oligomeric and polymeric forms, (i.e. viniferins) which are 
induced by oxidative polymerization of the monomer resveratrol (Chong et al. 2009) (Figure 
16).  
In grapes, stilbenes (especially the trans-resveratrol) are produce by the skin cells and 
by the leaves in response to Botrytis cinerea and other fungal infections on grapevines 
(Jeandet et al. 1995b) and can be transferred into musts and wines during the winemaking 
process. Resveratrol is presented in both cis and trans form in wine, but trans-resveratrol 
predominates and may be further methylated, glycosylated and polymerized (Chong et al. 
2009). In recent years, numerous resveratrol derivatives have been reported in wine including 
the dehydrodimers, ε-viniferin (Landrault et al. 2002), δ-viniferin (Vitrac et al. 2005), 
parthenocissin A, quadrangularin A (Chen et al. 2009), and ampelopsin D (Mattivi et al. 
2011), the dimer pallidol (Vitrac et al. 2001), cis- and trans-scirpusin A (Mattivi et al. 2011), 
the trimer α-viniferin (Guebailia et al. 2006) and ε-miyabenol C (Flamini et al. 2013), and the 
tetramer hopeaphenol (Guebailia et al. 2006). In addition, some oligomeric glucosides like 
cis- and trans-ε-viniferin diglucosides, cis- and trans-pallidol-3-O-glucoside and pallidol-
3,3"-diglucoside have also been detected (Baderschneider et al. 2000). Concentrations of 
some stilbenes are given in Table 1. 
Red wines usually contain higher stilbene concentrations than rosé or white wines 
because of the more prolonged skin contact of the must during fermentation and the high 
phenolic content of red grape cultivars (Perrone et al. 2007).The average concentration of 
resveratrol in red wine is 7 mg/L , 2 mg/L in rosé and 0.5 mg/L in white wine (Romero-Pérez 
et al. 1996).  
I.3. Phenolic compounds in grapes and wines 
Grapes (Vitis vinifera L.) are considered the world’s most prevalent fruit crop and their 
large amounts of phenolic compounds have been extensively studied. Phenolic compounds 
reside mainly in the skins and seeds. Figure 17 shows phenolic compounds distribution in 
grape berry (Kennedy 2008). Polyphenols from grapes are mainly concentrated in seeds 
(60%) and skins (30%), and to a lower extent in the pulp and stems (less than 10%). 
The main polyphenols present in wine are phenolic acids, anthocyanins, flavonols, 
dihydroflavonols, flavan-3-ol monomers (catechins), flavan-3-ol polymers 
(proanthocyanidins) and stilbenes. Phenolic acids are largely present in the pulp, anthocyanins 
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and stilbenes in the skin, and other polyphenols (flavonols, flavan-3-ols and 
proanthocyanidins) in the skin and the seeds (Chira et al. 2008). The proportion of the 
different polyphenols in wines will therefore vary according to variety, vineyard location and 
type of vinification. 
 
 
Figure 17: Phenolic compounds distribution in the grape berry 
 
Average total polyphenol contents measured by the Folin-Ciocalteu method is 216 
mg/100 ml for red wine and 32 mg/100 ml for white wine (Frankel et al. 1995; Carando et al. 
1999b; Teissedre et al. 2000). The content of polyphenols in rosé wine (82 mg/100 ml) is 
intermediate between red and white wines (Sato et al. 1996; Arnous et al. 2002). Table 1 
showed the mean concentration of principal polyphenols obtained by reverse phase HPLC and 
normal phase for procyanidins. 
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Table 1: Mean concentration of principal polyphenols in red and white wines. 
Adapted from the online database Phenol-Explorer (Neveu et al. 2010). 
 
Red wine (mg/100 mL) 
 
White wine (mg/100mL) 
 
Mean 
content
a
 
Mina Maxa 
 
Mean 
content
a
 
Mina Maxa 
Anthocyanins 
       
Cyanidin-3-O-glucoside 0.21 0.01 0.9 
    
Peonidin-3-O-glucoside 0.82 0.15 5.97 
    
Delphinidin-3-O-glucoside 1.06 0.17 2.50 
    
Petunidin-3-O-glucoside 1.40 0.26 3.44 
    
Malvidin-3-O-glucoside 9.97 0.00 38.2 
    
Delphinidin-3-O-(6″-acetyl-glucoside) 0.42 0.06 1.24 
    
Cyanidin-3-O-(6″-acetyl-glucoside) 0.08 0.05 0.29 
    
Petunidin-3-O-(6″-acetyl-glucoside) 0.57 0.07 1.58 
    
Malvidin-3-O-(6″-acetyl-glucoside) 3.52 0.48 11.29 
    
Peonidin-3-O-(6″-acetyl-glucoside) 0.47 0.08 1.10 
    
Malvidin-3-O-(6″-p-coumaroyl-glucoside) 1.95 0.58 4.47 
    
Peonidin-3-O-(6″-p-coumaroyl-glucoside) 0.52 0.02 1.02 
    
Petunidin-3-O-(6″-p-coumaroyl-glucoside) 0.39 0.01 1.16 
    
Delphinidin-3-O-(6″-p-coumaroyl-glucoside) 0.18 0.01 0.27 
    
Malvidin-3-O-(6″-caffeoyl-glucoside) 0.18 0.18 0.18 
    
Vitisin A 0.31 0.15 0.98 
    
Pinotin A 0.22 0.01 1.79 
    
Dihydroflavonols 
       
Dihydroquercetin-3-O-rhamnoside 0.97 0.11 1.51 
 
0.27 0.07 1.29 
Dihydromyricetin-3-O-rhamnoside 4.47 4.47 4.47 
 
0.30 0.30 0.30 
Flavanols 
       
(+)-Catechin 6.81 1.38 39 
 
1.08 0.00 4.60 
(–)-Epicatechin 3.78 0.00 16.5 
 
0.95 0.00 6.00 
(+)-Gallocatechin 0.08 0.00 0.42 
 
3.33e-03 0.00 0.01 
(–)-Epigallocatechin 0.06 0.00 0.28 
 
0.02 0.00 0.13 
(–)-Epicatechin-3-O-gallate 0.77 0.00 0.93 
    
Procyanidin dimer B1 4.14 2.15 14.0  
8.43e-03 0.00 0.05 
Procyanidin dimer B2 4.97 0.43 9.00 
 
4.71e-03 0.00 0.03 
Procyanidin dimer B3 9.47 0.00 11.96  
2.86e-03 0.00 0.02 
Procyanidin dimer B4 7.29 0.08 11.3 
 
7.14e-03 0.00 0.05 
Procyanidin dimer B7 0.27 0.27 0.27 
    
Prodelphinidin dimer B3 0.11 0.11 0.11 
    
Procyanidin trimer C1 2.56 0.22 2.63 
    
Procyanidin trimer T2 6.71 6.71 6.71 
    
Flavanols (normal phase) 
       
Monomers 2.00 2.00 2.00 
    
Dimers 4.00 4.00 4.00 
    
Trimers 2.70 2.70 2.70 
    
Tetra-hexamers 6.70 6.70 6.70 
    
Hepta-decamers 5.00 5.00 5.00 
    
Polymers (>10 mers) 11.00 11.0 11.0 
    
Flavonols 
       
Kaempferol 0.23 0.00 0.36 
 
0.02 0.00 0.26 
Quercetin 0.83 0.00 3.16 
 
0.04 0.00 0.83 
Quercetin-3-O-glucoside 1.14 0.79 2.32 
    
Quercetin-3-O-rhamnoside 1.15 0.00 1.82 
    
Quercetin-3-O-rutinoside 0.81 0.00 3.17 
 
0.19 0.00 0.92 
Quercetin-3-O-arabinoside 0.49 0.44 0.54 
 
0.22 0.13 0.32 
Myricetin 0.83 0.00 1.79 
    
Isorhamnetin 0.33 0.006 0.65 
    
Kaempferol-3-O-glucoside 0.79 0.57 1.08 
    
Isorhamnetin-3-O-glucoside 0.26 0.16 0.51 
    
Hydroxybenzoic acids 
       
Protocatechuic acid 0.17 0.00 0.96 
 
0.33 0.01 1.30 
Gallic acid 3.59 0.00 12.6 
 
0.22 0.00 1.10 
Vanillic acid 0.32 0.00 0.75 
 
0.04 0.01 0.12 
Gentisic acid 0.46 0.00 0.80 
 
1.82 0.00 2.00 
4-Hydroxybenzoic acid 0.55 0.00 2.18 
 
0.02 0.00 0.04 
Syringic acid 0.27 0.00 2.33 
 
5.43e-03 0.00 0.02 
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2-Hydroxybenzoic acid 0.04 0.00 0.09 
 
0.04 0.02 0.10 
2,3-Dihydroxybenzoic acid 0.08 0.00 0.64 
    
Gallic acid ethyl ester 1.53 1.37 1.70 
    
Hydroxycinnamic acids 
       
p-Coumaric acid 0.55 0.00 4.00 
 
0.15 0.00 0.49 
Caffeic acid 1.88 0.00 7.70 
 
0.24 0.00 0.70 
Ferulic acid 0.08 0.00 1.04 
 
0.09 0.03 0.21 
Caffeoyl tartaric acid 3.35 0.14 17.94 
 
2.15 2.14 2.20 
o-Coumaric acid 0.03 0.02 0.04 
 
0.03 0.00 0.07 
Sinapic acid 0.07 0.00 0.54 
 
0.06 0.00 0.28 
p-Coumaroyl tartaric acid 1.18 0.21 1.79 
    
2,5-di-S-Glutathionyl caftaric acid 2.86 1.12 4.71 
    
Stilbenes 
       
Trans-Resveratrol 0.18 0.00 1.05 
 
0.03 0 0.08 
Trans-Resveratrol-3-O-glucoside 0.41 0.00 2.92 
 
0.17 0.00 0.45 
Piceatannol 0.58 0.00 2.57 
    
Cis-Resveratrol 0.13 0.00 2.32 
 
0.02 0.00 0.07 
ε-Viniferin 0.15 0.01 0.43 
 
5.57e-03 0.00 0.01 
δ-Viniferin 0.64 0.00 2.24 
    
Cis-Resveratrol-3-O-glucoside 0.22 0.00 1.48 
 
0.08 0.00 0.25 
Pallidol 0.20 0.00 0.25 
 
6.82e-04 0.00 0.03 
Piceatannol-3-O-glucoside 0.95 0.63 1.31 
 
0.46 0.14 0.80 
Resveratrol 0.27 0.00 2.78 
 
0.04 0.00 0.17 
Resveratrol-3-O-glucoside 0.62 0.00 4.40 
 
0.25 0.00 0.61 
Hydroxybenzaldehydes 
       
Syringaldehyde 0.66 0.00 4.45 
    
Protocatechuic aldehyde 0.05 0.00 0.11 
 
0.10 0.10 0.10 
Tyrosols 
       
Tyrosol 3.12 0.59 4.47 
 
0.21 0.11 0.30 
Hydroxytyrosol 0.53 0.05 0.96 
 
0.21 0.16 0.27 
aMin, minimum concentration detected, Max, maximum concentration detected. Data are expressed as mg/100 mL. 
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II. Phenolic compounds: intake, bioavailability 
and health effects 
II.1. Dietary intake and sources of (poly)phenols 
The reference data of dietary (poly)phenols intake was firstly given by Kuhnau (1976) 
who estimated the intake in the United States at ~ 1 g/day with the following distribution: 16 
% of flavonols, flavones and flavanones, 17% of anthocyanins and 20 % of catechins. 
Similar to Kuhnau, Scalbert and Williamson (2000) estimated dietary intake of 
(poly)phenols at 1 g/day in which phenolic acids account for about one third of the total 
intake and flavonoids for the remaining two third. Their intake is 10 times greater than that of 
vitamin C (70-100 mg/day) and 100 times that of vitamin E (7-10 mg/day) or the carotenoids 
(2-3 mg/day) (Hertog et al. 1993a; Scalbert et al. 2005). Hertog et al. (1993a) calculated the 
intake of flavonols and flavones in the Dutch diet among 4,112 adults and found it to be 
averagely 23 mg/day with quercetin being the most important flavonoid ingested (16 mg/day). 
A similar flavonol intake was found in other studies in the United States and Denmark (ca. 
20-22 mg/day and 26 mg/day respectively) (Justesen et al. 1997; Sampson et al. 2002). 
Considering both extractable and non-extractable (poly)phenols, Saura-Calixto et al., (2007) 
estimated the mean daily intake of (poly)phenols in the Spanish diet to be somewhat larger at 
25903016 mg/day. 
In the framework of the PREDIMED study, using a total of 7200 participants, the 
mean total (poly)phenol intake was estimated at 820 ± 323 mg/day, in which 443 ± 218 
mg/day were flavonoids, 304 ± 156 mg/day phenolic acids and 73 mg belonged to other 
(poly)phenol groups. Fruits were the main source of (poly)phenols (44% of the total, with 
more than half of total flavonoids and 23% of total phenolic acids) (Tresserra-Rimbau et al. 
2013). In another Spanish investigation, the EPIC study, including 40,683 subjects aged from 
35 to 64 years from northern and southern regions of Spain, the mean total flavonoid intakes 
were 313 mg/day and the most abundant subgroup was proanthocyanidins (60.1%), followed 
by flavanones (16.9%), flavan-3-ols (10.3%), flavonols (5.9%), anthocyanidins (5.8%), 
flavones (1.1%), and isoflavones (<0.01%) (Zamora-Ros et al. 2010). In the USA, a study 
with 8809 subjects over 19 years of age revealed the mean daily total flavonoid intake was 
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189.7 mg/day. Flavan-3-ols accounted for 83.5% followed by flavanones (7.6%), flavonols 
(6.8%), anthocyanins (1.6%), flavones (0.8%) and isoflavones (0.6%) (Chun et al. 2007).  
The consumption of anthocyanins in the USA was recently estimated at 12.5 mg/day 
(Wu et al. 2006) compared to early paper published in the 1970s in which an intake of 185-
215 mg/day was estimated (Kuhnau 1976) and this figure is still widely quoted. According to 
Wu et al., these data have limitations due to the lack of comprehensive data on anthocyanin 
content, daily food intake data and individual anthocyanins. The authors estimated that 
cyanidin, delphinidin and malvidin contributed for 45%, 21% and 15 % of the total 
anthocyanins intake, respectively. Non-acylated accounted for 77% compared to 23% of 
acylated anthocyanins.  
Concerning flavan-3-ols, a recent publication surveyed 15,371 subjects in Germany 
aged between 14-80 years and the mean intake of total flavan-3-ols, flavan-3-ol monomers 
and procyanidins were 386, 120 and 196 mg/day respectively (Vogiatzoglou et al. 2013).  
With the “5-a-day for better Health Program” which was initiated in 1991 in the 
United States which encouraged people to eat at least five servings of fruits and vegetables 
every day, it can be seen that an individual who consumes 5-a-day could take in average > 
500 mg of (poly)phenols daily. When beverages such as cocoa, tea, coffee and wine are 
consumed on a regular basis this can easily increase the daily intake by 500-1000 mg 
(Carando et al. 1999a). Subjects who eat small quantities of fruits and vegetables and who do 
not drink coffee ingest less than 25 mg/day of (poly)phenols. (Clifford 1999; Pulido et al. 
2003; Williamson et al. 2008).  
All these different data illustrate the difficulties to achieve an accurate estimation of 
dietary intake of (poly)phenols because of the poor characterisation in foods (raw and process 
food) and the great variability within foods due to cultivar, year, growing conditions and 
seasons, etc. (Manach et al. 2004). Furthermore, the high variability in (poly)phenols intake 
differs from one country to another because of different diets, ethnicity, the availability of 
fruits and vegetables and individual food preferences. Cultural habits, lifestyle factor, age and 
gender should also be also taken into consideration. 
Significant dietary sources of (poly)phenols are provided by plant foods (fruits, 
vegetables, cereals, nuts, etc.) and beverages (wine, cider, cocoa, tea, coffee etc.). The 
phenolic content of all these products can vary substantially even between cultivars of the 
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same species and are greatly influence by genetic factors and environmental conditions (soil 
type, sun exposure, culture in greenhouse or fields, conventional or biological culture, fruit 
yield per tree etc.). In addition, the content can also be influence by factors such as degree of 
ripeness, variety, processing, storage and culinary preparation (Kuhnau 1976; Herrmann 
1988; Mazza et al. 1995). For instance, simple peeling can eliminate a significant portion of 
the (poly)phenols because of their predominant presence in the outer parts of fruits and 
vegetables. Cooking may also have a major effect. Onions and tomatoes can lose up to 75%-
80% of their initial quercetin content after boiling for 15 min, 65% after cooking in a 
microwave oven and 30% after frying (Manach et al. 2004).  
Oxidation, which leads to the formation of polymerized compounds during processing 
or storage, results in either beneficial or undesirable characteristics of food products. For 
example, oxidative change such as browning of cocoa or the oxidative polymerization of tea 
(poly)phenols during the processing and manufacture result in the development of distinctive 
and desirable organoleptic properties. Conversely, the enzymatic browning reactions, 
typically mediated by polyphenol oxidases, result in the formation of undesirable color and 
flavor on fruits and vegetables.  
However, beneficial health effects of these food constituents is highly depend upon 
their uptake into the body, and their metabolism and disposition in target tissues and cells. 
Once in the body, (poly)phenols can be poorly absorbed from the gastrointestinal tract, highly 
metabolized and/or rapidly eliminated. A further complication is that the biological activity of 
metabolites resulting from digestive or hepatic activity is likely to differ from that of the 
parent molecules that are ingested.  
II.2. Bioavailability of (poly)phenols 
Bioavailability differs greatly between (poly)phenols. The absorption of food 
phenolics is determined primarily by their chemical structure, which depends on factors such 
as the degree of glycosylation/acylation, their basic structure (i.e., benzene or flavones 
derivatives), conjugation with other phenolics, molecular size, degree of polymerization, and 
solubility (Karakaya 2004). In addition, each (poly)phenols may be present in foods in 
different forms and can affect the intestinal absorption. The bioavailability may be even lower 
when the food (poly)phenols have a large molecular weight, which is the case for 
hydrolysable and condensed tannins and complex flavonoid conjugates with several sugars or 
acylated with hydroxycinnamic acids. Food contains usually more complex phenolics as 
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opposed to simpler derivatives and these complex molecules might be underestimated due to 
analytical problems. Food matrix can also have an impact on bioavailability. Direct 
interaction between (poly)phenols and some components of food such as binding proteins and 
polysaccharides can occur and this may affect absorption. In addition, the diet may influence 
diverse parameters of gut physiology (e.g., pH, intestinal fermentations, biliary excretion, 
transit time) and consequently alter the absorption of (poly)phenols. Other components such 
as some micronutrients or xenobiotics may also induce or inhibit enzymes involved in this 
process. 
It is generally accepted that the bioavailability of phenolics is low and the relative 
urinary excretion of the intake range from 0.1% for anthocyanins to 20-50 % for isoflavones 
such as daidzein (Crozier et al. 2009). This demonstrates the great variability in the 
bioavailability of the different (poly)phenols. Moreover, the gut microbiota composition and 
metabolism, which can vary between individuals, has to be taken into account because it can 
alter absorption, bioavailability and biological activity of dietary phenolics. 
II.2.1 Absorption, metabolism and excretion 
II.2.1.a. Composition of the intestinal microbiome 
Apart from the role of digestion, the gut microbiota has been associated with diverse 
body functions such as gastrointestinal tract permeability, vitamin synthesis, detoxification of 
xenobiotics and immune system homeostasis (Kau et al. 2011; Littman et al. 2011). The 
composition of the microbial community in the gut is governed by age, diet and environment 
(Ley et al. 2008). The gut is mainly populated by bacteria accounting for about 100 trillion 
cells representing hundreds of species and thousand of subspecies, with the largest community 
residing in the colon. The concentration is estimated at 10
12
 microorganisms per gram of gut 
content (Whitman et al. 1998). Over 50 bacterial phyla have been identified in the human gut 
but four main phyla, Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria are 
reported to be dominant (Arumugam et al. 2011; Moco et al. 2012). The bacterial 
communities composition varies along the digestive tract and have the capability to adapt 
through life according to lifestyle and nutrition of the host, conferring humans the capacity to 
live on widely diverse diets (Xu et al. 2007). This capacity of adaptation is possible because 
of the 2-4 million genes of the microbial genome in the gut (Qin et al. 2010). All these genes 
are responsible for considerable processes such as substrate breakdown, protein synthesis, 
biomass production and production of signaling molecules. The intestinal microbiota genome 
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also encodes biochemical pathways that human have not evolved (Egert et al. 2006). 
Therefore, the gastrointestinal tract microbiota constitutes a very important element in the 
absorption and bioavailability and their further roles will be discussed below.  
II.2.1.b. Intestinal and colonic absorption 
After ingestion, native (poly)phenols have to pass a multitude of barriers and are 
exposed to extensive metabolism prior to entry into the systemic circulation. With the 
exception of flavan-3-ols and proanthocyanins, almost all flavonoids are present in the diet as 
glycosides, The type of sugar attached to the flavonoid is a determinant for the site and extent 
of absorption whereas the position of the sugar moiety on the flavonoid skeleton mostly 
affects the mechanisms involved in intestinal uptake.  
Phenolic compounds are released from the matrix after mastication. Flavonoid 
glycosides can be already deglycosylated in the mouth by microbiota and/or oral epithelial 
cells (Walle et al. 2005). The stomach reduces the particle size of food and enhances further 
the release of phenolic compounds. Absorption occurs mostly in the small intestine with 
multiple factors appearing to influence the rate and extent of the process. In general, 
aglycones can readily be absorbed in the small intestine after hydrolysis by lactase phloridzin 
hydrolase (LPH) in the brush-border of the small intestine epithelial cells (Day et al. 2000; 
Sesink et al. 2003). LPH shows broad substrate specificity for flavonoid-O-β-D-glucosides 
and the resulting aglycones may enter the epithelial cells by passive diffusion as a result of its 
increased lipophilicity and its proximity to the cellular membrane. Within the epithelial cell, 
an alternative way of hydrolysis is possible via the action of the cytosolic-β-glucosidase 
(CBG). The polar glucosides must be transported into the epithelial cell by the active sodium-
dependent glucose transporter SGLT1 in order for CBG-catalysed hydrolysis to occur (Gee et 
al. 2000). Thus, there are two possible routes by which the glycoside conjugates are 
hydrolysed and the resultant aglycones appear in the epithelial cells, namely “LPH/diffusion” 
and “transport/CBG”. However, in a recent investigation, contradicting data indicated that 
once SLGT1 was expressed in Xenopus laevis oocytes, at least in this model system, SLGT1 
does not transport flavonoids and that glycosylated flavonoids, and some aglycones, have the 
capability to inhibit the glucose transporter (Kottra et al. 2007). Moreover, numerous studies 
have shown that the relative contributions of “LPH/diffusion” and “transport/CBG” depend 
on the position of glycosylation (Day et al. 1998; Gee et al. 2000; Day et al. 2003).  
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Prior the passage into the blood stream, the aglycones undergo extensive metabolism 
forming sulphate, glucuronide and/or methylated metabolites through the respective action of 
sulfotransferases (SULT), uridine-5-diphosphate glucuronosyltransferases (UGTs) and 
catechol-O-methyltransferases (COMT). This mechanism reflects a metabolic detoxification 
process common to many xenobiotics that restricts their potential toxic effects and facilitates 
their biliary and urinary elimination by increasing their hydrophilicity. Glucuronidation 
occurs on the luminal side of the endoplasmic reticulum whereas sulphation and methylation 
both occur in the cytosol. The conjugation reactions occur within various tissues and cells. 
The intestine and the liver appear to be the most important organs involved in flavonoid 
metabolism, although other organs such as kidney may also contribute. Some of the 
conjugated metabolites are actively effluxed back into the lumen of the small intestinal 
involving members of the adenosine triphosphate (ATP)-binding cassette (ABC) family 
transporters, including multidrug resistance protein (MRP) and P-glycoprotein (P-gp) 
(Walgren et al. 2000; Vaidyanathan et al. 2003). MRP-3 and the glucose transporter GLUT2 
are also implicate in the efflux of metabolites from the basolateral membrane in the 
enterocytes (van de Wetering et al. 2009; Manzano et al. 2010). Once in the portal 
bloodstream, metabolites can be subjected to phase II metabolism with further conversions 
occurring in the liver.  
After an extensive phase I and phase II metabolism, a fraction of the absorbed 
(poly)phenols is excreted back into the small intestine by enterohepatic recirculation via bile 
excretion as glucuronides and/or sulphates and reach the colon where bacterial β-
glucuronidases and sulfatases can release the aglycones (Donovan et al. 2007). The fraction of 
the (poly)phenols that reaches the colon directly or indirectly can subsequently be absorbed 
from the colon or subjected to the action of colonic microflora with their extensive metabolic 
potential. Investigations with ileal fluid collected from ileostomists after ingestion of various 
foodstuffs revealed that even when dietary flavonoids are absorbed in the proximal 
gastrointestinal tract, considerable quantities pass from the small to the large intestine where a 
wide array of low molecular weight aromatic acids are produced by breakdown due to 
microbial activity (Kahle et al. 2005; Jaganath et al. 2006; Marks et al. 2009; Crozier et al. 
2010). Gut microbiota can hydrolyse glycosides, glucuronides, sulphates, amides, esters and 
lactones via esterase, glucosidase, reduction, demethylation, dehydroxylation and 
decarboxylation activities (Simons et al. 2005; Ávila et al. 2009; Selma et al. 2009). The 
degree of degradation of many phenolic compounds is significantly influenced by the 
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substrate concentration in the diet as well as individual variations in the composition of the 
colonic microbiota. The dissimilarities in the populations of colonic microbiota can explain 
the large inter-individual variability in the health benefits.  
The resultant aglycones can be absorbed and may be subjected to phase II metabolism 
in the liver before being excreted in urine in substantial quantities that, in most instances, are 
well in excess of the flavonoid metabolites that entered the circulatory system via the small 
intestine. (Jaganath et al. 2006; Roowi et al. 2010; Stalmach et al. 2013).  
II.2.1.c. Elimination of phenolic compounds 
Seen as xenobiotics by the body, (poly)phenol metabolites are rapidly eliminated by 
biliary and urinary excretion. Extensively conjugated metabolites are more likely to be 
eliminated in the bile whereas small conjugated such as monosulphates are preferentially 
excreted in urine where only a small fraction containing the intact flavonoid ring is recovered. 
An investigation showed that the relative biliary and urinary excretion varies from one 
(poly)phenol to another (Crespy et al. 2003).  
Several authors published detailed reviews on the bioavailability of (poly)phenols in 
human and their potential health effect (Manach et al. 2005; Williamson et al. 2005). Kinetics 
and extent of (poly)phenols absorption among adults, after ingestion of a single dose of 
(poly)phenols provided as pure compound, plant extract or whole food/beverage were 
described. Urinary excretion is extensively studied in human and the total amount of 
metabolites excreted in urine is roughly correlated with maximum plasma concentration. 
Isoflavones were highly excreted (16-66% of intake for daidzein and 10-24% of intake for 
genistein) (Watanabe et al. 1998; Richelle et al. 2002; Zhang et al. 2003), followed by 
flavanones citrus fruit (4-30% of intake) and especially for naringenin in grapefruit juice 
(Fuhr et al. 1995; Ishii et al. 1999; Erlund et al. 2001; Manach et al. 2003). Concerning 
anthocyanins, the urinary excretion was very low with only 0.005-0.1% of intake (Wu et al. 
2002; Frank et al. 2003; Milbury et al. 2010) but up to 5% were found by Lapidot et al. after 
red wine consumption (Lapidot et al. 1998). Urinary recovery of flavonols accounted for 0.3-
1.4% of the ingested dose for quercetin and its glycosides (Hollman et al. 1995; Hollman et al. 
1997a; Graefe et al. 2001), 0.5-6% of intake for some tea catechins (Lee et al. 1995; Yang et 
al. 2000), 2-10% for red wine catechin (Donovan et al. 2002a), and up to 30% for cocoa 
epicatechin (Baba et al. 2000). Some of these data were obtained using enzyme treatments 
such as glucuronidases/sulfatases releasing aglycones quantifiable by HPLC using 
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absorbance, fluorescence or electrochemical detection. More recently, a review by Crozier et 
al., (2010) concentrates principally post-2005 human bioavailability studies where metabolites 
and related compounds were identified by mass spectrometric-based methods without 
recourse to the use of enzyme hydrolysis prior to analysis. 
II.2.2. (Poly)phenol metabolites 
In this paragraph, only flavan-3ols, proanthocyanins, anthocyanins and resveratrol 
metabolites will be emphasize.  
II.2.2.a. Flavan-3-ols 
The absorption and metabolism of flavan-3-ol monomers was investigated extensively. 
Both human and animal studies indicated that (+)-catechin and ()-epicatechin were rapidly 
absorbed from the upper portion of the small intestine. During digestion and transfer across 
the small intestine and the liver, flavan-3-ols undergoes phase II metabolism forming O-
sulphated, O-glucuronidated and O-methylated form conjugated (Kuhnle et al. 2000; 
Vaidyanathan et al. 2002). The methylated metabolites of catechin, epicatechin and 
epicatechin gallate predominated over the original unmethylated forms in plasma (García-
Ramírez et al. 2006). A maximum level of (+)-catechin at 76.7 nmol/L was detected in human 
plasma at 1.4 h after intake of 121 µmol (+)-catechin in dealcoholized red wine (Bell et al. 
2000). The presence or absence of alcohol does not necessary influence the absorption and/or 
metabolism of flavan-3-ols. Moreover, a peak plasma ()-epicatechin level of 260 nmol/L 
was detected within 2 h in humans after the ingestion of 557 mg of a procyanidin-rich 
chocolate containing 137 mg of ()-epicatechin (Rein et al. 2000). High recovery was also 
observed in other investigations using green tea and cocoa products (Manach et al. 2005; 
Auger et al. 2008), confirming that ()-epicatechin and (+)-catechin are highly bioavailable 
especially for the ()-epicatechin. Stalmach et al. (2009) reported a lower concentration of 
green tea flavan-3-ol metabolites in plasma than in urine showing that flavan-3-ols are rapidly 
turned over the circulatory system, and, rather than accumulating, are excreted via the 
kidneys.  
In a paper publish in 1971 (Das 1971), eleven metabolites were identified in human 
urine after (+)-catechin ingestion. The major ones were 3-(3-hydroxyphenyl)propionic acid 
and 5-δ-(3-hydroxyphenyl)-γ-valerolactone. More recently, the main metabolites detected in 
urine after the intake of catechin and epicatechin were 3-(3-hydroxyphenyl)propionic acid, 5-
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(3,4-dihydroxyphenyl)-γ-valerolactone, 5-(3-hydroxyphenyl)-γ-valerolactone and 3-
hydroxyhippuric acid (Selma et al. 2009). An in vitro study by Tzounis et al. (2008b) in which 
()-epicatechin and (+)-catechin were incubated with faecal bacteria led to the formation of 
several metabolites summarize in Table 2. The formation of these metabolites from (+)-
catechin needed to be converted into (+)-epicatechin first. 
Table 2: Metabolites of dietary flavan-3-ols and proanthocyanindins from in vitro 
microbial conversion experiments 
 
Metabolites in vitro Microbiota References 
(+)-Catechin 
()-5-(3′,4′-Dihydroxyphenyl)-γ-valerolactone (M6) Human feacal 
microbiota 
(Tzounis et 
al. 2008b) 5-Phenyl-γ-valerolactone  
3-Phenylpropionic acid 
  
3-(3,4-Dihydroxyphenyl)propionic acid  Human feacal 
microbiota 
(Aura et al. 
2008) 3-(3-Hydroxyphenyl)propionic acid 
3-Phenylpropionic acid 
  
5-(3,4-Dihydroxyphenyl)valeric acid 
  
()-Epicatechin 
()-5-(3′,4′-Dihydroxyphenyl)-γ-valerolactone (M6) Human feacal 
microbiota 
(Tzounis et 
al. 2008b) 5-Phenyl-γ-valerolactone  
Phenylpropionic acid 
  
3-(3-Hydroxyphenyl)propionic acid Human feacal 
microbiota 
(Aura et al. 
2008) 3-Phenylpropionic acid 
5-(3,4-Dihydroxyphenyl)valeric acid 
  
5-(3-Hydroxyphenyl)valeric acid 
  
(+)-Catechin 
and/or ()-
epicatechin 
4-Hydroxy-5-(3-hydroxyphenyl)valeric acid 
Rat faecal microbiota 
(Takagaki et 
al. 2013) 4-Oxo-5-(3,4-dihydroxyphenyl)valeric acid  
4-Oxo-5-(3-hydroxyphenyl)valeric acid 
  
1-(4-hydroxyphenyl)-3-(2,4,6-trihydroxyphenyl)propan-2-ol 
  
()-Epicatechin-3-
O-gallate and ()-
epigallocatechin 
gallate 
Gallic acid Human feacal 
microbiota 
(Meselhy et 
al. 1997) Pyrogallol 
()-5-(3',4'-Dihydroxyphenyl)-γ-valerolactone 
  
()-5-(3',5'-Dihydroxyphenyl)-γ-valerolactone 
  
5-(3,4-Dihydroxyphenyl)valeric acid 
  
5-(3-hydroxyphenyl)valeric acid 
  
3-(3,4-Dihydroxyphenyl)propionic acid 
  
3-(3-Hydroxyphenyl)propionic acid 
  
3-(3-Methoxyphenyl)valeric acid 
  
Procyanidin 
dimers 
5-(3,4-Dihydroxyphenyl)-γ-valerolactone Human faecal 
microbiota 
(Appeldoorn 
et al. 2009a) 3,4-Dihydroxyphenylacetic acid 
Proanthocyanidins 
5-(3-Hydroxyphenyl)valeric acid Human feacal 
microbiota 
(Déprez et 
al. 2000) 3-(3-Hydroxyphenyl)propionic acid 
2-(4-Hydroxyphenyl)acetic acid 
  
3-(4-Hydroxyphenyl)propionic acid 
  
3-(3-Hydroxyphenyl)propionic acid 
  
3-(3-Hydroxyphenyl)acetic acid 
  
3-(Phenyl)propionic acid 
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In another in vitro study (Meselhy et al. 1997), by incubating ()-epicatechin, ()-
epigallocatechin and their 3-O-gallates with human faecal suspension, the authors detected 
pyrogallol, 5-(3,4-dihydroxyphenyl)valeric acid, 5-(3-hydroxyphenyl)valeric acid, 3-(3,4-
dihydroxyphenyl)propionic acid, 3-(3-hydroxyphenyl)propionic acid, 3-(3-
methoxyphenyl)valeric acid and 2,3-dihydroxyphenoxyl 3-(3,4-dihydroxyphenyl)propionic 
acid (Table 2). This research also showed that gallates resist any degradation by a rat caecal 
suspension, suggesting species differences in metabolic activity of the two microbiota. A very 
recent investigation by Takagaki et al. (2013), investigated the in vitro catabolism of (+)-
catechin and ()-epicatechin by rat intestinal microbiota. Using LC-MS and NMR analyses, 
the authors have identified new metabolites: the 4-hydroxy-5-(3-hydroxyphenyl)valeric acid, 
4-oxo-5-(3,4-dihydroxyphenyl)valeric acid, 4-oxo-5-(3-hydorxyphenyl)valeric acid and 1-
(4-hydroxyphenyl)-3-(2,4,6-trihydroxyphenyl)propan-2-ol. A study in which volunteers 
drink green tea, ()-epigallocatechin and ()-epigallocatechin-3-O-gallate could generated 5-
(3,4,5-trihydroxyphenyl)-γ-valerolactone, 5-(34-dihydroxyphenyl)-γ-valerolactone and 5-
(3,5-dihydroxyphenyl)-γ-valerolactone both of which also appeared as sulphated and 
glucuronidated derivatives at high concentrations in urine and plasma (Table 3) (Lambert et 
al. 2007).  
Table 3: Metabolites of dietary flavan-3-ols and proanthocyanidins from in vivo 
body fluid. 
 
Metabolites in vivo Body Fluid References 
(+)-Catechin 
3-(3-Hydroxyphenyl)propionic acid  
Human urine 
(Das 1971) 
5-δ-(3',4'-Dihydroxyphenyl)-γ-valerolactone 
 
5-δ-(3'-Hydroxyphenyl)-γ-valerolactone 
  
3-(3-Hydroxyphenyl)propionic acid 
  
3-Hydroxyhippuric acid 
  
()-
Epigallocatechin 
gallate 
()-5-(3′,4′,5′-Trihydroxyphenyl)-γ-valerolactone (M4) Human urine (Li et al. 2000; Meng 
et al. 2002; Lambert et 
al. 2007) 
()-5-(3′,4′-Dihydroxyphenyl)-γ-valerolactone (M6) 
 
()-5-(3′,5′-Dihydroxyphenyl)-γ-valerolactone(M6′) 
 
Proanthocyanidins 
2-(3,4-Dihydroxyphenyl)acetic acid 
Human urine (Rios et al. 2002) 
3-(3-Hydroxyphenyl)propionic  acid 
3-Hydroxyphenylacetic acid 
  
Ferulic acid 
  
3-Methoxy-4-hydroxyphenylacetic acid 
  
3-Hydroxybenzoic acid 
  
5-(3,4-Dihydroxyphenyl)valeric acid Rat urine 
(Gonthier et al. 2003) 
5-(3-Hydroxyphenyl)valeric acid 
 
3-(3,4-Dihydroxyphenyl)propionic acid 
  
3-(3-Hydroxyphenyl)propionic acid 
  
3,4-Dihydroxybenzoic acid 
  
3-Methoxy-4-hydroxybenzoic acid 
  
4-Hydroxybenzoic acid 
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II.2.2.b. Condensed tannins 
In an early study, the used of simulated gastric fluid (pH 2.0, 37°C) suggested that 
proanthocyanidin oligomers (trimers to hexamers) were depolymerized into mixtures of ()-
epicatechin and dimers (Spencer et al. 2000). These authors also evidenced in an ex vivo 
perfusion of rat small intestines with procyanidin dimer B2 or B5 extracted from cocoa, that 
()-epicatechin was the major metabolites (Spencer et al. 2001). In addition, another report 
stipulated that once procyanidins were degraded, they yielded more readily absorbable flavan-
3-ol monomers in an in vitro model of gastrointestinal condition (Kahle et al. 2011). 
However, numerous feeding studies with animals and humans using oligomeric and 
polymeric flavan-3-ols did not supported this conclusion (Donovan et al. 2002b; Rios et al. 
2002; Tsang et al. 2005a). Most pass unaltered to the large intestine where they are 
catabolised by the colonic microflora yielding a diversity of phenolic acids (Selma et al. 2009) 
including 3-(3-hydroxyphenyl)hydracrylic acid and 4-O-methyl-gallic acid (Déprez et al. 
2000; Gonthier et al. 2003; Ward et al. 2004; Crozier et al. 2010) which are absorbed in the 
circulatory system and excreted in urine. A study in human demonstrated that 
depolymerization did not occur and proanthocyanidins were stable under gastric transit (Rios 
et al. 2002). A later investigation, confirmed that proanthocyanidin dimers and trimers were 
highly stable under gastric and duodenal digestion conditions (Serra et al. 2010). Ottaviani et 
al. (2012a), have recently compared the plasma concentration of ()-epicatechin in human 
blood and urines after volunteers were given ()-epicatechin, cocoa procyanidin monomers 
(predominantly ()-epicatechin) through decamers, or cocoa procyanidins dimers through 
decamers. Results revealed that all the absorbed ()-epicatechin in blood and urine were from 
ingested ()-epicatechin. No ()-epicatechin was derived from ingested oligomers and 
polymers.  
Baba et al. (2002) detected procyanidins B2 and ()-epicatechin in rat plasma and 
urine after administration of pure procyanidins B2. The authors suggested the hypothesis of 
degradation of a portion of dimer into ()-epicatechin and the cleavage of interflavan bond 
was likely to occur in the large intestine microbiota. In two studies, where volunteers were 
given grape seed extract (Sano et al. 2003) and flavan-3-ol-rich cocoa (Holt et al. 2002), 
procyanidin dimers B1 and B2 were detected in human plasma. In the latter study, the Tmax and 
pharmacokinetic profile of the B2 dimer were similar to those of flavan-3-ol monomers, but 
the Cmax was ca. 100-fold lower. Urpi-Sarda et al. (2009b) also detected and quantified 
procyanidins B2 in human and rat urine after cocoa intake.  
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Using intestinal perfusion in rats, no glucuronidated or sulphated metabolites of 
dimers were detected in biological fluids (Appeldoorn et al. 2009b). Another investigation 
detected methylated B-type dimer and trimer, but not glucuronide forms, in rat plasma after 
ingestion of apple procyanidins. The amount of methylated metabolites was not determined 
but appeared to be low compared with the intact oligomers (Shoji et al. 2006). These results 
showed limited phase II metabolism on oligomers. 
Recent studies using procyanidins B2 and [
14
C]procyanidin B2 dimer have provided 
helpful information on their in vitro catabolism by the gut microbiota (Appeldoorn et al. 
2009a; Stoupi et al. 2010a; Stoupi et al. 2010b) and rodent pharmacokinetics (Stoupi et al. 
2010c). After ingestion of [
14
C]procyanidin B2 dimer, ca. 60% of the radioactivity was 
excreted in rat urine after 96 h with the vast majority in a form very different from the intact 
procyanidin dosed (Stoupi et al. 2010c). This observation is consistent with other in vitro 
studies that show extensive catabolism by the gut microbiota.  
The role of gut microflora in the catabolism of proanthocyanidins was often explored 
using anaerobic incubation system in which proanthocyanidins were fermented with freshly 
collected human colonic faecal bacteria (Table 2) (Déprez et al. 2000). When 
proanthocyanidins enter the colon, they were transformed to phenolic acids. Condensed 
tannins were degraded by human colonic microbiota, producing several derivatives of 
phenylvaleric, phenylpropionic, phenylacetic, phenyllactic and benzoic acids with different 
patterns of hydroxylation, and the total yields decreased significantly according to the degree 
of polymerization. Other compounds such as phloroglucinol, 5-(3-hydroxyphenyl)-γ-
valerolactone, and 1-(3-hydroxyphenyl)-3-(2,4,6-trihydroxyphenyl)propan-2-ol, were also 
produced (Groenewoud et al. 1986). In another study, condensed tannins also produced 4-
hydroxyphenylacetic acid, 3-(phenyl)propionic acid, 3-hydroxyphenylacetic acid, 3-(4-
hydroxyphenyl)propionic acid, 5-(3-hydroxyphenyl)valeric acid and 3-(3-
hydroxyphenyl)propionic acid whereas valerolactones were not detected (Déprez et al. 2000).  
The degradation of B-type dimers was extensively studied because of their abundance 
in the human diet and the availability of commercial standards. The microbial catabolism 
pathway of procyanidin dimer B2 is summarized in Figure 18. The scission of the interflavan 
bond to convert procyanidin B2 into two ()-epicatechin appeared to be slow and accounted 
for less than 10% of procyanidin B2 (Appeldoorn et al. 2009a). The detection of ()-
epicatechin in an in vitro experiment incubating procyanidin B2 with human faecal microbiota 
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has proven this minor pathway (Stoupi et al. 2010a). The dominant products were a series of 
phenolic acids, having one or two phenolic hydroxyls and between one and five aliphatic 
carbons in the side chain (Appeldoorn et al. 2009a; Stoupi et al. 2010a; Stoupi et al. 2010b). 
In addition, there were some C6-C5 catabolites with a side chain hydroxyl group and 
associated lactones, and several diaryl-propan-2-ols, most of which were produced from the 
flavan-3-ol monomers, whereas, 3,4-dihydroxyphenylacetic acid was derived from cleavage 
of the C-ring of the upper flavan-3-ol unit. However, Stoupi et al., (2010b) also indicated that 
a feature of flavan-3-ol catabolism is the conversion to C6-C5 valerolactones and the 
progressive β-oxydation to C6-C3 and C6-C1 products (Crozier et al. 2009; Del Rio et al. 
2013).  
Accordingly to the description above, monomeric metabolites formed by cleavage of 
interflavan bond or C-ring cleavage of procyanidins, were further degraded by gut microflora 
into 5-(3,4-dihydroxyphenyl)-γ-valerolactone. This latter can be methylated by catechol-O-
methyltransferase to form 5-(3-methyoxy-4-dihydroxyphenyl)-γ-valerolactone. Microflora 
can also removed a hydroxyl group from the 5-(3,4-dihydroxyphenyl)-γ-valerolactone and 
form 5-(3-hydroxyphenyl)-γ-valerolactone. Actually, C4’ and the aliphatic side chains were 
the favorably position for microbial dehydroxylation of metabolites. Phenylvalerolactones 
were slowly degraded into phenylvaleric acids after dehydroxylation of the side chain. 
Progressive shortening of the aliphatic chain by α- and β-oxidations further generated the 
phenylpropionic acids, phenylacetic acids and benzoic acid derivatives. An investigation by 
Appeldoorn et al. (2009a) showed in an in vitro study that procyanidin dimers, were degraded 
by human colonic microbiota to 5-(3,4-dihydoxyphenyl)-γ-valerolactone and 3,4-
dihydroxyphenylacetic acid (Table 2).  
Despite remarkable capabilities of the gut microflora, it should be noted that the ability 
of bacteria to catabolise proanthocyanidins and thus their bioavailability, decrease drastically 
with the increase of molecular size. The yield of phenolic acids in rat gut was 10% and 7% for 
monomers and dimers respectively. The capability decreased to 0.7% for trimers and 0.5% for 
polymers (Gonthier et al. 2003).  
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Figure 18: Proposed pathway for human microbial degradation of procyanidin 
B2 dimer. Main routes are indicated with solid arrows and minor with dotted arrows. Adapted from 
Appeldoorn et al. (2009a), Stoupi et al. (2010a,b) and Del Rio et al. (2013). 
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II.2.2.c. Anthocyanins 
Daily intake of anthocyanins has been estimated to be 12.5 mg/day per person in the 
United States but intakes could be easily over 200 mg/ day if a regular diet of berries and 
wine are consumed. Anthocyanins are among the few plant (poly)phenols that can be 
detected in the plasma in their native intact forms (i.e. glycosides). However, typically 
recoveries of anthocyanins in urine are ca. 0.1% of the ingested dose. The low bioavailability 
of anthocyanins can be influenced by the nature of the sugar moiety, the structure of the 
anthocyanin aglycones and by food matrices (Yang et al. 2011). In addition, low recoveries 
could be a consequence of anthocyanins undergoing structural rearrangements in response to 
pH. Anthocyanin actually occurs in equilibrium with essentially four molecular forms: the 
flavilium cation, the quinoidal base, carbinol pseudo-base form and chalcone. The relative 
amounts of these four forms vary with pH. The red flavilium cation predominates at pH 1-3 
and transforms to other form as the pH increase to 4 and above. The colorless carbinol 
pseudobase becomes the major component along with smaller amounts of chalcone 
pseudobase and quinoidal base (Clifford 2000). Such changes are likely to occur in vivo 
thought the gastrointestinal tract, as anthocyanins pass from low pH in the stomach to the 
more-basic conditions of the small intestine.  
Anthocyanins bioavailability in human and animal have been widely investigated. The 
wide array of anthocyanins in fruits and food supplements used in all the studies made the 
investigation of bioavailability more complex (Prior et al. 2006). Grapes contain more than 
10 anthocyanins including glycosylated, acetylated, coumaroylated and caffeoyl-glucosylated 
anthocyanins. Other fruits such as raspberries also contain numerous different anthocyanins 
ranging from mono- to tri-saccharides and blueberries retain up to 14 anthocyanins with 
mainly 3-O-glucosides, galactosides and arabinosides of cyanidin, delphinidin, petunidin and 
malvidin. According to this observation, the evaluation of anthocyanin content of plasma and 
urine, the interpretation in terms of absorption, metabolism, excretion and potential phase I 
and phase II metabolism is very difficult, especially when 3-O-methylation converts 
cyanidin to peonidin and delphinidin to petunidin, and 5-O-methylation converts petunidin to 
malvidin (Crozier et al. 2009).  
Numerous studies reported low urinary excretions, ranging from 0.004% to 0.1% of 
the intake, although Lapidot et al. (1998) and Felgines et al. (2003) measured high level of 
excretion up to 5% after red wine or strawberry consumption. In addition, it has been shown 
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that anthocyanins are absorbed and eliminated rapidly and once they are absorbed, their 
efficiency is poor (Prior et al. 2006). However, some studies revealed that the bioavailability 
of these compounds may be underestimated, because the metabolites and breakdown products 
of anthocyanins have not yet been identified (Manach et al. 2005).  
Only a small part of anthocyanins are absorbed in their native forms as glycosides or 
as hydrolysis products in which the sugar moiety is removed. Using HPLC-MS, glucuronides 
and sulphates of anthocyanins have been identified (Wu et al. 2002; Felgines et al. 2003; 
Mullen et al. 2008). Lapidot el al. (1998) investigated the bioavailability of red wine 
anthocyanins. The consumption of 300 mL of red wine containing 218 mg of total 
anthocyanins has been shown to yield 1.5-5.1% of the amount ingested in urine within 12 
hours. Two of the compounds found among the anthocyanins were unchanged in the urine 
but other anthocyanin compounds had undergone molecular modifications. In another study 
in which volunteers consumed 500 mL of red wine, dealcoholized red wine and red grape 
juice, containing 68, 58 and 117 mg of malvidin-3-O-glucoside, respectively, malvidin-3-O-
glucoside was found in plasma and urine after ingestion of all the beverages studied whereas 
the aglycones, glucuronidated and sulphate conjugates were not detected either in urine or 
plasma (Bub et al. 2001). The authors suggested that malvidin-3-O-glucoside may be poorly 
absorbed after a single ingestion of red wine and seems to be differently metabolized 
compared to the other grape (poly)phenols.  
Using HPLC-ESI-MS-MS, Felgines et al. (2003) studied the bioavailability of 200 g 
of strawberry (containing 179 µmol of pelargonidin-3-O-glucoside). Urinary excretion of ca. 
1.8% of the ingested amount was obtained with more than 80% of this excretion related to 
monoglucuronide of pelargonidin. From the same authors, in a separate human feeding study, 
200 g of blackberries containing 960 µmol of anthocyanins principally as cyanidin-3-O-
glucoside were given to volunteers. In addition to cyanidin-3-O-glucoside, lower levels of 
methylated glycosides, glucuronides of anthocyanidins and anthocyanins, sulfoconjugate of 
cyanidin and anthocyanidins were identified. Total urinary excretion was estimated at 0.16 % 
of the intake (Felgines et al. 2005). These results indicate that pelargonidin-3-O-glucoside 
and cyanidin-3-O-glucoside are absorbed differently. Pelargonidin-3-O-glucoside showed to 
be better absorbed than cyanidin-3-O-glucoside. This is in keeping with the evidence 
obtained with other flavonoids that the presence of a substituent group at 3- and 4-positions 
can influence absorption.  
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Anthocyanins which are not absorbed in the small intestine may be transferred to the 
colon and transform by colonic microbiota. Feeding study with ileostomists who consumed 
raspberries has shown that 40 % of anthocyanin intake remained in the ileal fluid with a 
recovery of individual compounds ranging from 5.9% for cyanidin-3-O-glucoside to 93 % for 
cyanidin-3-O-(2″-O-xylosyl)rutinoside. The colonic metabolism includes deconjugation and 
ring-fission. Cyanidin is converted to protocatechuic acid (3,4-dihydroxybenzoic acid) 
(Vitaglione et al. 2007), malvidin to syringic acid (4-hydroxy-3,5-dimethoxybenzoic acid), 
peonidin to vanillic acid (4-hydroxy-3-methoxybenzoic acid) and pelargonidin to 4-
hydroxybenzoic acid. González-Barrio et al. (2011), suggested in an in vivo and in vitro study 
that cyanidin-base anthocyanins are degraded by the colonic microbiota to a diversity of 
phenolic and aromatic catabolites. In a study by Keppler et al. (2005), various anthocyanin 
standards were metabolized to aldehydes and phenolic acids when incubated with pig cecum 
contents. Other metabolite produced in vitro by the pig gut microbiota include syringic acid, 
vanillic acid, phloroglucinol aldehyde (2,4,6-trihydroxybenzaldehyde), gallic acid and 3-O-
methylgallic acid (Forester et al. 2008).  
II.2.2.d. Resveratrol 
The interest of this compound begun when it was detected in wine (Siemann et al. 
1992) and it was attributed some cardioprotective effects (Bertelli et al. 1995). After the 
publication in science by Jang et al. (1997) on resveratrol anticancer potential, the scientific 
community became really interested in resveratrol and the number of scientific reports on the 
effects and properties of this compound increased exponentially. Since resveratrol and other 
stilbenes are not very abundant in the diet, the vast majority of studies on the health effects 
have been carried out using the pure compound (either purified or synthetic) and often at a 
high concentration. Trans-resveratrol is widely credited with being responsible for the 
protective health effect of red wine. Found in a low concentration in wine (0.3-7 mg 
aglycones/L and 15 mg glycosides/L) (Vitrac et al. 2002), more than 60 liters would have to 
be consumed on a daily basis by human for intake to reach the amounts that are required to 
provide protective effects in animal model systems. Trans-resveratrol concentration reached 
by drinking within the safe limits is below the therapeutic range. Thus, any protective effect 
of this molecule is unlikely at normal nutritional intakes. No beneficial effects of trans-
resveratrol should be attribute to wine.  
The presence of trans-resveratrol in the diet is scarce and its bioavailability is 
considered as very low (ca. 1%). Walle et al. (2004) used 
14
C-labelled resveratrol 
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administrated both orally and intravenously. While ca. 70% of resveratrol was absorbed 
following oral administration, only trace amount of <5 ng/mL of unmetabolised resveratrol 
could be detected in the systemic circulation following a 25 mg dose. Most of the oral dose 
was recovered in urine. HPLC-MS permitted to identify dihydroresveratrol glucuronides and 
sulphates. According to the authors, extremely rapid sulphate conjugation by the 
intestine/liver appears to be the rate-limiting step in resveratrol's bioavailability.  
Absorption of resveratrol is thought to occur mainly by transepithelial diffusion. 
Extensive metabolism in the intestine and liver produced resveratrol-3-O-glucuronide, 
resveratrol-4-O-glucuronide, resveratrol-3-O-sulphate, resveratrol-4-O-sulphate and a 
resveratrol-O-disulphate. These metabolites appeared to be the main in human with the 
sulphates being predominant (Walle 2011). Resveratrol-3-O-glucuronide, resveratrol-4-O-
glucuronide, Resveratrol-3-O-sulphate, resveratrol-4′-O-sulphate, a resveratrol-O-disulphate 
and an O-glucuronide-O-sulphate were detected in plasma of both healthy humans and 
colorectal cancer patient ingesting 2.2 and 4.4 mmol of trans-resveratrol. In subjects who 
ingested 128 µmol of trans-piceid, two novel trans-resveratol C/O-conjugated diglucuronides 
were detected (Burkon et al. 2008). Concentrations of these metabolites are 3–8 fold higher 
than resveratrol postabsorption, and have longer half-lives, so that the body is more exposed 
(up to 23-fold) to the metabolites compared to the aglycones (Patel et al. 2011). 
Aside from the extensive metabolism of trans-resveratrol which results in an oral 
bioavailability considerably less than 1%, a recent review focuses on the ABC transporter, 
specifically the multidrug resistance associated protein 2 (MRP2) and breast cancer resistance 
protein (BCRP), involved on the efflux of trans-resveratrol glucuronides and sulphate to the 
intestinal lumen affecting not only the bioavailability but also its distribution in the different 
organs (Planas et al. 2012).  
II.3. Bioavailability of wine-derived phenolic compounds 
To date, data on bioavailability of the different wine-derived phenolic compounds in 
humans are limited. It has been hypothesized that phenolic compounds which are present as 
soluble forms in wine, should be more bioavailable than those polymeric, insoluble or tightly 
bound and compartmentalized forms in fruits and vegetables (Soleas et al. 1997). 
De Vries et al. (2001) determined and compared the bioavailability of the flavonol 
quercetin, from red wine, tea and onions in humans. They concluded that although quercetin 
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and other flavonols are absorbed from the red wine, one 100 mL glass of red wine provides 
less available flavonols than one 125 mL cup of tea or one 15 g portion of onions. The 
absorption of flavonols from foods actually depends on the form in which the compound is 
present in food (Hollman et al. 1997a; Hollman et al. 1997b). For instance, glycosylation 
enhances absorption of quercetin. The bioavailability of the compound also depends on the 
sugar moiety. In fact, the bioavailability of quercetin glucoside is 20% greater than that of 
quercetin rutinoside, and this can be explain by the presence of different sites of absorption of 
the glucoside and rutinoside (Hollman et al. 1999).  
Another study determined in humans that the hydroxycinnamate, caffeic acid, was 
rapidly absorbed from wine and reached a maximum concentration in the plasma at 
approximately 60 min post consumption (Simonetti et al. 2001). Other studies founded that 
the time taken to reach the maximum plasma concentration for the wine-derived phenolic 
compounds, whether free, conjugated or total, ranged from approximately 30 to 90 min 
(Donovan et al. 1999; Bell et al. 2000; Goldberg et al. 2003). 
The bioavailability of catechin, quercetin and trans-resveratrol in white wine, grape 
juice and vegetable juice were determined and compared in humans (Goldberg et al. 2003). 
The authors observed that the three phenolic compounds were present in serum and urine 
primarily as glucuronide and sulfate conjugates. Actually, it had previously been observed 
that the phenolic compounds are primarily conjugated in serum and urine, which facilitates 
their elimination from the body (Paganga et al. 1997; Ader et al. 2000). Of the three 
compounds studied, trans-resveratrol was the most bioavailable phenolic compound followed 
by quercetin and catechin. However, the observed maximum serum concentration of 10 to 40 
nmoL/L is 100-fold less than the 5 to 100 mmol/L required in in vitro and ex vivo studies to 
demonstrate antioxidant and other biological activities of the wine-derived phenolic 
compounds (Bhat et al. 2001; Tsang et al. 2005b; Kennedy et al. 2010). Goldberg et al. 
(2003) also concluded that absorption of the wine-derived phenolic compounds does not 
require the presence of ethanol. This result supports the observations of Donovan et al.(1999) 
and Bell et al. (2000) who observed that catechin was absorbed equally from dealcoholised 
red wine and red wine containing alcohol. 
 
Although significant progress has been made, there are still some critical areas that 
need to be elucidated in order to truly understand the mechanisms linking (poly)phenol 
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consumption and health improvement. In view of the description about bioavailability and 
generated metabolites described above, research should be more concentrate on the health 
effect of circulating and excreted metabolites in their glucuronidated or sulphated forms and 
colonic ring-fission products rather than their native forms. Actually, it is not the 
(poly)phenolic compounds found in fruits, vegetables and beverages which are transported in 
the systemic circulation and reached the body tissues to elicit bioactive effects. Recently, 
methods to synthesize (poly)phenol metabolites and their colonic catabolites are emerging, 
making the evaluation of health effect easier and will help to understand their role in disease 
prevention by dietary (poly)phenols.  
II.4. Biological effects of (poly)phenols 
Phenolic compounds are currently receiving much attention because of their beneficial 
health effects related to their antioxidant, anti-microbial, anti-inflammatory, cardio-
protective, cancer chemo-preventive and neuro-protective properties. The biological activity 
of phenolics has been extensively studied in vitro on pure enzymes, cultured cells or isolated 
tissues by using (poly)phenol aglycones or some glycosides that are present in food. Because 
of the lack of commercial standards, very little is known about the biological properties of the 
conjugated derivatives (i.e. glucuronides, sulphates and/or methylated). However, scientists 
start considering the importance of (poly)phenol metabolites and their colonic catabolites as 
these compounds are present in the systemic circulation and might elicit biological activity.  
The assumption of beneficial biological effects of (poly)phenols originally came from 
in vitro studies showing the antioxidant properties of several (poly)phenols and their ability 
to modulate the activity of certain enzymes. More evidence of their protective role derives 
from numerous experiments on animal models, epidemiological studies and clinical trials. 
Most of the time, clinical studies used foods or beverages containing a mixture of different 
(poly)phenols and the exact nature of the most active compounds remains largely unknown. 
(poly)phenol families includes a wide range of diverse compounds with highly different 
bioavailability, thus, the results obtained for one type of (poly)phenols cannot be generalized 
to others.  
In this chapter, cardiovascular protective effects of (poly)phenols will be highlight. 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among adults 
in western countries. Although some of the major risk factors are not modifiable (e.g., genetic 
predisposition, sex, age), diet and lifestyle can be modulated. For instance, it is well 
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established that excessive dietary intake of saturated fats and cholesterol contribute to the 
development of CVDs via changes in low-density lipoprotein-cholesterol (LDL-c) (Murray et 
al. 1996). Several epidemiological studies suggest that regular consumption of foods and 
beverages rich in (poly)phenols is associated with a reduction in the relative risk to die for a 
range of pathological conditions, ranging from hypertension to coronary heart diseases, 
strokes and dementias. Some of the potential mechanisms of preventing CVD after 
consumption of (poly)phenols could be related to their antioxidant activity (Rice-Evans et al. 
1996). In fact, (poly)phenols interfere with a large number of biochemical signaling pathways 
and, therefore, physiological and pathological processes. The protective effect is in part due 
to their ability to delay the development and progression of early atherosclerotic lesions to 
advances atherosclerotic plaques. Antioxidant flavonoids have been shown to reduce 
oxidation of LDL-c which is a key and early event of the atherogenic process (Frankel et al. 
1993; Frankel et al. 1995; Frei 1995). Other potential mechanisms by which (poly)phenols 
may exert cardioprotective effects include reduction in oxidative stress (Bagchi et al. 2000; 
Rouanet et al. 2011), reduction of LDL-c oxidation (Stein et al. 1999; Sano et al. 2007), 
modulation of inflammatory cascade (Delmas et al. 2005; Castilla et al. 2006), improvement 
on vascular endothelial function and protection against atherothrombotic episode including 
myocardial ischemia and inhibition of platelet aggregation (Auger et al. 2002; 
Shanmuganayagam et al. 2002; Arts et al. 2005). 
Moreover, (poly)phenols contribute to the prevention of high blood pressure and 
endothelial dysfunctions by preventing the NADPH oxidase vascular-dependent oxidative 
stress and the formation of vasoconstrictors. (poly)phenols have been shown, on the one hand 
to increase the formation of endothelium-derived relaxing factor such as nitric oxide (NO) 
(Fitzpatrick et al. 1993; Andriambeloson et al. 1997; Soares de Moura et al. 2002), the 
endothelium-derived hyperpolarizing factor (EDHF) (Kwan et al. 2004; Ndiaye et al. 2004) 
and prostacyclin (Mizugaki et al. 2000; Aldini et al. 2003) through the redox sensitive PI3-
Kinase/Akt pathway and on the other hand, to inhibit the synthesis of the vasocontracting 
factors such as endothelin-1 (Corder et al. 2001). 
II.4.1. (Poly)phenols as antioxidants 
Some of the potential mechanisms of preventing CVD after consumption of 
(poly)phenols could be related to their antioxidant activity. 
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Oxidative property of oxygen plays both a vital role in various biological phenomena 
and can also aggravate the damages within the cells by excess oxidative events. Oxygen is 
used by the cell to generate energy and free radicals are form as a consequence of ATP 
(adenosine triphosphate) production by the mitochondria. Reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) are the by-products resulting from the cellular redox 
process. Reactive oxygen species include different radicals described in Table 4.  
 
Table 4: Example of Reactive Oxygen Species (ROS). Adapted from Mimić-Oka et 
al. (1999). 
The radicals 
Superoxide O2
•-
 Oxygen-centered radical with selective reactivity. This 
species is produced by a number of enzyme systems, by auto-
oxidation reactions and by non-enzymatic electron transfers 
that univalently reduce molecular oxygen. Superoxide 
dismutase (SOD) accelerates the dismutation of O2
•-
. 
Hydroxyl OH
•
 A highly reactive oxygen-centered radical that attacks all 
molecules in the human body. 
Peroxyl alkoxyl RO2
•
, 
RO
•
 
Typically, organic radicals often encountered as 
intermediates during the breakdown of peroxides of lipids in 
the free radical reaction of peroxidation. 
Oxides of nitrogen NO
•
, 
NO2
•
 
Nitric oxide is formed in vivo from the amino acid L-
arginine. Nitrogen dioxide is formed when NO reacts with O2 
and is found in polluated air and smoke. 
The nonradicals 
Hydrogen peroxide H2O2 Formed in vivo when O2
•-
 dismutates and also by many 
oxidase enzymes. Higher levels of H2O2 can attack several 
cellular energy-producing systems. H2O2 also form OH
•
 in 
the presence of transition metal ion (Fe
2+
) and O2
•-
 can 
facilitate this reaction.  
Hypochlorous acid HOCl Powerful oxidant formed in the human neutrophils at sites of 
inflammation by action of the enzyme myeloperoxidase. May 
also react with O2
•-
 to generate OH
•
. 
Ozone O3 This noxious gas has been shown to deplete plasma 
antioxidants vitamin D, vitamin E and uric acid. 
Singlet oxygen 
1
O2 This molecule can react with unsaturated fatty acids 
producing a complex mixture of hydroperoxides.  
 
The reactive species play both a beneficial and toxic role and the balance between 
them have to be maintained. To prevent an overload in free radicals and peroxides, aerobic 
organisms use a sophisticated defense system which operates both in intra- and extracellular 
aqueous phases and in membranes. Antioxidant defense strategies are committed to prevent 
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the oxidative attack in its early moment by the formation of priming radicals as well as during 
the initiation and chain propagation processes.  
Actually, at low or moderate levels, reactive species exert beneficial effects on 
cellular redox signaling and immune function. For instance, free radicals take part in cascade 
events in the antimicrobial action of the phagocytic cells via NADPH-oxidase and act as 
regulator molecules. However, at high concentrations, they cause oxidative stress, a harmful 
process in which cell functions and structures can be damaged.  
Due to the great diversity of (poly)phenols, the structure-activity relationship, 
bioavailability and therapeutic efficacy of the antioxidants differ extensively (Huang et al. 
2005). Phenol itself is inactive as an antioxidant, but ortho- and para- diphenolics have 
antioxidant capacity which increases with the substitution of hydrogen atoms by ethyl or n-
butyl groups. Flavonoids are among the most potent plant antioxidants because they possess 
one or more of the following structural elements involved on the antiradical activity: (1) an o-
diphenolic group (in the ring B), (2) a 2-3 double bond conjugated with the 4-oxo function 
and (3) hydroxyl groups in positions 3 and 5 (Leopoldini et al. 2011). Quercetin is the 
flavonol that combines all of these characteristics and is one of the most potent natural 
antioxidant. Moreover, the antioxidant efficiency of flavonoids is directly correlated with 
their degree of hydroxylation and decreases with the presence of a sugar moiety (Cotelle 
2001).  
(Poly)phenols may act though various mechanisms leading to free radicals 
scavenging. These include inhibition or potentiation of the action of many enzymes and direct 
interaction with free radical (Mimić-Oka et al. 1999; Carillon et al. 2012). In addition, 
(poly)phenols can chelate metals such as iron which is involved in free radicals formation 
(Korkina et al. 1997). Indirectly, they can interfere with the cellular detoxification systems, 
such as superoxide dismutases (SOD), catalase or glutathione peroxidases (Krinsky 1992). 
Besides, (poly)phenols can also inhibit enzymes generating ROS such as xanthine oxidase 
and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Green tea flavonoids 
showed by in vitro investigations that they are strong antioxidants, being up to 5 times more 
effective than vitamin C and E (Dreosti 1996; Balentine et al. 1997). A study demonstrated 
that epigallocatechin-3-O-gallate from tea can modulate the oxidative stress by affecting the 
production of ROS, gluthatione and cytochrome P450 activity (Raza et al. 2005).  
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However, a gap between these antioxidant effects and the risk of CVDs exists. A 
direct scavenging of free radicals by (poly)phenols, as often suggested, may not be the key 
mechanism explaining their effects on oxidative stress biomarkers and CVD risk factors.  
II.4.2. (Poly)phenols and vascular protection 
II.4.2.a. Endothelial cells and regulation of vascular homeostatis 
Endothelial cells of healthy blood vessels form a monolayer at the luminal surface and 
mediate chemically the vascular homeostasis. These cells prevent the contact of circulating 
blood with the underlying prothrombotic arterial wall. The endothelium plays a critical in the 
control of vascular tone by synthesizing and releasing various substances into the 
bloodstream which are classified as vasodilators and vasoconstrictors, based on their 
mechanism of action. Vasodilators are generally referred to as endothelium-derived relaxing 
factor (EDRF), represented mainly by nitric oxide (NO), endothelium-derived 
hyperpolarizing factor (EDHF) and prostacyclin (PGI2), and vasoconstrictors, known as 
endothelium-derived contracting factors (EDCFs), represented by endothelin-1.  
The gas NO is generated from L-arginine by the enzyme endothelial NO synthase 
(eNOS) and diffuses toward the underlying vascular smooth muscle, where it stimulated 
guanylate cyclase in the sarcoplasm and increase the production of cyclic guanosine 
monophosphate (cGMP) (Vanhoutte 2009). NO is the most potent of all endogenous 
compounds causing vascular muscle relaxation, but also displays paracrine action by 
preventing platelet aggregation, adhesion and exerting an anti-proliferative effect on smooth 
muscle cells. In addition, NO also limits the oxidation of low-density lipoproteins (LDLs) 
and can lower the activity of reactive oxygen species (Frankel et al. 1995; Teissedre et al. 
1996). The physiological effect of NO is very short (less than 20 sec) because of the 
inactivation of haemoglobin (Stankevicius et al. 2003; Stoclet et al. 2004). 
PGI2 can be synthesized through transcellular metabolism. Similarly to NO, PGI2 
dilates blood vessels, causing smooth muscle relaxation. This is mainly attributed to the 
stimulation of adenylate cyclase and thus to an increased content of intracellular adenosine 
monophosphate (cAMP) and the activation of potassium channels in smooth muscle cells 
(Kawashima et al. 2004; Fetalvero et al. 2007; Vanhoutte 2009).  
Mechanical damages to endothelium or a loss of functional integrity disturbs the 
fragile multifactorial equilibrium ensured by endothelial cells and thus, causing the 
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development of pathological changes such as hypertension, atherosclerotic lesions, thrombi 
and disturbed tissues perfusion (Goch et al. 2009). Endothelial dysfunction is often associated 
with pronounced oxidative stress which is due, at least in part, to an increased expression of 
NADPH oxidase, an enzyme generating superoxide anions on the arterial wall (Griendling et 
al. 2000; Griendling et al. 2003). Superoxide anions react with NO to reduce its 
bioavailability and, hence, vascular protective effects. Furthermore, the dysfunction can 
activate the endothelium-dependent contractile responses involving the contractile actions of 
endothelin-1 and vasoconstrictor factors acting on tromboxane receptors. The latter 
stimulates platelet aggregation and vessel constriction.  
II.4.2.b. Vascular protection by (poly)phenols 
Pioneer study by Fitzpatrick et al. (1993), using rat aorta with various grape products 
including wines, grape juices and grape skin extracts, have showed that (poly)phenols 
increase the formation of NO by endothelial NO synthase action. Using another animal 
model, in porcine coronary artery ring, the endothelium-dependent relaxation induced by red 
wine (poly)phenols is observed at concentration of 3 µg/mL (Ndiaye et al. 2004). Several 
other aortic ring experiments using physiological concentrations of (poly)phenols have also 
shown that (poly)phenols induce endothelium-dependent relaxation (Fitzpatrick et al. 1993; 
Karim et al. 2000; Chin-Dusting et al. 2001; Woodman et al. 2004). This regulation of vascular 
nitric oxide is thought to involve the ability of (poly)phenols to interact with kinase signaling 
pathways such as the PI3-kinase/Akt pathway and intracellular Ca
+2
 on eNOS 
phosphorylation and subsequent NO production (Lorenz et al. 2004; Stoclet et al. 2004). 
However, in vitro experiment results are of limited value and (poly)phenol in vivo effects 
might not be effectively evaluated. 
In humans, 30 min after the consumption of red wine, circulating NO concentration 
increased to 30-40 nM, respectively. In addition, a reduction of the blood pressure (11 mm 
Hg) and an increase of heart rate was observed (Matsuo et al. 2001). A study using olive oil, 
showed a reduction of blood pressure in hypertensive patients, possibly through enhanced 
NO levels stimulated by (poly)phenols. (Ferrara et al. 2000). Short-term and long-term 
effects of tea consumption were also investigated (Duffy et al. 2001). This study used water 
as a control beverage and results showed that both short-term and long-term consumption 
improved endothelial function. However, this study did not demonstrated any effect on 
plasma antioxidant capacity, on plasma concentration of F2-isoprostanes, a marker of 
systemic lipid peroxidation or on 8-hydroxydeoxyguanosine, a marker of DNA oxidation. 
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These findings are consistent with several other well-conducted studies that failed to 
demonstrate a reduction in markers of oxidative stress after tea consumption (O'Reilly et al. 
2001).  
Several other studies demonstrated that flavonoid-containing beverages have 
beneficial effects on endothelial function. Stein et al. (1999) observed that consumption of 
grape juice for 14 days was associated with improved brachial artery flow-mediated dilation 
among 15 adults with angiographically proven coronary artery disease. A second study from 
the same group also indicated beneficial effects of purple grape juice on endothelial function 
(Chou et al. 2001). The effect of cocoa on flow-mediated dilation was also investigated. 
Among patients with at least one cardiovascular disease risk factor, impaired endothelial 
function was observed. Two hours after the patients consumed cocoa containing 176 mg/dL 
flavan-3-ols, the investigators observed a significant increase in flow-mediated dilation. They 
also observed increased in nitrosylated and nitrosated species in plasma, which suggested an 
increase in nitric oxide production (Heiss et al. 2003).  
Endothelium- and NO-dependent relaxation has been reported for several isolated 
flavonoids, especially the anthocyanin delphinidin (Andriambeloson et al. 1998) and the 
flavone chrysin (Duarte et al. 2001). These effects are related to a pro-oxidant effect because 
it can be inhibited by superoxide dismutase and catalase and a subsequent increased in 
endothelial cystolic Ca
2+
 levels (Andriambeloson et al. 1998). Using ERα deficient mice, a 
recent study evidenced an activation of NO pathway leading to the induction of endothelial 
vasodilatation in aorta endothelial cells by the anthocyanin delphinidin (Chalopin et al. 2010). 
The authors also demonstrate the implication of the alpha isoform estrogen receptor (ERα) in 
the transduction of the vascular benefits of (poly)phenols. Actually, silencing the effects of 
ERα completely prevented the effects of delphinidin to activate NO pathway (Chalopin et al. 
2010). Some group have also described that the effects of quercetin were partially 
endothelium-dependent and related to the release of endothelium-derived relaxing factors 
(Ajay et al. 2003; Khoo et al. 2010). A pro-oxidant mechanism involving the release of H2O2 
has been proposed (Khoo et al. 2010). 
A complex array of information has been reviewed by Stoclet et al. (2004), proposing 
a global view of vascular protection by dietary (poly)phenols. Briefly, plant (poly)phenols 
firstly act on endothelial cells by enhancing the production of vasodilating factors (i.e., NO, 
EDHF and prostacyclin) and inhibit the synthesis of vasoconstrictor endothelin-1. This 
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mechanism involves an increase of Ca
2+
 level and redox-sensitive activation of the 
phosphoinositide 3 (PI3)-kinase/Akt pathway (leading to rapid and sustained activation of 
nitric oxide synthase and formation of EDHF) and enhance expression of nitric oxide 
synthase. Secondly, (poly)phenols can operate in smooth muscle cells by inhibiting the 
expression of two major pro-angiogenic factors: vascular endothelial growth factor (VEGF) 
and matrix metalloproteinase-2 (MMP-2). The mechanism requires both redox-sensitive 
inhibition of the p38 mitogen-activated protein kinase (p38 MAPK) pathway activation 
(leading to inhibition of platelet-derived growth factor (PDGF)-induced VEGF gene 
expression) and redox-insensitive mechanisms (leading to inhibition of thrombin-induced 
MMP-2 formation). A more recent review by Schini-Kerth et al. (2011), describes the in vitro 
and in vivo vascular protection by natural product-derived (poly)phenols during the last 15 
years. Grape-derived products (i.e. juices, extracts, wines and marc extracts), berries, tea and 
plants are able to improve the endothelial function in both in vitro and in vivo mostly by 
stimulating the endothelial formation of NO. The in vitro experiments are of limited value 
and cannot be generalized to in vivo effects.  
II.4.3. (Poly)phenols and platelet function 
II.4.3.a. Role of platelets in vascular hemostasis 
Physiological hemostasis is a natural protection against excessive blood loss and is 
based on controlled thrombus formation at the site of damage of blood vessels. Platelets, the 
smallest (2–4 μm) blood corpuscles, produced in the bone marrow from megakaryocytes at a 
rate of 40×103/ml/day, play the primary role in hemostasis. The role of platelets in 
hemostasis is not limited to the formation of platelets but also contribute to clotting reaction. 
When the endothelium is damaged, collagen and tissue factor (TF) present in the 
subendothelial matrix interact with the flowing blood, initiating the formation of a clot (Davì 
et al. 2007). The presence of collagen causes platelet pooling and activation while tissue 
factor initiates the formation of thrombin, which not only converts fibrinogen into fibrin, but 
also activates platelets (Furie et al. 2008). The interaction between platelets and the 
subendothelial layer is possible due to the presence of collagen receptors (including integrin 
α2β1 and glycoprotein complex GPIb/IX/V) on the platelet surface (Jagroop et al. 2000). 
Association of these mechanisms lead to the platelet aggregation.  
Increased activation of platelets, including their adhesion, secretion, and aggregation 
at the site of vessel damage or in vessels affected by atherosclerosis, plays an important role 
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in the pathogenesis of cardiovascular diseases (Jagroop et al. 2007). Chronic atherosclerotic 
lesions in coronary artery walls are associated with the formation of plaques which may 
narrow the vessel lumen. Biochemical markers of increase platelet activation include 
metabolites generated from arachidonic acid converted via cyclooxygenase (COX). 
Thromboxane A2 (TXA2) is the main platelet and a potent vasoconstrictor with proliferative 
and cell adhesion-stimulating properties. In addition, under conditions of increased platelet 
activation, two platelet surface molecules are also expressed: integrin αIIbβ3, a receptor for 
fibrinogen (GP IIb/IIIa) and P-selectin (Praticò et al. 2009). P-selectin is an adhesion 
molecule characteristic of platelets and is stored in α-granules of platelets and in endothelial 
cells. This molecule mediates the red blood flow along the endothelial surface and the 
activation of leukocyte binding processes to platelets, endothelial cells and other leukocytes 
at the tissue damage or inflammatory site. An increase of soluble P-selectin (sP-selectin), a 
procoagulant factor present in blood, is a predictive factor for cardiovascular events (Polek et 
al. 2009; Kaplan et al. 2011).  
II.4.3.b. (Poly)phenols and anti-platelet action 
The antioxidant action of (poly)phenols is important from the point of view of platelet 
activation, including platelet adhesion and aggregation. As mentioned above, the first stage of 
platelet activation is platelet adhesion to collagen. The interaction between platelet receptors 
and adhesion proteins, including fibrinogen, fibronectine, vitronectin and thrombospondin, 
mediates the adhesion of platelets, the triggering of the intracellular signaling pathway and as 
a consequence, platelet activation (Jennings 2009). The mechanisms responsible for the 
inhibitory effect of (poly)phenols on platelet adhesion have not been fully elucidated. 
The platelet anti-aggregant effects of flavonols were initially described by Beretz et al 
(1982). Study reported the inhibition of platelet adhesion to collagen by extracts rich in 
(poly)phenolic compounds such as grape seed extracts. Resveratrol and its derivatives present 
in the extracts could reduced the adhesion of platelets stimulated by thrombin. Chokeberry 
fruit extract have also showed to display a similar effect. Integrin α2β1 (GPIa/IIa) and 
glycoproteins GPIV and GPVI are responsible for the adhesion of platelets to collagen. An 
additional receptor for collagen may also be the αIIbβ3 receptor (Olas et al. 2008). 
(Poly)phenol effects on platelet adhesion is believed to be due to their capacity to regulate the 
expression of these receptors and the potential interaction with them.  
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In addition, (poly)phenols target molecule may be both cyclooxygenase and 
lipoxygenase (Vanhoutte 2009). Flavonols present in cocoa have been found to reduce TXA2 
synthesis. Moreover, they have also shown to inhibit the activity of phospholipase C, limiting 
the formation of inositol 1,4,5‑trisphosphate (IP3,) and diacylglycerol (DAG), which are 
secondary messengers in platelets (Nardini et al. 2007). Some flavonoid compounds, for 
example quercetin, were able to stimulate adenylate cyclase and guanylate cyclase and to 
inhibit phosphodiesterase, contributing to an elevation of cAMP and cGTP levels, limiting 
the activation of platelets. In vitro studies indicated that resveratrol was able to block calcium 
channels and inhibited Ca
2+
 ion flux on platelets activated by thrombin, while quercetin 
inhibited the intracellular mobilization of ca
2+
 from the endoplasmic reticulum. This is 
particular importance from the point of view of the anti-platelet properties of (poly)phenols, 
since many platelet enzymes are calcium dependent (Nardini et al. 2007).  
It has been previously suggested that the inhibition of platelet reactivity by wine may 
partly explain some of its cardioprotective effects, for example, the French paradox as 
mentioned earlier (Renaud et al. 1992). Once red wine and grape juice, but not white wine 
were infused intravenously and intragastrically into anesthetized dogs, coronary artery blood 
flow parameters and inhibited platelet aggregation were improved (Demrow et al. 1995). In 
another study involving 10 subjects, the effects of drinking purple grape juice, grapefruit 
juice and orange juice for one week were examined (Keevil et al. 2000). Platelet aggregation 
responses to collagen were significantly reduced in the grape juice group only and appear to 
reflect the total phenolic contents of the test components. In fact, the total phenolics 
expressed as gallic acid equivalent were 2.26, 0.75 and 0.86 g/L for purple grape juice, 
orange juice and grape fruit, respectively. Another human study demonstrated a decrease in 
platelet aggregation, increase in platelet-derived NO release and a decrease in superoxide 
formation, both in vitro and after oral supplementation with purple grape juice, confirming 
the absorption and bioavailability of the bioactive compounds from purple grape juice 
(Freedman et al. 2001).  
II.4.4. (Poly)phenols and anti-inflammatory properties 
In cardiovascular diseases, important inflammatory processes take place and are 
associated with dysfunction of endothelial cells with accumulation of monocytes/ 
macrophages in the vascular intima, the formation of foam cells, and the proliferation of 
vascular smooth muscle (Wong et al. 2012). Many pro-inflammatory cytokines are release 
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such as interleukin-1 (IL-1), IL-2, IL-6, IL-8, tumor necrosis factor (TNF-α), interferon-g 
(INF-γ), growth factors (e.g., granulocyte- macrophage colony-stimulating factor [GM-CSF], 
macrophage colony-stimulating factor [M-CSF], platelet- derived growth factor [PDGF]). In 
addition, other inflammation mediator factors are also release and can intensify the growth 
process and destabilization of the atherosclerotic plaque, such as the monocyte chemotactic 
protein-1 (MCP-1) and matrix metalloproteinases (MMPs) (Libby 2002).  
Recent studies showed that catechins are able to inhibit the adhesion and migration of 
neutrophils through the monolayer of endothelial cells by inhibiting the production of 
chemokines at the site of inflammation and reducing the expression of VCAM-1 (Ludwig et 
al. 2004; Takano et al. 2004). Kawai and colleagues (2004) demonstrated that flavan-3-ols 
contributed to the reduced expression of CD11b molecules on monocytes and granulocytes, a 
circumstance which limited the recruitment of these cells to the inflammation site. In humans, 
Badia et al. (2004), observed that moderate red wine consumption was able to reduce the 
adhesion of monocytes to endothelial and associated this effect with the regulation of 
adhesion molecules located of the surface of the monocytes.  
Nuclear factor kappa beta (NF-κB) can regulate the inflammatory process by 
modulating expression of pro-inflammatory genes. This protein is likely the major molecular 
target for the anti-inflammatory effects of (poly)phenols in the vasculature. Several 
mechanisms may be involved in the inhibition of NF-κB by (poly)phenols, and these 
compounds may inhibit ROS-mediated NF-κB activation. The efficient transcriptional 
activation of NF-κB depends on the phosphorylation of its active subunit P65, and 
(poly)phenols have showed to block P65 phosphorylation, rendering NF-κB transcriptionally 
inactive (Manna et al. 2000). Moreover, overexpression of SIRT1 mimic the effects of some 
(poly)phenols, including resveratrol (Kaeberlein et al. 2005). It has also been shown that 
resveratrol could promoted the deacylation of P65 by SIRT1 (Yeung et al. 2004). In addition, 
it was evidenced that curcumin was able to block cytokine-mediated NF-κB activation and 
pro-inflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity (Jobin 
et al. 1999).  
II.4.5. (Poly)phenols and anti-atherogenic properties 
One of the most frequently studied beneficial effects of (poly)phenols is their ability 
to improve lipid profile. The enzymes and free radicals released by immune system cells, 
platelets, and endothelial cells modify native LDLs by oxidation. Oxidized LDLs (oxLDLs) 
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are responsible for further development and destabilization of atherosclerotic plaque. 
Oxidative stress produces an increase in enzymes such as cyclooxygenase (COX) and 
lipooxygenase (LPO), which are implicated in the release of factors such as chemokines, pro-
inflammatory substances, growth factors, free radicals, TF and proteolytic enzymes 
specialized in the digestion of connective tissue elements (MMPs) and other factors that have 
direct chemotactic properties for monocytes to adhere to the endothelium (Aviram et al. 
1994). The accumulation of macrophage in this area eliminated the oxLDLs molecules but 
also provokes an inflammatory response, with requisite cell recruitment and proliferation 
accompanied by migration of smooth muscle cells. Oxidized LDL is preferentially taken up 
by macrophage cells via scavenger receptors, and they consequently become loaded with 
lipids and convert into “foam cell” (Aviram 1996). Extracellular matrix deposits increase 
around the inflamed area, and this permits the formation of so called atheroma plaque, which 
more or less blocks the vessel. Along with these processes, vasoconstriction episodes occur, 
caused by inhibition of NO formation and loss of arteries’ natural relaxation capacity (Ross 
1999).  
The beneficial effects of (poly)phenols on atherosclerosis have been widely studied 
and it was proposed that these compounds are able to attenuate the onset and development of 
the disease thanks to their ability to limit LDL oxidation. Numerous studies investigated the 
protective effect of flavan-3-ols, both monomeric and oligomeric, against LDL oxidation 
(Fuhrman et al. 2001; Auger et al. 2004). The development of foam cells in the aorta is a 
good model and indicator of atherosclerotic lesions. Using a hamster model of 
atherosclerosis, Vinson et al. (2002) found that grape seed proanthocyanidins induced a 
pronounced reduction in plasma cholesterol (25%) and triglyceride levels (up to 34%). 
Accompanying these changes was a reduction in the percentage of aorta covered in foam 
cells. The latter was reduced by 50% and 63% after supplementation of the animals with 50 
and 100 mg/kg grape seed proanthocyanidins, respectively. Furthermore, these beneficial 
effects were associated with a significant decrease in plasma lipid peroxidation levels. 
In a randomized, double-blind, placebo-controlled study, grape seed proanthocyanidin 
extracts was given to 40 hypercholesterolemic patients for 8 weeks (Bagchi et al. 2003). 
There was a significant reduction in LDL-c levels and total cholesterol levels for the grape 
seed proanthocyanidins group, but only when this group was additionally supplemented with 
niacin-bound chromium. This phenomenon suggested that the mechanisms of action are 
complex and may require other “factors” for nutritional benefit. 
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Apolipoprotein E
-/-
 (ApoE
-/-
)-deficient mice represent a good model for 
atherosclerosis. They are characterized by accelerated development of atherosclerosis and are 
more susceptible to oxidative stress. Grape extract effects were extensively considered. 
Fuhrman et al. (2005) investigated atherosclerotic lesions using ApoE
-/-
deficient mice 
following the dietary supplementation of freeze-dried extracts of fresh grapes. For ApoE
-/-
-
deficient mice that consumed 150 μg total (poly)phenolics per day for 10 weeks, a 41% 
reduction in the atherosclerotic lesion area was observed compared with control (no 
supplements) or placebo (glucose and fructose supplementation) groups. This effect was 
associated with a significant reduction in serum oxidative stress as indicated by an 8% 
reduction in plasma lipid peroxide concentration and an increase in antioxidant capacity 
(16%-20%) as well as a reduction in macrophage uptake of oxidized LDL (33%). Another 
study by Frederiksen et al. (2007) using Watanabe heritable hyperlipidemic rabbits 
demonstrated that consumption of a red grape skin extract was associated with a delay of the 
development of aortic atherosclerosis in male rabbits but not females, as determined by 
cholesterol content within the abdominal aorta.  
Anti-atherogenic effects were also observed with other type of fruits and beverages. 
Administration of pomegranate juice, rich in anthocyanins, and ellagitannins such as 
punicalagin, to apoE
–/–
 mice resulted in dramatic reductions in lipid peroxides and 
macrophage accumulations, without significantly affecting plasma cholesterol. After three 
months of pomegranate juice supplementation, atherosclerosis was reduced by 44% (Aviram 
et al. 2008). In another study, administration of pomegranate by-product to apoE
–/– 
mice 
attenuated atherosclerosis development as a result of decreased macrophage oxidative stress 
and cellular uptake of oxidized LDL (Rosenblat et al. 2006).  
It has been demonstrated that resveratrol, impeded LDL oxidation and lowered 
cytotoxicity caused by oxidized LDL in endothelial cells (Delmas et al. 2005). Using the 
same apoE
–/– 
mouse model, four-month supplementation of a regular chow diet with 
resveratrol led to a reduction in total plasma cholesterol and LDL-c, and an increase in HDL 
cholesterol. The mechanism for the reduction in plasma cholesterol was through a reduction 
in hepatic cholesterol synthesis, which may have stimulated LDL receptor-mediated uptake 
of LDL from plasma (Do et al. 2008). Berrougui et al. (2009) showed in an in vitro 
experiment that resveratrol could prevented lipid peroxidation and increased cholesterol 
efflux from macrophages. Through these mechanisms, resveratrol significantly reduced 
atherosclerotic plaque development in the aortic arch of apoE
–/– 
mice. 
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The reduction of vascular inflammation, the prevention of leukocyte adhesion, the 
inhibition of vascular smooth muscle proliferation and the stimulation of NO production may 
also contribute to the anti-atherosclerotic effects of (poly)phenols. Nie et al. (2006) showed 
that avenanthramides, polyphenols found in oats (Avena sativa L.), might contributed to the 
prevention of atherosclerosis through inhibition of smooth muscle proliferation and 
increasing NO production. A recent study by Choi et al. (2009), suggested that through its 
ability to inhibit type A scavenger receptors and CD36 (Cluster of Differentiation 36) on the 
macrophage surface, quercetin reduced oxLDLs uptake and absorption. Moreover, quercetin 
contributed to the production of pro-inflammatory and pro‑atherogenic vascular endothelial 
growth factor (VEGF) and inhibited the expression of MIP-2 (macrophage-inflammatory 
protein-2) and MCP-1. Quercetin has also been shown to reduce the activation of PPAR-γ 
(peroxisome proliferatoractivated receptor gamma) participating in the regulation of CD36 
receptor expression on macrophages (Choi et al. 2009). 
II.4.6. Conclusion on health effects  
Although the beneficial effects, controversial results were found. Current limited 
evidence suggested that fruits containing relatively high concentrations of flavonols, 
anthocyanins and procyanidins, such as pomegranate, purple grapes and berries, were more 
effective at reducing CVD risk, particularly with respect to anti-hypertensive, inhibition of 
platelet aggregation and increasing endothelial-dependant vasodilatation than other fruits 
investigated. In fact, one of the reasons why it is difficult to draw a clear conclusion from the 
current evidence is the heterogeneity in study design. (Poly)phenols were mainly consumed 
in the form of fruit juices or fruits and a small number of studies provided (poly)phenols in 
the form of supplements (Conquer et al. 1998; Clifton 2004; Hubbard et al. 2004; Gorinstein 
et al. 2006). Between studies, duration of study period ranged from weeks to months and the 
dose of (poly)phenols investigated was not consistent between studies. Moreover, the dose 
administrated is often high and exceeds the dietary intake. 
In addition, the types of subjects recruited differed, with some studies using healthy 
volunteers while others recruited subjects at risk of CVD or with CVD (Stein et al. 1999; 
Kurowska et al. 2000; Sumner et al. 2005; Gorinstein et al. 2006; Erlund et al. 2008; Wilson 
et al. 2008). It appears that observed effects were generally more marked in subjects with 
higher CVD risks. Moreover, subject compliance should also be considered because this 
could impact significantly the results. Difference in the degree of dietary compliance could 
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account for inconsistencies in the results obtained from various studies. Most of the time, 
compliance including diet diaries, log books, frequent interviews by the researchers and 
biomarkers, was not assessed.  
Besides, analytical methodologies should be standardized to allow valid comparison 
between studies. This is particularly important in the quantification of specific (poly)phenols 
in fruits. Differences in the concentration of the bioactive flavonoid components within the 
fruits ingested in the various studies have been consistently highlighted as a possible factor 
influencing the variable effects of similar types of fruits/fruit juices. In some investigations, 
details of the (poly)phenols content of the fruits investigated were omitted and thus, 
generating inconsistent results. 
All these factors may be the reasons for heterogeneous results and have to be 
considered for an acute investigation of (poly)phenol health effects. Long intervention 
periods and subject’s compliance to treatments should be encouraged and evaluated in future 
studies. Improvements and standardization in the methodology for quantifying the 
(poly)phenolic content of fruits have to be taken into account.  
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III. Hypertension and treatments 
III.1. Blood pressure  
Blood pressure is defined as the force of blood exerts against the arteries wall. It is 
measured as millimeters of mercury (mm Hg) and recorded as two numbers: systolic pressure 
(i.e. rhythmic contraction of the heart) and diastolic pressure (i.e. relaxation and dilatation of 
the heart between two beats and refill with blood). An individual has a normal blood pressure 
when its systolic blood pressure (SBP) is less than 120 mm Hg and its diastolic blood 
pressure (DBP) less than 80 mm Hg. Cardiac output, peripheral resistance and blood volume 
are the three main factors influencing BP following this equation: 
Blood Pressure = cardiac output × peripheral resistance 
Any change in cardiac output, peripheral resistance and blood volume will lead to a 
change in blood pressure.  
III.2. Regulation of blood pressure 
III.2.1. Short-term regulation 
Generally, the regulatory system functions to correct deviations of arterial blood 
pressure from the setpoint value. Such a system requires three components: 
• Sensors that respond to a pressure-related variable and convey an appropriately 
coded signal to an evaluator. 
• Evaluators translate the incoming code from the sensors, compare the existing blood 
pressure with the setpoint and issue the appropriate commands for compensatory actions. 
• Effector mechanisms bring changes in heart rate, cardiac performance and total 
peripheral vascular resistance to reduce the difference between existing blood pressure and 
setpoint. 
The short term regulation occurs rapidly within second in response to posture, acute 
stresses and hemorrhage. Short term control of BP is mediated by the nervous system and 
need the contribution of the three important factors listed above (i.e; the sensors, the 
evaluators and the effectors).The dominant short-term regulator of arterial blood pressure is 
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the baroreceptor mechanism. The baroreceptors are unencapsulated nerve endings located in 
the wall of the carotid sinus and the aortic arch. They monitor the BP coming from the aorta 
and carotid artery (Ottesen et al. 2011). Stretch sensors in the cardiac atria and the stretch-
sensitivity of a few cells in the juxtaglomerular apparatus of renal afferent arterioles also 
participate in this regulation. The evaluators are mostly situated in the pons/medulla region of 
the midbrain, particularly in the neurons of the nucleus tractus solitaries.  
Arterial blood pressure is sensed by baroreceptors which translate wall stretch into 
action potentials that are conveyed to the midbrain region by fibres in the glossopharyngeal 
and vagus nerves. Neurons in the pons and medulla regions of the midbrain compare existing 
blood pressure against the setpoint, which represents the desirable blood pressure under the 
circumstances. If there is a deviation of arterial blood pressure from the setpoint then 
neurohumoral signals are generated and conveyed to the periphery in order to make 
appropriate corrective changes in heart rate, cardiac stroke volume and total peripheral 
vascular resistance (Convertino 1998). Figure 19 summarize this mechanism.  
In order to ensure this regulation, the effectors have to complete these following 
mechanisms:  
1/ Increase the production of angiotensin II (Ang II), a powerful vasoconstrictor via 
the renin-angiotensin cascade. Ang II is mediated by the activation of AT1 receptors in the 
membranes of vascular smooth muscle cells. Activation elevates levels of intracellular 
calcium ions and leads to vasoconstriction. Angiotensin II also increases renal retention of 
sodium ions and water by acting on receptors in the proximal and late distal convoluted 
tubule of the nephron and by promoting the synthesis and release of the salt-retaining 
hormone aldosterone, from adrenal cortical zona glomerulosa cells . 
2/ Synthesize vasopressin by the paraventricular and supraoptic nuclei of the 
hypothalamus which are transported along axons towards the posterior pituitary, and released 
by exocytosis into the circulation. Vasopressin result from the activation of V1 receptors in 
vascular smooth muscle and such activation causes vasoconstriction. Vasopressin also acts on 
V2 receptors in the cortical collecting duct of the nephron. Such action results mostly in the 
insertion of aquaporins into the luminal membrane and leads to increased reabsorption of 
water from the nephrons (Toba et al. 1999). 
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3/ Stimulate cardiac parasympathetic outflow from the neurons of the nucleus 
ambiguus and conveyed to the heart by the way of the vagus nerve. Efferent fibres of the 
vagus nerves innervate the cardiac pacemaker cells and, to some extent, the atrial myocytes 
and conductive tissue of the cardiac ventricles. Action potentials result in the release of 
acetylcholine from the terminal butons and subsequent activation of M2 muscarinic receptors, 
which leads mainly to a decrease in heart rate.  
4/ Stimulate sympathetic nervous outflow from the neurons of the rostral ventrolateral 
medulla. Potential action is translated into release of adrenaline from chromaffin cells in the 
adrenal medulla, renin release from renal juxtaglomerular cells, and noradrenaline release at 
peripheral synapses, which are found in cardiac myocytes and the vascular smooth muscle 
that surrounds blood vessels. Subsequent cardiovascular effects of adrenaline and 
noradrenaline are initiated when these catecholamines activate α and β adrenoreceptors 
located in cell membranes of the target tissues. The final effects of increased sympathetic 
nervous activity are the increase of heart rate and cardiac contractility by β1- activation and 
the increase of vascular resistance by α1-activation.  
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Figure 19: Baroreceptor mechanism of blood pressure control 
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III.2.2. Long term regulation  
The long-term regulation system is mainly maintained by kidney and the renin-
angiotensin system.  
Early experiments suggested that hypertension develops when a small defect in 
kidney function causes renal retention of sodium ions and water, increases the volume of 
extracellular fluid and causes arterial blood pressure to rise to a level at which the pressure 
natriuresis mechanism can again maintain a balance between intake and output of sodium 
ions and water. It appears, therefore, that the long-term-controlled variable is not arterial 
blood pressure, but the balance between intake and output of fluid and electrolytes. While 
several organs excrete water and salt, only the kidney excretes them in a controlled manner. 
Kidneys have the capability to regulate the total body content of sodium ions and water. A 
key feature of the renal body fluid feedback control system is pressure natriuresis or the 
ability of the kidneys to respond to changes in arterial pressure by altering the renal excretion 
of salt and water. The nervous system induced changes in peripheral resistance and cardiac 
output, which are essential for rapid regulation of arterial pressure (Blaustein 1977; Hall 
2003). 
The sensitivity of the pressure natriuresis mechanism can be modified by a number of 
extra-renal neurohormonal regulatory systems. For instance, the renin-angiotensin system is 
one of the hormonal system which is particularly important to arterial pressure homeostasis 
(Hall et al. 1990). The renin-angiotensin system is a nonadapting hormonal mechanism that 
chronically alters the sensitivity of pressure natriuresis. As arterial pressure or sodium intake 
increases, the renin-angiotensin system is suppressed, which enhances the ability of the 
kidneys to excrete salt and water. Conversely, when either arterial pressure or sodium intake 
is reduced, high endogenous levels of Ang II decrease renal excretory function, which 
promotes sodium retention. In the absence of appropriate changes in the renin-angiotensin 
system, there is an abnormal shift in the pressure natriuresis relationship, resulting in 
sustained alterations in arterial pressure. 
Angiotensin II (Ang II) plays an important role in the regulation. Ang II is produced 
in an enzymatic cascade which starts when the acid protease, renin, cleaves 4 amino acids 
from the terminal end of angiotensinogen, a 14-amino acid plasma globulin produced mainly 
in the liver. This step forms angiotensin I (Ang I), which has little biological activity. 
Angiotensin-converting enzyme (ACE), located on the plasma membrane of endothelial cells, 
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cleaves two amino acids from Ang I and produces Ang II. The major source of renin is the 
juxtaglomerular cells of the renal afferent arteriole, but a variety of tissues produce small 
quantities of renin that can have large local significance. Small quantities of renin may be 
significant if the local action involves a tissue (e.g., kidney, rostral ventrolateral medulla) and 
has the capacity to influence systemic function. The actions of angiotensin are initiated by its 
interaction with the membrane receptors AT1 and AT2. The most apparent actions of Ang II 
are due to activation of the AT1 receptor (Oliverio et al. 1997; Zhuo et al. 2011).  
III.3. Hypertension 
Hypertension is the most important of cardiovascular risk factors worldwide. 
According to the World Health Organization 2012 (WHO 2012) data, hypertension accounted 
for approximately 9.4 million deaths a year, contributing to 45% of deaths due to heart 
disease and 51% of deaths due to stroke. The prevalence of hypertensive people under 25 
years of age is low (5.5% in young men and 1.2% in young women) but steadily increases to 
~40 % in 65 year olds and 90% at 85 years of age. It is estimated that by 2030, more than 23 
million people will die annually from cardiovascular diseases (CVDs).  
According the Mona Lisa epidemiological study established between 2005 and 2007 
in France (Wagner et al. 2011), the age-adjusted prevalence of hypertension was 47% in men 
and 35% in women aged 35–74 years. These values were similar to the rates reached 44.8% 
and 30.6% in Italy, and 44.8% and 32.0% in Sweden. They were much lower than those 
reported in Germany (55.3%) or Finland (48.7%) but higher than that of North America 
(27.6%) (Wolf-Maier et al. 2004). Hypertension is one of the most prevalent modifiable risk 
factors for coronary heart disease, stroke, congestive heart failure and renal insufficiency, and 
clinical trials have demonstrated the efficacy of lowering blood pressure (BP) to decrease 
cardiovascular morbidity and mortality. The importance of oxidative stress, vascular 
inflammation and endothelial dysfunction has to be highlighted in the development of CVDs. 
The knowledge of the process has provided new perspectives to elaborate novel 
pharmaceutical or dietary strategies to control the development of vascular diseases.  
The Sixth Report of the Joint National Committee on Prevention (1997), Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC VI) defined and classified 
hypertension in adults, as shown in Table 5.  
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Table 5: Definition and classification of blood pressure levels according to the 
JNC VI 
Category Systolic, mm Hg 
 
Diastolic, mm Hg 
Optimal < 120 and < 80 
Normal < 130 and < 85 
High normal 130-139 or 85-89 
Hypertension 
   
Stage 1 (mild) 140-159 or 90-99 
Subgroup: borderline 140-149 or 90-94 
Stage 2 (moderate) 160-179 or 100-109 
Stage 3 (severe) ≥ 180 or ≥ 110 
Isolated systolic hypertension ≥ 140 and < 90 
Subgroup: borderline 140-149 and < 90 
 
The diagnosis of hypertension is made when the average of 2 or more DBP 
measurements on at least 2 subsequent visits is ≥ 90 mm Hg or when the average of multiple 
SBP readings on 2 or more subsequent visits is consistently ≥ 140 mm Hg. Isolated systolic 
hypertension is defined as SBP ≥ 140mm Hg and DBP < 90 mm Hg. Individuals with high 
normal BP tend to maintain pressures that are above average for the general population and 
are at greater risk for development of definite hypertension and cardiovascular events than 
the general population. Hypertension prevalence changes according to different factors: 
• Race: according to WHO, the prevalence of raised blood pressure was higher in the 
African region where it was 46% for both sexes combined and lower in the WHO region of 
the Americas, with 35% for both sexes. 
• Age: in industrialized countries, SBP rises throughout life whereas DBP rises until 
age 55 to 60 years and thus the greater increase in prevalence of hypertension among the 
elderly is mainly due to systolic hypertension. 
• Geographical patterns: hypertension is more prevalent in industrialized countries 
than rural ones. 
• Gender: men had a slightly higher prevalence than women. In all WHO regions, 
men have slightly higher prevalence of raised blood pressure than women, but this difference 
was only statistically significant in the region of the Americas and the European region. 
• Socio-economic status: the prevalence of raised blood pressure was consistently 
high, with low-, lower-middle- and upper-middle-income countries, all having rates of around 
40% for both sexes. The prevalence in high-income countries was lower, at 35% for both 
sexes (WHO). 
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Two different type of hypertension exists: the essential or primary hypertension and 
the secondary hypertension. Essential hypertension is defined as high BP in which secondary 
causes such as renovascular disease, renal failure, pheochromocytoma, aldosteronism, or 
other causes of secondary hypertension or mendelian forms (monogenic) are not present. 
Essential hypertension accounts for 85% of all cases of hypertension. Essential hypertension 
is a heterogeneous disorder, with different patients having different causal factors leading to 
high BP.  
The evolution of gene sequencing techniques permit to provide information on genetic 
variations or genes that are overexpressed or underexpressed as well as the intermediary 
phenotypes that they regulate to cause high BP (Luft 1998). The elevation of blood pressure 
is multifactorial in origin, and probably represents a complex interaction of multiple genetic 
traits with lifestyle factors including obesity, insulin resistance, high alcohol intake, high salt 
intake (in salt-sensitive patients), aging, sedentary lifestyle, stress, low potassium intake and 
low calcium intake (Dyer et al. 1989; Sever et al. 1989). Furthermore, many of these factors 
are additive, such as obesity and alcohol intake. 
The Seventh Report of the Joint National Commission on the Evaluation and 
Treatment of High Blood Pressure recommends considering secondary causes of 
hypertension if blood pressure cannot be controlled (<140/90 mm Hg) by a combination of 
three drugs (Chobanian et al. 2003). Secondary hypertension has been encountered with 
increasing frequency. The common causes of secondary hypertension include renal 
parenchymal disease, renal artery stenosis, primary aldosteronism, phaeochromocytoma, and 
Cushing’s syndrome. 
III.4. Mechanisms of hypertension 
Many pathophysiologic factors have been implicated in the genesis of essential 
hypertension: increased sympathetic nervous system activity, perhaps related to heightened 
exposure or response to psychosocial stress; overproduction of sodium-retaining hormones 
and vasoconstrictors; long-term high sodium intake; inadequate dietary intake of potassium 
and calcium; increased or inappropriate renin secretion with resultant increased production of 
Ang II and aldosterone; deficiencies of vasodilators, such as prostacyclin, nitric oxide and the 
natriuretic peptides; diabetes mellitus; insulin resistance; obesity; increased activity of 
vascular growth factors; alterations in adrenergic receptors that influence heart rate, inotropic 
properties of the heart, and vascular tone; and altered cellular ion transport. Figure 20 
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facilitated the visualization of all these mechanisms. Recently, investigations also considered 
endothelial dysfunction, increased oxidative stress, vascular remodeling, and decreased 
compliance as a cause of hypertension and contribute to its pathogenesis.  
 
Figure 20: Pathophysiologic mechanisms of hypertension (Oparil et al. 2003) 
 
In a review by Oparil et al. 2003, the authors provide a clear understanding of the 
pathogenesis of hypertension and underlined important factors contributing to its 
development. 
III.4.1. Genetics 
Oparil et al. 2003, firstly highlighted genetics evidence. Improvement of genetic 
analysis, especially genome-wide linkage analysis have enabled a search for genes that 
contribute to the development of primary hypertension in the population. Preliminary 
investigations evidenced that genetic might contribute to the development of hypertension. 
For instance, the most promising findings concern the genes of the renin–angiotensin–
aldosterone system, such as the M235T variant in the angiotensinogen gene, which has been 
associated with increased circulating angiotensinogen levels and blood pressure in many 
distinct populations (Corvol et al. 1999; Staessen et al. 1999), and a common variant in the 
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angiotensin-converting enzyme (ACE) gene that has been associated in some studies with 
blood pressure variation in men (Fornage et al. 1998; O’Donnell et al. 1998). 
III.4.2. Sympathetic nervous system 
As previously described, sympathetic nervous system plays a key role in the 
regulation of a normal blood pressure. An important activity of the sympathetic nervous 
system activity increases blood pressure and contributes to the development and maintenance 
of hypertension through stimulation of the heart, peripheral vasculature, and kidneys, causing 
increased cardiac output, increased vascular resistance, and fluid retention (Mark 1996). 
Indeed, increased of the sympathetic nervous system activity in hypertension involve 
alterations in baroreflex and chemoreflex pathways at both peripheral and central level. In a 
normotensive individual, baroreflex function helps maintain reductions in arterial pressure by 
activating the sympathetic nervous system which has a direct action by increasing the heart 
rate and cardiac output and an indirect action via the stimulation of adrenalin and 
noradrenalin. In hypertensive patient, arterial baroreceptors are reset to a higher pressure, 
resulting in suppression of sympathetic inhibition after activation of aortic baroreceptor 
nerves (Guo et al. 1984b). 
This baroreflex resetting seems to be mediated, at least partly, by a central action of 
Ang II (Guo et al. 1984a). Ang II also amplifies the response to sympathetic stimulation by a 
peripheral mechanism, that is, presynaptic facilitatory modulation of norepinephrine release. 
Additional small-molecule mediators that suppress baroreceptor activity and contribute to 
exaggerated sympathetic drive in hypertension include reactive oxygen species and 
endothelin (Chapleau et al. 1992; Li et al. 1996). In addition, chronic sympathetic stimulation 
induces vascular remodeling and left ventricular hypertrophy, by direct and indirect actions 
of norepinephrine on its own receptors, as well as on release of various trophic factors, 
including transforming growth factor-β (TGF-β), insulin-like growth factor 1 (IGF-1), and 
fibroblast growth factors (FGF) (Brook et al. 2000). 
III.4.3. Vascular remodeling 
Peripheral vascular resistance is characteristically elevated in hypertension because of 
alterations in structure, mechanical properties, and function of small arteries. Remodeling of 
these vessels contributes to high blood pressure and its associated target organ damage 
(Folkow 1982; Mulvany et al. 1990). Peripheral resistance is determined at the level of the 
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precapillary vessels, including the arterioles (arteries containing a single layer of smooth-
muscle cells) and the small arteries (lumen diameters < 300 µm). The elevated resistance in 
hypertensive patients is related to decrease in number of parallel-connected vessels and 
narrowing of the lumen of resistance vessels. 
III.4.4. Nitric oxide (NO) 
Nitric oxide has an important role in the vascular maintenance because of its potent 
vasodilator function, its inhibitor of platelet adhesion and aggregation role and its capacity to 
suppress migration and proliferation of vascular smooth-muscle cells. NO is produced during 
the metabolism of L-arginine by NO synthase (eNOS) (Govers et al. 2001). Reduced NO has 
often been reported in the presence of impaired endothelial function and may result from 
reduced activity of endothelial NO synthase and the decrease of NO bioavailability. ROS are 
known to quench NO with formation of peroxynitrite (Koppenol et al. 1992), which is a 
cytotoxic oxidant. Through nitration of proteins, peroxinitrite will affect protein function and 
therefore endothelial function. Peroxynitrite is an important mediator of oxidation of LDL 
and can causes degradation of the eNOS cofactor tetrahydrobiopterin (BH4) (Milstien et al. 
1999), leading to “uncoupling of eNOS”. When this phenomenon occurs, formation of the 
active dimer of eNOS with oxygenase activity and production of NO is reduced. The 
reductase function of eNOS is activated and more ROS are formed. As a result, NO synthase 
goes from its oxygenase function producing NO to its reductase function producing ROS, 
with the consequent exaggeration of oxidant excess and deleterious effect on endothelial and 
vascular function.  
III.4.5. Endothelin-1 and other factors 
In addition to being the main determinant of basal vascular smooth muscle tone, NO 
opposes the actions of potent endothelium-derived contracting factors such as Ang II and 
endothelin-1 (ET-1). Nitric oxide inhibits platelet and leukocyte activation and maintains the 
vascular smooth muscle in a nonproliferative state. Beside its production of Ang II, 
prostaglandin endoperoxides, the endothelium is the source of the potent vasoconstrictor 
peptide ET-1 described as the most potent vasoconstrictor known and acts mainly in a 
paracrine manner by binding to two G-protein coupled receptors, ETA and ETB, which are 
located on endothelial cells (ETB), vascular smooth muscle cells, and fibroblasts (ETA and 
ETB). Endothelial ETB receptors can elicit endothelium-dependent relaxation by inducing 
NO release, whereas ETA and ETB receptors located on smooth muscle cells and fibroblasts 
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trigger vasoconstriction, cell proliferation, inflammation, and fibrosis. Importantly, ET 
receptor distribution has been shown to be modified in pathological conditions. ET-1 
increases the vascular actions of others vasoactive peptides such as Ang II, norepinephrine, 
and serotonin; participates actively in leukocyte and platelet activation; and facilitates a 
prothrombotic and proatherogenic phenotype (Govers et al. 2001; Aird 2005). 
Oxidative excess is also linked to a proinflammatory state of the vessel wall. ROS 
upregulate adhesion (VCAM-1 and ICAM-1) and chemotactic molecules (macrophage 
chemoattractant peptide-1 [MCP-1]) (Griendling et al. 2003). Reduced NO bioavailability, 
increased oxidant excess and expression of adhesion molecules contribute not only to the 
initiation but also to the progression of atherosclerotic plaque formation and triggering of 
cardiovascular events. 
III.4.5. Endothelial dysfunction 
The endothelium, the largest organ in the body, is strategically located between the 
wall of blood vessels and the blood stream. It senses mechanical stimuli, such as pressure and 
shear stress, and hormonal stimuli, such as vasoactive substances. In response, it releases 
agents that regulate vasomotor function, trigger inflammatory processes, and affect 
hemostasis. Among the vasodilatory substances produced by the endothelium are nitric oxide 
(NO), prostacyclin, different endothelium-derived hyperpolarizing factors (EDHF), and C-
type natriuretic peptide. Vasoconstrictors include endothelin-1 (ET-1), angiotensin II (Ang 
II), thromboxane A2 (TXA2), and reactive oxygen species (ROS) (Panza et al. 1990). The 
endothelium also contributes to mitogenesis, angiogenesis, vascular permeability, and fluid 
balance. Inflammatory modulators include NO, intercellular adhesion molecule-1 (ICAM-1), 
vascular adhesion molecule-1 (VCAM- 1), E-selectin, and NF-κB. 
A chronic imbalance between endothelium-derived relaxing and contracting factors 
could lead to an abnormal vasodilating response and to high BP. Under physiological 
conditions, the vascular endothelium responds to mechanical and biochemical agonists by 
producing antiplatelet, anticlotting, fibrynolitic, vasodilating, and vasoconstricting factors 
(Deanfield et al. 2005). It basically involves either an increase/decrease in any of the 
endothelial cell-related chemical messenger and/or by alteration in any of the functional 
changes. Some examples of endothelial cell dysfunction include an increased permeation of 
macromolecules, increased or decreased production of vasoactive factors producing abnormal 
vasoconstriction/vasodilation, and increased prothrombotic and/or procoagulant activity (Vita 
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et al. 2002; Aird 2005; Förstermann et al. 2006). However, the most commonly accepted 
endothelial cell dysfunction alteration relates to abnormalities in the regulation of the lumen 
of vessels. 
The best known endothelium-derived relaxing factors are nitric oxide, endothelium-
derived hyperpolarizing factor, and the prostanoid prostaglandin I2 (prostacyclin, PGI2). 
Together with NO, EDHF contributes to relaxation of large conducting arteries, and appears 
to be a major determinant of vascular resistance in small arteries (Govers et al. 2001). Several 
studies have provided evidence that eNOS is important in the regulation of vascular 
functions. Oxidative stress in the vascular wall and vascular hypertrophy might contribute to 
decrease NO bioavailability and, thus, blunted endothelium-mediated vasodilation. When the 
homeostasis between endothelium-derived relaxing and contracting factors is disrupted, it 
predisposes the vasculature to vasoconstriction, leukocyte adherence, platelet activation, 
mitogenesis, pro-oxidation, thrombosis, impaired coagulation, vascular inflammation, and 
atherosclerosis. Endothelial dysfunction has been described in many cardiovascular and 
metabolic disorders such as hypertension, coronary heart disease, dyslipidemia, and types 1 
and 2 diabetes. Endothelial dysfunction appears to precede the clinical manifestations of 
many of these cardiovascular disorders (Govers et al. 2001; Endemann et al. 2004). 
III.4.6. Dietary sodium and potassium 
In today’s society, Western industrialized society diets contain much more salt than 
truly required in order to ensure nutrient adequacy. The majority of daily salt intake (75–
80%) comes from processed foods, while only 12% comes from natural sources, and 
approximately 10% comes from salt added during food preparation or consumption (Mattes 
et al. 1991). The most accurate measure of dietary salt intake is the amount of sodium 
excreted in a 24-h urine collection with over 90% of dietary sodium intake is excreted renally 
(Holbrook et al. 1984). 
Dietary sodium, mostly consumed as sodium chloride (NaCl), has been considered the 
main environmental determinant of hypertension pathogenesis (Jones 2004). It is currently 
well established that increased sodium intake is related to hypertension (Jones 2004). 
Kidneys play fundamental role for sodium handling and long-term blood pressure 
homeostasis (Guyton et al. 1972). The major pathophysiological mechanisms underlying the 
positive association between salt and blood pressure include intravascular fluid volume 
expansion and vascular dysfunction, both resulting from increased sodium intake (Meneton et 
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al. 2005; Safar et al. 2009). The salt-induced rise in blood pressure is followed by a 
phenomenon called pressure natriuresis, in which increased renal perfusion pressure leads to 
increased excretion of sodium and fluid. In essential hypertension, renal sodium excretion is 
functionally defective. It has been hypothesized that essential hypertension is mainly a 
genetic disorder, involving several individual genes that regulate renal sodium handling, 
which becomes clinically expressed in the context of an unhealthy dietary environment 
characterized particularly by excessive salt intake (O'Shaughnessy et al. 2004). 
Experimental and clinical studies have revealed that, besides affecting blood pressure, 
high sodium intake exerts multiple detrimental effects independent of blood pressure 
elevation (Frohlich et al. 2004). In addition, strong correlations between sodium intake and 
left ventricular hypertrophy, myocardial fibrosis, arterial stiffness and arteriosclerotic 
thickening of vessel walls, abnormally increased platelet aggregation, loss of renal function, 
urolithiasis, and reduced bone density due to increased renal calcium excretion have been 
observed (Cirillo et al. 1994; Devine et al. 1995; du Cailar et al. 2002).  
According to evidence-based medicine, the strongest evidence is provided by 
controlled randomized clinical trials, such as the DASH-Sodium Trial, the Trials of 
Hypertension Prevention (TOHP) I and II, and the Trial of Nonpharmacologic Interventions 
in the Elderly (TONE). The DASH-Sodium Trial revealed a direct and progressive blood 
pressure response to decreased sodium intake, independent of the diet followed (Sacks et al. 
1995). Subgroup analyses of this trial have shown that reduced sodium intake could lower 
blood pressure in all participants studied, including men, women, blacks, nonblacks, 
hypertensive subjects, and nonhypertensive subjects, although the exact magnitude of this 
benefit may vary slightly (Vollmer et al. 2001; Bray et al. 2004). TOHP I and II confirmed 
the findings of the DASH-Sodium Collaborative Research Group in a large number of 
subjects with prehypertension, (TOHP 1997) while the TONE Trial has shown that even a 
moderate sodium reduction of only 40 mmol (0.9 g)/day was able to decrease by 30% the 
need for extra antihypertensive medications in elderly hypertensive patients (Whelton et al. 
1998). 
In contrast to sodium, which is the major extracellular cation of the human body, 
potassium is the major intracellular cation and plays an important physiological role in 
multiple body functions. There is also an association between dietary sodium and dietary 
potassium in terms of blood pressure regulation (Adrogué et al. 2007). More specifically, 
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increased potassium intake enhances natriuresis, and, conversely, increased sodium intake 
promotes kaliuresis. It has been demonstrated that the blood pressure-lowering effects of 
dietary potassium are more profound in the context of increased sodium intake, and vice 
versa. 
Modern Western diets are sodium rich and potassium poor generate a sodium excess 
and a potassium deficit and promote increased peripheral vascular resistance and 
hypertension development (Adrogué et al. 2007). The deficit in intracellular potassium 
triggers cells, including renal epithelial cells, to preserve sodium in order to maintain their 
volume and osmolarity. Low potassium adversely affects blood pressure through several 
major pathophysiological mechanisms (Adrogué et al. 2007). First, hypokalemia stimulates 
both the sympathetic nervous system and the renin-angiotensin-aldosterone system, and this 
can lead to the acquired renal injury involved. Experimental data in rats fed a potassium-
deficient diet have demonstrated that potassium depletion can induce intracellular acidosis, 
leading to significant alterations in the luminal transport systems of the rat renal cortex, such 
as an enhanced activity of sodium-hydrogen exchanger type 3, which promotes increased 
renal sodium reabsorption (Soleimani et al. 1990). Finally, long-term potassium depletion 
increases the activity of renal sodium pumps, leading again to abnormal sodium retention 
(Adrogué et al. 2007). 
Although data from individual trials have been inconsistent, three meta-analyses of 
these trials have documented a significant inverse relationship between potassium intake and 
blood pressure in both normotensive and hypertensive individuals. (Cappuccio et al. 1991; 
Whelton et al. 1997; Geleijnse et al. 2003). Whelton et al. (1997) showed an average 
reductions of SBP/DBP associated with a net increase in urinary potassium excretion of 50 
mmol/day were 4.4/2.5 mmHg in hypertensive individuals and 1.8/ 1.0 mmHg in 
normotensive individuals. In addition, INTERSALT researchers evidenced a decrease in 
urinary potassium excretion by 50 mmol/day was associated with an increase of SBP and 
DBP by 3.4 and 1.9 mmHg, respectively (Intersalt 1988). The urinary potassium:sodium ratio 
was a more significant inverse determinant of blood pressure than the urinary excretion of 
either electrolyte alone. 
III.5. High blood pressure prevention 
Treatments for all grades of hypertension are classified as either lifestyle or 
pharmacotherapy. The JNC 7 guidelines state that lifestyle modifications should be adopted 
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for the treatment of pre-hypertension, and in conjunction with drug therapy for stage 1 and 
stage 2 hypertension. Lifestyle modifications are generally beneficial in reducing a variety of 
CVD risk factors and promoting good health and should therefore be used in all hypertensive 
patients. In well-motivated patients with stage 1 or 2 hypertension, modifying lifestyle 
effectively lowers BP and may be more important than the initial choice of antihypertensive 
drug. 
Although sustained modifications in diet and lifestyle are sometimes difficult to 
achieve, they may lower BP and obviate the need for drug treatment or reduce the dosages of 
antihypertensive drugs needed to control BP. A reasonable generalized approach for all 
patients includes (1) weight loss for the overweight patient; (2) regular physical activity; (3) 
moderation of alcohol consumption; (4) dietary modification to reduce sodium and fat and 
increase calcium, potassium, magnesium, vitamins, and fiber from food sources; (5) adoption 
of a DASH-type (Dietary Approaches to Stop Hypertension) dietary pattern. Each of the five 
modifiable lifestyle factors has substantial scientific evidence supporting its effectiveness, 
either alone or in combination, in promoting a significant reduction in BP. Bond Brill et al., 
(2011) reviewed a summary of well-established lifestyle strategies in addition to several 
novel interventions that have shown promise in the intervention and treatment of 
hypertension.  
III.5.1. Weight reduction 
Weight loss is closely correlated with reduction in BP and appears to be the most 
effective of all non-pharmacological measures used to treat hypertension. A body mass index 
(BMI) above 25 is a strong risk factor for hypertension (Forman et al. 2009). Numerous trials 
have shown that weight loss is an effective lifestyle intervention for lowering BP in 
overweight and obese individuals (Schotte et al. 1990; Davis et al. 1993; Neter et al. 2003) 
and according to JNC 7, a 10-kg weight loss promotes a 5- to 20-mm-Hg reduction in BP 
(Chobanian et al. 2003). Because sustained weight reduction is so difficult to achieve, more 
emphasis should be placed on prevention of weight gain, particularly in younger individuals 
with high normal BP and in families with a high prevalence of hypertension. 
III.5.2. Increased physical activity 
Considerable study demonstrates that physical activity lowers the risk of developing 
hypertension and is an effective BP-lowering treatment for diagnosed hypertension 
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(Pescatello et al. 2004). Epidemiological studies clearly show an inverse relationship between 
physical activity level and BP (Fagard 2005) with higher physical activity levels reducing 
risk of incident hypertension by approximately 15% (Cornelissen et al. 2005). According to 
the Physical Activity Guidelines Advisory Committee Report (2008) by the Department of 
Health and Human Services (DHHS), frequency, intensity, and mode of exercise yield 
important reductions in both SBP and DBP. Both aerobic exercise and resistance exercise 
reduce BP, but the evidence backing aerobic exercise is more substantial. Additional benefits 
of regular physical activity include weight loss, enhanced sense of well-being, improved 
functional health status, and reduced risk of CVD. Accordingly, regular aerobic physical 
activity is recommended for all hypertensive individuals, including those with target organ 
damage. Patients with advanced or unstable CVD may require a medical evaluation before 
initiation of exercise or a medically supervised exercise program. Isometric exercise such as 
heavy weight lifting can have a pressor effect and should be avoided. 
III.5.3. The DASH-diet 
Named simply from Dietary Approaches to Stop Hypertension, it was funded by the 
National Heart, Lung and Blood Institute (NHLBI) (Sacks et al. 1995). Published data in 
1997 showed the main results of the DASH diet trial (Appel et al. 1997). For the time, it was 
evidenced that dietary intervention alone (holding body weight and sodium intake [3 g/d] 
constant) significantly lowered systolic and diastolic BP by an average of 11.4 and 5.5 mm 
Hg in hypertensive participants and by 3.5 and 2.1 mm Hg in normotensive participants, 
respectively. The magnitude of BP reduction is similar to that achieved by BP-lowering drug 
monotherapy for mild hypertension. The DASH diet is rich in fruits, vegetables, and whole 
grains, with the additional inclusion of legumes, nuts, lean poultry, fish, and low-fat or fat-
free dairy products. The diet allows only a small amount of red meat, sweets, and added 
sugars and is exceptionally high in potassium, calcium, magnesium, and fiber.  
III.5.4. Sodium restriction 
According to a report of the Council on Science and Public Health regarding sodium 
and cardiovascular disease (Dickinson et al. 2007), the rise in BP with age and the prevalence 
of hypertension are directly related to sodium intake. This effect appears to be augmented by 
concomitant low potassium intake. Additional benefits of sodium reduction include reduced 
diuretic-induced hypokalemia and greater ease of BP control with diuretic therapy, protection 
from osteoporosis and fractures by reducing urinary calcium excretion, and favorable effects 
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on left ventricular hypertrophy. The recommended daily amount of salt by the US 
Departments of Agriculture and Health and Human Services is 3.7 g of salt (2300 mg of 
sodium). Oftenly, the consumption largely exceeds this recommendation. For instance, in the 
United States, 10.4 g of salt/d and 7.3 g of salt/d is consumed by man and woman 
respectively. Salt restriction can be achieved by avoiding obviously salty foods, not adding 
salt at the table, and eating more meals cooked directly from natural ingredients.  
III.5.5. Potassium and calcium intake 
Studies have shown that a high dietary intake of the minerals potassium, calcium, and 
magnesium has a BP-lowering effect.  
Maintenance of adequate potassium intake (100 mmol/d), preferably from dietary 
sources, is recommended for hypertensive individuals and those with high normal BP. A diet 
rich in fruits and vegetables is better than pills or other supplements as a source of potassium 
because these foods contain other nutrients, for example, calcium, magnesium, and vitamins, 
which may also have beneficial effects on BP. Moreover, it is clear that potassium 
supplements can be harmful and should be avoided or used only with extreme caution in 
patients with renal insufficiency, diabetics, and those receiving potassium-sparing diuretics, 
ACE inhibitors, or angiotensin II receptor blockers. (Kassirer et al. 1985). 
Inadequate calcium intake is particularly common in populations at high risk of 
developing hypertension. Calcium deficiency should be avoided. Maintaining the 
recommended daily allowance for calcium, preferably from food sources, is beneficial for a 
variety of reasons, such as preventing osteoporosis. The DASH trial showed that consuming 
calcium-rich low-fat or fat-free dairy foods in addition to a diet high in fruits and vegetables 
lowered SBP and DBP further than a diet high in fruits and vegetables alone (Appel et al. 
1997).  
III.5.6. Moderation of alcohol consumption 
Alcohol consumption elevates BP both acutely and chronically. In cross-sectional and 
prospective studies involving all kinds of populations, the relationship between alcohol 
consumption, BP levels, and the prevalence of hypertension has been remarkably consistent 
(Briasoulis et al. 2012). The relationship is linear, but some studies show a threshold effect of 
2 to 3 drinks a day. The effect increases with age, is independent of the type of alcoholic 
beverage, and is additive but independent of the effects of obesity, oral contraceptives, and 
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high salt intake (Arkwright et al. 1982). However, moderate alcohol consumption (3 standard 
drinks a day) reduces overall CVD risk in the general population (Puddey et al. 1997). Those 
having more than 2 standard alcohol drinks per day show an increase in both mortality rates 
and hypertension (Stranges et al. 2004). Excessive alcohol intake also appears to cause 
resistance to antihypertensive therapy. For unrelated health reasons, alcohol consumption is 
not recommended for nondrinkers and for drinkers, intake should be limited to 1 drink of 
alcohol per day (i.e., 12 oz beer, 5 oz of wine, 1.5 oz of spirit) in most men and half that 
amount in women. Actually, a standard drink is equivalent to 10 g of alcohol per drink. 
III.5.7. Novel lifestyle interventions 
Among the novel interventions, dark chocolate (Taubert et al. 2007; Desch et al. 
2010), soy (Yang et al. 2005; Welty et al. 2007), relaxation therapy (Wang et al. 2013) were 
listed as having the ability to reduce BP. Although promising, the research on these novel 
therapies is preliminary and need more published trials before definitive conclusions can be 
drawn. 
III.6. Hypertension treatments 
Aside from preventing high blood pressure by changing lifestyle, reducing BP by 
pharmacological means clearly reduces CVD morbidity and mortality rates. Benefits include 
protection from stroke, coronary events, heart failure, progression of renal disease, 
progression to more severe hypertension, and, most importantly, mortality from all causes. 
Clinicians can choose from several classes of antihypertensive drugs which have proven their 
efficacy to lower BP: diuretics, anti-adrenergics, calcium channel blockers, angiotensin-
converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Each of them 
possesses different mechanisms of action and different targets.  
III.6.1 Diuretics  
They are the oldest and least expensive class of drugs used to treat hypertension. 
Diuretics act by draining sodium and water from the body which decreases blood volume. 
Diuretics are used in patient with mild hypertension and take several weeks to produce 
vasodilating effects. In moderate to severe hypertension, the diuretics are combined with 
other antihypertensive drugs. However, one drawback of diuretics is the depletion of 
potassium and in order to counteract potassium depletion, clinicians prescribed another type 
of diuretic called potassium-sparing diuretics. The latter can also directly or indirectly block 
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aldosterone. As a result, potassium-sparing diuretics are sometimes also known as 
aldosterone-receptor blockers. Side effects of these drugs include frequent urination, 
lightheadedness, fatigue, diarrhea or constipation, and muscle cramps. Diuretics are 
contraindicated in patients with gout, a painful form of arthritis caused by the buildup of uric 
acid in the body. 
III.6.2. Anti-adrenergics 
Their anti-hypertensive action is lead to their ability to reduce the activity of 
sympatheric nervous system. Anti-adrenergics lower blood pressure by limiting the action of 
the hormones epinephrine and norepinephrine causing the relaxation of blood vessels. This 
class includes a variety of different agents acting differently: (1) peripheral adrenergic-
receptor blockers, including β-adrenergics and α-adrenergics; (2) central acting agents; and 
(3) peripheral nerve acting agents. 
Peripheral adrenergic-receptor blockers work by preventing the action of 
neurotransmitters and lead to a reduce activity of nerves to heart and blood vessels. β-
blockers do not only block β-receptors which inhibited the action of epinephrine on heart 
leading to a decrease of cardiac output but also block the release of renin in kidneys. The 
cardioselective of β-blockers target primilary the β1 receptors whereas the non selective form 
target the β1 and β2 receptors in lungs, blood vessels and other tissues. Common side effects 
are fatigue, depression, erectile dysfunction, shortness of breath, insomnia, and reduced 
tolerance for exercise. α-blockers have similar action to β-blockers but work on α-receptors in 
the heart and vascular smooth cells, which normally interact with norepinephrine causing 
vessel constriction. Its action consists of a vasodilation and a decrease of peripheral 
resistance. In addition, α-adrenergic blockers have several advantages. It can improve insulin 
sensitivity in patients with glucose intolerance and hyperglycemia, lowers LDL and increases 
HDL. It is oftently prescribed to patient with benign prostatic hyperplasia, a noncancerous 
enlargement of the prostate gland, because of its ability to relax smooth muscles surrounding 
the prostate, relieving the constriction of the urethra and easing urine flow. Common side 
effects are orthostatic hypotension, heart palpitations, dizziness, nasal congestion, headaches, 
dry mouth and erectile dysfunction. 
Central acting agents: these agents block the neurotransmitters implicate in the 
activation of the sympathetic nervous system to increase blood pressure. They are generally 
used in combination with other blood pressure medicines. Common side effects include 
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abnormally low blood pressure when standing up, dry mouth, depression, erectile 
dysfunction, and sedation. 
Peripheral nerve acting agents: these anti-adrenergics deplete the autonomic nerves 
of norepinephrine. They are recently less used alone because of their frequent side effects but 
they are usually prescribed along with other antihypertensive drugs.  
III.6.3. Calcium channel blockers 
They interfere with the influx of calcium in cardiac and vascular smooth muscles 
resulting in slow depolarization in the atrioventricular and sinoatrial nodes of the heart, 
reduction of cardiac muscle contractility, relaxation of smooth muscles and vasodilation. 
Because, calcium-channel blockers have also the ability to slow nerve impulses in the heart, 
they are often prescribed for arrhythmias. Unkike diuretics, common side effects do not cause 
adverse metabolic effects but mild adverse effects like dizziness, fatigue etc. Calcuim channel 
blockers do not compromise haemodynamics, no renal and male sexual function impairment. 
They can be given to asthma and angina patients and because of its no adverse fetal effects, 
they can be given during pregnancy. In overall, calcuim channel blockers have minimal effect 
on quality of life.  
III.6.4. Angiotensin-converting enzyme (ACE) inhibitors 
These agents prevent the kidneys from retaining sodium and water by inhibiting the 
formation of Ang II. Angiotensin-converting enzyme which converts inactive angiotensin I to 
the active Ang II is desactivated. ACE inhibitors also decrease release of aldosterone and 
antidiuretic hormone. They reduce blood pressure in most patients and produce fewer side 
effects than many other antihypertensive drugs. The most common side effects of these 
medications are a reduced sense of taste, dry cough and potassium retention.  
III.6.5. Angiotensin receptor blockers (ARBs) 
ARBs block angiotensin receptor type 1 and 2 (AT1 and AT2) located the surface of 
the target cells. For instance, in smooth muscle cells, transducer mechanisms of AT1 
stimulate the phospholipase c-IP3/DAG-intracellular leading to a Ca
+
 release mechanism and 
thus a vascular and visceral smooth muscle contraction. By blocking these receptors, Ang II 
is prevented from constricting the blood. Because ARBs are highly effective and well 
tolerated by most of the people, ARBs have become quite popular. 
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Because of the substantial anti-hypertensive drugs and the numerous different side 
effects, the choice of the right medication for the right patient becomes very important. Drugs 
can be prescribed alone or in combination with other drugs. The patient’s clinical state has to 
be examined meticulously. The key for a successful antihypertensive regime is to include 
highly effective medications that are well tolerated and affordable and keep a well-being 
lifestyle. 
III.7. Hypertension and (poly)phenols 
Hypertension causes modifications of the vascular walls that lead to hypertensive 
cardiomyopathy and heart failure. Changes in the mechanical properties of arteries affect 
vascular resistance by altering the pressure–lumen diameter relationship of small arteries. 
Part of the cardioprotective actions of (poly)phenols is due to their ability to lower blood 
pressure. Using pure compounds, an antihypertensive effect of resveratrol was reported in 
partially nephrectomised rats (Liu et al. 2005). In another study using double transgenic rats 
harbouring human renin and angiotensinogen genes, it was observed that resveratrol reduced 
blood pressure, ameliorated cardiac hypertrophy and prevented Ang II-induced mortality, 
probably by increasing mitochondrial biogenesis and SIRT1 activity (Biala et al. 2010). 
Resveratrol probably suppressed Ang II type 1 receptor expression through SIRT1 activation, 
suggesting that the inhibition of the renin–angiotensin system may contributed, at least in 
part, to the resveratrol-induced cardiprotective effects (Miyazaki et al. 2008). Other studies 
reported that resveratrol did not affected established hypertension in SHR (Rush et al. 2007), 
although it attenuated the compliance of arteries from SHR without changes in wall stiffness 
by reducing eutrophic remodelling (Behbahani et al. 2010).  
Chronic treatment with quercetin (10 mg/kg) have shown to reduce systolic blood 
pressure and significantly reduced left ventricular and renal hypertrophy in SHR (Romero et 
al. 2010), in hypertension induced by the inhibition of NOS rats (Perez-Vizcaino et al. 2009), 
and in deoxycorticosterone acetate-salt hypertensive rats (Galisteo et al. 2004). It appeared 
that quercetin was effective in all animal models of hypertension studied, and acted 
independently of the status of renin–angiotensin system, oxidative stress, NO, etc (Perez-
Vizcaino et al. 2009). 
Short-term oral administration of (poly)phenols from red wine decreased blood 
pressure in normotensive rats. This haemodynamic effect was associated with an enhanced 
endothelium-dependent relaxation and an induction of gene expression within the arterial 
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wall, which together maintain unchanged agonist-induced contractility (Diebolt et al. 2001). 
It has been evidenced that (poly)phenols from red wine reduced blood pressure elevations 
caused by chronic inhibition of NOS, attenuated end-organ damage such as myocardial 
fibrosis and aortic thickening, and decreased protein synthesis in the heart and aorta 
(Bernátová et al. 2002). (Poly)phenols also prevented endothelium dysfunction by increasing 
eNOS activity, moderately enhancing eNOS expression and reducing oxidative stress in the 
left ventricle and aorta. Sarr et al. (2006) showed that endothelial dysfunction associated with 
excessive NADPH oxidase-dependent vascular formation of ROS in angiotensin II-induced 
hypertension was prevented by (poly)phenols. Thus, (poly)phenols from red wine could 
reduced hypertension by modulating the NO and ROS balance in the cardiovascular system. 
When considering the effects of grape products on blood pressure, the ethanol content 
of red wine should be taken into account. It is well known that there is a linear relationship 
between alcohol intake and blood pressure (Briasoulis et al. 2012). Although several 
epidemiological studies have suggested that beer and spirits consumption may be associated 
with higher blood pressure, particularly SBP, than wine consumption (Klatsky et al. 1986; 
Fuchs et al. 2001), an in vivo trial (Zilkens et al. 2005) showed that daily consumption of 40 g 
alcohol as either red wine or beer for 4 weeks resulted in similar increases in SBP and heart 
rate. Therefore, studies on the effects of grape products on blood pressure should be focused 
more on grape products lacking ethanol.  
Substantial studies on animals dealing with the effects of grape (poly)phenols on 
blood pressure showed an hypotensive effect of these compounds. Grape skin extracts, red 
wine (poly)phenols and red wine extracts significantly reduced blood pressure (in several 
cases, both SBP and DBP) in normotensive and hypertensive rats (Diebolt et al. 2001; 
Bernátová et al. 2002; Soares de Moura et al. 2002; Al-Awwadi et al. 2004; Ranaivo et al. 
2004). In the case of human subjects, a study showed that the intake of a grape product rich in 
both dietary fibre and (poly)phenols by normotensive subjects for 16 weeks led to a non-
significant decrease in SBP and DBP (Jiménez et al. 2008) whereas a significant reduction in 
SBP and DBP was observed in hypertensive or coronary artery disease subjects after the 
intake of grape juice (Park et al. 2004).  
It has also been suggested that grape (poly)phenols could promoted the release by the 
vascular endothelium of NO, a compound with vasorelaxing and anti-aggregating effects and 
that in the long term induces the expression of protective genes for the cardiovascular system 
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(Chou et al. 2001; Diebolt et al. 2001). Wallerath et al. (2003) has proposed that wine may 
regulated the endothelial NO synthase gene in endothelial cells, through transcriptional and 
post-transcriptional factors. These hypotheses have only been partially proven. In an ex-vivo 
experiment performed by Andriambeloson et al. (1997), using aortic rings from rats 
incubated with red grape (poly)phenols, two-fold increase of Fe
2+
-diethyldithiocarbamate 
electron paramagnetic resonance was observed, indicating the generation of NO. Similarly, 
after supplementing rats with red wine, an anti-thrombotic effect was observed indicating the 
involvement of NO in this process (Wollny et al. 1999). 
In human subjects, although an acute intake of (poly)phenols did not significantly 
increase NO production (Matsuo et al. 2001), the supplementation to healthy volunteers with 
grape juice for 14 days led to a significant increase in platelet-derived NO production 
(Freedman et al. 2001). Another parameter that has been studied to investigate the effect of 
grape (poly)phenols on endothelial function has been the determination of effects on 
vasodilatation and, particularly, on flow-mediated dilatation of the brachial artery, which is 
considered to be an early marker of alterations in endothelial function. In animal studies, red 
wine (poly)phenols induced endothelium-dependent relaxation in rat aorta (Andriambeloson 
et al. 1997), red wine and dealcoholised red wine induced vasodilatation in isolated vessels 
from rats (Boban et al. 2006) and grape skin extracts had a vasodilator effect on the 
mesenteric cardiovascular bed of rats (Soares de Moura et al. 2002). In human subjects, it has 
been observed that an acute intake of red grape (poly)phenol extract, red wine or 
dealcoholised red wine cause an increase in flow-mediated dilatation, with a peak at 60 min 
(Hashimoto et al. 2001; Lekakis et al. 2005). Nevertheless, in another study by Boban et al. 
(2006), red wine, but not (poly)phenols from red wine, produced an enhancement of 
endothelial response, despite a similar catechin concentration in both products. Intake of 
grape juice or grape seed extract for 2–3 weeks also caused a significant increase in flow-
mediated dilatation, compared with the control group (Stein et al. 1999; Clifton 2004). 
Interestingly, in the Clifton et al. study the addition of quercetin to the grape seed extract 
abolished this effect indicating probably a pro-oxidant effect due to an excessive amount of 
antioxidants. Bernátová et al. (2002) showed that grape (poly)phenols may also have a 
reducing effect in myocardiac fibrosis, a process occurring in cases of hypertension which is 
produced by an excessive accumulation of collagen and is associated with an increase in 
alterations of cardiac and vascular functions. 
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I. Grapes and grape pomaces characterisation 
I.1. Experimental materials 
I.1.1. Chemicals 
Deionized water was purified with a Milli-Q water system (Millipore, Bedford, MA). 
HPLC grade acetonitrile (HPLC ≥ 99%), ethyl acetate (HPLC ≥ 99%), chloroform (HPLC ≥ 
99%), methanol (HPLC ≥ 99%), ethanol and acetone purchased from Scharlau (Sentmenat, 
Barcelona, Spain). The following chemicals were obtained from Sigma Aldrich (Saint Louis, 
USA): (+)-catechin (≥ 98%), ()-epicatechin (≥ 98%), B1 [()-epicatechin-(4-8)-(+)-
catechin] (≥ 98%), procyanidin dimer B2 [()-epicatechin-(4-8)-()-epicatechin] (≥ 98%), 
cyanidin-3-O-glucoside chloride (≥ 98%), delphinidin-3-O-glucoside chloride (≥ 98%), 
malvidin-3-O-glucoside chloride (≥ 98%), peonidin-3-O-glucoside chloride (≥ 98%), gallic 
acid (≥ 98%), 2,2-Diphenyl-1-picrylhydrazyl (DPPH), 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid (Trolox) (≥ 97%), 2,2′-azinobis(3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) (≥ 98%), potassium 
persulfate (≥ 99%), fluorescein (≥ 98%), 2,2′-azobis (2-methylpropionamidine) 
dihydrochloride (AAPH) (≥ 97%), sodium dihydrogen phosphate dehydrate (≥ 98%), 
disodium hydrogen phosphate dodecahydrate, 2,4,6-tri(2-pyridyl)-s-triazine (TPTZ) (≥ 98%), 
iron (III) chloride hexa-hydrate (≥ 98%), iron (II) sulfate hepta-hydrate (≥ 98%), Folin 
Ciocalteu’s phenol (2N), sodium bisulfate (97 %), sodium carbonate (99 %), phloroglucinol 
(≥ 98%), L(+)-tartaric acid (≥ 99%), L-ascorbic acid (≥ 99%), hydrochloric acid (37%), 
sodium hydroxide (≥ 98%), acetic acid (≥ 99%) and formic acid (≥ 95%). The Laboratory of 
Organic Chemistry and Organometallic (Université Bordeaux 1) synthesized procyanidins 
dimers B3 [(+)-catechin-(4-8)-(+)-catechin], and B4 [(+)-catechin-(4-8)-()-epicatechin] 
and a trimer (T) [(+)-catechin-(4-8)-(+)-catechin-(4-8)-()-epicatechin] (Tarascou et al. 
2006). 
I.1.2. Plant materials 
In the first instance, this study was conducted on crude materials, with 2009 and 2010 
grapes at maturity and their respective grape pomaces from V.vinifera L. cv. Grenache (from 
two different locations [GRE1 and GRE2]), Syrah (from two different locations [SYR1 and 
SYR2]), Carignan (CAR), Mourvèdre (MOU), Counoise (COU) and Alicante (ALI), 
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provided by the Château de Beaucastel located in the Vallée du Rhône, appellation of 
Châteauneuf-du-Pape. GRE2, COU and ALI pomaces were analysed only for the vintage 
2010. Details are provided below (Table 6): 
 
Table 6: Grape varieties provided by the Chateau de Beaucastel and 
abbreviations used 
Varieties Name used according to location Abbreviation used 
Grenache Grenache long du Coudoulet GRE1 
Grenache Grenache face aux Pins GRE2 
Syrah Syrah Plantier SYR1 
Syrah Syrah Haut de Julien SYR2 
Carignan Carignan Pont des Voleurs CAR 
Mourvèdre Mourvèdre Courrieux à beaucastel MOU 
Counoise Counoise Quicaro à Beaucastel COU 
Alicante Alicante au Grand Prébois ALI 
 
All the analysis performed on seeds and skins for the 2009 and 2010 vintage after 
skins and seeds separation was illustrated below. 
 
 
Another type of extracts was obtained after extraction process in collaboration with 
3INature Company and will be used for in vivo experiments. Grape pomace samples obtained 
after the vinification process (vintage 2010) from V.vinifera L. cv. Grenache (from two 
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different locations [GRE1 and GRE2]), Syrah (from two different locations [SYR1 and 
SYR2]), Carignan (CAR), Mourvèdre (MOU), Counoise (COU) and Alicante (ALI) were 
collected by the Château de Beaucastel. Seeds were separated from skins and both were 
frozen (− 20°C) prior being sent for extraction by 3iNature company. Pomace samples were 
extracted using water and hydro-alcoholic 70 % solution, thus, giving two types of samples, 
aqueous samples (EAQ) and hydro-alcoholic 70% (EA70). Samples were shipped to the 
university Bordeaux Segalen, as summarize in the Table 7. All the analysis carried out on 
seeds and skins for the 2010 vintage after skins and seeds separation was illustrated below. 
 
 
 
Table 7: Skin and seed extracts obtained from different varieties of grapes by 
EAQ and EA70 extraction 
Samples 
Skins Seeds 
EAQ EA70 EAQ EA70 
Grenache long du Coudoulet (GRE1) 
  
Χ Χ 
Grenache face aux Pins (GRE2) Χ Χ 
  
Syrah plantier (SYR1) Χ Χ Χ Χ 
Syrah Haut de Julien (SYR2) Χ Χ 
  
Carignan Joseph (CAR) Χ Χ Χ Χ 
Mourvèdre (MOU) Χ Χ 
  
Counoise (COU) 
    
Alicante (ALI) Χ Χ 
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I.1.3. Samples preparation 
Seeds and skins were carefully removed by hand from grapes and separated from 
pomaces, lyophilized and stored at 20°C prior to analysis. The dry seeds and skins were 
powdered in a ball grinder. Extracts of the powders were prepared in duplicate according to a 
previous study (Chira et al. 2009; Lorrain et al. 2011). A 6 g portion of powder was extracted 
using 55 mL of acetone/water (70:30, v/v) for 4 h followed by 55 mL of methanol/water 
(60:40, v/v) for 2.5 h. The centrifugal supernatants were combined and evaporated in vacuo 
at 30°C to remove organic solvents; the residue was dissolved in water and lyophilized to 
obtain a crude extract.  
I.1.4. Grape and pomace tannins extraction 
A small portion of the powders (eq. to 1 g of dried skin or seed powder from grape 
and pomace) was retained for further polyphenol analyses while the remaining (eq. to 3 g of 
dried skin powder and 900 mg of dried seed powder) was solubilized in 250 mL of 
water/ethanol (95:5, v/v) and partitioned three times with chloroform (250 mL) to remove 
lipophilic material. The aqueous phase was then extracted three times with ethyl acetate (250 
mL) to obtain two distinctive fractions: a low molecular weight procyanidin fraction 
(monomeric/oligomeric tannins) in the organic phase and a high weight procyanidin fraction 
(polymeric tannins) in the aqueous phase. These two fractions were concentrated and 
lyophilized to produce dry extracts (Chira et al. 2009; Lorrain et al. 2011). 
I.1.5. Grape and pomace anthocyanins extraction 
Anthocyanins extraction was adapted from the method of Sriram et al. (1999). A 1 g 
portion of dried skin powder was extracted four times with 40 mL of acidified methanol 
(0.1% HCl 12N) successively for 4 h, 12 h, 4 h and 12 h. The centrifugal supernatants were 
combined and evaporated in vacuo at 30°C to remove methanol; the residue was dissolved in 
water and lyophilized to obtain an anthocyanin-rich powder.  
I.2. Total phenolics, tannins and anthocyanins 
Total polyphenol, tannin and anthocyanin contents of grapes and pomace skin and seed 
extracts were determined. Crude extracts were solubilized in water/ethanol (90:10, v/v; pH 
3.5 adjusted with tartaric acid) at specific concentrations: for total phenol contents (TPC) and 
total anthocyanins determination, concentrations were of 2 g/L for the seed extracts and 6 g/L 
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for the skin extracts; for total tannin determination, they were of 0.25 g/L and 1 g/L for seed 
and skin extracts respectively. 
TPC was determined by the Folin Ciocalteu assay (Singleton et al. 1965) and the data 
expressed as mg of gallic acid equivalents (GAE) per g dry weight. The total tannin contents 
was measured by acidic hydrolysis of proanthocyanidins resulting in carbocation formation 
with partial conversion into red cyanidin using the method of Ribereau-Gayon and 
Stonestreet (1966). The procedure required the preparation of two samples, each containing 4 
mL of sample, 2 mL of water and 6 mL of HCl (12 N). One tube was heated at 100°C in a 
water bath for 30 min and 1 mL of pure ethanol was added. The other sample was not heated 
but received 1 mL of ethanol. The difference in absorbance was measured at 550 nm on a 10 
mm optical path. The concentration was obtained in g/L by the calculation: 19.33/50 x A. 
Anthocyanin content was determined by the SO2 bleaching procedure (Ribéreau Gayon et al. 
1965). 
I.3. HPLC analysis of monomeric and oligomeric tannins 
Monomeric/oligomeric tannin extracts were solubilized in a methanol/water solution 
(50:50, v/v) at concentrations of 1 g/L for seed extracts and 6 g/L for skin extracts. Analyses 
were carried out according to Silva et al. (2011). The equipment used for HPLC analysis 
consisted of a Thermo-Finnigan Surveyor HPLC system (Thermo-Fisher, San Jose, CA, 
USA) comprising a UV–Vis detector (Surveyor PDA Plus), a Thermo-Finnigan autosampler 
and a Thermo-Finnigan quaternary pump system (Surveyor LC pump Plus) controlled by an 
Xcalibur data treatment system. It is also coupled with a Thermo-Finnigan fluorescence 
detector (FL plus Detector) operated with ChromQuest 4.2 software. Separations were 
performed on a reversed-phase Lichrospher C18 (250 mm x 4 mm, 5 µm) column. A binary 
gradient system was employed using 1% (v/v) aqueous formic acid (solvent A) and 1% acid 
formic/acetonitrile (v/v) (solvent B) at a flow rate of 1 mL/min. Initial B were set at 8%. The 
mobile phase gradient was as following: 18% B at 21 min and 100% at 22 min. The column 
was then washed with 100% B for 3 min and re-equilibrated with 8% B for 5 min before the 
next injection. Eluting peaks were recorded at excitation and emission wavelengths of 280 
nm and 320 nm respectively. Identification of mean peaks was carried out by co-
chromatography with authentic standards [(+)-catechin, ()-epicatechin, procyanidin dimers 
B1, B2, B3, B4, and trimer C1] which were also used as reference compounds for quantitative 
analysis. The results were presented as amounts present per mg of dried skins or seeds.  
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I.4. HPLC analysis of proanthocyanidins 
Aqueous and hydro-alcoholic 70% grape pomace extracts were solubilized in 
methanol/water (50:50, v/v) containing 1% formic acid. Analysis was carried out on a 
Surveyor HPLC system equipped with sampler cooler maintained at 4ºC, a PDA detector 
scanning from 200 to 600 nm and a fluorescence detector (FP-920m Jasco (U.K.) Ltd.) linked 
to a Finnigan LCQ Duo mass spectrometer set with a split volume at 0.2 mL/min and ESI 
operating in full-scan negative ionization mode scanning from m/z 200 to 1000. Fluorescence 
detection was set respectively at an excitation and emission wavelengths of 230 nm and 320 
nm. 
Separation was performed on a 250 × 4.6 mm i.d. 5 µm Develosil Diol 100Å column 
(Phenomenex, Cheshire, UK) maintained at 35 ºC in a column oven. The mobile phase 
pumped at 1 mL/min and consisted of acidic acetonitrile ((A), CH3CN:HOAc, 98:2; v/v) and 
acidic aqueous methanol ((B), CH3OH:H2O:HOAc, 95:3:2; v/v/v). The gradient was set at 
7% B for 3 min then increased to 37.6% over 57 min. The column was then washed with 
100% B for 7 min prior to returning to 7% over 6 min. The column was re-equilibrating with 
7% B during 10 min. The injection volume was 10 µL for seed extracts and 20 µL for skin 
extracts. Two different gain were used in order to quantify monomers and dimers on the one 
side and the procyanidins with Dpm higher than 2 on the other side. 
Peak detection and quantification were mainly carried out by fluorescence because of 
its more selectivity and stronger signal than UV absorption detection for procyanidins. 
Identification was confirmed by mass spectrometry in full-scan negative ionization, data 
dependent MS. Procyanidins were quantified as ()-epicatechin equivalents and expressed in 
mg per dry weight of seeds or skins ± SD (n=3). 
I.5. Determination of mean degree of polymerization, %G and 
%P 
The proanthocyanidin mean degree of polymerization (mDP), percentage of 
galloylation (%G) and percentage of prodelphinidins (%P) was determined for seeds and 
skins extracts both in monomeric/oligomeric and polymeric tannin fractions by the means of 
phloroglucinolysis (Drinkine et al. 2007). The oligomeric and polymeric products were 
depolymerized in the presence of a nucleophilic agent (phloroglucinol) in an acid medium. 
The reaction released the terminal unit as a flavan-3-ol monomer and ethylideneflavan-3-ol-
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phloroglucinol adducts from extension units. Phloroglucinolysis reaction is summarized in 
Figure 21.  
 
Figure 21: Reaction pathway of phloroglucinolysis. Adapted by Drinkine et al. 
(2007). Procyanidins, R’ = H and R’’ = OH; prodelphinidins, R’ = OH and R’’ = OH. 
For procyanidins, terminal units release were (+)-catechin (C), ()-epicatechin (EC) 
and ()-epicatechin gallate (ECG). Phloroglucinol adducts from extension units were the (+)-
catechin–phloroglucinol (C-P), ()-epicatechin phloroglucinol (EC-P) and ()-epicatechin 
gallate phloroglucinol (ECG-P). Concerning prodelphinidins, in addition to the cited 
compounds, they also released the ()-epigallocatechin (EGC) and his phloroglucinol adduct 
the ()-epigallocatechin phloroglucinol (EGC-P) (Figure 22).  
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Figure 22: Proposed compounds released by the phloroglucinolysis of ethylidene-
bridged flavan-3-ols. Adapted by Drinkine et al. (2007). 
Monomeric/oligomeric tannin seed and skin extracts were prepared as followed: 100 
µL of extracts solubilized in MeOH (5 g/L) and 100 µL of phloroglucinolyse reagent were 
placed in an amber glass vial and reacted at 50 °C for 20 min. The mixture was then 
combined with 1 mL of aqueous sodium acetate (40 mmol/L) to stop the reaction. 
Phloroglucinolyse reagent is a mix of phloroglucinol (50 g/L), ascorbic acid (10 g/L) dissolve 
in acidified methanol with 0.1N HCl. Phloroglucinolysis reaction were carried out in 
duplicate.  
Reaction products were analyzed by HPLC-MS on a Hewlett-Packard 1100 HPLC 
(Agilent, Massy, France) system comprising a pump module and an absorbance detector 
coupled to a Micromass Platform II quadruple mass spectrometer (Micromass-Beckman, 
Roissy Charles de Gaulle, France) equipped with an electrospray ion source. The system was 
operated using Masslynx 3.4 software. 
Separations were performed on a reversed-phase Waters XTerra RR C18 (100 mm x 
4.6 mm, 3.5 µm) column at room temperature. A binary gradient system was employed using 
1% (v/v) aqueous acetic acid (solvent A) and MeOH (solvent B) at a flow rate of 1 mL/min. 
The elution conditions were: 5% B at 0 min; 16% B at 1 min, 22% B at 7 min, 35% B at 8 
min, 42% B at 15 min; the column was then washed with 100% B for 3 min and re-
equilibrated with 5% B for 4 min before next injection. The mass spectrometer was operated 
in negative-ionisation mode. The source temperature was 120°C, the capillary voltage was set 
at 3.5 kV and the cone voltage was –30 eV. The absorbance was recorded at 280 nm and 
mass spectra were recorded in the range of 50 to 1500 amu.  
105 
 
Concentration of breakdown products was obtained thought molar extinction 
coefficient, specific for each product and expressed as mol/L using this formula: 
  
    
                            
 
Identification of reaction products was confirmed by mass spectrometry in full scan 
negative ionization, data MS dependant (Table 8).  
Table 8: Reaction products and their MS characteristics 
Compounds [M-] (m/z) 
(+)-Catechin (C) 289 
()-Epicatechin (EC) 289 
()-Epicatechin-O-gallate (ECG) 441 
()-Epigallocatechin (EGC) 305 
(+)-Catechin–phloroglucinol (C-P) 413 
()-Epicatechin phloroglucinol (EC-P) 413 
()-Epicatechin-O-gallate phloroglucinol (ECG-P) 565 
()-Epigallocatechin phloroglucinol (EGC-P) 429 
 
Reverse phase HPLC allowed the dosage of phloroglucinol breakdown products and 
thus, the determination of the mDP, %G and %P. 
    
                                                                             
                                                       
 
   
                                                                                 
                                                                                   
  
 
    
                                                                                 
                                                                                  
 
I.6. HPLC analysis of anthocyanins  
Powder skin extracts were dissolved in water/methanol solution (50:50, v/v) at a 
concentration of 10 mg/mL prior to UPLC-UV analyses using a Thermo-Accela HPLC-UV 
system (Thermo-Fisher, San Jose, CA, USA) composed of a PDA detector, an autosampler 
and a quaternary 600 series pump system controlled by an Xcalibur data system. Separation 
was performed on a C18 Kinetex column (100 mm x 2.1 mm, 1.7 µm). The injected volume 
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was 2 µL. The mobile phases were water/formic acid (95:5, v/v) (solvent A) and 
acetonitrile/formic acid (95:5, v/v) (solvent B) at a flow rate of 200 µL/min. Initial solvent B 
was set at 7%. The mobile phase gradient was as following: 26% B at 18 min, 100% B at 19 
min. The column was then washed with 100% B for 3 min and re-equilibrated with 7% B for 
5 min before next injection. Eluting peaks were monitored at 520 nm. Identification of mean 
peaks was performed by comparison to injected external standards. The data was expressed 
as malvidin-3-O-monoglucoside equivalent/g dry weight of skins.  
Grape pomace extracts used for in vivo study were studied in another HPLC system. 
Grape pomace extracts were solubilized in methanol/water (50:50, v/v) containing 1% formic 
acid. Analysis were carried out using a Surveyor HPLC with sampler cooler maintained at 
4ºC, a PDA detector scanning from 200 to 600 nm and a LCQ Advantage ion trap mass 
spectrometer with a split volume set at 0.2 mL/min and ESI operating in full-scan positive 
mode scanning from m/z 200 to 1000. Separation was performed on a 250 × 4.6 mm i.d. 4 µm 
Synergi RP-Max column (Phenomenex, Macclesfield, UK) maintained at 40 ºC in a column 
oven. The mobile phase pumped at 1 mL/min comprised a 65 min, 10-45% gradient of 
methanol in water with both solvents containing 1% formic acid. The injection volume was 
10 µL. Peak detection and quantification were monitored at 520 nm and performed by 
comparison with available standards or confirmed by mass spectrometry in full-scan positive 
ionization, data dependent MS
2
. Anthocyanins were quantified as malvidin-3-O-glucoside 
equivalents and expressed in mg per dry weight of seed or skin ± SE (n=3). 
I.7 Antioxidant assays 
I.7.1. Oxygen Radical Absorbance Capacity (ORAC) Assay 
The ORAC assay was applied according to the method of Ou et al. (2001), as 
modified by Dávalos et al. (2004). The ORAC assay was carried out on the BGM FLUOstar 
Omega plate reader with a fluorescence detector (BMG LABTECH GmbH, Ortenberg, 
Germany). The fluorescent filters were set at excitation and emission wavelengths of 485 nm 
and 530 nm respectively. The temperature of the incubator was set at 37°C. A black 96-well 
plate was loaded with phosphate buffer (blank, 30 µL), Trolox standard series (1 µM-100 
µM, 30 µL) and samples (grape and pomace crude extract; solubilized in phosphate buffer at 
appropriate concentration, 30 µL) into the respective wells, fluorescein (117 nM, 180 µL) 
were then added to every well followed by AAPH (40 mM, 90 µL). Readings were taken 
every minute for 90 minutes. All samples were analyzed in triplicate. The area under the 
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curve (AUC) was calculated for each sample by integrating the relative fluorescence curve. 
The net AUC was calculated by subtracting the AUC of the blank. The final ORAC values 
were determined by linear regression equation of Trolox concentrations and are expressed as 
µM Trolox equivalents/g dry weights. 
I.7.2. Ferric Reducing Antioxidant Potential assay (FRAP) 
The ferric reducing power of crude extracts was measured based on the method of 
Benzie et al. (1996). The FRAP assay was carried out on the BGM FLUOstar Omega plate 
reader set at 593 nm absorbance readings. FRAP reagent were prepared daily by mixing 10 
volumes of 300 mM sodium acetate buffer (pH 3.6) with 1 volume of 10 mM TPTZ (2,4,6-
tri(2-pyridyl)-s-triazine) and 1 volume 20 mM ferric chloride. A standard curve was prepared 
using various concentrations of FeSO4 Χ 7 H2O. 96-well plate was loaded with sodium 
acetate buffer (blank, 40 µL), FeSO4 Χ 7 H2O standard series (3 mM-0.50 mM, 40 µL) and 
samples (grape and pomace crude extract; solubilized in sodium acetate buffer at appropriate 
concentration, 40 µL) into the respective wells, FRAP reagent (300 µL) were then added to 
every well. Readings were taken after 4 minutes of reaction. All samples were analyzed in 
triplicate. Blank values were subtracted from samples and standards values then difference 
were used to calculate the FRAP value. In this assay, the reducing capacity of grape and 
pomace skin and seed extracts was calculated with the reference to the signal given by Fe
2+
 
solution. FRAP values were expressed as µM Fe
2+/
g of dry skin and seed weights. 
I.7.3. ABTS assay 
The free radical scavenging capacity of grape and pomace skin and seed crude 
extracts were also studied using the ABTS radical cation decolorization assay (Re et al. 
1999). When combined with an oxidant (2.45 mM potassium persulfate), ABTS (7 mM in 
deionized water) reacts to create a stable dark blue-green ABTS
+• 
radical solution following a 
12-16 h incubation in the dark at room temperature. Before use, the ABTS
+•
 solution was 
diluted with deionized water to an absorbance of 0.7 ± 0.02 at 734 nm using a Jenway-6305 
UV-vis spectrophotometer (Jenway, Stone, Staffordshire, UK). This solution was prepared 
daily and all samples were analyzed in triplicate. One hundred µL of aqueous skin and seed 
crude extracts were added to 2 mL of ABTS
+•
 solution. The absorbance was taken 10 min 
after the initial mixing. An appropriate solvent blank reading was also taken. Blank values 
were subtracted from samples and standard values and a linear regression for the Trolox 
standards were constructed. Results were expressed as µM Trolox equivalents/g dry weights. 
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I.7.4. DPPH assay 
This method was used according to Brand-Williams et al. (1995), modified by 
Miliauskas et al. (2004). DPPH
 
 has an intense violet color which turns colorless as unpaired 
electrons are scavenged by antioxidants. Reaction mixtures containing 100 µL of sample and 
200 mL of DPPH

 solution (6 Χ 10
-5
 M, dissolve in methanol, prepared daily) were gently 
mixed and stored at room temperature during 20 min. The absorbance of the resulting 
solution was measured at 515 nm using a Jenway-6305 UV-vis spectrophotometer (Jenway, 
Stone, Staffordshire, United Kingdom). An appropriate solvent blank reading was also taken. 
Blank values were subtracted from samples and standard values. A linear regression for the 
Trolox standards was constructed. Results were expressed as µM Trolox equivalents/g dry 
weights. 
I.8. Statistical analysis 
All measurements were performed in triplicate. Results are expressed as means ± 
standard deviation (SD). One-way ANOVA was performed to test the effects of variation 
factors (different samples) on each variable (TPC, total tannin, anthocyanin, phenol 
concentrations, mDP, etc). If significant effects were found at a 95% confidence interval, 
ANOVA was followed by a Tukey’s HSD and Duncan post hoc test to identify differences 
among groups. These analyses were performed using Statistica V.7 Software (Statsoft InC., 
Tulsa, O.K). 
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II. In vivo study 
II.1. Chemicals 
Deionized water was purified with a Milli-Q water system (Millipore, Bedford, MA). 
HPLC grade ethyl acetate, methanol and ethanol were purchased from Rathburn Chemicals 
(Walkerburn, Scotland). The following chemicals: (+)-catechin (≥ 98%), ()-epicatechin (≥ 
98%), ()-Epigallocatechin (≥ 98%), ()-epigalocatechin3-O-gallate (≥ 98%), ethyl gallate (≥ 
96%), L-ascorbic acid (≥ 99%), derivatization reagent (pyridine (≥ 99.8%) and N-methyl-N-
(trimethylsilyl)trifluoroacetamide [MSTFA] (≥ 98.5%)), N,N-dimethyl formamide (DMF) (≥ 
99.8%) and all other chemicals including phenolic acid standards were purchased from Sigma 
Aldrich (Saint Louis, USA). Ferulic acid (≥ 99%), was obtained from AASC Chemicals 
(Southampton, U.K.). (±)-Verapamil hydrochloride ≥ 99%, EDTA and pentobarbital solution 
used in rats feeding studies were supplied by Sigma Aldrich. HCl (37%), acetic acid (≥ 99%), 
phosphoric acid (≥ 85%), formic acid (≥ 95%), were purchased from Fisher Scientific Ltd 
(Loughborough, Leicestershire, U.K.). 
II.2. Plant materials 
SHR rats used in this study were fed with aqueous (EAQ) and hydro-alcoholic 70% 
(EA70) grape pomace extracts provided by 3INature. Composition of these extracts is 
provided in the chapter III of the manuscript. Grape pomace samples were dissolved daily in 
3% EtOH before administration.  
II.3. Animals and experimental protocols 
For all the experiments, spontaneously hypertensive rats (SHR) and normotensive 
control Wistar-Kyoto (WKY) rats were purchased from Laboratoire Janvier (Le Genest St. 
Isle, France). Animals were maintained at a temperature of 23°C with 12h light/dark cycles. 
Tap water and standard diet A 04 SAFE (Augy, France) composed of 83.9 % of cereals and 
cereal biproducts, 8.0 % of vegetable proteins (soya bean meal, yeast), 4.1 % of vitamin and 
mineral mixtures and 4 % of animal proteins (fish) were given ad libitum. Food intake and 
body weight of animals were recorded once a week. Prior to each experiment, adaptation 
period was allowed. Experiments were performed following European Community animal 
experiments ethical regulations. 
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II.3.1. 1st study: Grape pomace extracts screening 
Male nine week-old spontaneously hypertensive rats (SHR) and normotensive control 
Wistar-Kyoto (WKY) rats were used to determine the in vivo effect of grape pomace extracts 
and their potential effect on hypertension. This experiment was held over 6 weeks including 
three weeks of treatment, one week of treatment resumption followed again by two weeks of 
treatment. Rats were treated orally by gavage with hydro-alcoholic 70% grape pomace 
samples at a dose of 21 mg/kg/day which in terms of phenolic compounds is equivalent to a 
70 kg human consuming of ~0.5 L of red wine. Extracts were solubilised with 3 % ethanol. 
Rats were randomly assigned to different experimental group organized as follows:  
- Control group (6 WKY rats) 
- SHR control group (5 SHR treated with 3% EtOH) 
- 6 groups of 4 SHR rats treated with hydro-alcoholic 70% grape pomace 
extracts dissolved in 3% EtOH: 
*SHR1: GRE1 (EA70) seed pomace extract 
*SHR2: SYR1 (EA70) seed pomace extract 
*SHR3: SYR2 (EA70) skin pomace extract 
*SHR4: CAR (EA70) seed pomace extract 
*SHR5: MOU (EA70) skin pomace extract 
*SHR6: ALI (EA70) skin pomace extract 
II.3.2. 2nd study: Effect of the verapamil (model validation) 
Three male nine week-old spontaneously hypertensive rats (SHR) and three 
normotensive control Wistar-Kyoto (WKY) rats were used to study the effect of verapamil on 
SHR blood pressure. This experiment was held over twelve weeks. During the first two 
weeks, only blood pressure was followed. Then, SHR were treated with verapamil at 30, 20 
and 40 mg/kg/day during 10 weeks. Throughout this time, blood pressure was monitored. 
II.3.3. 3rd study: Effect of grape pomace extracts associated with verapamil 
This study was carried out in three steps 
1) “Grape pomace extract + verapamil model” development using extract GRE1 
(EA70) seed pomace extract. Three experimental groups were established and experiment 
lasted during three weeks: group SHR control (3 SHR treated with 3% EtOH), group SHR 
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verapamil control (3 SHR treated with verapamil at 40 mg/k), group verapamil + extract 
GRE1 (EA70) seed pomace extract (3 SHR treated with 21 mg/kg of extract). 
2) Comparison of grape pomace extracts efficiency in association with verapamil. 
Rats were randomly assigned to different experimental group organized as follows:  
- Control group (3 WKY rats) 
- SHR control group (3 SHR treated with 3% EtOH) 
- SHR verapamil control group (3 SHR treated with verapamil at 40 mg/kg) 
- 6 groups of 3 SHR rats treated with hydro-alcoholic 70% grape pomace 
extracts dissolved in 3% EtOH (21 mg/kg) associated with verapamil (40 
mg/kg): 
 
*SHR1+V: GRE1 (EA70) seed pomace extract + verapamil  
*SHR2+V: SYR1 (EA70) seed pomace extract + verapamil 
*SHR3+V: SYR2 (EA70) skin pomace extract + verapamil 
*SHR4+V: CAR (EA70) seed pomace extract + verapamil 
*SHR5+V: MOU (EA70) skin pomace extract + verapamil 
*SHR6+V: ALI (EA70) skin pomace extract + verapamil 
Blood pressure was recorded all along the three weeks experiment. 
3) Results confirmation. For this experiment, seven SHR rats were used in order to 
confirm previous results. Animals were fed with Alicante (EA70) skin pomace extract 
(extract n°6) at a concentration of 21 mg/kg associated with verapamil (40 mg/kg) and blood 
pressure was followed during three weeks. 
II.3.4. Supplementary experiments of grape pomace extracts associated with 
verapamil screening 
a/ Verapamil co-ingested with SYR1 seed (EAQ), SYR1 skin (EAQ), ALI skin 
(EAQ) and GRE2 skin (EA70) screening 
Eighteen male nine week-old spontaneously hypertensive rats (SHR) and six male 
normotensive control Wistar-Kyoto (WKY) rats were used to determine the in vivo effect of 
additional grape pomace extracts associated with verapamil and their potential effect on 
hypertension. This experiment was held over 9 weeks including 7 weeks of treatment with 
gradual increasing dose of verapamil from 10 mg/kg/day to 40 mg/kg/day and 2 week of 
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grape pomace extracts in association with verapamil. Rats were treated orally by gavage with 
hydro-alcoholic 70% and aqueous extract of grape pomace samples at a dose of 21 mg/kg/day 
which in terms of phenolic compounds is equivalent to a 70 kg human consuming of ~0.5 L 
of red wine. Extracts were solubilised with 3 % ethanol. Verapamil was administrated at a 
dose of 40 mg/kg/day. 
Rats were randomly assigned to different experimental group organized as follows:  
- Control group (6 WKY rats) 
- SHR control group (3 SHR treated with 3% EtOH) 
- SHR verapamil control group (3 SHR treated with verapamil at 40 
mg/kg/day) 
- 4 groups of 3 SHR rats treated with aqueous and hydro-alcoholic 70% grape 
pomace extracts dissolved in 3% EtOH in association with verapamil: 
*SHR1+V: SYR1 (EAQ) seed pomace extract + verapamil 
*SHR2+V: SYR1 (EAQ) skin pomace extract + verapamil 
*SHR3+V: ALI (EAQ) skin pomace extract + verapamil 
*SHR4+V: GRE2 (EA70) skin pomace extract + verapamil 
b/ Verapamil co-ingested with CAR seed (EAQ), GRE2 skin (EAQ), SYR2 skin 
(EAQ) and SYR1 skin (EA70) screening 
Eighteen male twenty-three week-old spontaneously hypertensive rats (SHR) and six 
male normotensive control Wistar-Kyoto (WKY) rats were used to determine the in vivo 
effect of additional grape pomace extracts and their potential effect on hypertension. This 
experiment was held over 6 weeks including 15 days without treatment, 13 days of treatment 
with verapamil only, 7 days of grape pomace extracts in association with verapamil treatment 
followed again by 4 day of treatment with verapamil only. Rats were treated orally by gavage 
with hydro-alcoholic 70% and aqueous extract of grape pomace samples at a dose of 21 
mg/kg/day which in terms of phenolic compounds is equivalent to a 70 kg human consuming 
of ~0.5 L of red wine. Extracts were solubilised with 3 % ethanol. Verapamil was 
administrated at a dose of 40 mg/kg/day. 
Rats were randomly assigned to different experimental group organized as follows:  
- Control group (6 WKY rats) 
- SHR control group (3 SHR treated with 3% EtOH) 
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- SHR verapamil control group (3 SHR treated with verapamil at 
40mg/kg/day) 
- 4 groups of 3 SHR rats treated with aqueous and hydro-alcoholic 70% grape 
pomace extracts dissolved in 3% EtOH in association with verapamil: 
*SHR1+V: CAR (EAQ) seed pomace extract + verapamil 
*SHR2+V: GRE2 (EAQ) skin pomace extract + verapamil 
*SHR3+V: SYR2 (EAQ) skin pomace extract + verapamil 
*SHR4+V: SYR1 (EA70) skin pomace extract + verapamil 
 
II.3.5. Feeding protocol and sample collection for the evaluation of grape pomace 
extracts bioavailability 
Based on previous results, the extract GRE1 (EA70) seed pomace extract, MOU 
(EA70) skin pomace extract and ALI (EA70) skin pomace extract have been chosen to 
bioavailability study.  
Male nine week-old SHR rats, weighting 207 ± 8 g, were randomly assigned to 
different experimental group organized as follows: 
- SHR control group (6 SHR treated with 3% EtOH)  
- SHR verapamil control group (6 SHR treated with verapamil at 40 
mg/kg/day)  
- 3 groups of 6 SHR rats treated with hydro-alcoholic 70 % grape pomace 
extracts at 21 mg/kg/day: 
*E1: GRE1 (EA70) seed pomace extract  
*E5: MOU (EA70) skin pomace extract 
*E6: ALI (EA70) skin pomace extract 
- 3 groups of 6 SHR rats treated with hydro-alcoholic 70% grape pomace 
extract in association with verapamil: 
*VE1: GRE1 (EA70) seed pomace extract + verapamil  
*VE5: MOU (EA70) skin pomace extract + verapamil  
*VE6: ALI (EA70) skin pomace extract + verapamil  
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Experiment lasted three weeks. After one week of adaption, only animal from SHR 
verapamil control, VE1, VE5 and VE6 group were treated with verapamil (40 mg/kg) by 
gavage at week two. At week three, all the animals were daily administrated as stated above 
during all the week. The experiment procedure is summarized below: 
 
Urine and faeces were collected at two time point (0-8h and 8-24h) at day 1 and day 7 
of gavage from metabolic cage in falcon tubes and immediately stored at -80 °C. At day 7, 
four hours after gavage, rats were anaeasthetized with lethal dose of pentobarbital (60 g/L 
pentobarbital, 60 mg/kg body weight) and sacrificied by decapitation. Blood was drawn in an 
EDTA-moistened tube. Tubes were centrifuged at 2300g for 10 min at 4 °C. Plasma was 
separated from erythrocytes before being stored at -80°C. Tissues including heart, liver and 
kidneys were collected, rinsed, blottled and stored at -80°C. Samples were shipped to the 
University of Glasgow on dry ice. Upon arrival, tissues and faeces were freeze dried (Thermo 
Savant SuperMosulyo), weighted, grounded to a powder and stored at -80°C along with 
plasmas and urines prior to analysis. 
II.4. Blood pressure measurement 
Blood pressure was followed and accessed by tail-cuff method with a LETICA LE 
5002 Scientific Instrument electrosphygomanometer (Barcelona, Spain) under conscious 
condition, in a calmed and regulated between 29°C and 32°C darkened room. Rats were 
trained to the measurements, handled with care and covered with a fabric during the record in 
order to minimize stress. In this method, the reappearance of pulsation on a digital display of 
the blood pressure cuff is detected by a pressure transducer, amplified and recorded digitally 
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as the systolic blood pressure. The average of the three pressure readings was recorded if only 
the difference between two measurements was below 20 mmHg. 
II.5. HPLC-PDA-ESI-MSn analysis of urines, faeces, tissues and 
plasmas  
II.5.1. Extraction of phenolics from faeces and tissues 
Rat faeces and tissues from the same experimental group were pooled together in 
equal proportions. Faeces and tissues were extracted using a method optimized by Serra et 
al., (2011). To 100 mg of freeze-dried faeces and 60 mg to freeze-dried tissues were added 50 
µL of ascorbic acid 1% and 100 µL of phosphoric acid 4%. Each sample was spiked with 1 
µg of ethyl gallate as an internal standard. The samples were first extracted with 800 µL of 
water/methanol/phosphoric acid 4 % (94/4.5/1.5, v/v/v) using a sonicator during 30 secondes 
(Digital Sonifier® model S-150D ultrasonic cell disruptor, Branson, Teltow, Germany) and 
maintained in ice to avoid heat. Samples were then centrifuged for 15 min at 16 100 × g, 20 
°C in a 0.2 µm Micro-Spin
TM
 Eppendorf filter (Alltech Associates Applied Sciences, 
Lancashire, U.K.). The supernatant was decanted and the pellet re-extracted three more times 
with 500 µL of the same solvent as described above, after which it was centrifuged. The four 
supernatants were combined. A mixture of 1 mL of the assembled supernatant and 1 mL of 
phosphoric acid 4 % was loaded onto OASIS® HLB cartridges (3cc, 60 mg) previously 
conditioned with 1 mL of methanol and 1 mL of 0.2% acetic acid. Column was washed with 
1 mL of phosphoric acid 4% and with 1 mL of 0.2% acetic acid. The retained compounds 
were eluted with 2 × 1 mL acetone/Milli-Q water/acetic acid solution (70/29.5/0.5, v/v/v). 
The eluate was reduced to dryness using a Speedvac concentrator (SPS SpeedVac, Thermo 
Savant, Waltham, MA) and resuspended in 25 µL of acidified methanol (1% acid formic) to 
which was added 225 µL of 0.1% aqueous formic acid. Once resuspended, extracts were 
centrifuged at 16,100 × g for 10 min at 4°C in a 0.2 µm Micro-Spin
TM
 Eppendorf filter 
(Alltech Associates Applied Sciences, Lancashire, U.K.) prior to analysis by HPLC-PDA-
MS
n
. 
II.5.2. Extraction of phenolics from plasmas 
Rat plasmas from the same group were pooled together in equal proportions before 
extraction based on Ottaviani et al., (2012c) method. Plasma samples were defrosted and 
spiked with 1 µg of ethyl gallate as an internal standard. Plasma was added drop wise while 
vortex to a 15 mL falcon tube containing 3.4 % phosphoric acid and kept on a freeze water 
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bath. Sample was then loaded onto OASIS® HLB cartridge (3 mL, 60 mg) previously 
conditioned with 1 mL of N,N-dimethyl formamide (DMF)/methanol (7/3, v/v) and 0.5% 
(v/v) acetic acid in water. Cartridge was washed with 3 mL of 0.5 % acetic acid in water (v/v) 
and 1 mL of water/methanol/acetic acid (80/20/0.5). For elution, cartridge was dried and 
eluted with 2 × 1 mL of DMF/methanol (7/3, v/v). The eluate was collected in a tube 
containing 200 µL of 0.5% (v/v) acetic acid in methanol and reduced to approximately 50 µL 
using a Speedvac concentrator (SPS SpeedVac, Thermo Savant, Waltham, MA). Sample was 
then resuspended in 25 µL of acidified methanol (1% acid formic) to which was added 225 
µL of 0.1% aqueous formic acid. Extract was then centrifuged at 16,100 × g for 10 min at 
4°C prior to analysis by HPLC-PDA-MS
n 
within 24 hours. 
II.5.3. Urine analysis 
Urine samples were defrosted, vortexed and centrifuged at 16,100 × g for 10 min at 
4°C prior to the analysis by HPLC-PDA-MS
n
. 
II.5.4. HPLC-PDA-ESI-MSn analysis of procyanidin metabolites 
Quantification of metabolites in urines, faeces, plasmas and tissues was carried out 
using two Surveyor HPLC system both equipped with sampler cooler maintained at 4ºC, a 
PDA detector and a Finnigan LCQ Duo ion trap mass spectrometer for urine and faeces 
analysis or a LCQ Adavantage ion trap mass spectrometer for tissue and plasma analysis. 
Mass spectrometers were both fitted with an electrospay interface (ESI) (Thermo Fisher 
scientific, San Jose, CA). Separation was performed on a 250 × 4.6 mm i.d. 5 µm Kinetex 
phenyl-hexyl 100Å column (Phenomenex, Macclesfield, U.K.) maintained at 40 °C. The 
mobile phase was pumped at a flow rate of 1 mL/min with either a gradient over 20 min of 
15-60 % methanol in 0.1% aqueous formic acid (analysis in faeces), a gradient over 30 min 
of 5-60% methanol in 0.1% aqueous formic acid (analysis of urines) or a gradient over 30 
min of 5-65% in 0.1% aqueous formic acid (analysis of tissues and plasmas). The column 
eluate initially passed through the PDA detector and was then split, with 0.2 mL/min directed 
to the mass spectrometer fitted with an electrospay interface operating in negative ion mode. 
The tuning of the mass spectrometer was optimized by infusing a standard of ()-epicatechin, 
dissolved in the initial HPLC mobile phase, into the source at a flow rate of 0.2 mL/min.  
Procyanidin metabolites were firstly identified using full-scan data-dependent MS
2
 
scanning from m/z 100 to 700. Compound identities were confirmed by MS3 consecutive 
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reaction monitoring with a collision energy set at 30%. Following HPLC separation and MS
3
 
identification, flavan-3-ols and their metabolites were quantified using selected ion 
monitoring (SIM mode) for faeces and selective reaction monitoring (SRM mode) for urine, 
tissues and plasma. 
Quantification of 5-(hydroxyphenyl)-4-hydroxyvaleric acid-O-glucuronide (m/z, 
401/225) and 5-(hydroxyphenyl)-γ-valerolactone-O-sulfate (m/z, 287/207) was by reference 
to the aglycone 5-(3,4-dihydroxyphenyl)-γ-valerolactone while 5-(hydroxyphenyl)-4-
hydroxyvaleric acid-O-sulfate (m/z, 305/225) levels were measured using a calibration curve 
obtained with 5-(3,4-dihydroxyphenyl)-4-hydroxyvaleric acid. Reference compounds were 
supplied by Daniel Del Rio (University of Parma, Italy). 
The other metabolites were quantified as ()-epicatechin equivalents and expressed as 
nmol ± SE (n=3). 
II.6. GC-MS analysis of urines and faeces 
II.6.1. Purification of phenolic acids in urines 
Urine samples were prepared as described previously by Roowi et al. (2010), and 
further developed. After thawing, 1 mL of urine was added to 3 mL of 0.2 M HCl containing 
60 µg of 3,4,5-trimethoxycinnamic acid (TMCA) as an internal standard. A styrene divinyl 
benzene solid phase extraction cartridge (Strata SDB-L 200 mg, Phenomenex, Macclesfield, 
U.K.) was used for sample purification. Acidified urine sample was loaded onto cartridge 
previously preconditioned with 3 mL of ethyl acetate, followed by 3 mL of methanol and 3 
mL of 0.1 M HCl. Thereafter, cartridge was washed with 3 mL of 0.1 M HCl and dry with 
nitrogen gas for 20 min before being eluted with 3 mL of ethyl acetate. The eluate was 
transferred to an amber glass vial and reduced to dryness under nitrogen flow at 35 °C. The 
dried extract was silylated in sealed vial using 300 µL of a mix of pyridine and N-methyl-N-
(trimethylsilyl)trifluoroacetamide (MSTFA) (1:4, v/v) heated at 80 °C for 20 min on a 
heating block. Samples were cooled in a closed dry container prior to analysis by GC-MS. 
II.6.2. Purification of phenolic acid in faeces 
Faecal extracts preparation was adapted from Grün et al. (2008). Briefly, 1 mL of 
distilled water was added to 50 mg of freeze-dried faecal sample, mixture was vortexed for 
60 s and centrifuged at 16 100 × g at 8°C during 10 min in a 0.2 µm Micro-Spin
TM
 Eppendorf 
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filter (Alltech Associates Applied Sciences, Lancashire, U.K.). The supernatant was 
collected, purified and silylated with the same procedure than those described for urines. 
II.6.3. GC-MS analysis of derivatized urine and faeces 
Derivatized phenolic acids in urine and faeces samples were analysed using an 
Agilent Technologies 6890 Chromatograph equipped with an autosampler and a mass 
selective detector 5973 (Agilent Technologies, Berkshire, U.K.). Helium was the carrier gas 
with a flow rate of 1.2 mL/min. One microliter of sample was injected in the split mode with 
a 25:1 ratio. The injector temperature as maintained at 220°C. The mass spectrometer was 
used in the positive ionization mode with the ion source and transfer line set at 230°C and 
150°C, respectively. Separation was carried out using a ZB-5MS Zebron 30 m × 0.25 mm i.d. 
× 0.25 µm capillary column (Phenomenex, Macclesfield, U.K.). The initial temperature was 
set at 40 °C and raised to 160°C at 20°C/min, 200°C at 15°C/min, 250 °C at 10°C/min to a 
final temperature of 300°C at 40°C/min, held for 5 min. Data acquisition was performed in 
full scan mode (m/z 50-470) with ionization energy of 70 eV. Phenolic acids were identified 
according to the mass spectra and retention times obtained from authentic standards analysed 
under identical conditions. When standards were not available, identification was achieved 
through the integrated NIST mass spectral library with a confidence of 80 % or above. 
Quantification was based on calibration curves of the ratio between the target ion (m/z) of the 
standard of interest and the target ion of the internal standard (m/z 310). Data were expressed 
in µmol as mean values ± SE (n=3).  
Analyses were carried out using MSD ChemStation Data Analysis (Agilent 
Technologies, Berkshire, U.K).  
II.7. Statistical analysis 
All measurements were performed in triplicate. Results are expressed as means ± 
standard deviation (SD). One-way ANOVA was performed to test the effects of variation 
factors (different samples) on each variable (concentration of different phenolic acids, 
procyanidin metabolites, etc). If significant effects were found at a 95% confidence interval 
following a Student’s t-test, ANOVA was followed by a Tukey’s HSD and Duncan post hoc 
test to identify differences among groups. These analyses were performed using Statistica V.7 
Software (Statsoft InC., Tulsa, O.K).  
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Chapter 3: 
 
Grapes and grape pomaces phenolic and 
antioxidant characterisation 
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I. State of the art: assessing the value of grape 
pomaces and their potential applications 
Today’s society is characterized by rising costs and often decreasing availability of 
raw materials together with much concern about environmental pollution. The demand for 
appropriate nutritional standards is increasing and thus, there is a considerable emphasis on 
the recovery, recycling and upgrading of wastes. The food processing industry permits waste 
effluents, residues and by-products to be recovered and often to be upgraded to higher value 
and useful products. Using appropriate technology, food industry by-products can be 
converted into commercial products either as raw materials for secondary processes or as 
ingredients of new products.  
I.1. Grape pomace composition 
Bustamante et al. (2008), analyzed different residues from the wine industry and 
found that winery and distillery waste has a low pH (mean values ranged from 3.8 to 6.8), 
electrical conductivity (1.62–6.15 dS m−1) and high organic matter content (669–920 g/kg). 
Moreover winery residues have high concentrations of macronutrients, especially potassium 
(11.9–72.8 g/kg), as well as high concentrations of (poly)phenols (1.2–19.0 g/kg) and low 
concentrations of micronutrients and heavy metal contents (Bustamante et al. 2008).  
Grape pomace represents an important under utilised residue of the winemaking 
process. The dry grape by-product consists of pressed skins, seeds and stems and accounts for 
ca. 20%-25% of the weight of the grapes used to make wine (Laufenberg et al. 2003; Llobera 
et al. 2007). During winemaking the extraction of grape (poly)phenols typically reaches only 
30–40%, depending upon grape variety, vineyard location and the technological parameters 
used during the winemaking process including destemming, crushing, maceration and 
pressing (Kammerer et al. 2004; Ruberto et al. 2007). Kammerer et al. (2004), have screened 
pomaces after winemaking from red Vitis vinifera grape varieties (i.e. Cabernet Mitos, 
Lemberger, Spa  tburgunder, Trollinger) and white wine cultivars (Kerner, Müller-Thurgau, 
Weisser Riesling and Merzling) for their phenolic contents and results are presented in Table 
9. 
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Table 9: Mean concentration of principal (poly)phenols in red grape seed and 
skin pomaces after winemaking after Kammerer et al. (2004). 
Anthocyanins 
Mean contents in 
skins (mg/kg DW) 
Min
a
 Max
a
 
Delphinidin 3-O-glucoside 1035   68 5552 
Cyanidin 3-O-glucoside 403 37 1903 
Petunidin 3-O-glucoside 1247 65 6680 
Peonidin 3-O-glucoside 2639 515 12450 
Malvidin 3-O-glucoside 12123 1117 20533 
Delphinidin 3-O-(6″-acetyl-glucoside) 150 0 956 
Petunidin 3-O-(6″-acetyl-glucoside) 213 27 1375 
Peonidin 3-O-(6″-acetyl-glucoside) 329 27 1484 
Malvidin 3-O-(6″-acetyl-glucoside) 1336 45 8688 
Cyanidin 3-O-(6″-p-coumaroyl-glucoside) 160 0 1071 
Petunidin 3-O-(6″-p-coumaroyl-glucoside) 381 0 2458 
Peonidin 3-O-(6″-p-coumaroyl-glucoside) 1077 68 6828 
Malvidin 3-O-(6″-p-coumaroyl-glucoside) 4934 271 31442 
    
Flavanols Skins (mg/kg DW) Seeds (mg/kg DW) 
 
Catechin 226.7 ± 24.6 790.2 ± 11.2 
 
Epicatechin 134.6 ± 12.1 674.5 ± 24.9 
 
Epicatechin gallate 35.5 ± 3.6 457.9 ± 35.8 
 
Procyanidin B1 191.5 ± 6.6 1053.7 ± 29.3  
Procyanidin B2 91.0 ± 2.5 506.2 ± 41.1  
Quercetin nd nd 
 
Quercetin-3-O-galactoside 156.7 ± 9.3 14.7 ± 0.9 
 
Quercetin-3-O-glucoside 351.7 ± 23.3 32.6 ± 3.0 
 
Quercetin -3-O-glucuronide 509.9 ± 30.4 38.0 ± 0.8 
 
Quercetin-3-O-rhamnoside 57.7 ± 3.5 14.4 ± 1.0 
 
Kaempferol nd nd 
 
Kaempferol-3-O-glucoside 247.6 ± 15.6 20.0 ± 1.4 
 
Trans-resveratrol 86.4 ± 4.5 14.2 ± 1.8 
 
Trans-polydatin 15.5 ± 0.1 4.7 ± 0.2 
 
Isorhamnetin-3-O-glucoside 35.5 ± 0.1 nd 
 
    Phenolic acids Skins (mg/kg DW) Seeds (mg/kg DW) 
 
Gallic acid 15.0 ± 0.2 106.5 ± 8.8 
 
Protocatechuic  acid 42.8 ± 0.5 102.8 ± 25.5 
 
Caftaric  acid 61.0 ± 2.8 9.3 ± 3.4 
 
p-Hydroxybenzoic  acid 31.1 ± 0.1 13.8 ± 0.9 
 
Coutaric acid 54.5 ± 1.4 30.2 ± 16.3 
 
Caffeic  acid 1.7 ± 0.2 1.9 ± 0.6 
 
Fertaric  acid 17.3 ± 1.1 3.0 ± 0.1 
 
Syringic  acid 1.0 ± 1.2 1.1 ± 0.1 
 
p-Coumaric acid Nd 7.2 ± 0.7 
 
Ferulic acid 2.6 ± 0.0 3.9 ± 0.4 
 
Sinapic  acid Nd 1.0 ± 0.1 
 aMin, minimum concentration detected, Max, maximum concentration detected. Data are expressed as mg/kg. 
 
Grape pomaces contain up to 75% of dietary fiber and over 60% of grape pomace dry 
matter that was indigestible in vitro (Bravo et al. 1998). The indigestible grape pomace 
dietary fibers include pectin, cellulose, lignin and (poly)phenols (Llobera et al. 2007; 
González-Centeno et al. 2010; Deng et al. 2011; González-Centeno et al. 2012) and the 
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composition depends on grape varieties and the part of pomace. White grape pomace had 
lower fiber concentrations (i.e. crude fibers, neutral detergent fibers and acid detergent fibers) 
than red wine pomace (Baumgärtel et al. 2007). Pomace and stems of Manto Negro red grape 
(V.vinifera) dietary fibers were studied by Llobera et al. (2007). A high percentage of soluble 
fibers (15%) in relation to the total dietary fibers was found in pomaces, while a high content 
of lignin, which had important amounts of condensed tannins and resistant proteins, was 
found in both by-products but especially in stems (31.6%). González-Centeno et al. (2010) 
investigated the dietary fiber compositions of pomace and stems from ten grape (V.vinifera 
L.) different varieties (six red and four white). Both presented considerable quantities of 
dietary fibers, ranging from 60 to 90% of total dry matter. Grape pomace and stem cell wall 
polysaccharides composition were very different with pectic substances being the main 
component of pomace cell walls (40–54% of total cell wall polysaccharides) and cellulose 
being predominant in stem cell wall polysaccharides (40–49% of total cell wall 
polysaccharides). Lignin accounted for around 20–25% of dietary fibers in both grape 
pomaces and stems. In addition, the pectin content and the degree of methyl-esterification of 
uronic acids of grape pomaces varied depending on the varieties of grapes. A study by Deng 
et al. (2011) using grape pomace from two white grape varieties and three red grape varieties 
showed that insoluble dietary fibers were composed of lignin (7.9–36.1% dry matter), neutral 
sugars (4.9–14.6% dry matter) and uronic acids (3.6–8.5% dry matter) and weighed more 
than 95.5% of total dietary fibers in all pomace samples. White grape pomaces were 
significantly lower in dietary fibers (17.3–28.0% dry matter) than those of red grape pomaces 
(51.1–56.3%). 
Like other plant materials, grape pomace contain relatively higher amount of non-
extractable (poly)phenols (NEP). Although the total (poly)phenol content in dry grape 
pomace are about 4.8–5.4% (Makris et al. 2007), only 2% of (poly)phenols is extractable 
under mild conditions (Bravo et al. 1998). The majority portion of grape pomace 
(poly)phenols has been reported to be highly polymerised condensed tannins, and some 
(poly)phenols form complexes with fibers and are non-extractable unless strong acidic 
treatments are applied (Arranz et al. 2010). Monomeric and oligomeric proanthocyanidins are 
certainly soluble in the organic solvents usually used for (poly)phenols extraction, but a 
major proportion of high-molecular-weight proanthocyanidins and (poly)phenols complexed 
with proteins or cell wall polysaccharides remain insoluble. The NEP quantification needs 
hydrolysis of grape pomace residual to release the bound phenolics from cell walls or 
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proteins after the extraction of soluble (poly)phenols (Ignat et al. 2011). The NEP content can 
be as high as 67 mg/g of dry matter in red grape pomace (var. Cencibel) and as low as 1.68 
mg/g in white grape pomace (var. Thompson, seedless) (Pérez-Jiménez et al. 2009). 
I.2. Grape pomace and their potential uses 
Grape pomace is usually transformed in distilleries, after washing, to obtain alcohol 
and tartrates. It is often distilled in wineries to recover ethanol to produce spirits, although 
substantial amounts of distilled grape pomace are not used efficiently after winemaking 
process.  
Grape pomace contain large amounts of hemicellulosic sugars, that can be hydrolyzed 
to produce solutions containing monomers of xylose and glucose, which in turn could be used 
as a substrate by Lactobacillus pentosus to produce lactic acid (Rivera et al. 2007). The same 
investigators found that the mineral and organic nitrogen present in grape pomace 
hydrolyzates enhance xylose consumption allowing L. pentosus to produced cell bound 
biosurfactants, which not only reduced the surface tension, but also have emulsifying 
properties that might facilitate the bioremediation of hydrocarbon contaminated sites (Rivera 
et al. 2009) using tomato plants. The effectiveness of this bioemulsifier was investigated by 
preparing kerosene/water emulsions in the presence and absence of emulsifiers. The volumes 
of kerosene/water emulsions stabilized by the bioemulsifiers produced by L. pentosus from 
hydrolyzed grape pomaces were approximately 74.5% after 72 hours of emulsion formation, 
with a stability capacity of emulsion about 97% (Portilla-Rivera et al. 2010). The authors 
reported that these results were better than those achieved using sodium dodecyl sulfate 
(SDS), a highly effective surfactant use in detergents, to stabilize kerosene/water emulsions. 
Another study found promising results by testing the biosurfactants obtained by L. pentosus-
induced fermentation of hemicellulosic sugars from grape pomaces, on various hydrophobic 
plant substrates in order to reduce their water repellence (Paradelo et al. 2009b). 
Most of the time, conditioning treatments such as composting, is necessary before by-
products can be used for agricultural purposes. Actually, grape by-products contain large 
amounts of organic matter and macronutrients such as potassium, which are important factors 
in soil fertility, and also contain (poly)phenols, which may exert phytotoxic and antimicrobial 
effects. Studies on the co-composting of winery and distillery wastes with animal manures 
have indicated a reduction in phytotoxicity during the process (Bustamante et al. 2008). 
Efficiency of composts derived from winery wastes was evaluated by García-Martínez et al. 
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(2009). The authors compared the use of winery waste composts and perlite and did not find 
any differences in the tomato solid soluble content and titratable acidity which indicates that 
winery waste compost could be used as an alternative. Pardo et al (2007), used vineyard 
wastes to formulate a high quality, low cost substrate for the cultivation of the most widely 
consumed edible mushroom, Agaricus bisporus (Lange) Imbach. The study demonstrated that 
this bio-compost was found to be economically viable and environmentally advantageous. 
Grape pomace composts were also tested for their ability to remove color components from 
vinasse, the remaining residual liquid from the fermentation or distillation of alcoholic 
liquors. Results showed comparable results to those achieved with activated carbon (Paradelo 
et al. 2009a).  
Grape pomace can also be used for other applications. Some authors proposed the use 
of grape marc as a metal adsorbent. For instance, Farinella et al. (2008), found that grape 
pomace can be used as a natural absorbent for cadmium and lead to the treatment of effluents. 
Other investigations proposed the use of grape by-products to obtain hydrolytic enzymes by 
solid state fermentation (Botella et al. 2005; Díaz et al. 2011). The possibility of using grape 
pomace as animal feeds was also studied (Brenes et al. 2008; Molina-Alcaide et al. 2008; 
Basalan et al. 2011). Basalan et al. (2011) investigated the nutrient contents and in vitro 
digestibility of twenty-eight fresh grape pomace samples from white and red wine grape 
varieties in Turkey. They found that in vitro the disappearance of dry matter and neutral 
detergent fiber at 48 h determined using ruminal fluid was similar for pomace from both 
white and red grapes. This study suggests that fresh grape pomace rich in skin and seed could 
be a suitable feed for ruminants and to non-ruminants with extensive cecal fermentation. 
Applications such as the use of grape pomace as a wood adhesive (Ping et al. 2011), 
bioethanol (Rodríguez et al. 2010) and (poly)phenol oil (Fiori 2010) have been proposed.  
In the health field, grape pomace can be of value as natural antioxidants replacing 
synthetic antioxidants, extracted with organic solvents and/or supercritical carbon dioxide 
(Vatai et al. 2009) and isothermal autohydrolysis (Conde et al. 2011). Some food processing 
methods such as extrusion increased extractable and bioavailable (poly)phenols and reduced 
the NEP by reducing the degree of polymerisation (Khanal et al. 2009). These studies suggest 
that thermal processing may increase the extractability and bioavailability of some 
(poly)phenols while destroying heat sensitive (poly)phenols in grape skins and seeds.  
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A large number of publications have shown the abundance quantity of (poly)phenols 
in grape seeds and skins, showing significant antioxidant capacity. It is therefore obvious that 
grape-derived products such as wines, grape juices and eventually pomace are natural sources 
of (poly)phenols. Significant effort has been made over the past decade to explore the 
potential of using grape pomace to produce functional food ingredients, such as natural 
antioxidants for nutrition fortification and food preservation. Sáyago-Ayerdi et al. (2009) 
showed by feeding chicken (3–6 weeks old) with different concentration of grape pomace (0, 
30 and 60 mg/kg body weight) for 3 weeks that chicken's growth performance were not 
affected, but lipid oxidation of raw and cooked breast chicken patties were significantly 
inhibited compared with samples obtained from birds fed the control diet at 20 days and long-
term frozen storage (6 months). These results indicate that dietary grape pomace 
(poly)phenols could be effective in inhibiting lipid oxidation of chilled and long-term frozen 
stored chicken patties.  
Other alternative potential commercial uses of grape pomaces that have been 
advocated inclcude food coloring (Metivier et al. 1980; Ayed et al. 1999), dietary fibers 
(Saura-Calixto 1998; Llobera et al. 2007) and phytochemical products (González-Paramás et 
al. 2003).  
Wines by-products have been recently assessed by several patents in the last few 
years. Galbreath et al. (2001)under the patent US 6190716, described a method for preparing 
a grape derived product with Muscadine grapes. Howard et al. (2001) had described a method 
of concentrating grape flavonols from wine, juice or de-alcoholized wine, grape skins and 
fermented grape skins. In this invention, several solvents were tested as eluents. Although the 
organic solvents are eliminated at the drying stage, the use of water would be preferable. 
Aware of the nutraceutical benefits of grape derived substances, recent patents have 
presented advanced extraction methods. Shrikhande et al. (2003) reviewed some patents 
concerning the extraction of polyphenols from whole grapes, grape seeds and grape pomace. 
The authors proposed a method using hot water extraction and an adsorb resin to obtain the 
concentration and purification of polyphenols. 
Newly developed foods and beverages have incorporated grape derived extracts in 
order to obtain health appeal. Wild and Sass (2006) developed a concentrated food ingredient 
comprising the extracts of green tea, grape skin and grape seed. Shrikhande et al. (2007) 
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developed new grape extracts by maximizing the extraction of monomeric and oligomeric 
procyanidins and minimizing the content of polymeric procyanidins. 
In 2008, a patent application by Perlman et al. (2008) presented an interesting use of 
the “rich” by-product of the grape juice industry. Based on the fact that grape pomace solids 
contain at least ten times greater amounts of polyphenols than one time pressed grape juice, 
the authors proposed the fortification of such juice with a pomace polyphenol extract. The 
beverage was tested at different extract concentrations for sensorial acceptance and 
antioxidant activity. Draijer et al. (2009) described the invention of a beverage containing 
550 mg red wine polyphenols + 250 mg of red grape polyphenols added to 200 mL of a soy-
based drink (3.4% protein and 2% fat contents). 
Thus, grape pomace potentially constitutes a very abundant and relatively inexpensive 
source of a wide range of (poly)phenols including monomeric and oligomeric 
proanthocyanidins and a diversity of anthocyanins providing important economic advantages.  
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II. Grape and grape pomace extracts: phenolics 
and antioxidant activities characterisation 
II.1 Grapes and grape pomaces composition of the different 
varieties in 2009 and 2010 
Grapes at maturity and the pomace samples from six different V.vinifera L. varieties 
were analyzed for their phenolic contents and antioxidant activities in order to select extracts 
with the highest potential. Figure 23 summarized all the analysis performed on seeds and 
skins for the 2009 and 2010 vintage after skins and seeds separation. This study was 
conducted on crude materials, with 2009 and 2010 grapes at maturity and their respective 
grape pomace from V.vinifera L. cv. Grenache (from two different locations [GRE1 and 
GRE2]), Syrah (from two different locations [SYR1 and SYR2]), Carignan (CAR), 
Mourvèdre (MOU), Counoise (COU) and Alicante (ALI), provided by the Château de 
Beaucastel located in the Vallée du Rhône, appellation of Châteauneuf-du-Pape. GRE2, COU 
and ALI pomaces were analysed only for the 2010 vintage. The ratio of initial phenolic 
compounds from grape to pomace was also determined.  
 
Figure 23: Analysis performed on grape and pomace seeds and skins 
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II.1.1 Grapes and grape seed pomace phenolic composition in 2009 and 2010 
First, total phenolic contents (TPC) and total tannin contents were determined (Table 
10 and 11). For the 2009 vintage five varieties were analyzed: Grenache from two different 
locations (GRE1, GRE2), Syrah (SYR1), Carignan (CAR), Mourvèdre (MOU) and Counoise 
(COU). The TPC of seed extracts varied slightly between varieties and ranged from 36.6 mg 
GAE/g DW in CAR to 49.7 mg GAE/g DW in MOU. Total tannins ranged from 62.3 mg/g 
DW in COU to 106.4 mg/g DW in GRE2. In grape pomaces, values ranged from 12.6 mg 
GAE/g DW in GRE2 to 35.3 mg GAE/g DW in GRE1 for TPC and from 39.1 mg/g DW to 
105.8 mg/g DW for total tannins in GRE2 and GRE1, respectively (Table 10). The amount of 
extracted TCP was different according to grape varieties and locations (GRE1 vs GRE2). 
Indeed, in GRE2 and MOU, up to 70% of their initial TCP was extracted during fermentation 
whereas in GRE1, it was only 15%.  
Table 10: Total phenol contents and total tannins in 2009 grape and pomace seed 
extracts 
Grapes- 2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 COU
a
 
TPC 41.2 ± 1.0 42.1 ± 1.7 47.4 ± 1.0 36.6 ± 0.8 49.7 ± 4.0 42.7 ± 1.7 
Total tannins 89.8 ± 0.4 106.5 ± 4.4 89.1± 0.1 91.4 ± 0.8 101.0 ± 4.8 62.3 ± 1.9 
       
Pomaces-2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 COU
a
 
TPC 35.3 ± 1.1 12.6 ± 1.0 30.2 ± 1.2 27.5 ± 1.0 19.0 ± 2.0 - 
Total tannins 105.8 ± 1.0 39.1 ± 1.2 54.3 ± 0.9 59.8 ± 0.7 51.5 ± 0.9 - 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, COU, Counoise. In units of mg/g 
DW seeds or skins. Data are expressed as the mean of triplicate ± standard deviation. TPC, total phenol contents. 
 
In the case of the 2010 vintage, two more samples were added to the study: another 
Syrah sample (SYR2) and Alicante (ALI). A greater variability in the amount of 
(poly)phenols can be observed in grape seeds (Table 11). The highest levels of TPC were 
founded in GRE1 and COU (88.7 and 83.4 mg GAE/g DW respectively) while GRE2, MOU 
and CAR contained lowest amounts with an average of 59 mg GAE/g DW. Total tannin 
levels ranged from 115.6 mg/g DW in SYR2 to 167.8 mg/g DW in GRE1. After vinification 
the variability was smaller ranging from 33.0 to 44.5 mg GAE/g DW for TPC and 68.9 to 
84.9 mg/g DW for total tannins (Table 11). With all the varieties, more than 45% of TCPs 
remained in the pomaces (Figure 24). 
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Table 11: Total phenol contents and total tannins in 2010 grape and seed pomace 
extracts 
Grapes-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
TPC 88.7 ± 1.0 58.6 ± 0.2 72.8 ± 0.7 65.6 ± 0.2 58.6 ± 3.7 59.6 ± 1.5 83.4 ± 15.0 76.4 ± 8.0 
TT 167.8 ± 0.9 136.8 ± 5.2 123.3 ± 1.4 115.6 ± 1.3 131.7 ± 1.4 153.0 ± 5.2 143.1 ± 21.9 148.4 ± 7.3 
Pomaces-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
TPC 40.5 ± 1.1 34.9 ± 0.2 35.6 ± 1.8 33.0 ± 1.4 38.8 ± 0.3 34.5 ± 0.1 40.8 ± 3.1 44.5 ± 0.4 
TT 83.1 ± 0.0 74.9 ± 1.1 79.2 ± 1.4 68.9 ± 2.3 78.7 ± 0.2 69.4 ± 3.1 70.9 ± 4.4 84.9 ± 34.0 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, COU, Counoise ; ALI, Alicante. In 
units of mg/g DW seeds or skins. Data are expressed as the mean of triplicate ± standard deviation. TPC, total phenol contents; TT, Total 
tannins. 
 
 
 
Figure 24: Residual phenolics (total polyphenol contents, total tannins and total 
anthocyanins) in 2010 grape seed and skin pomace extracts 
 
Concerning proanthocyanidins characterisation, flavan-3-ol monomers [(+)-catechin, 
()-epicatechin] and oligomers (B1, B2, B3, B4) were identified and quantified (Table 12 and 
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13). A typical HPLC-Fluo chromatogram of grape and grape pomace extracts with an 
excitation and emission wavelengths at 230 nm and 320 nm were showed in Figure 25. 
In grapes, for both vintages, COU contained the highest amount of monomeric and 
oligomeric proanthocyanidins whereas CAR and MOU had the lowest. SYR1 contained a 
particular rich level of monomers represented by the sum of (+)-catechin and (–)-epicatechin 
(4.1 mg/g DW in 2009 and 7.8 mg/g DW in 2010) while ALI was a source of an appreciable 
quantity of proanthocyanidins (7.4 mg/g DW of monomers and 2.2 mg/g DW of dimers [Σ of 
B1, B2, B3, B4]). Regarding their respective grape pomaces, 2009 and 2010 SYR1 and ALI 
retained a high concentration of monomers with up to 6.5 mg/g DW remaining in ALI. The 
2009 and 2010 GRE1, COU and ALI were still relatively rich in dimers (Table 12 and 13). 
Indeed, 90% of monomers and 55% of dimers remained in GRE1 seed pomace and the 
respective figures for ALI, were 88% and 62%. 
 
Figure 25: Typical HPLC-Fluo chromatogram of grape and grape pomace extracts 
with an excitation and emission wavelengths at 230 nm and 320 nm. In this chromatogram, CAR 
seed extract flavan-3-ol chromatogram is presented. C, (+)-Catechin; EC, (–)-Epicatechin; B1, B2; B3, B4, 
Procyanidin dimers B1, B2; B3, B4. 
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Table 12: Proanthocyanidins characterisation of 2009 grape and pomace seed 
extracts from the vintage 2009 
Grapes-2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 COU
a
 
C 2.33 ± 0.00 1.14 ± 0.13 1.81 ± 0.00 0.70 ± 0.01 0.43 ± 0.16 2.21 ± 0.04 
EC 1.01 ± 0.00 0.91 ± 0.11 2.31 ± 0.00 0.62 ± 0.00 0.38 ± 0.14 2.52 ± 0.06 
Σ Monomers 3.34 ± 0.00 2.05 ± 0.23 4.12 ± 0.00 1.32 ± 0.01 0.81 ± 0.30 4.72 ± 0.09 
B1 0.15 ± 0.00 0.13 ± 0.02 0.13 ± 0.00 0.10 ± 0.01 0.08 ± 0.03 0.14 ± 0.00 
B2 0.43 ± 0.00 0.43 ± 0.05 0.34 ± 0.00 0.37 ± 0.01 0.18 ± 0.07 0.57 ± 0.01 
B3 0.26 ± 0.00 0.18 ± 0.02 0.14 ± 0.00 0.13 ± 0.01 0.11 ± 0.04 0.14 ± 0.00 
B4 0.19 ± 0.00 0.17 ± 0.02 0.15 ± 0.00 0.15 ± 0.00 0.11 ± 0.04 0.19 ± 0.00 
Σ Dimerss 1.03 ± 0.00 0.91 ± 0.10 0.76 ± 0.00 0.76 ± 0.03 0.49 ± 0.18 1.04 ± 0.02 
Monomeric/oligomeric fraction 
mDP 2.70 ± 0.00 2.60 ± 0.10 2.24 ± 0.03 3.11 ± 0.05 4.56 ± 0.21 2.11 ± 0.00 
%G 37.48 ± 0.00 34.90 ± 1.45 35.27 ± 1.50 36.05 ± 0.09 51.88 ± 0.71 28.70 ± 0.36 
Polymeric fraction 
mDP 17.6 ± 0.62 16.70 ± 0.66 13.36 ± 0.08 15.16 ± 0.68 25.11 ± 0.14 11.78 ± 0.11 
%G 58.16 ± 0.13 58.70 ± 0.34 54.38 ± 0.12 46.14 ± 0.16 58.90 ± 0.25 44.92 ± 10.76 
       
Pomaces-2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 COU
a
 
C 0.75 ± 0.01 0.255 ± 0.020 0.63 ± 0.10 0.33 ± 0.00 0.19 ± 0.02 - 
EC 0.46 ± 0.02 0.229 ± 0.020 0.75 ± 0.12 0.22 ± 0.00 0.13 ± 0.01 - 
Σ Monomers 1.20 ± 0.03 0.484 ± 0.04 1.38 ± 0.22 0.55 ± 0.01 0.32 ± 0.03 - 
B1 0.09 ± 0.00 0.024 ± 0.002 0.08 ± 0.01 0.06 ± 0.00 0.03 ± 0.00 - 
B2 0.24 ± 0.01 0.073 ± 0.010 0.17 ± 0.03 0.15 ± 0.00 0.04 ± 0.00 - 
B3 0.11 ± 0.00 0.026 ± 0.003 0.07 ± 0.01 0.05 ± 0.00 0.03 ± 0.00 - 
B4 0.11 ± 0.01 0.038 ± 0.010 0.08 ± 0.02 0.06 ± 0.00 0.03 ± 0.00 - 
Σ Dimers 0.56 ± 0.02 0.161 ± 0.019 0.40 ± 0.07 0.31 ± 0.00 0.12 ± 0.01 - 
Monomeric/oligomeric fraction 
mDP 3.97 ± 0.13 6.99 ± 0.37 2.95 ± 0.14 4.11 ± 0.00 9.20 ± 0.70 - 
%G 45.34 ± 0.39 48.89 ± 2.45 41.86 ± 1.96 44.19 ± 0.00 54.10 ± 0.99 - 
Polymeric fraction 
mDP 16.27 ± 0.63 25.81 ± 0.00 12.26 ± 0.49 19.21 ± 0.03 13.28 ± 0.00 - 
%G 54.91 ± 0.50 34.30 ± 0.00 53.21 ± 0.51 50.12 ± 0.75 62.75 ± 0.00 - 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, COU, Counoise. In units of mg/g 
DW seeds or skins. Data are expressed as the mean of triplicate ± standard deviation. C, (+)-Catechin; EC, (–)-Epicatechin; B1, B2; B3, B4, 
Procyanidin dimers B1, B2; B3, B4. Σ Monomers, sum of catechin and epicatechin; Σ Dimers, sum of B1, B2, B3 and B4; mDP, mean degree of 
polymerization ; %G, percentage of galloylation ; %P, percentage of prodelphinidins. 
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Table 13: Proanthocyanidins characterisation of grape and pomace seed extracts from the vintage 2010 
Grapes-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
C 1.85 ± 0.10 2.99 ± 0.15 4.53 ± 0.05 2.38 ± 0.06 3.82 ± 0.50 2.62 ± 0.03 2.71 ± 0.12 4.24 ± 0.01 
EC 0.79 ± 0.00 1.39 ± 0.18 3.23 ± 0.24 2.93 ± 0.09 0.81 ± 0.13 0.87 ± 0.03 5.16 ± 0.77 3.12 ± 0.33 
Σ Monomers 2.63 ± 0.09 4.31 ± 0.16 7.76 ± 0.22 5.31 ± 0.12 4.63 ± 0.52 3.49 ± 0.03 7.87 ± 0.56 7.36 ± 0.29 
B1 0.26 ± 0.03 0.38 ± 0.02 0.36 ± 0.01 0.27 ± 0.01 0.17 ± 0.04 0.17 ± 0.01 0.33 ± 0.03 0.46 ± 0.07 
B2 0.44 ± 0.01 0.53 ± 0.11 0.39 ± 0.01 0.40 ± 0.07 0.32 ± 0.06 0.20 ± 0.01 0.50 ± 0.01 0.64 ± 0.00 
B3 0.29 ± 0.04 0.49 ± 0.02 0.27 ± 0.04 0.20 ± 0.03 0.18 ± 0.03 0.10 ± 0.00 0.29 ± 0.01 0.71 ± 0.01 
B4 0.23 ± 0.01 0.26 ± 0.05 0.23 ± 0.03 0.22 ± 0.01 0.21 ± 0.05 0.13 ± 0.00 0.25 ± 0.03 0.41 ± 0.02 
Σ Dimers 1.22 ± 0.07 1.65 ± 0.06 1.25 ± 0.07 1.10 ± 0.09 0.88 ± 0.08 0.59 ± 0.01 1.37 ± 0.05 2.22 ± 0.06 
C1 0.23 ± 0.04 0.29 ± 0.04 0.29 ± 0.01 0.28 ± 0.01 0.19 ± 0.04 0.20 ± 0.00 0.34 ± 0.03 0.34 ± 0.03 
Monomeric/oligomeric fraction 
mDP 1.98 ± 0.29 2.02 ± 0.24 2.02 ± 0.19 1.62 ± 0.32 3.04 ± 0.00 3.54 ± 0.49 1.77 ± 0.02 1.72 ± 0.02 
%G 48.16 ± 2.27 47.13 ± 0.07 48.67 ± 0.12 33.35 ± 5.72 55.16 ± 0.00 68.05 ± 2.47 41.13 ± 2.23 43.26 ± 0.59 
Polymeric fraction 
        
mDP 10.86 ± 0.41 11.44 ± 1.47 10.51 ± 1.9 9.93 ± 0.13 9.97 ± 0.46 13.23 ± 1.78 12.11 ± 1.01 10.82 ± 0.49 
%G 80.35 ± 8.24 92.03 ± 4.95 91.28 ± 0.15 83.3 ± 0.15 90.73 ± 4.37 92.77 ± 0.3 89.49 ± 4.39 86.43 ± 1.57 
Pomaces-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
C 2.34 ± 0.01 2.33 ± 0.06 2.773 ± 0.162 1.86 ± 0.07 0.89 ± 0.09 0.43 ± 0.01 0.14 ± 0.02 4.11 ± 0.63 
EC 0.03 ± 0.01 0.69 ± 0.02 2.61 ± 0.07 1.15 ± 0.02 0.39 ± 0.01 0.55 ± 0.02 2.70 ± 0.13 2.40 ± 0.43 
Σ Monomers 2.37 ± 0.01 3.02 ± 0.07 5.38 ± 0.14 3.01 ± 0.08 1.28 ± 0.08 0.99 ± 0.04 2.84 ± 0.09 6.51 ± 0.92 
B1 0.12 ± 0.01 0.12 ± 0.01 0.09 ± 0.01 0.09 ± 0.01 0.11 ± 0.01 0.11 ± 0.01 0.17 ± 0.01 0.20 ± 0.01 
B2 0.21 ± 0.03 0.16 ± 0.02 0.09 ± 0.01 0.18 ± 0.03 0.15 ± 0.00 0.11 ± 0.01 0.22 ± 0.03 0.49 ± 0.02 
B3 0.15 ± 0.02 0.13 ± 0.02 0.03 ± 0.00 0.10 ± 0.01 0.08 ± 0.00 0.08 ± 0.01 0.11 ± 0.01 0.33 ± 0.02 
B4 0.19 ± 0.02 0.16 ± 0.02 0.04 ± 0.00 0.17 ± 0.03 0.12 ± 0.01 0.11 ± 0.01 0.16 ± 0.01 0.33 ± 0.06 
Σ Dimers 0.67 ± 0.05 0.57 ± 0.06 0.26 ± 0.02 0.54 ± 0.08 0.46 ± 0.02 0.39 ± 0.02 0.65 ± 0.05 1.37 ± 0.08 
C1 0.13 ± 0.01 0.11 ± 0.02 0.05 ± 0.01 0.14 ± 0.02 0.11 ± 0.01 0.10 ± 0.01 0.17 ± 0.01 0.32 ± 0.03 
Monomeric/oligomeric fraction 
mDP 2.60 ± 0.12 2.69 ± 0.02 1.85 ± 0.21 2.26 ± 0.11 3.04 ± 0.03 4.23 ± 0.69 2.53 ± 0.30 1.90 ± 0.07 
%G 62.67 ± 4.97 63.87 ± 4.11 49.63 ± 4.12 55.32 ± 0.34 69.67 ± 1.65 73.07 ± 3.94 57.14 ± 1.87 43.66 ± 2.98 
Polymeric fraction 
        
mDP 14.55 ± 0.01 10.95 ± 1.07 7.99 ± 0.73 12.04 ± 1.80 10.43 ± 0.42 12.18 ± 1.13 11.02 ± 0.78 8.06 ± 0.05 
%G 95.56 ± 0.01 92.37 ± 2.66 92.93 ± 2.75 92.42 ± 0.38 87.11 ± 1.95 91.67 ± 0.98 91.35 ± 2.53 88.51 ± 3.50 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, COU, Counoise ; ALI, Alicante. In units of mg/g DW seeds or skins. Data are expressed as the mean of triplicate 
± standard deviation. C, (+)-Catechin; EC, (–)-Epicatechin; B1, B2; B3, B4, Procyanidin dimers B1, B2; B3, B4. Σ Monomers, sum of catechin and epicatechin; Σ Dimers, sum of B1, B2, B3 and B4; mDP, mean degree of 
polymerization ; %G, percentage of galloylation ; %P, percentage of prodelphinidins. 
1
3
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Concerning the 2009 monomeric/oligomeric fraction of the different grape pomace 
varities, the mDP ranged from 2.1 to 4.6 and %G from 28.7 to 51.9 while in 2010, it varied 
respectively from 1.6 to 3.5 (mDP) and %G from 33.3 to 68.1 (Table 12 and 13). Seeds from 
MOU were the most polymerized and galloylated followed by CAR seeds. The same trend 
was observed in their respective grape pomaces where MOU has a mDP of 9.2 and 4.2 and a 
%G of 54.1 and 73.1 in 2009 and 2010 respectively. Compared to grapes, mDP values were 
higher in grape pomaces especially in 2009 with an increase of 1.3-fold of %G being 
observed. Indeed, as the alcohol level increases during the winemaking process, tissues 
become more permeable and low molecular weight tannins are released from seeds into 
wines toward the mid-point of fermentation and as a consequence the remaining seed 
pomaces has a higher mDP. 
For the polymeric fraction, higher values were generally observed for both vintages. 
MOU was still the most highly polymerized with grapes mDP values ranging from 11.78 to 
25.11 in 2009 and from 9.93 to 13.23 in 2010 (Tables 12 and 13). These results are in 
agreement with those obtained in other studies with other V. vinifera varieties where mDP 
values of polymeric proanthocyanidins in grape seed extracts extended from 2.7 to 18.6 
(Monagas et al. 2003; Vidal et al. 2003). In pomaces, mDP fluctuated from 12.3 to 25.8 in 
2009 and from 7.9 to 14.5 in 2010. The %G of 2010 grapes and their pomaces on average 
were 1.7-fold more galloylated than in 2009. No significant changes in the mDP and %G in 
polymeric fractions between grapes and pomaces from the same variety and the same vintage 
were observed. Values were predominantly vintage dependant. 
II.1.2. Grape and grape pomace skin phenolics composition in 2009 and 2010 
The TPC, total tannin and total anthocyanin contents of grape skins were analysed 
(Tables 14 and 15). Samples were the same as for seed extracts and for the two vintages. As 
expected, grape skins contained a lower concentration of phenolic compounds than in seeds. 
The TPC in 2009, ranged from 20.2 mg GAE/g DW in COU to 35.5 mg GAE/g DW in SYR1 
and in 2010 from 34.8 mg GAE/g DW in COU to 52.3 mg GAE/g DW in ALI (Tables 14 and 
15). Varieties with the highest total tannin levels were 2009 GRE1 (72.5 mg/g DW) and 2010 
ALI (85.8 mg/g DW). For total anthocyanins, SYR1, CAR, MOU and ALI possessed high 
amounts for both vintages. These results are in good agreement with an earlier report on the 
high anthocyanin contents of grapes from Vitis vinifera cultivars (Alicante, Merlot, Syrah, 
Cinsault, Grenache, Carignan, Cabernet Sauvignon and Mourvèdre) (Jensen et al. 2008).  
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Table 14: Total phenol contents, total tannins and total anthocyanins in grape 
and pomace skin extracts from the 2009 vintage 
Grapes-2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 COU
a
 
TPC 23.4 ± 0.7 21.2 ± 0.0 35.5 ± 1.5 21.7 ± 0.4 27.3 ± 0.7 20.2 ± 0.3 
Total tannins 72.5 ± 3.0 57.9 ± 1.4 66.4 ± 6.9 44.9 ± 6.1 67.2 ± 6.1 49.4 ± 0.8 
Total antho 4.3 ± 0.9 10.0 ± 0.6 12.9 ± 1.4 24.5 ± 0.3 17.8 ± 2.1 13.7 ± 0.5 
       
Pomaces-2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 COU
a
 
TPC 18.7 ± 0.1 11.8 ± 0.7 15.5 ± 0.1 22.7 ± 0.1 12.1 ± 0.8 - 
Total tannins 53.4 ± 1.2 31.5 ± 0.4 33.0± 0.1 56.1 ± 0.3 31.8 ± 4.9 - 
Total antho 3.7 ± 0.0 3.3 ± 0.5 5.1 ± 0.0 7.1 ± 0.5 3.4 ± 0.7 - 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, COU, Counoise. In units of mg/g 
DW seeds or skins. Data are expressed as the mean of triplicate ± standard deviation. TPC, total phenol contents; total antho, total 
anthocyanins. 
 
Table 15: Total phenol contents, total tannins and total anthocyanins in grape 
and pomace skin extracts from the 2010 vintage 
Grapes-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
TPC 37.4 ± 0.7 37.9 ± 0.1 45.2 ± 2.2 39.7 ± 0.3 45.0 ± 0.1 41.3 ± 1.6 34.8 ± 0.0 52.3 ± 3.9 
TT 59.5 ± 5.2 63.8 ± 0.7 73.0 ± 6.0 66.3 ± 3.3 65.2 ± 0.7 70.8 ± 3.1 61.3 ± 1.1 85.8 ± 8.4 
TA 11.2 ± 0.2 8.4 ± 0.7 12.1 ± 0.3 10.8 ± 0.1 15.2 ± 0.0 11.8 ± 0.3 8.7 ± 0.4 18.1 ± 2.5 
         
Pomaces-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
TPC 17.1 ± 0.4 19.5 ± 1.0 24.3 ± 0.0 20.8 ± 0.2 25.1 ± 1.1 26.3 ± 0.3 20.5 ± 0.2 31.6 ± 1.7 
TT 33.9 ± 1.4 35.2 ± 0.2 35.9 ± 1.1 31.8 ± 0.1 46.1 ± 0.3 47.3 ± 1.3 37.6 ± 0.3 55.3 ± 5.7 
TA 1.5 ± 0.1 3.2 ± 0.0 4.9 ± 0.1 5.0 ± 0.1 7.7 ± 0.5 3.8 ± 0.3 2.0 ± 0.0 10.0± 0.8 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, COU, Counoise ; ALI, Alicante. In 
units of mg/g DW seeds or skins. Data are expressed as the mean of triplicate ± standard deviation. TPC, total phenol contents; TT, Total 
tannins; TA, total anthocyanins. 
 
More than 45% of TPC and total tannins remained in the grape skin pomaces of all 
the varieties. A different trend was observed concerning total anthocyanins especially for 
MOU in 2009 and GRE1 in 2010 (Figure 24) where up to 80% of the initial amounts were 
extracted. Thus, anthocyanins appeared to be the most easily extractable phenolic compounds 
during vinification. Indeed, skins are more altered than seeds by the procedures such as 
pressing, crushing and maceration. During maceration, appreciable substantial quantities of 
anthocyanins are extracted into wine. As the level of alcohol increases during vinification, 
anthocyanins are solubilized and released in the acidic matrix (Ribéreau-Gayon et al. 2006). 
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Additional information was obtained when monomeric flavan-3-ols and oligomeric 
proanthocyanidins were analysed by HPLC. They showed substantial amounts of epicatechin, 
catechin, and procyanidin dimers B2, B3 and B4 in 2009 GRE1 and SYR1 grape skins (Table 
16). In their respective skin pomaces, GRE1 and MOU retained the highest concentration of 
flavan-3-ols (Table 16). SYR1 and CAR were the most extracted varieties and retaining less 
than 10% of monomers and dimers. In 2010, grape varieties with the highest amounts of 
monomers and dimers in skins were the CAR, MOU and especially ALI which contained 8.7 
mg/g DW of monomers and 0.3 mg/g DW of dimers. The vinification process removed more 
than 65% of the monomers and especially affected catechin levels (Table 16). Pomaces from 
2010 skins of COU and ALI were the richest in monomeric and oligomeric 
proanthocyanidins (Table 16 and Figure 24). 
As already observed in previous studies (Prieur et al. 1994; Lorrain et al. 2011) the 
proanthocyanidins in skins differed from those in seeds primarily by the presence of 
prodelphinidins, higher mDP values and lower amounts of galloylated derivatives. In the case 
of the 2009 vintage, substantial difference in grape skins were observed between varieties 
especially concerning the %G which varied from 18.3 in MOU to 50.7 in COU and the %P 
which ranged 5.6 in COU to 52.1 in MOU in the monomeric/oligomeric fraction. mDP values 
varied from 1.4 in CAR to 5.7 in GRE1. In the polymeric fraction, mDP ranged from 14.1 to 
23, %G from 23.2 to 46.1 and only the %P was found for GRE1, GRE2 and COU. 
In 2010 grape skins, in the monomeric/oligomeric fractions, mDP varied from 4.9 to 
11.1, %G from 30.5 to 59.1 and %P from 8.5 to 25.2 (Table 17). In the polymeric fraction, 
mDP fluctuated from 18.8 to 24.8. Non-significant differences were observed between 
varieties and values ranged from 6.9 to 9.5 for %G and from 22.2 to 30.5 for %P. These 
results are consistent with data concerning mDP values of polymeric proanthocyanidins 
which can vary from 10 to ~83, depending on the fractionation technique employed, the 
grape variety and the vintage (Souquet et al. 1996; Bordiga et al. 2011). Compared to other 
studies on Italian and Bordeaux grape varieties with vintages 2008, 2009 and 2010, our %G 
and %P are higher. Indeed, these results can be related to the varieties and vintage effects 
(Chira et al. 2009; Bordiga et al. 2011; Lorrain et al. 2011). Grape skin pomace analysis 
underlined that vinification affected the characteristics of proanthocyanidins in skins. 
Actually, for the two vintages, in grape skin pomace extracts, an increase in mDP and a 
decrease in %G in the monomeric/oligomeric fractions were observed.  
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Table 16: Proanthocyanidins characterisation of grape and pomace skin extracts 
from the vintage 2009 
Grapes-2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 COU
a
 
C 0.14 ± 0.01 0.01 ± 0.00 0.28 ± 0.02 0.08 ± 0.01 0.04 ± 0.01 0.03 ± 0.00 
EC 0.06 ± 0.00 0.001 ± 0.00 0.08 ± 0.06 0.02 ± 0.01 0.01 ± 0.02 0.02 ± 0.00 
Σ Monomers 0.20 ± 0.01 0.01 ± 0.00 0.36 ± 0.07 0.10 ± 0.02 0.05 ± 0.01 0.05 ± 0.00 
B1 0.05 ± 0.01 0.02 ± 0.00 0.92 ± 0.06 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.00 
B2 0.05 ± 0.01 
0.0004 ± 
0.00 
0.04 ± 0.00 0.03 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 
B3 0.02 ± 0.00 0.003 ± 0.00 0.03 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 
B4 0.02 ± 0.00 0.003 ± 0.00 0.02 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
Σ Dimers 0.15 ± 0.02 0.02 ± 0.00 1.01 ± 0.07 0.09 ± 0.03 0.05 ± 0.02 0.04 ± 0.00 
Monomeric/oligomeric fraction 
   
mDP 5.68 ± 0.28 4.05 ± 0.00 1.67 ± 0.02 1.37 ± 0.04 5.34 ± 0.54 2.82 ± 0.02 
%G 29.86 ± 8.46 28.3 ± 0.00 29.92 ± 0.21 18.85 ± 2.73 18.32 ± 1.13 50.67 ± 0.73 
%P 47.41 ± 5.08 16.15 ± 0.00 11.27 ± 1.1 8.55 ± 0.38 52.12 ± 0.82 5.75 ± 0.24 
Polymeric fraction 
      
mDP 17.28 ± 0.55 22.92 ± 0.40 18.54 ± 0.00 15.16 ± 0.68 14.14 ± 0.32 18.92 ± 0.4 
%G 23.2 ± 3.95 27.37 ± 1.80 42.29 ± 2.13 46.14 ± 0.16 28.99 ± 0.24 26.61 ± 1.57 
%P 16.77 ± 0.13 11.29 ± 2.18 nd nd nd 16.17 ± 0.02 
       
Pomaces- 2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 COU
a
 
C 0.03 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 - 
EC 0.003 ± 0.00 0.003 ± 0.00 0.002 ± 0.00 0.002 ± 0.00 0.01 ± 0.00 - 
Σ Monomers 0.03 ± 0.00 0.011 ± 0.00 0.01 ± 0.00 0.008 ± 0.00 0.016 ± 0.00 - 
B1 0.02 ± 0.00 0.003 ± 0.00 0.007 ± 0.00 0.008 ± 0.00 0.007 ± 0.00 - 
B2 0.002 ± 0.00 0.007 ± 0.00 0.001 ± 0.00 0.002 ± 0.00 0.007 ± 0.00 - 
B3 0.005 ± 0.00 0.001 ± 0.00 0.001 ± 0.00 0.001 ± 0.00 0.003 ± 0.00 - 
B4 0.004 ± 0.00 0.003 ± 0.00 0.001 ± 0.00 0.001 ± 0.00 0.004 ± 0.00 - 
Σ Dimers 0.032 ± 0.00 0.013 ± 0.00 0.01 ± 0.00 0.012 ± 0.00 0.022 ± 0.01 - 
Monomeric/oligomeric fraction 
  
mDP 3.76 ± 0.03 3.80 ± 0.10 3.96 ± 0.25 2.23 ± 0.22 7.50 ± 0.37 - 
%G 17.17 ± 0.46 19.81 ± 1.40 19.27 ± 0.40 10.00 ± 1.49 21.27 ± 2.13 - 
%P 6.37 ± 0.89 28.19 ± 2.27 6.62 ± 0.40 14.22 ± 6.72 17.87 ± 4.98 - 
Polymeric fraction 
      
mDP 13.69 ± 0.43 17.64 ± 0.00 13.00 ± 0.59 12.04 ± 0.24 11.09 ± 0.00 - 
%G 33.26 ± 0.13 20.48 ± 0.00 38.02 ± 0.99 34.81 ± 0.71 4.70 ± 0.00 - 
%P 7.11 ± 0.82 26.88 ± 0.00 ND ND 58.37 ± 0.00 - 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, COU, Counoise ; ALI, Alicante. In 
units of mg/g DW seeds or skins. Data are expressed as the mean of triplicate ± standard deviation. C, (+)-Catechin; EC, (–)-Epicatechin; 
B1, B2; B3, B4, Procyanidin dimers B1, B2; B3, B4. Σ Monomers, sum of catechin and epicatechin; Σ Dimers, sum of B1, B2, B3 and B4; mDP, 
mean degree of polymerization ; %G, percentage of galloylation ; %P, percentage of prodelphinidins. 
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Table 17: Proanthocyanidins characterisation of grape and pomace skin extracts from the vintage 2010 
Grapes-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
C 1.24 ± 0.06 2.81 ± 0.00 1.42 ± 0.02 1.81 ± 0.01 3.96 ± 0.05 2.86 ± 0.03 2.78 ± 0.00 7.59 ± 0.08 
EC 0.33 ± 0.01 0.36 ± 0.03 0.40 ± 0.03 0.67 ± 0.13 0.34 ± 0.01 1.03 ± 0.02 0.78 ± 0.00 1.11 ± 0.01 
Σ Monomères 1.57 ± 0.01 3.19 ± 0.00 1.84 ± 0.00 2.48 ± 0.11 4.29 ± 0.02 3.89 ± 0.03 3.56 ± 0.00 8.69 ± 0.05 
B1 0.04 ± 0.00 0.05 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 0.07 ± 0.01 0.07 ± 0.00 0.07 ± 0.00 0.17 ± 0.00 
B2 0.01 ± 0.00 0.004 ± 0.00 0.003 ± 0.00 0.003 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
B3 0.02 ± 0.00 0.02 ± 0.00 0.013 ± 0.00 0.01 ± 0.00 0.03 ± 0.01 0.02 ± 0.00 0.03 ± 0.00 0.08 ± 0.00 
B4 0.01 ± 0.00 0.004 ± 0.00 0.002 ± 0.00 0.002 ± 0.00 0.005 ± 0.00 0.02 ± 0.00 0.004 ± 0.00 0.01 ± 0.00 
Σ Dimères 0.07 ± 0.00 0.07 ± 0.00 0.04 ± 0.00 0.04 ± 0.00 0.11 ± 0.01 0.12 ± 0.00 0.10 ± 0.01 0.27 ± 0.00 
Monomeric/oligomeric fraction 
mDP 4.88 ± 0.00 5.19 ± 0.17 11.1 ± 2.04 7.35 ± 1.45 8.16 ± 0.55 6.45 ± 0.6 7.42 ± 1.11 5.35 ± 1.19 
%G 37.55 ± 6.21 30.47 ± 6.62 44.18 ± 26.12 46.61 ± 7.28 59.12 ± 2.33 47.13 ± 7.48 46.91 ± 7.02 40.09 ± 9.59 
%P 25.2 ± 6.93 19.42 ± 3.42 24.74 ± 15.65 17.56 ± 2.57 10.33 ± 1.50 14.57 ± 2.02 12.92 ± 0.84 8.49 ± 0.74 
Polymeric fraction 
       
mDP 22.43 ± 1.23 19.42 ± 0.05 21.41 ± 2.28 18.76 ± 0.01 24.85 ± 0.73 21.36 ± 0.45 21.98 ± 0.57 22.10 ± 0.18 
%G 7.65 ± 0.52 7.07 ± 0.46 6.89 ± 1.40 7.77 ± 0.01 9.00 ± 0.16 7.68 ± 0.44 9.54 ± 1.01 8.38 ± 0.45 
%P 25.97 ± 2.80 28.52 ± 0.70 29.81 ± 3.28 26.46 ± 0.01 30.50 ± 0.35 23.51 ± 1 22.18 ± 1.10 25.85 ± 1.00 
Pomaces-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
C 0.50 ± 0.00 0.51 ± 0.05 0.40 ± 0.03 0.58 ± 0.12 0.43 ± 0.01 0.29 ± 0.02 0.65 ± 0.07 1.28 ± 0.07 
EC 0.01 ± 0.00 0.26 ± 0.03 0.25 ± 0.03 0.23 ± 0.00 0.24 ± 0.01 0.23 ± 0.015 0.63 ± 0.08 1.14 ± 0.15 
Σ Monomères 0.51 ± 0.00 0.76 ± 0.07 0.65 ± 0.04 0.82 ± 0.10 0.67 ± 0.00 0.52 ± 0.03 1.29 ± 0.13 2.42 ± 0.19 
B1 0.02 ± 0.00 0.03 ± 0.00 0.05 ± 0.00 0.01 ± 0.00 0.03 ± 0.00 0.04 ± 0.00 0.05 ± 0.00 0.04 ± 0.00 
B2 0.02 ± 0.00 0.02 ± 0.00 0.04 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.03± 0.00 0.05 ± 0.00 0.03 ± 0.00 
B3 0.02 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
B4 0.02 ± 0.00 0.02 ± 0.00 0.03 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.03 ± 0.00 0.04 ± 0.01 0.03 ± 0.00 
Σ Dimères 0.07 ± 0.00 0.08 ± 0.00 0.15 ± 0.01 0.04 ± 0.00 0.08 ± 0.01 0.11 ± 0.00 0.16 ± 0.00 0.12 ± 0.01 
Monomeric/oligomeric fraction 
mDP 12.13 ± 0.89 7.76 ± 0.01 9.35 ± 0.02 10.22 ± 0.04 10.29 ± 0.13 9.20 ± 0.45 11.22 ± 0.45 9.94 ± 2.40 
%G 9.70 ± 0.34 19.24 ± 0.01 20.86 ± 0.76 23.82 ± 0.14 17.27 ± 0.31 18.59 ± 0.09 25.27 ± 0.33 13.81 ± 0.81 
%P 16.94 ± 2.13 24.88 ± 0.01 29.08 ± 0.16 26.27 ± 0.03 34.92 ± 0.64 26.06 ± 0.28 32.38 ± 0.55 31.05 ± 0.62 
Polymeric fraction 
       
mDP 10.74 ± 0.21 10.97 ± 0.82 11.48 ± 0.75 12.20 ± 1.17 12.11 ± 0.57 12.20 ± 1.17 11.70 ± 0.32 10.85 ± 1.76 
%G 10.04 ± 0.52 7.62 ± 0.47 7.16 ± 0.23 10.53 ± 0.18 6.07 ± 0.03 10.53 ± 0.18 10.20 ± 0.57 11.02 ± 0.90 
%P 17.73 ± 0.30 19.23 ± 0.16 18.96 ± 0.43 18.12 ± 0.09 20.67 ± 0.36 18.12 ± 0.09 18.79 ± 0.02 16.72 ± 1.03 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, COU, Counoise ; ALI, Alicante. In units of mg/g DW seeds or skins. Data are expressed as the mean of triplicate ± standard 
deviation. C, (+)-Catechin; EC, (–)-Epicatechin; B1, B2; B3, B4, Procyanidin dimers B1, B2; B3, B4. Σ Monomers, sum of catechin and epicatechin; Σ Dimers, sum of B1, B2, B3 and B4; mDP, mean degree of 
polymerization ; %G, percentage of galloylation ; %P, percentage of prodelphinidins. 
1
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As for seeds, these values suggest that proanthocyanidins with low mDP were the 
most readily extracted into wines. In the polymeric fractions, the trend was opposite since 
mDP decreased in pomaces. This observation demonstrates that not only the small 
proanthocyanidins but also the more polymerized ones can be extracted from skins, probably 
during different periods of the vinification process. No conclusions can be drawn concerning 
%P in 2009 because of varietal differences. However, in 2010, %P tended to increase in 
monomeric/oligomeric fractions while the opposite was observed in polymeric fractions.  
The anthocyanin contents of skin extracts was analysed by HPLC and the profiles 
obtained were in good agreement with those obtained in earlier studies with V. vinifera L. 
grapes (Romero-Cascales et al. 2005; Liang et al. 2008) and individual anthocyanin 
concentrations were well correlated with estimates of total anthocyanin contents. For both 
vintages and for all varieties, malvidin-3-O-monoglucoside was the major anthocyanin and 
accounted for 40% to 55% of total anthocyanins depending on the variety (Tables 18 and 19). 
In 2009 grapes, it is observed that SYR1, CAR and MOU contained more glycosylated, 
acetylated and p-coumaroylated anthocyanins than the other varieties. Values ranged from 
1.4 mg/g DW to 10.6 mg/g DW for glycosylated anthocyanins, from 0.2 mg/g DW to 1.1 
mg/g DW for acetyl-anthocyanins and from 0.2 mg/g DW to 2.7 mg/g DW for p-
coumaroylated anthocyanins. In grape skin pomace samples, CAR and SYR1 still contained 
the highest amounts of glycosylated and p-coumaroylated anthocyanins, with 8.9 mg/g DW 
and 5.2 mg/g DW respectively. MOU was the most affected by vinification since more than 
70 % of the initial anthocyanins were extracted into wines (Table 18). 
Table 18: Anthocyanins characterisation of grape and pomace skin extracts from 
the vintage 2009 
Grapes-2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 COU
a
 
Dp 0.38 ± 0.01 nd nd 0.35 ± 0.01 0.51 ± 0.01 nd 
Cy 0.42 ± 0.01 nd nd 0.33 ± 0.00 0.98 ± 0.01 nd 
Pt 0.49 ± 0.01 0.16 ± 0.00 0.31 ± 0.00 0.39 ± 0.01 0.89 ± 0.01 0.19 ± 0.00 
Pn 0.91 ± 0.00 0.30 ± 0.00 1.17 ± 0.01 0.77 ± 0.00 2.24 ± 0.01 0.49 ± 0.00 
Mv 3.90 ± 0.01 0.91 ± 0.01 5.81 ± 0.05 8.08 ± 0.05 5.96 ± 0.01 0.76 ± 0.00 
Σ Glu 6.10 ± 0.02 1.38 ± 0.01 7.28 ± 0.06 9.91 ± 0.05 10.59 ± 0.02 1.43 ± 0.00 
Σ Ace 0.38 ± 0.01 0.17 ± 0.01 1.13 ± 0.01 0.48 ± 0.01 0.57 ± 0.01 0.22 ± 0.00 
Σ Coum 0.87 ± 0.01 0.24 ± 0.01 2.72 ± 0.01 2.53 ± 0.01 1.58 ± 0.01 0.24 ± 0.00 
Pomaces-2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 COU
a
 
Dp 0.26 ± 0.00 0.24 ± 0.00 0.24 ± 0.00 0.67 ± 0.01 0.22 ± 0.01 - 
Cy 0.22 ± 0.00 0.21 ± 0.00 0.17 ± 0.00 0.21 ± 0.00 0.18 ± 0.01 - 
Pt 0.32 ± 0.01 0.33 ± 0.00 0.31 ± 0.00 0.87 ± 0.01 0.32 ± 0.00 - 
Pn 0.41 ± 0.00 0.45 ± 0.01 0.35 ± 0.00 0.42 ± 0.02 0.27 ± 0.00 - 
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Mv 1.73 ± 0.02 2.60 ± 0.00 3.09 ± 0.05 6.77 ± 0.01 1.96 ± 0.01 - 
Σ Glu 2.94 ± 0.01 3.83 ± 0.01 4.16 ± 0.06 8.96 ± 0.02 2.94 ± 0.02 - 
Σ Ace 0.36 ± 0.00 0.45 ± 0.00 0.79 ± 0.01 0.43 ± 0.01 0.18 ± 0.01 - 
Σ Coum 1.28 ± 0.00 1.43 ± 0.02 2.34 ± 0.00 5.23 ± 0.00 0.69 ± 0.00 - 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, COU, Counoise ; ALI, Alicante. In 
units of mg/g DW seeds or skins. Data are expressed as the mean of triplicate ± standard deviation. Dp, delphinidin-3-O-monoglucoside ; 
Cy, Cyanidin-3-O-monoglucoside ; Pt, Petunidin-3-O-monoglucoside ; Pn, Peonidin-3-O-monoglucoside ; Mv, Malvidin-3-O-
monoglucoside ; Σ Glu, sum of monoglucoside anthocyanins; Σ Ace, sum of petunidin-3-O-acetylmonoglucoside, peonidin-3-O-
acetylmonoglucoside and malvidin-3-O-acetylmonoglucoside; Σ Coum, sum of peonidin-3-(6-O-p-coumaroyl)monoglucoside and malvidin-
3-(6-O-p-coumaroyl)monoglucoside; nd, not detected. 
 
As previously noted, the anthocyanin contents of grape skins were higher in 2010 than 
2009. Grape skin extracts from ALI contained the highest quantities of glycoside-, acetyl- 
and p-coumaroyl-anthocyanins, 17.40, 1.57 and 2.38 mg/g DW, respectively (Table 19). 
“Teinturier “cultivars had higher anthocyanin contents than “non-teinturier “grapes. It has 
been reported that Alicante skins contain principally malvidin-3-O-glucoside (39-48% of the 
total) as expected for the V.vinifera cultivars, but also contain unusually high amounts of 
peonidin-3-O-glucoside (19-31%) when compared to Cabernet Sauvignon and Tempranillo 
(Hermosin Gutierrez et al. 2004). Among “non-teinturier” varieties, SYR1 and CAR were 
particularly rich in glycosylated and p-coumaroylated anthocyanins, for both 2009 and 2010 
vintages, while MOU was rich in acetylated anthocyanins, especially in 2010. Appreciable 
amounts of anthocyanins remained in grape skin pomaces of SYR1, CAR and ALI, with up 
to 14.3 mg/g DW, 0.22 mg/g DW and 5.3 mg/g DW of glycoside-, acetyl- and p-coumaroyl-
anthocyanins, respectively, being retained (Table 18 and 19). In 2009 and 2010 skin pomaces 
of GRE1 and COU contained the lowest levels of anthocyanins whereas CAR (2009 and 
2010), GRE2 (2010), SYR2 (2010) and MOU (2010) retained high quantities of glycoside-, 
acetyl- and p-coumaroyl-anthocyanins. Furthermore, for the two vintages, the data obtained 
with grape skins and pomace skins indicated that the winemaking process resulted in a 
relative increase p-coumaroyl derivatives and a decrease of the acetyl-anthocyanins. This 
phenomenon has also been observed in an earlier study which found that the relative content 
of p-coumaroyl derivatives of malvidin and peonidin was lower in wines than in fresh grape 
skins but higher in pomace. (García-Beneytez et al. 2002). Slow rates of extraction of the p-
coumaroyl anthocyanins from skins during vinification have been reported, explaining the 
presence of similar amounts of these anthocyanins in fresh grape skins and pomace skins 
(Fournand et al. 2006). 
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Table 19: Anthocyanins characterisation of grape and pomace skin extracts from the vintage 2010 
Grapes-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
Dp 2.51 ± 0.31 0.74 ± 0.11 1.44 ± 0.02 1.51 ± 0.02 2.92 ± 0.10 1.16 ± 0.01 0.94 ± 0.00 1.45 ± 0.00 
Cy 0.45 ± 0.05 0.11 ± 0.01 0.13 ± 0.00 0.15 ± 0.00 0.13 ± 0.02 0.50 ± 0.03 0.16 ± 0.01 0.14 ± 0.00 
Pt 1.40 ± 0.03 0.58 ± 0.04 1.10 ± 0.00 1.03 ± 0.01 2.61 ± 0.66 1.24 ± 0.06 0.80 ± 0.00 1.40 ± 0.01 
Pn 1.55 ± 0.09 0.86 ± 0.04 0.95 ± 0.00 0.89 ± 0.02 0.74 ± 0.16 1.43 ± 0.11 0.85 ± 0.01 2.73 ± 0.03 
Mv 6.26 ± 0.47 4.10 ± 0.28 6.96 ± 0.03 4.47 ± 0.05 8.17 ± 0.33 2.45 ± 0.18 3.62 ± 0.01 11.53 ± 0.06 
Σ Glu 12.17 ± 0.00 6.39 ± 0.01 10.38 ± 0.20 8.15 ± 0.10 14.55 ± 0.01 6.78 ± 0.16 6.38 ± 0.01 17.40 ± 0.12 
Σ Ace 0.61 ± 0.01 0.98 ± 0.30 0.70 ± 0.00 0.63 ± 0.00 0.74 ± 0.00 2.81 ± 0.03 0.73 ± 0.01 1.57 ± 0.00 
Σ Coum 1.14 ± 0.00 0.74 ± 0.01 1.97 ± 0.00 1.12 ± 0.00 3.11 ± 0.05 1.62 ± 0.01 1.43 ± 0.00 2.38 ± 0.01 
 
        
Pomaces-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
Dp 0.34 ± 0.00 1.48 ± 0.31 1.15 ± 0.01 1.45 ± 0.00 4.23 ± 0.72 1.39 ± 0.21 0.56 ± 0.00 1.57 ± 0.09 
Cy 0.06 ± 0.00 0.09 ± 0.01 0.06 ± 0.00 0.07 ± 0.00 0.10 ± 0.01 0.10 ± 0.01 0.09 ± 0.00 0.10 ± 0.01 
Pt 0.27 ± 0.00 0.94 ± 0.17 0.92 ± 0.01 1.01 ± 0.00 1.88 ± 0.24 0.94 ± 0.13 0.39 ± 0.00 1.18 ± 0.06 
Pn 0.29 ± 0.00 0.68 ± 0.13 0.64 ± 0.03 0.64 ± 0.01 0.46 ± 0.03 0.46 ± 0.06 0.45 ± 0.01 2.58 ± 0.11 
Mv 1.63 ± 0.00 5.39 ± 0.75 7.77 ± 0.09 5.28 ± 0.04 7.09 ± 0.69 3.34 ± 0.33 1.75 ± 0.01 8.89 ± 0.11 
Σ Glu 2.58 ± 0.01 8.57 ± 0.01 10.54 ± 0.00 8.46 ± 0.00 13.74 ± 0.02 6.23 ± 0.00 3.28 ± 0.05 14.33 ± 0.00 
Σ Ace 0.18 ± 0.00 0.19 ± 0.00 0.22 ± 0.00 0.18 ± 0.00 0.18 ± 0.00 0.17 ± 0.00 0.20 ± 0.00 0.20 ± 0.01 
Σ Coum 0.37 ± 0.00 0.97 ± 0.00 5.29 ± 0.00 1.15 ± 0.10 3.05 ± 0.01 0.67 ± 0.01 0.60 ± 0.00 4.07 ± 0.00 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, COU, Counoise ; ALI, Alicante. In units of mg/g DW seeds or skins. Data are expressed as the mean of 
triplicate ± standard deviation. Dp, delphinidin-3-O-monoglucoside ; Cy, Cyanidin-3-O-monoglucoside ; Pt, Petunidin-3-O-monoglucoside ; Pn, Peonidin-3-O-monoglucoside ; Mv, Malvidin-3-O-monoglucoside ; Σ 
Glu, sum of monoglucoside anthocyanins; Σ Ace, sum of petunidin-3-O-acetylmonoglucoside, peonidin-3-O-acetylmonoglucoside and malvidin-3-O-acetylmonoglucoside; Σ Coum, sum of peonidin-3-(6-O-p-
coumaroyl)monoglucoside and malvidin-3-(6-O-p-coumaroyl)monoglucoside; nd, not detected. 
 
  
1
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Higher concentrations of (poly)phenols were found in 2010 vintage seeds and skins 
than in 2009. A previous study of vintage effects on Bordeaux grape phenolic compositions 
considered the recorded climatic conditions and weather indicators such as temperatures, 
sunlight exposure and vine water status, and hypothesized about the impact of these 
parameters (Lorrain et al. 2011). In the present investigation, cumulated precipitation 60 days 
before flowering in the Rhône Valley area was 127 mm in 2009 and 99 mm in 2010. 
According to Lorrain et al. (2011), the water deficit induced by low rain falls in 2010 could 
lead to an activation of the flavonoid pathway responsible for tannin and anthocyanin 
biosynthesis which occurs from the flowering stage and the beginning of berry growth 
(Gagné et al. 2009). This observation would explain the higher TPCs obtained with 2010 
grapes. Other investigators have mentioned the impact of climatic conditions such as sunlight 
exposure and average temperatures as factors impacting (poly)phenols accumulation in 
grapes (Downey et al. 2004; Cortell et al. 2006; Chorti et al. 2010). In the Rhône valley 
region, sunlight exposure in 2009 and 2010 were 2958 and 2753 hours respectively while 
average temperatures from May to September were 22°C and 22.5 °C respectively. 
According to Chorti et al. (2010) sunlight exposure which is essential for grape berry 
ripening could be responsible for excessive sunburn, qualitative and quantitative vine 
damages especially on anthocyanins. The sunlight exposure in 2009 was higher than in 2010 
which could also explain a lower phenolic content in 2009 grapes. This vintage impact had 
direct consequences on the phenolic contents of grape pomaces which followed the same 
pattern as their parent grapes, with higher concentrations being evident in the 2010 vintage 
material. 
II.2. Antioxidant activities of grape pomace extracts 
The antioxidant potential of each sample was determined in order to select the most 
active grape pomace seeds and skins among studied varieties. Antioxidant capacity of each 
extracts cannot be assessed by a single method. Indeed, antioxidant measurements can be 
related either to the capacity of extracts to directly transfer hydrogen to a radical (DPPH or 
ABTS) or to act as competitors for the peroxy radicals (ORAC test) (Roginsky et al. 2005). 
Hence, more than one type of antioxidant measurement needs to be performed to take into 
account the various mode of action of antioxidants (Huang et al. 2005). In that context, the 
free radical scavenging capacities of seed and skin extracts were evaluated by four types of 
analytical methods: the FRAP, ABTS
•+
 decolorization, DPPH and ORAC assays.  
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II.2.1 Antioxidant activities of grape pomace seed extracts 
Concerning the vintage 2009, only purified extracts including the 
monomeric/oligomeric and polymeric fractions were tested in the antioxidant assays. 
Different classification of pomace seed varieties was obtained. Radical scavenging capacities 
of their grape seed and skins extracts for 2009 and 2010 vintages are presented in Table 23 
and 24. With the monomeric/oligomeric fraction, GRE1 contained the most antioxidants 
(ORAC: 146.3 µM TE/g DW; FRAP: 114.6 µM Fe
2+
/g DW, ABTS: 94.8 µM TE/g DW and 
DPPH: 56.4 TE/g DW) in all four assays (Table 20), followed by SYR1 seed extracts. These 
results are in accordance with tannin analysis since SYR1 and GRE1 contain appreciable 
amounts of TPC and tannins as well as high levels of monomeric and dimeric 
proanthocyanidins. 
Table 20: Radical scavenging capacities of grape seed pomaces in 2009 
Pomaces-2009 
 GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 
Purified extracts:     
Monomeric/oligomeric fraction    
ORAC 146.3 ± 17.8 102.2 ± 16.0 84.4 ± 29.0 42.4 ± 10.8 41.8 ± 4.9 
FRAP 114.6 ± 11.8 53.7 ± 2.4 106.8 ± 17.3 74.9 ± 8.0 60.4 ± 3.7 
ABTS 94.8 ± 2.1 53.1 ± 3.6 83.3 ± 13.8 71.6 ±  6.0 62.6 ± 2.1 
DPPH 56.4 ± 2.6 38.0 ± 5.7 49.7 ± 8.7 39.8 ± 2.2 38.7 ± 4.4 
Polymeric fraction     
ORAC 94.1 ± 1.9 42.3 ± 8.9 66.5 ± 5.5 54.6 ± 2.7 51.9 ± 0.6 
FRAP 185.2 ± 1.5 59.8 ± 6.3 118.4 ± 2.7 138.0 ± 15.1 93.2 ± 1.9 
ABTS 421.4 ± 8.9 311.0 ± 48.7 262.9 ± 10.0 324.3 ± 26.6 234.0 ± 26.5 
DPPH 300.9 ± 19.4 335.6 ± 23.0 208.4 ± 24.1 191.0 ± 11.8 212.7 ± 8.8 
a GRE1 and GRE2, Grenache ; Syr1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre. Data are expressed as the mean of 
triplicate ± SD. bORAC, ABTS and DPPH are expressed as µmol Trolox/g DW and FRAP as µmol Fe2+/g DW. 
 
Regression analyses (correlation coefficient R
2
) were attempted in order to correlate 
results obtained with the different methods. The highest correlations were obtained with 
FRAP followed by DPPH and ABTS (R
2
 = 0.94, R
2
 = 0.87 and R
2
 = 0.81 respectively) 
(Figure 26). A weaker correlation was obtained with the ORAC assay (R
2
 = 0.41) confirming 
the variations in reactivity of the different assays (Figure 26). Positive correlations between 
TPC and antiradical activity using similar tests on grape seed samples and various plant 
samples have also been observed by other investigators (Bozan et al. 2008; Dudonné et al. 
2009; Ma et al. 2011).  
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Figure 26: Correlations between radical scavenging capacity assays (ORAC, 
FRAP, ABTS and DDPH) and total proanthocyanidin contents (sum of monomers and 
dimers) in grape pomace seeds in 2009 
 
In the current study, MOU was the most polymerized and galloylated sample but this 
feature did not seem to confer it particular higher antioxidant potential than the other samples 
in spite of the results of Plumb and co-workers who demonstrated that galloylated 
compounds have a higher antioxidant capacity in aqueous phase than their non galloylated 
homologues (Plumb et al. 1998). With the polymeric fraction, GRE1 again appeared as the 
most in-vitro active in all four assays. No particular correlation between mDP and %G in 
seed pomace and antioxidant activity were evident. The antioxidant capacity in the polymeric 
fraction was more important than in the monomeric/oligomeric fraction, especially for the 
ABTS
•+
, DPPH and FRAP assays while the ORAC values showed the opposite trend. 
For 2010, antioxidant activities were evaluated on crude and purified extracts (Table 
21). In agreement with previous analysis, the antioxidant potential of seed extracts was higher 
in 2010 than those from 2009. Considering crude extracts, the highest antioxidant activity 
were obtained in ALI (ORAC: 561.2 µM TE/g DW; FRAP: 267.5 µM Fe
2+
/g DW, ABTS: 
603.1 µM TE/g DW and DPPH: 450.1 TE/g DW) for all tests combined followed by GRE1.  
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Table 21: Radical scavenging capacities of grape seed pomaces in 2010 
Pomaces-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
Crude extracts: 
       
ORAC 322.0 ± 20.5 303.1 ± 45.4 266.9 ± 10.9 267.9 ± 18.2 248.7 ± 14.8 201.8 ± 16.5 327.6 ± 34.2 561.2 ± 29.3 
FRAP 212.2 ± 24.2 193.0 ± 19.9 232.7 ± 27.7 186.7 ± 9.9 176.4 ± 17.1 188.2 ± 29.1 205.4 ± 10.0 267.5 ± 25.9 
ABTS 438.1 ± 54.2 445.7 ± 7.2 486.3 ± 13.0 425.8 ± 31.6 403.5 ± 23.0 526.4 ± 23.8 468.6 ± 51.9 603.1 ± 28.5 
DPPH 450.7 ± 4.6 324.7 ± 6.0 322.0 ± 27.0 324.1 ± 48.3 318.5 ± 1.4 262.7 ± 15.9 536.2 ± 117.4 450.1 ± 18.3 
Purified extracts: 
       
Monomeric/oligomeric fraction 
   
ORAC 189.0 ± 10.7 194.5 ± 16.5 72.1 ± 3.7 86.0 ± 15.1 241.0 ± 16.5 237.3 ± 18.6 291.6 ± 37.5 448.4 ± 35.4 
FRAP 43.8 ± 4.7 43.1± 2.1 19.0 ± 1.9 41.3 ± 6.8 35.6 ± 0.8 40.2 ± 2.7 51.6 ± 2.7 88.9 ± 7.0 
ABTS 81.5 ± 7.2 77.4 ± 7.3 28.4 ± 1.9 77.9 ± 6.2 64.4 ± 0.4 85.0 ± 4.6 96.5 ± 5.5 133.0 ± 9.6 
DPPH 39.6 ± 4.8 41.4 ± 2.9 13.1 ± 1.0 35.5 ± 3.3 31.9 ± 1.2 42.1 ± 2.1 48.6 ± 0.5 73.0 ± 4.3 
Polymeric fraction 
       
ORAC 281.1 ± 13.4 195.4 ± 6.4 234.6 ±  32.1 140.4 ± 1.9 180.8 ± 6.7 125.1 ± 9.8 242.4 ± 25.3 361.0 ± 6.1 
FRAP 120.1 ± 0.7 115.8 ± 1.5 124.5 ± 21.1 112.0 ± 3.0 141.1 ± 4.8 149.2 ± 7.5 123.3 ± 12.5 208.3 ± 50.9 
ABTS 355.9 ± 15.8 284.3 ± 8.1 384.4 ± 15.9 285.4 ± 0.7 329.6 ± 5.1 408.1 ± 16.0 322.3 ± 22.5 388.7 ± 10.6 
DPPH 268.2 ± 7.9 236.1 ± 10.7 246.9 ± 42.7 212.7 ± 11.9 229.9 ± 3.1 301.9 ± 5.5 282.4 ± 28.9 338.6 ± 10.9 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. Data are expressed as the mean of triplicate ± SD. bORAC, ABTS and DPPH are expressed as 
µmol Trolox/g DW and FRAP as µmol Fe2+/g DW. 
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In monomeric/oligomeric and polymeric purified extracts, ALI still retained the 
highest radical scavenging capacity. The lowest rate was observed in SYR1 monomeric 
/oligomerc fraction (ORAC: 72.1 µM TE/g DW; FRAP: 19 µM Fe
2+
/g DW, ABTS: 28.4 µM 
TE/g DW and DPPH: 13.1 TE/g DW) and SYR2 in both type of extracts.  
The antioxidant assay results were similar with the 2009 and 2010 vintages. The 
different tests conducted in different antioxidant activity classifications of grapes varieties. 
Regarding monomeric/oligomeric fraction, ALI and COU which contained high amounts of 
monomeric and dimeric proanthocyanidins possessed the highest antioxidant capacities for all 
types of tests (Table 21). The two Syrah samples exhibited the least in vitro activity. 
Furthermore, the most polymerized and galloylated (CAR and MOU seeds) did not exert a 
distinctive antiradical potential. In polymeric fractions, values from FRAP, ABTS and DPPH 
tests were higher than those obtained with monomeric/oligomeric fractions and established 
ALI as the most effective variety. Results obtained from ORAC analyses varied according to 
varieties. As already noticed, the 2009 and 2010 polymeric fraction exhibited a higher 
antioxidant than the monomeric and oligomeric fraction, in agreement with previous reports 
(Es-Safi et al. 2006; Spranger et al. 2008). 
II.2.2 Antioxidant activities of grape pomace skin extracts 
As anticipated, it was established that antioxidant activities in grape seed pomace 
extracts were higher than those in skins. GRE1 and CAR in 2009 and SYR1, CAR and ALI 
in 2010 contained the highest antioxidant activity (Table 22). These extracts consistently 
exhibited the highest values of TPC, proanthocyanidins and anthocyanins. Even though 
proanthocyanidin contents of grape pomace skins was low, a large amount of anthocyanins 
still remained and this could explain their antiradical activity. 
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Table 22: Radical scavenging capacities of grape skin pomace extracts in 2009 and 2010 
Grapes-2009 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 
   
Purified extracts: 
       
Monomeric/oligomeric fraction 
      
ORAC 63.8 ± 3.2 63.8 ± 2.2 94.0 ± 1.4 37.4 ± 1.8 47.8 ± 14.7 
   
FRAP 57.3 ± 6.6 13.7 ± 2.4 53.1 ± 3.1 91.4 ± 2.6 15.2 ± 0.7 
   
ABTS 40.6 ± 4.2 25.3 ± 1.5 37.1 ± 1.5 62.0 ± 1.6 33.7 ± 0.9 
   
DPPH 20.5 ± 0.6 16.6 ± 0.6 18.8 ± 1.5 26.9 ± 1.4 19.3 ± 1.6 
   
Polymeric fraction 
       
ORAC 86.8 ± 0.3 55.4 ± 3.6 57.2 ± 1.5 66.9 ± 7.3 42.4 ± 4.0 
   
FRAP 120.9 ± 6.9 35.1 ± 4.4 78.7 ± 0.2 112.7 ± 14.1 78.0 ± 13.7 
   
ABTS 286.7 ± 19.9 77.9 ± 3.7 121.1 ± 7.1 197.0 ± 21.5 129.8 ± 8.8 
   
DPPH 203.1 ± 10.6 97.0 ± 11.0 76.1 ± 5.9 113.8 ± 13.4 110.7 ± 8.1 
   
Pomaces-2010 
 
GRE1
a
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 COU
a
 ALI
a
 
Crude extracts: 
       
ORAC 200.6 ± 15.4 224.8 ± 17.0 355.8 ± 32.2 267.4 ± 18.0 326.2 ± 18.1 269.2 ± 21.5 212.3 ± 12.4 531.9 ± 30.2 
FRAP 105.3 ± 4.9 137.2 ± 2.6 190.8 ± 6.4 157.4 ± 11.6 225.3 ± 5.9 202.7 ± 9.8 122.4 ± 8.8 266.8 ± 40.5 
ABTS 263.4 ± 6.7 294.2 ± 22.5 299.3 ± 9.3 338.8 ± 11.3 390.8 ± 0.4 405.7 ± 2.0 255.6 ± 28.9 464.1 ± 44.5 
DPPH 161.2 ± 3.7 134.6 ± 0.5 190.6 ± 1.5 151.0 ± 0.6 195.3 ± 7.4 161.3 ± 7.1 185.0 ± 12.6 290.7 ± 50.1 
Purified extracts: 
       
Monomeric/oligomeric fraction 
      
ORAC 82.1 ± 3.4 83.9 ± 4.6 154.5 ± 11.1 87.1 ± 9.1 73.2 ± 7.1 72.2 ± 8.1 133.6 ± 11.3 204.9 ± 24.5 
FRAP 15.4 ± 0.9 21.3 ± 1.9 31.9 ± 2.8 24.2 ± 2.1 27.0 ± 4.0 30.9 ± 1.9 24.9 ± 1.4 38.9 ± 2.1 
ABTS 31.7 ± 4.4 42.0 ± 0.1 60.1 ± 9.1 36.9 ± 2.7 40.2 ± 3.0 68.2 ± 1.4 44.3 ± 2.0 64.6 ± 2.4 
DPPH 14.5 ± 0.9 16.1 ± 0.4 35.3 ± 3.9 17.1 ± 0.3 19.3 ± 3.9 23.4 ± 0.9 16.0 ± 0.6 27.1 ± 1.6 
Polymeric fraction 
       
ORAC 137.9 ± 6.8 132.5 ± 5.1 142.9 ± 15.6 117.2 ± 1.6 148.3 ± 3.2 125.9 ± 6.2 99.7 ± 2.6 266.8 ± 26.1 
FRAP 85.3 ± 4.2 98.4 ± 7.1 135.9 ± 4.5 117.8 ± 1.3 162.8 ± 7.2 173.9 ± 10.4 91.7 ± 39.1 188.5 ± 14.8 
ABTS 166.1 ± 20.4 175.2 ± 7.6 214.1 ± 7.5 176.7 ± 4.7 265.5 ± 17.6 295.9 ± 10.9 118.0 ± 10.1 307.6 ± 62.0 
DPPH 107.8 ± 7.3 87.1 ± 12.7 113.9 ± 11.2 92.4 ± 13.3 121.8 ± 2.5 193.5 ± 15.4 133.0 ± 4.1 160.8 ± 24.4 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. Data are expressed as the mean of triplicate ± SD. bORAC, ABTS and DPPH are expressed as 
µmol Trolox/g DW and FRAP as µmol Fe2+/g DW. 
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The highest correlations between total anthocyanins and antioxidant tests were 
obtained for the FRAP and ORAC tests (R
2 
= 0.86 and R
2 
= 0.84 respectively) (Figure 27) in 
2010. 
 
Figure 27: Correlations between radical scavenging capacity assays (ORAC, 
FRAP, ABTS and DPPH) and total anthocyanin contents in grape pomace skin extracts 
in 2010 
 
Correlations between grape pomace contents and antioxidant levels were higher with 
total values than with the specific compound concentrations quantified by HPLC. As reported 
in a recent publication (Rockenbach et al. 2011), our result illustrate that antioxidant activity 
is more related to the total constituent levels than to the concentration of any individual 
compound despite the fact that some compounds may contribute more than the others.  
Overall, grape seed pomaces exerted greater antioxidant capacities than grape skin 
pomaces. This observation can be explained by a greater concentration in total and individual 
phenolic contents in seeds. Furthermore, a lower amount of galloylated derivatives in skins 
may contributory factor as it has been demonstrated that galloylated compounds have a 
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higher antioxidant capacity in aqueous phase than their non-galloylated homologues (Plumb 
et al. 1998). 
To conclude on this first characterisation, grape seed and skin pomace extracts still 
contained appreciable amounts of flavan-3-ols and anthocyanins, despite extraction during 
vinification. The quantitative and qualitative distribution of (poly)phenols in grape pomaces 
showed significant differences through varieties and vintages. Seeds from Grenache (GRE1), 
Syrah (SYR1) and Alicante and skins from Syrah (SYR1), Carignan and Alicante were 
evidenced as the most interesting fractions because of their richest (poly)phenol contents and 
highest antioxidant capacities. They, therefore represent useful by-products as a natural 
source of (poly)phenols and antioxidants. Varieties and part (seeds or skins) exhibiting the 
highest antioxidant capacity was pre-selected for further extraction using adequate extraction 
process for commercialization.  
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Table 23: Radical scavenging capacities of grape seeds and skins in 2009 
Grapes-2009 
Seeds 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 GRE1
a
 
Purified extracts: 
      
Monomeric/oligomeric fraction 
   
ORAC
b
 289.48 ± 54.40 98.89 ± 16.55 328.73 ± 4.75 157.27 ± 4.82 95.22 ± 22.55 173.21 ± 10.48 
FRAP
b
 153.06 ± 8.45 141.27 ± 37.42 247.26 ± 13.99 116.53 ± 1.14 86.11 ± 26.14 208.44 ± 8.47 
ABTS
b
 145.25 ± 1.88 126.91 ± 1.26 174.05 ± 10.91 82.36 ± 3.59 126.12 ± 0.58 150.99 ± 4.37 
DPPH
b
 74.58 ± 2.25 76.10 ± 1.82 108.32 ± 11.10 47.45 ± 1.62 62.12 ± 12.23 81.92 ± 4.79 
Polymeric fraction 
      
ORAC
b
 87.23 ± 11.49 86.59 ± 10.80 97.96 ± 1.27 83.54 ± 2.82 91.01 ± 12.05 93.39 ± 7.58 
FRAP
b
 157.40 ± 17.63 154.59 ± 10.04 159.68 ± 11.63 185.19 ± 9.29 286.73 ± 10.91 174.07 ± 10.76 
ABTS
b
 437.68 ± 31.06 331.24 ± 17.24 370.67 ± 22.25 446.54 ± 19.28 573.25 ± 61.89 330.02 ± 61.02 
DPPH
b
 282.03 ± 13.67 274.56 ± 5.09 305.02 ± 16.87 319.51 ± 8.52 447.67 ± 25.39 264.23 ± 12.96 
Skins 
 
GRE1
a
 GRE2
a
 SYR1
a
 CAR
a
 MOU
a
 GRE1
a
 
Purified extracts: 
      
Monomeric/oligomeric fraction 
   
ORAC
b
 88.07 ± 9.92 85.69 ± 4.63 175.20 ± 17.32 133.57 ± 22.67 107.66 ± 35.69 43.02 ± 10.84 
FRAP
b
 46.27 ± 2.29 32.75 ± 3.79 65.61 ± 2.29 45.35 ± 0.13 50.34 ± 16.25 36.17 ± 3.15 
ABTS
b
 30.19 ± 0.90 18.11 ± 0.40 37.49 ± 2.32 29.39 ± 3.88 49.61 ± 1.15 24.51 ± 0.97 
DPPH
b
 14.29 ± 0.78 - 23.37 ± 1.59 19.15 ± 1.14 20.72 ± 3.67 12.93 ± 1.29 
Polymeric fraction 
      
ORAC
b
 108.44 ± 9.35 99.02 ± 2.46 125.66 ± 4.21 169.11 ± 8.80 142.91 ± 8.60 94.41 ± 1.84 
FRAP
b
 25.62 ± 0.42 28.22 ± 0.81 43.02 ± 2.64 23.55 ± 1.80 21.30 ± 2.14 4.55 ± 0.38 
ABTS
b
 218.71 ± 26.26 161.97 ± 5.89 272.50 ± 16.99 149.82 ± 14.34 184.58 ± 12.46 157.70 ± 13.63 
DPPH
b
 228.93 ± 13.12 167.55 ± 10.89 312.24 ± 14.68 150.32 ± 4.78 205.30 ± 20.40 302.17 ± 26.82 
a GRE1 and GRE2, Grenache ; Syr1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. Data are expressed as the mean of triplicate ± SD. bORAC, ABTS and DPPH are expressed as 
µmol Trolox/g DW and FRAP as µmol Fe2+/g DW. 
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Table 24: Radical scavenging capacities of grape seeds and skins in 2010 
Grapes-2010 
Seeds 
 
GRE1a GRE2a SYR1a SYR2a CARa MOUa COUa ALIa 
Crude extracts: 
        
ORACb 1248.51 ± 192.02 1436.87 ± 61.95 1340.58 ± 69.22 1447.65 ± 100.79 860.34 ± 50.70 722.89 ± 52.82 1259.78 ± 101.81 1869.87 ± 100.83 
FRAPb 356.95 ± 47.53 315.45 ± 36.85 335.90 ± 24.56 323.58 ± 28.40 303.12 ± 23.47 393.90 ± 34.30 340.89 ± 38.52 397.65 ± 42.29 
ABTSb 1030.92 ± 74.24 815.61 ± 23.68 795.67 ± 49.32 734.51 ± 8.01 783.38 ± 59.40 1028.65 ± 33.02 996.57 ± 120.32 979.00 ± 103.03 
DPPHb 781.15 ± 49.25 599.75 ± 31.24 514.11 ± 45.08 630.25 ± 12.50 623.66 ± 31.90 925.79 ± 113.11 632.98 ± 66.10 624.24 ± 36.06 
Purified extracts: 
        
Monomeric/oligomeric fraction 
     
ORACb 668.50 ± 59.85 804.15 ± 22.35 1014.42 ± 80.53 754.37 ± 101.85 428.45 ± 44.29 399.96 ± 77.17 852.29 ± 38.54 785.02 ± 57.45 
FRAPb 99.81 ± 14.70 120.63 ± 12.36 142.86 ± 7.13 106.72 ± 22.59 57.83 ± 3.30 71.20 ± 2.22 138.35 ± 8.04 180.21 ± 15.59 
ABTSb 148.96 ± 18.44 210.79 ± 12.73 254.97 ± 15.62 179.19 ± 40.71 103.98 ± 7.70 152.88 ± 10.88 255.47 ± 3.27 300.47 ± 24.10 
DPPHb 70.73 ± 12.36 101.51 ± 5.68 121.46 ± 6.58 80.42 ± 19.47 54.29 ± 4.54 64.84 ± 7.64 92.66 ± 6.38 132.66 ± 6.86 
Polymeric fraction 
       
ORACb 715.44 ± 109.90 578.22 ± 41.35 555.65 ± 49.52 566.15 ± 97.30 525.55 ± 29.86 451.35 ± 27.78 540.56 ± 32.87 650.97 ± 17.42 
FRAPb 322.19 ± 12.37 228.02 ± 15.46 232.31 ± 20.89 237.30 ± 17.25 234.20 ± 27.48 270.58 ± 15.01 256.24 ± 26.67 265.72 ± 9.40 
ABTSb 876.83 ± 42.46 628.66 ± 21.01 540.72 ± 11.97 585.26 ± 38.01 617.25 ± 19.44 789.98 ± 4.41 646.66 ± 38.49 633.70 ± 24.78 
DPPHb 737.86 ± 50.80 485.75 ± 2.09 455.56 ± 6.87 561.72 ± 32.97 456.18 ± 38.13 569.05 ± 24.43 464.87 ± 32.29 493.82 ± 17.95 
Skins 
 
GRE1a GRE2a SYR1a SYR2a CARa MOUa COUa ALIa 
Crude extracts: 
        
ORACb 504.85 ± 33.60 663.67 ± 23.59 646.61 ± 24.63 476.18 ± 14.50 712.67 ± 54.94 763.83 ± 28.89 709.62 ± 58.98 866.78 ± 36.72 
FRAPb 203.31 ± 10.61 181.74 ± 19.72 226.40 ± 20.64 192.68 ± 4.64 245.54 ± 17.89 238.59 ± 27.60 169.95 ± 13.50 284.88 ± 17.75 
ABTSb 285.62 ± 16.68 283.25 ± 33.32 419.14 ± 82.81 363.59 ± 32.08 458.52 ± 8.42 430.95 ± 23.09 271.21 ± 4.37 576.71 ± 59.84 
DPPHb 218.98 ± 17.99 162.79 ± 21.50 315.10 ± 26.89 209.38 ± 30.67 302.75 ± 24.30 92.42 ± 3.92 218.34 ± 2.16 337.07 ± 24.36 
Purified extracts: 
        
Monomeric/oligomeric fraction 
     
ORACb 142.02 ± 4.29 77.58 ± 10.23 269.96 ± 15.05 226.18 ± 23.10 231.41 ± 15.59 206.90 ± 14.68 187.70 ± 7.97 233.82 ± 31.16 
FRAPb 70.45 ± 9.99 28.31 ± 1.90 45.13 ± 3.76 29.90 ± 1.43 37.90 ± 2.19 27.61 ± 1.59 26.99 ± 1.06 55.54 ± 4.14 
ABTSb 53.55 ± 8.30 48.05 ± 3.05 68.03 ± 1.11 48.48 ± 6.09 70.63 ± 6.23 43.29 ± 14.40 43.67 ± 3.83 85.27 ± 13.15 
DPPHb 15.45 ± 3.28 14.92 ± 0.61 25.39 ± 0.76 20.04 ± 1.65 25.23 ± 0.08 12.35 ± 2.67 12.78 ± 0.11 24.81 ± 2.33 
Polymeric fraction 
       
ORACb 477.21 ± 48.19 414.06 ± 42.91 500.03 ± 50.76 477.32 ± 17.80 481.80 ± 38.09 349.64 ± 4.07 320.64 ± 0.95 569.82 ± 15.61 
FRAPb 193.75 ± 19.28 189.33 ± 18.60 282.55 ± 16.47 202.19 ± 17.50 277.53 ± 14.53 249.76 ± 12.72 204.37 ± 8.99 312.86 ± 27.83 
ABTSb 153.66 ± 7.79 215.78 ± 24.59 277.17 ± 2.60 228.81 ± 7.68 294.81 ± 6.27 218.14 ± 20.03 254.52 ± 20.76 397.33 ± 19.04 
DPPHb 104.86 ± 4.54 115.11 ± 5.32 429.63 ± 2.87 552.32 ± 41.09 151.55 ± 27.56 212.41 ± 4.06 318.84 ± 9.54 282.92 ± 4.83 
a GRE1 and GRE2, Grenache ; Syr1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. Data are expressed as the mean of triplicate ± SD. bORAC, ABTS and DPPH are expressed as µmol Trolox/g 
DW and FRAP as µmol Fe2+/g DW.  
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III. Grape pomace extracts for in vivo study 
phenolics and antioxidants characterisation 
After vintage 2010 vinification, different pomaces from six varieties were collected. 
Seeds were separated from skins using a mechanic separator at the chateau de Beaucastel. 
Samples were frozen at -20°C and sent to the 3INature Company for extraction. The pre-
selection of varieties and parts (seeds or skins) resulted from previous analysis on grape 
pomace extracts. Samples were extracted using aqueous solution and hydro-alcoholic 70% 
solution generating two types of extracts: an aqueous extract (EAQ) and a hydro-alcoholic 
extract (EA70). Figure 28 and Table 25 summarized varieties and part extracted by 3INature 
Company and analysis carried out on these grape pomace extracts. Some of these extracts 
will be chosen for in vivo study.  
 
 
Figure 28: Analysis performed on EAQ and EA70 grape pomace seed and skin 
extracts 
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Table 25: EAQ and EA70 grape pomace skin and seed extracts 
Samples 
Skins Seeds 
EAQ EA70 EAQ EA70 
GRE1 
  
Χ Χ 
GRE2 Χ Χ 
  
SYR1 Χ Χ Χ Χ 
SYR2 Χ Χ 
  
CAR Χ Χ Χ Χ 
MOU Χ Χ 
  
COU 
    
ALI Χ Χ 
  
 
III.1. Total phenol, tannin and anthocyanin analysis of grape 
pomace extracts  
Aqueous and hydro-alcoholic 70% extracts were characterized for their overall 
composition by total phenol content, total tannin and total anthocyanin analysis via Folin 
Ciocalteu assay, acidic hydrolysis and SO2 bleaching procedure, respectively, after being 
solubilized and diluted at appropriate concentration for each test. Results are presented in 
Table 26 and Table 27.  
Table 26: Total phenol contents, total tannin and total anthocyanin contents in 
EAQ and EA70 grape pomace seed extracts 
Seeds-EAQ 
 
GRE1
a
 SYR1
a
 CAR
a
 
TPC 128.22 ± 0.37 215.93 ± 1.17 186.08 ± 0.28 
Total tannins 157.02 ± 0.56 266.87 ± 2.62 264.61 ± 2.39 
Total anthocyanins 3.98 ± 0.16 10.55 ± 0.56 11.35 ± 0.51 
Seeds-EA70 
 
GRE1
a
 SYR1
a
 CAR
a
 
TPC 195.66 ± 1.06 207.38 ± 2.15 215.84 ± 1.47 
Total tannins 302.86 ± 4.85 455.42 ± 1.84 423.11 ± 15.13 
Total anthocyanins 12.17 ± 0.51 38.67 ± 4.34 57.34 ± 1.86 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, ALI, Alicante. In units of mg/g 
DW seeds or skins. Data are expressed as the mean of triplicate ± standard deviation. TPC, total phenol contents. 
 
In overall, results showed that an extraction with hydro-alcoholic 70% solution 
allowed a better extraction of phenolic compounds whether in seeds or in skins. Among seed 
extracts, seed from SYR1 and CAR were particularly rich in (poly)phenols, tannins and 
anthocyanins in EAQ and EA70 extracts (Table 26). SYR 1 (EA70) contained a higher 
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tannins concentration until 455.42 mg/g DW while CAR (EA70) has a higher quantity in total 
anthocyanins (57.34 mg/g DW). In both extracts, phenolic contents in GRE1 remained low 
compared in comparison with other varieties.  
Table 27: Total phenol contents, total tannin and total anthocyanin contents in 
EAQ and EA70 grape pomace skin extracts 
Skins-EAQ 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
TPC 109.72 ± 0.19 146.50 ± 1.19 71.88 ± 0.08 120.83 ± 1.12 102.27 ± 0.38 196.71 ± 0.37 
Total tannins 112.28 ± 2.67 156.63 ± 2.63 86.36 ± 1.86 161.61 ± 1.32 104.79 ± 20 221.40 ± 3.47 
Total 
anthocyanins 
8.70 ± 0.01 16.01 ± 0.01 1.76 ± 0.01 14.62 ± 0.75 5.65 ± 0.01 21.40 ± 0.20 
Skins-EA70 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
TPC 195.15 ± 0.28 224.92 ± 0.18 173.58 ± 0.08 203.47 ± 0.83 219.88 ± 0.18 188.94 ± 0.69 
Total tannins 256.07 ± 3.65 312.46 ± 10.77 250.17 ± 7.07 345.34 ± 4.18 268.6 ± 11.68 232.65 ± 3.14 
Total 
anthocyanins 
53.66 ± 0.83 86.68 ± 1.71 45.38 ± 0.20 88.44 ± 0.59 46.64 ± 0.39 54.41 ± 2.66 
a GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, ALI, Alicante. In units of mg/g DW seeds or 
skins. Data are expressed as the mean of triplicate ± standard deviation. TPC, total phenol contents. 
 
Concerning skins, results revealed in EAQ extracts that ALI contained the highest 
phenolic contents for the three test combined (TPC: 196.71 mg GAE/g DW, total tannins: 
221.40 mg/g DW and total anthocyanins: 21.40 mg/g DW) while in EA70, SYR1 skins were 
predominantly high in phenolic contents (total phenol contents: 224.92 mg GAE /g DW, total 
tannins: 312.46 mg/g DW and total anthocyanins: 86.68 mg/g DW) (Table 27). The poorest 
extracts was SYR2 whether in EAQ or in EA70. As it was already observed in seeds extracts, 
EA70 were characterized by higher total phenol contents, total tannins and total 
anthocyanins. This result illustrated a better extraction by alcoholic 70 % solution. Ethanol 
could facilitate tissues dissolution and thus, liberate a greater amount of (poly)phenols. 
Actually, between EAQ and EA70, total (poly)phenols and total tannins rate were 1.5- to 2.5- 
and 1- to 3-fold respectively, higher in EA70. Anthocyanins extraction varied largely through 
varieties: by 2.5- to 25.8 -fold higher in ALI skin extracts (21.40 mg/g DW in EAQ and 54.41 
mg/g DW in EA70) and SYR2 skins (1.76 mg/g DW in EAQ and 45.38 mg/g DW), 
respectively.  
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III.2. Flavan-3-ol and procyanidin analysis of grape pomace 
extracts  
III.2.1. Flavan-3-ol analysis of grape pomace extracts 
Flavan-3-ol monomers [(+)-catechin and (–)-epicatechin], dimers (B1, B2, B3 and B4) 
and trimer C1 were identified and quantified in seed and skin aqueous and hydro-alcoholic 
70% extracts by HPLC-UV-Fluo.  
For both type of seed extracts, SYR1 was the richest whether in monomers (8.88 mg/g 
DW in EAQ and 13.84 mg/g DW in EA70), in dimers (6.87 mg/g DW in EAQ and 7.10 mg/g 
DW in EA70) and trimer C1 (2.00 mg/g DW in EAQ and 1.25 mg/g DW in EA70) as 
opposite to GRE1 (Table 28). This latter had already appeared to contain low amount of 
(poly)phenols in previous total analysis. However, despite this low content, GRE1 still 
possessed an exploitable potential especially when extracted with hydro-alcoholic 70 % 
solution. 
Table 28: Flavan-3-ol monomers, dimers and trimers characterisation in EAQ 
and EA70 grape pomace seed extracts 
Seeds-EAQ 
 
GRE1
a
 SYR1
a
 CAR
a
 
C 2.07 ± 0.09 5.12 ± 0.04 2.27 ± 0.00 
EC 0.98 ± 0.04 3.76 ± 0.03 0.94 ± 0.00 
Σ Monomers 3.04 ± 0.09 8.88 ± 0.00 3.21 ± 0.00 
B1 1.01 ± 0.08 2.94 ± 0.01 0.87 ± 0.01 
B2 0.70 ± 0.01 2.23 ± 0.02 0.68 ± 0.00 
B3 0.28 ± 0.02 0.86 ± 0.00 0.25 ± 0.00 
B4 0.51 ± 0.01 0.85 ± 0.04 0.11 ± 0.00 
Σ Dimers 2.50 ± 0.05 6.870 ± 0.03 1.90 ± 0.01 
C1 0.48 ± 0.01 2.00 ± 0.06 0.53± 0.01 
Seeds-EA70 
 
GRE1
a
 SYR1
a
 CAR
a
 
C 3.60 ± 0.02 8.60 ± 0.00 5.28 ± 0.03 
EC 1.46 ± 0.00 5.24 ± 0.00 2.02 ± 0.06 
Σ Monomers 5.07 ± 0.01 13.84 ± 0.00 7.29 ± 0.02 
B1 1.68 ± 0.01 3.53 ± 0.01 3.06 ± 0.00 
B2 0.84 ± 0.00 2.16 ± 0.02 1.29 ± 0.00 
B3 0.45 ± 0.02 0.87 ± 0.02 0.58 ± 0.01 
B4 Nd 0.53 ± 0.01 Nd 
Σ Dimers 2.97 ± 0.00 7.10 ± 0.03 4.92 ± 0.01 
C1 0.54 ± 0.00 1.25 ± 0.03 0.83 ± 0.01 
a GRE1, Grenache ; SYR1, Syrah ; CAR, Carignan. In units of mg/g DW seed or skin. Data are expressed as the mean of 
triplicate ± standard deviation. C, (+)-Catechin; EC, (–)-Epicatechin; B1, B2; B3, B4, Procyanidin dimers B1, B2; B3, B4; C1, procyanidin 
trimers C1. Σ Monomers, sum of catechin and epicatechin; Σ Dimers, sum of B1, B2, B3 and B4; C1, trimer C1; Nd, Not determined. 
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For grape pomace skin extracts (Table 29), values in EAQ ranged from 0.89 mg/g 
DW to 3.4 mg/g DW for the sum of monomers, from 0.91 mg/g DW to 2.34 mg/g DW for the 
sum of dimers and values from 1.88 mg/g W to 7.71 mg/g DW and 1.61 mg/g DW to 4.83 
mg/g DW were found in EA70 extracts, for the sum of monomers and dimers, respectively. 
ALI and SYR1 showed a higher flavan-3-ol monomers and dimers in both type of extract. 
Among EAQ samples, SYR2 skin extracts was evidenced as having fewer amounts than other 
skin EAQ samples but in EA70 it was GRE2 and CAR. 
Table 29: Flavan-3-ol monomers, dimers and trimers characterisation in EAQ 
and EA70 grape pomace skin extracts 
Skins-EAQ 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
C 0.76 ± 0.00 1.42 ± 0.01 0.52 ± 0.06 1.01 ± 0.00 0.66 ± 0.01 2.03 ± 0.13 
EC 0.29 ± 0.00 1.04 ± 0.01 0.37 ± 0.03 0.35 ± 0.01 0.38 ± 0.00 1.39 ± 0.09 
Σ Monomers 1.05 ± 0.00 2.46 ± 0.02 0.89 ± 0.06 1.36 ± 0.01 1.03 ± 0.01 3.40 ± 0.15 
B1 0.62 ± 0.00 0.92 ± 0.01 0.37 ± 0.00 0.74 ± 0.01 0.62 ± 0.00 0.91 ± 0.17 
B2 0.41 ± 0.00 0.66 ± 0.01 0.36 ± 0.04 0.43 ± 0.01 0.57 ± 0.00 0.77 ± 0.05 
B3 0.28 ± 0.00 0.39 ± 0.01 0.18 ± 0.01 0.28 ± 0.01 0.29 ± 0.01 0.35 ± 0.12 
B4 ND ND ND ND ND 0.32 ± 0.09 
Σ Dimères 1.31 ± 0.00 1.96 ± 0.00 0.91 ± 0.03 1.45 ± 0.02 1.47 ± 0.01 2.34 ± 0.30 
C1 0.47 ± 0.00 0.82 ± 0.01 0.34 ± 0.08 0.54 ± 0.00 0.55 ± 0.13 0.67 ± 0.15 
Skins-EA70 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
C 1.42 ± 0.00 2.29 ± 0.10 2.09 ± 0.05 1.44 ± 0.00 1.52 ± 0.02 5.08 ± 0.03 
EC 0.44 ± 0.00 1.36 ± 0.01 1.10 ± 0.20 0.44 ± 0.00 0.69 ± 0.00 2.63 ± 0.01 
Σ Monomers 1.86 ± 0.00 3.65 ± 0.08 3.19 ± 0.11 1.88 ± 0.00 2.18 ± 0.02 7.71 ± 0.02 
B1 0.92 ± 0.01 1.27 ± 0.01 1.19 ± 0.16 1.14 ± 0.01 1.15 ± 0.01 2.59 ± 0.00 
B2 0.40 ± 0.02 0.64 ± 0.01 0.60 ± 0.01 0.39 ± 0.02 0.57 ± 0.00 1.28 ± 0.00 
B3 0.30 ± 0.00 0.29 ± 0.00 0.36 ± 0.00 0.27 ± 0.00 0.31 ± 0.00 0.60 ± 0.01 
B4 Nd Nd Nd Nd Nd 0.35 ± 0.00 
Σ Dimères 1.61 ± 0.01 2.19 ± 0.00 2.15 ± 0.11 1.79 ± 0.03 2.02 ± 0.01 4.83 ± 0.01 
C1 0.34 ± 0.00 0.44 ± 0.00 0.66 ± 0.13 0.31± 0.00 0.37 ± 0.00 0.63 ± 0.00 
a GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. In units of mg/g DW seed or 
skin. Data are expressed as the mean of triplicate ± standard deviation. C, (+)-Catechin; EC, (–)-Epicatechin; B1, B2; B3, B4, Procyanidin 
dimers B1, B2; B3, B4; C1, procyanidin trimers C1. Σ Monomers, sum of catechin and epicatechin; Σ Dimers, sum of B1, B2, B3 and B4; C1, 
trimer C1; Nd, Not determined. 
 
III.2.2. Procyanidin analysis of grape pomace extracts 
Detection of procyanidins was assessed by HPLC-Fluo-MS
n
 using a normal phase 
column where the stationary phase is made of polar packing material while the mobile phase 
is of non-polar solvents. Due to the complexity in their structural diversity, analytical 
methodology for procyanidins has been chromatographic separation based upon mDP as 
opposed to the individual compounds and specific isomers. This approach has permitted the 
measurement of the large structural diversity of these compounds in a categorical manner 
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(e.g. oligomeric size, %G and %P) but limited because no information about the molecular 
mass distribution can be obtained. Actually, reversed-phase HPLC is successful in separating 
monomers up to tetramers only and the increasing numbers of isomers with the degree of 
polymerization produce a very broad and unresolved UV-absorbing peak late in the 
chromatogram. By using Normal phase HPLC coupled with mass spectrometry and 
fluorescence detection, procyanidins can be separate and identify simultaneously on the basis 
of their molecular characteristics. Indeed, the resolution of these compounds has been 
improved recently (Núñez et al. 2006; Robbins et al. 2009; Hanlin et al. 2011). Normal phase 
HPLC technique proved to be a powerful tool for the analysis of oligomers > tetramers. 
Peak detection and quantification were mainly carried out by fluorescence with an 
excitation and emission wavelengths at 230 nm and 320 nm because of its more selectivity 
and stronger signal than UV absorption detection for procyanidins. Identification was 
confirmed by mass spectrometry in full-scan negative ionization, data dependent MS 
(Robbins et al., 2009). In total, 17 compounds were founds and listed in Table 30. Figures 29 
and 30 showed the typical HPLC-Fluo chromatogram of grape pomace extracts and the ESI 
(electrospray ionization) spectrum of grape pomace extracts of mass range from m/z 200 to 
2000, respectively.  
Table 30: Diol-HPLC and MS characteristics of procyanidins detected in grape 
pomace extracts 
Peak Rt (min) Procyanidins  [M-] (m/z) 
1 4.92 Monomers (epi)C 289 
2 6.98 (Epi)catechin-O-gallate (epi)Cg 441 
3 8.67 Dimers (epi)C-(epi)C 577 
4 13.26 Dimers-O-gallate (epi)C-(epi)Cg 729 
5 15.5 Trimers (epi)C-(epi)C-(epi)C 865 
6 17.25  (Epi)gallocatechin trimers (epi)C-(epi)-(epi)GC  881 
7 20.69 Trimers-O-gallate (epi)C-(epi)C-(epi)Cg 1017 
8 22.59 Tetramers (epi)C-(epi)C-(epi)C-(epi)C 1153 
9 23.52 (Epi)gallocatechin tetramers (epi)C-(epi)C-(epi)-(epi)GC 1169 
10 27.08 Tetramers-O-gallate (epi)C-(epi)C-(epi)C-(epi)Cg 1305 
11 29.28 Pentamers (epi)C-(epi)C-(epi)C-(epi)C-(epi)C 1441 
12 30.23 (Epi)gallocatechin pentamers (epi)C-(epi)C-(epi)C-(epi)-(epi) GC 1457 
13 34.79 Hexamers (epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C 1729 
14 39.74 Heptamers (epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)-(epi)C 2017 
15 43.78 Octamers (epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C 2305 
16 47.16 Nonamers (epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C 2593 
17 50.21 Decamers (epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)C-(epi)-(epi)C 2881 
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Figure 30: ESI Spectrum of a grape pomace extract of mass range from m/z 200 
to 2000  
Figure 29: Typical HPLC-Fluo chromatogram of a grape pomace extract with 
an excitation and emission wavelengths at 230 nm and 320 nm using different 
sensitivity (A ten-fold higher than B) 
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In grape pomace seed extracts (Table 31), total procyanidin (Σ monomers-decamers) 
detected in EA70 extracts was more important than in EAQ, except for CAR where a total of 
50.22 mg/g DW was found in EA70 and 73.34 mg/g DW in EAQ. SYR1 was the most 
interesting because of its particularly high amount of total procyanidins with up to 137.24 
mg/g DW in EAQ and 157.12 mg/g DW in EA70. SYR1 also retained about 2- and 2.8-fold 
more procyanidins than GRE1 and CAR in EAQ and EA70, respectively. Hydro-alcoholic 
70% solution permitted to extract more highly polymerized compounds. 
Table 31: Procyanidins characterisation in EAQ and EA70 grape pomace seed 
extracts 
Seeds-EAQ 
Procyanidins GRE1
a
 SYR1
a
 CAR
a
 
Monomers 37.74 ± 0.06 76.30 ± 0.39 45.42 ± 0.93 
(Epi)catechin gallate 0.70 ± 0.00 0.77 ± 0.01 0.66 ± 0.01 
Dimers 11.65 ± 0.13 21.52 ± 0.16 15.82 ± 0.22 
Dimers gallate 0.22 ± 0.00 1.20 ± 0.01 0.40 ± 0.02 
Trimers 3.81 ± 0.04 17.76 ± 0.21 4.94 ± 0.07 
(Epi)gallocatechin trimers 0.25 ± 0.01 1.27 ± 0.03 0.21 ± 0.04 
Trimers gallate 0.27 ± 0.02 0.68 ± 0.02 0.18 ± 0.01 
Tetramers 1.56 ± 0.06 7.05 ± 0.05 1.89 ± 0.00 
(Epi)gallocatechin tetramers 0.91 ± 0.04 2.66 ± 0.07 0.92 ± 0.01 
Tetramers gallate 0.01 ± 0.00 0.15 ± 0.00 0.04 ± 0.00 
Pentamers 0.79 ± 0.01 3.95 ± 0.06 1.29 ± 0.02 
(Epi)gallocatechin pentamers 0.12 ± 0.01 0.61 ± 0.01 0.26 ± 0.00 
Hexamers 0.55 ± 0.02 1.64 ± 0.06 0.67 ± 0.02 
Heptamers 0.22 ± 0.01 1.01 ± 0.01 0.39 ± 0.02 
Octamers 0.10 ± 0.00 0.43 ± 0.01 0.16 ± 0.01 
Nonamers 0.02 ± 0.00 0.17 ± 0.01 0.07 ± 0.01 
Decamers nd 0.07 ± 0.00 0.02 ± 0.00 
Seeds-EA70 
Procyanidins GRE1
a
 SYR1
a
 CAR
a
 
Monomers 32.59 ± 0.60 72.11 ± 0.93 29.72 ± 0.35 
(Epi)catechin gallate 1.01 ± 0.02 1.34 ± 0.05 0.79 ± 0.02 
Dimers 10.63 ± 0.17 28.15 ± 0.11 9.22 ± 0.15 
Dimers gallate 0.33 ± 0.01 1.94 ± 0.00 0.34 ± 0.00 
Trimers 4.16 ± 0.23 20.74 ± 0.03 3.49 ± 0.04 
(Epi)gallocatechin trimers 0.63 ± 0.01 2.18 ± 0.02 0.58 ± 0.01 
Trimers gallate 0.30 ± 0.00 1.42 ± 0.01 0.28 ± 0.00 
Tetramers 1.98 ± 0.06 9.46 ± 0.19 1.69 ± 0.04 
(Epi)gallocatechin tetramers 0.97 ± 0.13 4.50 ± 0.04 0.80 ± 0.01 
Tetramers gallate 0.04 ± 0.01 0.82 ± 0.05 0.06 ± 0.00 
Pentamers 1.30 ± 0.01 6.27 ± 0.15 1.25 ± 0.00 
(Epi)gallocatechin pentamers 0.32 ± 0.01 1.37 ± 0.05 0.20 ± 0.00 
Hexamers 0.92 ± 0.03 3.43 ± 0.05 0.83 ± 0.02 
Heptamers 0.51 ± 0.00 1.82 ± 0.01 0.51 ± 0.00 
Octamers 0.28 ± 0.00 0.90 ± 0.00 0.24 ± 0.01 
Nonamers 0.13 ± 0.01 0.43 ± 0.00 0.15 ± 0.01 
Decamers 0.09 ± 0.00 0.24 ± 0.01 0.07 ± 0.00 
a GRE1, Grenache ; SYR1, Syrah ; CAR, Carignan. Data are expressed as the mean of triplicate ± standard deviation as 
mg (–)-epicatechin equivalents/g of dry weight. 
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Procyanidins composition in EAQ and EA70 grape pomace skin extracts were showed 
in Table 32. Interestingly, unlike seed extracts, a higher amount of procyanidins were 
evidenced in EAQ skin extracts, especially in SYR2, MOU and ALI in which total 
procyanidins were 2-fold more extracted by aqueous solution than hydro-alcoholic 70%. The 
most interesting extracts in term of procyanidins were the SYR 1 and ALI which contained 
up to 60 mg/g DW in EAQ, SYR1 and CAR in EA70 (51.65 mg/g DW and 39.08 mg/g DW 
respectively). MOU in both type of extract appeared to be the less interesting because of its 
low total procyanidin contents (27.35 mg/g DW in EAQ and 11.89 mg/g DW in EA70). A 
further extraction of highly polymerized procyanidins by hydro-alcoholic 70% solution was 
better illustrated in skin extracts. Actually, with the exception of ALI, nonamers were only 
detected in SYR1 and any decamers were evidenced in EAQ skin extracts.  
Table 32: Procyanidins characterisation in EAQ and EA70 grape pomace skin 
extracts 
Skins-EAQ 
Procyanidins GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
Monomers 13.01 ± 0.34 26.30 ± 0.05 17.44 ± 0.00 14.20 ± 0.03 10.19 ± 0.15 12.20 ± 0.00 
(Epi)catechin gallate 0.20 ± 0.01 0.37 ± 0.01 0.28 ± 0.02 0.31 ± 0.02 0.17 ± 0.00 0.24 ± 0.01 
Dimers 4.17 ± 0.10 7.96 ± 0.06 5.32 ± 0.05 5.29 ± 0.02 3.92 ± 0.06 3.73 ± 0.07 
Dimers gallate 0.37 ± 0.01 0.83 ± 0.03 0.35 ± 0.02 0.45 ± 0.01 0.37 ± 0.01 2.25 ± 0.01 
Trimers 5.48 ± 0.00 11.24 ± 0.29 6.13 ± 0.15 6.68 ± 0.11 5.64 ± 0.09 19.44 ± 0.11 
(Epi)gallocatechin trimers 0.82 ± 0.01 1.45 ± 0.01 0.90 ± 0.02 1.25 ± 0.04 0.48 ± 0.01 2.15 ± 0.01 
Trimers gallate 0.23 ± 0.01 0.35 ± 0.07 0.17 ± 0.00 0.20 ± 0.03 0.16 ± 0.01 0.94 ± 0.00 
Tetramers 1.94 ± 0.06 4.19 ± 0.00 2.14 ± 0.01 2.50 ± 0.04 2.33 ± 0.02 7.13 ± 0.01 
(Epi)gallocatechin 
tetramers 
0.89 ± 0.02 1.17 ± 0.00 0.70 ± 0.02 1.06 ± 0.04 0.73 ± 0.00 2.64 ± 0.09 
Tetramers gallate nd nd nd nd nd nd 
Pentamers 1.03 ± 0.00 2.41 ± 0.08 1.05 ± 0.02 1.45 ± 0.02 1.32 ± 0.01 3.42 ± 0.01 
(Epi)gallocatechin 
pentamers 
0.69 ± 0.00 0.66 ± 0.01 0.66 ± 0.03 1.04 ± 0.00 0.66 ± 0.02 1.26 ± 0.01 
Hexamers 0.80 ± 0.00 1.68 ± 0.00 0.58 ± 0.02 0.70 ± 0.00 0.92 ± 0.01 1.90 ± 0.01 
Heptamers 0.36 ± 0.01 0.86 ± 0.01 0.27 ± 0.01 0.34 ± 0.01 0.39 ± 0.03 0.92 ± 0.01 
Octamers 0.08 ± 0.00 0.30 ± 0.02 nd 0.15 ± 0.01 0.07 ± 0.01 0.29 ± 0.03 
nonamers nd 0.10 ± 0.01 nd nd nd 0.10 ± 0.00 
Decamers nd nd nd nd nd 0.04 ± 0.00 
Skins-EA70 
Procyanidins GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
Monomers 9.89 ± 0.08 19.28 ± 0.28 9.62 ± 0.05 12.58 ± 0.05 3.80 ± 0.07 12.71 ± 0.03 
(Epi)catechin gallate 0.28 ± 0.00 0.47 ± 0.01 0.64 ± 0.02 0.49 ± 0.03 0.02 ± 0.00 0.44 ± 0.01 
Dimers 4.05 ± 0.03 6.76 ± 0.09 2.70 ± 0.02 4.65 ± 0.02 1.9 ± 0.05 4.51 ± 0.08 
Dimers gallate 0.40 ± 0.01 0.89 ± 0.00 0.49 ± 0.00 0.61 ± 0.00 0.17 ± 0.00 0.44 ± 0.01 
Trimers 6.31 ± 0.08 10.51 ± 0.01 4.35 ± 0.06 7.91 ± 0.14 2.34 ± 0.01 4.52 ± 0.06 
(Epi)gallocatechin trimers 0.62 ± 0.00 0.78 ± 0.01 0.49 ± 0.04 0.35 ± 0.01 0.07 ± 0.00 0.08 ± 0.00 
Trimers gallate 0.27 ± 0.00 0.47 ± 0.01 0.23 ± 0.01 0.38 ± 0.01 0.06 ± 0.00 0.31 ± 0.00 
Tetramers 2.79 ± 0.01 4.79 ± 0.01 1.94 ± 0.01 3.58 ± 0.04 1.14 ± 0.00 1.97 ± 0.01 
(Epi)gallocatechin 1.03 ± 0.00 1.16 ± 0.01 0.45 ± 0.01 1.30 ± 0.03 0.33 ± 0.02 0.67 ± 0.03 
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tetramers 
Tetramers gallate nd 0.11 ± 0.01 0.09 ± 0.01 0.40 ± 0.01 nd 0.05 ± 0.00 
Pentamers 1.87 ± 0.00 2.78 ± 0.00 1.10 ± 0.02 2.42 ± 0.01 0.84 ± 0.01 1.22 ± 0.00 
(Epi)gallocatechin 
pentamers 
0.56 ± 0.00 0.36 ± 0.00 0.37 ± 0.01 0.80 ± 0.04 0.18 ± 0.00 0.16 ± 0.00 
Hexamers 1.16 ± 0.01 1.61 ± 0.00 1.02 ± 0.02 1.74 ± 0.01 0.47 ± 0.00 0.69 ± 0.01 
Heptamers 0.87 ± 0.00 0.93 ± 0.01 0.32 ± 0.01 1.00 ± 0.07 0.30 ± 0.01 0.28 ± 0.00 
Octamers 0.18 ± 0.00 0.44 ± 0.01 0.19 ± 0.00 0.59 ± 0.00 0.16 ± 0.00 0.17 ± 0.00 
nonamers 0.16 ± 0.00 0.20 ± 0.01 nd 0.26 ± 0.01 0.07 ± 0.00 0.08 ± 0.00 
Decamers 0.03 ± 0.00 0.11 ± 0.00 nd 0.03 ± 0.00 0.04 ± 0.00 0.03 ± 0.00 
a GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. In units of mg/g DW 
seed or skin. Data are expressed as the mean of triplicate ± standard deviation as mg (–)-epicatechin equivalents/g of dry weight. Nd, not 
determined.  
 
III.3. mDP, %G, %P analysis of grape pomace extracts 
For the analysis of mDP, %G (% galloylation) and %P (% prodelphinidins) and in 
order to facilitate the investigation, extracts were inevitably lyophilized because of their semi 
liquid viscous form, hard to manipulate and hard to dissolve with methanol. Results are 
presented in Table 33. 
Table 33: mDP, %G and %P characterisation in EAQ and EA70 grape pomace 
seed and skin extracts 
Seeds-EAQ 
 
GRE1
a
 SYR1
a
 CAR
a
 
   
Dpm 4.36 ± 0.00 3.77 ± 0.09 4.13 ± 0.14 
   
% G 46.4 ± 0.35 64.06 ± 0.97 57.92 ± 1.12 
   
% P 26.93 ± 0.25 11.09 ± 0.47 17.82 ± 1.89 
   
Seeds-EA70 
 
GRE1
a
 SYR1
a
 CAR
a
 
   
Dpm 5.21 ± 0.33 4.67 ± 0.10 4.05 ± 0.05 
   
% G 66.37 ± 0.46 71.75 ± 0.15 57.97 ± 0.71 
   
% P 16.63 ± 0.12 11.01 ± 0.00 17.07 ± 0.96 
   
       
Skins -EAQ 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
Dpm 6.15 ± 0.64 4.44 ± 0.36 6.81 ± 0.15 4.92 ± 0.15 7.31 ± 0.30 3.94 ± 0.01 
% G 39.44 ± 0.51 54.46 ± 1.90 20.33 ± 0.40 41.28 ± 2.91 31.8 ± 2.02 42.25 ± 1.68 
% P 38.21 ± 1.43 22.23 ± 0.36 53.32 ± 0.56 33.17 ± 2.81 43.86 ± 1.24 28.58 ± 1.38 
Skins-EA70 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
Dpm 4.37 ± 0.16 5.34 ± 0.01 5.49 ± 0.04 3.35 ± 0.02 4.5 ± 0.09 3.4 ± 0.17 
% G 47.16 ± 1.05 57.79 ± 0.17 44.3 ± 0.63 46.82 ± 0.18 51.85 ± 0.23 50.39 ± 3.08 
% P 29.12 ± 0.58 23.65 ± 0.02 34.35 ± 0.44 23.38 ± 0.35 25.48 ± 0.70 22.01 ± 1.49 
a GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. mDP, mean degree of 
polymerization ; %G, percentage of galloylation ; %P, percentage of prodelphinidins. 
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In seed grape pomace extracts, mDPs varied from 3.77 to 4.36 in EAQ and 4.05 to 
5.21 in EA70 and were slightly higher in EA70 than EAQ. GRE1 and SYR1 presented a 
more important %G (66.4 and 71.8 respectively) in EA70 whereas in CAR, %G was similar 
in EAQ and EA70 (57.9 for both types of extracts). For %P, similar results were obtained for 
SYR1 and CAR in EAQ and EA70 but a greater %P was found in GRE1 aqueous extract (27 
in EAQ vs 17 in EA70). GRE1 has the bigger mDP and %P values. 
In skin pomace extracts, mDPs ranged in aqueous extracts from 3.9 in ALI to 7.3 in 
MOU and in hydro-alcoholic 70% extracts from 3.4 in ALI to 5.5 in SYR2. Higher mDPs 
were observed in EAQ skin extracts on the contrary to seed extracts. EA70 extracts were 
evidenced as being more galloylated than EAQ extracts and varied from 47.2 to 57.8. The 
contrary was evidenced concerning %P which was bigger in EAQ (from 22.2 in SYR1 to 
53.3 in SYR2) than in EA70 (from 22 in ALI to 34.3 in SYR2).  
Results were in accordance with previous studies evidencing seed extracts as more 
galloylated than skin extracts and %P as higher in skin extracts due to substantial quantities 
of galloylated compounds (Souquet et al. 1996; Chira et al. 2009). Previous procyanidins 
analysis evidenced that high polymerized procyanidins was better extracted with hydro-
alcoholic 70% solution. In this current analysis, this observation was supported only by seed 
extracts but not in skin extracts where bigger procyanidins were evidenced in aqueous 
extracts. In overall, independently to mDP, aqueous extraction showed to increase the %P 
value while hydro-alcoholic 70% solution affected especially the %G.  
III.4. Anthocyanin analysis of grape pomace extracts by HPLC-
UV-MSn 
In total, 18 anthocyanins were detected by HPLC-PDA-MS. A typical chromatogram 
is illustrated in (Figure 31). Compounds were identified on the basis of absorbance spectra, 
retention time of commercially available standards, elution order, m/z of the positively 
charged molecular ion ([M]
+
) and on the MS
2
 fragmentation according to previous reports. 
Tables 34-36 summarize the anthocyanin contents of grape seed and skin pomace extracts in 
which total anthocyanins represented the sum of individual anthocyanins.  
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Table 34: Anthocyanins characterisation in EAQ and EA70 grape pomace seed 
extracts 
Seeds-EAQ 
Peak Compounds GRE1
a
 SYR1
a
 CAR
a
 
1 Delphinidin-3-O-glucoside 0.03 ± 0.00 0.08 ± 0.00 0.40 ± 0.00 
2 Cyanidin-3-O-glucoside 0.02 ± 0.00 0.02 ± 0.00 0.05 ± 0.00 
3 Petunidin-3-O-glucoside 0.05 ± 0.00 0.14 ± 0.00 0.43 ± 0.00 
4 Peonidin-3-O-glucoside 0.11 ± 0.00 0.12 ± 0.00 0.15 ± 0.01 
5 Malvidin-3-O-glucoside 0.39 ± 0.00 0.93 ± 0.00 1.48 ± 0.02 
6 Malvidin-3-O-glucoside-acetaldehyde (vitisin B) Nd 0.02 ± 0.00 0.02 ± 0.00 
7 Delphinidin-3-O-(6″-O-acetyl) glucoside Nd 0.02 ± 0.00 Nd 
8 Malvidin-catechin dimer 0.01 ± 0.00 0.03 ± 0.00 Nd 
9 Malvidin-3-O-glucoside-pyruvate (vitisin A) 0.02 ± 0.00 0.04 ± 0.00 0.04 ± 0.00 
10 Malvidin-catechin dimer 0.002 ± 0.00 0.07 ± 0.00 0.05 ± 0.00 
11 Malvidin-catechin dimer 0.01 ± 0.00 0.03 ± 0.00 0.02 ± 0.00 
12 Peonidin-3-O-(6″-O-acetyl) glucoside 0.01 ± 0.00 0.07 ± 0.00 Nd 
13 Malvidin-3-O-(6″-O-acetyl) glucoside 0.02 ± 0.00 0.32 ± 0.00 0.09 ± 0.00 
14 Delphinidin-3-O-(6″-O-coumaroyl) glucoside 0.01 ± 0.00 0.06 ± 0.00 0.10 ± 0.00 
15 Malvidin-3-O-(6″-O-caffeoyl) glucoside 0.01 ± 0.00 0.04 ± 0.00 0.02 ± 0.00 
16 Cyanidin-3-O-(6″-O-coumaroyl) glucoside 0.01 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
17 Petunidin-3-O-(6″-O-coumaroyl) glucoside 0.01 ± 0.00 0.11 ± 0.00 0.11 ± 0.00 
18 Malvidin-3-O-(6″-O-coumaroyl) glucoside 0.06 ± 0.00 1.14 ± 0.01 0.65 ± 0.00 
 
Total anthocyanin glucosides 0.60 ± 0.00 1.30 ± 0.00 2.52 ± 0.03 
 
Total acetylated anthocyanins 0.03 ± 0.00 0.41 ± 0.00 0.09 ± 0.00 
 
Total coumaroylated anthocyanins 0.08 ± 0.00 1.32 ± 0.01 0.88 ± 0.00 
 
Total anthocyanins 0.76 ± 0.00 3.26 ± 0.01 3.63 ± 0.03 
Figure 31: Typical HPLC chromatogram of grape pomace extract with detection 
wavelength at 520 nm 
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Seeds-EA70 
Peak Compounds GRE1
a
 SYR1
a
 CAR
a
 
1 Delphinidin-3-O-glucoside 0.19 ± 0.00 0.31 ± 0.00 3.11 ± 0.02 
2 Cyanidin-3-O-glucoside 0.09 ± 0.00 0.05 ± 0.00 0.23 ± 0.00 
3 Petunidin-3-O-glucoside 0.33 ± 0.01 0.58 ± 0.02 3.18 ± 0.01 
4 Peonidin-3-O-glucoside 0.56 ± 0.03 0.47 ± 0.02 1.11 ± 0.00 
5 Malvidin-3-O-glucoside 2.36 ± 0.12 3.57 ± 0.08 10.52 ± 0.11 
6 Malvidin-3-O-glucoside-acetaldehyde (vitisin B) 0.01 ± 0.00 0.05 ± 0.00 0.03 ± 0.00 
7 Delphinidin-3-O-(6″-O-acetyl) glucoside nd 0.09 ± 0.00 0.06 ± 0.00 
8 Malvidin-catechin dimer 0.04 ± 0.00 0.05 ± 0.00 0.06 ± 0.00 
9 Malvidin-3-O-glucoside-pyruvate (vitisin A) 0.12 ± 0.00 0.07 ± 0.00 0.14 ± 0.00 
10 Malvidin-catechin dimer nd 0.13 ± 0.00 0.17 ± 0.00 
11 Malvidin-catechin dimer 0.10 ± 0.00 0.13 ± 0.00 0.16 ± 0.00 
12 Peonidin-3-O-(6″-O-acetyl) glucoside 0.07 ± 0.00 0.32 ± 0.01 0.12 ± 0.00 
13 Malvidin-3-O-(6″-O-acetyl) glucoside 0.06 ± 0.00 0.90 ± 0.03 0.31 ± 0.00 
14 Delphinidin-3-O-(6″-O-coumaroyl) glucoside 0.05 ± 0.00 0.18 ± 0.00 0.58 ± 0.01 
15 Malvidin-3-O-(6″-O-caffeoyl) glucoside 0.08 ± 0.00 0.11 ± 0.00 0.33 ± 0.00 
16 Cyanidin-3-O-(6″-O-coumaroyl) glucoside 0.07 ± 0.00 0.07 ± 0.00 0.11 ± 0.00 
17 Petunidin-3-O-(6″-O-coumaroyl) glucoside 0.08 ± 0.00 0.35 ± 0.01 0.66 ± 0.00 
18 Malvidin-3-O-(6″-O-coumaroyl) glucoside 0.80 ± 0.00 2.85 ± 0.00 4.51 ± 0.04 
 
Total anthocyanin glucosides 3.53 ± 0.16 4.99 ± 0.12 18.15 ± 0.09 
 
Total acetylated anthocyanins 0.13 ± 0.00 1.30 ± 0.02 0.49 ± 0.00 
 
Total coumaroylated anthocyanins 1.00 ± 0.00 3.44 ± 0.01 5.86 ± 0.02 
 
Total anthocyanins 5.00 ± 0.17 10.28 ± 0.14 25.38 ± 0.11 
a GRE1, Grenache ; SYR1, Syrah ; CAR, Carignan. Data are expressed as the mean of triplicate ± standard deviation as mg 
malvidin-3-O-glucoside equivalents/g of dry weight. Nd, not determined. 
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Table 35: Anthocyanins characterisation in EAQ grape pomace skin extracts 
Skins-EAQ 
Peak Compounds GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
1 Delphinidin-3-O-glucoside 0.24 ± 0.01 0.15 ± 0.00 0.01 ± 0.00 0.53 ± 0.00 0.20 ± 0.00 0.31 ± 0.00 
2 Cyanidin-3-O-glucoside 0.09 ± 0.00 0.01 ± 0.00 0.004 ± 0.00 0.05 ± 0.00 0.07 ± 0.00 0.11 ± 0.00 
3 Petunidin-3-O-glucoside 0.33 ± 0.01 0.25 ± 0.01 0.03 ± 0.00 0.54 ± 0.00 0.30 ± 0.00 0.47 ± 0.02 
4 Peonidin-3-O-glucoside 0.35 ± 0.01 0.20 ± 0.01 0.02 ± 0.00 0.19 ± 0.00 0.22 ± 0.00 1.49 ± 0.03 
5 Malvidin-3-O-glucoside 1.78 ± 0.05 1.54 ± 0.05 0.11 ± 0.00 1.74 ± 0.02 1.01 ± 0.01 3.14 ± 0.03 
6 Malvidin-3-O-glucoside-acetaldehyde (vitisin B) 0.01 ± 0.00 0.02 ± 0.00 nd 0.02 ± 0.00 0.01 ± 0.00 nd 
7 Delphinidin-3-O-(6″-O-acetyl) glucoside nd 0.05 ± 0.00 nd 0.02 ± 0.00 nd nd 
8 Malvidin-catechin dimer 0.01 ± 0.00 0.03 ± 0.00 nd nd 0.01 ± 0.00 0.03 ± 0.00 
9 Malvidin-3-O-glucoside-pyruvate (vitisin A) 0.05 ± 0.00 0.04 ± 0.00 0.02 ± 0.00 0.04 ± 0.00 0.06 ± 0.00 0.10 ± 0.00 
10 Malvidin-catechin dimer nd 0.08 ± 0.00 0.002 ± 0.00 0.05 ± 0.00 0.01 ± 0.00 0.05 ± 0.00 
11 Malvidin-catechin dimer 0.01 ± 0.00 0.03 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.03 ± 0.00 
12 Peonidin-3-O-(6″-O-acetyl) glucoside 0.02 ± 0.00 0.10 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.01 ± 0.00 0.09 ± 0.00 
13 Malvidin-3-O-(6″-O-acetyl) glucoside nd 0.52 ± 0.00 0.02 ± 0.00 0.07 ± 0.00 0.04 ± 0.00 0.19 ± 0.00 
14 Delphinidin-3-O-(6″-O-coumaroyl) glucoside nd 0.09 ± 0.00 nd 0.13 ± 0.00 0.02 ± 0.00 0.06 ± 0.00 
15 Malvidin-3-O-(6″-O-caffeoyl) glucoside 0.02 ± 0.00 0.05 ± 0.00 nd 0.03 ± 0.00 0.02 ± 0.00 0.05 ± 0.00 
16 Cyanidin-3-O-(6″-O-coumaroyl) glucoside 0.01 ± 0.00 0.02 ± 0.00 nd 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 
17 Petunidin-3-O-(6″-O-coumaroyl) glucoside 0.04 ± 0.00 0.16 ± 0.00 nd 0.12 ± 0.00 0.03 ± 0.00 0.07 ± 0.00 
18 Malvidin-3-O-(6″-O-coumaroyl) glucoside 0.22 ± 0.00 1.59 ± 0.00 0.01 ± 0.00 0.68 ± 0.01 0.15 ± 0.00 1.11 ± 0.01 
 
Total anthocyanin glucosides 2.80 ± 0.07 2.15 ± 0.06 0.17 ± 0.00 3.05 ± 0.02 1.80 ± 0.01 5.52 ± 0.08 
 
Total acetylated anthocyanins 0.02 ± 0.00 0.67 ± 0.00 0.03 ± 0.00 0.11 ± 0.00 0.05 ± 0.00 0.27 ± 0.00 
 
Total coumaroylated anthocyanins 0.27 ± 0.00 1.86 ± 0.00 0.01 ± 0.00 0.96 ± 0.01 0.24 ± 0.00 1.27 ± 0.01 
 
Total anthocyanins 3.19 ± 0.08 4.92 ± 0.06 0.24 ± 0.00 4.25 ± 0.03 2.20 ± 0.01 7.32 ± 0.08 
a GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. Data are expressed as the mean of triplicate ± standard deviation as mg malvidin-3-O-glucoside 
equivalents/g of dry weight. Nd, not determined. 
  
1
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Table 36: Anthocyanins characterisation in EA70 grape pomace skin extracts 
Skins-EA70 
Peak Compounds GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
1 Delphinidin-3-O-glucoside 1.43 ± 0.00 0.78 ± 0.00 0.97 ± 0.00 5.35 ± 0.21 2.35 ± 0.00 1.06 ± 0.01 
2 Cyanidin-3-O-glucoside 0.34 ± 0.02 0.05 ± 0.00 0.12 ± 0.00 0.39 ± 0.01 0.52 ± 0.00 0.24 ± 0.00 
3 Petunidin-3-O-glucoside 2.05 ± 0.08 1.29 ± 0.00 1.53 ± 0.00 5.04 ± 0.21 3.38 ± 0.02 1.65 ± 0.03 
4 Peonidin-3-O-glucoside 1.91 ± 0.02 0.87 ± 0.01 0.94 ± 0.02 1.71 ± 0.03 2.00 ± 0.01 5.32 ± 0.01 
5 Malvidin-3-O-glucoside 10.96 ± 0.22 7.59 ± 0.04 6.76 ± 0.09 14.82 ± 0.42 10.55 ± 0.03 11.18 ± 0.05 
6 Malvidin-3-O-glucoside-acetaldehyde (vitisin B) 0.03 ± 0.00 0.06 ± 0.00 0.07 ± 0.00 0.05 ± 0.00 0.04 ± 0.00 0.03 ± 0.00 
7 Delphinidin-3-O-(6″-O-acetyl) glucoside 0.04 ± 0.00 0.16 ± 0.00 0.13 ± 0.00 0.09 ± 0.00 0.05 ± 0.00 0.05 ± 0.00 
8 Malvidin-catechin dimer 0.05 ± 0.00 0.07 ± 0.00 0.11 ± 0.00 nd 0.10 ± 0.00 0.06 ± 0.00 
9 Malvidin-3-O-glucoside-pyruvate (vitisin A) 0.22 ± 0.01 0.17 ± 0.01 0.39 ± 0.00 0.18 ± 0.01 0.32 ± 0.00 0.20 ± 0.00 
10 Malvidin-catechin dimer 0.12 ± 0.00 0.27 ± 0.01 0.21 ± 0.00 0.16 ± 0.00 0.07 ± 0.00 0.14 ± 0.00 
11 Malvidin-catechin dimer 0.10 ± 0.00 0.11 ± 0.00 0.21 ± 0.01 0.10 ± 0.00 0.08 ± 0.00 0.23 ± 0.00 
12 Peonidin-3-O-(6″-O-acetyl) glucoside 0.17 ± 0.00 0.52 ± 0.01 0.39 ± 0.01 0.10 ± 0.00 0.19 ± 0.00 0.52 ± 0.14 
13 Malvidin-3-O-(6″-O-acetyl) glucoside 0.46 ± 0.01 2.11 ± 0.05 1.06 ± 0.00 0.41 ± 0.02 0.39 ± 0.00 0.61 ± 0.00 
14 Delphinidin-3-O-(6″-O-coumaroyl) glucoside 0.25 ± 0.01 0.12 ± 0.00 0.35 ± 0.01 0.75 ± 0.00 0.30 ± 0.00 0.27 ± 0.00 
15 Malvidin-3-O-(6″-O-caffeoyl) glucoside 0.34 ± 0.01 0.15 ± 0.00 0.56 ± 0.00 0.24 ± 0.00 0.32 ± 0.00 0.25 ± 0.00 
16 Cyanidin-3-O-(6″-O-coumaroyl) glucoside 0.13 ± 0.00 0.05 ± 0.00 0.17 ± 0.01 0.13 ± 0.00 0.52 ± 0.00 0.14 ± 0.00 
17 Petunidin-3-O-(6″-O-coumaroyl) glucoside 0.36 ± 0.00 0.20 ± 0.00 0.51 ± 0.01 0.82 ± 0.01 0.65 ± 0.00 0.55 ± 0.00 
18 Malvidin-3-O-(6″-O-coumaroyl) glucoside 3.09 ± 0.02 1.53 ± 0.00 4.12 ± 0.00 3.80 ± 0.03 3.24 ± 0.00 6.25 ± 0.04 
 
Total anthocyanin glucosides 16.68 ± 0.34 10.59 ± 0.05 10.33 ± 0.10 27.30 ± 0.88 18.79 ± 0.02 19.45 ± 0.08 
 
Total acetylated anthocyanins 0.67 ± 0.01 2.79 ± 0.04 1.59 ± 0.01 0.60 ± 0.02 0.62 ± 0.00 1.18 ± 0.14 
 
Total coumaroylated anthocyanins 3.82 ± 0.01 1.89 ± 0.00 5.14 ± 0.01 5.49 ± 0.04 4.71 ± 0.00 7.21 ± 0.04 
 
Total anthocyanins 22.03 ± 0.35 16.10 ± 0.10 18.60 ± 0.11 34.11 ± 0.95 25.06 ± 0.01 28.74 ± 0.01 
a GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. Data are expressed as the mean of triplicate ± standard deviation as mg malvidin-3-O-glucoside 
equivalents/g of dry weight. Nd, not determined. 
 
  
1
6
6
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From all studied varieties, the main compounds consisted of 3-O-monoglucosides ([M 
– 162]+) of delphinidin (m/z 303), cyanidin (m/z 287), petunidin (m/z 317), peonidin (m/z 
301) and malvidin (m/z 331) which accounted for 63% in EAQ, 64% in EA70 to 72 % in 
EAQ, 70% in EA70 of the total anthocyanins content in seed and skin pomace extracts, 
respectively. Other compounds were largely represented by 3-O-(6"-O-coumaroyl) glucoside 
anthocyanins ([M – 308] +) followed by the 3-O-(6"-O-acetyl) glucoside one ([M – 204]+) 
(Table 37 and 38). These results are in agreement with previously reported data which 
illustrated the monoglucoside character of V.vinifera species (Ribéreau-Gayon 1959; Mazza 
et al. 1995; Acevedo De la Cruz et al. 2012). Besides, malvidin-3-O-glucoside and its 
derivatives, mainly p-coumaroyl derivatives, petunidin-3-O-glucoside and peonidin-3-O-
glucoside were the major compounds. Malvidin-3-O-glucoside alone accounted for 30% in 
seeds to 40% in skins whereas the minor compound, the cyanidin-3-O-glucoside, represented 
no more than 2% of the total anthocyanins. 
 
Table 37: Percentage of different forms of anthocyanins in seed pomace extracts 
of total anthocyanins. Data expressed in percentage (%). 
Seeds-EAQ 
 
GRE1
a
 SYR1
a
 CAR
a
  Average (%) 
Cyanidin-3-O-glucoside 3 1 1  2 
Malvidin-3-O-glucoside 52 29 41  40 
Σ Anthocyanin glucosides 80 40 69  63 
Σ Anthocyanins acetylated 4 13 2  6 
Σ Anthocyanins coumaroylated 11 41 24  25 
Seeds-EA70 
 
GRE1
a
 SYR1
a
 CAR
a
  Average (%) 
Cyanidin-3-O-glucoside 2 0.4 1  1 
Malvidin-3-O-glucoside 47 35 41  41 
Σ Anthocyanin glucosides 71 49 72  64 
Σ Anthocyanins acetylated 3 13 2  6 
Σ Anthocyanins coumaroylated 20 33 23  26 
a
 GRE1, Grenache ; SYR1, Syrah ; CAR, Carignan. 
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Table 38: Percentage of different forms of anthocyanins in skin pomace extracts 
of total anthocyanins. Data expressed in percentage (%). 
Skins-EAQ 
 
GRE2
a
  SYR1
a 
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 Average (%) 
Cyanidin-3-O-glucoside 3 0.3 2 1 3 2 2 
Malvidin-3-O-glucoside 56 31 44 41 46 43 43 
Σ Anthocyanin glucosides 88 44 71 72 82 75 72 
Σ Anthocyanins acetylated 1 14 11 3 2 4 6 
Σ Anthocyanins coumaroylated 9 38 5 22 11 17 17 
Skins-EA70 
 
GRE2
a
  SYR1
a 
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 Average (%) 
Cyanidin-3-O-glucoside 2 0.3 1 1 2 1 1 
Malvidin-3-O-glucoside 50 47 36 43 42 39 43 
Σ Anthocyanin glucoside 76 66 56 80 75 68 70 
Σ Anthocyanins acetylated 3 17 9 2 2 4 6 
Σ Anthocyanins coumaroylated 17 12 28 16 19 25 19 
a GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. 
Furthermore, malvidin-3-O-glucoside-pyruvate (vitisin A) and malvidin-3-O-
glucoside-acetaldehyde (vitisin B) have also been identified. These compounds form a group 
called pyranoanthocyanins which have been previously described in red wines (Bakker et al. 
1997) and later isolated from grape pomaces after fermentation as stable anthocyanins even 
during SO2 bleaching or when a change of pH occurred (Fulcrand et al. 1998; Amico et al. 
2004; Boido et al. 2006). Indeed, vitisin A and vitisin B derived during the fermentation 
process from reactions of malvin-3-O-glucoside with pyruvic acid and acetaldehyde, 
respectively (Asenstorfer et al. 2003; Marquez et al. 2012). 
III.4.1. Anthocyanin analysis of grape pomace seed extracts 
In seed pomace extracts, an appreciable amount of anthocyanins still remained. This 
is due, in the first instance, to the contact between seeds and skins throughout the 
winemaking process, in particular during the pressing and maceration. Moreover, despite the 
separation of skins from seeds, the operation was not complete and some skins residues 
remained. 
In the aqueous extracts, total anthocyanin contents ranged from 0.76 ± 0.001 mg/g 
DW to 3.63 ± 0.03 mg/g DW in GRE1 and CAR respectively. CAR samples possessed the 
highest level of 3-O-glucoside anthocyanins (2.52 ± 0.03 mg/g DW) while SYR1 contained 
more acetylated and coumaroylated anthocyanins (0.41 ± 0.001 mg/g DW and 1.32 ± 0.01 
mg/g DW respectively). Extracts of these two varieties contained four times more 
anthocyanins than Grenache which was composed of only 0.76 ± 0.001 mg/g DW of total 
anthocyanins. 
169 
 
Regarding the hydro-alcoholic 70% extract, overall, the level of anthocyanins was 
higher: 6.6-, 3.2- and 7-fold more anthocyanins were extracted from GRE1, SYR1 and CAR 
respectively than with the aqueous extraction method (Figure 32). 
Total anthocyanin levels ranged from 5.00 ± 0.17 mg/g DW in GRE1 to 25.38 ± 0.11 
mg/g DW in CAR which also possessed the highest 3-O-glucosides and 3-O-(6"-O-
coumaroyl) glucoside anthocyanins (18.15 ± 0.09 mg/g DW and 5.86 ± 0.02 mg/g DW 
respectively). Besides, an important amount of 3-O-(6"-O-acetyl) glucoside (1.3 ± 0.02 mg/g 
DW) was founded in SYR1 grape seed pomaces. 
Among the three studied varieties, CAR variety proved to be a promising source of 
anthocyanins especially in EA70 extract compared to EAQ and the two other varieties. 
 
Figure 32: Comparison between aqueous and hydro-alcoholic 70% extraction of 
total anthocyanins in seed pomaces 
 
III.4.2. Anthocyanin analysis of grape pomace skin extracts 
As expected, anthocyanin levels in skin pomace extracts were higher than those in 
seeds and the predominant compound was the malvidin-3-O-glucoside mostly followed by 
the petudinin-3-O-glucoside and peonidin-3-O-glucoside. Indeed, despite the vinification 
process, a surprisingly large amount of anthocyanins still remained in grape skin pomaces. 
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With the aqueous extract, total anthocyanins value ranged from 0.24 ± 0.001 mg/g 
DW in SYR2 to 7.32 ± 0.08 mg/g DW in ALI. SYR1 possessed appreciable levels especially 
3-O-(6"-O-acetyl) glucoside and 3-O-(6"-O-coumaroyl) glucoside anthocyanins which 
reached up to 0.67 ± 0.001 mg/g DW and 1.86 ± 0.001 mg/g DW respectively. Concerning 
the hydro-alcoholic 70% extract, levels ranged from 16.1 ± 0.1 mg/g DW in SYR1 to 34.11 ± 
0.95 mg/g DW in CAR. Moreover, CAR, ALI and MOU were the varieties which possessed 
the highest amounts of anthocyanin 3-O-glucosides (27.3 ± 0.88 mg/g DW, 19.45 ± 0.08, 
18.79 ± 0.02 mg/g DW respectively). Regarding the 3-O-(6"-O-acetyl) glucoside 
anthocyanins, the two Syrah (SYR1 and SYR2) retained the highest amounts reaching 2.79 ± 
0.04 mg/g DW and 1.59 ± 0.01 mg/g DW respectively. The 3-O-(6"-O-coumaroyl) glucoside 
anthocyanins were predominant in ALI, CAR and SYR2. 
 
Figure 33: Comparison between aqueous extraction and hydro-alcoholic 70% 
extraction of total anthocyanins in skin pomaces 
 
Considering the difference between the two extraction methods, extraction yield was 
superior in hydro-alcoholic 70% extracts with the amounts, depended on the variety, varying 
from 3- to 77-fold. Surprisingly, in SYR2, 77 times more of total anthocyanins were 
extracted. The level of 3-O-(6"-O-acetyl) glucoside and 3-O-(6"-O-coumaroyl) glucoside 
anthocyanins reached up to 1.59 ± 0.01 mg/g DW and 5.14 ± 0.01 mg/g DW respectively 
(Figure 33). 
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Among the studied varieties, CAR and ALI were shown to be a rich source of 
anthocyanins especially with the hydro-alcoholic 70% extract. The SYR2 also contained 
substantial amounts of acetylated and coumaroylated anthocyanins in EA70. 
In overall, extraction with 70% of ethanol was shown to improve the recovery of 
anthocyanins from the grape by-products. The grape pomaces were obtained after vinification 
and had been pressed to remove residual juice. During the maceration process, mainly in the 
aqueous phase, more soluble and less stable compounds are released. As the alcohol level rise 
up, the efficiency to degrade cell walls increase and rate of dissolved phenols are more 
important. Nevertheless, reaching a certain level of alcohol, a decrease is observed and this 
mechanism is mainly due to the adsorption on solids (yeast, pomace), modifications in their 
structure (formation of tannin-anthocyanin complexes) (Ribéreau Gayon et al. 1965). At this 
stage, extraction of anthocyanins is almost complete. By using a high alcohol level for the 
extraction of grape pomaces, less soluble and more stable compounds can be release while 
more soluble and less stable had already been extracted. Extraction yield were then 
optimized. 
However, the two different methods of extraction did not strictly increase or decrease 
the ratio of 3-O-glucoside, 3-O-(6"-O-acetyl) glucoside and 3-O-(6"-O-coumaroyl) glucoside 
in grape skin and seed pomace extracts (Table 37 and 38). In some varieties, using hydro-
alcoholic 70% extraction increased the relative amount of 3-O-(6"-O-coumaroyl) glucoside 
obtained but in other instances, it was decreased the ratio. For instance, GRE1 skin pomace 
extract comprised of 9% coumaroylated anthocyanins in EAQ which increased to 17% when 
using 70% alcohol whereas in SYR1, 38% were extracted in EAQ and the ratio decreased to 
12% in EA70. Overall, the data showed that the two different extraction methods did not 
substantially affect the ratio of 3-O-glucoside, 3-O-(6"-O-acetyl) glucoside and 3-O-(6"-O-
coumaroyl) glucoside anthocyanins. 
III.5. Antioxidant activities evaluation of grape pomace extracts  
Grape pomace seed and skin extracts radical scavenging potential were evaluated by 
three spectrophotometric tests: the FRAP, ABTS
•+
 and DPPH and a spectrofluorimetric test, 
the ORAC test.  
Concerning seed extracts, the four antioxidant analytical techniques gave the same 
classification both in EAQ and EA70. The highest antioxidant activities were found in SYR1 
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for both types of extracts. Results were correlated with previous analysis which evidenced 
SYR 1 as having a substantial amount of flavan-3-ols, procyanidins and anthocyanins. GRE1 
extract presented a low antioxidant activity as a consequence of its low phenolic contents 
(ORAC: 1466.4 µM TE/g DW; FRAP: 0.63 mM Fe
2+
/g DW, ABTS: 1203.2 µM TE/g DW 
and DPPH: 410.8 TE/g DW in EAQ and ORAC: 1926.7 µM TE/g DW; FRAP: 1.28 mM 
Fe
2+
/g DW, ABTS: 2813.1 µM TE/g DW and DPPH: 1277.6 TE/g DW in EA70). 
Antioxidant activities of EAQ and EA70 grape pomace seed extracts were showed in Table 
39.  
Table 39: Antioxidant activities characterisation in EAQ and EA70 grape 
pomace seed extracts 
Seeds-EAQ 
 
GRE1
a
 SYR1
a
 CAR
a
 
ORACb 1466.39 ± 29.58 2230.69 ± 101.74 2058.58 ± 85.11 
FRAPb 0.63 ± 0.02 1.33 ± 0.08 1.06 ± 0.08 
ABTSb 1203.20 ± 24.09 2432.62 ± 55.95 1948.75 ± 61.10 
DPPHb 410.79 ± 43.30 1037.12 ± 64.04 1050.59 ± 30.11 
Seeds-EA70 
 
GRE1
a
 SYR1
a
 CAR
a
 
ORACb 1926.73 ± 108.55 2613.98 ± 150.86 2332.90 ± 91.94 
FRAPb 1.28 ± 0.01 1.45 ± 0.16 1.20 ± 0.06 
ABTSb 2813.15 ± 89.95 3601.20 ± 88.59 3495.58 ± 66.40 
DPPHb 1277.59 ± 54.69 1685.87 ± 130.65 1536.77 ± 38.92 
a GRE1, Grenache ; SYR1, Syrah ; CAR, Carignan. Data are expressed as the mean of triplicate ± SD. bORAC, ABTS and DPPH 
are expressed as µmol Trolox/g DW and FRAP as mmol Fe2+/g DW. 
 
In skins, results obtained by different antioxidant analysis were more disparate 
especially in EA70 extracts (Table 40). In aqueous extracts, the highest antioxidant activity 
was found in SYR1 and ALI. This observation was observed by every test and well correlated 
with previous results evidencing these extracts as containing high phenolic content. In EA70, 
different antioxidant tests did not give the same extract classification. Despite this fact, SYR1 
skin extract was classified as being the first or second extract showing the highest antioxidant 
capacity between the four tests (ORAC: 1912.6 µM TE/g DW; FRAP: 1.52 mM Fe
2+
/g DW, 
ABTS: 2614.5 µM TE/g DW and DPPH: 1391.7 TE/g DW). 
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Table 40: Antioxidant activities characterisation in EAQ and EA70 grape 
pomace skin extracts 
Skins EAQ 
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
ORACb 1190.70 ± 183.58 1345.94 ± 19.15 1065.98 ± 84.21 1077.76 ± 60.16 1033.76 ± 77.61 1714.62 ± 14.77 
FRAPb 0.56 ± 0.01 0.88 ± 0.01 0.14 ± 0.02 0.67 ± 0.02 0.32 ± 0.01 1.13 ± 0.00 
ABTSb 934.12 ± 11.90 1427.98 ± 54.80 668.30 ± 29.99 1048.83 ± 101.57 965.59 ± 16.63 1760.08 ± 91.03 
DPPHb 99.45 ± 10.82 690.29 ± 147.01 263.85 ± 71.54 591.01 ± 85.59 279.43 ± 61.65 1057.12 ± 45.22 
Skins-EA70 
 GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
ORACb 1828.26 ± 40.37 1912.56 ± 6.09 1701.83 ± 88.34 1238.38 ± 11.09 2070.03 ± 60.64 1628.45 ± 82.58 
FRAPb 1.32 ± 0.03 1.52 ± 0.05 0.94 ± 0.03 1.34 ± 0.03 1.03 ± 0.02 1.13 ± 0.01 
ABTSb 2612.08 ± 130.93 2614.50 ± 10.42 2010.64 ± 146.96 2555.92 ± 146.04 2674.84 ± 187.30 1923.37 ± 87.01 
DPPHb 876.96 ± 74.32 1391.69 ± 37.24 1164.91 ± 55.55 1075.39 ± 46.16 833.28 ± 26.37 1749.31 ± 112.65 
a GRE1 and GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. Data are expressed 
as the mean of triplicate ± SD. bORAC, ABTS and DPPH are expressed as µmol Trolox/g DW and FRAP as mmol Fe2+/g DW. 
 
III.6. Complementary phenolic analysis on grape pomace 
lyophilized extracts 
As already mention above in the mDP, %G and %P analysis of grape pomace extracts 
paragraph, extracts were lyophilized in other to facilitate analysis. Further investigations such 
as total analysis, flavan-3-ol and anthocyanin analysis and evaluation of antioxidant activity 
were achieved to evaluate the potential of completely dry samples. Results are presented in 
Tables 41-46 for total contents, flavan-3-ols, anthocyanins and antioxidant activity analysis 
respectively. 
 
Figure 34: Comparison between non-lyophilized and lyophilized EAQ and EA70 
seeds pomace extracts 
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In overall, lyophilization increased the potential of seed and skin grape pomace 
extracts especially in EA70 by concentrating compounds. For instance, all the analysis in 
both seed and skin extracts showed that lyophilized extracts contained 1- to 2.5-fold more 
(poly)phenolic compounds than non-lyophilized ones. Figures 34 and 35 compared the seed 
and skin TPC values in non-lyophilized and lyophilized extracts in EAQ and EA70.  
 
Figure 35: Comparison between non-lyophilized and lyophilized EAQ and EA70 
skins pomace extracts 
Actually, the techniques employed by 3INature Company, suitable for 
commercialization, didn’t allow a complete drying of the samples and the use of 
lyophilization will increase the cost of production. This additional step in the samples 
elaboration can be beneficial and have to be further discussed. Lyophilization can be taken 
into account if it doesn’t intensively increase the cost of production. However, even if the 
analysis showed a better potential of lyophilized extracts, their in vivo capacities have to be 
evaluated and might not have the same effects as the non-lyophilized extracts. 
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Table 41: Total phenol contents, total tannin and total anthocyanin contents in lyophilized 
EAQ and EA70 grape pomace seed and skin extracts 
Seeds-EAQ 
 
GRE1
a SYR1a CARa 
   
TPC 193.18 ± 2.97 337.50 ± 5.35 323.27 ± 10.19 
   
Total tannins 254.19 ± 0.89 439.16 ± 16.61 475.87 ± 18.75 
   
Total antho 3.47 ± 0.23 11.94 ± 0.00 26.53 ± 0.66 
   
Seeds-EA70 
 
GRE1
a SYR1a CARa 
   
TPC 324.98 ± 5.01 483.58 ± 3.33 338.10 ± 11.36 
   
Total tannins 550.22 ± 14.99 738.50 ± 12.11 724.42 ± 4.42 
   
Total antho 19.51 ± 0.96 47.43 ± 0.96 95.29 ± 4.06 
   
       
Skins-EAQ 
 
GRE2
a SYR1a SYR2a CARa MOUa ALIa 
TPC 231.55 ± 24.71 318.26 ± 10.17 108.53 ± 3.68 205.74 ± 9.17 216.68 ± 2.68 359.5 ± 1.28 
Total tannins 250.86 ± 16.39 402.53 ± 1.44 154.61 ± 4.69 278.58 ± 7.81 281.29 ± 5.88 469.33 ± 1.23 
Total anthocyanins 15.01 ± 0.56 37.93 ± 0.77 1.001 ± 0.00 28.73 ± 0.00 23.31 ± 2.00 49.14 ± 0.35 
Skins-EA70 
 
GRE2
a SYR1a SYR2a CARa MOUa ALIa 
TPC 250.97 ± 34.48 375.6 ± 15.64 153.08 ± 6.67 273.75 ± 24.59 335.51 ± 10.81 267.52 ± 17.78 
Total tannins 476.24 ± 19.79 731.04 ± 57.01 306.68 ± 10.38 536.31 ± 18.57 555.56 ± 8.13 488.63 ± 13.11 
Total anthocyanins 83.95 ± 3.14 117.25 ± 0.90 58.467 ± 0.96 146.48 ± 0.96 103.12 ± 1.92 104.34 ± 0.00 
a
 GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre, ALI, Alicante. In units of mg 
GAE/g DW seeds or skins for TPC and mg/g DW seeds or skins for total tannins and total anthocyanins. Data are 
expressed as the mean of triplicate ± standard deviation. TPC, total phenol contents. 
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Table 42: Flavan-3-ol monomers, dimers and trimers characterisation in lyophilized EAQ 
and EA70 grape pomace seed extracts 
Seeds-EAQ 
 
GRE1
a
 SYR1
a
 CAR
a
 
C 3.96 ± 0.00 10.26 ± 0.01 4.15 ± 0.01 
EC 1.80 ± 0.06 7.25 ± 0.06 1.66 ± 0.02 
Σ Monomers 5.77 ± 0.04 17.51 ± 0.03 5.81 ± 0.02 
B1 1.76 ± 0.03 6.46 ± 0.17 1.91 ± 0.05 
B2 1.41 ± 0.01 4.36 ± 0.01 1.20 ± 0.02 
B3 0.96 ± 0.02 2.18 ± 0.09 0.85 ± 0.03 
B4 Nd 1.28 ± 0.03 Nd 
Σ Dimers 4.13 ± 0.06 14.28 ± 0.21 3.95 ± 0.07 
C1 1.34 ± 0.11 3.67 ± 0.08 1.14 ± 0.02 
Seeds-EA70 
 
GRE1
a
 SYR1
a
 CAR
a
 
C 6.13 ± 0.19 11.22 ± 0.19 8.45 ± 0.15 
EC 2.44 ± 0.15 7.15 ± 0.15 3.45 ± 0.00 
Σ Monomers 8.57 ± 0.24 18.37 ± 0.24 11.90 ± 0.10 
B1 2.88 ± 0.29 4.88 ± 0.43 5.20 ± 0.21 
B2 1.56 ± 0.27 2.99 ± 0.17 2.38 ± 0.12 
B3 1.00 ± 0.20 1.31 ± 0.01 1.28 ± 0.06 
B4 Nd 0.80 ± 0.12 Nd 
Σ Dimers 5.44 ± 0.54 9.97 ± 0.50 8.85 ± 0.28 
C1 1.00 ± 0.04 2.28 ± 0.23 1.72 ± 0.04 
a GRE1, Grenache ; SYR1, Syrah ; CAR, Carignan. In units of mg/g DW seeds or skins. Data are expressed as the mean of triplicate ± standard 
deviation. C, (+)-Catechin; EC, (–)-Epicatechin; B1, B2; B3, B4, Procyanidin dimers B1, B2; B3, B4; C1, procyanidin trimers C1. Σ Monomers, sum of 
catechin and epicatechin; Σ Dimers, sum of B1, B2, B3 and B4; C1, trimer C1. Nd, Not determined. 
Table 43: Flavan-3-ol monomers, dimers and trimers characterisation in lyophilized EAQ 
and EA70 grape pomace skin extracts 
Skins-EAQ 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
C 1.34 ± 0.01 2.40 ± 0.18 0.50 ± 0.00 1.61 ± 0.01 1.11 ± 0.04 3.38 ± 0.02 
EC 0.48 ± 0.06 1.76 ± 0.15 0.36 ± 0.00 0.48 ± 0.01 0.63 ± 0.08 2.17 ± 0.01 
Σ Monomers 1.82 ± 0.03 4.16 ± 0.02 0.86 ± 0.00 2.09 ± 0.00 1.73 ± 0.08 5.55 ± 0.00 
B1 1.16 ± 0.01 1.64 ± 0.05 0.46 ± 0.01 1.19 ± 0.00 1.03 ± 0.05 1.82 ± 0.01 
B2 0.80 ± 0.03 1.20 ± 0.01 0.56 ± 0.02 0.71 ± 0.01 0.97 ± 0.10 1.32 ± 0.01 
B3 0.62 ± 0.02 0.77 ± 0.01 0.39 ± 0.01 0.59 ± 0.00 0.54 ± 0.04 0.93 ± 0.01 
B4 Nd Nd Nd Nd Nd 0.55 ± 0.01 
Σ Dimers 2.57 ± 0.00 3.60 ± 0.05 1.40 ± 0.00 2.48 ± 0.01 2.54 ± 0.14 4.62 ± 0.01 
C1 0.78 ± 0.06 1.05 ± 0.21 0.41 ± 0.00 0.68 ± 0.00 0.78 ± 0.05 0.98 ± 0.02 
Skins-EA70 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
C 2.57 ± 0.05 6.34 ± 0.13 2.86 ± 0.02 4.03 ± 0.07 2.99 ± 0.02 12.00 ± 0.18 
EC 0.76 ± 0.00 3.76 ± 0.02 1.76 ± 0.03 1.32 ± 0.05 1.51 ± 0.01 6.56 ± 0.06 
Σ Monomers 3.33 ± 0.04 10.10 ± 0.11 4.62 ± 0.04 5.35 ± 0.09 4.50 ± 0.00 18.56 ± 0.08 
B1 1.61 ± 0.00 3.58 ± 0.03 1.92 ± 0.08 3.15 ± 0.05 2.56 ± 0.03 6.44 ± 0.21 
B2 0.71 ± 0.01 1.82 ± 0.00 1.08 ± 0.07 1.09 ± 0.07 1.27 ± 0.03 3.34 ± 0.08 
B3 0.56 ± 0.00 0.94 ± 0.03 0.57 ± 0.04 0.72 ± 0.04 0.74 ± 0.01 1.85 ± 0.09 
B4 Nd Nd Nd Nd Nd 0.88 ± 0.07 
Σ Dimers 2.87 ± 0.01 6.35 ± 0.04 3.57 ± 0.13 4.96 ± 0.11 4.58 ± 0.05 12.51 ± 0.33 
C1 0.60 ± 0.00 1.25 ± 0.00 0.73 ± 0.03 0.83 ± 0.08 0.91 ± 0.02 1.87 ± 0.05 
a GRE2, Grenache ; SYR1 and SYR2, Syrah ; CAR, Carignan ; MOU, Mourvèdre; ALI, Alicante. In units of mg/g DW seeds or skins. Data are 
expressed as the mean of triplicate ± standard deviation. C, (+)-Catechin; EC, (–)-Epicatechin; B1, B2; B3, B4, Procyanidin dimers B1, B2; B3, B4; C1, 
procyanidin trimers C1. Σ Monomers, sum of catechin and epicatechin; Σ Dimers, sum of B1, B2, B3 and B4. Nd, Not determined.                                                                                                    
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Table 44: Anthocyanins characterisation in lyophilized EAQ and EA70 grape pomace 
seed extracts 
 
Seeds-EAQ 
  
 
GRE1
a
 SYR1
a
 CAR
a
 
Delphinidin-3-O-glucoside 0.60 ± 0.00 0.26 ± 0.02 1.47 ± 0.02 
Cyanidin-3-O-glucoside 0.48 ± 0.00 0.09 ± 0.00 0.14 ± 0.00 
Petunidin-3-O-glucoside 1.05 ± 0.00 0.24 ± 0.00 0.79 ± 0.03 
Peonidin-3-O-glucoside 0.92 ± 0.00 0.19 ± 0.01 0.30 ± 0.02 
Malvidin-3-O-glucoside 1.40 ± 0.00 1.12 ± 0.01 2.45 ± 0.21 
Σ Anthocyanin glucosides 4.44 ± 0.01 1.89 ± 0.01 5.16 ± 0.27 
Petunidin-3-O-(6"-O-acetyl) glucoside 0.99 ± 0.00 0.13 ± 0.00 0.19 ± 0.00 
Peonidin-3-O-(6"-O-acetyl) glucoside 0.99 ± 0.00 0.18 ± 0.00 0.20 ± 0.00 
Malvidin-3-O-(6"-O-acetyl) glucoside 1.00 ± 0.00 0.49 ± 0.01 0.29 ± 0.00 
Σ Acetylated anthocyanins 2.99 ± 0.00 0.79 ± 0.01 0.68 ± 0.00 
Peonidin-3-O-(6"-O-coumaroyl) glucoside 1.00 ± 0.00 0.22 ± 0.01 0.21 ± 0.02 
Malvidin-3-O-(6"-O-coumaroyl) glucoside 1.03 ± 0.00 0.95 ± 0.02 1.05 ± 0.04 
Σ Coumaroylated anthocyanins 2.03 ± 0.00 1.17 ± 0.01 1.27 ± 0.02 
    
 
Seeds-EA70 
  
 
GRE1
a
 SYR1
a
 CAR
a
 
Delphinidin-3-O-glucoside 0.48 ± 0.01 0.81 ± 0.00 5.83 ± 0.14 
Cyanidin-3-O-glucoside 0.13 ± 0.00 0.13 ± 0.00 0.17 ± 0.00 
Petunidin-3-O-glucoside 0.48 ± 0.01 0.85 ± 0.02 3.4 ± 0.16 
Peonidin-3-O-glucoside 0.53 ± 0.02 0.57 ± 0.01 0.94 ± 0.07 
Malvidin-3-O-glucoside 2.75 ± 0.06 4.79 ± 0.00 12.49 ± 0.56 
Σ Anthocyanin glucosides 4.37 ± 0.10 7.14 ± 0.02 22.83 ± 0.94 
Petunidin-3-O-(6"-O-acetyl) glucoside 0.22 ± 0.00 0.25 ± 0.00 0.25 ± 0.01 
Peonidin-3-O-(6"-O-acetyl) glucoside 0.19 ± 0.00 0.44 ± 0.01 0.24 ± 0.01 
Malvidin-3-O-(6"-O-acetyl) glucoside 0.19 ± 0.00 1.73 ± 0.05 0.60 ± 0.02 
Σ Acetylated anthocyanins 0.6 ± 0.00 2.42 ± 0.05 1.09 ± 0.04 
Peonidin-3-O-(6"-O-coumaroyl) glucoside 0.34 ± 0.01 0.65 ± 0.01 0.55 ± 0.06 
Malvidin-3-O-(6"-O-coumaroyl) glucoside 0.66 ± 0.00 2.85 ± 0.08 5.07 ± 0.24 
Σ Coumaroylated anthocyanins 0.99 ± 0.01 3.49 ± 0.10 5.62 ± 0.30 
a
 GRE1, Grenache ; SYR1, Syrah ; CAR, Carignan. Data are expressed as the mean of triplicate ± standard 
deviation as mg malvidin-3-O-glucoside equivalents/g of dry weight. Nd, not determined. 
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Table 45: Anthocyanins characterisation in lyophilized EAQ and EA70 grape pomace skin extracts 
Skins-EAQ 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
Delphinidin-3-O-glucoside 0.66 ± 0.03 0.81 ± 0.01 0.23 ± 0.02 1.86 ± 0.00 1.19 ± 0.01 4.34 ± 3.57 
Cyanidin-3-O-glucoside 0.15 ± 0.00 0.15 ± 0.00 0.10 ± 0.00 0.15 ± 0.00 0.18 ± 0.00 0.15 ± 0.00 
Petunidin-3-O-glucoside 0.52 ± 0.00 0.66 ± 0.01 0.17 ± 0.00 0.94 ± 0.01 0.89 ± 0.00 0.81 ± 0.01 
Peonidin-3-O-glucoside 0.47 ± 0.01 0.48 ± 0.01 0.14 ± 0.00 0.37 ± 0.01 0.59 ± 0.00 1.69 ± 0.04 
Malvidin-3-O-glucoside 2.48 ± 0.01 3.83 ± 0.10 0.32 ± 0.02 3.10 ± 0.00 2.74 ± 0.00 4.82 ± 0.04 
Σ Anthocyanin glucosides 4.29 ± 0.05 5.93 ± 0.09 0.95 ± 0.05 6.43 ± 0.01 5.60 ± 0.01 11.81 ± 3.57 
Petunidin-3-O-(6"-O-acetyl) glucoside 0.19 ± 0.00 0.21 ± 0.00 ND 0.19 ± 0.00 0.19 ± 0.00 0.18 ± 0.00 
Peonidin-3-O-(6"-O-acetyl) glucoside 0.21 ± 0.00 0.40 ± 0.01 ND 0.20 ± 0.00 0.21 ± 0.01 0.27 ± 0.01 
Malvidin-3-O-(6"-O-acetyl) glucoside 0.31 ± 0.00 1.32 ± 0.02 0.16 ± 0.01 0.31 ± 0.00 0.23 ± 0.02 0.45 ± 0.01 
Σ Acetylated anthocyanins 0.72 ± 0.01 1.92 ± 0.01 0.16 ± 0.01 0.70 ± 0.00 0.63 ± 0.03 0.89 ± 0.02 
Peonidin-3-O-(6"-O-coumaroyl) glucoside 0.23 ± 0.00 0.51 ± 0.02 ND 0.25 ± 0.01 0.23 ± 0.02 0.51 ± 0.00 
Malvidin-3-O-(6"-O-coumaroyl) glucoside 0.38 ± 0.00 2.51 ± 0.06 0.15 ± 0.01 1.17 ± 0.00 0.39 ± 0.05 1.32 ± 0.03 
Σ Coumaroylated anthocyanins 0.61 ± 0.00 3.02 ± 0.09 0.15 ± 0.01 1.42 ± 0.01 0.62 ± 0.07 1.82 ± 0.02 
Skins-EA70 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
Delphinidin-3-O-glucoside 3.66 ± 0.19 2.38 ± 0.03 1.60 ± 0.02 11.42 ± 0.29 4.64 ± 0.00 1.87 ± 0.02 
Cyanidin-3-O-glucoside 0.27 ± 0.00 0.76 ± 0.00 0.50 ± 0.00 0.28 ± 0.01 0.85 ± 0.00 0.16 ± 0.00 
Petunidin-3-O-glucoside 2.88 ± 0.18 2.94 ± 0.00 1.94 ± 0.00 6.17 ± 0.37 4.52 ± 0.02 1.61 ± 0.01 
Peonidin-3-O-glucoside 2.16 ± 0.03 1.98 ± 0.02 1.24 ± 0.00 1.62 ± 0.15 2.53 ± 0.01 3.90 ± 0.06 
Malvidin-3-O-glucoside 16.82 ± 1.27 10.37 ± 0.00 5.55 ± 0.00 19.85 ± 1.19 12.16 ± 0.03 11.58 ± 0.10 
Σ Anthocyanin glucosides 25.78 ± 1.67 18.40 ± 0.03 10.83 ± 0.02 39.35 ± 2.02 24.71 ± 0.00 19.12 ± 0.13 
Petunidin-3-O-(6"-O-acetyl) glucoside 0.26 ± 0.01 ND 1.19 ± 0.03 0.28 ± 0.01 1.62 ± 0.01 0.23 ± 0.00 
Peonidin-3-O-(6"-O-acetyl) glucoside 0.37 ± 0.01 2.07 ± 0.05 1.26 ± 0.058 0.33 ± 0.01 1.81 ± 0.02 0.41 ± 0.00 
Malvidin-3-O-(6"-O-acetyl) glucoside 0.92 ± 0.03 4.71 ± 0.01 1.90 ± 0.08 0.98 ± 0.06 1.89 ± 0.01 0.54 ± 0.03 
Σ Acetylated anthocyanins 1.55 ± 0.05 6.78 ± 0.04 4.35 ± 0.12 1.59 ± 0.08 5.32 ± 0.00 1.18 ± 0.04 
Peonidin-3-O-(6"-O-coumaroyl) glucoside 0.91 ± 0.04 1.84 ± 0.02 1.65 ± 0.00 0.57 ± 0.04 2.29 ± 0.010 1.99 ± 0.01 
Malvidin-3-O-(6"-O-coumaroyl) glucoside 3.69 ± 0.24 2.70 ± 0.00 3.34 ± 0.04 4.53 ± 0.38 4.09 ± 0.05 4.36 ± 0.08 
Σ Coumaroylated anthocyanins 4.59 ± 0.29 4.54 ± 0.02 4.99 ± 0.02 5.10 ± 0.42 6.38 ± 0.00 6.36 ± 0.09 
a GRE2. Grenache ; SYR1 and SYR2. Syrah ; CAR. Carignan ; MOU. Mourvèdre; ALI. Alicante. Data are expressed as the mean of triplicate ± standard deviation as mg malvidin-3-O-glucoside equivalents/g of dry 
weight. Nd. not determined.
1
7
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Table 46: Antioxidant activities characterisation in lyophilized EAQ and EA70 
grape pomace skin extracts 
Seeds-EAQ 
 
GRE1
a
 SYR1
a
 CAR
a
 
   
ORAC 3094.2 ± 209.0 4070.8 ± 199.0 6059.2 ± 597.1 
   
FRAP 1.3 ± 0.2 3.2 ± 0.0 2.5 ± 0.0 
   
ABTS 2110.9 ± 381.3 3964.9 ± 250.9 4062.0 ± 417.9 
   
DPPH 961.7 ± 42.4 1248.3 ± 37.4 1351.5 ± 290.2 
   
Seeds-EA70 
 
GRE1
a
 SYR1
a
 CAR
a
 
   
ORAC 4374.4 ± 290.6 6252.5 ± 430.7 5125.1 ± 43.2 
   
FRAP 2.9 ± 0.1 4.0 ± 0.2 2.4 ± 0.1 
   
ABTS 4666.1 ± 668.0 7662.6 ± 261.7 4605.9 ± 46.1 
   
DPPH 3322.5 ± 26.7 4076.8 ± 79.7 2552.9 ± 150.7 
   
       
Skins-EAQ 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
ORAC 3209.3 ± 109.8 4528.0 ± 65.8 2783.6 ± 115.1 3834.5 ± 451.2 3651.8 ± 166.9 5666.7 ± 216.5 
FRAP 1.7 ± 0.2 2.9 ± 0.0 1.3 ± 0.0 2.0  ± 0.1 1.8 ± 0.0 2.9 ± 0.1 
ABTS 2232.0 ± 305.0 4217.9 ± 597.3 1335.5 ± 97.9 2722.2 ± 207.5 2539.2 ± 131.2 2624.2 ± 340.0 
DPPH 484.3 ± 93.8 606.9 ± 125.7 750.3 ± 0.0 575.0 ± 98.2 685.7 ± 41.1 1571.4 ± 94.9 
Skins-EA70 
 
GRE2
a
 SYR1
a
 SYR2
a
 CAR
a
 MOU
a
 ALI
a
 
ORAC 4293.7 ± 102.0 4829.2 ± 32.0 2769.1 ± 14.9 4964.7 ± 102.3 3913.8 ± 467.1 4969.3 ± 32.2 
FRAP 2.4 ± 0.1 2.9 ± 0.1 1.3 ± 0.0 3.2 ± 0.1 1.9 ± 0.1 1.8 ± 0.2 
ABTS 3880.7 ± 648.1 4539.9 ± 253.5 1713.9 ± 29.9 3695.6 ± 333.1 4494.5 ± 336.4 3580.4 ± 128.5 
DPPH 2340.3 ± 0.0 1886.9 ± 53.5 947.1 ± 69.5 1912.9 ± 170.3 2285.1 ± 31.4 1681.9 ± 67.9 
a GRE1 and GRE2. Grenache ; Syr1 and SYR2. Syrah ; CAR. Carignan ; MOU. Mourvèdre; ALI. Alicante. Data are expressed as 
the mean of triplicate ± SD. bORAC. ABTS and DPPH are expressed as µmol Trolox/g DW and FRAP as mmol Fe2+/g DW. 
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IV. Conclusions 
The first part of our work screened the phenolic compositions of by-products obtained 
after vinification of different Mediterranean grape varieties, in order to assess their potential 
for nutraceutical applications against hypertension. The comparison of several wine industry 
by-products with their respective grapes provided evidence that pomaces are very rich 
sources of antioxidants, despite extraction during vinification. Grape seed and skin pomace 
extracts still contained appreciable amounts of flavan-3-ols and anthocyanins. The 
quantitative and qualitative distribution of (poly)phenols in grape pomaces showed 
significant differences through varieties and vintages. In addition, seeds were shown to 
contain particularly high amounts of phenolics and thus an important antioxidant potential 
compared to skins.  
In the first study of grape and grape pomace characterisations, seeds from Grenache 
(GRE1), Syrah (SYR1) and skins from Syrah (SYR1), Carignan and Alicante were evidenced 
as the most interesting fractions because of their higher (poly)phenol contents in term of 
flavan-3-ols (i.e. monomers, dimers and trimer) and anthocyanins (i.e. glycosides, acetylated 
and coumaroylated). These extracts also exerted the highest antioxidant capacities thought 
four different tests. As a result, these varieties and their parts (seeds and skins) were chosen 
for further extraction with aqueous and hydro-alcoholic 70% solution suitable for 
consumption and commercialization.  
The investigation of aqueous and hydro-alcoholic 70% evidenced seeds from 
Carignan and Syrah (SYR1) and skins from Carignan and Alicante as containing high 
phenolic contents and antioxidant activity. Hydro-alcoholic 70% solution showed to be more 
effective because of a higher flavan-3-ol, procyanidin and anthocyanin contents in EA70 
extracts. However, EAQ extracts displayed also interesting amount of (poly)phenolic and 
radical scavenging capacity and should not be ignored. Lyophilization step permitted to 
obtain extracts with more concentrated (poly)phenolic compounds. Nevertheless, this step 
can intensively increases the cost of production and has to be further discussed. 
Although selected extracts presented high content of (poly)phenolic compounds, the 
in vivo effects might not be that effective because bioavailability greatly differs between 
(poly)phenols. Several extracts, even those which contain low phenolic amounts, have to be 
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tested. The next chapter will highlight the in vivo biological effects on hypertension using a 
SHR rat model (spontaneously hypertensive rats), with our selected seed and skin grape 
pomace extracts.  
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Résumé chapitre 3 
Actuellement, les polyphénols sont bien connus pour leurs effets bénéfiques sur la 
santé et sont actuellement au centre de nouvelles collaborations entre scientifiques et 
industries. De nombreuses études épidémiologiques ont démontré qu’une alimentation riche 
en polyphénols est associée à une réduction de la mortalité globale avec une diminution du 
nombre de décès dus aux maladies cardiovasculaires et aux cancers (Mennen et al. 2004; He 
et al. 2007; Chong et al. 2010). Les composés phénoliques sont dotés de propriétés 
antioxydantes qui protègent l’organisme contre la production excessive de radicaux libres. 
Ces derniers possèdent une forte réactivité pouvant mener à un désordre dans les structures 
moléculaires par oxydation des lipides membranaires, des protéines cellulaires et des acides 
nucléiques et provoquer ainsi la mort cellulaire (Halliwell 1994; Dröge 2002). Outre ces 
particularités, les polyphénols peuvent aussi contribuer à réduire le stress oxydatif (Bagchi et 
al. 2000), à moduler la cascade inflammatoire (Delmas et al. 2005; Castilla et al. 2006), à 
réduire l’oxydation des LDL-c responsable des évènements athérogéniques (Stein et al. 1999; 
Sano et al. 2007) ainsi qu’à la protection contre les épisodes athérothrombotiques incluant 
l’ischémie cardiaque et l’inhibition des agrégations plaquettaires (Keevil et al. 2000; 
Shanmuganayagam et al. 2002). 
De plus, les composées phénoliques peuvent prévenir l’hypertension artérielle et le 
dysfonctionnement endothélial induit par l’angiotensine II en partie en prévenant le stress 
oxydant vasculaire-dépendant de la NADPH oxydase et la formation de métabolites 
vasoconstricteurs. D’une part, les polyphénols accroissent la production des facteurs 
vasodilatatrices tel que le monoxyde d’azote (NO) (Fitzpatrick et al. 1993; Andriambeloson 
et al. 1997; Soares de Moura et al. 2002), l’EDHF (endotheluim-derived hyperpolarizing 
factor) (Kwan et al. 2004; Ndiaye et al. 2004) et la prostacycline (Mizugaki et al. 2000; 
Aldini et al. 2003) via la stimulation de la voie PI3-Kinase/Akt redox-sensible et d’autre part, 
ils inhibent la synthèse de vasoconstricteur, l’endotheline-1 dans les cellules endothéliales 
(Corder et al. 2001). 
La protection contre les maladies cardiovasculaires par les polyphénols citée 
précédemment résulte d’association de différents effets produits par différents mécanismes et 
dans certains cas, par différents composés. En effet, les composés phénoliques sont présents 
sous des formes diverses (plus de 8000 composés phénoliques identifiés dans les végétaux en 
quantité variable) mais présentent toutefois une structure commune, constituée d’un ou 
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plusieurs cycles benzéniques portant une ou plusieurs fonctions hydroxyles. Parmi ces 
composés, les flavonoïdes sont les constituants majeurs avec plus de 4000 composés et sont 
sous divisés en plusieurs familles: les flavan-3-ols (catéchine, épicatéchine), les flavonols 
(quercétine, myricétine, kaempférol..), les anthocyanidines (malvidine, cyanidine, 
delphinidine..), les flavones (apigénine, lutéoline…), et les flavanonols. Du fait de leurs 
structures, leurs modes d’action au niveau l’organisme ainsi que leurs biodisponibilités sont 
différents (Kris-Etherton et al. 2002; Crozier et al. 2010; Del Rio et al. 2010). Il est pour cela 
intéressant de connaitre la composition des différents extraits utilisés lors des expériences in 
vivo. 
A l’heure actuelle, les polyphénols, notamment ceux issus des raisins et du vin ont 
prouvé leur efficacité à réduire l’HTA sur les modèles animaux (Al-Awwadi et al. 2004). La 
plupart des études concernant les effets bénéfiques des ces composés sur la santé ont été 
effectué avec les extraits de pépins et/ou de pellicules de raisins et des vins. Ces derniers 
renferment une quantité non négligeable de polyphénols. Une revue récente de (Garrido et al. 
2011) en illustre la composition. La vinification permet l’extraction de polyphénols contenus 
dans les raisins que l’on peut retrouver dans les vins. Leurs concentrations dépendent des 
cépages, de la localisation du vignoble et des différents paramètres techniques appliqués lors 
de la vinification (Kammerer et al. 2004; Ruberto et al. 2007). Cependant l’extraction n’est 
pas complète (environ 30 à 40 % seulement), une certaine quantité subsiste dans les marcs et 
sont essentiellement composés de pellicules et de pépins pressés qui comptent pour environ 
20 % du poids originale des raisins utilisé pour l’élaboration du vin (Laufenberg et al. 2003; 
Llobera et al. 2007). 
Ce chapitre étudie la composition phénolique des sous-produits de la vigne obtenus 
après la vinification de différents cépages caractéristiques de la Vallée du Rhône dans le but 
de procéder au développement d’extraits phénoliques de marcs en tant que complément 
alimentaire préventif de l’hypertension artérielle. Les analyses globales telles que les 
polyphénols totaux, les tannins totaux et les anthocyanes totales ont été effectuées. Une 
analyse poussée par HPLC-UV-Fluo a permis d’obtenir la composition en tannins et 
anthocyanes individuels. Le pouvoir antioxydant des extraits a été évalué à l’aide de quatre 
tests antioxydants différents : l’ORAC, le FRAP, l’ABTS et le DPPH. La comparaison des 
extraits de raisins et de leurs marcs respectifs montre que les marcs représentent une source 
importante d’antioxydants phénoliques malgré le processus de vinification. Les pépins et 
pellicules de marcs renferment des quantités appréciables de flavan-3-ols et anthocyanines. 
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La distribution qualitative et quantitative des polyphenols dans les marcs de raisins présentent 
des différences significatives au travers des variétés et millésimes allant de 15% à 70% de 
polyphénols extraits. Par ailleurs, les pépins possèdent une quantité importante en 
polyphénols et par conséquent un pouvoir antioxydant plus élevé comparé aux pellicules.  
Dans une première étude de caractérisation de raisins et de marcs après séparation 
pépins-pellicules, il a été démontré que les pépins de Grenache (GRE1), Syrah (SYR1) et les 
pellicules de Syrah (SYR1), Carignan et Alicante sont les fractions les plus intéressantes dues 
a la présence d’importantes quantités de flavan-3-ols (monomères, dimères et trimère) 
jusqu’à 8.7 mg/g MS et d’anthocyanes (glycosylées, acétylées et coumaroylées jusqu’à 17.40 
mg/g MS, 1.57 mg/g MS et 2.38 mg/g MS respectivement). De même, ces extraits présentent 
les pouvoirs antioxydants les plus élevés pour tous les tests confondus. Par conséquent, ces 
variétés et leurs parties (pépins/pellicules) ont été sélectionnées pour des extractions 
supplémentaires avec d’autres types de solvants tels que l’eau et une solution hydro-
alcoolique 70 % compatible à la consommation et la commercialisation. Deux différentes 
extractions ont été effectuées afin d’obtenir deux types d’extraits pour chaque échantillons : 
un extrait aqueux (EAQ) et un extrait hydro-alcoolique 70% (EA70). 
L’analyse des extraits aqueux (EAQ) et hydro-alcoolique 70% (EA70) indique que les 
pépins de Carignan et Syrah (SYR1) et les pellicules de Carignan et d’Alicante contiennent 
les plus fort taux en composés phénoliques et activités antioxydantes. La solution hydro-
alcoolique 70% permet une meilleure extraction de flavan-3-ols, procyanidins et anthocyanes 
dans les extraits EA70. Cependant, les extraits aqueux (EAQ) affichent tout de même des 
quantités de polyphénols et de pouvoir antioxydants intéressants et ne devrait pas être ignoré. 
La lyophilisation permet une meilleure concentration des composés phénoliques dans les 
extraits. Toutefois, cette étape augmentera considérablement le coût de production des 
extraits. Ce point devrait être discuté d’avantage lors de l’élaboration des extraits finaux.  
Bien que les extraits sélectionnés présentent une quantité importante en composés 
phénoliques et de forts pouvoirs antioxydants in vitro, ceci ne permet pas d’évaluer leur 
efficacité biologique in vivo dûe à une différence de biodisponibilité de chaque composé 
phénolique dans le milieu gastro-intestinale. Certains extraits, même ceux contentant de 
faible quantité en polyphénols ont été choisis afin d’évaluer leur efficacité in vivo.  
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Chapter 4: 
 
In vivo study of grape pomace extracts 
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I. State of knowledge: SHR rats 
For centuries, animals have been used by humans to understand their own biology. In 
cardiovascular research, animal models have allowed the study of cardiovascular disease in 
the early stages, as well as the investigation of the mechanisms of the pathogenesis of 
cardiovascular disease, pathophysiology, complications and the effects of drug intervention.  
An ideal animal model for any cardiovascular disease in humans should fulfill the 
following criteria:  
1/ mimic the human disease, 
2/ allow studies in chronic, stable disease, 
3/ produce symptoms which are predictable and controllable, 
4/ satisfy economical, technical and animal welfare considerations, 
5/ allow measurement of relevant cardiac, biochemical and haemodynamic 
parameters. 
Over the past 50 years various animal models of hypertension have been developed, 
predominantly in the rat. The spontaneously hypertensive rat (SHR) is the most widely used 
rat model and reflects the primary stages hypertension of human hypertension. Many other 
aspects of the etiology of hypertension are found in other rat models such as the Dahl/Salt 
sensitive (Dhal/SS) which develop hypertension in response to a high NaCl diet (Dahl et al. 
1962b), deoxycorticosterone acetate (DOCA)-salt hypertensive rats (Katholi et al. 1980), 
fructose-fed rats which develop insulin resistance and hypertension (Hwang et al. 1987), two-
kidney one-clip and one kidney one clip hypertensive rats or even the transgenic Ren-2 
TGR(mRen2)27 hypertensive rat (Langheinrich et al. 1996). However, these models are less 
frequently employed. 
The most commonly used model of cardiovascular disease is the spontaneously 
hypertensive rat (SHR) with the Wistar Kyoto rat (WKY) as the normotensive control. SHR 
represents the genetic strain of hypertensive rats and is the animal of choice for screening 
antihypertensive agents. 
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SHR rats introduced by Okamoto and Aoki in 1963 represented a new model of 
experimental hypertension that required no physiological, pharmacological or surgical 
intervention. The SHR model was developed by meticulous genetic inbreeding that uniformly 
resulted in 100% of the progeny having naturally occurring hypertension. Indeed, SHRs are 
descendants of an outbred Wistar male with spontaneous hypertension mating with a female 
with an elevated blood pressure, and then brother × sister mating continued with selection for 
spontaneous hypertension, defined as a SBP of over 150 mm Hg persisting for more than one 
month. From 1968, this inbred strain of SHRs was further developed in the USA (Kurtz et al. 
1987). The various colonies of SHR are pre-hypertensive for the first 6-8 weeks of their lives 
with systolic blood pressure around 100-120 mm Hg, and then hypertension develops over 
the next 12-15 weeks (Adams et al. 1989). In SHRs male, mean arterial pressure is 
approximately 190-200 mm Hg as compared to 115-130 mm Hg in normal rats.  
The WKY normotensive controls were established in 1971 by the National Institutes 
of Health (USA) as an inbreed of the Wistar Kyoto colony via brother × sister mating (Kurtz 
et al. 1987). The degree of genetic difference between the SHR and WKY strains and within 
different colonies of each strain is substantial and comparable to the maximum divergence 
possible between unrelated humans. WKY may share some of the genes responsible for 
hypertension with the SHRs because they were derived from the WKY and hypertension may 
develop spontaneously in the WKY (Johnson et al. 1992; St Lezin et al. 1992). 
The male SHR is commonly used as a model of established human hypertension and 
to test new antihypertensive medication. Because substantial individual variation in 
polygenetic disposition and excitatory environmental factors exist, many variations in the 
direct and indirect effects on the cardiovascular system are difficult to differentiate and 
complicate the study of human hypertension. Researchers in hypertension have commonly 
resorted to the use of SHRs which have, within each colony, uniform polygenetic disposition 
and excitatory factors which produce uniform changes in the indirect and direct effects on the 
cardiovascular system. This lack of inter-individual variation is one of the major advantages 
of the SHR but it means that the SHR can only model one of many possible causes of human 
hypertension (Lindpaintner et al. 1992).  
Another advantage of the SHRs is that it follows the same progression of hypertension 
as human hypertension with pre-hypertensive, developing and sustained hypertensive phases 
with each phase lasting at least several weeks (Folkow 1993). However the SHRs differ from 
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human hypertension in that SHRs reproducibly develop hypertension in young adulthood 
rather than in middle age as in humans. Because SHRs have a pre-hypertensive state, they 
have the important potential to be used in studies of the cause and development of 
hypertension. The SHR model is also suitable for gender studies in hypertension but only a 
few recent studies have considered gender differences in SHR responses (Kauser et al. 1995). 
Spontaneous hypertension has been observed in a number of different strains of 
common laboratory animals. The New Zealand strain of Smirk seems to be most similar to 
the Japanese SHR, though this has not been studied as widely (Smirk et al. 1958). In contrast, 
the Milan strain developed by Bianchi et al, (1975) seems to be different involving primarily 
alterations in renal sodium and water metabolism; therefore it may not be analogous to 
essential hypertension. Another developed by Dahl and coworkers shows a high sensitivity 
(“S” strain) to sodium intake in comparison to its normotensive control (“R” strain), which is 
sodium resistant (Dahl et al. 1962a). Furthermore, other strain such as Milan (Bianchi et al. 
1975), Prague (Heller et al. 1993), Lyon (Sassard et al. 1997) and San Juan (Crespo et al. 
1996) hypertensive rats were developed.  
Among these strains, SHRs develop not only moderate to severe hypertension but also 
typical complications of hypertension. Stroke prone SHRs (SHRSP), which are selectively 
bred from among SHRs, are extreme examples that develop cerebrovascular lesions 
spontaneously in over 80% of rats (Ogata et al. 1982). Because of high mortality rate of 
stroke in man, the similarity of stroke in SHRSP is important for further application of this 
model to studies of stroke in man. Other variants derived from SHRs is the arteriolipidosis-
prone (Yamori et al. 1981).  
Extreme environmental conditions such as stress and excess salt accelerate the 
development of hypertension and aggravate the hypertensive complications (Pinto et al. 
1998). Complications such as cerebral hemorrhage, thrombosis, nephrosclerosis, myocardial 
lesions in SHRs and especially cerebral lesions in SHRSPs, are pathogenically, 
pathologically and epidemiologically similar to those observed in essential hypertension in 
man. Therefore, these models can be used to study not only the pathogenesis and therapy but 
also prophylaxis in essential hypertension and its complications. Because of apparent 
similarities of the SHRs to essential hypertension, SHR models are highly recommended for 
screening potential drug candidates for hypertension (Kacew et al. 1996). Experimental 
models of genetic hypertension have also been developed in animals other than the rat. 
190 
 
Though it has been produced in one strain of rabbit and dog they have not been studied 
extensively for practical, financial and other reasons. Rats are mainly used because of their 
small size, short lifespan and low cost. 
Multiple quantitative trait loci associated with haemodynamic and metabolic 
parameters have been mapped in the SHR. Recently, it has become possible to identify some 
of the specific quantitative trait gene (QTG) variants that underline quantitative trait loci 
linked to complex cardiovascular and metabolic traits in SHR related strains. As in humans, 
spontaneous hypertension and associated metabolic disturbances in the SHRs are governed 
by complex polygenic traits. Identification of responsible genes in the SHRs could be used to 
study the role of human orthologous genes in complex cardiovascular and metabolic diseases 
and to identify new pathways and targets for pharmaceutical interventions (Pravenec et al. 
2007). Linkage analyses of crosses between the SHRs and various control strains have 
revealed multiple quantitative trait loci (QTL) associated with blood pressure variation and 
with parameters of lipids and glucose metabolism on practically all rat chromosomes. 
However, only a few of the responsible quantitative trait genes (QTGs) underlying these QTL 
for blood pressure and metabolic phenotypes has been confirmed in SHR-related models. The 
first one is the deletion variant of Cd36 (fatty acid translocase) and has been confirmed as a 
genetic determinant of multiple features of the metabolic syndrome including dyslipidemia, 
insulin resistance, and hypertension (Pravenec et al. 2008a). The second one consisted of the 
mutated form of Ogn (osteoglycin) which has been validated as a gene predisposing to 
cardiac hypertrophy (Petretto et al. 2008), and the last one is a variant in Srebf1 (sterol 
regulatory element binding factor 1c isoform), which proved to exert effects on hepatic lipid 
levels (Pravenec et al. 2008b). This illustrates the inherent difficulty of identifying causative 
QTGs even in animal models in which the effects of genetic background and environmental 
variables can be strictly controlled. 
Origin of hypertension is multiple. As in humans, hypertension develops more rapidly 
and becomes more severe in male than female SHR. In vivo studies have shown that, in the 
early stages of hypertension, SHRs have an increased cardiac output with normal total 
peripheral resistance. As the SHRs progress into the established hypertension state, the 
cardiac output returns to normal and the hypertrophied blood vessels produce an increase in 
the total peripheral resistance (Smith et al. 1979). In addition, According to Dietz et al (1984), 
SHRs presented an abnormality of intracellular electrolyte balance with increased 
intracellular sodium and calcium concentration. Calcification of vasculature which sometimes 
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occurs in humans has also been demonstrated by Kanemaru et al. (2008) in the SHRs smooth 
muscle cells that Osterix (a transcription factor for osteogenesis ), and alkaline phosphatise 
(ALP) (a marker of vascular calcification) were significantly increased in aortic smooth 
muscle cells from SHRs compared to similar cells from WKYs. Reduction in active transport 
of calcium by the intestine (Shibata et al. 1990) and excess loss through urine (Hsu et al. 
1987) may lead to hypocalcemia.  
It has been showed that SHR have fewer glomeruli than WKY rats, but still with 
similar size, resulting in a reduced glomerular volume. This is consistent with the hypothesis 
that the kidney plays an important role in hypertension (Skov et al. 1994).  
Compared to normotensive rats, the abnormal development of the intra renal renin-
angiotensin system (RAS) is thought to contribute to adult-onset hypertension in the SHRs 
(Tikellis et al. 2006). Studies have shown the expression and angiotensin-converting enzyme 
2 (ACE2) activities are significantly increased in the SHRs kidney at birth. With the onset of 
hypertension, the tubular expression of ACE2 falls in SHRs compared to WKYs and remains 
reduced in the adult SHR kidney. The overall developmental pattern of ACE2 expression in 
the SHRs kidney is also modified, with declining expression over the course of renal 
development (Tikellis et al. 2006). The developmental pattern of ACE2 expression in the 
SHRs kidney is altered before the onset of hypertension, consistent with the key role of the 
RAS in the pathogenesis of adult-onset hypertension (Obata et al. 2000). 
It is well established that the RAS has a central role in the regulation of blood 
pressure and angiotensin-converting enzyme 2 (ACE2), is involved in the regulation of the 
RAS (Crackower et al. 2002). ACE2 is a carboxypeptidase converting Angiotensin I (Ang I) 
to the nonapeptide angiotensin(1–9) (Ang 1–9) and Angiotensin II (Ang II) to the 
angiotensin(1–7) (Ang 1–7) by removing a single amino-acid residue from the carboxy-
terminus of the substrate (Donoghue et al. 2000). This action is distinct and complementary 
to the dipeptidyl carboxypeptidase activity of ACE that generates Ang II from Ang I. ACE2 
is thought to represent the major renal source of Ang 1–7, a peptide with anti-angiogenic and 
vasodilatory actions that antagonize the effects of Ang II (Ferrario et al. 2004), thus, a deficit 
of ACE2 induces an increase of Ang II which lead to a vasoconstriction.  
Dysfunction and vascular hypertrophy in SHRs is also a part due to an important 
oxidative stress. Oxidative stress is actually caused, on the one hand, by an excess of 
superoxide anion (•O2
–
) production by nicotinamide adenine dinucleotide/nicotinamide 
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adenine dinucleotide phosphate (NADH/NADPH) oxidase (Grunfeld et al. 1995; Zalba et al. 
2000) and on the other hand, by a low activity of the endothelial NO synthase (eNOS) which 
catalyses the production of nitric oxide (NO), a potent vasodilatator agent generated from L-
arginine (Palmer et al. 1987). Actually, •O2
–
 and NO are known to rapidly react to form the 
stable peroxynitrite anion (ONOO-), a powerful oxidant, which will prevent the 
vasodilatating action of NO (Beckman et al. 1990; Pacher et al. 2007; Vera et al. 2007).  
Thus, SHRs have been used extensively and successfully to test drugs for their 
effectiveness in lowering blood pressure and to study the mechanisms of established 
hypertension. The SHR is a chronic stable model producing symptoms which are predictable 
and controllable and avoiding difficult or life-threatening technical interventions. Similarity 
of SHRs to essential hypertension and its complication made the SHR the main animal model 
of hypertension. 
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II. Evaluation of grape pomace extracts anti-
hypertensive effects on SHR rats 
In this part, in vivo anti-hypertensive effects of grape pomace extracts on SHR were 
investigated. Different experimental groups were made and blood pressure (BP) was 
followed. Rats were fed with aqueous (EAQ) and hydro-alcoholic 70% (EA70) grape pomace 
extracts at a dose of 21 mg/kg/day which in terms of phenolic compounds is equivalent to a 
70 kg human consuming of ~0.5 L of red wine. Grape pomace extracts were dissolved in 3% 
EtOH solution in order to facilitate the complete dissolution before administration. Moreover, 
the effect of verapamil administrated alone or in association with grape pomace extracts were 
evaluated.  
II.1. 1st study: Grape pomace extracts screening 
In this experiment, six EA70 grape pomace extracts were screened for their anti-
hypertensive effect. The study was conducted for a period of six weeks: three weeks of 
treatment, a one week break followed again by two weeks of treatment on male nine-week-
old SHR and WKY. Blood pressure was recorded during all along the experiment. Rats were 
randomly assigned to different experimental group as follows:  
- Control group (6 WKY rats) 
- SHR control group (5 SHR treated with 3% EtOH) 
- 6 groups of 4 SHR rats treated with hydro-alcoholic 70% grape pomace 
extracts (21 mg/kg/day) dissolved in 3% EtOH: 
*SHR1: GRE1 (EA70) seed pomace extract 
*SHR2: SYR1 (EA70) seed pomace extract 
*SHR3: SYR2 (EA70) skin pomace extract 
*SHR4: CAR (EA70) seed pomace extract 
*SHR5: MOU (EA70) skin pomace extract 
*SHR6: ALI (EA70) skin pomace extract 
As expected, the growth of WKYs (3.3 ± 0.1 g/day) was higher than that of SHR rats 
(2.5 ± 0.2 g/day) without a significant influence of grape pomace extracts on weight gain. 
The mean systolic blood pressure (SBP) of SHR rats was ranged from 150 mm Hg at the 
beginning of the experiment to 190 mm Hg after five weeks (Figure 36). (Poly)phenolic 
extracts given to SHR rats had little effect on SBP which increased gradually (except for the 
SHR1 after 2 weeks of treatment) (Figure 37).   
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Figure 36: Effect of (poly)phenolic extracts on the mean systolic blood pressure 
(mm Hg) during the 6-weeks study. Results correspond to the mean of triplicate measurements ± 
standard deviation. 
 
 
Figure 37: Mean systolic blood pressure (mm Hg) measured at week 2 (after 14 
days of treatment with pomace extracts) and at week 4 (after 7 days of a therapeutic 
break). Results correspond to the mean of triplicate measurements ± Std. *p<0.05).    
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However, after three weeks, gavage intolerance was observed and caused difficulties 
to the extracts administration of the extracts, with the necessity to interrupt the treatment for 
one week (Figure 36). This interruption was followed by an increase of the SBP in SHR1 
(Grenache [GRE1] seed pomace extract), SHR2 (Syrah [SYR1] seed pomace extract) and 
SHR6 (Alicante [ALI] skin pomace extract) group compared to the SHR control group. It is 
well know that some anti-hypertensive agents that are used to lower arterial pressure may 
acutely increase arterial pressure and a rebound increase in pressure may be encountered after 
discontinuation of certain antihypertensive agents (Grossman et al. 1995). Thus, this 
phenomenon can be interpreted as a “rebound effect” and may reveal an anti-hypertensive 
effect of grape pomace extracts (Figure 38).  
 
Figure 38: Variations of the mean systolic blood (mm Hg) pressure during 
interruption and resumption period. Results correspond to the mean of triplicate 
measurements ± Std. (*p<0.05, **p<0.01). 
 
However, treatment resumption at weeks 5 and 6 was not followed by a decrease of 
the SBP nor was another “rebound effect” observed during the re-interruption of the 
treatment during 48 h at week 8 (Figure 39).   
196 
 
Figure 39: Effect of (poly)phenolic extracts on the mean systolic blood pressure 
(mm Hg) during the 9-weeks study. Results correspond to the mean of triplicate 
measurements ± Std. 
 
This first experiment evidenced the ability of Grenache seeds (GRE1), Syrah seed 
(SYR1) and Alicante skin (ALI) hydro-alcoholic 70% grape pomace extracts to regulate 
blood pressure which was illustrated by a rebound effect. 
II.2. 2nd study: Effect of the verapamil (model validation) 
Verapamil or the 5-[N-(3,4-dimethoxyphenylethyl)methylamino]-2-(3,4-
dimethoxyphenyl)-2-isopropylvaleronitrile (Figure 40) is a calcium channel antagonist with 
anti-arrhythmic (PR-interval prolongation), angina, and antihypertensive effects (Harder et al. 
1993). Verapamil can be found as the (R)-, (S)-verapamil and racemate which contains equal 
amounts of (R)-verapamil and (S)-verapamil. The enantiomers have different 
pharmacodynamic properties. (S)-Verapamil is 20-fold more potent than (R)-verapamil for 
prolongation of the PR interval in healthy volunteers. In contrast, (R)-verapamil causes a 
decrease in mean blood pressure (Busse et al. 2006). Verapamil is lipophilic and is easily 
absorbed from the gut. The drug is, however, the subject of extensive first-pass metabolism in 
the gut wall and the liver and the total oral bioavailability is only 10% to 30% (Echizen et al. 
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1986). After multiple dosing of controlled-release verapamil, the oral bioavailabilty was 27% 
for (S)-verapamil and 55% for (R)-verapamil (Busse et al. 2001).  
Verapamil is the most extensively characterized and a reference compound of P-gp 
inhibitor and multi-drug resistance (MDR) reversal agent (Potschka et al. 2001; Potschka et 
al. 2002). P-glycoprotein (P-gp) was first studied in the context of cancer research where its 
overexpression in tumor cells has been associated with the multidrug MDR phenotype 
(Kartner et al. 1983; Gottesman et al. 1993). In cancer cells, P-gp acts as an eflux pump that 
extrudes chemotherapeutic agents out of the cells and decreasing their intracellular 
concentration. P-gp is also expressed in normal tissues. High levels of P-gp expression have 
been observed in the endothelial cells of brain capillaries, in kidney and in adrenal glands 
while moderate expression has been detected in lung, liver and intestines (Fojo et al. 1987; 
Cordon-Cardo et al. 1990; Barrand et al. 1995). P-gp is involved in organism detoxification 
by excreting toxic compounds into the bile, urine and gastrointestinal tract (Schinkel et al. 
1994; Trambas et al. 1997). Moreover, it seems to play an important role in brain protection 
at the blood-brain barrier by preventing the passage of many drugs into the brain (Schinkel 
1999; Potschka et al. 2001).  
 
 
 
Figure 40: S-verapamil and R-verapamil structures 
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The effect of verapamil on SHR blood pressure was evaluated using three male nine 
week-old SHRs and three WKY rats. This experiment was held over twelve weeks. During 
the first four weeks, only blood pressure was followed. Then, SHR were treated with 
verapamil at 30, 20 and 40 mg/kg/day during 8 weeks. Throughout this time, blood pressure 
was monitored. 
WKY blood pressure remained stable between 100 mm Hg and 110 mm Hg 
throughout the experiment. At the beginning of the experiment, without any drug 
administration, SHR blood pressure gradually increased from 158 mm Hg to 194 mm Hg. At 
day 28, treatment with 30 mg/kg/day of verapamil caused a sudden drop of SBP to 120 mm 
Hg followed by a progressive blood pressure rise to 183 mm Hg within two weeks and 
reached 217 mm Hg after five weeks of treatment with 20 mg/kg/day of verapamil. An 
increase dose of verapamil at 40 mg/kg/day caused a drop of blood pressure to 180 mm Hg 
followed again by an increase to 200 mm Hg in 10 days (Figure 41).  
 
Figure 41: Effect of different concentration of verapamil on SHR and WKY on 
the mean systolic blood pressure (mm Hg). Symbols correspond to the mean of triplicate ± 
standard deviation. 
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Despite the administration of a higher dose of verapamil at 40 mg/kg/day, SBP 
remained high and fluctuated around 200 mm Hg. These results indicate that over time, SHR 
rats develop resistance to anti-hypertensive drugs including the calcium channel blocker drug, 
verapamil.  
II.3. 3rd study: Effect of grape pomace extracts associated with 
verapamil 
It is well known that anti-hypertensive drugs including diuretics, anti-adrenergics, 
calcium channel blockers or even those affecting the Renin–angiotensin-aldosterone system 
(RAAS) are not effective in every patients and a combination of drugs is often needed to treat 
high blood pressure. The previous study demonstrated that SHR rats develop a resistance to 
verapamil over time and considering the anti-hypertensive potential of grape pomace extracts, 
the combined intake of grape pomace extracts rich in (poly)phenols with verapamil might 
have beneficial effect on blood pressure regulation by amplifying (poly)phenols or verapamil 
action. In order to evaluate the potential of grape pomace extracts in association with 
verapamil, study was carried out in three steps.  
1/ « Grape pomace extract + verapamil » model development 
The first step consisted of the development of “grape pomace extract + verapamil” 
model using extract GRE1 (EA70) seed pomace extract. Three experimental groups were 
established and experiment lasted during three weeks: 
- Group SHR control (3 SHR treated with 3% EtOH), 
- Group SHR verapamil control (3 SHR treated with verapamil at 40 
mg/kg/day),  
- Group verapamil + extract GRE1 (EA70) seed pomace extract (3 SHR treated 
with 21 mg/kg/day of extract + 40mg/kg/day of verapamil). 
Hydro-alcoholic 70% extract of GRE1 seed grape pomace was chosen because of its 
highest ability to regulate blood pressure evidenced in the 1
st
 study. Following the treatment, 
a gradual decrease of blood pressure was observed and the minimum SBP was reached after 3 
weeks compared to SHR control and WKY group (Figure 42 and Table 47). The association 
of GRE1 (EA70) seed pomace extract + verapamil showed its efficacy to lower blood 
pressure, thus, the model is validated. 
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Figure 42: Effect of GRE1 (EA70) seed pomace extract and ALI (EA70) skin 
pomace extract (21 mg/kg/day) in association with verapamil (40 mg/kg/day) on blood 
pressure in SHR rats. 
The shades area correspond to maximum deviation between maximum and minimum 
values of SHR (blue) and WKY (grey) individual SBP measurements along the experiment.  
 
2/ Comparison of grape pomace extracts efficiency in association with verapamil. 
Following the “grape pomace extract + verapamil” model validation, the other grape 
pomace extracts in association with verapamil were also tested. Rats were randomly assigned 
to different experimental group organized as follows and blood pressure was recorded all 
along the three weeks experiment:  
- Control group (3 WKY rats) 
- SHR control group (3 SHR treated with 3% EtOH) 
- SHR verapamil control group (3 SHR treated with verapamil at 40 mg/kg/day) 
- 6 groups of 3 SHR rats treated with hydro-alcoholic 70% grape pomace 
extracts dissolved in 3% EtOH (21 mg/kg/day) associated with verapamil (40 
mg/kg/day): 
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*SHR1+V: GRE1 (EA70) seed pomace extract + verapamil  
*SHR2+V: SYR1 (EA70) seed pomace extract + verapamil 
*SHR3+V: SYR2 (EA70) skin pomace extract + verapamil 
*SHR4+V: CAR (EA70) seed pomace extract + verapamil 
*SHR5+V: MOU (EA70) skin pomace extract + verapamil 
*SHR6+V: ALI (EA70) skin pomace extract + verapamil 
Results are presented in Table 47 and evidenced an anti-hypertensive effect of ALI 
(EA70) skin extract without any effect from the other extracts. According to this comparative 
study, ALI (EA70) skin pomace extract, which already showed its anti-hypertensive ability in 
the 1
st
 screening study, was chosen to confirm the preliminary results obtained with GRE1 
(EA70) seed extracts (Table 47). 
Table 47: The impact over time of “grape pomace extracts + verapamil” on mean 
systolic blood pressure 
Groups 6 days 13 days 20-23 days 
WKY 
108,5 ± 1,2 108, 5 ± 1,2 108,5 ± 1,2 
(102-121) (102-121) (102-121) 
SHR 
200,3 ± 1,8 200,3 ± 1,8 200,3 ± 1,8 
(190-214) (190-214) (190-214) 
SHR+ V
a
 
198,0 ± 1,5 198,0 ± 1,5 198,0 ± 1,5 
(195-202) (195-202) (195-202) 
SHR1+V
a
 
193,1 ± 3,2 161,4 ± 10,5 146,3 ± 5,9 
(183, 189, 197) (144, 157, 183) (138, 143, 158) 
SHR2+V
a
 
191,7 ± 3,7 192,5 ± 0,8 
 (188, 195) (192, 193) 
 
SHR3+V
a
 
188,7 ± 2,7 192 ± 1 ,0 
 (186, 191) (191, 193) 
 
SHR4+V
a
 
187,2 ± 5,8 189,5 ± 5,5 
 (181, 193) (184, 195) 
 
SHR5+V
a
 
186,3 ± 0,0 185,3 ± 5,7 
 (186,2, 186,4 (183, 194) 
 
SHR6+V
a
 
168,8 ± 10,6 173,0 ± 24,7 171,8 ± 18,8 
(144,182 124,191, 
206, 167, 173) 
(148, 197) (153, 190) 
SHR6
a
 
200,9 ± 2,8 
  (195-204) 
  a
V, Verapamil; SHR1 + V to SHR6 + V, experimental group fed with GRE1 (EA70) seed pomace 
extract, SYR1 (EA70) seed pomace extract, SYR2 (EA70) skin pomace extract, CAR (EA70) seed pomace 
extract, MOU (EA70) skin pomace extract, ALI (EA70) skin pomace extract in association with verapamil 
respectively; SHR6, experimental group fed with ALI (EA70) skin. Number in parentheses indicated individual 
SBP values measured during the “grape pomace extract + verapamil” model validation (in green), during the 
comparative study (in red) and during the result confirmation (in blue). Number in parentheses without any 
colour corresponded to the minimum and maximum SBP values along the experiment. 
 
 
202 
 
3/ Results confirmation 
The extract ALI (EA70) was chosen to confirm results obtained with GRE1 (EA70) 
seed pomace extracts. The number of SHR rats fed with ALI (EA70) skin pomace extract (21 
mg/kg) in association with verapamil (40 mg/kg) was increased to seven rats. The results 
obtained showed a gradual decrease of blood pressure after 3 weeks of treatment (Table 47 
and Figure 42). It should to be noted that, as in human species (Hanes et al. 1996), individual 
responses of SHR rats is variable from one animal to another with the existence of highly 
receptive and non-receptive rats. In this experiment, one of the SHR rats had normal blood 
pressure which is exceptional for the SHR rat model. The experiment confirmed the 
efficiency of ALI (EA70) skin pomace extract to lower blood pressure in agreement with the 
first screening experiment in which ALI (EA70) skin pomace extract was administrated alone 
(Figure 7). Thus, GRE1 (EA70) seed and ALI (EA70) skin grape pomace extracts in 
association with verapamil proved to be efficient in lowering blood pressure.  
II.4. Supplementary experiments of grape pomace extracts 
associated with verapamil 
II.4.1. Verapamil co-ingested with SYR1 seed (EAQ), SYR1 skin (EAQ), ALI skin 
(EAQ) and GRE2 skin (EA70) screening 
As previously demonstrated, certain grape pomace extracts in association with 
verapamil have an ability to lower blood pressure. Supplemental extracts associated with 
verapamil were then tested for their anti-hypertensive ability. In the first experiment, 18 male 
nine week-old spontaneously hypertensive rats (SHR) and 6 male normotensive control 
Wistar-Kyoto (WKY) rats were used. This experiment was held over 9 weeks including 7 
weeks of treatment with a gradual increase of verapamil dose from 10 mg/kg/day to 40 
mg/kg/day and 2 week treatment with grape pomace extracts in association with verapamil. 
Rats were randomly assigned to different experimental group organized as follows:  
- Control group (6 WKY rats) 
- SHR control group (3 SHR treated with 3% EtOH) 
-SHR verapamil control group (3 SHR treated with verapamil at 40mg/kg/day) 
- 4 groups of 3 SHR rats treated with aqueous and hydro-alcoholic 70% grape 
pomace extracts (21 mg/kg/day) dissolved in 3% EtOH in association with 
verapamil (40 mg/kg/day): 
*SHR1+V: SYR1 (EAQ) seed pomace extract + verapamil 
*SHR2+V: SYR1 (EAQ) skin pomace extract + verapamil 
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*SHR3+V: ALI (EAQ) skin pomace extract + verapamil 
*SHR4+V: GRE2 (EA70) skin pomace extract + verapamil 
 
WKY blood pressure remained stable between 100 and 110 mm Hg. No significant 
differences were founded between SHR control group and SHR administrated with verapamil 
even with a dose of 40 mg/kg. Administration of a gradual dose of verapamil from 10 
mg/kg/day to 40 mg/kg/day during 7 weeks led to SHR resistance and SBP was stabilized 
around 170 mm Hg (Figure 43).  
 
After seven weeks of administration of verapamil, different grape pomace extracts 
associated to verapamil were administrated to SHRs. After 8 days of administration, lower 
SBP was observed (Figure 44). The percentage of SBP variation after 8 days of grape pomace 
associated with verapamil treatment reached and varied from 4% in SHRs fed with ALI 
(EAQ) skin grape pomace extract to 14% in SHRs fed with SYR1 (EAQ) seed grape pomace 
extract (Figure 45). However, only SYR1 (EAQ) seed grape pomace extract showed a 
significant anti-hypertensive effect (Figures 44 and 45).   
Figure 43: Mean systolic blood pressure evolution in SHR and WKY and effect 
of verapamil. Results correspond to the mean of triplicate measurements ± standard deviation. 
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Figure 44: Mean systolic blood pressure (mm Hg) measured 2 days before and 8 
days after grape pomace ex tract associated with verapamil administration.* Paired 
Student’s t-test, (p = 0.06). 
Figure 45: Mean systolic blood pressure variation (%) after 8 days of grape 
pomace extract associated with verapamil administration. * Significant decrease compared to 
blood pressure measurement before grape pomace extract treatment (p < 0.05).  
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This experiment again indicated that verapamil was not effective in treating high 
blood pressure in SHR rats. Among the extract tests, only SYR1 (EAQ) seed pomace extract 
was shown to have an anti-hypertensive capacity. In addition, previous screening study has 
demonstrated by a rebound effect that SYR1 (EA70) seed pomace extract administrated alone 
also exerted an anti-hypertensive effect.  
II.4.2. Verapamil co-ingested with CAR seed (EAQ), GRE2 skin (EAQ), SYR2 skin 
(EAQ) and SYR1 skin (EA70) screening 
For this complementary experiment, 18 male twenty-three week-old SHR and six 
male WKY rats were used to determine the in vivo effect of additional grape pomace extracts 
and their potential effect on hypertension. This experiment was held over 6 weeks including 
15 days without treatment, 13 days of treatment with verapamil only, 7 days of grape pomace 
extracts in association with verapamil treatment followed again by 4 days of treatment with 
verapamil only. Rats were randomly assigned to different experimental group organized as 
follows:  
- Control group (6 WKY rats) 
- SHR control group (3 SHR treated with 3% EtOH) 
- SHR verapamil control group (3 SHR treated with verapamil at 40 
mg/kg/day) 
- 4 groups of 3 SHR rats treated with aqueous and hydro-alcoholic 70% grape 
pomace extracts (21 mg/kg/day) dissolved in 3% EtOH in association with 
verapamil (40 mg/kg/day): 
*SHR1+V: CAR (EAQ) seed pomace extract + verapamil 
*SHR2+V: GRE2 (EAQ) skin pomace extract + verapamil 
*SHR3+V: SYR2 (EAQ) skin pomace extract + verapamil 
*SHR4+V: SYR1 (EA70) skin pomace extract + verapamil 
 
SBP of normotensive WKY rats fluctuated between 125 and 140 mm Hg all along the 
experiment. During the first 15 days in which any rats received any treatments, SHR rats SBP 
was around 200 mm Hg. At day 15, verapamil at 40 g/kg/day was administrated to SHR 
(SHR1+V-SHR4+V) rats and SHR verapamil control. A rapid and significant decrease of 
SBP down to 175 mm Hg was observed after 3 days. However, this fall was transient as 
blood pressure increased and reached a similar SBP to that of Sthe HR control (Figure 46).  
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Figure 46: Mean systolic blood pressure (mmHg) evolution in SHR and WKY 
and effect of verapamil. The arrow indicated the beginning of verapamil treatment. Results correspond to 
the mean of triplicate measurements ± standard deviation. * Significant decrease compared to the SHR control 
group (p < 0.05). 
 
The administration of different grape pomace extracts began once the SBP of SHR 
rats which were treated with verapamil reached the same values as those in SHR control (i.e. 
200 mm Hg). Figure 47 showed the mean SBP at day 28 (the first day of treatment with grape 
pomace extracts) and at day 35 (7 days after). A decrease of SBP on the borderline of 
statistical significance was observed in SHR rats fed with SYR2 (EAQ) skin pomace extract 
associated with verapamil with a p = 0.056 (difference between SBP measured at day 28 and 
35 using Paired Student’s t-test). Expressing results as percentage of SBP variation, the mean 
variation (%) for SYR2 (EAQ) skin pomace extract associated with verapamil was 
significantly different from 0 indicating a significant decrease of SBP (p < 0.05) (Figure 48). 
However, SYR1 (EA70) skin pomace extract induced a significant elevation of SBP once 
associated with verapamil (Figures 47 and 48).   
207 
 
Figure 47: Mean systolic blood pressure before (day 28) and after (day 35) grape 
pomace extracts associated with verapamil treatment. Results correspond to the mean of 
triplicate measurements ± standard deviation. * p < 0.05. 
Figure 48: Variation of mean systolic blood pressure (%) between day 35 and 
day 28 of grape of grape pomace extracts associated with verapamil. * Significant decrease or 
increase of blood pressure after 7 days of administration (p < 0.05). 
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After being treated for 7 days with grape pomace extract in association with 
verapamil, at day 35, SHR1+V to SHR4+V did not receive any grape pomace extract but 
were still administrated with verapamil at 40 mg/kg/day. SBP was measured four days later. 
In the SHR1+V, SHR2+V and SHR4+V group, SBP did not vary and remained stable at 
around 200 mm Hg. Nevertheless, in SHR3+V group which was observed previously as 
having anti-hypertensive ability when SYR2 (EAQ) skin pomace extract was associated with 
verapamil (SBP = 178 ± 5 mm Hg at day 35), SBP increased significantly after the treatment 
with grape pomace extract was interrupted (SBP = 202 ± 11 mm Hg at day 39) (Figure 49).  
 
Figure 49: Mean systolic blood pressure at day 39, after grape pomace extracts 
administration interruption. * Significant increase of blood pressure between day 35 and day 39 (p < 
0.05). 
 
This experiment confirmed the resistance of SHR rat to verapamil treatment. 
However, once verapamil was associated with SYR2 (EAQ) skin pomace extract, an anti-
hypertensive effect was apparent. This observation was confirmed by an increase of blood 
pressure after the interruption of SYR2 (EAQ) skin grape pomace extract while SHR rats 
were still under verapamil treatment. Nevertheless, SYR1 (EA70) skin pomace extract 
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induced an elevation of SBP. These results demonstrated the possibility using grape pomace 
polyphenols to modulate drug activity on blood pressure.  
II.5. Conclusions 
The experiments demonstrated that some grape pomace extracts administrated alone 
or in association with verapamil possessed an anti-hypertensive potential. This ability was 
evidenced with GRE1 (EA70) seed pomace extract, SYR1 (EA70) seed pomace extract, ALI 
(EA70) skin pomace extract administrated alone; and with GRE1 (EA70) seed pomace 
extract, SYR1 (EAQ) seed pomace extract, ALI (EA70) skin pomace extract and SYR2 
(EAQ) skin pomace extract administrated in association with verapamil. In the last in vivo 
experiment, SYR1 (EA70) skin pomace extract with verapamil showed to exert an adverse 
effect by elevating SBP. Table 48 summarized the anti-hypertensive efficiency of different 
tested grape pomace extracts. 
Table 48: Anti-hypertensive efficiency of different grape pomace extracts 
Grape pomace extracts 
tested 
Treatment 
time 
Effect on 
hypertension 
Efficiency 
GRE1 seed (EA70) 3 weeks + Indirect effect, rebound effect, + 19% 
SYR1 seed (EA70) 3 weeks + Indirect effect, rebound effect, +24 % 
SYR 2 skin (EA70) 3 weeks ~ - 
CAR seed (EA70) 3 weeks ~ - 
MOU skin (EA70) 3 weeks ~ - 
ALI skin (EA70) 3 weeks + Indirect effect, rebound effect, +16 % 
    
GRE1 seed (EA70) + verapamil 3 weeks + Direct effect, -26 % 
SYR1 seed (EA70) +verapamil 3 weeks ~ - 
SYR 2 skin (EA70) + verapamil 3 weeks ~ - 
CAR seed (EA70) + verapamil 3 weeks ~ - 
MOU skin (EA70) +verapamil 3 weeks ~ - 
ALI skin (EA70) + verapamil 3 weeks + Direct effect, -13 % 
    
SYR1 seed (EAQ) + verapamil 2 weeks + Direct effect, -14 % 
SYR1 skin (EAQ) + verapamil 2 weeks ~ - 
ALI skin (EAQ) + verapamil 2 weeks ~ - 
GRE2 Skin (EA70) + verapamil 2 weeks ~ - 
    
CAR seed (EAQ) + verapamil 1 week ~ - 
GRE2 skin (EAQ) + verapamil 1 week ~ - 
SYR2 skin (EAQ) + verapamil 1 week + Direct effect, -11 % 
SYR1 skin (EA70) + verapamil 1 week − Direct effect, +15 % 
Grape pomace extracts were administrated at a dose of of 21 mg/kg/day which in terms of phenolic 
compounds is equivalent to a 70 kg human consuming of ~0.5 L of red wine and verapamil at a dose of 40 
mg/kg/day. +, positive effect on hypertension regulation; − negative effect on hypertension regulation; ~ no 
effect. Extract efficiency fed to SHR rats was illustrated by the percentage of variation (%) of blood pressure 
before and after the ingestion. 
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Grape pomace extracts ingested without verapamil were shown to exert anti-
hypertensive effects indirectly, by increasing blood pressure after a rebound effect. An 
increase of +19 %, +24 % and +16 % were observed, respectively, for GRE1 seed (EA70), 
SYR1 seed (EA70) and ALI skin (EA70) after three weeks of treatment. Grape pomace 
extracts co-ingested with verapamil, lowering blood pressure by -26 % with GRE1 seed 
(EA70) + verapamil and -13% using ALI skin (EA70) + verapamil after 3 weeks of treatment 
and by -14 % after 2 weeks of treatment. Moreover, experiments showed that one week of 
treatment was sufficient to induce anti-hypertensive effect in rats fed with SYR2 skin (EAQ) 
+ verapamil in which an 11 % reduction in blood pressure while a pro-hypertensive effect 
was observed in rats fed with SYR1 skin (EA70) + verapamil (+ 15 %). 
According to the extract used, it is actually possible to modulate anti-hypertensive 
drug effects. The composition of the grape pomace extracts used in this study might have a 
crucial role and should be taken into account. Both EAQ and EA70 proved to be effective 
even though the overall grape pomace characterisation study showed that EA70 extracts were 
richer in (poly)phenolic compounds than EAQ. 
Among seed extracts, CAR seed pomace extract in both EAQ and EA70 contained 
higher amounts of (poly)phenols compare to GRE1 seed pomace extract, but did not exert 
any anti-hypertensive effects whereas GRE1 seed pomace extract did. Seed extracts exerting 
anti-hypertensive effects (i.e. GRE1 [EA70] seed pomace extract, SYR1 [EA70] seed pomace 
extract and SYR1 [EAQ] seed pomace extract) contained the highest amount of total 
procyanidins ranging from 56 to 157 mg/g of DW, especially in the Syrah varieties where 
137 and 157 mg/g of DW of total procyanidins was found in EAQ and EA70, respectively. In 
addition, these extracts also contained high amount of gallo- and gallate derivatives and were 
highly galloylated compared to CAR seed EAQ and EA70 extracts. In addition, grape 
pomace characterisation also showed seed from Syrah contained the highest amount of 
monomer and dimer flavan-3-ols in both types of extracts. In fact, Syrah was the only variety 
which exhibited anti-hypertensive in both EAQ and EA70 extracts. In term of anthocyanins, 
the highest concentration was found in CAR seed extracts. Actually, GRE1 and SYR1 
possessed only 5 mg/g DW and 10.3 mg/g DW in EA70 compared to 25.4 mg/g DW in CAR 
(EA70). Evaluation of antioxidant activity indicated the highest radical scavenging activity of 
SYR1 in both types of extracts. In vivo anti-hypertensive ability of GRE1 (EA70) seed 
pomace extract, SYR1 (EA70) seed pomace extract and SYR1 (EAQ) seed pomace extract is 
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most likely conferred by the large amount of flavan-3-ols and procyanidins rather than 
anthocyanins. 
Among the nine skin extracts tested, only two exhibited anti-hypertensive effect, the 
ALI (EA70) skin pomace extract and SYR2 (EAQ) skin pomace extract. In pomace 
characterisation analysis, ALI skin in both EAQ and EA70 was shown to be one of the 
extracts which contains high phenolic compounds and high antioxidant capacity. Even if ALI 
(EA70) has higher amounts of flavan-3-ol monomers and dimers but only 28 mg/g DW of 
total procyanidins was found compared to its EAQ extract which has 59 mg/g DW but did not 
show any ability to lower SBP. The extract anti-hypertensive effect is more likely linked to 
its anthocyanins content. Actually, ALI (EA70) skin contained up to 19.5 mg/g DW, 1.2 
mg/g and 7.2 mg/g DW of anthocyanins total glucosides, acetylated and coumaroylated 
anthocyanins, respectively. According to these observations, it is not surprising that ALI 
(EA70) skin was not classified as the most antioxidant by every test. However, the high 
content of (poly)phenol in an extract did not always lead to an in vivo effect. Paradoxically, 
SYR2 (EAQ) skin pomace extract which contained the lowest levels of phenolics for every 
analysis combined, was able to lower SBP once associated with verapamil while other skin 
pomace extracts, much richer in (poly)phenolic compounds, did not showed any anti-
hypertensive effects and could also increase SBP (i.e. SYR1 (EA70) skin pomace extract). 
Unlike seed extracts, anti-hypertensive ability of skin extracts is more difficult to predict. 
Other compounds in these skin extracts such as polysaccharides or fibers might prevent the 
anti-hypertensive effect by affecting (poly)phenol absorption. 
It is well established that the renin–angiotensin system (RAS) has a central role in the 
regulation of blood pressure and angiotensin-converting enzyme 2 (ACE2), is involved in the 
regulation of the RAS (Crackower et al. 2002). Compared to normotensive rats, SHR 
presented an abnormal development on the intra renal RAS (Obata et al. 2000; Tikellis et al. 
2006). Studies have shown that the expression and ACE2 activities are significantly increased 
in the SHR kidney at birth. With the onset of hypertension, the tubular expression of ACE2 
falls in SHR compared to WKY and remains reduced in the adult SHR kidney (Tikellis et al. 
2006). As previously explain in the “chapter 4-I. State of knowledge: SHR rats”, a deficient 
in ACE2 induces an increase of Ang II which reduces the production of NO and lead to 
vasoconstriction phenomenon and vascular dysfunction. Oxidative stress contributes to 
vascular dysfunction and it is actually caused, on the one hand, by an excess of superoxide 
anion (•O2
–
) production by NADH/NADPH oxidase (Grunfeld et al. 1995; Zalba et al. 2000) 
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and on the other hand, by a low activity of eNOS which catalyses the production of nitric 
oxide (Palmer et al. 1987). Actually, •O2
–
 and NO are known to rapidly react to form the 
stable peroxynitrite anion (ONOO-), a powerful oxidant, which will prevent the 
vasodilatating action of NO (Beckman et al. 1990; Pacher et al. 2007; Vera et al. 2007). 
As oxidative stress is involved in the pathogenesis of hypertension, scientists have 
focused their interest on anti-hypertensive effects of (poly)phenolic compounds which have 
been confirmed in several studies (Galisteo et al. 2004; Sarr et al. 2006; Perez-Vizcaino et al. 
2009) and might be linked to the capacity of (poly)phenols to regulate the eNOS and NADPH 
oxidase activity. A study by Al Awwadi et al.(2004) showed that a red wine (poly)phenolic 
extract was able to prevent cardiac hypertrophy and inhibit production of reactive oxygen 
species in the insulin resistant fructose-fed rat. More precisely, another paper from the same 
group (Al-Awwadi et al. 2005), showed that anthocyanins and catechin oligomers prevented 
hypertension, cardiac hypertrophy and production, whereas procyanidins had only minor 
effects on hypertension. This result illustrated that antioxidant activity is not the only mode of 
action of (poly)phenolic compounds. These observations are in accordance with our results, 
in which highest amounts of monomer and dimer flavan-3-ols were found in seed extracts 
exerting anti-hypertensive effects. 
Grape pomace extracts on their own might be used alone but their impact may be 
enhanced by co-ingestion with verapamil. It is now widely recognized that P-gp influences 
drug transport across various biological membranes. P-gp transporter is occurs prominently in 
the luminal surface of enterocytes, biliary canicule surfaces of hepatocytes, apical surface of 
proximal tubular cells of kidney, endothelial cells of blood brain barrier, etc. and 
consequently can affect absorption, distribution, metabolism and excretion of xenobiotics. In 
fact, more than fifty percent of existing anti-cancer drugs undergo P-gp-mediated efflux. 
Consequently, there is an increasing trend to optimize pharmacokinetics, enhance antitumour 
activity and reduce systemic toxicity of existing anti-cancer drugs by inhibiting P-gp 
mediated transport. Although a wide variety of P-gp inhibitors have been discovered, 
flavonoids form the third generation of non-pharmaceutical category of P-gp inhibitors 
(Bansal et al. 2009). The effects produced by some of these components are found to be 
comparable to those of well-known P-gp inhibitors verapamil and cyclosporine. 
As verapamil is the reference compound of P-gp inhibitors and multi-drug resistance 
(MDR) reversal agents, several researchers have demonstrated that (poly)phenols presented 
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inhibitor properties on P-gp transport affecting the bioavailability and uptake of certain drugs 
(Jodoin et al. 2002; Kitagawa 2006; Eichhorn et al. 2012). The association of grape pomace 
extracts rich in (poly)phenols and verapamil might have beneficial effect on blood pressure 
regulation by modifying the absorption of (poly)phenols and/or verapamil. 
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III. Absorption, metabolism and excretion of 
grape pomace extracts: metabolite analysis 
Based on previous results, two of the extracts exerting anti-hypertensive effects, the 
GRE1 (EA70) seed pomace extract and ALI (EA70) skin pomace extract, and one which 
didn’t showed any anti-hypertensive potential, the MOU (EA70) skin pomace extract, were 
chosen for bioavailability studies. Feeding protocol was detailed in the chapter II: materials 
and methods. Briefly, male nine week-old SHR rats were used for this experiment and were 
randomly assigned to different experimental group organized as follows: 
- SHR control group (6 SHR treated with 3% EtOH)  
- SHR verapamil control group (6 SHR treated with verapamil at 40 mg/kg)  
- 3 groups of 6 SHR rats treated with EA70 grape pomace extracts at 21 
mg/kg: 
*E1: GRE1 (EA70) seed pomace extract  
*E5: MOU (EA70) skin pomace extract 
*E6: ALI (EA70) skin pomace extract 
- 3 groups of 6 SHR rats treated with EA70 grape pomace extracts in 
association with verapamil: 
*VE1: GRE1 (EA70) seed pomace extract + verapamil  
*VE5: MOU (EA70) skin pomace extract + verapamil  
*VE6: ALI (EA70) skin pomace extract + verapamil  
 
The experiment procedure and different collection is summarized in Figure 50: 
 
Figure 50: Experimental protocol and different collection periods 
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Urines and faeces were collected at 0-8 h and 8-24 h at day 1 and day 7 after grape 
pomace extracts ingestion. Tissues (i.e. heart, liver and kidneys) and plasma were collected 4 
h after of gavage at day 7. Grape pomace extracts analysis (chapter III) allowed the 
evaluation of polyphenols ingested by SHR rats in µmol. A total of 5.20 µmol, 2.4 µmol and 
4.1 µmol of polyphenols were ingested by SHR rats fed with GRE1 (EA70) seed pomace 
extract (E1/VE1), MOU (EA70) skin pomace extract (E5/VE5) and ALI (EA70) skin pomace 
extract (E6/VE6), respectively (Table 49).  
Table 49: Amounts of polyphenols in µmol ingested by SHR rats fed with GRE1 
(EA70) seed pomace extract (E1/VE1), MOU (EA70) skin pomace extract (E5/VE5), 
ALI (EA70) skin pomace extract (E6/VE6). Data are expressed as nmol ± standard deviation. 
Ingested amount (nmol) 
 
E1/VE1 
 
E5/VE5 
 
E6/VE6 
 
Mean SD 
 
Mean SD 
 
Mean SD 
Anthocyanins 
        
Delphinidin-3-O-glucoside 12.7 0.1 
 
141.5 2.9 
 
75.5 2.3 
Cyanidin-3-O-glucoside 6.4 0.1 
 
32.2 0.7 
 
17.8 0.5 
Petunidin-3-O-glucoside 21.9 0.2 
 
197.2 4.1 
 
114.2 3.5 
Peonidin-3-O-glucoside 38.3 0.4 
 
120.5 2.5 
 
380.6 11.5 
Malvidin-3-O-glucoside 151.5 1.5 
 
597.8 12.3 
 
751.1 22.8 
Malvidin-3-O-glucoside-acetaldehyde (vitisin B) 0.5 0.0 
 
2.2 0.0 
 
1.8 0.1 
Delphinidin-3-O-(6′′-O-acetyl) glucoside 0.0 0.0 
 
2.5 0.1 
 
3.2 0.1 
Dimer malvidin-catechin 1.5 0.0 
 
3.3 0.1 
 
2.3 0.1 
Malvidin-3-O-glucoside-pyruvate (vitisin A) 6.7 0.1 
 
16.0 0.3 
 
11.7 0.4 
Dimer malvidin-catechin 0.0 0.0 
 
2.6 0.1 
 
5.5 0.2 
Dimer malvidin-catechin 3.8 0.0 
 
2.7 0.1 
 
9.5 0.3 
Peonidin-3-O-(6′′-O-acetyl) glucoside 4.6 0.0 
 
10.4 0.2 
 
33.8 1.0 
Malvidin-3-O-(6′′-O-acetyl) glucoside 3.3 0.0 
 
20.4 0.4 
 
38.0 1.2 
Delphinidin-3-O-(6′′-O-coumaroyl) glucoside 2.5 0.0 
 
13.6 0.3 
 
14.6 0.4 
Malvidin-3-O-(6′′-O-caffeoyl) glucoside 3.9 0.0 
 
13.5 0.3 
 
12.7 0.4 
Cyanidin-3-O-(6′′-O-coumaroyl) glucoside 4.3 0.0 
 
24.5 0.5 
 
8.0 0.2 
Petunidin-3-O-(6′′-O-coumaroyl) glucoside 3.7 0.0 
 
28.9 0.6 
 
28.9 0.9 
Malvidin-3-O-(6′′-O-coumaroyl) glucoside 39.8 0.4 
 
141.8 2.9 
 
323.7 9.8 
Total anthocyanin glucosides 230.9 2.4 
 
1089.2 22.4 
 
1339.2 40.6 
Total anthocyanins acetylated 7.9 0.1 
 
33.3 0.7 
 
75.0 2.3 
Total anthocyanins coumaroylated 50.2 0.5 
 
208.9 4.3 
 
375.3 11.4 
Total anthocyanins 305.3 3.1 
 
1371.7 28.2 
 
1833.0 55.6 
Procyanidins 
        
Monomers 3553.6 36.2 
 
365.0 7.5 
 
1448.6 43.9 
(Epi)catechin-O-gallate 72.1 0.7 
 
1.5 0.0 
 
33.2 1.0 
Dimers 581.7 5.9 
 
91.6 1.9 
 
258.0 7.8 
Dimers gallate 14.3 0.1 
 
6.5 0.1 
 
19.8 0.6 
Trimers 151.9 1.5 
 
75.3 1.5 
 
172.7 5.2 
(Epi)gallocatechin trimers 22.6 0.2 
 
2.3 0.0 
 
3.1 0.1 
Trimers gallate 9.3 0.1 
 
1.6 0.0 
 
10.2 0.3 
Tetramers 54.2 0.6 
 
27.5 0.6 
 
56.3 1.7 
(Epi)gallocatechin tetramers 26.3 0.3 
 
8.0 0.2 
 
18.9 0.6 
Tetramers gallate 0.0 0.0 
 
0.0 0.0 
 
1.3 0.0 
Pentamers 28.5 0.3 
 
16.3 0.3 
 
28.0 0.8 
(Epi)gallocatechin pentamers 7.0 0.1 
 
3.5 0.1 
 
3.7 0.1 
Hexamers 16.8 0.2 
 
7.6 0.2 
 
13.1 0.4 
Heptamers 8.0 0.1 
 
4.1 0.1 
 
4.6 0.1 
Octamers 3.8 0.0 
 
1.9 0.0 
 
2.4 0.1 
nonamers 1.6 0.0 
 
0.7 0.0 
 
1.0 0.0 
Decamers 1.0 0.0 
 
0.3 0.0 
 
0.4 0.0 
Total procyanidins 4552.8 46.4 
 
613.7 12.6 
 
2075.3 62.9 
Quercetin-3-O-glucuronide 62.6 0.6 
 
102.1 2.1 
 
49.7 1.5 
Resveratrol 23.7 0.2 
 
18.9 0.4 
 
25.8 0.8 
Quercetin 244.7 2.5 
 
251.0 5.2 
 
111.1 3.4 
Total 5189.1 52.9 
 
2357.3 48.5 
 
4094.8 124.1 
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III.1. HPLC-ESI-MSn analysis of urines, tissues, plasma and faeces 
In this study, reversed-phase HPLC with multistage mass detection (i.e. MS
n
) without 
any pre-treatment of samples with enzymatic preparations was used to identified and 
quantified metabolites in body fluid, tissues and faeces. The use of glucuronidase/sulfatase 
preparations for urine/plasma analysis converts metabolites to the native aglycones and 
provides indirect information together with varying and unmeasured error factors. In the first 
instance, urine was screened for metabolites using full-scan MS. Metabolites which were 
present in higher concentrations in most of the samples were then selected for quantification. 
The same procedure was used for tissues and plasma. Concerning faeces, only compounds 
found in grape pomace extracts were targeted, especially procyanidins and flavan-3-ol dimers 
and monomers. 
III.1.1 HPLC-ESI-MSn analysis of SHR rat urines  
III.1.1.a. Identification of phenolic compounds in SHR rat urines 
SHR rat urines were firstly screened for anthocyanins and flavan-3-ol procyanidin 
metabolites. Because of generally low levels in urine, anthocyanin metabolites were 
undetectable. Purification and concentration steps were undertaken but the levels detected in 
SHR rat urine were still very low. Previous studies have shown that unlike other flavonoids 
that are absorbed and excreted, anthocyanins do not appear to undergo extensive metabolism 
to glucuronide and sulfate derivatives. Typical recoveries in human urine are < 0.1% of 
intake (Crozier et al. 2009). These low recoveries could be a consequence of anthocyanins 
undergoing structural rearrangements in response to pH. The red flavilium cation 
predominates at pH 1-3, but as the pH increases to 4 and above, the colorless carbinol 
pseudobase becomes the major component along with smaller amounts of a colorless 
chalcone pseudobase and a blue quinoidal base (Clifford 2000). Such changes are likely to 
occur in vivo as anthocyanins pass from low pH in the stomach to the more-basic conditions 
of the small intestine. As a consequence, the study focused on procyanidins and flavan-3-ol 
oligomers and monomers.  
SHR rat urine from different experimental groups and different time points (i.e. 0-8 h 
and 8-24 h) were screened for procyanidin and flavan-3-ol metabolites using HPLC with the 
MS scanning from m/z 100 to 700 in negative ionization mode. Identification of HPLC peaks 
was based on data dependent MS
2 
and on previous studies (Touri o et al. 2009; Urpi-Sarda et 
al. 2009a; van der Hooft et al. 2012). For this experiment, urine was defrosted, centrifuged at 
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16,100 × g for 10 min at 4 °C prior to the analysis. Separation was performed on a 250 × 4.6 
mm i.d. 5 µm Luna phenyl-hexyl 100Å column (Phenomenex, Macclesfield, U.K.) using a 
gradient over 120 min of 5-35% methanol in 0.1% aqueous formic acid. Identification results 
are presented in Table 50. 
Table 50: Identification of metabolites after ingestion of grape pomace extracts 
by SHR rats: HPLC retention times and MS fragmentation patterns 
Peak 
Rt 
(min) 
Metabolites identified 
[M-
H]
-
 
(m/z)
a
 
MS
2
 
fragment 
(m/z)
b
 
 Flavan-3-ol conjugates 
  
M1 18.0 (Epi)catechin-O-glucuronide 1 465 289 
M2 24.7 (Epi)catechin-O-glucuronide 2 465 289 
M3 33.2 (Epi)catechin-O-glucuronide 3 465 289 
M4 48.0 O-Methyl-(epi)catechin-O-glucuronide 1 479 303 
M5 57.1 O-Methyl-(epi)catechin-O-glucuronide 2 479 303 
M6 80.6 O-Methyl-(epi)catechin-O-sulfate 383 303 
M7 95.7 (Epi)catechin-O-sulfate 1 369 289 
M8 97.8 (Epi)catechin-O-sulfate 2 369 289 
 Hydroxyphenylvalerolactone conjugates 
  
M9 9.8 5-(O-Methyl-phenyl)-γ-valerolactone-O-glucuronide 381 205 
M10 11.2 5-(3′,4′-Dihydroxyphenyl)-γ-valerolactone 223 179 
M11 15.9 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 1 383 207, 163 
M12 27.0 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 2 383 207, 163 
M13 46.1 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 3 383 207, 163 
M14 76.8 5-(Hydroxyphenyl)-γ-valerolactone-O-sulfate 1 287 207 
M15 78.0 5-(Hydroxyphenyl)-γ-valerolactone-O-sulfate 2 287 207 
M16 78.8 5-(3′,4′-Dihydroxyphenyl)-γ-valerolactone-O-glucuronide 399 223 
M17 89.6 5-(Phenyl)-γ-valerolactone-O-sulfate  271 191 
M18 113.3 5-(3′-Methoxy-4′-phenyl)-γ-valerolactone-O-sulfate 301 221 
 Hydroxyphenylvaleric acid conjugates 
  
M19 13.7 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-glucuronide 401 225 
M20 46.1 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 305 225, 207 
M21 50.2 5-(Phenyl)-4-hydroxyvaleric acid-O-glucuronide 385 209 
M22 57.5 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 1 289 209 
M23 84.5 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 2 289 209 
 Hydroxyphenylacetic acid conjugates 
  
M24 13.0 Hydroxy-methoxyphenylacetic acid-O-glucuronide / 3-(3′,4′-
dihydroxyphenyl)propionic acid-O-glucuronide* 
357 181 
M25 16.9 Hydroxy-methoxyphenylacetic acid-O-glucuronide / 3-(3′,4′-
dihydroxyphenyl)propionic acid-O-glucuronide* 
357 181 
M26 21.0 Dihydroxyphenylacetic acid-O-glucuronide / O-methyl-dihydroxybenzoic acid-
O-glucuronide* 
343 167 
M27 25.0 Hydroxyphenyl-acetic acid-O-sulfate / O-methyl-hydroxybenzoic acid-O-sulfate* 231 151 
M28 27.6 Dihydroxyphenylacetic acid-O-sulfate / O-methyl-dihydroxybenzoic acid-O-
sulfate* 
247 167 
218 
 
M29 28.7 Hydroxy-O-methylphenylacetic acid-O-sulfate / dihydroxyphenylpropionic acid-
O-sulfate* 
261 181 
M30 30.2 Hydroxyphenylacetic acid-O-sulfate / O-methyl-hydroxybenzoic acid-O-sulfate* 231 151 
M31 33.6 Hydroxyphenylacetic acid-O-glucuronide 327 151 
M32 36.0 Hydroxyphenylacetic acid-O-sulfate / O-methyl-hydroxybenzoic acid-O-sulfate* 231 151 
M33 46.3 Dihydroxyphenylacetic acid-O-sulfate / O-methyl-dihydroxybenzoic acid-O-
sulfate* 
247 167 
 Hydroxybenzoic acid conjugates 
  
M34 15.0 Hydroxybenzoic acid-O-glucuronide 313 137 
M35 15.5 Dihydroxybenzoic acid-O-sulfate 233 153 
M36 21.0 O-Methyl-dihydroxybenzoic acid-O-glucuronide / dihydroxyphenylacetic acid-O-
glucuronide* 
343 167 
M37 25.0 Hydroxyphenylacetic acid-O-sulfate / O-methyl-hydroxybenzoic acid-O-sulfate* 231 151 
M38 27.6 O-Methyl-dihydroxybenzoic acid-O-sulfate / dihydroxyphenylacetic acid-O-
sulfate* 
247 167 
M39 30.2 O-Methyl-hydroxybenzoic acid-O-sulfate / hydroxyphenylacetic acid-O-sulfate* 231 151 
M40 22.2 Hydroxybenzoic acid-O-sulfate 217 137 
M41 27.8 Dihydroxybenzoic acid-O-sulfate 233 153 
M42 27.3 Hydroxybenzoic acid glucuronide-O-sulfate 393 217, 137 
M43 33.2 Hydroxybenzoic acid-O-sulfate 217 137 
M44 36.0 O-Methyl-hydroxybenzoic acid-O-sulfate / Hydroxyphenylacetic acid-O-sulfate* 231 151 
M45 46.3 O-Methyl-dihydroxybenzoic acid-O-sulfate / Dihydroxyphenylacetic acid-O-
sulfate* 
247 167 
 Hydroxyphenylpropionic acid conjugates 
  
M46 13.0 3-(Dihydroxyphenyl)propionic acid-O-glucuronide / O-methyl-
hydroxyphenylacetic acid-O-glucuronide* 
357 181 
M47 16.9 3-(Dihydroxyphenyl)propionic acid-O-glucuronide / O-methyl-
hydroxyphenylacetic acid-O-glucuronide* 
357 181 
M48 28.7 3-(Dihydroxyphenyl)propionic acid-O-sulfate /Hydroxy-methoxy-phenylacetic 
acid-O-sulfate* 
261 181 
M49 37.7 3-(O-Methyl-hydroxyphenyl)propionic acid-O-sulfate/ caffeic acid-O-sulfate* 259 179 
M50 44.5 3-(O-Methyl-dihydroxypheny)propionic acid-O-sulfate 275 195 
M51 53.6 3-(-O-Methyl-hydroxyphenyl)propionic acid-O-sulfate/ caffeic acid-O-sulfate* 259 179 
M52 56.1 3-(Hydroxyphenyl)propionic acid-O-sulfate 245 165 
M53 60.7 3-(O-Methyl-dihydroxyphenyl)propionic acid-O-sulfate 275 195 
M54 67.8 3-(Hydroxyphenyl)propionic acid-O-sulfate 245 165 
 Hydroxycinnamic acid conjugates 
  
M55 37.7 Caffeic acid-O-sulfate / 3-(O-methyl-3′-hydroxyphenyl)propionic acid-O-sulfate* 259 179 
M56 33.7 Ferulic acid-O-glucuronide* 369 193 
M57 53.6 Caffeic acid-O-sulfate / 3-(O-methyl-3′-hydroxyphenyl)propionic acid-O-sulfate* 259 179 
M58 60.0 Isoferulic acid-O-sulfate 1 273 193 
M59 62.2 Isoferulic acid-O-sulfate 2 273 193 
M60 70.4 Coumaric acid 163 119 
 Hydroxyhippuric acid conjugates 
  
M61 17.3 3′-Hydroxyhippuric acid 194 150 
a
 Tentative identification based on mass spectra, 
b
molecular ion (m/z) identification in negative 
ionization mode. * MS
3
 required for identification; Rt, retention time; [M-H]
-
, negatively charged molecular ion.  
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Following ingestion of 21 mg/kg of grape pomace extracts, a total of 61 metabolites 
and polyphenolic derivatives were identified or tentatively identified in urine samples 
collected from SHR rats. Some of them need to be subjected to MS
3
 analysis in order to be 
further fragment and provide information necessary to distinguish between different 
compounds with the same parent ion mass. 
Metabolites were classified into different groups of compounds, namely flavan-3-ol 
conjugates, 5-(hydroxyphenyl)--valerolactone conjugates, 5-(hydroxyphenyl)valeric acid 
conjugates, hydroxyphenylacetic acid conjugates, hydroxybenzoic acid conjugates, 3-
(hydroxyphenyl)propionic acid conjugates, hydroxycinnamic acid conjugates and a 
hydroxyhippuric acid.  
Eight flavan-3-ol metabolites were detected in urine. Peak M1-M8 were identified as 
a complex array of glucuronide, sulfate, and methyl metabolites of (epi)catechin which have 
been detected in previous studies following the ingestion of grape seed extracts (Tsang et al. 
2005a; Serra et al. 2009). Epicatechin and catechin metabolites are referred as (epi)catechin 
as without reference compounds which can be separated by reversed phase HPLC, mass 
spectrometry is unable to distinguish between epicatechin and catechin metabolites. 
Peak M9-M18 were identified as 5-(phenyl)--valerolactone derivatives and were 
presented as substituted phenyl structures in the form of glucuronide and sulfate conjugates, 
or as a combination of methoxy-sulfate derivatives. These compounds could undergo in-
source fragmentation resulting in signals corresponding to the loss of the glucuronide (176 
amu) or sulfate (80 amu) moieties. The MS/MS spectra of 5-(phenyl)--valerolactone 
conjugates were characterized by a product ion at m/z 163 resulting from the decarboxylation 
(44 amu) of the the γ-valerolactone ring, as previously described (Urpi-Sarda et al. 2009a; 
Sang et al. 2008). The m/z 207 and m/z 221 fragments correspond to the loss of different 
conjugate groups from hydroxy- and methoxy-phenylvalerolactones. These 5-(phenyl)--
valerolactone conjugates are derived the interaction of valerolactones, produced from the 
ring-fission of (epi)catechin/procyanidins by the colonic microbiota (Gonthier et al. 2003; 
Appeldoorn et al. 2009; Déprez et al. 2009), with UDP-glucuronosyl-transferases, 
sulfotransferases and catechol-O-methyltransferases. 
Peak M19-M61 corresponded to five metabolites of 5-(hydroxyphenyl)valeric acid 
(peak M19-M23), ten metabolites of hydroxyphenylacetic acid (peak M24-M33), twelve 
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metabolites of hydroxybenzoic acid (peak M34-M45), nine metabolites of 3-
(hydroxyphenyl)propionic acid (peak 46-54), six metabolites of hydroxycinnamic acids (peak 
M55-M60) and one hydroxyhippuric acid (peak M61) were identified in urine. They were 
presented as non- and mono-, and di-substituted phenyl structures in the form of glucuronide 
and sulfate conjugates, or as a combination of methyl-glucuronide, methyl-sulfated and 
methyl-sulfate derivatives. Their identification was obtained by comparing metabolite 
fragmentation patterns to those found in previous studies (Touri o et al. 2009; Urpi-Sarda et 
al. 2009a; van der Hooft et al. 2012). The aglycones of these metabolites and 5-
(hydroxyphenyl)propionic acid conjugates (sulfates) were found by Touriño et al. 2009 in rat 
urine after ingestion grape dietary fiber containing a large proportion of polyphenolic 
compounds, mainly oligomeric and polymeric procyanidins, and by Gonthier et al. (2003) 
who fed wine powder to rats.  
Phenylvalerolactones are derived from microbial degradation of monomeric flavan-3-
ols and procyanidins (Gonthier et al. 2003; Sang et al. 2008; Appeldoorn et al. 2009a). 
Mediated by the action of UDP-glucuronosyl-transferases, sulfotransferases and catechol-O-
methyltransferases on the aglycones, glucuronidated, sulfated, and methylated metabolites are 
formed in the liver and kidney before being excreted in the urine. Microbial degradation 
involves firstly a reductive cleavage of the ()-epicatechin heterocyclic C-ring resulting in the 
formation of diphenylpropan-2-ols followed by a lactonization of diphenylpropan-2-ols into 
hydroxyphenylvalerolactones. Fission of the valerolactone ring leads to 
hydroxyphenylvaleric acids (Meselhy et al. 1997; Gonthier et al. 2003). Oxidation of 
hydroxyphenylvaleric acid side chains results in the formation of hydroxyphenylpropionic 
and hydroxybenzoic acids (Meselhy et al. 1997). Hydroxyphenylpropionic acids can undergo 
α- and β-oxidation and form phenylacetic acids which can be subjected to 3- and 4-
dehydroxylation reactions (Gonthier et al. 2003). This colonic catabolism pathway of flavan-
3-ol monomer is outlined in Figure 51. 
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Figure 51: Proposed pathways involved in the colonic catabolism and urinary 
excretion of green tea flavan-3-ols.  
Following consumption of green tea more than 50% of the ingested (–)-epicatechin, (–)-epigallocatechin and (–)-
epigallocatechin-3-O-gallate (blue structures) pass into the large intestine. When incubated with faecal slurries these 
compounds are catabolised by the colonic microflora probably via the pathways illustrated with red structures. Analysis of 
urine after green tea consumption indicates that some of the colonic catabolites enter the circulation and undergo further 
metabolism before being excreted in urine. Boxed black structures indicate catabolites detected in urine but not produced by 
faecal fermentation of (–)-epicatechin, (–)-epigallocatechin or (–)-epigallocatechin-3-O-gallate. The dotted arrow between 
pyrogallol and pyrocatechol indicate this is a minor conversion. Double arrows indicate conversions where the 
intermediate(s) did not accumulate and are unknown. Compounds detected in ileal fluid after green tea consumption (IF); 
catabolites detected in fecal slurries (F) and in urine (U); potential intermediates that did not accumulate in detectable 
quantities in fecal slurries (*). After Roowi et al. (2010).  
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III.1.1.b. Quantification of polyphenolic compounds in SHR rat urines 
After the initial qualitative analysis, a targeted analysis of urine samples was carried 
out by HPLC with MS in the SRM (selected reaction monitoring) mode. As described 
previously, a considerable number of metabolites were found in urine but only metabolites 
presented in high amounts and in all urine samples screened were chosen for quantification.  
In addition, because of the lack of glucuronidated or sulfated reference compounds, 
some of the metabolites were not quantified. Indeed, the quantification based on a calibration 
curve made of aglycone reference compounds for the quantification of glucuronidated and 
sulfated metabolites might introduce a potential source of error in the quantitative estimates 
caused by different slopes of the glucoside and glucuronide SRM dose-response curves. In 
fact, different aglycones of phenolic acids were tested in order to determine their ionization 
characteristics and their limit of detection. The 3-hydroxybenzoic acid (m/z 137), 4-
hydroxybenzoic acid (m/z 137), 3′-hydroxyphenylacetic acid (m/z 151), 4′-
hydroxyphenylacetic acid (m/z 151), 3-(3′-hydroxyphenyl)propionic acid (m/z 165) and 4′-
hydroxyhippuric acid (m/z 194) were identified and quantified using SRM mode. Results 
revealed a limit of detection of 150 ng for the 3-hydroxybenzoic acid, 67 ng for the 4-
hydroxybenzoic acid, 170 ng for the 3-(3′-hydroxyphenyl)propionic acid and 16 ng for 4′-
hydroxyhippuric acid. 3′-Hydroxyphenylacetic acid, 4′-hydroxyphenylacetic acid underwent 
limited fragmentation and as a consequence the limit of detection was 2 µg. Therefore, 3-
(hydroxyphenyl)propionic acid, hydroxyphenylacetic acid, hydroxybenzoic acid and 
hydroxycinnamic derivatives were identified but not quantified by HPLC-ESI-MS
n
. Phenolic 
acid excretion derived from colonic microbiota in urine were analysed by GC-MS as will be 
outlined later. 
Compounds chosen were listed by elution order in Table 51 and their chromatograms 
are illustrated in Figure 52. 
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Table 51: Identification of urinary metabolites selected for quantification: HPLC 
retention times and MS fragmentation patterns obtained by SRM 
Peak 
Rt 
(min) 
Compounds 
 
[M-H]
-
 
(m/z)
a 
MS
2
 fragment 
(m/z)
b 
1 6.13 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 383 207, 163 
2 7.28 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-glucuronide 401 225, 113 
3 7.76 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 383 207, 163 
4 9.39 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 383 207, 163 
5 9.48 (Epi)catechin-O-glucuronide 465 289, 245 
6 10.05 (Epi)catechin-O-glucuronide 465 289, 245 
7 11.31 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 305 225, 207 
8 13.14 (Epi)catechin-O-glucuronide 465 289, 245 
9 13.83 O-Methyl-(epi)catechin-O-glucuronide 479 303, 223 
10 14.23 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 305 225, 207 
11 15.22 O-Methyl-(epi)catechin-O-glucuronide 479 303, 223 
12 17.03 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 289 209 
13 17.08 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 305 225, 207 
14 18.63 Isoferulic acid-4-O-sulfate 273 193 
15 19.33 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 289 209 
16 20.11 5-(Hydroxyphenyl)-γ-valerolactone sulfate 287 207, 163 
17 22.55 5-(Hydroxyphenyl)-γ-valerolactone sulfate 287 207, 163 
18 24.45 Isoferulic acid-4-O-sulfate 
 
273 193 
a
Tentative identification based on mass spectra, 
b
molecular ion (m/z) identification in negative 
ionization mode. Rt, retention time; [M-H]
-
, negatively charged molecular ion.  
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Figure 52: HPLC-SRM quantification of flavan-3-ol and procyanidin metabolites 
in SHR rat urines collected after ingestion of 21 mg/kg/day 
Chromatograms represent gradient RP-HPLC analysis with detection of flavan-3-ol and procyanidin 
metabolites by using SRM at m/z 401, m/z 383, m/z 465, m/z 305, m/z 479, m/z 289, m/z 287 and m/z 273. Peak 
number in chromatograms corresponded to compounds having the same peak number provided in Table 51. 
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Urine samples were collected at 0-8 h and 8-24 h on day 1 and day 7 after the 
ingestion of different grape pomace extracts. The urine did not contain any of the original 
grape pomace extract flavan-3-ols and procyanidins but glucuronides and methyl-
glucuronides of (epi)catechin, as well as valerolactone and valeric acid phase II glucuronide 
and sulfate metabolites were detected. Compared to other studies in which rats were fed 
grape derived products (Tsang et al. 2005a; Touri o et al. 2009; Serra et al. 2011), sulfate 
derivatives were found as one of the main metabolites, whereas in this work, sulfates were 
present in a very low amounts. The reason for these varying metabolite profiles, especially 
the dominance of glucuronides in some studies and sulfates in order could be due to losses of 
(epi)catechin-O-sulfates during sample processing before analysis (Day et al. 2003). The 
difference in the metabolic profile of (epi)catechins may also be attributed to the different 
flavan-3-ols composition of the matrix (e.g.,. grape seed/skin extracts, tea, cocoa). 
Without reference compounds which can be separated by reversed phase HPLC, mass 
spectrometry is unable to distinguish between epicatechin and catechin metabolites. 
Therefore, epicatechin and catechin metabolites are referred as (epi)catechin. Moreover, it 
was not possible to determine the position on the flavan-3-ol skeleton of the methyl and 
glucuronic acid substituents. In this study, three (epi)catechin-O-glucuronides (m/z 465) and 
two O-methyl-(epi)catechin-O-glucuronides (m/z 479/303, 223) were detected. According to 
Baba et al. (2000), who studied the bioavailability of ()-epicatechin, the authors suggested 
that ()-epicatechin bioavailability was higher than that of (+)-catechin in rats and that 
chemical features such as solubility and lipophilicity of each substances might be involve in 
these differences. Other investigations also found that ()-epicatechin was highly 
bioavailable (Manach et al. 2005; Auger et al. 2008). Considering these observations, at least 
two of the metabolites found could be partially identified as ()-epicatechin-O-glucuronide 
and O-methyl-()-epicatechin-O-glucuronide. They could be ()-epicatechin-7-O-
glucuronide and O-methyl-()-epicatechin-7-O-glucuronide as demonstrated by Natsume et 
al. (2003) who identified these metabolites in rat urine after ()-epicatechin ingestion. Unlike 
human subjects, which produce 4′-O- and 3′-O-methylated derivatives (Ottaviani et al. 
2012b), rats accumulated predominantly 3′-O-methylated metabolites of flavan-3-ols 
(Nakamura et al. 2003; Natsume et al. 2003). Therefore, it is probable that one of the 
metabolites found was the 3′-O-methyl-()-epicatechin-7-O-glucuronide. However, these are 
tentative identifications and require further investigation.  
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Detection of valerolactone and valeric acid conjugates in this study is in agreement 
with previous reports. Their presence in urine as aglycones has been established in human 
and rats feeding studies with flavan-3-ol- and procyanidin-rich products (i.e. grape derived 
products, cocoa, green tea) (Gonthier et al. 2003; Serra et al. 2009; Urpi-Sarda et al. 2009a; 
Del Rio et al. 2010). 5-(Hydroxyphenyl)--valerolactones are considered to be the main 
metabolites deriving from the first stages of the colonic microbial metabolism of flavan-3-ols, 
after the opening of the C-ring to form hydroxyphenylpropan-2-ols (Meselhy et al. 1997) (see 
Figure 51). The presence of methylated, glucuronide and sulfate metabolites results from the 
action of UDP-glucuronosyl-transferases, sulfotransferases and catechol-O-
methyltransferases in the liver and kidneys and arguably the wall of the colon. Several studies 
have detected the presence of glucuronide and sulfate metabolites of 5-(3′,4′,5′-
trihydroxyphenyl)-γ-valerolactone, 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone and 5-(3′,5′-
dihydroxyphenyl)-γ-valerolactone after green tea consumption and procyanidin-rich products 
such as almond skins (Lee et al. 1995; Meng et al. 2002; Sang et al. 2008; Urpi-Sarda et al. 
2009a; Del Rio et al. 2010). Subsequent fission of the valerolactone ring leads to the 
formation of 5-(hydroxyphenyl)valeric acids which were also detected and quantified in this 
study. 
Quantification of 5-(hydroxyphenyl)-4-hydroxyvaleric acid-O-glucuronide (m/z, 
401/225) and 5-(hydroxyphenyl)-γ-valerolactone-O-sulfate (m/z, 287/207) was by reference 
to the aglycone 5-(3,4-dihydroxyphenyl)-γ-valerolactone while 5-(hydroxyphenyl)-4-
hydroxyvaleric acid-O-sulfate (m/z, 305/225) levels were measured using a calibration curve 
obtained with 5-(3,4-dihydroxyphenyl)-4-hydroxyvaleric acid. Data are expressed as nmol ± 
SE (n=3). Details are provided in chapter II: material and methods. The other metabolites 
were quantified as ()-epicatechin equivalents and expressed as nmol ± SE (n=3). 
Quantification of metabolites in urine collected of 0-8 h and 8-24 h after pomace 
extract ingestion at day 1 and day 7 are presented in Tables 52 to55. Compounds present in 
significantly higher amounts in urine from SHRs fed with grape pomace extracts than the 
control urine are mark by an asterisk (*). A paired student’s t-test was performed at a 
threshold of p < 0.05. 
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Table 52: Urinary excretion at day 1, 0-8 h after ingestion of grape pomace extracts. Data are expressed as nmol ± SE (n=3). 
  
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Peak Metabolites Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
1 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 1.0* 0.1 
 
1.3* 0.2 
 
1.2 0.4 
 
0.7 0.1 
 
1.1* 0.2 
 
0.8 0.2 
2 5-Hydroxyphenyl-4-hydroxyvaleric acid-O-glucuronide 0.8* 0.1 
 
0.8 0.2 
 
0.9 0.3 
 
0.6 0.1 
 
0.6 0.1 
 
0.8 0.1 
3 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
4 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
0.0 Nd 
5 (Epi)catechin-O-glucuronide 0.1 0.1 
 
Nd Nd 
 
1.3* 0.0 
 
Nd Nd 
 
1.3* 0.1 
 
0.2 Nd 
6 (Epi)catechin-O-glucuronide 1.0* 0.3 
 
0.5 0.2 
 
0.7* 0.2 
 
0.2* 0.1 
 
0.7* 0.2 
 
0.3 0.2 
7 5-Hydroxyphenyl-4-hydroxyvaleric acid-O-sulfate 0.6* 0.2 
 
0.5* 0.2 
 
0.7* 0.3 
 
0.3 0.0 
 
0.3 0.1 
 
0.5* 0.1 
8 (Epi)catechin-O-glucuronide 0.3 0.0 
 
0.5* 0.0 
 
0.6* 0.0 
 
0.5 Nd 
 
0.5 Nd 
 
Nd Nd 
9 O-Methyl-(epi)catechin-O-glucuronide 6.7* 1.2 
 
10.5* 3.5 
 
3.2 0.4 
 
3.4 0.8 
 
8.7* 2.1 
 
6.8 1.6 
10 5-Hydroxyphenyl-4-hydroxyvaleric acid-O-sulfate 1.4* 0.3 
 
1.0* 0.2 
 
1.3* 0.3 
 
1.1 0.1 
 
1.3* 0.3 
 
2.8* 0.9 
11 O-Methyl-(epi)catechin-O-glucuronide 1.8* 0.5 
 
3.0* 1.3 
 
0.5 0.2 
 
0.6* 0.2 
 
1.8* 0.6 
 
2.2* 0.7 
12 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 6.9 1.3 
 
9.4* 0.6 
 
7.6 1.6 
 
4.1 1.1 
 
6.1* 3.7 
 
9.0 3.4 
13 5-Hydroxyphenyl-4-hydroxyvaleric acid-O-sulfate 0.5* 0.1 
 
0.6* 0.2 
 
1.7 1.2 
 
0.5* 0.1 
 
0.3 0.1 
 
1.1* 0.4 
14 Isoferulic acid-4-O-sulphate 98.3 22.2 
 
88.5* 6.0 
 
75.0* 15.6 
 
69.1 8.3 
 
47.1 12.4 
 
85.7 10.6 
15 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
16 5-(Hydroxyphenyl)-γ-valerolactone sulfate 1.4 0.4 
 
1.6* 0.5 
 
4.2 2.9 
 
1.6* 0.4 
 
0.8 0.1 
 
3.2* 1.2 
17 5-(Hydroxyphenyl)-γ-valerolactone sulfate 0.3 0.2 
 
0.7 0.4 
 
0.7 0.0 
 
0.4 0.2 
 
0.7 0.4 
 
1.1 0.9 
18 Isoferulic acid-4-O-sulphate 58.7* 13.2 
 
39.0 5.2 
 
Nd Nd 
 
22.9 4.7 
 
35.8 7.5 
 
30.6 6.5 
*Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; VE1, Grenache (GRE1) EA70 seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) EA70 skin 
pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. Nd, not determined; SE, 
standard error. 
2
2
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Table 53: Urinary excretion at day 1, 8-24 h after ingestion of grape pomace extracts. Data are expressed as nmol ± SE (n=3). 
  
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Peak Metabolites  Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
1 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 0.2 0.0 
 
0.3 0.0 
 
0.6 0.1 
 
0.2 0.1 
 
0.4* 0.1 
 
0.4* 0.0 
2 5-Hydroxyphenyl-4-hydroxyvaleric acid-O-glucuronide 0.1 0.0 
 
0.2* 0.1 
 
0.3 0.1 
 
0.2 0.1 
 
0.2 0.1 
 
0.2* 0.0 
3 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd 
  
Nd Nd 
 
Nd 
 
4 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd 
  
Nd Nd 
 
0.0 
 
5 (Epi)catechin-O-glucuronide 0.2 0.1 
 
0.3 Nd 
 
0.2 Nd 
 
Nd 
  
Nd Nd 
 
0.5 0.0 
6 (Epi)catechin-O-glucuronide 1.0 0.2 
 
1.1 0.3 
 
1.7 0.6 
 
0.8 0.1 
 
1.4 0.3 
 
1.6* 0.2 
7 5-Hydroxyphenyl-4-hydroxyvaleric acid-O-sulfate 0.1 0.0 
 
0.2 0.0 
 
0.2 0.0 
 
0.2 0.0 
 
0.3 0.1 
 
0.2* 0.0 
8 (Epi)catechin-O-glucuronide Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd 
  
Nd Nd 
 
Nd 
 
9 O-Methyl-(epi)catechin-O-glucuronide 3.8 0.7 
 
4.0 0.7 
 
7.6 1.5 
 
3.4 0.7 
 
7.1* 1.3 
 
5.5 0.9 
10 5-Hydroxyphenyl-4-hydroxyvaleric acid-O-sulfate 0.6 0.1 
 
1.5 0.6 
 
2.0 0.8 
 
1.4* 0.4 
 
1.4* 0.4 
 
2.1* 0.6 
11 O-Methyl-(epi)catechin-O-glucuronide Nd Nd 
 
Nd Nd 
 
1.7* 0.0 
 
Nd 
  
Nd Nd 
 
0.0 
 
12 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 11.7 0.8 
 
12.8 2.5 
 
13.2 3.6 
 
13.4 4.0 
 
13.9* 0.8 
 
12.1* 1.4 
13 5-Hydroxyphenyl-4-hydroxyvaleric acid-O-sulfate 0.3 0.0 
 
0.4 0.1 
 
0.5 0.2 
 
0.7* 0.2 
 
0.6* 0.1 
 
0.8* 0.3 
14 Isoferulic acid-4-O-sulphate 39.2* 4.3 
 
56.4* 7.0 
 
45.0* 0.0 
 
31.2 8.1 
 
55.2 14.1 
 
83.0 7.6 
15 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 8.9 0.8 
 
10.9 2.2 
 
16.8 3.2 
 
14.6 1.7 
 
17.6 1.2 
 
16.2 4.4 
16 5-(Hydroxyphenyl)-γ-valerolactone sulfate 0.9 0.1 
 
1.3* 0.3 
 
1.3 0.4 
 
1.7 0.6 
 
1.1 0.2 
 
1.8 0.5 
17 5-(Hydroxyphenyl)-γ-valerolactone sulfate 0.4 0.1 
 
0.6* 0.2 
 
0.6 0.2 
 
0.7* 0.2 
 
0.5 0.1 
 
0.8* 0.2 
18 Isoferulic acid-4-O-sulphate 41.2 9.3 
 
43.6 11.0 
 
54.7 16.1 
 
57.1 8.9 
 
56.4* 11.5 
 
69.4* 5.4 
*Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; VE1, Grenache (GRE1) EA70 seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) EA70 skin 
pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. Nd, not determined; SE, 
standard error. 
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Table 54: Urinary excretion at day 7, 0-8 h after ingestion of grape pomace extracts. Data are expressed as nmol ± SE (n=3). 
  
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Peak Metabolites Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
1 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 0.2* 0.0 
 
0.2* 0.0 
 
0.1 0.0 
 
0.1 0.0 
 
0.1 0.0 
 
0.2 0.0 
2 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-glucuronide 0.1 0.0 
 
0.2* 0.1 
 
0.3* 0.1 
 
0.1 0.0 
 
0.2 0.1 
 
0.1 0.0 
3 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 0.3 0.2 
 
0.3* 0.0 
 
0.3 0.1 
 
0.5* 0.0 
 
0.3 0.1 
 
0.1 0.0 
4 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide Nd Nd 
 
Nd Nd 
 
0.1 Nd 
 
Nd Nd 
 
Nd Nd 
 
0.1* 0.0* 
5 (Epi)catechin-O-glucuronide 0.0 0.0 
 
0.3 Nd 
 
Nd Nd 
 
0.2* 0.0 
 
0.1* 0.0 
 
0.0 0.0 
6 (Epi)catechin-O-glucuronide 1.0 0.5 
 
0.7 0.3 
 
1.6 0.9 
 
0.6 0.2 
 
2.1* 0.9 
 
1.7 1.0 
7 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 0.2* 0.1 
 
0.1 0.0 
 
0.2 0.1 
 
0.2 0.1 
 
0.3* 0.1 
 
0.3 0.1 
8 (Epi)catechin-O-glucuronide 1.1 1.0 
 
0.3 0.0 
 
3.1 1.7 
 
Nd Nd 
 
0.9* 0.3 
 
1.5* 0.6* 
9 O-Methyl-(epi)catechin-O-glucuronide 4.6* 1.7 
 
2.1* 0.4 
 
4.2 1.5 
 
4.3* 1.3 
 
5.9* 2.3 
 
5.2 2.0 
10 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 0.2 0.0 
 
0.5 0.2 
 
0.4 0.1 
 
0.6* 0.1 
 
0.3 0.2 
 
0.6* 0.0* 
11 O-Methyl-(epi)catechin-O-glucuronide 1.2 0.6 
 
1.8* 0.5 
 
3.0 0.9 
 
0.8 0.3 
 
1.9 0.1 
 
1.8 0.8 
12 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 5.9 1.2 
 
2.9 0.6 
 
7.6 2.3 
 
7.4 2.2 
 
7.2 0.6 
 
2.6 0.0 
13 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 0.1 0.1 
 
0.2* 0.1 
 
0.1* 0.0 
 
0.2 0.1 
 
0.7 0.6 
 
0.2 0.1 
14 Isoferulic acid-4-O-sulphate 73.0* 11.3 
 
65.3* 11.8 
 
76.8* 14.8 
 
73.4* 14.0 
 
62.5* 16.8 
 
38.3 9.5 
15 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 4.4 0.8 
 
7.8* 2.9 
 
6.3 1.9 
 
6.6 1.5 
 
5.3 1.9 
 
6.4 1.4 
16 5-(Hydroxyphenyl)-γ-valerolactone sulfate 0.2 0.0 
 
0.5* 0.2 
 
0.4* 0.2 
 
0.6* 0.2 
 
0.6* 0.3 
 
0.5* 0.1* 
17 5-(Hydroxyphenyl)-γ-valerolactone sulfate 0.1 Nd 
 
0.1 0.0 
 
0.0 0.0 
 
0.4 0.2 
 
0.0 0.0 
 
0.2 0.0 
18 Isoferulic acid-4-O-sulphate 58.3 14.6 
 
94.3 23.1 
 
72.4 19.1 
 
60.9 23.7 
 
74.9 29.1 
 
94.8* 8.6* 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; VE1, Grenache (GRE1) EA70 seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) EA70 skin 
pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. Nd, not determined; SE, 
standard error. 
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Table 55: Urinary excretion at day 7, 8-24 h after ingestion of grape pomace extracts. Data are expressed as nmol ± SE (n=3). 
  
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Peak Metabolites Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
 
Mean SE 
1 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 0.4 0.1 
 
0.3 0.0 
 
0.5 0.1 
 
0.2 0.1 
 
0.5* 0.0 
 
0.2 0.1 
2 5-Hydroxyphenyl-4-hydroxyvaleric acid-O-glucuronide 0.7 0.3 
 
0.2 0.0 
 
0.3 0.1 
 
0.1 0.0 
 
0.2 0.0 
 
0.2 0.0 
3 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 0.5* 0.0 
 
0.2 0.0 
 
0.8 0.2 
 
0.5 0.1 
 
0.7* 0.2 
 
0.4 0.1 
4 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 0.1 0.0 
 
Nd Nd 
 
0.0 Nd 
 
0.1* 0.0 
 
Nd 
  
0.1 0.1 
5 (Epi)catechin-O-glucuronide 0.7 0.5 
 
1.1 0.0 
 
1.1 0.4 
 
0.9 0.0 
 
1.3 
  
1.6 Nd 
6 (Epi)catechin-O-glucuronide 1.1 0.1 
 
0.9* 0.1 
 
1.1 0.2 
 
0.7 0.1 
 
2.0 0.5 
 
1.1 0.5 
7 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 0.6 0.4 
 
0.3 0.1 
 
0.4 0.1 
 
0.5 0.3 
 
0.4 0.1 
 
1.0 0.5 
8 (Epi)catechin-O-glucuronide Nd Nd 
 
0.8 Nd 
 
0.7 Nd 
 
Nd Nd 
 
0.3 
  
0.5 Nd 
9 O-Methyl-(epi)catechin-O-glucuronide 8.1 1.8 
 
3.2* 0.6 
 
5.7 1.4 
 
2.5 0.5 
 
5.2 0.8 
 
3.6* 0.8 
10 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 0.7 0.2 
 
0.8 0.3 
 
1.5 0.7 
 
0.5 0.2 
 
0.9 0.3 
 
0.7 0.2 
11 O-Methyl-(epi)catechin-O-glucuronide Nd Nd 
 
Nd Nd 
 
1.3 0.9 
 
Nd Nd 
 
0.0 0.0 
 
0.5 0.3 
12 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 14.2 2.6 
 
11.2 3.5 
 
16.0 2.7 
 
8.9 1.6 
 
16.0 3.7 
 
8.0 1.8 
13 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 0.2 0.0 
 
0.2 0.1 
 
0.2 0.1 
 
0.2 0.1 
 
0.3 0.1 
 
0.3 0.1 
14 Isoferulic acid-4-O-sulphate 152.2 26.0 
 
87.2 20.2 
 
152.8 41.0 
 
61.8 17.1 
 
129.8 30.5 
 
85.1 20.3 
15 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 11.2 1.2 
 
10.8* 2.8 
 
6.2 0.0 
 
1.2 0.6 
 
3.4 0.0 
 
12.4 2.7 
16 5-(Hydroxyphenyl)-γ-valerolactone sulfate 0.6 0.1 
 
0.7 0.1 
 
1.0 0.3 
 
0.6 0.2 
 
0.7 0.1 
 
1.0 0.2 
17 5-(Hydroxyphenyl)-γ-valerolactone sulfate 0.3 0.1 
 
0.6 0.2 
 
0.9* 0.2 
 
0.2 0.1 
 
1.2* 0.1 
 
0.5 0.2 
18 Isoferulic acid-4-O-sulphate 57.3* 12.6 
 
36.2* 4.9 
 
65.4* 19.6 
 
27.8 7.6 
 
41.7* 12.5 
 
31.4* 9.9 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; VE1, Grenache (GRE1) EA70 seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) EA70 skin 
pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. Nd, not determined; SE, 
standard error.  
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In order to have an overall picture of metabolite excretion, the sum of urinary 
(epi)catechin-O-glucuronide, O-methyl-(epi)catechin-O-glucuronide, 5-(hydroxyphenyl)-
γ-valerolactone-O-glucuronide, 5-(hydroxyphenyl)-γ-valerolactone-O-sulfate, 5-
hydroxyphenyl-4-hydroxyvaleric acid-O-sulfate, 5-(phenyl)-4-hydroxyvaleric acid-O-
sulfate, isoferulic acid-4-O-sulphate was calculated. The results are presented in Tables 56 
and 57. 
At day 1 of gavage, SHR urines from the experimental group E1 exhibited 
significantly higher excretion of metabolites than other SHR group at the 0-8 h collection 
period whereas rats from the E6 and VE6 groups (i.e. fed with GRE1 [EA70] seed pomace 
extract and ALI [EA70] skin pomace extract + verapamil, respectively), excreted high 
amounts at over the later 8-24 h period. Urinary excretion of VE5 group rats (i.e. fed with 
MOU [EA70] skin pomace extract + verapamil) was not different from that detected in 
verapamil control group urine. At day 7, urinary excretion from VE1 group (i.e. fed with 
GRE1 [EA70] seed pomace extract + verapamil) at 0-8 h contained substantial amounts of 
metabolites. In contrast to day 1, VE5 rat urine at day 7, in the 0-8 h sample, showed 
sizable metabolite excretion. Overall, higher amounts of metabolites were observed in 
SHR urine of rats fed grape pomace extracts alone or in association with verapamil, 
especially for (epi)catechin-O-glucuronide, O-methyl-(epi)catechin-O-glucuronide and 
isoferulic acid-4-O-sulfate at day 1 and day 7. 
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Table 56: Sum of structurally related urinary metabolites at day 1, 0-8 h and 8-24 h after ingestion of grape pomace extracts. 
Data are expressed as nmol ± SE. 
 Σ of structurally related metabolites 
(Day 1, 0-8 h) 
E1 VE1 E5 VE5 E6 VE6 Control Verapamil control 
Peak Mean SD Mean SD Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE 
1 (Epi)catechin-O-glucuronide 1.0* 0.3 0.6* 0.3 2.0* 0.2 0.2 0.1 1.2* 0.5 0.3 0.1 0.1 0.0 0.1 0.0 
2 O-Methyl-(epi)catechin-O-glucuronide 8.5* 1.5 10.8 4.3 3.5 0.4 3.9 0.9 6.1 2.7 9.0 2.2 3.5 1.0 4.2 1.6 
3 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 1.0* 0.1 0.8 0.3 1.2 0.4 0.7 0.1 0.5 0.3 0.8 0.2 0.4 0.2 0.5 0.2 
4 5-(Hydroxyphenyl)-γ-valerolactone-O-sulfate 1.5 0.3 1.6 0.5 4.4 2.9 1.9 0.3 1.2 0.4 3.7* 1.1 1.1 0.3 1.0 0.2 
5 5-(Hydroxyphenyl-)4-hydroxyvaleric acid-O-sulfate 2.5* 0.6 1.8 0.4 3.5 1.3 2.0 0.2 2.0* 0.5 4.3* 1.3 0.9 0.3 1.2 0.3 
6 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 6.9* 1.3 6.3 2.0 7.6 1.6 4.1 1.1 6.1 3.7 9.0* 3.4 3.1 0.7 4.8 0.8 
7 Isoferulic acid-4-O-sulfate 157.0* 35.5 127.5* 11.2 75.0* 15.6 92.0 13.1 82.8 19.9 116.3 17.1 82.2 19.9 75.6 18.4 
                  
                  
 
Σ of structurally related metabolites 
(Day 1, 8-24 h) 
E1 VE1 E5 VE5 E6 VE6 Control Verapamil control 
Peak Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE 
1 (Epi)catechin-O-glucuronide 1.1 0.2 1.1 0.2 1.8 0.6 0.8 0.1 1.4 0.3 1.8* 0.2 1.0 0.3 0.6 0.2 
2 O-Methyl-(epi)catechin-O-glucuronide 3.8 0.7 4.0 0.7 6.9* 2.1 3.4 0.7 7.1* 1.3 5.5 0.9 2.7 1.0 3.3 1.2 
3 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 0.2 0.0 0.3 0.0 0.4 0.1 0.2 0.1 0.4* 0.1 0.4* 0.0 0.2 0.0 0.2 0.0 
4 5-(Hydroxyphenyl)-γ-valerolactone-O-sulfate 1.3 0.2 1.9* 0.5 1.8 0.6 2.4* 0.8 1.6 0.2 2.7* 0.7 1.3 0.3 0.8 0.2 
5 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 1.0 0.1 2.0 0.7 2.6* 0.9 2.3* 0.4 2.2* 0.4 3.1* 0.9 0.7 0.1 0.7 0.1 
6 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 12.7 1.8 12.2 1.7 14.4 2.5 13.8 2.6 15.8* 1.1 13.5* 1.7 8.7 0.9 9.9 2.4 
7 Isoferulic acid-4-O-sulfate 80.4 13.6 100.0 18.0 99.7 16.1 88.2 17.0 111.5* 25.7 152.4* 13.0 74.2 4.3 83.6 12.6 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; VE1, Grenache (GRE1) EA70 seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) EA70 skin 
pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. SE, standard error. 
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Table 57: Sum of structurally related urinary metabolites at day 7, 0-8 h and 8-24 h after ingestion of grape pomace extracts. 
Data are expressed as nmol ± SE 
 
Σ of structurally related metabolites 
(Day 7, 0-8 h) 
E1 VE1 E5 VE5 E6 VE6 Control Verapamil control 
Peak Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE 
1 (Epi)catechin-O-glucuronide 1.6 1.0 0.7* 0.3 3.1 1.9 0.6 0.2 2.9* 1.0 1.9 1.0 0.5 0.3 0.1 0.0 
2 O-Methyl-(epi)catechin-O-glucuronide 5.7 2.2 2.9* 0.4 5.7 2.3 4.0* 1.3 5.9* 2.1 6.1* 2.6 1.7 0.4 1.5 0.4 
3 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 0.2 0.1 0.2 0.1 0.3 0.1 0.3 0.1 0.3 0.1 0.2 0.0 0.2 0.1 0.1 0.0 
4 5-(Hydroxyphenyl)-γ-valerolactone-O-sulfate 0.2 0.0 0.5* 0.2 0.4 0.2 0.7* 0.3 0.5 0.2 0.6* 0.1 0.2 0.1 0.2 0.1 
5 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 0.4 0.1 0.6* 0.2 0.6* 0.1 0.9* 0.2 0.9 0.4 0.9* 0.2 0.4 0.2 0.3 0.1 
6 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 6.6 1.6 7.5 2.5 6.7 2.6 10.3* 2.7 8.4 2.3 7.3 1.1 7.7 2.0 3.5 1.2 
7 Isoferulic acid-4-O-sulfate 131.2* 25.9 159.6* 34.9 149.2* 34.0 134.3 37.7 137.4 45.8 133.1* 18.1 71.8 29.5 82.5 7.5 
 
                
                 
 
Σ of structurally related metabolites 
(Day 7, 8-24 h) 
E1 VE1 E5 VE5 E6 VE6 Control Verapamil control 
Peak Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE 
1 (Epi)catechin-O-glucuronide 1.6 0.4 1.4* 0.2 1.6 0.1 1.0 0.3 2.2* 0.4 1.4 0.5 1.1 0.3 0.6 0.2 
2 O-Methyl-(epi)catechin-O-glucuronide 8.1 1.8 3.2* 0.6 6.2 1.3 2.5 0.5 5.2* 0.8 3.8* 0.8 3.7 0.8 2.1 0.7 
3 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 0.5 0.1 0.3 0.0 0.7 0.3 0.4 0.1 0.7* 0.1 0.3 0.1 0.4 0.1 0.3 0.1 
4 5-(Hydroxyphenyl)-γ-valerolactone-O-sulfate 0.8 0.1 1.1 0.3 1.4 0.5 0.8 0.2 1.6 0.3 1.1* 0.2 1.1 0.3 0.4 0.1 
5 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 1.2 0.4 1.1 0.3 1.8 0.6 1.1 0.3 1.4 0.3 1.7* 0.5 1.1 0.3 0.4 0.1 
6 5-(Phenyl)-4-hydroxyvaleric acid-O-sulfate 13.2 4.2 12.9* 2.6 15.4 3.6 8.0 1.7 14.5 4.0 10.8 2.8 12.4 2.8 5.5 1.7 
7 Isoferulic acid-4-O-sulfate 209.4* 38.6 123.3 25.1 218.2* 60.6 89.6 24.7 171.5 43.0 116.5 30.2 121.2 20.8 96.4 27.6 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; VE1, Grenache (GRE1) EA70 seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) EA70 skin 
pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. SE, standard error. 
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Higher levels of O-methyl-(epi)catechin-O-glucuronide relative to (epi)catechin-O-
glucuronide were found in every urine sample. Sulfate derivatives of 5-(hydroxyphenyl)-γ-
valerolactone were excreted in greater amounts than glucuronides. Glucuronidated 5-
(hydroxyphenyl)-4-hydroxyvaleric acid and 5-(phenyl)-4-hydroxyvaleric acid were 
identified (Table 51) but because of their low concentration, they were not quantified 
unlike their sulfated counterparts. A decrease of 5-(hydroxyphenyl)-4-hydroxyvaleric acid-
O-sulfate from 0-8 h to 8-24 h at day 1 was observed while an increase of 5-(phenyl)-4-
hydroxyvaleric acid-O-sulfate occurred at 8-24 h compared to 0-8 h in all rat urines at day 
1 and day 7. A previous report by Llorach et al. (2010) on a human almond skin 
polyphenol bioavailability suggested that partial dehydroxylation reactions occur gradually 
as colonic metabolism progresses. These authors observed a change in the hydroxylation 
pattern of the phenyl ring from di- to mono- and unhydroxylated forms. Dihydroxylated 
derivatives were found 6-10 h after the intake, monohydroxylated forms were observed at 
6-24 h, and unhydroxylated derivatives were found 10-24 h after the intake. 
In order to compare efficiency of grape pomace extracts, the sum of metabolites 
that are excreted in significantly higher amounts compared to their respective control (p < 
0.05) are presented in Figure 53 for day 1 of extract ingestion and Figure 54 for day 7 of 
extract intake.  
 
 
 
 
 
 
 
 
 
 
 
 
235 
 
 
 
Figure 53: Total urinary metabolites excreted at day 1, 0-8 h, 8-24 h and 0-24h 
after ingestion of grape pomace extracts 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre 
(MOU) EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, 
Alicante (ALI) EA70 skin pomace extract + verapamil. a,A,α; Anova was made to compare values between 
different experimental groups during 0-8h, 8-24 and 24h at day 1. Same letters indicate no significant 
differences between the values (p < 0.05). Data are expressed as mean values in nmol ± standard error. 
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Figure 54: Total urinary metabolites excreted at day 7, 0-8 h, 8-24 h and 0-24h 
after ingestion of grape pomace extracts 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre 
(MOU) EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, 
Alicante (ALI) EA70 skin pomace extract + verapamil. a,A,α; Anova was made to compare values between 
different experimental groups during 0-8h, 8-24 and 24h at day 7. Same letters indicate no significant 
differences between the values (p < 0.05). Data are expressed as mean values in nmol ± standard error. 
 
At day 1 of SHR rat gavage, substantial 0-8 h urinary excretion of metabolites was 
observed in the E1, VE1 and E5 experimental groups unlike E6 and VE6 in which highest 
excretion occurred in 8-24 h urine. Considering the 0-8 h samples, high urinary excretion 
was found in VE1 (117 ± 12 nmol) followed by E5 (80 ± 16 nmol) and E1 (70 ± 16 nmol). 
The lowest amount was in VE5 with only 2.9 ± 0.7 nmol of metabolites excreted. During 
8-24 h collection period, excretion of metabolites was more pronounced with VE6 and E6 
(88 ± 3 nmol and 80 ± 7 nmol respectively). VE1 showed the highest 0-24 h excretion 
metabolites with 175 ± 20 nmol. However, the excretion rate was not significantly 
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different from those obtained in E1 E5 E6 and VE6. Only VE5 presented a significant 
lower rate of excretion (6 ± 1.4 nmol).  
Unlike day 1 in which high variability of excretion pattern was observed, at day 7, 
all SHR groups excreted metabolites in the same way with the highest amount at 0-8 h 
(from 98 ± 9 nmol in VE6 to 72 ± 21 nmol in E6) rather than 8-24 h time point (from 35 ± 
11 nmol in VE6 to 82 ± 24 nmol in E5). No significant difference was observed between 
different experimental groups in both 0-8 h, 8-24 h and even over 0-24h. This phenomenon 
can be due to a high absorption and excretion reducing variability between subjects of the 
same group. Overall, total 24 h urinary excretion at day 7 ranged from 117 ± 33 nmol in 
E6 to 160 ± 40 nmol in E5 and was higher than that obtained at day 1 which varied from 6 
± 1.4 to 175 ± 20 nmol. The percentage of intake of grape pomace extracts administrated 
alone or in association with verapamil to SHR rats was calculated for each time point 
(Table 58). 
Table 58: Percentage of intake of different grape pomace extracts excreted in 
urine at day 1 and day 7, 0-8 h, 8-24 h and 0-24 h after intake 
Percentage of intake day 1 (%) 
 
E1
a
 VE1
 a
 E5
 a
 VE5
 a
 E6
 a
 VE6
 a
 
Day1 0-8 h 0.83 0.99 0.83 0.08 0.51 0.19 
Day1 8-24 h 0.19 0.30 0.74 0.08 0.51 0.83 
Total 24 h 1.02 1.29 1.57 0.16 1.02 1.02 
       
Percentage of intake day 7 (%) 
 
E1
a
 VE1
 a
 E5
 a
 VE5
 a
 E6
 a
 VE6
 a
 
Day7 0-8 h 0.94 0.64 2.10 1.63 1.03 1.32 
Day7 8-24 h 0.58 0.43 2.31 2.62 0.39 0.32 
Total 24 h 1.52 1.08 4.41 4.25 1.43 1.64 
a 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) 
EA70 seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre 
(MOU) EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, 
Alicante (ALI) EA70 skin pomace extract + verapamil. 
 
At day 1, excretion as a percentage of intake varied from 0.16 % to 1.57 %. Highest 
recoveries were observed in the VE1 and E5 SHR groups (1.29 % and 1.57 % respectively, 
over 0-24 h). The lowest recovery was obtained in SHR group fed with Mourvèdre [MOU 
EA70] skin pomace extract + verapamil (0.16%). At day 7, an increase of intake was 
observed for the two collection periods and, as a consequence, over 0-24 h. The recoveries 
ranged from 1.08 % in VE1 to 4.25 % in VE5. A large increase in metabolite excretion 
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was observed in VE5 SHR group with 4.25% of intake at day 7 compared to 0.16 % at day 
1. These observations suggested that over time, SHR rats may be able to ingest higher 
doses of polyphenols especially those contained in Mourvèdre [MOU EA70] skin pomace 
extract. 
The recoveries obtained in this study were low compared to other studies. For 
instance, Tsang et al. (2005), found urinary excretion corresponding to 33% of intake 0-24 
h after ingestion of a grape seed extract containing a wide array of monomeric to 
polymeric flavan-3-ols ingestion. In humans, urinary recovery of flavan-3-ols accounted 
0.5-6 % of intake for some tea catechins (Lee et al. 1995; Yang et al. 2000), 2-10% for red 
wine catechins (Donovan et al. 2002a), and up to 30 % for cocoa epicatechin (Baba et al. 
2000). However, higher amounts of flavan-3-ol monomers and polymers were ingested by 
humans than rats. Auger et al. (2008) showed in a green tea flavan-3-ol feeding study with 
ileostomists that (epi)gallocatechins are subjected to strictly limited absorption whereas 
(epi)catechins can be readily absorbed even with an increasing dose. Thus, the low amount 
of polyphenols fed in this study compared to other studies could be the cause of these 
recovery differences. 
III.1.2. HPLC-ESI-MSn analysis of SHR rat plasma  
SHR rats plasma were screened for flavan-3-ol and procyanidin metabolites using, 
in the first instance, the full-scan MS mode from m/z 100 to 700 in negative ionization 
mode. Peak identifications was based on data dependent MS
2 
and on previous studies 
(Tsang et al. 2005a; Touri o et al. 2009; Urpi-Sarda et al. 2009a; van der Hooft et al. 
2012). Metabolites detected were listed in Table 59. Their levels, expressed as nmol ± SD, 
were determined using SRM, calculated by the same procedure to that used with urine. 
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Table 59: Identification of metabolites detected in SHR rat plasma at day 7, 4 
h after ingestion of grape pomace extracts: HPLC and MS characteristics obtained in 
SRM mode 
Peak 
Rt 
(min) 
Compounds 
[M-H]
-
 
(m/z)
a 
MS
2
 fragment 
(m/z)
b 
1 9.34 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 1 383 207, 163 
2 9.4 (Epi)catechin-O-glucuronide 1 465 289, 245 
3 11.03 (Epi)catechin-O-glucuronide 2 465 289, 245 
4 13.3 O-Methyl-(epi)catechin-O-glucuronide 1 479 303, 223 
5 15.05 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 2 383 207, 163 
6 15.16 Methyl-(epi)catechin-O-glucuronide 2 479 303, 223 
7 16.2 Methyl-(epi)catechin-O-glucuronide 3 479 303, 223 
8 16.87 Di-methyl-(epi)catechin-O-glucuronide 1 493 493, 289 
9 18.43 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 2 305 225, 207 
10 19.49 Di-methyl-(epi)catechin-O-glucuronide 2 493 493, 289 
11 25.67 5-(Hydroxyphenyl)-γ-valerolactone sulfate 1 287 207, 163 
a
Tentative identification based on mass spectra, 
b
molecular ion (m/z) identification in negative 
ionization mode. Rt, retention time; [M-H]
-
, negatively charged molecular ion.  
 
A total of 11 metabolites were found in SHR rat plasma collected 4 h after grape 
pomace extract ingestion. Plasma did not contain any of the original grape pomace extract 
flavan-3-ols and procyanidins but glucuronide, methyl-glucuronide and di-methyl-
glucuronide of (epi)catechin and glucuronide, sulfate and mono-substituted valerolactone 
and valeric acid were present. These metabolites were also detected in urine with the 
exception of the di-methyl-(epi)catechin-O-glucuronide. Metabolites were occurred mainly 
as glucuronides rather than sulfates. These observations were in accordance with a 
previous study by Tsang et al. (2005) in which rats were fed grape seed extracts. These 
investigators detected only glucuronidated forms of (epi)catechins in plasma while sulfates 
predominated in urine.  
Quantitative data are presented in Table 60. Generally, lower amounts of 
metabolites was observed in plasma than in urine showing that flavan-3-ols are rapidly 
turned over the circulatory system, and, rather than accumulating, are excreted via the 
kidneys. Figure 55, summarizes plasma metabolite amounts in different experimental 
group at day 7, 4 hours after grape pomace extracts ingestion (p< 0.05) and their 
respective recoveries (%).  
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Table 60: Mean plasma metabolite levels at day 7, 4 h after ingestion of grape pomace extracts. Data are expressed as nmol ± SD. 
  
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Peak Metabolites Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
1 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 1 0.62* 0.06 
 
0.31 0.02 
 
0.71 0.02 
 
0.63* 0.01 
 
0.46 0.01 
 
0.40 0.07 
2 (Epi)catechin-O-glucuronide 1 Nd Nd 
 
0.05 0.05 
 
Nd Nd 
 
Nd Nd 
 
0.25* 0.02 
 
Nd Nd 
3 (Epi)catechin-O-glucuronide 2 0.34* 0.01 
 
0.34 0.04 
 
0.32 0.03 
 
0.29* 0.00 
 
0.39* 0.03 
 
0.25 0.02 
4 O-Methyl-(epi)catechin-O-glucuronide 1 0.24* 0.02 
 
0.16 0.01 
 
0.17* 0.02 
 
0.33* 0.01 
 
0.23* 0.01 
 
0.13* 0.00 
5 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 2 0.26* 0.01 
 
0.16 0.02 
 
0.31* 0.00 
 
0.23 0.02 
 
0.22* 0.01 
 
0.18 0.01 
6 Methyl-(epi)catechin-O-glucuronide 2 0.62* 0.05 
 
0.62* 0.01 
 
0.41 0.00 
 
0.41 0.04 
 
0.71* 0.04 
 
0.60* 0.04 
7 Methyl-(epi)catechin-O-glucuronide 3 Nd Nd 
 
0.26* 0.01 
 
Nd Nd 
 
Nd Nd 
 
0.37* 0.01 
 
0.33* 0.01 
8 Di-methyl-(epi)catechin-O-glucuronide 1 0.54* 0.06 
 
0.00 0.00 
 
0.86* 0.03 
 
1.99* 0.03 
 
0.50* 0.02 
 
Nd Nd 
9 5-(Hydroxyphenyl)-4-hydroxyvaleric acid-O-sulfate 2 Nd Nd 
 
0.20* 0.01 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
0.35* 0.02 
10 Di-methyl-(epi)catechin-O-glucuronide 2 0.42* 0.04 
 
Nd Nd 
 
0.35* 0.04 
 
0.83* 0.00 
 
0.19* 0.01 
 
Nd Nd 
11 5-(Hydroxyphenyl)-γ-valerolactone sulfate 1 0.42* 0.04 
 
0.80* 0.05 
 
0.31* 0.05 
 
0.49* 0.01 
 
0.42* 0.06 
 
1.08* 0.04 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; VE1, Grenache (GRE1) EA70 seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) EA70 skin 
pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. SD, standard deviation. 
 
  
2
4
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Figure 55: Mean plasma metabolite levels in different experimental group at 
day 7, 4 h after ingestion of grape pomace extracts (p< 0.05) and their respective 
recoveries (%). Data expressed as nmol ± standard deviation. SHR rats fed with: E1, Grenache (GRE1) 
EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 seed pomace extract + verapamil; E5, Mourvèdre 
(MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) EA70 skin pomace extract +verapamil; E6, 
Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. 
 
The highest metabolite amount was evidenced in plasma from VE5 experimental 
group in which SHR rats were fed MOU (EA70) skin pomace extracts + verapamil. Up to 
4.6 ± 0.07 nmol and a recovery of 0.15 % were observed compared to other plasma in 
which only 0.03-0.09 % recoveries were found. These results are in accordance with those 
obtained with urine, showing a high intake of grape pomace polyphenols in VE5 
experimental group (4.25 %). E5 urinary excretion indicated substantial absorption of 
polyphenols (4.41 % of intake) but a recovery of 0.09 % in plasma implies a rapid turnover 
of polyphenols in the circulatory system. Grape pomace polyphenols were absorbed to a 
lesser extent by rats fed with other extracts (i.e. E1, VE1, E6 and VE6), as illustrated by 
low recoveries of metabolites in urine and plasma. 
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III.1.3. HPLC-ESI-MSn analysis of SHR rat tissues (heart, liver and kidneys)  
Metabolites in SHR rat tissues were detected using the same procedure as described 
for urine and plasma. No (epi)catechin conjugates were found but a 5-(hydroxyphenyl)-γ-
valerolactone-O-glucuronide (m/z 383/207, 163) and a 5-(hydroxyphenyl)-γ-valerolactone-
O-sulfate (m/z 287/207, 163) were detected and quantified by SRM. Their distribution in 
tissues is presented in Table 61. Data are expressed as nmol per organ ± standard 
deviation. Both glucuronide and sulfate metabolites of the 5-(hydroxyphenyl)-γ-
valerolactone were detected but the glucuronide predominated.  
Heart tissues contained more glucuronidated metabolites than sulfated, ranging 
from 1.32 ± 0.02 nmol in VE6 to 2.64 ± 0.03 nmol in E5. Significantly higher amounts 
were observed in the E1, VE1, E5, VE5 and E6 experimental groups. 5-(Hydroxyphenyl)-
γ-valerolactone-O-sulfate, was detected only in E1 and E5 experimental groups at a level 
of 0.11 ± 0.00 nmol.  
Kidneys contained more 5-(hydroxyphenyl)-γ-valerolactone-O-sulfate than the 
liver and the amount was significantly higher in all the SHR experimental group which 
received grape pomace extracts compared to control groups. Rats from VE5 experimental 
group contained up to 9.19 ± 0.85 nmol of 5-(hydroxyphenyl)-γ-valerolactone-O-
glucuronide followed by VE6 group which retained 7.73 ± 0.65 nmol. 
Liver contained the highest level of metabolites with most present as glucuronides. 
A 5-(hydroxyphenyl)-γ-valerolactone-O-sulfate was only detected in SHR rats fed with 
ALI (EA70) skin pomace extract + verapamil at 7.24 ± 0.6 nmol. Only SHR from E5, VE5 
and VE6 experimental groups contained significantly higher amounts (210 ± 12 nmol, 198 
± 3 nmol and 194 ± 7 nmol, respectively) of 5-(hydroxyphenyl)-γ-valerolactone-O-
glucuronide compared to control groups. 
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Table 61: Mean tissue metabolite levels at day 7, after 4 hours of grape pomace extracts ingestion. Data are expressed as nmol per 
organ ± standard deviation. 
 Heart 
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Peak Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
1 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 2.50* 0.25 
 
2.04* 0.23 
 
2.64* 0.03 
 
1.83* 0.07 
 
2.27* 0.08 
 
1.32 0.02 
2 5-(Hydroxyphenyl)-γ-valerolactone-O-sulfate 0.11* 0.00 
 
Nd Nd 
 
0.11* 0.00 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
                   
 Kidneys 
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Peak Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
1 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 5.55 0.11 
 
6.27 0.07 
 
6.62 0.08 
 
9.19* 0.85 
 
5.23 0.34 
 
7.73* 0.65 
2 5-(Hydroxyphenyl)-γ-valerolactone-O-sulfate 0.38* 0.00 
 
1.55* 0.07 
 
0.37* 0.02 
 
0.55* 0.04 
 
0.45* 0.03 
 
1.34* 0.05 
                   
 Liver 
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Peak Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
1 5-(Hydroxyphenyl)-γ-valerolactone-O-glucuronide 167.19 8.77 
 
180.88 3.44 
 
209.98* 12.20 
 
197.73* 2.87 
 
179.26 0.25 
 
193.64* 6.53 
2 5-(Hydroxyphenyl)-γ-valerolactone-O-sulfate Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
7.24* 0.58 
 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; VE1, Grenache (GRE1) EA70 seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) EA70 skin 
pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. SD, standard deviation.
2
4
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Table 62: Metabolites in heart, kidneys and liver as a % of polyphenol intake 
Heart E1a VE1 a E5 a VE5 a E6 a VE6 a 
% intake 0.024 0.011 0.059 0.016 0.022 0.000 
       
Kidneys E1a VE1 a E5 a VE5 a E6 a VE6 a 
% intake 0.005 0.025 0.010 0.137 0.008 0.063 
       
Liver E1a VE1 a E5 a VE5 a E6 a VE6 a 
% intake Nd Nd 1.76 1.64 Nd 1.02 
 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) 
EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) 
EA70 skin pomace extract + verapamil. 
 
It has to be noted that rats fed with MOU (EA70) skin pomace extract + verapamil 
(VE5 SHR group) contained high amounts of these metabolites and with higher accumulation 
after ingestion of MOU (EA70) skin pomace extract + verapamil than other extracts, 
especially in the kidneys and liver (0.14 % and 1.64 %, respectively) (Table 62). A higher 
accumulation of metabolites in rats fed with grape pomace extracts + verapamil was observed 
in kidneys. Accumulation of metabolites was 5-fold higher in VE1 than E1, 14-fold higher in 
VE5 than E5 and 8-fold higher in VE6 than E6.In contrast, the heart presented 2-fold and 4- 
fold higher accumulation of polyphenol metabolites in rats fed with grape pomace extracts 
without co-ingestion with verapamil in E1 and E5, respectively. No significant accumulation 
was found in VE6 heart tissues compared to E6 which contained metabolites corresponding 
to 0.022 % of the ingested polyphenols. 
The absorption, and arguably metabolism, of flavan-3-ols and procyanidins initially 
takes place during transfer through the wall of the small intestine after which further phase II 
metabolism occurs in the liver. As liver appear to be the most important organs involved in 
flavonoid metabolism, it was not surprising to find such a high level of metabolites. Some of 
the conjugated metabolites can be actively effluxed back into the lumen of the small intestinal 
and/or may be transported to other organs through the bloodstream as shown by their 
presence in the heart. In addition, metabolites were also detected in kidneys no doubt as a 
consequence of renal excretion. It should be noted that the time of tissue sampling may be of 
importance, and metabolites detection depend on the kinetics of their accumulation and 
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elimination in the tissues. In this study, tissues which were shown to contain metabolites were 
collected 4 h after the ingestion of grape pomace extracts. Tsang et al. (2005) found flavan-3-
ol metabolites in the liver of rats 1 h and 4 h after ingestion of a grape seed extract but none 
were detected 6, 12 and 24 h after intake. This indicates a rapid elimination of flavan-3-ol 
metabolites in keeping with them being treated as xenobiotics by the body.  
III.1.4. HPLC-ESI-MSn analysis of SHR rat faeces  
In the first instance, faecal extracts were subjected to normal phase HPLC with mass 
spectrometry and fluorescence detection for the analysis of procyanidins polymers. Faeces 
were then screened for the original grape pomace flavan-3-ols and procyanidins using HPLC-
MS
n
 in SIM mode (selected ion monitoring). Seven compounds were partially identified and 
quantified, including (epi)catechin (m/z 289/245, 205), (epi)catechin-3-O-gallate (m/z 
441/289,169), two dimers (m/z 577/425, 407, 289), one trimer (m/z 865/577, 289), two 
(epi)gallocatechin trimers (m/z 881, 729, 577, 407) and one tetramer (m/z 153/865, 577). 
Quantitative data are presented in Table 63.  
Table 63: Faecal excretion of polyphenolics at day 1 and day 7 after ingestion of 
grape pomace extracts. Data are expressed in nmol ± SD. 
J1 0-8h 
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
(Epi)catechin 3.6* 0.0 
 
3.9* 0.2 
 
4.2* 0.3 
 
2.1 0.1 
 
3.2* 0.0 
 
4.5 0.2 
(Epi)catechin-O-gallate Nd Nd 
 
Nd Nd 
 
Nd 
   
Nd 
 
Nd 
    
Dimer 1.8 0.0 
 
2.1* 0.1 
 
2.1 0.2 
 
0.6 0.0 
 
2.1 0.2 
 
2.5 0.1 
Trimer Nd Nd 
 
Nd Nd 
 
Nd 
   
Nd 
 
Nd 
    
(Epi)gallocatechin trimer 1 1.4* 0.0 
 
1.4* 0.1 
 
1.3* 0.0 
  
Nd 
 
1.2* 0.0 
 
1.4 0.0 
(Epi)gallocatechin trimer 2 1.7 0.0 
 
Nd Nd 
 
1.5 0.1 
  
Nd 
 
1.8 0.0 
 
1.3 0.0 
Tetramer 5.5* 0.2 
 
2.0 0.1 
 
3.7* 0.1 
 
1.8 0.1 
 
3.9* 0.2 
 
9.3 0.5 
J1 8-24 h 
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
(Epi)catechin 32.9* 1.2 
 
33.7* 1.6 
 
34.3* 1.7 
 
27.2 1.6 
 
27.5 1.1 
 
28.5 2.5 
(Epi)catechin-O-gallate Nd Nd 
 
37.1* 1.4 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
Dimer 28.7 0.6 
 
27.1 1.1 
 
27.3 2.5 
 
31.1* 1.2 
 
31.4 1.6 
 
28.3* 0.6 
Trimer 9.3 0.4 
 
9.5 0.9 
 
8.9 0.6 
 
10.8 0.7 
 
11.5* 0.9 
 
10.3 1.0 
(Epi)gallocatechin trimer 1 17.3* 0.1 
 
17.4 0.9 
 
19.4* 0.8 
 
21.9* 1.5 
 
20.7* 0.9 
 
15.4 0.5 
(Epi)gallocatechin trimer 2 7.3 0.3 
 
11.8 0.2 
 
13.5 1.1 
 
16.8* 0.4 
 
11.1* 0.7 
 
11.0* 0.1 
Tetramer 52.3* 0.6 
 
20.7 1.1 
 
51.6* 3.4 
 
23.3 1.8 
 
27.1* 0.7 
 
28.5 2.2 
J7 0-8 h 
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
(Epi)catechin 4.7 0.1 
 
6.5* 0.2 
 
5.0 0.3 
 
5.0 0.2 
 
4.1 0.1 
 
7.6* 0.3 
(Epi)catechin-O-gallate Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
 
Nd Nd 
Dimer 2.2 0.2 
 
3.0 0.1 
 
2.7 0.1 
 
2.9 0.1 
 
4.3 0.4 
 
3.4 0.1 
Trimer Nd Nd 
 
Nd Nd 
 
2.2* 0.1 
 
Nd Nd 
 
Nd Nd 
 
2.3 0.2 
(Epi)gallocatechin trimer 1 2.7 0.1 
 
3.0 0.1 
 
3.9 0.4 
 
3.4* 0.0 
 
4.7* 0.2 
 
4.7* 0.3 
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(Epi)gallocatechin trimer 2 2.5* 0.1 
 
2.0 0.0 
 
2.6* 0.2 
 
1.9 0.1 
 
3.0* 0.1 
 
2.5 0.2 
Tetramer 11.0* 0.4 
 
4.1 0.1 
 
4.7 0.2 
 
1.8 0.1 
 
6.5* 0.1 
 
7.8 0.6 
J7 8-24 h 
E1 
 
VE1 
 
E5 
 
VE5 
 
E6 
 
VE6 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
(Epi)catechin 31.0* 1.0 
 
35.7* 2.4 
 
34.1* 1.3 
 
44.6* 2.8 
 
32.2* 1.0 
 
41.8* 3.3 
(Epi)catechin-O-gallate Nd 
  
29.1* 0.2 
 
Nd Nd 
 
42.5* 2.1 
 
Nd Nd 
 
29.2* 1.6 
Dimer 17.4 0.2 
 
22.9* 1.4 
 
17.6 0.2 
 
25.8* 0.1 
 
27.3* 0.3 
 
17.2* 1.3 
Trimer 4.4 0.1 
 
7.2* 0.2 
 
7.1 0.1 
 
10.0* 0.9 
 
7.7 0.1 
 
9.3* 0.3 
(Epi)gallocatechin trimer 1 12.6 1.0 
 
15.9* 1.2 
 
12.6 0.9 
 
29.6* 1.6 
 
19.7* 0.6 
 
19.3* 1.3 
(Epi)gallocatechin trimer 2 13.3* 1.4 
 
15.1* 0.2 
 
12.5* 0.9 
 
13.1* 0.5 
 
19.4* 0.2 
 
15.3* 0.7 
Tetramer 68.1* 3.5 
 
25.9 0.8 
 
33.5* 1.6 
 
21.8 0.1 
 
27.8* 0.4 
 
27.5 1.8 
* Metabolites that were excreted in significantly higher amounts compared to their respective control 
(p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) 
EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) 
EA70 skin pomace extract + verapamil. SD, standard deviation. 
 
In order to have a clear picture, Figures 56 and 57 illustrate the total excreted 
compounds in faeces at day 1 and day 7, 0-8 h and 8-24 h and 0-24 h after pomace extract 
intake. 
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Figure 56: Total faecal excretion of phenolic metabolites in nmol at day, 0-8h, 8-
24h and 0-24h after ingestion of grape pomace extracts 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) 
EA70 skin pomace extract + verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) 
EA70 skin pomace extract + verapamil. a,A,α; Anova was made to compare values between different 
experimental groups during 0-8h, 8-24 and 24h at day 1. Same letters indicate no significant differences 
between the values (p < 0.05). Data are expressed as mean values in nmol ± Standard deviation. 
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Figure 57: Total faecal excretion of phenolic metabolites in nmol at day 7, 0-8 h, 
8-24 h and 0-24 h after ingestion of grape pomace extracts 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) 
EA70 skin pomace extract + verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) 
EA70 skin pomace extract + verapamil. a,A,α; Anova was made to compare values between different 
experimental groups during 0-8h, 8-24 and 24h at day 7. Same letters indicate no significant differences 
between the values (p < 0.05). Data are expressed as mean values in nmol ± standard deviation. 
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Faecal phenolic excretion occurred predominantly at 8-24 h after pomace intake. At 
day 1, SHR rats fed with GRE1 (EA70) seed pomace extract and MOU (EA70) skin pomace 
extract excreted the highest amount of flavan-3-ol monomers and oligomers over the 0-24 h 
collection period (113 ± 0.1 nmol and 115 ± 0.1 nmol, respectively) corresponding to 1.05 % 
and 2.37 % of polyphenolic intake (Table 64). The lowest excretion was observed in VE6 
SHR group (57 ± 0.2 nmol over 24 h, 0.3 % of polyphenolic intake). At day 7, unlike day 1, 
higher level of flavan-3-ol monomers and oligomers was observed in faeces from VE5 SHR 
group (169 ± 0.01 nmol) and corresponding to up to 3.93 % of the intake of grape pomace 
polyphenols. 
 
Table 64: Total faecal excretion of phenolic compounds as % of intake 0-8 h, 8-
24 h and 0-24 h after the ingestion of different grape pomace extracts at day 1 and day 7 
Percentage of intake day 1 
 
E1
a
 VE1
 a
 E5
 a
 VE5
 a
 E6
 a
 VE6
 a
 
Day1 0-8 h 0.08 0.03 0.12 0.00 0.05 0.17 
Day1 8-24 h 0.97 0.30 2.26 0.89 0.84 0.13 
Total 0-24 h 1.05 0.34 2.37 0.89 0.88 0.30 
       
Percentage of intake day 7 
 
E1
a
 VE1
 a
 E5
 a
 VE5
 a
 E6
 a
 VE6
 a
 
Day7 0-8 h 0.18 0.02 0.20 0.01 0.15 0.09 
Day7 8-24 h 1.31 1.02 1.51 3.92 1.27 1.44 
Total 0-24h 1.49 1.03 1.72 3.93 1.42 1.53 
a
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) 
EA70 skin pomace extract + verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) 
EA70 skin pomace extract + verapamil. 
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III.2. GC-MS analysis of urines and faeces 
III.2.1 GC-MS analysis of urines 
Urine samples at day 1 and day 7 were collected at 0-8 h and 8-24 h after feeding the 
different grape pomace extracts by gavage. The phenolic acids in urine and faecal samples 
were analysed quantitatively by GC-MS. Catabolites detected represented urinary excretion 
of phenolic acids in their unconjugated form.  
A total of 21 phenolic acids and aromatic compounds were identified in urines of 
SHR rats. In SHR group fed with grape pomace extracts, the production of some compounds 
increased significantly. Thus, only catabolites that are excreted in significantly higher 
amounts than the control were taken into account in order to exclude the background noise. 
Information of the 21 phenolic acid GC-MS properties identified in urine is presented in 
Table 65.  
Table 65: GC-MS identification of phenolic acids detected in urines following 
ingestion of seed or skin grape pomace extracts 
Rt (min) Compounds Target ion (m/z)a Qualifier ion (m/z)a 
6.19 Benzoic acid 179 105, 135, 77, 147 
6.72 Pyrocatechol (1,2-dihydroxybenzene) 73 254, 239 
9.73 3-Hydroxybenzoic acid 267 73, 147, 193, 223, 282, 253 
10.03 Phenylacetic acid 193 147 73, 220, 267, 295 
10.49 3′-Hydroxyphenylacetic acid 73 164, 147, 296, 281 
10.91 4-Hydroxybenzoic acid 267 223, 193, 73, 282 
11.14 4′-Hydroxyphenylacetic acid 73 179, 164. 252, 281, 296 
12.98 3′,4′-Dimethoxyphenylacetic acid 209 73, 268, 151, 253 
13.28 3-(3′-Hydroxyphenyl)propionic acid 205 192, 310, 177,73 
14.16 3-(3′,4′-Dihydroxyphenyl)propionic acid 179 73, 192, 174, 310 
14.28 3-Methoxy-4-hydroxybenzoic acid 297 267, 312, 73, 223, 253, 282, 126, 193 
14.46 4′-Hydroxy-3′-methoxyphenylacetic acid 73 326, 209, 311, 179, 267, 147 
14.76 4′-Hydroxmandelic acid 267 73, 147, 341 
15.55 Hippuric acid 105 206, 73 
18.65 3-(3′-Methoxy-4′-hydroxyphenyl)propionic acid 209 340, 73, 192, 79, 310, 325 
20.41 p-Coumaric acid 219 293, 308, 73, 249 
21.91 Gallic acid 281 398, 293, 73 
27.11 Ferulic acid 338 309, 323, 247, 73, 293 
29.47 Caffeic acid 396 219, 291, 73, 307, 381 
29.70 3′-Hydroxyhippuric acid 294 73, 193, 147 
33.37 Sinapic acid 193 294, 73, 147 
a,
 based on the retention time and mass spectra of commercially available standards and from previous 
published works (Roowi et al. 2010; Stalmach et al. 2013). 
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Some catabolites detected in this study have been previously showed to derived from 
procyanidins and flavan-3-ol monomers (Aura et al. 2008; Touri o et al. 2009; Roowi et al. 
2010). An investigation by Ward et al. (2004) reported significant increase in 3-(3′-
hydroxyphenyl)propionic and 3′-hydroxyphenylacetic acids in 24-h urine samples after 
regular consumption of grape seed polyphenols in humans compared with a placebo group. 
The 3-(3′-hydroxyphenyl)propionic acid was evidenced as an important metabolite of 
procyanidins in humans. Another study by Cueva et al. (2013), showed by in vitro 
fermentation of grape seed momomeric and oligomeric flavan-3-ol fractions with human 
faecal microbiota that fraction can influence subsequent stages of catabolism. Larger 
concentration of 3-(3′,4′-dihydroxyphenyl)propionic acid was produced rapidly once 
incubated with oligomeric fraction than monomeric one and was progressively transformed to 
3-(4′-hydroxyphenyl)propionic acid and then to phenylpropionic acid. In addition, the 
detection of 3-(3′-hydroxyphenyl)propionic acid and 3-(3′,4′-dihydroxyphenyl)propionic acid 
indicated the capacity of microflora to carry out side chain hydrogenation and 
dehydroxylation of the phenyl ring of hydroxycinnamates (Chesson et al. 1999; Poquet et al. 
2008). This phenomenon was already observed in urines analysed by HPLC-ESI-MS
n 
and has 
been discussed previously in paragraph III.1.1.b. Actually, Appeldoorn et al. (2009a), 
proposed that the colonic catabolism of procyanidin dimers involved the production of 3′,4′-
dihydroxyphenylacetic acid, yielding 3′-hydroxyphenylacetic acid from the degradation of 
the upper unit, whereas the lower unit resulted in the formation of 5-(3′-4′-dihydroxyphenyl)-
γ-valerolactone and 3-(3′-hydroxyphenyl)propionic acid. 
Unlike previous study in which hydroxyphenyl--valerolactone acids were found after 
grape seed extracts ingestion and products rich in flavan-3-ol monomers and polymers 
(Touri o et al. 2009; Roowi et al. 2010; Cueva et al. 2013), no unconjugated of 
hydroxyphenyl--valerolactone acids was detected by GC-MS. However, their conjugated 
forms were found in urine and quantified by HPLC-ESI-MS
n
. In addition, HPLC-ESI-MS
n
 
analysis of SHR rat urines evidenced the presence of 3-(3′-hydroxyphenyl)propionic acid, 3-
(3′,4′-dihydroxyphenyl)propionic acid, 3′,4′-dihydroxyphenylacetic acid and 3′-methoxy-4′-
hydroxyphenylacetic acid in glucuronidated and sulfated form suggesting glucuronidation 
and sulfatation of these catabolites either in the wall of the colon or post-absorption in the 
liver and kidneys. Quantification results of catabolites are presented in Tables 66-69. 
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Table 66: Quantification of phenolic acids detected in rat urine 0-8 h 8-24 h and 0-24 h after ingestion of seed and skin grape 
pomace extracts. Data are expressed as µmol ± SD. 
 
E1 
 
E5 
 
E6 
Compounds 0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
Benzoic acid 0.10 ± 0.00* 0.12 ± 0.00* 0.22 ± 0.00* 
 
0.06 ± 0.00* 0.17 ± 0.00* 0.23 ± 0.00* 
 
0.05 ± 0.00 0.15 ± 0.00* 0.21 ± 0.01* 
Pyrocatechol 0.18 ± 0.01 0.30 ± 0.01 0.48 ± 0.02 
 
0.14 ± 0.00 0.63 ± 0.02* 0.77 ± 0.02* 
 
0.14 ± 0.01 0.49 ± 0.03 0.63 ± 0.03 
3-Hydroxybenzoic acid 0.03 ± 0.00* 0.04 ± 0.00 0.08 ± 0.00 
 
0.03 ± 0.00 0.11 ± 0.00* 0.13 ± 0.00* 
 
0.02 ± 0.00 0.06 ± 0.00* 0.09 ± 0.00 
Phenylacetic acid 0.06 ± 0.00* 0.07 ± 0.00 0.13 ± 0.01 
 
0.05 ± 0.00 0.10 ± 0.00 0.15 ± 0.01 
 
0.04 ± 0.00 0.08 ± 0.00 0.12 ± 0.00 
3′-Hydroxyphenylacetic acid 0.18 ± 0.00* 0.23 ± 0.01 0.41 ± 0.01 
 
0.13 ± 0.01 0.49 ± 0.02* 0.62 ± 0.03* 
 
0.12 ± 0.00 0.37 ± 0.02 0.49 ± 0.02 
4-Hydroxybenzoic acid 0.04 ± 0.00* 0.05 ± 0.00 0.09 ± 0.00 
 
0.03 ± 0.00 0.11 ± 0.01* 0.15 ± 0.01* 
 
0.03 ± 0.00 0.08 ± 0.00* 0.12 ± 0.00* 
4′-Hydroxyphenylacetic acid 0.55 ± 0.00* 0.96 ± 0.04 1.51 ± 0.04 
 
0.48 ± 0.03 1.93 ± 0.10* 2.42 ± 0.12* 
 
0.54 ± 0.01* 1.48 ± 0.07 2.02 ± 0.08 
3′,4′-Dimethoxyphenylacetic acid nd nd nd 
 
nd nd nd 
 
nd nd nd 
3-(3′-Hydroxyphenyl)propionic acid 0.36 ± 0.02* 0.93 ± 0.01 1.29 ± 0.03 
 
0.29 ± 0.02 1.14 ± 0.07 1.43 ± 0.08 
 
0.27 ± 0.01 1.40 ± 0.07* 1.67 ± 0.08* 
3-(3′,4′-Dihydroxyphenyl)propionic acid 0.07 ± 0.00 0.11 ± 0.00 0.18 ± 0.00 
 
0.07 ± 0.00 0.15 ± 0.01 0.22 ± 0.01 
 
0.07 ± 0.00 0.21 ± 0.01* 0.28 ± 0.01* 
3-Methoxy-4-hydroxybenzoic acid 0.04 ± 0.00* 0.02 ± 0.00 0.06 ± 0.00 
 
0.03 ± 0.00* 0.08 ± 0.00* 0.11 ± 0.00* 
 
0.02 ± 0.00 0.04 ± 0.00* 0.07 ± 0.00* 
4′-Hydroxy-3′-methoxyphenylacetic acid 0.08 ± 0.00 0.14 ± 0.00 0.22 ± 0.00 
 
0.07 ± 0.00 0.19 ± 0.01* 0.27 ± 0.01* 
 
0.06 ± 0.00 0.18 ± 0.01* 0.24 ± 0.01 
4′-Hydroxymandelic acid 0.11 ± 0.00* 0.04 ± 0.00* 0.15 ± 0.00* 
 
0.10 ± 0.00* 0.09 ± 0.00* 0.19 ± 0.01* 
 
0.09 ± 0.00* 0.10 ± 0.00* 0.18 ± 0.01* 
Hippuric acid 20.52 ± 0.73 33.83 ± 0.49 54.34 ± 1.22 
 
16.22 ± 1.08 47.39 ± 2.86* 63.61 ± 3.95 
 
14.56 ± 1.54 42.24 ± 0.74 56.80 ± 2.28 
3-(3′-Methoxy-4′-hydroxyphenyl)propionic acid 0.06 ± 0.00* 0.08 ± 0.00 0.14 ± 0.01 
 
0.03 ± 0.00 0.08 ± 0.00 0.11 ± 0.00 
 
0.03 ± 0.00 0.13 ± 0.00* 0.16 ± 0.00* 
p-Coumaric acid 0.03 ± 0.00* 0.07 ± 0.00 0.10 ± 0.00 
 
0.03 ± 0.00* 0.12 ± 0.01 0.15 ± 0.01* 
 
0.05 ± 0.00* 0.15 ± 0.01* 0.20 ± 0.01* 
Gallic acid 1.07 ± 0.03 1.26 ± 0.04 2.33 ± 0.07 
 
0.95 ± 0.04 5.43 ± 0.30* 6.38 ± 0.34* 
 
0.86 ± 0.03 2.79 ± 0.01 3.65 ± 0.04 
Ferulic acid 0.13 ± 0.01 0.23 ± 0.01 0.35 ± 0.01 
 
0.08 ± 0.00 0.69 ± 0.00* 0.76 ± 0.00* 
 
0.06 ± 0.00 0.51 ± 0.03 0.56 ± 0.03 
Caffeic acid 0.01 ± 0.00* 0.00 ± 0.00 0.01 ± 0.00 
 
0.00 ± 0.00 0.04 ± 0.00* 0.04 ± 0.00* 
 
0.00 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
3′-Hydroxyhippuric acid 0.02 ± 0.00 0.02 ± 0.00 0.05 ± 0.00 
 
0.02 ± 0.00 0.09 ± 0.00* 0.12 ± 0.00* 
 
0.02 ± 0.00 0.04 ± 0.00* 0.06 ± 0.00 
Sinapic acid 0.04 ± 0.00 0.05 ± 0.00 0.08 ± 0.00 
 
0.04 ± 0.00 0.10 ± 0.01* 0.14 ± 0.01* 
 
0.03 ± 0.00 0.07 ± 0.00* 0.10 ± 0.00* 
Total 23.66 ± 0.71 38.56 ± 0.63 62.22 ± 1.09 
 
18.85 ± 1.19 59.14 ± 3.41* 77.99 ± 4.60* 
 
17.05 ± 1.49 50.61 ± 1.02* 67.65 ± 2.51 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; E5, Mourvèdre (MOU) EA70 skin pomace extract and E6, Alicante (ALI) EA70 skin pomace extract. SD, standard deviation. 
  
2
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Table 67: Quantification of phenolic acids detected in rat urine 0-8 h, 8-24 and 0-24 h after ingestion of seed and skin grape 
pomace extracts in association with verapamil. Data are expressed as µmol ± SD. 
 
VE1 
 
VE5 
 
VE6 
Compounds 0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
Benzoic acid 0.05 ± 0.00 0.15 ± 0.00 0.21 ± 0.00 
 
0.05 ± 0.00 0.10 ± 0.00 0.15 ± 0.00 
 
0.06 ± 0.00 0.11 ± 0.00 0.17 ± 0.01 
Pyrocatechol 0.17 ± 0.01 0.40 ± 0.01 0.57 ± 0.02 
 
0.18 ± 0.01 0.35 ± 0.01 0.53 ± 0.02 
 
0.19 ± 0.01 0.52 ± 0.00* 0.72 ± 0.01* 
3-Hydroxybenzoic acid 0.03 ± 0.00 0.05 ± 0.00 0.08 ± 0.00 
 
0.02 ± 0.00 0.04 ± 0.00 0.07 ± 0.00 
 
0.03 ± 0.00 0.08 ± 0.00* 0.11 ± 0.00* 
3-Phenylacetic acid 0.06 ± 0.00* 0.10 ± 0.00 0.16 ± 0.00* 
 
0.04 ± 0.00 0.09 ± 0.00 0.13 ± 0.01 
 
0.05 ± 0.00 0.11 ± 0.00 0.16 ± 0.00 
3′-Hydroxyphenylacetic acid 0.15 ± 0.01* 0.36 ± 0.01 0.52 ± 0.02* 
 
0.10 ± 0.00 0.35 ± 0.02 0.45 ± 0.02 
 
0.12 ± 0.00 0.42 ± 0.00* 0.54 ± 0.01* 
4-Hydroxybenzoic acid 0.04 ± 0.00* 0.08 ± 0.00* 0.12 ± 0.00* 
 
0.03 ± 0.00 0.06 ± 0.00 0.10 ± 0.00 
 
0.04 ± 0.00* 0.09 ± 0.00* 0.13 ± 0.01* 
4′-Hydroxyphenylacetic acid 0.56 ± 0.03 1.60 ± 0.02 2.15 ± 0.05* 
 
0.37 ± 0.01 1.53 ± 0.14 1.90 ± 0.14 
 
0.54 ± 0.02 1.40 ± 0.01 1.95 ± 0.03 
3′,4′-Dimethoxyphenylacetic acid 2.68 ± 0.05 1.28 ± 0.01 3.96 ± 0.06 
 
2.19 ± 0.01 1.48 ± 0.05 3.67 ± 0.06 
 
2.82 ± 0.06 1.79 ± 0.03 4.61 ± 0.08 
3-(3′-Hydroxyphenyl)propionic acid 0.31 ± 0.01* 1.08 ± 0.01* 1.39 ± 0.02* 
 
0.22 ± 0.01 0.88 ± 0.06 1.10 ± 0.07 
 
0.23 ± 0.01 1.28 ± 0.04* 1.51 ± 0.05* 
3-(3′,4′-Dihydroxyphenyl)propionic acid 0.05 ± 0.00* 0.13 ± 0.00 0.18 ± 0.01 
 
0.04 ± 0.00 0.14 ± 0.01 0.18 ± 0.01 
 
0.05 ± 0.00* 0.17 ± 0.01 0.22 ± 0.01* 
3-Methoxy-4-hydroxybenzoic acid 0.03 ± 0.00* 0.03 ± 0.00* 0.06 ± 0.00* 
 
0.03 ± 0.00* 0.02 ± 0.00 0.06 ± 0.00 
 
0.03 ± 0.00* 0.05 ± 0.00* 0.09 ± 0.00* 
4′-Hydroxy-3′-methoxyphenylacetic acid 0.11 ± 0.01 0.22 ± 0.01 0.33 ± 0.01 
 
0.10 ± 0.00 0.21 ± 0.00 0.31 ± 0.01 
 
0.11 ± 0.00 0.25 ± 0.00* 0.35 ± 0.01 
4′-Hydroxymandelic acid 0.08 ± 0.00 nd 0.08 ± 0.00 
 
0.09 ± 0.00 nd 0.09 ± 0.00 
 
0.13 ± 0.01* nd 0.13 ± 0.01* 
Hippuric acid 15.16 ± 0.07 39.93 ± 0.65 55.10 ± 0.72 
 
13.26 ± 0.40 34.39 ± 5.34 47.65 ± 5.74 
 
16.88 ± 0.67* 45.94 ± 1.02 62.82 ± 1.69* 
3-(3′-Methoxy-4′-hydroxyphenyl)propionic acid 0.04 ± 0.00 0.08 ± 0.00 0.12 ± 0.00 
 
0.03 ± 0.00 0.09 ± 0.00 0.11 ± 0.00 
 
0.04 ± 0.00 0.10 ± 0.01* 0.14 ± 0.01* 
p-Coumaric acid 0.03 ± 0.00* 0.11 ± 0.00* 0.13 ± 0.00* 
 
0.03 ± 0.00* 0.10 ± 0.00 0.13 ± 0.00* 
 
0.06 ± 0.00* 0.18 ± 0.01* 0.24 ± 0.01* 
Gallic acid 0.99 ± 0.05 2.79 ± 0.13* 3.78 ± 0.18* 
 
1.02 ± 0.05 1.70 ± 0.15 2.72 ± 0.20 
 
1.29 ± 0.04* 4.16 ± 0.04* 5.45 ± 0.08* 
Ferulic acid 0.10 ± 0.00 0.41 ± 0.02* 0.50 ± 0.02* 
 
0.07 ± 0.00 0.26 ± 0.01 0.33 ± 0.02 
 
0.08 ± 0.00 0.62 ± 0.00* 0.70 ± 0.00* 
Caffeic acid 0.00 ± 0.00 0.01 ± 0.00* 0.01 ± 0.00* 
 
0.00 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
 
0.01 ± 0.00* 0.02 ± 0.00* 0.03 ± 0.00* 
3′-Hydroxyhippuric acid 0.02 ± 0.00* 0.05 ± 0.00* 0.07 ± 0.00* 
 
0.01 ± 0.00 0.03 ± 0.00 0.04 ± 0.00 
 
0.02 ± 0.00* 0.07 ± 0.00* 0.09 ± 0.00* 
Sinapic acid 0.03 ± 0.00 0.06 ± 0.00* 0.08 ± 0.00* 
 
0.03 ± 0.00 0.04 ± 0.00 0.07 ± 0.00 
 
0.04 ± 0.00* 0.08 ± 0.00* 0.11 ± 0.00* 
Total 20.70 ± 0.23 48.91 ± 0.49 69.61 ± 0.72 
 
17.93 ± 0.50 41.86 ± 5.80 59.80 ± 6.30 
 
22.81 ± 0.83 57.44 ± 1.03* 80.25 ± 1.86* 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; VE5, Mourvèdre (MOU) EA70 skin pomace extract +verapamil and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. SD, 
standard deviation. 
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Table 68: Quantification of phenolic acids detected in rat urine 0-8 h 8-24 h and 0-24 h after ingestion of seed and skin grape 
pomace extracts. Data are expressed as µmol ± SD. 
 
E1 
 
E5 
 
E6 
Compounds 0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
Benzoic acid 0.73 ± 0.02* 2.75 ± 0.11* 3.48 ± 0.12* 
 
0.09 ± 0.00 0.29 ± 0.01 0.38 ± 0.01 
 
0.08 ± 0.00 0.25 ± 0.00 0.33 ± 0.01 
Pyrocatechol 0.20 ± 0.01 1.20 ± 0.04 1.41 ± 0.05 
 
0.26 ± 0.01 1.10 ± 0.02 1.36 ± 0.03 
 
0.22 ± 0.01 1.37 ± 0.04 1.59 ± 0.05 
3-Hydroxybenzoic acid 0.04 ± 0.00* 0.21 ± 0.00 0.25 ± 0.00 
 
0.05 ± 0.00* 0.19 ± 0.01 0.24 ± 0.01 
 
0.05 ± 0.00* 0.18 ± 0.010 0.24 ± 0.01 
3-Phenylacetic acid 0.04 ± 0.00 0.15 ± 0.00 0.20 ± 0.01 
 
0.04 ± 0.00 0.12 ± 0.00 0.16 ± 0.00 
 
0.04 ± 0.00 0.11 ± 0.00 0.15 ± 0.00 
3′-Hydroxyphenylacetic acid 0.18 ± 0.01* 0.70 ± 0.03 0.88 ± 0.03 
 
0.17 ± 0.00* 0.74 ± 0.03 0.91 ± 0.03 
 
0.16 ± 0.00 0.61 ± 0.03 0.77 ± 0.03 
4-Hydroxybenzoic acid 0.04 ± 0.00* 0.23 ± 0.00* 0.27 ± 0.00* 
 
0.05 ± 0.00* 0.18 ± 0.00 0.24 ± 0.00 
 
0.05 ± 0.00* 0.18 ± 0.01 0.23 ± 0.01 
4′-Hydroxyphenylacetic acid 0.60 ± 0.01* 2.35 ± 0.10 2.95 ± 0.11 
 
0.64 ± 0.01* 2.29 ± 0.10 2.93 ± 0.11 
 
0.77 ± 0.03* 2.42 ± 0.07 3.19 ± 0.09 
3′,4′-Dimethoxyphenylacetic acid nd nd nd 
 
nd nd nd 
 
nd nd nd 
3-(3′-Hydroxyphenyl)propionic acid 0.39 ± 0.00* 1.26 ± 0.04 1.65 ± 0.04 
 
0.41 ± 0.01* 1.24 ± 0.08 1.64 ± 0.09 
 
0.65 ± 0.01* 1.46 ± 0.08 2.11 ± 0.09* 
3-(3′,4′-Dihydroxyphenyl)propionic acid 0.06 ± 0.00* 0.21 ± 0.00 0.27 ± 0.00* 
 
0.05 ± 0.00 0.17 ± 0.01 0.22 ± 0.01 
 
0.07 ± 0.00* 0.19 ± 0.00 0.26 ± 0.00 
3-Methoxy-4-hydroxybenzoic acid 0.03 ± 0.00 0.15 ± 0.00 0.19 ± 0.00 
 
0.05 ± 0.00* 0.10 ± 0.00 0.15 ± 0.01 
 
0.05 ± 0.00* 0.13 ± 0.00 0.18 ± 0.00 
4′-Hydroxy-3′-methoxyphenylacetic acid 0.09 ± 0.00* 0.29 ± 0.01* 0.38 ± 0.01* 
 
0.10 ± 0.00* 0.24 ± 0.01 0.34 ± 0.01 
 
0.14 ± 0.00* 0.22 ± 0.00 0.36 ± 0.00* 
4′-Hydroxymandelic acid 0.08 ± 0.00 0.37 ± 0.02* 0.45 ± 0.02* 
 
0.13 ± 0.01* 0.39 ± 0.01* 0.52 ± 0.01* 
 
0.06 ± 0.00 0.36 ± 0.02* 0.42 ± 0.02* 
Hippuric acid 16.70 ± 1.34 48.80 ± 2.79 65.50 ± 4.14 
 
23.97 ± 0.37* 46.55 ± 6.22 70.52 ± 6.60 
 
26.93 ± 1.71* 49.23 ± 3.41 76.16 ± 5.12* 
3-(3′-Methoxy-4′-hydroxyphenyl)propionic acid 0.07 ± 0.00* 0.16 ± 0.00 0.24 ± 0.00* 
 
0.06 ± 0.00* 0.18 ± 0.00* 0.24 ± 0.01* 
 
0.05 ± 0.00 0.13 ± 0.00 0.18 ± 0.00 
p-Coumaric acid 0.04 ± 0.00 0.18 ± 0.00 0.22 ± 0.01 
 
0.07 ± 0.00* 0.18 ± 0.00 0.25 ± 0.01 
 
0.11 ± 0.00* 0.17 ± 0.00 0.27 ± 0.00* 
Gallic acid 1.78 ± 0.11 8.03 ± 0.50 9.81 ± 0.62 
 
2.66 ± 0.10* 5.51 ± 0.07 8.17 ± 0.18 
 
2.73 ± 0.06* 5.97 ± 0.30 8.70 ± 0.37 
Ferulic acid 0.30 ± 0.01* 0.61 ± 0.02 0.91 ± 0.03 
 
0.37 ± 0.00* 0.64 ± 0.02 1.01 ± 0.03 
 
0.35 ± 0.02* 0.48 ± 0.02 0.84 ± 0.03 
Caffeic acid 0.01 ± 0.00* 0.05 ± 0.00 0.06 ± 0.00 
 
0.02 ± 0.00* 0.03 ± 0.00 0.05 ± 0.00 
 
0.01 ± 0.00* 0.03 ± 0.00 0.04 ± 0.00 
3′-Hydroxyhippuric acid 0.02 ± 0.00 0.11 ± 0.00 0.13 ± 0.00 
 
0.03 ± 0.00* 0.11 ± 0.00 0.14 ± 0.00 
 
0.04 ± 0.00* 0.11 ± 0.00 0.15 ± 0.01 
Sinapic acid 0.04 ± 0.00 0.16 ± 0.01 0.19 ± 0.01 
 
0.05 ± 0.00* 0.11 ± 0.00 0.16 ± 0.01 
 
0.04 ± 0.00* 0.12 ± 0.00 0.16 ± 0.00 
Total 21.46 ± 1.42 67.98 ± 1.94 89.44 ± 3.36 
 
29.26 ± 0.50* 60.35 ± 6.55 89.61 ± 7.05 
 
32.60 ± 1.82* 63.73 ± 3.99 96.33 ± 5.81 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; E5, Mourvèdre (MOU) EA70 skin pomace extract and E6, Alicante (ALI) EA70 skin pomace. SD, standard deviation. 
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Table 69: Quantification of phenolic acids detected in rat urine 0-8 h, 8-24 and 0-24 h after ingestion of seed and skin grape 
pomace extracts in association with verapamil. Data are expressed as µmol ± SD. 
 
VE1 
 
VE5 
 
VE6 
Compounds 0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
Benzoic acid 0.07 ± 0.00 0.15 ± 0.01 0.22 ± 0.01 
 
0.06 ± 0.00 0.20 ± 0.01* 0.27 ± 0.01* 
 
0.06 ± 0.00 0.17 ± 0.00 0.23 ± 0.00* 
Pyrocatechol 0.24 ± 0.00 1.06 ± 0.01* 1.30 ± 0.02* 
 
0.29 ± 0.02* 0.74 ± 0.01 1.03 ± 0.03 
 
0.23 ± 0.00 0.83 ± 0.00 1.05 ± 0.01 
3-Hydroxybenzoic acid 0.04 ± 0.00* 0.16 ± 0.00* 0.20 ± 0.00* 
 
0.04 ± 0.00* 0.12 ± 0.00 0.16 ± 0.00* 
 
0.03 ± 0.00* 0.16 ± 0.01* 0.20 ± 0.01* 
3-Phenylacetic acid 0.05 ± 0.00* 0.11 ± 0.00* 0.17 ± 0.00* 
 
0.05 ± 0.00* 0.13 ± 0.00* 0.18 ± 0.00* 
 
0.04 ± 0.00 0.12 ± 0.01* 0.16 ± 0.01* 
3′-Hydroxyphenylacetic acid 0.13 ± 0.00 0.58 ± 0.03* 0.71 ± 0.03* 
 
0.14 ± 0.00 0.54 ± 0.01 0.68 ± 0.01 
 
0.12 ± 0.00 0.53 ± 0.03 0.65 ± 0.03 
4-Hydroxybenzoic acid 0.04 ± 0.00* 0.16 ± 0.00* 0.20 ± 0.00* 
 
0.04 ± 0.00* 0.14 ± 0.01 0.18 ± 0.01* 
 
0.04 ± 0.00* 0.14 ± 0.00 0.18 ± 0.01* 
4′-Hydroxyphenylacetic acid 0.60 ± 0.00* 1.85 ± 0.07 2.45 ± 0.07 
 
0.62 ± 0.00* 2.11 ± 0.08 2.73 ± 0.08* 
 
0.48 ± 0.00 1.51 ± 0.07 1.99 ± 0.07 
3′,4′-Dimethoxyphenylacetic acid 2.27 ± 0.02* 1.09 ± 0.08 3.36 ± 0.10* 
 
2.58 ± 0.01* 1.34 ± 0.05* 3.92 ± 0.06* 
 
2.14 ± 0.02* 1.40 ± 0.02* 3.54 ± 0.03* 
3-(3′-Hydroxyphenyl)propionic acid 0.33 ± 0.01* 0.97 ± 0.00* 1.30 ± 0.02* 
 
0.36 ± 0.00* 1.04 ± 0.03* 1.40 ± 0.03* 
 
0.31 ± 0.01* 1.24 ± 0.03* 1.54 ± 0.04* 
3-(3′,4′-Dihydroxyphenyl)propionic acid 0.05 ± 0.00 0.14 ± 0.01 0.19 ± 0.01 
 
0.05 ± 0.00 0.13 ± 0.00 0.18 ± 0.01 
 
0.04 ± 0.00 0.16 ± 0.00* 0.20 ± 0.00* 
3-Methoxy-4-hydroxybenzoic acid 0.04 ± 0.00* 0.12 ± 0.01 0.15 ± 0.01* 
 
0.04 ± 0.00* 0.09 ± 0.00 0.13 ± 0.00 
 
0.04 ± 0.00* 0.10 ± 0.01 0.14 ± 0.01 
4′-Hydroxy-3′-methoxyphenylacetic acid 0.12 ± 0.00* 0.23 ± 0.00* 0.35 ± 0.00* 
 
0.14 ± 0.00* 0.23 ± 0.01* 0.37 ± 0.01* 
 
0.10 ± 0.00* 0.25 ± 0.00* 0.35 ± 0.00* 
4′-Hydroxymandelic acid 0.08 ± 0.00* 0.19 ± 0.01 0.27 ± 0.02 
 
0.05 ± 0.00* 0.22 ± 0.02 0.27 ± 0.02 
 
0.07 ± 0.00* 0.24 ± 0.01 0.31 ± 0.01 
Hippuric acid 22.77 ± 0.10* 41.99 ± 1.23* 64.76 ± 1.33* 
 
20.5 ± 0.31* 44.02 ± 0.36* 64.52 ± 0.66* 
 
16.15 ± 0.35 46.99 ± 1.42* 63.14 ± 1.77* 
3-(3′-Methoxy-4′-hydroxyphenyl)propionic acid 0.04 ± 0.00 0.11 ± 0.01 0.15 ± 0.01 
 
0.04 ± 0.00 0.12 ± 0.01 0.16 ± 0.01 
 
0.04 ± 0.00 0.11 ± 0.00 0.15 ± 0.01 
p-Coumaric acid 0.05 ± 0.00* 0.17 ± 0.00* 0.22 ± 0.00* 
 
0.07 ± 0.00* 0.17 ± 0.01* 0.24 ± 0.01* 
 
0.09 ± 0.00* 0.18 ± 0.01* 0.27 ± 0.01* 
Gallic acid 2.05 ± 0.13* 6.21 ± 0.23 8.25 ± 0.36* 
 
1.83 ± 0.05* 4.34 ± 0.21 6.16 ± 0.26 
 
1.69 ± 0.08* 5.64 ± 0.20 7.33 ± 0.28 
Ferulic acid 0.27 ± 0.01* 0.53 ± 0.02* 0.80 ± 0.02* 
 
0.25 ± 0.01* 0.48 ± 0.03 0.73 ± 0.04 
 
0.23 ± 0.01* 0.59 ± 0.00* 0.83 ± 0.01* 
Caffeic acid 0.01 ± 0.00* 0.04 ± 0.00 0.06 ± 0.00 
 
0.01 ± 0.00* 0.03 ± 0.00 0.04 ± 0.00 
 
0.01 ± 0.00 0.04 ± 0.00 0.05 ± 0.00 
3′-Hydroxyhippuric acid 0.02 ± 0.00* 0.14 ± 0.00* 0.17 ± 0.01* 
 
0.03 ± 0.00* 0.1 ± 0.00* 0.13 ± 0.00* 
 
0.02 ± 0.00* 0.15 ± 0.00* 0.17 ± 0.00* 
Sinapic acid 0.03 ± 0.00* 0.15 ± 0.00* 0.18 ± 0.00* 
 
0.03 ± 0.00* 0.1 ± 0.00 0.13 ± 0.00 
 
0.03 ± 0.00* 0.14 ± 0.00* 0.17 ± 0.00* 
Total 29.32 ± 0.02* 56.15 ± 1.23* 85.47 ± 1.25* 
 
27.21 ± 0.38* 56.41 ± 0.63* 83.62 ± 1.01* 
 
21.97 ± 0.47* 60.67 ± 1.28* 82.64 ± 1.74* 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; VE5, Mourvèdre (MOU) EA70 skin pomace extract +verapamil and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. SD, 
standard deviation. 
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Total significant urinary catabolites excreted are illustrated in Figures 58 and 59. 
 
 
Figure 58: Total urinary catabolites excreted at day 1 during 0-8h, 8-24h and 
over 24h after ingestion of grape pomace extracts 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre 
(MOU) EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, 
Alicante (ALI) EA70 skin pomace extract + verapamil. a,A,α: Anova was made to compare values between 
different experimental groups during 0-8h, 8-24 and 24h at day 1. Same letters indicate no significant 
differences between the values (p < 0.05). Data are expressed as mean values in µmol ± Std. 
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Figure 59: Total urinary catabolites excreted at day 7 during 0-8h, 8-24h and 
over 24h after ingestion of grape pomace extracts 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre 
(MOU) EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, 
Alicante (ALI) EA70 skin pomace extract + verapamil. a,A,α: Anova was made to compare values between 
different experimental groups during 0-8h, 8-24 and 24h at day 7. Same letters indicate no significant 
differences between the values (p < 0.05). Data are expressed as mean values in µmol ± Std. 
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The great majority of the phenolic acids were excreted in 8-24 h urine after 
ingestion of grape pomace extracts. Total significant catabolites excreted values over 24 h 
ranged from 0.16 µmol in VE5 to 12.7 µmol in E5 at day 1 and from 3.17 µmol in E6 to 
17.4 µmol in VE1 at day 7. The maximum excretion rates were observed in rats fed with 
E5 followed by VE1 whether at day 1 or day 7.  
At day 1, rats from E5 and VE6 experimental group absorbed higher amount of 
grape pomace polyphenols (182 % and 106% of intake, respectively) (Table 70) unlike rats 
fed with MOU (EA 70) skin pomace extract (i.e.VE5 group) which excreted catabolites at 
a level equivalent to only 1.2 % of ingested polyphenols. At day 7, an increase of 
absorption was evidenced in VE5 group (up to 102 % of intake) followed by E5 group 
(76%). Results are in accordance with those obtained by HPLC-ESI-MS
n
 which showed 
that solution fed to VE5 group (i.e. MOU (EA 70) skin pomace extract + verapamil) 
presented a low bioavailability at day 1 of gavage but increase at day 7 and metabolites 
were observed in high quantities in plasma and body tissues compared to other extracts. 
Using GC-MS, a difference of absorption between E1/VE1 and E6/VE6 was evidenced. At 
day 1, rats fed with GRE1 (EA70) seed pomace extract + verapamil absorbed 12-fold more 
grape pomace polyphenols than those fed with GRE1 (EA70) seed pomace extract alone 
and rats fed with ALI (EA70) skin pomace extract + verapamil absorbed 5-times more 
than those fed with extract without verapamil. At day 7, the same observation can be seen 
but to a lower extent (same absorption rate for E1/VE1 and 4-fold higher for E6/VE6).  
Table 70: Percentage of intake of each type of extracts in urines analysed by 
GC-MS (in %) 
Day 1 
 
E1 VE1 E5 VE5 E6 VE6 
0-8h 2.0 6.1 0.0 0.7 1.9 11.9 
8-24h 1.5 35.8 181.7 0.4 20.0 93.6 
24h 3.5 41.9 181.7 1.2 22.0 105.5 
Day 7 
 
E1 VE1 E5 VE5 E6 VE6 
0-8h 14.2 31.7 69.7 53.5 12.6 17.3 
8-24h 52.2 34.1 6.2 48.7 1.1 36.1 
24h 66.4 65.8 75.9 102.2 13.7 53.4 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre 
(MOU) EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, 
Alicante (ALI) EA70 skin pomace extract + verapamil. 
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Considering the percentage of intake, HPLC-ESI-MS
n
 results did not show clear 
differences in absorption between E1/VE1, E5/VE5 and E6/VE6 group in urine except for 
the fact that polyphenols from MOU (EA70) skin pomace extract had a 27-fold higher 
excretion at day 7 of gavage than at day 1 especially when associated with verapamil (VE5 
group). However, a higher accumulation of metabolites in rats fed with grape pomace 
extracts + verapamil was observed in kidneys. Accumulation of metabolites was 5-fold 
higher in VE1 than E1, 14-fold in VE5 than E5 and 8-fold in VE6 than E6. 
High percentage of intake evidenced by GC-MS might be explained by extensive 
activity of colonic microbiota which degraded phenolic compounds especially flavan-3-ol 
polymers to numerous smaller compounds such as phenolic acids. As grape pomace 
extracts contain monomeric, oligomeric and polymeric flavan-3-ols, different catabolism 
pathway might be involved as proposed by previous studies (Tzounis et al. 2008a; 
Appeldoorn et al. 2009a; Serra et al. 2009). 
III.2.1 GC-MS analysis of faeces 
Rat faeces were collected at 0-8 h and 8-24 h time points after grape pomace extracts 
ingestion at day 1 and day 7 of gavage. A total of 10 phenolic acids were detected in SHR 
faeces (Table 71).  
Table 71: GC-MS identification of phenolic acids detected in faeces following 
ingestion of seed or skin grape pomace extracts 
Rt 
(min) 
Compounds 
Target ion 
(m/z)
a
 
Qualifier ion (m/z)
a
 
6.22 Benzoic acid 179 105, 77, 135, 147, 194 
6.60 Phenylacetic acid 73 147, 164, 193, 91 
7.80 3-(Phenyl)propionic acid 104 75, 147, 207, 179, 222, 91 
10.09 3-(Phenyl)lactic acid 193 73, 147, 220, 295 
10.56 3′-Hydroxyphenylacetic acid 73 147, 164, 281, 296 
10.88 4-Hydroxybenzoic acid 267 147, 223, 193, 282 
11.21 4′-Hydroxyphenylacetic acid 73 179, 164, 296, 281, 252, 147 
13.38 3-(3′-Hydroxyphenyl)propionic acid 205 192, 310, 177, 73 
18.60 3-(3′-Methoxy-4′-hydroxyphenyl)propionic acid 340 209, 192, 73, 310. 179, 222 
27.28 Ferulic acid 338 249, 323, 308, 293, 73, 147 
a
 based on the retention time and mass spectra of commercially available standards and from 
previous published works (Roowi et al. 2010; Stalmach et al. 2013). 
These catabolites were produced from ingested polyphenols degradation by colonic 
microbiota and represented catabolites which have not been absorbed in the colon. Tables 
72-75 showed catabolite quantifications in faeces at day 1 and day 7 in SHR rats which 
received grape pomace extracts.  
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Table 72: Quantification of phenolic acids detected in rat faeces 0-8 h 8-24 h and 0-24 h after ingestion of seed and skin grape 
pomace extracts. Data are expressed as µmol ± SD. 
 
E1 
 
E5 
 
E6 
Compounds 0-8h 8-24h 0-24h 
 
0-8h 8-24h 0-24h 
 
0-8h 8-24h 0-24h 
Benzoic acid 0.35 ± 0.02* 0.67 ± 0.01 1.01 ± 0.02 
 
0.33 ± 0.02* 0.73 ± 0.00 1.06 ± 0.02* 
 
0.18 ± 0.03 0.50 ± 0.02 0.67 ± 0.05 
Phenylacetic acid 0.73 ± 0.05* 0.75 ± 0.02 1.48 ± 0.07 
 
0.50 ± 0.01 0.78 ± 0.03 1.29 ± 0.05 
 
0.43 ± 0.15 0.70 ± 0.02 1.13 ± 0.17 
3’-Phenylpropionic acid 1.61 ± 0.18* 0.78 ± 0.07 2.40 ± 0.25* 
 
1.08 ± 0.12 0.69 ± 0.07 1.77 ± 0.19 
 
0.91 ± 0.37 0.49 ± 0.04 1.40 ± 0.41 
3-(Phenyl)-lactic acid 0.01 ± 0.00* 0.07 ± 0.00 0.08 ± 0.00 
 
0.01 ± 0.00* 0.06 ± 0.00 0.07 ± 0.00 
 
0.01 ± 0.00* 0.08 ± 0.00* 0.09 ± 0.00* 
3’-Hydroxyphenylacetic acid 0.16 ± 0.01 0.17 ± 0.00* 0.34 ± 0.01 
 
0.18 ± 0.00 0.22 ± 0.00* 0.40 ± 0.00* 
 
0.14 ± 0.05 0.10 ± 0.00 0.24 ± 0.05 
4-Hydroxybenzoic acid 0.00 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
 
0.01 ± 0.00 0.03 ± 0.00* 0.03 ± 0.00* 
 
0.00 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 
4’-Hydroxyphenylacetic acid 0.36 ± 0.00 0.52 ± 0.01* 0.88 ± 0.02* 
 
0.41 ± 0.00* 0.43 ± 0.01* 0.84 ± 0.01* 
 
0.36 ± 0.09 0.23 ± 0.01 0.59 ± 0.10 
3-(3'-Hydroxyphenyl)propionic acid 0.03 ± 0.00 0.94 ± 0.02* 0.97 ± 0.02* 
 
0.09 ± 0.01 0.77 ± 0.01* 0.86 ± 0.02* 
 
0.09 ± 0.01 0.59 ± 0.00 0.68 ± 0.01 
3-(3’-Methoxy-4’-hydroxy)phenylpropionic acid 0.01 ± 0.00* 0.06 ± 0.00* 0.07 ± 0.00* 
 
0.01 ± 0.00* 0.04 ± 0.00 0.05 ± 0.01* 
 
0.01 ± 0.00* 0.09 ± 0.01* 0.10 ± 0.01* 
Ferulic acid 0.03 ± 0.00 0.16 ± 0.00 0.19 ± 0.00 
 
0.04 ± 0.00 0.10 ± 0.00 0.13 ± 0.00 
 
0.03 ± 0.00 0.12 ± 0.00 0.15 ± 0.01 
Total 3.28 ± 0.27* 4.15 ± 0.13 7.43 ± 0.40* 
 
2.66 ± 0.17 3.83 ± 0.13 6.49 ± 0.31 
 
2.16 ± 0.71 2.92 ± 0.10 5.08 ± 0.81 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; E5, Mourvèdre (MOU) EA70 skin pomace extract and E6, Alicante (ALI) EA70 skin pomace extract. SD, standard deviation. 
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Table 73: Quantification of phenolic acids detected in rat faeces 0-8 h, 8-24 and 0-24 h after ingestion of seed and skin grape pomace 
extracts in association with verapamil. Data are expressed as µmol ± SD. 
 
VE1 
 
VE5 
 
VE6 
Compounds 0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
Benzoic acid 0.16 ± 0.01 0.46 ± 0.03* 0.62 ± 0.03 
 
0.18 ± 0.02 0.50 ± 0.01* 0.68 ± 0.03 
 
0.10 ± 0.00 0.38 ± 0.01 0.48 ± 0.02 
Phenylacetic acid 0.24 ± 0.00 0.86 ± 0.00* 1.11 ± 0.01 
 
0.23 ± 0.03 0.85 ± 0.02* 1.08 ± 0.05 
 
0.19 ± 0.00 0.56 ± 0.01 0.75 ± 0.01 
3’-Phenylpropionic acid 0.65 ± 0.01 0.79 ± 0.01* 1.44 ± 0.02 
 
0.55 ± 0.07 0.98 ± 0.03* 1.53 ± 0.10 
 
0.34 ± 0.01 0.63 ± 0.01* 0.96 ± 0.03 
3-(Phenyl)-lactic acid 0.01 ± 0.00 0.10 ± 0.00* 0.11 ± 0.00* 
 
0.00 ± 0.00 0.10 ± 0.00* 0.10 ± 0.00* 
 
0.01 ± 0.00 0.06 ± 0.00* 0.06 ± 0.00* 
3’-Hydroxyphenylacetic acid 0.10 ± 0.00 0.25 ± 0.00* 0.35 ± 0.01* 
 
0.07 ± 0.01 0.22 ± 0.00* 0.29 ± 0.01* 
 
0.08 ± 0.00 0.10 ± 0.01 0.17 ± 0.01 
4-Hydroxybenzoic acid 0.00 ± 0.00 0.03 ± 0.00* 0.03 ± 0.00* 
 
0.00 ± 0.00 0.03 ± 0.01* 0.03 ± 0.01 
 
0.00 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
4’-Hydroxyphenylacetic acid 0.21 ± 0.00 0.63 ± 0.01* 0.84 ± 0.01* 
 
0.24 ± 0.02 0.60 ± 0.00* 0.84 ± 0.02* 
 
0.13 ± 0.02 0.10 ± 0.00 0.23 ± 0.02 
3-(3'-Hydroxyphenyl)propionic acid 0.12 ± 0.00 0.99 ± 0.00* 1.11 ± 0.01* 
 
0.05 ± 0.00 0.80 ± 0.01* 0.85 ± 0.01* 
 
0.21 ± 0.01* 0.50 ± 0.01* 0.71 ± 0.02* 
3-(3’-Methoxy-4’-hydroxy)phenylpropionic acid nd nd nd 
 
0.01 ± 0.00 0.04 ± 0.00* 0.04 ± 0.00* 
 
nd nd nd 
Ferulic acid 0.03 ± 0.00 0.32 ± 0.00* 0.34 ± 0.00* 
 
0.03 ± 0.00 0.21 ± 0.01* 0.25 ± 0.01* 
 
0.06 ± 0.00 0.18 ± 0.00* 0.23 ± 0.00* 
Total 1.52 ± 0.03 4.44 ± 0.06* 5.96 ± 0.09* 
 
1.37 ± 0.15 4.33 ± 0.08* 5.70 ± 0.24* 
 
1.11 ± 0.05 2.51 ± 0.06* 3.62 ± 0.11 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; VE5, Mourvèdre (MOU) EA70 skin pomace extract +verapamil and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. SD, 
standard deviation. 
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Table 74: Quantification of phenolic acids detected in rat faeces 0-8 h, 8- 24 h and 0-24 h after daily ingestion of seed and skin 
grape pomace extracts for a period of seven days. Data are expressed as µmol ± SD. 
 
E1 
 
E5 
 
E6 
Compounds 0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
Benzoic acid 0.20 ± 0.01* 1.07 ± 0.03 1.27 ± 0.05 
 
0.25 ± 0.01 0.82 ± 0.05 1.06 ± 0.06 
 
0.15 ± 0.02 0.81 ± 0.05 0.96 ± 0.08 
Phenylacetic acid 0.53 ± 0.03 2.14 ± 0.00* 2.67 ± 0.03* 
 
0.48 ± 0.01 1.60 ± 0.00 2.08 ± 0.01 
 
0.38 ± 0.12 1.82 ± 0.01* 2.20 ± 0.13 
3’-Phenylpropionic acid 1.10 ± 0.08 1.79 ± 0.00 2.89 ± 0.08 
 
1.03 ± 0.11 1.83 ± 0.10 2.85 ± 0.20 
 
0.80 ± 0.29 1.86 ± 0.05 2.66 ± 0.34 
3-(Phenyl)-lactic acid 0.01 ± 0.00* 0.05 ± 0.00 0.06 ± 0.00 
 
0.01 ± 0.00* 0.08 ± 0.00 0.09 ± 0.00 
 
0.01 ± 0.00 0.10 ± 0.01 0.11 ± 0.01* 
3’-Hydroxyphenylacetic acid 0.11 ± 0.00 0.24 ± 0.01 0.35 ± 0.02 
 
0.14 ± 0.00 0.29 ± 0.00* 0.43 ± 0.00* 
 
0.11 ± 0.03 0.19 ± 0.00 0.30 ± 0.03 
4-Hydroxybenzoic acid 0.00 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
 
0.00 ± 0.00 0.03 ± 0.00 0.04 ± 0.00 
 
0.00 ± 0.00 0.03 ± 0.00 0.04 ± 0.00 
4’-Hydroxyphenylacetic acid 0.21 ± 0.00 0.66 ± 0.00 0.87 ± 0.00 
 
0.29 ± 0.00 0.68 ± 0.00* 0.98 ± 0.00 
 
0.24 ± 0.05 0.92 ± 0.01* 1.16 ± 0.06* 
3-(3'-Hydroxyphenyl)propionic acid 0.02 ± 0.00 0.75 ± 0.05 0.77 ± 0.05 
 
0.06 ± 0.01 0.53 ± 0.01 0.60 ± 0.02 
 
0.07 ± 0.02 0.77 ± 0.02 0.83 ± 0.03 
3-(3’-Methoxy-4’-hydroxy)phenylpropionic acid 0.00 ± 0.00* nd 0.00 ± 0.00 
 
0.01 ± 0.00* 0.00 ± 0.00 0.01 ± 0.00* 
 
0.01 ± 0.00* 0.06 ± 0.00* 0.07 ± 0.00* 
Ferulic acid 0.02 ± 0.00 0.24 ± 0.00 0.26 ± 0.00 
 
0.03 ± 0.00 0.22 ± 0.00 0.25 ± 0.01 
 
0.02 ± 0.01 0.39 ± 0.02* 0.41 ± 0.03* 
Total 2.21 ± 0.12 6.95 ± 0.11 9.16 ± 0.23 
 
2.30 ± 0.14 6.07 ± 0.17 8.38 ± 0.31 
 
1.79 ± 0.54 6.95 ± 0.18 8.74 ± 0.71 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: E1, Grenache (GRE1) EA70 seed 
pomace extract; E5, Mourvèdre (MOU) EA70 skin pomace extract and E6, Alicante (ALI) EA70 skin pomace extract. SD, standard deviation. 
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Table 75: Quantification of phenolic acids detected in rat faeces 0-8 h, 8-24 h and 0-24 h after daily ingestion of seed and skin 
grape pomace extracts in association with verapamil for a period of seven days. Data are expressed as µmol ± SD. 
 
VE1 
 
VE5 
 
VE6 
Compounds 0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
 
0-8h 8-24h 24h 
Benzoic acid 0.16 ± 0.01 0.87 ± 0.00* 1.03 ± 0.01 
 
0.24 ± 0.00 1.05 ± 0.01* 1.29 ± 0.01* 
 
0.10 ± 0.01 0.71 ± 0.04 0.81 ± 0.05 
Phenylacetic acid 0.32 ± 0.00 1.56 ± 0.04* 1.88 ± 0.04 
 
0.46 ± 0.02 1.67 ± 0.08* 2.13 ± 0.10* 
 
0.21 ± 0.01 1.28 ± 0.06 1.49 ± 0.07 
3’-Phenylpropionic acid 0.82 ± 0.02 1.84 ± 0.03* 2.66 ± 0.05 
 
0.92 ± 0.05 2.09 ± 0.02* 3.02 ± 0.07* 
 
0.37 ± 0.02 1.57 ± 0.09 1.95 ± 0.11 
3-(Phenyl)-lactic acid 0.01 ± 0.00 0.11 ± 0.03* 0.12 ± 0.03 
 
0.00 ± 0.00 0.08 ± 0.00 0.08 ± 0.00 
 
0.01 ± 0.00 0.05 ± 0.00 0.06 ± 0.00 
3’-Hydroxyphenylacetic acid 0.11 ± 0.00 0.20 ± 0.01* 0.31 ± 0.02* 
 
0.12 ± 0.01 0.28 ± 0.00* 0.40 ± 0.01* 
 
0.07 ± 0.00 0.15 ± 0.00 0.22 ± 0.00 
4-Hydroxybenzoic acid 0.00 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 
 
0.00 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 
 
0.00 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
4’-Hydroxyphenylacetic acid 0.20 ± 0.01 0.42 ± 0.00 0.62 ± 0.01 
 
0.35 ± 0.02 0.73 ± 0.03* 1.08 ± 0.05* 
 
0.11 ± 0.01 0.17 ± 0.00 0.28 ± 0.01 
3-(3'-Hydroxyphenyl)propionic acid 0.13 ± 0.00* 0.38 ± 0.04* 0.50 ± 0.04* 
 
0.07 ± 0.00 0.59 ± 0.01* 0.66 ± 0.01* 
 
0.18 ± 0.00* 0.40 ± 0.00* 0.59 ± 0.00* 
3-(3’-Methoxy-4’-hydroxy)phenylpropionic acid nd 0.03 ± 0.00* 0.03 ± 0.00* 
 
0.01 ± 0.00 0.06 ± 0.00* 0.07 ± 0.01* 
 
nd nd nd 
Ferulic acid 0.03 ± 0.00 0.26 ± 0.04* 0.30 ± 0.04 
 
0.04 ± 0.00 0.35 ± 0.01* 0.39 ± 0.01* 
 
0.05 ± 0.00 0.21 ± 0.01 0.26 ± 0.01 
Total 1.78 ± 0.05 5.71 ± 0.19* 7.49 ± 0.24* 
 
2.22 ± 0.11 6.93 ± 0.17* 9.15 ± 0.28* 
 
1.10 ± 0.05 4.57 ± 0.20* 5.67 ± 0.25 
* Metabolites that were excreted in significantly higher amounts compared to their respective control (p< 0.05). SHR rats fed with: VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; VE5, Mourvèdre (MOU) EA70 skin pomace extract +verapamil and VE6, Alicante (ALI) EA70 skin pomace extract + verapamil. SD, 
standard deviation. 
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Significant catabolites excreted from different SHR experimental groups compared to 
their controls were presented in Figure 60 for day1 and Figure 61for day 7. 
 
 
 
Figure 60: Total faecal catabolites excreted 0-8 h, 8-24h and 0-24 h after 
ingestion of grape pomace extracts 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) 
EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) 
EA70 skin pomace extract + verapamil. a,A,α: Anova was made to compare values between different 
experimental groups during 0-8h, 8-24 and 24h at day 1. Same letters indicate no significant differences 
between the values (p < 0.05). Data are expressed as mean values in µmol ± Std. 
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Figure 61: Total faecal catabolites excreted 0-8 h, 8-24 h and 0-24 h after 
ingestion of grape pomace extracts for a period of seven days 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) 
EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) 
EA70 skin pomace extract + verapamil. a,A,α: Anova was made to compare values between different 
experimental groups during 0-8h, 8-24 and 24h at day 7. Same letters indicate no significant differences 
between the values (p < 0.05). Data are expressed as mean values in µmol ± Std. 
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The highest faecal excretion was observed in rats from E1 group with a maximum 
excretion of 4.3 µmol followed by E5 group with 3.23 µmol excreted at day 1. At day 7, the 
maximum excretion was observed in VE5 experimental group (9.03 µmol) compared to E5 
group which only excreted 0.44 µmol. 
Table 76 showed the corresponding percentage of intake of polyphenols excreted 
from different SHR experimental group. Higher catabolites were excreted at day 1 than at day 
7, showing once again a better absorption of polyphenols by SHR rats over time. The highest 
excretion rate was evidenced in rat fed with MOU (EA70) skin pomace extract and excretions 
corresponded to 54 % at day 1 and 108 % at day 7 of polyphenols ingested, suggesting 
extensive catabolism of polyphenols contain in this extract by colonic microbiota. 
Table 76: Percentage of intake of each type of extracts in faeces analysed by GC-
MS 
Day 1 
 
E1 VE1 E5 VE5 E6 VE6 
0-8h 23 0 21 0 0 2 
8-24h 7 31 6 54 2 7 
0-24h 29 31 28 54 2 9 
 
Day 7 
 
E1 VE1 E5 VE5 E6 VE6 
0-8h 0 0 1 0 0 2 
8-24h 9 6 2 108 10 5 
0-24h 9 6 4 108 11 7 
SHR rats fed with: E1, Grenache (GRE1) EA70 seed pomace extract; VE1, Grenache (GRE1) EA70 
seed pomace extract + verapamil; E5, Mourvèdre (MOU) EA70 skin pomace extract; VE5, Mourvèdre (MOU) 
EA70 skin pomace extract +verapamil; E6, Alicante (ALI) EA70 skin pomace extract and VE6, Alicante (ALI) 
EA70 skin pomace extract + verapamil. 
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III.3. Conclusions 
This chapter described the bioavailability of polyphenolic compounds of three 
different grape pomace extracts, in which two of them exerted anti-hypertensive activity with 
or without co-ingestion with verapamil. HPLC-ESI-MS
n
 permitted the detection of a wide 
array of metabolites including glucuronide, sulfate and methylated derivatives of flavan-3-ol 
conjugates, non-, mono- and di-substituted phenyl structures in the form of glucuronide and 
sulfate conjugates, or as a combination of methoxy-sulfate derivatives of 
hydroxyphenylvalerolactone conjugates, hydroxyphenylvaleric acid conjugates, 
hydroxyphenylacetic acid conjugates, hydroxybenzoic acid conjugates, 
hydroxyphenylpropionic acid conjugates, hydroxycinnamic acid conjugates and 
hydroxyhippuric acid conjugates. A total of 61 metabolites were detected but only 18 in 
amounts that facilitated quantification. It should be noted that in the absence of reference 
compounds quantification using aglycone standards might introduce varying and unmeasured 
error factors due to the different aglycone/glucuronide and aglycone/sulfate SIM/SRM dose 
response curves.  
Urine analysis by HPLC-ESI-MS
n
 revealed a higher urinary excretion of metabolites 
in SHR rats fed with grape pomace extracts and verapamil. However, considering the 
percentage of intake corresponding to the excreted amount in urine, the data did not show 
clear differences between E1/VE1 (1.02 vs 1.29 % at day 1 and 1.52 % vs 1.08 % at day 7) 
and E6/VE6 (1.02% vs 1.02% at day1 and 1.42% vs 1.64% at day 7) except for the fact that 
polyphenols from MOU (EA70) skin pomace extract were 27-fold better absorb at day 7 of 
gavage than at day 1, especially when co-ingested with verapamil (0.16 % at day 1 to 4.25 % 
at day 7). This result suggested that polyphenols were better absorbed or accumulated over 
time in SHR rats.  
A total of 11 metabolites were found in SHR rat plasma collected 4 h after grape 
pomace extracts ingestion. Plasma did not contain any of the original grape pomace extract 
flavan-3-ols and procyanidins but contained glucuronide, methyl-glucuronide and di-methyl-
glucuronide of (epi)catechin and glucuronide, sulfate, non- and mono-substitutes 
valerolactones and valeric acid. These metabolites were also detected in urine with the 
exception of the di-methyl-(epi)catechin-O-glucuronide. Metabolites were mainly present as 
glucuronides rather than sulfates. Generally, lower concentrations of metabolites were 
observed in plasma than in urine. The highest metabolites concentration was observed in 
268 
 
plasma from VE5 experimental group in which SHR rats were fed MOU (EA70) skin pomace 
extracts + verapamil. In fact, an amount up to 4.6 ± 0.07 nmol and a recovery of 0.15 % were 
observed compared to other plasma in which only a 0.03 % to 0.09 % recovery was found. 
These results are in accordance with those obtained in urine, showing a high intake of grape 
pomace polyphenols in VE5 experimental group (4.25 %). The E5 group also showed 
substantial urinary excretion (poly)phenols (4.41 % of intake) while no more than 0.09 % of 
intake accumulated in plasma. This indicates a rapid excretion of metabolites from the 
circulatory system. Grape pomace polyphenols were less well absorbed by rats fed with other 
extracts (i.e. E1, VE1, E6 and VE6), as illustrated by low levels in urine and plasma. 
In SHR rat tissues, no (epi)catechin conjugates were found but only the 5-
(hydroxyphenyl)-γ-valerolactone-O-glucuronide (m/z 383/207, 163) and the 5-
(hydroxyphenyl)-γ-valerolactone-O-sulfate (m/z 287/207, 163) was detected and quantified 
by SRM mode. Liver, heart and kidneys all contained these metabolites. It was observed that 
rats fed with MOU (EA70) skin pomace extract + verapamil (VE5 SHR group) there was a 
higher accumulation of these metabolites. Likewise there were higher accumulations of 
metabolites after ingestion of MOU (EA70) skin pomace extract + verapamil than other 
extracts, especially in the kidneys and liver (0.14 % and 1.64 %, respectively). In addition, a 
higher accumulation of metabolites in rats fed with grape pomace extracts + verapamil was 
also observed in kidneys. Accumulation of metabolites was 5-fold higher in VE1 than E1, 14-
fold in VE5 than E5 and 8-fold in VE6 than E6. 
Faeces were screened for the original grape pomace extract flavan-3-ols and 
procyanidins using HPLC-MS
n
 in SIM mode for the detection of flavan-3-ol oligomers and 
monomers. Seven compounds were identified and quantified, including (epi)catechin (m/z 
289/245, 205), (epi)catechin gallate (m/z 441/289,169), two dimers (m/z 577/425, 407, 289), 
trimers (m/z 865/577, 289), two gallo(epi)catechin trimers (m/z 881, 729, 577, 407) and 
tetramers (m/z 153/865, 577). Faecal phenolic excretion occurred predominantly at 8-24 h 
time point. Recoveries ranged from 0.3 % in VE6 to 2.31 % in E5 at day 1 and 1.03 % in 
VE1 to 1.72 % in E5 after seven days of grape pomace extracts ingestion. 
Urine and faeces were further analysed for catabolites using GC-MS techniques. A 
total of 21 phenolic acids and aromatic compounds were identified in urines of SHR rats. The 
great majority of the phenolic acids were excreted in 8-24 h urine after grape pomace extract 
ingestion. Total 24 h excretion of catabolites over 24 h ranged from 0.16 µmol in VE5 to 12.7 
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µmol in E5 at day 1 and from 3.17 µmol in E6 to 17.4 µmol in VE1 at day 7. Results 
obtained by GC-MS confirmed those obtained by HPLC-ESI-MS
n
 and showed an increase of 
bioavailability of MOU (EA 70) skin pomace extract + verapamil which was low at day 1 but 
increased up to 85-fold at day 7 (1.2 % of intake at day 1 and 102 % of intake at day 7). 
Using GC-MS, the difference of absorption between E1/VE1 and E6/VE6 was better 
evidenced. At day 1, rats fed with GRE1 (EA70) seed pomace extract + verapamil absorbed 
12-fold more grape pomace polyphenols than those fed with GRE1 (EA70) seed pomace 
extract alone and rats fed with ALI (EA70) skin pomace extract + verapamil absorbed 5-
times more than those fed with an extract without verapamil. At day 7, the same observation 
can be evidenced but with a lower extent (same absorption rate for E1/VE1 and 4-fold higher 
for E6/VE6).  
Analysis of faeces by GC-MS reflected phenolic acids which had not been absorbed 
in the colon. Higher catabolites were excreted at day 1 than at day 7, showing once again a 
better absorption of polyphenols by SHR rats over time. The highest excretion rate was 
evidenced in rat fed with MOU (EA70) skin pomace extract and excretions corresponded to 
54 % and 108 % of polyphenols ingested, suggesting extensive catabolism of polyphenols 
contain in this extract by colonic microbiota. 
This study investigated the bioavailability of different grape pomace extracts in SHR 
rats, including both phase II and colonic microbial metabolism. Grape pomace extracts and 
grape pomace extracts associated to verapamil were absorb as phase II metabolites mainly 
including glucuronide, O-methyl glucuronide, sulfate, and O-methyl sulfate derivatives of 
(epi)catechin which arise from the metabolism of monomeric flavan-3-ols. The detection of 
microbial- derived metabolites of flavan-3-ols, hydroxyphenyl-γ-valerolactones in their 
glucuronide and sulfate forms confirmed the absorption of metabolites derived from both 
monomeric and polymeric flavan-3-ols from grape pomace extracts and subsequent 
conjugation in the liver. Numerous metabolites derived from further microbial degradation of 
hydroxyvalerolactones were also detected. The urinary excretion of these metabolites 
accounted for a larger proportion of the total polyphenol ingested than phase II metabolites of 
monomeric flavan-3-ols, indicating the important role of intestinal bacteria in the metabolism 
of highly polymerized compounds. All these metabolites may have exerted biological effects 
during the period in which they circulated in the bloodstream. 
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The association of grape pomace extracts with verapamil showed to have beneficial 
effects according to results obtained from in vivo study on SHR rats. GRE1 (EA70) seed 
pomace extract (fed to rats belonging to EI/VE1experimental group) and ALI (EA70) skin 
pomace extract (fed to rats belonging to E6/VE6 experimental group) administrated alone or 
in association to verapamil were able lower blood pressure of SHR rats whereas MOU 
(EA70) skin pomace extract (fed to rats belonging to E5/VE5 experimental group) 
administrated alone or in association with verapamil did not exerted any anti-hypertensive 
effects. Bioavailability studies indicated that rats fed with grape pomace extracts in 
association with verapamil excreted higher amount of metabolites and catabolites than those 
administrated with only grape pomace extracts. However, the intake of polyphenols in E1 and 
E6 group appeared to be slightly higher to those fed with verapamil (VE1 and VE6). Unlike 
E1/VE1 and E6/VE6, E5/VE SHR rats absorbed higher amounts of polyphenols. Analysis by 
HPLC-ESI-MS
n
 showed at day 1 of feeding that E5 group exhibited the highest polyphenols 
excretion over 24 h (1.57 %) compared to other groups (1.02 % - 1.29%). The lowest 
excretion occurred with the VE5 group at 0.16 % of intake. The same observation was 
obtained by GC-MS in which E5 group exhibited the highest 0-24 h excretion of catabolites 
(181% of polyphenol intake) compared to other groups (3.5% - 105.5%). Once again the VE5 
group showed the lowest excretion level (1.2 %). After 7 days of ingestion, E5 group still 
appeared to exhibit the 0-24 h excretion, and hence absorption, of the ingested polyphenols 
(4.41 % of intake estimated by HPLC-ESI-MS
n
 and 76 % by GC-MS). Unlike day 1, 
excretion by VE5 rats was than other groups (4.25 % of intake was detected by HPLC-ESI-
MS
n
 and 102 % by GC-MS). Substantial accumulation of metabolites was evidenced in VE5 
rat tissues and plasma.  
Anti-hypertensive effects of polyphenols have been confirmed in several studies (Al-
Awwadi et al. 2004; Galisteo et al. 2004; Sarr et al. 2006; Perez-Vizcaino et al. 2009) and 
might be linked to the capacity of polyphenols to regulate the eNOS and NADPH oxidase 
activity. Verapamil is a P-gp inhibitor and multi-drug resistance (MDR) reversal agent. 
Several studies have demonstrated that polyphenols inhibit P-gp transport affecting the 
bioavailability and uptake of certain drugs (Jodoin et al. 2002; Kitagawa 2006; Eichhorn et al. 
2012). Therefore, considering these observations and those obtained in this study, anti-
hypertensive effects could be attributed to the action of polyphenols contained in grape 
pomace extracts (in the case rats from E1 and E6 group) and/or by the action of verapamil. In 
E1, E5 and E6, polyphenols, especially flavan-3-ol monomers and procyanidins, contained in 
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each grape pomace extracts were responsible for the non- or anti-hypertensive effect. In fact, 
GRE1 (EA70) seed pomace extract and ALI (EA70) skin pomace extract were showed to 
contain higher levels of polyphenols than MOU (EA70) skin pomace extract. In VE1 and 
VE6 group, verapamil might allow a higher absorption of polyphenols or vice versa. The 
anti-hypertensive might be due to the action of polyphenols and/or verapamil. In the case of 
E5/VE5 group, polyphenols was showed to be highly absorbed in E5 group and when 
associated to verapamil, the polyphenol metabolite/catabolite urinary excretion, and hence 
absorption, increased. Thus, verapamil might allow better absorption of polyphenols, but, 
because of low concentration or the composition of MOU (EA70) skin pomace extract no 
anti-hypertensive effects were observed.  
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Résumé chapitre 4 
Dans un premier temps, différents groupes expérimentaux ont été mis en place et les 
extraits de pépins et pellicules de raisins et de marcs ont été administrés seuls ou en 
association avec le vérapamil aux SHR. La pression artérielle a été suivie et l’effet des 
extraits sur l’hypertension a été apprécié. Trois extraits ont été choisis afin d’étudier leur 
biodisponibilité. Les urines, fèces, plasmas et organes (foie, reins et cœur) ont été récoltés. 
Les métabolites ont été identifiés et quantifiés par HPLC-UV-MS
n
 et GC-MS. 
Les expériences in vivo ont été réalisées sur un modèle animal de rat génétiquement 
hypertendus communément appelé SHR pour Spontaneaously Hypertensive Rats. Parmi les 
modèles de rats hypertendus, le SHR constitue le modèle de choix pour le screening des 
agents anti-hypertenseurs (Wada et al. 1996; Bravo et al. 1998; Maghrani et al. 2005; 
Quiñones et al. 2010, Mukai et al. 2011; Yang et al. 2012) et il est actuellement le plus utilisé 
pour étudier l’HTA. Leurs contrôles normotendus sont les rats Wistar-Kyoto (WKY). La 
souche de rat SHR a été sélectionnée par Okamota et al. (1963) dans les années 60, à partir de 
deux rats Wistar de leur élevage à Kyoto présentant une pression artérielle relativement 
élevée et persistante pendante plus d’un mois. Par croissement intra-génération successif, ils 
obtiennent à partir de la génération F3 approximativement 100 % de rats spontanément 
hypertendus. La naissance d’une telle souche hypertendue uniquement par reproduction 
démontre l’extrême importance du facteur génétique dans la transmission de cette pathologie. 
Les résultats des expériences in vivo démontrent que certains extraits administrés 
seuls ou en association avec le vérapamil possèdent un effet anti-hypertenseur. Cette capacité 
a été mise en évidence une fois que les extraits de pépins de marcs de GRE1 (EA70) et SYR1 
(EA70) et de pellicules de marcs d’ALI (EA70) ont été administrés seuls ou lorsque les 
extraits de pépins de marcs GRE1 (EA70) et SYR1 (EAQ) et les pellicules de marcs d’ALI 
(EA70) et SYR2 (EAQ) ont été administrés en association avec le vérapamil. Dans la 
dernière expérience in vivo, les pellicules de marcs de SYR1 (EA70) en association avec le 
vérapamil révèle un effet inverse en élevant la pression systolique. Le tableau ci-dessous 
résume l’efficacité in vivo des extraits de pépins et de pellicules de marcs testés seuls ou en 
association avec le vérapamil sur la pression artérielle (PA).  
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Table 1: Effet in vivo des extraits de pépins et pellicules de marcs sur la pression 
artérielle. 
Extraits de marcs testés 
Temps de 
traitement 
Effet sur la 
PA 
Efficacité 
GRE1 pep (EA70) 3 semaines + Effet indirect, effet rebond, + 19% 
SYR1 pep (EA70) 3 semaines + Effet indirect, effet rebond, +24 % 
SYR2 pell (EA70) 3 semaines ~ - 
CAR pep (EA70) 3 semaines ~ - 
MOU pell (EA70) 3 semaines ~ - 
ALI pell (EA70) 3 semaines + Effet indirect, effet rebond, +16 % 
    
GRE1 pep (EA70) + vérapamil 3 semaines + Effet direct, -26 % 
SYR1 pep (EA70) +vérapamil 3 semaines ~ - 
SYR2 pell (EA70) + vérapamil 3 semaines ~ - 
CAR pep (EA70) + vérapamil 3 semaines ~ - 
MOU pell (EA70) +vérapamil 3 semaines ~ - 
ALI pell (EA70) + vérapamil 3 semaines + Effet direct, -13 % 
    
SYR1 pep (EAQ) + vérapamil 2 semaines + Effet direct, -14 % 
SYR1 pell (EAQ) + vérapamil 2 semaines ~ - 
ALI pell (EAQ) + vérapamil 2 semaines ~ - 
GRE2 Pell (EA70) + vérapamil 2 semaines ~ - 
    
CAR pep (EAQ) + vérapamil 1 semaine ~ - 
GRE2 pell (EAQ) + vérapamil 1 semaine ~ - 
SYR2 pell (EAQ) + vérapamil 1 semaine + Effet direct, -11 % 
SYR1 pell (EA70) + vérapamil 1 semaine − Effet direct, +15 % 
Les extraits ont été administrés à une dose de 21mg/kg/jour de polyphénols par jour ce qui équivaut à 
une consommation de polyphénols contenus dans 500 mL de vin rouge par un adulte de 70kg et le vérapamil à 
une dose de 40 mg/kg/jour. Pell, pellicules; pép, pépins; +, effet positif sur la régulation de l’hypertension; −, 
effet négatif sur la régulation de l’hypertension ; ~, pas d’effet. L’efficacité des extraits administrés aux rats 
SHR a été illustrée par le pourcentage de variation (%) de la pression artérielle avant et après l’ingestion des 
extraits.  
Les extraits de marcs administrés seuls régulent la pression artérielle et a été démontré 
par l’effet rebond bien connu dans ce type de traitement. Une augmentation de + 19%, +24% 
et +16% a été observée pour les extraits de pépins GRE1 (EA70) et SYR1 (EA70) et de 
pellicules ALI (EA70) après 3 semaines de traitement. Ingéré en association avec le 
vérapamil, les pépins de GRE1 (EA70) diminuent la pression artérielle de -26% et les 
pellicules d’ALI (EA70) de -13% après 3 semaines de traitement et de -14% après 2 semaines 
de traitement. De plus, les expériences montrent qu’une semaine suffise pour induire des 
effets antihypertenseurs dans le groupe de rats SHR ayant reçu l’extrait de pellicules de marcs 
SYR2 (EAQ) + vérapamil dans lequel une réduction de 11 % a été observé et des effets pro-
hypertenseurs dans le groupe de rat ayant reçu l’extrait de pellicules SYR1 (EA70) + 
vérapamil (+15%). 
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Selon le type d’extraits administrés aux rats SHR, il est possible de moduler les effets 
antihypertenseurs du médicament. La composition des extraits de marcs en composés 
phénoliques joue un rôle crucial et devrait être pris en compte. Malgré une quantité plus 
importante en composés phénoliques dans les extraits EA70, les extraits EAQ ont tout de 
même prouvé leurs efficacités dans la régulation de la pression artérielle.  
Afin d’approfondir les connaissances sur le niveau d’absorption des polyphénols et 
leurs contributions aux effets antihypertenseurs, une étude de biodisponibilité des trois 
extraits de marcs administrés seuls ou associés au vérapamil, dont deux ayant montré une 
capacité anti-hypertenseur, a été réalisée par la suite. L’HPLC-ESI-MSn a permit la détection 
de grandes variétés de métabolites y compris les dérivés méthylés, glucuronidés et sulfatés de 
flavan-3-ols, des structures non-, mono- et di- phényles glucuronides et sulfates ou même des 
methoxy-sulfates d’acide hydroxyphenylvalérolactone, d’acide hydroxyphenylvalerique, 
d’acide hydroxyphenylacétique, d’acide hydroxybenzoique, d’acide 
hydroxyphenylpropionique, d’acide hydroxycinnamique et d’acide hydroxyhippurique. Un 
totale de 61 métabolites a été détecté mais seulement 18 ont été quantifiés. En l’absence de 
standards glucuronidés et sulfatés, une quantification par le biais d’aglycones pourrait 
introduire des erreurs de quantification due a des réponses SIM/SRM différentes entre 
aglycones/glucuronides et aglycones/sulfates. L’analyse des urines par HPLC-ESI-MSn 
révèle une plus grande excrétion de métabolites chez les SHR ayant reçu des extraits de 
marcs associés au vérapamil.  
Compte tenu du pourcentage de l'apport correspondant à la quantité excrétée dans 
l'urine, les données n'ont pas montré de différences significatives entre E1/VE1 (1,02% vs 
1,29% au 1
er
 jour de gavage et de 1,52% vs 1,08% au 7
ème
 jour de gavage) et E6/VE6 (1,02 % 
vs 1,02% au 1
er
 jour de gavage et 1,42% vs 1,64% au 7
ème
 jour de gavage), excepté pour les 
polyphénols contenus dans les extraits de pellicules de MOU (EA70) qui sont 27 fois mieux 
absorber au 7
ème
 jour de gavage qu’au 1er jour de gavage, en particulier lorsqu’il est associé 
au vérapamil (0,16% 1
er
 jour de gavage à 4,25% au 7
ème
 jour de gavage). Ce résultat suggère 
qu’au fil du temps, les polyphénols sont mieux absorbés ou accumulés chez les rats SHR. 
Concernant les plasmas, un total de 11 métabolites composé de dérivés glucuronidés, 
méthyl-glucuronidés et di-méthylglucuronidés d’épicatéchine ainsi que des dérivés 
glucuronidés, sulfatés, non- et mono-substitués de valerolactone et d’acide valérique ont été 
retrouvés 4 heures suivant l’ingestion des extraits de marcs. Aucun composé détecté dans les 
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extraits de pépins et pellicules de marcs tels que les flavan-3-ols et procyanidins n’a été 
décelé dans les plasmas. Ces métabolites ont aussi été retrouvés dans les urines à l’exception 
du di-méthyl-(épi)catéchin-O-glucuronide et sont principalement présents sous forme de 
glucuronides que sulfates. Généralement, de plus faibles concentrations ont été retrouvées 
dans les plasmas que dans les urines. La plus forte concentration a été décelée dans les 
plasmas des rats SHR appartenant au groupe expérimental VE5, ayant reçu l’extrait de 
pellicules MOU (EA70) + verapamil. En effet, jusqu’à 4,6 ± 0,07 nmol et 0.15 % 
d’absorption a été observé par rapport aux autres plasmas dans lequel seulement un taux de 
0.03% à 0.09% a été retrouvée. Ces résultats sont en accords avec ceux observés dans les 
urines montrant une importante absorption des polyphenols dans le groupe expérimental VE5 
(4.25%). Le groupe E5 excrète une grande quantité de polyphénols dans l’urine (4.41% de 
polyphénols ingérés) alors qu’une petite quantité a été détectée dans les plasmas. Ce résultat 
indique une rapide excrétion des métabolites du système circulatoire. Une faible absorption 
illustrée par une légère excrétion de métabolites dans les urines et plasmas a été mise en 
évidence dans les groupes de rat (E1, VE1, E6 et VE6).  
Dans les tissus des rats SHR (foie, reins et cœur), aucuns dérivés de l’épicatéchine 
n’ont été retrouvés mis à part la 5-(hydroxyphényl)-γ-valérolactone-O-glucuronide (m/z 
383/207, 163) et la 5-(hydroxyphényl)-γ-valérolactone-O-sulfate (m/z 287/207, 163) qui ont 
été détectées et quantifiées en mode SRM. Il a été observé que les rats ayant reçu les extraits 
de pellicules de MOU (EA70) + vérapamil (groupe VE5) concentre une plus forte 
concentration de métabolites dans leurs tissus par rapport aux autres groupes de rats SHR, 
particulièrement dans les reins et le foie (0.14% et 1.64%, respectivement). De plus, une plus 
importante accumulation de métabolites dans les rats administrés avec des extraits + 
vérapamil a été décelée dans les reins avec 5 fois plus dans le groupe VE1 que dans le groupe 
E1, 14 fois plus dans VE5 que dans E5 et 8 fois plus dans VE6 que dans E6.  
Les fèces ont été dépistés pour les composés contenus dans les extraits de marcs par 
HPLC-MS
n
 en mode SIM pour la détection d'oligomères et de monomères flavan-3-ols. Sept 
composés incluant l’épicatéchine (m/z 289/245, 205), l’ (épi)catéchine gallate (m / z 441/289, 
169), un dimère (m/z 577/425, 407, 289), un trimère (m/z 865/577, 289), deux gallo 
(épi)catéchine trimères (m/z 881, 729, 577, 407) et un tétramère (m/z 153/865, 577) ont été 
détectés. 
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L’excrétion fécale de polyphénols survient principalement entre 8-24 h. Le 
pourcentage de polyphénols ingérés et excrétés dans les fèces varie de 0.3% dans VE6 à 
2.31% dans E5 au 1
er
 jour de gavage et de 1.03% dans VE1 à 1.72% dans E5 après sept jours 
de gavage avec les extraits de marcs.  
Les urines et les fèces ont été analysés pour les catabolites utilisant les techniques de 
GC-MS. Un total de 21 acides phénoliques a été identifié dans les urines des rats SHR. La 
grande majorité des acides phénoliques ont été excrétée dans l'urine après 8-24 h d’ingestion 
d’extraits de pépins et pellicules de marcs. L’excrétion de catabolites au bout de 24 h varie de 
0,16 µmol dans VE5 à 12,7 µmol dans E5 au 1
er
 jour de gavage et de 3,17 µmol dans E6 à 
17,4 µmol dans VE1 au 7
ème
 jour de gavage. Les résultats obtenus par GC-MS confirment 
ceux obtenus par HPLC-ESI-MS
n
 et ont montré une augmentation de la biodisponibilité de 
l’extrait de pellicule MOU (EA 70) associé au vérapamil. En effet, au 7ème jour de gavage, 85 
fois plus de polyphénols a été absorbé par rapport au 1
er
 jour de gavage (1.2 % de 
polyphénols ingérés détecté dans les urines au 1
er
 jour et 102% au 7
ème
 jour). Au 1
er
 jour de 
gavage, les rats ayant reçu des les extraits de pépins de GRE1 (EA70) + vérapamil ont 
absorbé 12 fois plus de polyphénols que ceux ayant reçu GRE1 (EA70) seul et les rats ayant 
reçu l’extrait de pellicules de marcs ALI (EA70) + vérapamil ont absorbés 5 fois plus de 
polyphénols que ceux ayant eux l’extrait seul. Au 7ème jour de gavage, la même observation a 
été constatée mais avec une plus faible ampleur (même taux d’absorption pour E1/VE1 et 4 
fois plus pour E6/VE6). 
L’analyse des fèces par GC-MS reflète les acides phénoliques qui n’ont pas été 
absorbés au niveau du colon. Les résultats montrent une plus importante quantité de 
métabolites excrétés au 1
er
 jour de gavage par rapport au 7
ème
 jour illustrant encore une fois 
de plus une meilleure absorption des polyphénols au cours du temps. Le plus fort taux 
d’excrétion a été détecté dans les fèces des rats administré par l’extrait MOU (EA70) et 
correspond à 54 % de polyphénols ingérés au 1
er
 jour de gavage et à 108% de polyphénols 
ingérés au 7
ème
 jour de gavage. Cette observation suggère un catabolisme extensif des 
polyphénols contenus dans cet extrait par la microflore intestinale.  
Cette étude met en évidence la biodisponibilité des extraits de pépins et de pellicules 
de marcs des rats SHR incluant à la fois le métabolisme de phase II et de la microflore 
intestinale. Les extraits de marcs administrés seuls et en association au vérapamil sont 
absorbés en tant que métabolites de phase II présent sous forme de dérivé O-
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methylglucuronidé, sulfaté, O-methylsulfaté d’(épi)catéchine dérivant du métabolisme des 
monomères de flavan-3-ols. La détection de métabolites microbiens dérivés de flavan-3-ols, 
d’hydroxyphényl-γ-valérolactones sous leurs formes glucuronidés et sulfatés confirme 
l'absorption des métabolites dérivés des flavan-3-ols, la fois monomères et polymères des 
extraits de marcs et des conjugaisons supplémentaires dans le foie. De nombreux métabolites 
issus de la dégradation microbienne des hydroxyvalerolactones ont également été détectés. 
L’excrétion urinaire de ces métabolites représente une plus grande proportion de polyphénols 
ingérés comparé à ceux issus de métabolisme de phase II des monomères de flavan-3-ols, 
indiquant un rôle important des bactéries intestinales dans le métabolisme des molécules 
hautement polymérisées. Ces métabolites peuvent avoir exercé leurs effets biologiques lors 
de leur passage dans la circulation sanguine.  
Suite aux résultats obtenus lors des tests in vivo, l'association des extraits de pépins et 
de pellicules de marcs avec le vérapamil a prouvé son efficacité chez les rats SHR. L’extrait 
de pépins GRE1 (EA70) (administré au groupe E1 et VE1) et l’extrait de pellicules d’ALI 
(EA70) (administré aux groupe E6 et VE6) avec ou en association avec le vérapamil sont 
capables de faire diminuer la pression artérielle des rats SHR alors que dans les groupe de 
rats E5 et VE5 ayant reçu l’extrait de pellicules de MOU (EA70) seul ou en association avec 
le vérapamil, aucun effet sur la pression artérielle n’a été observé. Les études de 
biodisponibilité ont indiqué que les rats administrés avec les extraits de marcs associés au 
vérapamil génèrent une quantité plus importante de métabolites et catabolites que ceux ayant 
reçu l’extrait seul. Cependant, l’absorption de polyphénols dans les groupes E1 et E6 semble 
tout de même être légèrement supérieure à ceux ayant reçu du vérapamil (VE1 et VE6). 
Contrairement aux E1/VE1 et E6/VE6, les SHR des groupes E5/VE5 absorbent de plus 
grandes quantités de polyphénols. L'analyse par HPLC-ESI-MS
n
 a montré qu’au 1er jour de 
gavage, les SHR du groupe E5 excrètent la plus grande quantité de polyphénols sur 24 h 
(1,57 %) comparé aux autres groupes (1,02%-1,29%). La plus faible excrétion a été observé 
chez les VE5 avec une excrétion de seulement 0.16 % des polyphénols ingérés. La même 
observation a été obtenue par GC- MS où il a été démontré que les SHR du groupe E5 
excrètent une importante quantité de catabolites (181 % de l'apport en polyphénols) par 
rapport aux autres groupes (3,5%-105,5 %) même après 7 jours d’administration (excrétion 
de 4.41 % de polyphénols ingérés estimés par HPLC-ESI-MS
n
 et 76 % par GC-MS). Une fois 
de plus, les SHR du groupe VE5 excrètent la plus faible quantité de polyphénols (1.2% des 
polyphénols ingérés). Contrairement au 1
er
 jour de gavage, l’excrétion des SHR du groupe 
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VE5 est plus élevé par rapport aux autres groupes avec 4.25% d’absorption détecté par 
HPLC-ESI-MS
n
 et 102% par GC-MS). En effet, une importante accumulation de métabolites 
a été démontrée dans les tissus et plasmas des rats appartenant au groupe VE5. 
Il a été établi que les SHR développent spontanément une hypertension artérielle qui 
augmente avec l’âge de vie. L’HTA se manifeste à partir de la sixième semaine d’âge et se 
stabilise autour de la 20ème semaine d’âge avec une pression artérielle systolique atteignant 
200 à 220 mmHg. L’origine de cette hypertension est multiple. Par rapport aux rats 
normotendus, les rats SHR présentent un déficit de l’enzyme de conversion 2 (ACE2), une 
mono-carboxypeptidase qui catalyse à la fois l’angiotensine I (Ang I) en angiotensine (1-9) 
(Ang 1-9) et l’angiotensine II (Ang II) en angiotensine (1-7) (Ang 1-7) (Donoghue et al. 2000). 
L’ACE2 est impliquée dans la régulation du système rénine-angiotensine (RAS) (Tikellis et 
ak. 2006) et est reconnue pour son rôle majeur dans le contrôle de la pression artérielle. En 
effet, l’heptapeptide Ang 1-7 est un vasodilatateur et natriurétique dont les effets s’opposent à 
ceux de son précurseur. Le déficit d’ACE2 induit alors une augmentation de la concentration 
d’Ang II et conduit à une vasoconstriction. De plus, les rats SHR possèdent une relaxation 
endothéluim-dépendante réduite due à un dysfonctionnement endothéliale souvent associé à 
un fort stress oxydant. Ceci est causé d’un côté par un excès d’anion superoxyde (O2
-
) 
produit par l’enzyme NADPH oxydase (Grunfeld et al. 1995; Zalba et al. 2000) et d’un autre 
côté par une faible activité de la eNOS (endothelial NO synthase) qui catalyse la production 
du monoxyde d’azote ou NO, un puissant agent vasodilatateur produit par l’endothéluim à 
partir de la L-Arginine (Palmer et al. 1987). En effet, en présence du NO, l’ion superoxyde 
O2
- 
 forme le peroxynitrite (ONOO
-) empêchant ainsi le NO d’exercer sa fonction 
vasodilatatrice (Beckman et al. 1990; McIntyre et al. 1999; Pacher et al. 2007). 
Physiquement, l’étude des tissus du rat SHR montre qu’au cours de son âge, l’oxygénation 
tissulaire diminue et entraine progressivement ainsi une hypertrophie cardiaque (Engelmann 
et al. 1987) ainsi qu’une augmentation de la résistance périphérique (Smith et al. 1979; 
Folkow et al. 1992). 
Du fait de l’implication du stress oxydant dans la pathogenèse de l’hypertension, les 
chercheurs se sont intéressés aux effets antihypertenseurs des polyphénols retrouvés dans 
l’alimentation. Leur effet hypotenseur a été confirmé dans de nombreuses études (Galisteo et 
al. 2004 ; Sarr et al 2006 ; Perez-Vizcaino et al. 2009) et serait lié a la capacité des 
polyphénols de réguler l’activité de la eNOS et de la NADPH oxydase. Une étude par Al-
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Awwadi et al. (2004) a montré qu’un extrait de polyphénols issus du vin rouge permettait de 
diminuer l’hypertension chez des rats ayant développé un syndrome métabolique suite à un 
régime riche en fructose. Plus précisément, des extraits polyphénoliques enrichis en 
anthocyanes et en catéchines préviennent l’hypertension chez le même modèle animal ce qui 
n’est pas le cas des procyanidines (Al-Awwadi et al. 2005). L’effet antioxydant n’est donc 
pas le seul mode d’action de ces molécules. Ces observations sont en adéquation avec nos 
résultats dans lequel de fortes concentrations en monomères et dimères de flavan-3-ols ont 
été détectés dans les extraits de pépins de marcs exerçant des effets antihypertenseurs. 
Les extraits de marcs peuvent être utilisés seuls mais leurs effets peuvent être 
amplifiés une fois co-ingéré avec le vérapamil. Il est largement reconnu que la glycoprotéine 
P souvent nommé « P-gp » influence le transport des médicaments au travers des membranes. 
La P-pg se retrouve principalement au niveau des cellules du tubule contourné proximal du 
rein, des cellules de l’intestin, de l’endothélium de la barrière hémato-encéphalique etc. Par 
conséquent, elle peut influencer l’absorption, la distribution, le métabolisme et l’excrétion des 
xénobiotiques. La P-pg provoque par efflux, un phénomène de multirésitances à plus de 50% 
des agents anti-cancéreux. Par conséquent, les chercheurs tentent d’optimiser la 
pharmacocinétique, d’améliorer les activités anti-tumorales et de réduire la toxicité 
systémique des médicaments anti-cancéreux en inhibant les efflux de la P-glycoprotéine. 
Bien qu'une grande variété d'inhibiteur de la P-gp ont été découverts, les flavonoïdes 
constituent la troisième génération de la catégorie non-pharmaceutique d'inhibiteurs de la P-
gp (Bansal et al. 2009). Il a été démontré que les effets produits par certains de ces 
composants sont comparables à ceux des inhibiteurs connus de la P-pg tels que le vérapamil 
et la cyclosporine. 
Comme le vérapamil, un inhibiteur de référence de la P-pg et des phénomènes de 
multi-résistance aux médicaments (MDR), les polyphénols ont été démontrés comme ayant 
des propriétés inhibitrices sur le transport de la P-pg affectant la biodisponibilité et 
l’absorption de certains médicaments (Jodoin et al. 2002; Kitagawa 2006; Eichhorn et al. 
2012). De ce fait, l'association d'extraits de pépins et de pellicules de marcs riches en 
polyphénols au vérapamil peut avoir un effet bénéfique sur la régulation de la pression 
artérielle en modifiant l'absorption du (poly)phénols et/ou du vérapamil. 
En tenant compte de ces observations et des résultats obtenus lors de l’étude in vivo, 
les effets antihypertenseurs des polyphénols peuvent être attribués  à l’action des polyphénols 
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contenus dans les extraits de marcs (dans le cas des rats des groupes E1 et E6) et/ou par 
l’action du vérapamil. Dans les groupes E1, E5 et E6, les polyphénols, en particulier les 
monomères et procyanidins de flavan-3-ols, peuvent contribuer aux effets antihypertenseurs 
des extraits. En effet, les extraits de pépins de GRE1 (EA70) et de pellicules d’ALI (EA70) 
renferment une importante quantité de polyphénols que l’extrait de pellicules de MOU 
(EA70). Dans le groupe VE1 et VE6, le vérapamil pourrait permettre une meilleure 
absorption de polyphenols ou vice versa et l’effet antihypertenseur pourrait être du à l’action 
des polyphénols et/ou le vérapamil. Dans les cas des groupes E5 et VE5, il a été démontré 
que les polyphénols sont absorbés de manière importante dans le groupe E5 et une fois 
associée au vérapamil, l’absorption est encore plus élevée. De ce fait, le vérapamil devrait 
permettre une meilleure absorption des polyphénols mais dû à une faible teneur ou à la 
composition en polyphénols des pellicules de MOU (EA70), cet extrait ne possède aucun 
effet antihypertenseur.  
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This study investigated the beneficial effects of grape pomaces obtained after 
winemaking of different Mediterranean grape varieties from crude materials to its in vivo 
effectiveness. Grapes and their respective grape pomaces from six different V. vinifera L. cv. 
Grenache (from two different locations [GRE1 and GRE2]), Syrah (from two different 
locations [SYR1 and SYR2]), Carignan (CAR), Mourvèdre (MOU), Counoise (COU) and 
Alicante (ALI) grape varieties from Rhône Valley region were studied.  
Grapes and their respective grape pomaces, including seeds and skins were screened 
for their (poly)phenolic contents (total phenols, anthocyanins [glucosides, acetylated 
glucosides and coumarylic glucosides], tannins and monomeric and oligomeric 
proanthocyanidins. The in vitro antioxidant capacities of all the extracts were evaluated by 
four different analytical methods: ABTS
•+
, DPPH, FRAP and ORAC. 
The comparison of several wine industry by-products with their respective grapes 
provided evidence that pomaces are very rich sources of antioxidants, despite extraction 
during winemaking. The quantitative and qualitative distribution of polyphenols in grape 
pomaces showed significant differences through varieties and vintages. In addition, seed 
pomace was shown to contain particularly high amounts of phenolics and thus had a more 
substantial antioxidant potential than skin pomace. Grape seed and skin pomace extracts 
contained appreciable amounts of flavan-3-ols and anthocyanins. Seeds from Grenache 
(GRE1), Syrah (SYR1) and skins from Syrah (SYR1), Carignan and Alicante were of 
particular interest because of their higher polyphenol contents in terms of flavan-3-ols 
(monomers, dimers and trimers) and anthocyanins (glycosides, acetylated and coumaroylated 
derivatives). These extracts also exerted the highest antioxidant activity in four different 
assay systems. As a result, these varieties and their parts (seeds and skins) were chosen for 
further extraction with aqueous and hydro-alcoholic 70% solution suitable for consumption 
and commercialization. 
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The investigation of aqueous and hydro-alcoholic 70% extracts of seeds from 
Carignan and Syrah (SYR1) and skins from Carignan and Alicante was carried out as they 
contained high levels of total phenols and antioxidant activity. Hydro-alcoholic 70% solution 
was shown to be more effective because of higher flavan-3-ol, procyanidin and anthocyanin 
contents in EA70 extracts. However, EAQ extracts also displayed interesting amounts of 
polyphenolics and radical scavenging capacity and should not be ignored. Lyophilization 
enabled extracts to contain more concentrated polyphenolic compounds. Nevertheless, this 
step can intensively increases the cost of production and has to be further discussed. 
Although selected extracts had a high content of polyphenolic compounds, the in vivo 
effects might not be that effective because bioavailability greatly differs between 
polyphenols. Therefore, several extracts, even those which contain low phenolic amounts 
were tested in order to evaluate the in vivo biological effects on hypertension using a 
spontaneously hypertensive rat (SHR) model. Grape pomace extracts were administrated at a 
dose of 21 mg/kg/day which in terms of phenolic compounds is equivalent to a 70 kg human 
consuming of ~0.5 L of red wine. Different experimental groups were made, blood pressure 
was followed and the effect of grape pomace on hypertension determined. In the first 
instance, different grape pomace extracts were screened for their anti-hypertensive effects. 
Among extracts screened, Grenache GRE1 (EA70) seed pomace extract, Syrah SYR1 (EA70) 
seed pomace extract and Alicante ALI (EA70) skin pomace extract were able to reduce blood 
pressure which was followed by a rebound effect once extract administration was interrupted. 
SHR were also fed verapamil, a calcium-channel blocker anti-hypertensive drug 
commonly use to treat hypertension in humans. Results showed that throughout the 
experiment, SHR systolic blood pressure fluctuated depending on the administered verapamil 
dose (30 mg/kg/day – 20 mg/kg/day – 40 mg/kg/day), but finally end up with a constantly 
high SBP around 200 mm Hg. These results indicate that over time, SHR rats develop 
resistance to the verapamil. A model of “grape pomace extract + verapamil” was validated 
and a series of different grape pomace extracts associated with verapamil were tested in order 
to evaluate the anti-hypertensive ability. Results showed that the co-ingestion of verapamil 
with grape pomace extracts rich in polyphenols had beneficial effects on blood pressure 
regulation by amplifying the effects of polyphenols and/or verapamil. 
All in vivo experiments demonstrated that some grape pomace extracts administrated 
with or without co-ingestion with verapamil possessed an anti-hypertensive potential and was 
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evidenced with GRE1 (EA70) seed pomace extract, SYR1 (EA70) seed pomace extract, ALI 
(EA70) skin pomace extract once administrated alone and with GRE1 (EA70) seed pomace 
extract, SYR1 (EAQ) seed pomace extract, ALI (EA70) skin pomace extract and SYR2 
(EAQ) skin pomace extract once administrated in association with verapamil. However, 
SYR1 (EA70) skin pomace extract with verapamil was shown to exert an adverse effect by 
elevating systolic blood pressure. Table 77 summarized the anti-hypertensive efficiency of 
different tested grape pomace extracts. 
Table 77: Anti-hypertensive efficiency of different grape pomace extracts. 
Grape pomace extracts 
tested 
Treatment 
time 
Effect on 
hypertension 
Efficiency to regulate blood pressure 
GRE1 seed (EA70) 3 weeks + Indirect effect, rebound effect, + 19% 
SYR1 seed (EA70) 3 weeks + Indirect effect, rebound effect, +24 % 
SYR 2 skin (EA70) 3 weeks ~ - 
CAR seed (EA70) 3 weeks ~ - 
MOU skin (EA70) 3 weeks ~ - 
ALI skin (EA70) 3 weeks + Indirect effect, rebound effect, +16 % 
    
GRE1 seed (EA70) + verapamil 3 weeks + Direct effect, -26 % 
SYR1 seed (EA70) +verapamil 3 weeks ~ - 
SYR 2 skin (EA70) + verapamil 3 weeks ~ - 
CAR seed (EA70) + verapamil 3 weeks ~ - 
MOU skin (EA70) +verapamil 3 weeks ~ - 
ALI skin (EA70) + verapamil 3 weeks + Direct effect, -13 % 
    
SYR1 seed (EAQ) + verapamil 2 weeks + Direct effect, -14 % 
SYR1 skin (EAQ) + verapamil 2 weeks ~ - 
ALI skin (EAQ) + verapamil 2 weeks ~ - 
GRE2 Skin (EA70) + verapamil 2 weeks ~ - 
    
CAR seed (EAQ) + verapamil 1 week ~ - 
GRE2 skin (EAQ) + verapamil 1 week ~ - 
SYR2 skin (EAQ) + verapamil 1 week + Direct effect, -11 % 
SYR1 skin (EA70) + verapamil 1 week − Direct effect, +15 % 
Grape pomace extracts were administrated at a dose of of 21 mg/kg/day equivalent to a daily 70 kg 
human consumption of phenolic contained in 0.5 L of wine and verapamil at a dose of 40 mg/kg/day. +, positive 
effect on hypertension regulation; − negative effect on hypertension regulation; ~ no effect. Extract efficiency 
fed to SHR rats was illustrated by the percentage of variation (%) of blood pressure before and after the 
ingestion. 
 
Grape pomace extracts ingested without verapamil were shown to exert anti-
hypertensive effects indirectly, by increasing blood pressure after a rebound effect. An 
increase of +19 %, +24 % and +16 % were observed, respectively, for GRE1 seed (EA70), 
SYR1 seed (EA70) and ALI skin (EA70) after three weeks of treatment. Grape pomace 
extracts co-ingested with verapamil, lowering blood pressure by -26 % with GRE1 seed 
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(EA70) + verapamil and -13% using ALI skin (EA70) + verapamil after 3 weeks of treatment 
and by -14 % after 2 weeks of treatment. Moreover, experiments showed that one week of 
treatment was sufficient to induce anti-hypertensive effect in rats fed with SYR2 skin (EAQ) 
+ verapamil in which an 11 % reduction in blood pressure while a pro-hypertensive effect 
was observed in rats fed with SYR1 skin (EA70) + verapamil (+ 15 %). 
According to the extract used and its composition, it is actually possible to modulate 
anti-hypertensive drug effects. In vivo anti-hypertensive ability of GRE1 (EA70) seed 
pomace extract, SYR1 (EA70) seed pomace extract and SYR1 (EAQ) seed pomace extract is 
most likely conferred by the large amount of flavan-3-ols and procyanidins rather than 
anthocyanins. Skin pomace extracts contained large amount of anthocyanins and flavan-3-ols 
but unlike seed extracts, anti-hypertensive ability of skin extracts is more difficult to predict. 
Other compounds in these skin extracts such as polysaccharides or fibers might prevent the 
anti-hypertensive effect by affecting polyphenol absorption. 
The bioavailability of polyphenolic compounds in GRE1 (EA70) seed pomace 
extracts (E1/VE1 group), MOU (EA70) skin pomace extracts (E5/VE5 group) and ALI 
(EA70) skin pomace extracts (E6/VE6 group), with or without co-ingestion with verapamil 
was studied. Urine, faeces, tissues (heart, liver and kidneys) and plasma were collected from 
SHR rats and screened in order to determine the accumulation of polyphenol metabolites. A 
total of 61 metabolites were detected in urine but only 18 in amounts that facilitated 
quantification. Urine analysis by HPLC-ESI-MS
n
 revealed a higher urinary excretion of 
metabolites in SHR rats fed with grape pomace extracts and verapamil. However, considering 
the percentage of intake corresponding to the excreted amount in urine, the data did not show 
clear differences between E1/VE1 (1.02 vs 1.29 % at day 1 and 1.52 % vs 1.08 % at day 7) 
and E6/VE6 (1.02% vs 1.02% at day1 and 1.42% vs 1.64% at day 7) except for the fact that 
polyphenols from MOU (EA70) skin pomace extracts were 27-fold better absorb at day 7 of 
gavage than at day 1, especially when co-ingested with verapamil (0.16 % at day 1 to 4.25 % 
at day 7). This result suggested that polyphenols were better absorbed or accumulated over 
time in SHR rats.  
A total of 11 metabolites were found in SHR rat plasma collected 4 h after grape 
pomace extracts ingestion. Generally, lower concentrations of metabolites were observed in 
plasma than in urine. The highest metabolite accumulation was observed in plasma from VE5 
experimental group in which SHR rats were fed MOU (EA70) skin pomace extracts + 
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verapamil. In fact, an amount up to 4.6 ± 0.07 nmol and a recovery of 0.15 % were observed 
compared to other plasma in which only a 0.03 % to 0.09 % recovery was found. These 
results are in accordance with those obtained with urine, showing a high intake of grape 
pomace polyphenols in VE5 experimental group (4.25 %). The E5 group also showed 
substantial urinary excretion polyphenols (4.41 % of intake) while no more than 0.09 % of 
intake accumulated in plasma. This indicates a rapid excretion of metabolites from the 
circulatory system. Grape pomace polyphenols were less well absorbed by rats fed with other 
extracts (i.e. E1, VE1, E6 and VE6), as illustrated by low levels in urine and plasma. 
In SHR rat tissues, it was observed that rats fed with MOU (EA70) skin pomace 
extracts + verapamil (VE5 SHR group) accumulated high amounts of metabolites. Likewise 
there were higher accumulations of metabolites after ingestion of MOU (EA70) skin pomace 
extracts + verapamil than other extracts, especially in the kidneys and liver (0.14 % and 1.64 
%, respectively). Faecal phenolic excretion in SHR rats occurred predominantly at 8-24 h 
time point. Recoveries ranged from 0.3 % in VE6 to 2.31 % in E5 at day 1 and 1.03 % in 
VE1 to 1.72 % in E5 after seven days of grape pomace extracts ingestion. 
A total of 21 phenolic acids and aromatic compounds were identified in urine of SHR 
rats by GC-MS. Results obtained by GC-MS confirmed those obtained by HPLC-ESI-MS
n
 
and showed an increase of bioavailability of MOU (EA 70) skin pomace extracts + verapamil 
which was low at day 1 but increased up to 85-fold at day 7 (1.2 % of intake at day 1 and 102 
% of intake at day 7). Using GC-MS, the difference of absorption between E1/VE1 and 
E6/VE6 was more evident. At day 1, rats fed with GRE1 (EA70) seed pomace extracts + 
verapamil absorbed 12-fold more grape pomace polyphenols than those fed with GRE1 
(EA70) seed pomace extracts alone and rats fed with ALI (EA70) skin pomace extracts + 
verapamil absorbed 5-times more than those fed with an extract without verapamil. At day 7, 
the same profiles were apparent but to a lesser extent (same absorption rate for E1/VE1 and 
4-fold higher for E6/VE6). Analysis of faeces revealed higher excretion of catabolites at day 
1 than at day 7, showing once again a better absorption of polyphenols by SHR rats over 
time. The highest excretion rate was by rats fed MOU (EA70) skin pomace extract with 
excretions corresponding to 54 % and 108 % of polyphenols ingested, suggesting extensive 
catabolism of polyphenols contain in this extract by colonic microbiota. 
Grape pomace extracts with or without co-ingestion with verapamil were absorb as 
phase II metabolites mainly including glucuronide, O-methyl glucuronide, sulfate, and O-
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methyl sulfate derivatives of (epi)catechin which arise from the metabolism of monomeric 
flavan-3-ols. The detection of microbial-derived metabolites of flavan-3-ols, hydroxyphenyl-
γ-valerolactones in their glucuronide and sulfate forms confirmed the absorption of 
metabolites derived from both monomeric and polymeric flavan-3-ols from grape pomace 
extracts and subsequent conjugation in the liver. Numerous metabolites derived from further 
microbial degradation of hydroxyvalerolactones were also detected. The urinary excretion of 
these metabolites accounted for a larger proportion of the total polyphenol ingested than 
phase II metabolites of monomeric flavan-3-ols, indicating the important role of intestinal 
bacteria in the metabolism of highly polymerized compounds. All these metabolites may 
have exerted biological effects during the period in which they circulated in the bloodstream. 
Therefore, considering these observations, anti-hypertensive effects could be 
attributed to the action of polyphenols contained in grape pomace extracts (in the case rats 
from E1 and E6 group) and/or by the action of verapamil. In E1, E5 and E6, polyphenols, 
especially flavan-3-ol monomers and procyanidins, contained in each grape pomace extracts 
were responsible for the non- or anti-hypertensive effect. In fact, GRE1 (EA70) seed pomace 
extracts and ALI (EA70) skin pomace extracts were showed to contain higher levels of 
polyphenols than MOU (EA70) skin pomace extracts. In VE1 and VE6 group, verapamil 
might allow a higher absorption of polyphenols or vice versa. The anti-hypertensive might be 
due to the action of polyphenols and/or verapamil. In the case of E5/VE5 group, polyphenols 
was showed to be highly absorbed in E5 group and when associated to verapamil, the 
polyphenol metabolite/catabolite urinary excretion, and hence absorption, increased. Thus, 
verapamil might allow better absorption of polyphenols, but, because of low concentration or 
the composition of MOU (EA70) skin pomace extracts no anti-hypertensive effects were 
observed.  
This study constitutes the first step of assessing grape pomace as an enhancer of the 
verapamil, an anti-hypertensive drug. Substantial levels of polyphenols after the winemaking 
process, especially flavan-3-ols, procyanidins and anthocyanins remain in pomace in 
quantities sufficient to exert anti-hypertensive effects. In addition, according to the extract 
used and its composition, it is feasible to modulate anti-hypertensive effects by amplifying or 
decreasing polyphenols and/or verapamil absorption. Therefore, it will be interesting to 
elucidate the exact mechanisms and compounds involved in this phenomenon in order to 
have a better control on blood pressure regulation and facilitate the choice of effective grape 
pomace extracts for further experiments. Moreover, it will be useful to investigate the effect 
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of each flavan-3-ol fractions (i.e. oligomeric, monomeric) and anthocyanin fractions (i.e. 
glucosides, acetylated glucosides and coumarylic glucosides) in order to identify whether 
anti-hypertensive effects are linked to a particular compound or to the extracts as a whole. 
Additional bioavailability studies could be useful to confirm results obtain with the 
E5/VE5 group showing that verapamil might allow better absorption of polyphenols, but, 
because of low concentration or the composition of MOU (EA70) skin pomace extracts no 
anti-hypertensive effects were observed. In addition, the quantification of verapamil 
metabolites might be of great interest to evaluate verapamil absorption levels compared to 
those of polyphenols. 
As SHR represents a good model to investigate hypertension, study could be extended 
to human clinical trials. For clinical tests, different parameters have to be taken into account 
such as the subjects (i.e. pre-hypertensive or hypertensive subjects), the dose used, the diet, 
biological fluid collections, and biological markers to be quantified. In addition, different 
processes will have to be considered such as the choice grape pomace varieties and their parts 
(seeds/skins), the extraction processes which will be used, the dosage and the galenic 
formulation used in order to provide great stabilisation of the active substances. 
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Cette étude examine les effets bénéfiques des marcs de raisins obtenus après 
vinification de différents cépages caractéristiques de la Vallée du Rhône, de leurs 
compositions phénoliques à leurs effets in vivo. Les raisins et leurs marcs respectifs des 
cépages Grenache (provenant de deux endroits différents [GRE1] et [GRE2]), Syrah 
(provenant de deux endroits différents [SYR1] et [SYR2]), Carignan (CAR), Mourvèdre 
(MOU), Counoise (COU) et Alicante (ALI) ont été étudiés. Le contenu en polyphénols des 
extraits a été dosé de façon globale (composés phénoliques totaux, tanins totaux et 
anthocyanes totales) et individuelles par HPLC-UV-Fluo-MS (tanins monomériques et 
condensés, degrés de polymérisation, anthocyanes glycosylées, acétylées et coumaroylées). 
Par la suite, l’activité antioxydante a été appréciée en utilisant quatre tests différents 
d’activités antioxydantes : ABTS•+, DPPH, FRAP et ORAC. Les ratios entre la quantité de 
polyphénols issus des raisins et la quantité finale retrouvée dans les marcs ont été estimés et 
la corrélation entre le contenu en composés phénoliques et l’activité antioxydante a été 
établie.  
La comparaison des extraits de raisins et de leurs marcs respectifs montre que les 
marcs représentent une source importante d’antioxydants phénoliques malgré le processus de 
vinification. Les pépins et pellicules de marcs renferment des quantités appréciables de 
flavan-3-ols et anthocyanes. La distribution qualitative et quantitative des polyphenols dans 
les marcs de raisin présentent des différences significatives au travers des variétés et 
millésimes allant de 15% à 70% de polyphénols extraits.  
Dans une première étude de caractérisation de raisins et de marcs après séparation 
pépins-pellicules, il a été démontré que les pépins de Grenache (GRE1), Syrah (SYR1) et les 
pellicules de Syrah (SYR1), Carignan et Alicante sont les fractions les plus intéressantes dues 
a la présence d’importantes quantités de flavan-3-ols (monomères, dimères et trimère) 
jusqu’à 8.7 mg/g MS et d’anthocyanes (glycosylées, acétylées et coumaroylées jusqu’à 17.40 
mg/g MS, 1.57 mg/g MS et 2.38 mg/g MS respectivement). De même, ces extraits présentent 
les pouvoirs antioxydants les plus élevés pour tous les tests confondus. Par conséquent, ces 
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variétés et leurs parties (pépins/pellicules) ont été sélectionnées pour des extractions 
supplémentaires avec d’autres types de solvants tels que l’eau et une solution hydro-
alcoolique 70 % compatible à la consommation et la commercialisation. Deux différentes 
extractions ont été effectuées afin d’obtenir deux types d’extrait pour chaque échantillons : un 
extrait aqueux (EAQ) et un extrait hydro-alcoolique 70% (EA70). 
L’analyse des extraits aqueux (EAQ) et hydro-alcoolique 70% (EA70) indique que les 
pépins de Carignan et Syrah (SYR1) et les pellicules de Carignan et d’Alicante contiennent 
les plus fort taux en composés phénoliques et activités antioxydantes. La solution hydro-
alcoolique 70% permet une meilleure extraction de flavan-3-ols, procyanidins et anthocyanes 
dans les extraits EA70. Cependant, les extraits aqueux (EAQ) affichent tout de même des 
quantités de polyphénols et de pouvoir antioxydants intéressants et ne devrait pas être ignoré. 
La lyophilisation permet une meilleure concentration des composés phénoliques dans les 
extraits. Toutefois, cette étape augmentera considérablement le coût de production des 
extraits. Ce point devrait être discuté d’avantage lors de l’élaboration des extraits finaux.  
Bien que les extraits sélectionnés présentent une quantité importante en composés 
phénoliques et de forts pouvoirs antioxydants in vitro, ceci ne permet pas d’évaluer leur 
efficacité biologique in vivo dûe à une différence de biodisponibilité de chaque composé 
phénolique dans le milieu gastro-intestinale. Certains extraits, même ceux contentant de 
faible quantité en polyphénols ont été choisis afin d’évaluer leur efficacité in vivo. 
Dans un premier temps, différents groupes expérimentaux ont été mis en place et les 
extraits de pépins et pellicules de raisins et de marcs ont été administrés seuls ou en 
association avec le vérapamil aux SHR. La pression artérielle a été suivie et l’effet des 
extraits sur l’hypertension a été apprécié. Trois extraits ont été choisis afin d’étudier leur 
biodisponibilité. Les urines, fèces, plasmas et organes (foie, reins et cœur) ont été récoltés. 
Les métabolites ont été identifiés et quantifiés par HPLC-UV-MS
n
 et GC-MS. 
Les résultats des expériences in vivo démontrent que certains extraits administrés 
seuls ou en association avec le vérapamil possèdent un effet anti-hypertenseur. Cette capacité 
a été mise en évidence une fois que les extraits de pépins de marcs de GRE1 (EA70) et SYR1 
(EA70) et de pellicules de marcs d’ALI (EA70) ont été administrés seuls ou lorsque les 
extraits de pépins de marcs GRE1 (EA70) et SYR1 (EAQ) et les pellicules de marcs d’ALI 
(EA70) et SYR2 (EAQ) ont été administrés en association avec le vérapamil. Dans la 
dernière expérience in vivo, les pellicules de marcs de SYR1 (EA70) en association avec le 
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vérapamil révèle un effet inverse en élevant la pression systolique. Le tableau ci-dessous 
résume l’efficacité in vivo des extraits de pépins et de pellicules de marcs testés seuls ou en 
association avec le vérapamil sur la pression artérielle (PA). 
Table 1: Effet in vivo des extraits de pépins et pellicules de marcs sur la pression 
artérielle. 
Extraits de marcs testés 
Temps de 
traitement 
Effet sur la 
PA 
Efficacité 
GRE1 pep (EA70) 3 semaines + Effet indirect, effet rebond, + 19% 
SYR1 pep (EA70) 3 semaines + Effet indirect, effet rebond, +24 % 
SYR2 pell (EA70) 3 semaines ~ - 
CAR pep (EA70) 3 semaines ~ - 
MOU pell (EA70) 3 semaines ~ - 
ALI pell (EA70) 3 semaines + Effet indirect, effet rebond, +16 % 
    
GRE1 pep (EA70) + vérapamil 3 semaines + Effet direct, -26 % 
SYR1 pep (EA70) +vérapamil 3 semaines ~ - 
SYR2 pell (EA70) + vérapamil 3 semaines ~ - 
CAR pep (EA70) + vérapamil 3 semaines ~ - 
MOU pell (EA70) +vérapamil 3 semaines ~ - 
ALI pell (EA70) + vérapamil 3 semaines + Effet direct, -13 % 
    
SYR1 pep (EAQ) + vérapamil 2 semaines + Effet direct, -14 % 
SYR1 pell (EAQ) + vérapamil 2 semaines ~ - 
ALI pell (EAQ) + vérapamil 2 semaines ~ - 
GRE2 Pell (EA70) + vérapamil 2 semaines ~ - 
    
CAR pep (EAQ) + vérapamil 1 semaine ~ - 
GRE2 pell (EAQ) + vérapamil 1 semaine ~ - 
SYR2 pell (EAQ) + vérapamil 1 semaine + Effet direct, -11 % 
SYR1 pell (EA70) + vérapamil 1 semaine − Effet direct, +15 % 
Les extraits ont été administrés à une dose de 21mg/kg/jour de polyphénols par jour ce qui équivaut à 
une consommation de polyphénols contenus dans 500 mL de vin rouge par un adulte de 70kg et le vérapamil à 
une dose de 40 mg/kg/jour. Pell, pellicules; pép, pépins; +, effet positif sur la régulation de l’hypertension; −, 
effet negatif sur la régulation de l’hypertension ; ~, pas d’effet. L’efficacité des extraits administrés aux rats 
SHR a été illustrée par le pourcentage de variation (%) de la pression artérielle avant et après l’ingestion des 
extraits.  
Les extraits de marcs administrés seuls régulent la pression artérielle et a été démontré 
par l’effet rebond bien connu dans ce type de traitement. Une augmentation de + 19%, +24% 
et +16% a été observée pour les extraits de pépins GRE1 (EA70) et SYR1 (EA70) et de 
pellicules ALI (EA70) après 3 semaines de traitement. Ingéré en association avec le 
vérapamil, les pépins de GRE1 (EA70) diminuent la pression artérielle de -26% et les 
pellicules d’ALI (EA70) de -13% après 3 semaines de traitement et de -14% après 2 semaines 
de traitement. De plus, les expériences montrent qu’une semaine suffise pour induire des 
effets antihypertenseurs dans le groupe de rats SHR ayant reçu l’extrait de pellicules de marcs 
SYR2 (EAQ) + vérapamil dans lequel une réduction de 11 % a été observé et des effets pro-
293 
 
hypertenseurs dans le groupe de rat ayant reçu l’extrait de pellicules SYR1 (EA70) + 
vérapamil (+15%). 
Selon le type d’extraits administrés aux rats SHR, il est possible de moduler les effets 
antihypertenseurs du médicament. La composition des extraits de marcs en composés 
phénoliques joue un rôle crucial et devrait être pris en compte. Malgré une quantité plus 
importante en composés phénoliques dans les extraits EA70, les extraits EAQ ont tout de 
même prouvé leurs efficacités dans la régulation de la pression artérielle. 
Parmi les extraits de pépins de marcs, les extraits aqueux et hydro-alcoolique 70% de 
CAR qui contiennent une grande quantité de polyphenols comparé aux extraits de pépins 
GRE1, ne révèle aucun effet anti-hypertensive contrairement à GRE1. Les extraits de pépins 
exerçant un effet anti-hypertensif (GRE1 [EA70], SYR1 [EA70] et SYR1 [EAQ]) 
contiennent les plus grandes quantités en procyanidines (56 à 157 mg/g MS), en particulier 
dans la Syrah où 137 mg/g et 157 mg/g MS de procyanidins ont été détectés dans les EAQ et 
EA70, respectivement. De plus, ces extraits contiennent d’importantes quantités de dérivés 
gallates et sont fortement galloylés comparés aux extraits EAQ et EA70 de pépins de CAR. 
Les études de caractérisation ont aussi montré que les pépins de Syrah contiennent de grande 
quantité de monomères et dimères de flavan-3-ols dans les deux types d’extraits. En effet, 
parmi les extraits administrés aux SHR, la Syrah est la seule variété possédant des effets 
antihypertenseurs dans les deux types d’extraits. En terme d’anthocyanes, la plus grande 
concentration a été détectée dans les pépins de CAR. En effet, GRE1 et SYR1 possèdent 
seulement 5 mg/g MS et 10.3 mg/g MS dans les EA70 comparé à 25.5 mg/g MS dans CAR 
(EA70). L’évaluation des activités antioxydantes met en évidence la SYR1 EAQ et EA70 
comme ayant le plus fort potentiel. L’efficacité in vivo à moduler la pression artérielle des 
extraits de pépins de GRE1 (EA70), SYR1 (EA70) et SYR1 (EAQ) est serait plutôt liée à la 
grande quantité de flavan-3-ols et procyanidins que par les anthocyanes.  
Concernant les extraits des pellicules de marcs, parmi les neuf extraits testés, 
seulement deux révèlent des effets antihypertenseur : ALI (EA70) et SYR2 (EAQ). La 
caractérisation phénoliques des extraits a mis en évidence les extraits aqueux et hydro-
alcooliques de l’ALI comme étant la plus riche en composés phénoliques et ayant le plus fort 
pouvoir antioxydant. L’ALI (EA70) présente en effet une grande quantité en monomères et 
dimères de flavan-3-ols et 28 mg/g MS de procyanidines. Malgré une quantité de 59 mg/g 
MS de procyanidines, l’extrait aqueux d’ALI ne possède aucune capacité à moduler la 
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pression artérielle. La capacité antihypertensive des extraits serait probablement dûe au 
contenu en anthocyanes. En effet, les pellicules de marcs d’ALI (EA70) possèdent jusqu’à 
19.5 mg/g MS, 1.2 mg/g MS et 7.2 mg/g MS d’anthocyanes glycosylées, acétylées et 
coumaroylées respectivement. Toutefois, une grande composition en composés phénoliques 
ne se traduit pas toujours par un effet in vivo. SYR2 (EAQ) qui a été évalué comme possédant 
les plus faibles quantités en polyphénols pour toutes les analyses confondues, démontre tout 
de même une capacité à diminuer la pression systolique une fois administré en association 
avec le vérapamil aux SHR, alors que les autres extraits possédant une plus grande 
concentration en polyphénols ne possèdent aucuns effets antihypertenseurs et pourrait même 
augmenter la pression systolique comme dans le cas des extraits de SYR1 (EA70). 
Contrairement aux extraits de pépins de marcs, la capacité antihypertenseur des extraits de 
pellicules de marcs est plus difficile à prédire. D’autres composés contenus dans les pellicules 
tels que les polysaccharides ou les fibres pourraient empêcher les effets antihypertenseurs des 
extraits en affectant l’absorption des polyphénols.  
Afin d’approfondir les connaissances sur le niveau d’absorption des polyphénols et 
leurs contributions aux effets antihypertenseurs, une étude de biodisponibilité des trois 
extraits de marcs administrés seuls ou associés au vérapamil, dont deux ayant montré une 
capacité anti-hypertenseur, a été réalisée par la suite. L’HPLC-ESI-MSn a permit la détection 
de grandes variétés de métabolites y compris les dérivés méthylés, glucuronidés et sulfatés de 
flavan-3-ols, des structures non-, mono- et di- phényles glucuronides et sulfates ou même des 
methoxy-sulfates d’acide hydroxyphenylvalérolactone, d’acide hydroxyphenylvalerique, 
d’acide hydroxyphenylacétique, d’acide hydroxybenzoique, d’acide 
hydroxyphenylpropionique, d’acide hydroxycinnamique et d’acide hydroxyhippurique. Un 
totale de 61 métabolites a été détecté mais seulement 18 ont été quantifiés. En l’absence de 
standards glucuronidés et sulfatés, une quantification par le biais d’aglycones pourrait 
introduire des erreurs de quantification due a des réponses SIM/SRM différentes entre 
aglycones/glucuronides et aglycones/sulfates. L’analyse des urines par HPLC-ESI-MSn 
révèle une plus grande excrétion de métabolites chez les SHR ayant reçu des extraits de 
marcs associés au vérapamil. 
Compte tenu du pourcentage de l'apport correspondant à la quantité excrétée dans 
l'urine, les données n'ont pas montré de différences significatives entre E1/VE1 (1,02% vs 
1,29% au 1
er
 jour de gavage et de 1,52% vs 1,08% au 7
ème
 jour de gavage) et E6/VE6 (1,02 % 
vs 1,02% au 1
er
 jour de gavage et 1,42% vs 1,64% au 7
ème
 jour de gavage), excepté pour les 
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polyphénols contenus dans les extraits de pellicules de MOU (EA70) qui sont 27 fois mieux 
absorber au 7
ème
 jour de gavage qu’au 1er jour de gavage, en particulier lorsqu’il est associé 
au vérapamil (0,16% 1
er
 jour de gavage à 4,25% au 7
ème
 jour de gavage). Ce résultat suggère 
qu’au fil du temps, les polyphénols sont mieux absorbés ou accumulés chez les rats SHR. 
Concernant les plasmas, un total de 11 métabolites composé de dérivés glucuronidés, 
méthyl-glucuronidés et di-méthylglucuronidés d’épicatéchine ainsi que des dérivés 
glucuronidés, sulfatés, non- et mono-substitués de valerolactone et d’acide valérique ont été 
retrouvés 4 heures suivant l’ingestion des extraits de marcs. Aucun composé détecté dans les 
extraits de pépins et pellicules de marcs tels que les flavan-3-ols et procyanidins n’a été 
décelé dans les plasmas. Ces métabolites ont aussi été retrouvés dans les urines à l’exception 
du di-méthyl-(épi)catéchin-O-glucuronide et sont principalement présents sous forme de 
glucuronides que sulfates. Généralement, de plus faibles concentrations ont été retrouvées 
dans les plasmas que dans les urines. La plus forte concentration a été décelée dans les 
plasmas des rats SHR appartenant au groupe expérimental VE5, ayant reçu l’extrait de 
pellicules MOU (EA70) + verapamil. En effet, jusqu’à 4,6 ± 0,07 nmol et 0.15 % 
d’absorption a été observé par rapport aux autres plasmas dans lequel seulement un taux de 
0.03% à 0.09% a été retrouvée. Ces résultats sont en accords avec ceux observés dans les 
urines montrant une importante absorption des polyphenols dans le groupe expérimental VE5 
(4.25%). Le groupe E5 excrète une grande quantité de polyphénols dans l’urine (4.41% de 
polyphénols ingérés) alors qu’une petite quantité a été détectée dans les plasmas. Ce résultat 
indique une rapide excrétion des métabolites du système circulatoire. Une faible absorption 
illustrée par une légère excrétion de métabolites dans les urines et plasmas a été mise en 
évidence dans les groupes de rat (E1, VE1, E6 et VE6). 
Dans les tissus des rats SHR (foie, reins et cœur), aucuns dérivés de l’épicatéchine 
n’ont été retrouvés mis à part la 5-(hydroxyphényl)-γ-valérolactone-O-glucuronide (m/z 
383/207, 163) et la 5-(hydroxyphényl)-γ-valérolactone-O-sulfate (m/z 287/207, 163) qui ont 
été détectées et quantifiées en mode SRM. Il a été observé que les rats ayant reçu les extraits 
de pellicules de MOU (EA70) + vérapamil (groupe VE5) concentre une plus forte 
concentration de métabolites dans leurs tissus par rapport aux autres groupes de rats SHR, 
particulièrement dans les reins et le foie (0.14% et 1.64%, respectivement). De plus, une plus 
importante accumulation de métabolites dans les rats administrés avec des extraits + 
vérapamil a été décelée dans les reins avec 5 fois plus dans le groupe VE1 que dans le groupe 
E1, 14 fois plus dans VE5 que dans E5 et 8 fois plus dans VE6 que dans E6.  
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Les fèces ont été dépistés pour les composés contenus dans les extraits de marcs par 
HPLC-MS
n
 en mode SIM pour la détection d'oligomères et de monomères flavan-3-ols. Sept 
composés incluant l’épicatéchine (m/z 289/245, 205), l’ (épi)catéchine gallate (m / z 441/289, 
169), un dimère (m/z 577/425, 407, 289), un trimère (m/z 865/577, 289), deux gallo 
(épi)catéchine trimères (m/z 881, 729, 577, 407) et un tétramère (m/z 153/865, 577) ont été 
détectés. 
L’excrétion fécale de polyphénols survient principalement entre 8-24 h. Le 
pourcentage de polyphénols ingérés et excrétés dans les fèces varie de 0.3% dans VE6 à 
2.31% dans E5 au 1
er
 jour de gavage et de 1.03% dans VE1 à 1.72% dans E5 après sept jours 
de gavage avec les extraits de marcs.  
Les urines et les fèces ont été analysés pour les catabolites utilisant les techniques de 
GC-MS. Un total de 21 acides phénoliques a été identifié dans les urines des rats SHR. La 
grande majorité des acides phénoliques ont été excrétée dans l'urine après 8-24 h d’ingestion 
d’extraits de pépins et pellicules de marcs. L’excrétion de catabolites au bout de 24 h varie de 
0,16 µmol dans VE5 à 12,7 µmol dans E5 au 1
er
 jour de gavage et de 3,17 µmol dans E6 à 
17,4 µmol dans VE1 au 7
ème
 jour de gavage. Les résultats obtenus par GC-MS confirment 
ceux obtenus par HPLC-ESI-MS
n
 et ont montré une augmentation de la biodisponibilité de 
l’extrait de pellicule MOU (EA 70) associé au vérapamil. En effet, au 7ème jour de gavage, 85 
fois plus de polyphénols a été absorbé par rapport au 1
er
 jour de gavage (1.2 % de 
polyphénols ingérés détecté dans les urines au 1
er
 jour et 102% au 7
ème
 jour). Au 1
er
 jour de 
gavage, les rats ayant reçu des les extraits de pépins de GRE1 (EA70) + vérapamil ont 
absorbé 12 fois plus de polyphénols que ceux ayant reçu GRE1 (EA70) seul et les rats ayant 
reçu l’extrait de pellicules de marcs ALI (EA70) + vérapamil ont absorbés 5 fois plus de 
polyphénols que ceux ayant eux l’extrait seul. Au 7ème jour de gavage, la même observation a 
été constatée mais avec une plus faible ampleur (même taux d’absorption pour E1/VE1 et 4 
fois plus pour E6/VE6). 
L’analyse des fèces par GC-MS reflète les acides phénoliques qui n’ont pas été 
absorbés au niveau du colon. Les résultats montrent une plus importante quantité de 
métabolites excrétés au 1
er
 jour de gavage par rapport au 7
ème
 jour illustrant encore une fois 
de plus une meilleure absorption des polyphénols au cours du temps. Le plus fort taux 
d’excrétion a été détecté dans les fèces des rats administré par l’extrait MOU (EA70) et 
correspond à 54 % de polyphénols ingérés au 1
er
 jour de gavage et à 108% de polyphénols 
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ingérés au 7
ème
 jour de gavage. Cette observation suggère un catabolisme extensif des 
polyphénols contenus dans cet extrait par la microflore intestinale. 
Cette étude met en évidence la biodisponibilité des extraits de pépins et de pellicules 
de marcs des rats SHR incluant à la fois le métabolisme de phase II et de la microflore 
intestinale. Les extraits de marcs administrés seuls et en association au vérapamil sont 
absorbés en tant que métabolites de phase II présent sous forme de dérivé O-
methylglucuronidé, sulfaté, O-methylsulfaté d’(épi)catéchine dérivant du métabolisme des 
monomères de flavan-3-ols. La détection de métabolites microbiens dérivés de flavan-3-ols, 
d’hydroxyphényl-γ-valérolactones sous leurs formes glucuronidés et sulfatés confirme 
l'absorption des métabolites dérivés des flavan-3-ols, la fois monomères et polymères des 
extraits de marcs et des conjugaisons supplémentaires dans le foie. De nombreux métabolites 
issus de la dégradation microbienne des hydroxyvalerolactones ont également été détectés. 
L’excrétion urinaire de ces métabolites représente une plus grande proportion de polyphénols 
ingérés comparé à ceux issus de métabolisme de phase II des monomères de flavan-3-ols, 
indiquant un rôle important des bactéries intestinales dans le métabolisme des molécules 
hautement polymérisées. Ces métabolites peuvent avoir exercé leurs effets biologiques lors 
de leur passage dans la circulation sanguine. 
Suite aux résultats obtenus lors des tests in vivo, l'association des extraits de pépins et 
de pellicules de marcs avec le vérapamil a prouvé son efficacité chez les rats SHR. L’extrait 
de pépins GRE1 (EA70) (administré au groupe E1 et VE1) et l’extrait de pellicules d’ALI 
(EA70) (administré aux groupe E6 et VE6) avec ou en association avec le vérapamil sont 
capables de faire diminuer la pression artérielle des rats SHR alors que dans les groupe de 
rats E5 et VE5 ayant reçu l’extrait de pellicules de MOU (EA70) seul ou en association avec 
le vérapamil, aucun effet sur la pression artérielle n’a été observé. Les études de 
biodisponibilité ont indiqué que les rats administrés avec les extraits de marcs associés au 
vérapamil génèrent une quantité plus importante de métabolites et catabolites que ceux ayant 
reçu l’extrait seul. Cependant, l’absorption de polyphénols dans les groupes E1 et E6 semble 
tout de même être légèrement supérieure à ceux ayant reçu du vérapamil (VE1 et VE6). 
Contrairement aux E1/VE1 et E6/VE6, les SHR des groupes E5/VE5 absorbent de plus 
grandes quantités de polyphénols. L'analyse par HPLC-ESI-MS
n
 a montré qu’au 1er jour de 
gavage, les SHR du groupe E5 excrètent la plus grande quantité de polyphénols sur 24 h 
(1,57 %) comparé aux autres groupes (1,02%-1,29%). La plus faible excrétion a été observé 
chez les VE5 avec une excrétion de seulement 0.16 % des polyphénols ingérés. La même 
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observation a été obtenue par GC- MS où il a été démontré que les SHR du groupe E5 
excrètent une importante quantité de catabolites (181 % de l'apport en polyphénols) par 
rapport aux autres groupes (3,5%-105,5 %) même après 7 jours d’administration (excrétion 
de 4.41 % de polyphénols ingérés estimés par HPLC-ESI-MS
n
 et 76 % par GC-MS). Une fois 
de plus, les SHR du groupe VE5 excrètent la plus faible quantité de polyphénols (1.2% des 
polyphénols ingérés). Contrairement au 1
er
 jour de gavage, l’excrétion des SHR du groupe 
VE5 est plus élevé par rapport aux autres groupes avec 4.25% d’absorption détecté par 
HPLC-ESI-MS
n
 et 102% par GC-MS). En effet, une importante accumulation de métabolites 
a été démontrée dans les tissus et plasmas des rats appartenant au groupe VE5. 
Il a été établi que les SHR développent spontanément une hypertension artérielle qui 
augmente avec l’âge de vie. L’HTA se manifeste à partir de la sixième semaine d’âge et se 
stabilise autour de la 20ème semaine d’âge avec une pression artérielle systolique atteignant 
200 à 220 mmHg. L’origine de cette hypertension est multiple. Par rapport aux rats 
normotendus, les rats SHR présentent un déficit de l’enzyme de conversion 2 (ACE2), une 
mono-carboxypeptidase qui catalyse à la fois l’angiotensine I (Ang I) en angiotensine (1-9) 
(Ang 1-9) et l’angiotensine II (Ang II) en angiotensine (1-7) (Ang 1-7) (Donoghue et al. 2000). 
L’ACE2 est impliquée dans la régulation du système rénine-angiotensine (RAS) (Tikellis et 
al. 2006) et est reconnue pour son rôle majeur dans le contrôle de la pression artérielle. En 
effet, l’heptapeptide Ang 1-7 est un vasodilatateur et natriurétique dont les effets s’opposent à 
ceux de son précurseur. Le déficit d’ACE2 induit alors une augmentation de la concentration 
d’Ang II et conduit à une vasoconstriction. De plus, les rats SHR possèdent une relaxation 
endothéluim-dépendante réduite due à un dysfonctionnement endothéliale souvent associé à 
un fort stress oxydant. Ceci est causé d’un côté par un excès d’anion superoxyde (O2
-
) 
produit par l’enzyme NADPH oxydase (Grunfeld et al. 1995; Zalba et al. 2000) et d’un autre 
côté par une faible activité de la eNOS (endothelial NO synthase) qui catalyse la production 
du monoxyde d’azote ou NO, un puissant agent vasodilatateur produit par l’endothéluim à 
partir de la L-Arginine (Palmer et al. 1987). En effet, en présence du NO, l’ion superoxyde 
O2
- 
 forme le peroxynitrite (ONOO
-) empêchant ainsi le NO d’exercer sa fonction 
vasodilatatrice (Beckman et al. 1990; McIntyre et al. 1999; Pacher et al. 2007). 
Physiquement, l’étude des tissus du rat SHR montre qu’au cours de son âge, l’oxygénation 
tissulaire diminue et entraine progressivement ainsi une hypertrophie cardiaque (Engelmann 
et al. 1987) ainsi qu’une augmentation de la résistance périphérique (Smith et al. 1979; 
Folkow et al. 1992). 
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Du fait de l’implication du stress oxydant dans la pathogenèse de l’hypertension, les 
chercheurs se sont intéressés aux effets antihypertenseurs des polyphénols retrouvés dans 
l’alimentation. Leur effet hypotenseur a été confirmé dans de nombreuses études (Galisteo et 
al. 2004; Sarr et al. 2006; Perez-Vizcaino et al. 2009) et serait lié a la capacité des 
polyphénols de réguler l’activité de la eNOS et de la NADPH oxydase. Une étude par Al-
Awwadi et al. (2004) a montré qu’un extrait de polyphénols issus du vin rouge permettait de 
diminuer l’hypertension chez des rats ayant développé un syndrome métabolique suite à un 
régime riche en fructose. Plus précisément, des extraits polyphénoliques enrichis en 
anthocyanes et en catéchines préviennent l’hypertension chez le même modèle animal ce qui 
n’est pas le cas des procyanidines (Al-Awwadi et al. 2005). L’effet antioxydant n’est donc 
pas le seul mode d’action de ces molécules. Ces observations sont en adéquation avec nos 
résultats dans lequel de fortes concentrations en monomères et dimères de flavan-3-ols ont 
été détectés dans les extraits de pépins de marcs exerçant des effets antihypertenseurs. 
Les extraits de marcs peuvent être utilisés seuls mais leurs effets peuvent être 
amplifiés une fois co-ingéré avec le vérapamil. Il est largement reconnu que la glycoprotéine 
P souvent nommé « P-gp » influence le transport des médicaments au travers des membranes. 
La P-pg se retrouve principalement au niveau des cellules du tubule contourné proximal du 
rein, des cellules de l’intestin, de l’endothélium de la barrière hémato-encéphalique etc. Par 
conséquent, elle peut influencer l’absorption, la distribution, le métabolisme et l’excrétion des 
xénobiotiques. La P-pg provoque par efflux, un phénomène de multirésitances à plus de 50% 
des agents anti-cancéreux. Par conséquent, les chercheurs tentent d’optimiser la 
pharmacocinétique, d’améliorer les activités anti-tumorales et de réduire la toxicité 
systémique des médicaments anti-cancéreux en inhibant les efflux de la P-glycoprotéine. 
Bien qu'une grande variété d'inhibiteur de la P-gp ont été découverts, les flavonoïdes 
constituent la troisième génération de la catégorie non-pharmaceutique d'inhibiteurs de la P-
gp (Bansal et al. 2009). Il a été démontré que les effets produits par certains de ces 
composants sont comparables à ceux des inhibiteurs connus de la P-pg tels que le vérapamil 
et la cyclosporine. 
Comme le vérapamil, un inhibiteur de référence de la P-pg et des phénomènes de 
multi-résistance aux médicaments (MDR), les polyphénols ont été démontrés comme ayant 
des propriétés inhibitrices sur le transport de la P-pg affectant la biodisponibilité et 
l’absorption de certains médicaments (Jodoin et al. 2002; Kitagawa 2006; Eichhorn et al. 
2012). De ce fait, l'association d'extraits de pépins et de pellicules de marcs riches en 
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polyphénols au vérapamil peut avoir un effet bénéfique sur la régulation de la pression 
artérielle en modifiant l'absorption du (poly)phénols et/ou du vérapamil. 
En tenant compte de ces observations et des résultats obtenus lors de l’étude in vivo, 
les effets antihypertenseurs des polyphénols peuvent être attribués  à l’action des polyphénols 
contenus dans les extraits de marcs (dans le cas des rats des groupes E1 et E6) et/ou par 
l’action du vérapamil. Dans les groupes E1, E5 et E6, les polyphénols, en particulier les 
monomères et procyanidins de flavan-3-ols, peuvent contribuer aux effets antihypertenseurs 
des extraits. En effet, les extraits de pépins de GRE1 (EA70) et de pellicules d’ALI (EA70) 
renferment une importante quantité de polyphénols que l’extrait de pellicules de MOU 
(EA70). Dans le groupe VE1 et VE6, le vérapamil pourrait permettre une meilleure 
absorption de polyphenols ou vice versa et l’effet antihypertenseur pourrait être du à l’action 
des polyphénols et/ou le vérapamil. Dans les cas des groupes E5 et VE5, il a été démontré 
que les polyphénols sont absorbés de manière importante dans le groupe E5 et une fois 
associée au vérapamil, l’absorption est encore plus élevée. De ce fait, le vérapamil devrait 
permettre une meilleure absorption des polyphénols mais dû à une faible teneur ou à la 
composition en polyphénols des pellicules de MOU (EA70), cet extrait ne possède aucun 
effet antihypertenseur. 
Cette étude constitue une première étape de valorisation de marcs de raisins après 
vinification, en tant qu’activateur de vérapamil, un médicament couramment utilisé contre 
l’hypertension. Des quantités suffisantes de composés phénoliques subsistent dans les marcs, 
en particulier en terme de flavan-3-ols et d’anthocyanes, pour exercer des effets 
antihypertenseurs. En effet, selon le type et la composition des extraits, il est possible de 
moduler les effets antihypertenseurs en amplifiant ou en diminuant l’absorption des 
polyphénols et/ou du vérapamil. Par conséquent, il serait intéressant d'élucider les 
mécanismes exacts et des composés impliqués dans ce phénomène afin de mieux contrôler la 
régulation de la pression artérielle et de faciliter le choix des extraits de pépins et de 
pellicules de marcs. En outre, il serait utile d’étudier l’effet de chaque flavan-3-ols 
(monomères individuels, oligomères…) et des fractions d’anthocyanes (glycosylées, 
acétylées et coumaroylées) afin de déterminer si les effets antihypertenseurs sont liés à un 
composé particulier ou à l’extrait dans son ensemble.  
Des études complémentaires de biodisponibilité pourraient être utiles afin de 
confirmer les résultats obtenus avec le groupe E5/VE5 montrant que le vérapamil permet une 
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meilleure absorption des polyphénols mais en raison de la faible concentration ou de la 
composition en polyphénols de l’extrait de pellicules de marcs MOU (EA70), aucuns effets 
antihypertenseurs n’ont été observés. De plus, la quantification de métabolites de vérapamil 
pourrait être d'un grand intérêt pour évaluer les niveaux d'absorption du vérapamil par rapport 
à ceux de polyphénols. 
Ayant montré leurs efficacités dans un le modèle de rat SHR, les extraits de pépins et 
de pellicules de marcs seuls ou en association avec le vérapamil pourrait faire l’étude d’essais 
cliniques humains. Différents paramètres tels que les sujets (sujets pré-hypertendus ou 
hypertendus), la dose à administrer, l'alimentation, les différentes collections (plasmas, 
urines) et les marqueurs biologiques à quantifier devrait être pris en compte. De plus, le choix 
des variétés des extraits de pépins et de pellicules, les procédés d’extraction à employer, le 
dosage, la forme galénique à utiliser afin de stabiliser les principes actifs devraient être pris 
en compte. 
 
 
302 
 
303 
 
 
 
References 
 
  
 
305 
 
Physical Activity Guidelines Advisory Committee, Physical Activity Guidelines Advisory 
Committee Report, 2008. Washington, DC: US Department of Health and Human 
Services 
Acevedo De la Cruz, A., Hilbert, G., Rivière, C., Mengin, V., Ollat, N., Bordenave, L., 
Decroocq, S., Delaunay, J.-C., Delrot, S., Mérillon, J.-M., Monti, J.-P., Gomès, E. and 
Richard, T. (2012). Anthocyanin identification and composition of wild Vitis spp. 
accessions by using LC–MS and LC–NMR. Analytica Chimica Acta, 732 (0): 145-
152. 
Adams, M. A., Bobik, A. and Korner, P. I. (1989). Differential development of vascular and 
cardiac hypertrophy in genetic hypertension. Relation to sympathetic function. 
Hypertension, 14 (2): 191-202. 
Ader, P., Wessmann, A. and Wolffram, S. (2000). Bioavailability and metabolism of the 
flavonol quercetin in the pig. Free Radical Biology and Medicine, 28 (7): 1056-1067. 
Adrogué, H. J. and Madias, N. E. (2007). Sodium and Potassium in the Pathogenesis of 
Hypertension. New England Journal of Medicine, 356 (19): 1966-1978. 
Aird, W. C. (2005). Spatial and temporal dynamics of the endothelium. Journal of 
Thrombosis and Haemostasis, 3 (7): 1392-1406. 
Ajay, M., Gilani, A.-u. H. and Mustafa, M. R. (2003). Effects of flavonoids on vascular 
smooth muscle of the isolated rat thoracic aorta. Life Sciences, 74 (5): 603-612. 
Al-Awwadi, N. A., Araiz, C., Bornet, A., Delbosc, S., Cristol, J. P., Linck, N., Azay, J., 
Teissedre, P. L. and Cros, G. (2005). Extracts enriched in different polyphenolic 
families normalize increased cardiac NADPH oxidase expression while having 
differential effects on insulin resistance, hypertension, and cardiac hypertrophy in 
high-fructose-fed rats. Journal of Agricultural and Food Chemistry, 53 (1): 151-157. 
Al-Awwadi, N. A., Bornet, A., Azay, J., Araiz, C., Delbosc, S., Cristol, J. P., Linck, N., Cros, 
G. and Teissedre, P. L. (2004). Red wine polyphenols alone or in association with 
ethanol prevent hypertension, cardiac hypertrophy, and production of reactive oxygen 
species in the insulin-resistant fructose-fed rat. Journal of Agricultural and Food 
Chemistry, 52 (18): 5593-5597. 
Alarcón-Flores, M. I., Romero-González, R., Vidal, J. L. M. and Frenich, A. G. (2013). 
Multiclass determination of phytochemicals in vegetables and fruits by ultra high 
performance liquid chromatography coupled to tandem mass spectrometry. Food 
Chemistry, 141 (2): 1120-1129. 
Alcalde-Eon, C., Escribano-Bailón, M. T., Santos-Buelga, C. and Rivas-Gonzalo, J. C. 
(2007). Identification of dimeric anthocyanins and new oligomeric pigments in red 
wine by means of HPLC-DAD-ESI/MSn. Journal of Mass Spectrometry, 42 (6): 735-
748. 
Aldini, G., Carini, M., Piccoli, A., Rossoni, G. and Facino, R. M. (2003). Procyanidins from 
grape seeds protect endothelial cells from peroxynitrite damage and enhance 
endothelium-dependent relaxation in human artery: new evidences for cardio-
protection. Life Sciences, 73 (22): 2883-2898. 
Amico, V., Napoli, E. M., Renda, A., Ruberto, G., Spatafora, C. and Tringali, C. (2004). 
Constituents of grape pomace from the Sicilian cultivar `Nerello Mascalese'. Food 
Chemistry, 88 (4): 599-607. 
Amrani, J., Glories, Y. and Mercier, M. (1994). Localization of tannins in grape berry skins. 
Vitis, 33 (3): 133-138. 
Andriambeloson, E., Kleschyov, A. L., Muller, B., Beretz, A., Stoclet, J. C. and 
Andriantsitohaina, R. (1997). Nitric oxide production and endothelium-dependent 
vasorelaxation induced by wine polyphenols in rat aorta. British Journal of 
Pharmacology, 120 (6): 1053-1058. 
306 
 
Andriambeloson, E., Magnier, C., Haan-Archipoff, G., Lobstein, A., Anton, R., Beretz, A., 
Stoclet, J. C. and Andriantsitohaina, R. (1998). Natural dietary polyphenolic 
compounds cause endothelium-dependent vasorelaxation in rat thoracic aorta. The 
Journal of Nutrition, 128 (12): 2324-2333. 
Appel, L. J., Moore, T. J., Obarzanek, E., Vollmer, W. M., Svetkey, L. P., Sacks, F. M., Bray, 
G. A., Vogt, T. M., Cutler, J. A., Windhauser, M. M., Lin, P.-H., Karanja, N., 
Simons-Morton, D., McCullough, M., Swain, J., Steele, P., Evans, M. A., Miller, E. 
R. and Harsha, D. W. (1997). A clinical trial of the effects of dietary patterns on blood 
pressure. New England Journal of Medicine, 336 (16): 1117-1124. 
Appeldoorn, M. M., Vincken, J.-P., Aura, A.-M., Hollman, P. C. H. and Gruppen, H. 
(2009a). Procyanidin dimers are metabolized by human microbiota with 2-(3,4-
dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)-γ-valerolactone as the 
major metabolites. Journal of Agricultural and Food Chemistry, 57 (3): 1084-1092. 
Appeldoorn, M. M., Vincken, J.-P., Gruppen, H. and Hollman, P. C. H. (2009b). Procyanidin 
dimers A1, A2, and B2 are absorbed without conjugation or methylation from the 
small intestine of rats. The Journal of Nutrition, 139 (8): 1469-1473. 
Aquilano, K., Baldelli, S., Rotilio, G. and Ciriolo, M. (2008). Role of nitric oxide synthases 
in parkinson’s disease: a review on the antioxidant and anti-inflammatory activity of 
polyphenols. Neurochemical Research, 33 (12): 2416-2426. 
Arkwright, P. D., Beilin, L. J., Rouse, I., Armstrong, B. K. and Vandongen, R. (1982). 
Effects of alcohol use and other aspects of lifestyle on blood pressure levels and 
prevalence of hypertension in a working population. Circulation, 66 (1): 60-66. 
Arnous, A., Makris, D. P. and Kefalas, P. (2002). Correlation of pigment and flavanol content 
with antioxidant properties in selected aged regional wines from Greece. Journal of 
Food Composition and Analysis, 15 (6): 655-665. 
Aron, P. M. and Kennedy, J. A. (2008). Flavan-3-ols: nature, occurrence and biological 
activity. Molecular Nutrition & Food Research, 52 (1): 79-104. 
Arranz, S., Silván, J. M. and Saura-Calixto, F. (2010). Nonextractable polyphenols, usually 
ignored, are the major part of dietary polyphenols: A study on the Spanish diet. 
Molecular Nutrition & Food Research, 54 (11): 1646-1658. 
Arts, I. C. and Hollman, P. C. (2005). Polyphenols and disease risk in epidemiologic studies. 
The American Journal of Clinical Nutrition, 81 (1): 317S-325S. 
Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, 
G. R., Tap, J., Bruls, T., Batto, J.-M., Bertalan, M., Borruel, N., Casellas, F., 
Fernandez, L., Gautier, L., Hansen, T., Hattori, M., Hayashi, T., Kleerebezem, M., 
Kurokawa, K., Leclerc, M., Levenez, F., Manichanh, C., Nielsen, H. B., Nielsen, T., 
Pons, N., Poulain, J., Qin, J., Sicheritz-Ponten, T., Tims, S., Torrents, D., Ugarte, E., 
Zoetendal, E. G., Wang, J., Guarner, F., Pedersen, O., de Vos, W. M., Brunak, S., 
Dore, J., Weissenbach, J., Ehrlich, S. D. and Bork, P. (2011). Enterotypes of the 
human gut microbiome. Nature, 473 (7346): 174-180. 
Asen, S., Stewart, R. N. and Norris, K. H. (1975). Anthocyanin, flavonol copigments, and pH 
responsible for larkspur flower color. Phytochemistry, 14 (12): 2677-2682. 
Asenstorfer, R. E., Markides, A. J., Iland, P. G. and Jones, G. P. (2003). Formation of vitisin 
A during red wine fermentation and maturation. Australian Journal of Grape and 
Wine Research, 9 (1): 40-46. 
Auger, C., Caporiccio, B., Landrault, N., Teissedre, P. L., Laurent, C., Cros, G., Besançon, P. 
and Rouanet, J. M. (2002). Red wine phenolic compounds reduce plasma lipids and 
apolipoprotein B and prevent early aortic atherosclerosis in hypercholesterolemic 
golden Syrian hamsters (Mesocricetus auratus). Journal of Nutrition, 132 (6): 1207-
1213. 
307 
 
Auger, C., Gérain, P., Laurent-Bichon, F., Portet, K., Bornet, A., Caporiccio, B., Cros, G., 
Teissédre, P. L. and Rouanet, J. M. (2004). Phenolics from commercialized grape 
extracts prevent early atherosclerotic lesions in hamsters by mechanisms other than 
antioxidant effect. Journal of Agricultural and Food Chemistry, 52 (16): 5297-5302. 
Auger, C., Mullen, W., Hara, Y. and Crozier, A. (2008). Bioavailability of polyphenon E 
flavan-3-ols in humans with an Ileostomy. The Journal of Nutrition, 138 (8): 1535-
1542. 
Aura, A.-M., Mattila, I., Seppänen-Laakso, T., Miettinen, J., Oksman-Caldentey, K.-M. and 
Orešič, M. (2008). Microbial metabolism of catechin stereoisomers by human faecal 
microbiota: Comparison of targeted analysis and a non-targeted metabolomics 
method. Phytochemistry Letters, 1 (1): 18-22. 
Ávila, M., Hidalgo, M., Sánchez-Moreno, C., Pelaez, C., Requena, T. and de Pascual-Teresa, 
S. (2009). Bioconversion of anthocyanin glycosides by Bifidobacteria and 
Lactobacillus. Food Research International, 42 (10): 1453-1461. 
Aviram, M. (1996). Interaction of oxidized low density lipoprotein with macrophages in 
atherosclerosis, and the antiatherogenicity of antioxidants. European journal of 
clinical chemistry and clinical biochemistry, 34 (8): 599-608. 
Aviram, M. and Rosenblat, M. (1994). Macrophage-mediated oxidation of extracellular low 
density lipoprotein requires an initial binding of the lipoprotein to its receptor. 
Journal of Lipid Research, 35 (3): 385-398. 
Aviram, M., Volkova, N., Coleman, R., Dreher, M., Reddy, M. K., Ferreira, D. and 
Rosenblat, M. (2008). Pomegranate phenolics from the peels, arils, and flowers are 
antiatherogenic: studies in vivo in atherosclerotic apolipoprotein E-deficient (E0) 
mice and in vitro in cultured macrophages and lipoproteins. Journal of Agricultural 
and Food Chemistry, 56 (3): 1148-1157. 
Ayed, N., Yu, H. L. and Lacroix, M. (1999). Improvement of anthocyanin yield and shelf-life 
extension of grape pomace by gamma irradiation. Food Research International, 32 
(8): 539-543. 
Baba, S., Osakabe, N., Natsume, M. and Terao, J. (2002). Absorption and urinary excretion 
of procyanidin B2 [epicatechin-(4β-8)-epicatechin] in rats. Free Radical Biology and 
Medicine, 33 (1): 142-148. 
Baba, S., Osakabe, N., Yasuda, A., Natsume, M., Takizawa, T., Nakamura, T. and Terao, J. 
(2000). Bioavailability of (-)-epicatechin upon intake of chocolate and cocoa in 
human volunteers. Free Radical Research, 33 (5): 635-641. 
Baderschneider, B. and Winterhalter, P. (2000). Isolation and characterization of novel 
stilbene derivatives from riesling wine. Journal of Agricultural and Food Chemistry, 
48 (7): 2681-2686. 
Baderschneider, B. and Winterhalter, P. (2001). Isolation and characterization of novel 
benzoates, cinnamates, flavonoids, and lignans from riesling wine and screening for 
antioxidant activity. Journal of Agricultural and Food Chemistry, 49 (6): 2788-2798. 
Badía, E., Sacanella, E., Fernández-Solá, J., Nicolás, J. M., Antúnez, E., Rotilio, D., de 
Gaetano, G., Urbano-Márquez, A. and Estruch, R. (2004). Decreased tumor necrosis 
factor-induced adhesion of human monocytes to endothelial cells after moderate 
alcohol consumption. The American Journal of Clinical Nutrition, 80 (1): 225-230. 
Bagchi, D., Bagchi, M., Stohs, S. J., Das, D. K., Ray, S. D., Kuszynski, C. A., Joshi, S. S. and 
Pruess, H. G. (2000). Free radicals and grape seed proanthocyanidin extract: 
importance in human health and disease prevention. Toxicology, 148 (2–3): 187-197. 
Bagchi, D., Sen, C. K., Ray, S. D., Das, D. K., Bagchi, M., Preuss, H. G. and Vinson, J. A. 
(2003). Molecular mechanisms of cardioprotection by a novel grape seed 
308 
 
proanthocyanidin extract. Mutation Research/Fundamental and Molecular 
Mechanisms of Mutagenesis, 523–524 (0): 87-97. 
Bakker, J. and Timberlake, C. F. (1997). Isolation, identification, and characterization of new 
color-stable anthocyanins occurring in some red wines. Journal of Agricultural and 
Food Chemistry, 45 (1): 35-43. 
Balentine, D. A., Wiseman, S. A. and Bouwens, L. C. M. (1997). The chemistry of tea 
flavonoids. Critical Reviews in Food Science and Nutrition, 37 (8): 693-704. 
Baltenweck-Guyot, R., Trendel, J.-M., Albrecht, P. and Schaeffer, A. (2000). Glycosides and 
phenylpropanoid glycerol in Vitis vinifera Cv. Gewurztraminer wine. Journal of 
Agricultural and Food Chemistry, 48 (12): 6178-6182. 
Bansal, T., Jaggi, M., Khar, R. K. and Talegaonkar, S. (2009). Emerging significance of 
flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. Journal of 
Pharmaceutical Sciences, 12 (1): 46-78. 
Barrand, M. A., Robertson, K. J. and von Weikersthal, S. F. (1995). Comparisons of P-
glycoprotein expression in isolated rat brain microvessels and in primary cultures of 
endothelial cells derived from microvasculature of rat brain, epididymal fat pad and 
from aorta. FEBS Letters, 374 (2): 179-183. 
Basalan, M., Gungor, T., Owens, F. N. and Yalcinkaya, I. (2011). Nutrient content and in 
vitro digestibility of Turkish grape pomaces. Animal Feed Science and Technology 
169 (3): 194-198. 
Baumgärtel, T., Kluth, H., Epperlein, K. and Rodehutscord, M. (2007). A note on 
digestibility and energy value for sheep of different grape pomace. Small Ruminant 
Research, 67 (2–3): 302-306. 
Bautista-Ortín, A. B., Busse-Valverde, N., López-Roca, J. M., Gil-Muñoz, R. and Gómez-
Plaza, E. (2013). Grape seed removal: effect on phenolics, chromatic and organoleptic 
characteristics of red wine. International Journal of Food Science & Technology: doi: 
10.1111/ijfs.12270. 
Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A. and Freeman, B. A. (1990). 
Apparent hydroxyl radical production by peroxynitrite: implications for endothelial 
injury from nitric oxide and superoxide. Proceedings of the National Academy of 
Sciences, 87 (4): 1620-1624. 
Behbahani, J., Thandapilly, S. J., Louis, X. L., Huang, Y., Shao, Z., Kopilas, M. A., 
Wojciechowski, P., Netticadan, T. and Anderson, H. D. (2010). Resveratrol and small 
artery compliance and remodeling in the spontaneously hypertensive rat. American 
Journal of Hypertension, 23 (12): 1273-1278. 
Bell, J. R., Donovan, J. L., Wong, R., Waterhouse, A. L., German, J. B., Walzem, R. L. and 
Kasim-Karakas, S. E. (2000). (+)-Catechin in human plasma after ingestion of a 
single serving of reconstituted red wine. The American Journal of Clinical Nutrition, 
71 (1): 103-108. 
Benzie, I. F. F. and Strain, J. J. (1996). The ferric reducing ability of plasma (FRAP) as a 
measure of 'antioxidant power': The FRAP assay. Analytical Biochemistry, 239 (1): 
70-76. 
Beretz, A., Cazenave, J. P. and Anton, R. (1982). Inhibition of aggregation and secretion of 
human platelets by quercetin and other flavonoids: structure-activity relationships. 
Agents Actions, 12 (3): 382-387. 
Bernátová, I., Pechánová, O., Babál, P., Kyselá, S., Stvrtina, S. and Andriantsitohaina, R. 
(2002). Wine polyphenols improve cardiovascular remodeling and vascular function 
in NO-deficient hypertension. American Journal of Physiology - Heart and 
Circulatory Physiology, 282 (3): H942-H948. 
309 
 
Berrougui, H., Grenier, G., Loued, S., Drouin, G. and Khalil, A. (2009). A new insight into 
resveratrol as an atheroprotective compound: Inhibition of lipid peroxidation and 
enhancement of cholesterol efflux. Atherosclerosis, 207 (2): 420-427. 
Bertelli, A. A., Giovannini, L., Giannessi, D., Migliori, M., Bernini, W., Fregoni, M. and 
Bertelli, A. (1995). Antiplatelet activity of synthetic and natural resveratrol in red 
wine. International journal of tissue reactions, 17 (1): 1-3. 
Bhat, K. P. L., Kosmeder, J. W., 2nd and Pezzuto, J. M. (2001). Biological effects of 
resveratrol. Antioxidants & Redox Signaling, 3 (6): 1041-1064. 
Biala, A., Tauriainen, E., Siltanen, A., Shi, J., Merasto, S., Louhelainen, M., Martonen, E., 
Finckenberg, P., Muller, D. N. and Mervaala, E. (2010). Resveratrol induces 
mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in 
transgenic rats harboring human renin and angiotensinogen genes. Blood Press, 19 
(3): 196-205. 
Bianchi, G., Baer, P. G., Fox, U., Duzzi, L., Pagetti, D. and Giovannetti, A. M. (1975). 
Changes in renin, water balance, and sodium balance during development of high 
blood pressure in genetically hypertensive rats. Circulation Research, 36 (6 Suppl 1): 
153-161. 
Blaustein, M. P. (1977). Sodium ions, calcium ions, blood pressure regulation, and 
hypertension: a reassessment and a hypothesis. American Journal of Physiology - Cell 
Physiology, 232 (5): C165-C173. 
Boban, M., Modun, D., Music, I., Vukovic, J., Brizic, I., Salamunic, I., Obad, A., Palada, I. 
and Dujic, Z. (2006). Red wine induced modulation of vascular function: separating 
the role of polyphenols, ethanol, and urates. Journal of Cardiovascular Pharmacology 
47 (5): 695-701. 
Boido, E., Alcalde-Eon, C., Carrau, F., Dellacassa, E. and Rivas-Gonzalo, J. n. C. (2006). 
Aging effect on the pigment composition and color of Vitis vinifera L. Cv. tannat 
wines. Contribution of the main pigment families to wine color. Journal of 
Agricultural and Food Chemistry, 54 (18): 6692-6704. 
Bond Brill, J. (2011). Lifestyle Intervention Strategies for the Prevention and Treatment of 
Hypertension: A Review. American Journal of Lifestyle Medicine, 5 (4): 346-360. 
Bordiga, M., Travaglia, F., Locatelli, M., Coïsson, J. D. and Arlorio, M. (2011). 
Characterisation of polymeric skin and seed proanthocyanidins during ripening in six 
Vitis vinifera L. cv. Food Chemistry, 127 (1): 180-187. 
Botella, C., Ory, I. d., Webb, C., Cantero, D. and Blandino, A. (2005). Hydrolytic enzyme 
production by Aspergillus awamori on grape pomace. Biochemical Engineering 
Journal, 26 (2–3): 100-106. 
Boulton, R. (2001). The Copigmentation of Anthocyanins and Its Role in the Color of Red 
Wine: A Critical Review. American Journal of Enology and Viticulture, 52 (2): 67-
87. 
Bozan, B., Tosun, G. and Özcan, D. (2008). Study of polyphenol content in the seeds of red 
grape (Vitis vinifera L.) varieties cultivated in Turkey and their antiradical activity. 
Food Chemistry, 109 (2): 426-430. 
Brand-Williams, W., Cuvelier, M. E. and Berset, C. (1995). Use of a free radical method to 
evaluate antioxidant activity. LWT - Food Science and Technology, 28 (1): 25-30. 
Bravo, L. (1998). Polyphenols: chemistry, dietary sources, metabolism, and nutritional 
significance. Nutrition Reviews, 56 (11): 317-333. 
Bravo, L. and Saura-Calixto, F. (1998). Characterization of dietary fiber and the In vitro 
indigestible fraction of grape pomace. American Journal of Enology and Viticulture, 
49 (2): 135-141. 
310 
 
Bray, G. A., Vollmer, W. M., Sacks, F. M., Obarzanek, E., Svetkey, L. P. and Appel, L. J. 
(2004). A further subgroup analysis of the effects of the DASH diet and three dietary 
sodium levels on blood pressure: results of the DASH-Sodium Trial. American 
Journal of  Cardiology, 94 (2): 222-227. 
Brenes, A., Viveros, A., Goñi, I., Centeno, C., Sáyago-Ayerdy, S. G., Arija, I. and Saura-
Calixto, F. (2008). Effect of grape pomace concentrate and vitamin E on digestibility 
of polyphenols and antioxidant activity in chickens. Poultry Science, 87 (2): 307-316. 
Briasoulis, A., Agarwal, V. and Messerli, F. H. (2012). Alcohol consumption and the risk of 
hypertension in men and women: a systematic review and meta-analysis. The Journal 
of Clinical Hypertension, 14 (11): 792-798. 
Brook, R. D. and Julius, S. (2000). Autonomic imbalance, hypertension, and cardiovascular 
risk. American Jourmal of Hypertension, 13 (6): 112S-122S. 
Brouillard, R. and Dangles, O. (1994). Anthocyanin molecular interactions: the first step in 
the formation of new pigments during wine aging? Food Chemistry, 51 (4): 365-371. 
Brouillard, R., Delaporte, B. and Dubois, J. E. (1978). Chemistry of anthocyanin pigments. 3. 
Relaxation amplitudes in pH-jump experiments. Journal of the American Chemical 
Society, 100 (19): 6202-6205. 
Bub, A., Watzl, B., Heeb, D., Rechkemmer, G. and Briviba, K. (2001). Malvidin-3-glucoside 
bioavailability in humans after ingestion of red wine, dealcoholized red wine and red 
grape juice. European Journal of Nutrition, 40 (3): 113-120. 
Burkon, A. and Somoza, V. (2008). Quantification of free and protein-bound trans-resveratrol 
metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides – 
Two novel resveratrol metabolites in human plasma. Molecular Nutrition & Food 
Research, 52 (5): 549-557. 
Busse, D., Fromm, M. F., Morike, K., Drescher, S., Kuhlkamp, V. and Eichelbaum, M. 
(2001). Disposition and pharmacologic effects of R/S-verapamil in patients with 
chronic atrial fibrillation: an investigation comparing single and multiple dosing. 
Clinical Pharmacology Therapeutics, 69 (5): 324-332. 
Busse, D., Templin, S., Mikus, G., Schwab, M., Hofmann, U., Eichelbaum, M. and Kivisto, 
K. T. (2006). Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil 
in humans: a placebo-controlled study. European Journal of Clinical Pharmacology, 
62 (8): 613-619. 
Bustamante, M. A., Moral, R., Paredes, C., Pérez-Espinosa, A., Moreno-Caselles, J. and 
Pérez-Murcia, M. D. (2008). Agrochemical characterisation of the solid by-products 
and residues from the winery and distillery industry. Waste Management, 28 (2): 372-
380. 
Cappuccio, F. P. and MacGregor, G. A. (1991). Does potassium supplementation lower blood 
pressure? A meta-analysis of published trials. Journal of Hypertension, 9 (5): 465-
473. 
Carando, S. and Teissedre, P. L. (1999a). Catechin and procyanidin levels in French wines: 
contribution to dietary intake. Basic life sciences, 66: 725-737. 
Carando, S., Teissedre, P. L., Pascual-Martinez, L. and Cabanis, J. C. (1999b). Levels of 
flavan-3-ols in French wines. Journal of Agricultural and Food Chemistry, 47 (10): 
4161-4166. 
Carillon, J., Del Rio, D., Teissèdre, P. L., Cristol, J. P., Lacan, D. and Rouanet, J. M. (2012). 
Antioxidant capacity and angiotensin converting enzyme inhibitory activity of a 
melon concentrate rich in superoxide dismutase. Food Chemistry, 135 (3): 1298-1302. 
Castilla, P., Echarri, R., Dávalos, A., Cerrato, F., Ortega, H., Teruel, J. L., Lucas, M. F., 
Gómez-Coronado, D., Ortuño, J. and Lasunción, M. A. (2006). Concentrated red 
grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both 
311 
 
hemodialysis patients and healthy subjects. The American Journal of Clinical 
Nutrition, 84 (1): 252-262. 
Castillo-Muñoz, N., Gómez-Alonso, S., García-Romero, E. and Hermosín-Gutiérrez, I. 
(2007). Flavonol profiles of vitis vinifera red grapes and their single-cultivar wines. 
Journal of Agricultural and Food Chemistry, 55 (3): 992-1002. 
Castillo-Pichardo, L., Martínez-Montemayor, M., Martínez, J., Wall, K., Cubano, L. and 
Dharmawardhane, S. (2009). Inhibition of mammary tumor growth and metastases to 
bone and liver by dietary grape polyphenols. Clinical & Experimental Metastasis, 26 
(6): 505-516. 
Chalopin, M., Tesse, A., Martínez, M. C., Rognan, D., Arnal, J.-F. and Andriantsitohaina, R. 
(2010). Estrogen receptor alpha as a key target of red wine polyphenols action on the 
endothelium. Plos One, 5 (1): e8554. 
Chamkha, M., Cathala, B., Cheynier, V. and Douillard, R. (2003). Phenolic composition of 
champagnes from Chardonnay and Pinot Noir vintages. Journal of Agricultural and 
Food Chemistry, 51 (10): 3179-3184. 
Chapleau, M. W., Hajduczok, G. and Abboud, F. M. (1992). Suppression of baroreceptor 
discharge by endothelin at high carotid sinus pressure. American Journal of 
Physiology - Cell Physiology, 263 (1 Pt 2): R103-108. 
Chen, J., He, S., Mao, H., Sun, C. and Pan, Y. (2009). Characterization of polyphenol 
compounds from the roots and stems of Parthenocissus laetevirens by high-
performance liquid chromatography/tandem mass spectrometry. Rapid 
Communications in Mass Spectrometry, 23 (6): 737-744. 
Chesson, A., Provan, G. J., Russell, W. R., Scobbie, L., Richardson, A. J. and Stewart, C. 
(1999). Hydroxycinnamic acids in the digestive tract of livestock and humans. 
Journal of the Science of Food and Agriculture, 79 (3): 373-378. 
Cheynier, V., Dueñas-Paton, M., Salas, E., Maury, C., Souquet, J.-M., Sarni-Manchado, P. 
and Fulcrand, H. (2006). Structure and properties of wine pigments and tannins. 
American Journal of Enology and Viticulture, 57 (3): 298-305. 
Chin-Dusting, J. P. F., Fisher, L. J., Lewis, T. V., Piekarska, A., Nestel, P. J. and Husband, A. 
(2001). The vascular activity of some isoflavone metabolites: implications for a 
cardioprotective role. British Journal of Pharmacology, 133 (4): 595-605. 
Chira, K., Schmauch, G., Saucier, C., Fabre, S. and Teissedre, P. L. (2009). Grape variety 
effect on proanthocyanidin composition and sensory perception of skin and seed 
tannin extracts from Bordeaux wine grapes (cabernet Sauvignon and merlot) for two 
consecutive vintages (2006 and 2007). Journal of Agricultural and Food Chemistry, 
57 (2): 545-553. 
Chira, K., Suh, J. H., Saucier, C. and Teissèdre, P. L. (2008). Grape phenolics. Phytotherapie, 
6 (2): 75-82. 
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., 
Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., Roccella, E. J. and Committee, 
t. N. H. B. P. E. P. C. (2003). Seventh report of the joint national committee on 
prevention, detection, evaluation, and treatment of high blood pressure. Hypertension, 
42 (6): 1206-1252. 
Choi, J.-S., Bae, J.-Y., Kim, D. S., Li, J., Kim, J.-L., Lee, Y.-J. and Kang, Y.-H. (2009). 
Dietary compound quercitrin dampens VEGF induction and PPARγ activation in 
oxidized LDL-exposed murine macrophages: association with scavenger receptor 
CD36. Journal of Agricultural and Food Chemistry, 58 (2): 1333-1341. 
Chong, J., Poutaraud, A. and Hugueney, P. (2009). Metabolism and roles of stilbenes in 
plants. Plant Science, 177 (3): 143-155. 
312 
 
Chorti, E., Guidoni, S., Ferrandino, A. and Novello, V. (2010). Effect of different cluster 
sunlight exposure levels on ripening and anthocyanin accumulation in Nebbiolo 
grapes. American Journal of Enology and Viticulture, 61 (1): 23-30. 
Chou, E. J., Keevil, J. G., Aeschlimann, S., Wiebe, D. A., Folts, J. D. and Stein, J. H. (2001). 
Effect of ingestion of purple grape juice on endothelial function in patients with 
coronary heart disease. The American Journal of Cardiology, 88 (5): 553-555. 
Chun, O. K., Chung, S. J. and Song, W. O. (2007). Estimated dietary flavonoid intake and 
major food sources of U.S. adults. The Journal of Nutrition, 137 (5): 1244-1252. 
Chung, K.-T., Wong, T. Y., Wei, C.-I., Huang, Y.-W. and Lin, Y. (1998). Tannins and 
human health: a review. Critical Reviews in Food Science and Nutrition, 38 (6): 421-
464. 
Cirillo, M., Laurenzi, M., Panarelli, W. and Stamler, J. (1994). Urinary sodium to potassium 
ratio and urinary stone disease. The Gubbio Population Study Research Group. 
Kidney International, 46 (4): 1133-1139. 
Clifford, M. N. (1999). Chlorogenic acids and other cinnamates – nature, occurrence and 
dietary burden. Journal of the Science of Food and Agriculture, 79 (3): 362-372. 
Clifford, M. N. (2000). Anthocyanins – nature, occurrence and dietary burden. Journal of the 
Science of Food and Agriculture, 80 (7): 1063-1072. 
Clifton, P. M. (2004). Effect of grape seed extract and quercetin on cardiovascular and 
endothelial parameters in high-risk subjects. Journal of Biomedicine and 
Biotechnology, 5: 272-278. 
Conde, E., Moure, A., Domínguez, H. and Parajó, J. C. (2011). Production of antioxidants by 
non-isothermal autohydrolysis of lignocellulosic wastes. LWT - Food Science and 
Technology, 44 (2): 436-442. 
Conquer, J. A., Maiani, G., Azzini, E., Raguzzini, A. and Holub, B. J. (1998). 
Supplementation with quercetin markedly increases plasma quercetin concentration 
without effect on selected risk factors for heart disease in healthy subjects. The 
Journal of Nutrition, 128 (3): 593-597. 
Convertino, V. A. (1998). Gender differences in autonomic functions associated with blood 
pressure regulation. American Journal of Physiology - Regulatory, Integrative and 
Comparative Physiology, 275 (6): R1909-R1920. 
Corder, R., Douthwaite, J. A., Lees, D. M., Khan, N. Q., Viseu dos Santos, A. C., Wood, E. 
G. and Carrier, M. J. (2001). Health: Endothelin-1 synthesis reduced by red wine. 
Nature, 414 (6866): 863-864. 
Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R. and Melamed, M. R. 
(1990). Expression of the multidrug resistance gene product (P-glycoprotein) in 
human normal and tumor tissues. Journal of Histochemistry & Cytochemistry, 38 (9): 
1277-1287. 
Cornelissen, V. A. and Fagard, R. H. (2005). Effects of endurance training on blood pressure, 
blood pressure–regulating mechanisms, and cardiovascular risk factors. Hypertension, 
46 (4): 667-675. 
Cortell, J. M. and Kennedy, J. A. (2006). Effect of shading on accumulation of flavonoid 
compounds in (Vitis vinifera L.) Pinot Noir fruit and extraction in a model system. 
Journal of Agricultural and Food Chemistry, 54 (22): 8510-8520. 
Corvol, P., Persu, A., Gimenez-Roqueplo, A.-P. and Jeunemaitre, X. (1999). Seven lessons 
from two candidate genes in human essential hypertension: angiotensinogen and 
epithelial sodium channel. Hypertension, 33 (6): 1324-1331. 
Cotelle, N. (2001). Role of flavonoids in oxidative stress. Current Topics in Medicinal 
Chemistry, 1 (6): 569-590. 
313 
 
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-
dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., Scholey, J., Ferrario, C. M., 
Manoukian, A. S., Chappell, M. C., Backx, P. H., Yagil, Y. and Penninger, J. M. 
(2002). Angiotensin-converting enzyme 2 is an essential regulator of heart function. 
Nature, 417 (6891): 822-828. 
Crespo, M. J., Escobales, N. and Rodriguez-Sargent, C. (1996). Endothelial dysfunction in 
the San Juan hypertensive rat: possible role of the nitric oxide synthase. Journal of 
Cardiovascular Pharmacology, 27 (6): 802-808. 
Crespy, V., Morand, C., Besson, C., Cotelle, N., Vézin, H., Demigné, C. and Rémésy, C. 
(2003). The splanchnic metabolism of flavonoids highly differed according to the 
nature of the compound. American Journal of Physiology - Gastrointestinal and Liver 
Physiology, 284 (6): 980-988. 
Crozier, A., Del Rio, D. and Clifford, M. N. (2010). Bioavailability of dietary flavonoids and 
phenolic compounds. Molecular Aspects of Medicine, 31 (6): 446-467. 
Crozier, A., Jaganath, I. and Clifford, M. N. (2006). Phenols, polyphenols and tannins: an 
overview. In Plant Secondary Metabolites : Occurence, Structure and Role in the 
Human Diet.  pp. 1-24. Crozier, A., Clifford, M. N. and Hiroshi, A., Oxford, 
Blackwell Publishing. 
Crozier, A., Jaganath, I. B. and Clifford, M. N. (2009). Dietary phenolics: chemistry, 
bioavailability and effects on health. Natural Product Reports, 26 (8): 1001-1043. 
Crozier, A., Lean, M. E. J., McDonald, M. S. and Black, C. (1997). Quantitative analysis of 
the flavonoid content of commercial tomatoes, onions, lettuce, and celery. Journal of 
Agricultural and Food Chemistry, 45 (3): 590-595. 
Cueva, C., Sanchez-Patan, F., Monagas, M., Walton, G. E., Gibson, G. R., Martin-Alvarez, P. 
J., Bartolome, B. and Moreno-Arribas, M. V. (2013). In vitro fermentation of grape 
seed flavan-3-ol fractions by human faecal microbiota: changes in microbial groups 
and phenolic metabolites. FEMS Microbiology Ecology, 83 (3): 792-805. 
Dahl, L. K., Heine, M. and Tassinari, L. (1962a). Effects of chronia excess salt ingestion. 
Evidence that genetic factors play an important role in susceptibility to experimental 
hypertension. Journal of Experimental Medicine, 115: 1173-1190. 
Dahl, L. K., Heine, M. and Tassinari, L. (1962b). Role of genetic factors in susceptibility to 
experimental hypertension due to chronic excess salt ingestion. Nature, 194: 480-482. 
Darné, G. (1991). Recherces sur la composition en anthocyanes des grappes et des feuilles de 
vigne. Université de Bordeaux 2, Bordeaux 
Das, N. P. (1971). Studies on flavonoid metabolism: Absorption and metabolism of (+)-
catechin in man. Biochemical Pharmacology, 20 (12): 3435-3445. 
Dávalos, A., Gómez-Cordovés, C. and Bartolomé, B. (2004). Extending applicability of the 
oxygen radical absorbance capacity (ORAC-Fluorescein) assay. Journal of 
Agricultural and Food Chemistry, 52 (1): 48-54. 
Davì, G. and Patrono, C. (2007). Platelet Activation and Atherothrombosis. New England 
Journal of Medicine, 357 (24): 2482-2494. 
Davis, B. R., Blaufox, M., Oberman, A. and et al. (1993). Reduction in long-term 
antihypertensive medication requirements: Effects of weight reduction by dietary 
intervention in overweight persons with mild hypertension. Archives of Internal 
Medicine, 153 (15): 1773-1782. 
Day, A. J., Ca ada, F. J., D  az, J. C., Kroon, P. A., McLauchlan, R., Faulds, C. B., Plumb, G. 
W., Morgan, M. R. A. and Williamson, G. (2000). Dietary flavonoid and isoflavone 
glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS 
Letters, 468 (2–3): 166-170. 
314 
 
Day, A. J., DuPont, M. S., Ridley, S., Rhodes, M., Rhodes, M. J. C., Morgan, M. R. A. and 
Williamson, G. (1998). Deglycosylation of flavonoid and isoflavonoid glycosides by 
human small intestine and liver β-glucosidase activity. FEBS Letters, 436 (1): 71-75. 
Day, A. J., Gee, J. M., DuPont, M. S., Johnson, I. T. and Williamson, G. (2003). Absorption 
of quercetin-3-glucoside and quercetin-4′-glucoside in the rat small intestine: the role 
of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. 
Biochemical Pharmacology, 65 (7): 1199-1206. 
De Sanctis, F., Silvestrini, M. G., Luneia, R., Botondi, R., Bellincontro, A. and Mencarelli, F. 
(2012). Postharvest dehydration of wine white grapes to increase genistein, daidzein 
and the main carotenoids. Food Chemistry, 135 (3): 1619-1625. 
De Vries, J. H. M., Hollman, P. C. H., van Amersfoort, I., Olthof, M. R. and Katan, M. B. 
(2001). Red wine is a poor source of bioavailable flavonols in men. The Journal of 
Nutrition, 131 (3): 745-748. 
Deanfield, J., Donald, A., Ferri, C., Giannattasio, C., Halcox, J., Halligan, S., Lerman, A., 
Mancia, G., Oliver, J. J., Pessina, A. C., Rizzoni, D., Rossi, G. P., Salvetti, A., 
Schiffrin, E. L., Taddei, S. and Webb, D. J. (2005). Endothelial function and 
dysfunction. Part I: Methodological issues for assessment in the different vascular 
beds: a statement by the Working Group on Endothelin and Endothelial Factors of the 
European Society of Hypertension. Journal of Hypertension, 23 (1): 7-17. 
Del Rio, D., Costa, L. G., Lean, M. E. J. and Crozier, A. (2010). Polyphenols and health: 
What compounds are involved? Nutrition, Metabolism and Cardiovascular Diseases, 
20 (1): 1-6. 
Del Rio, D., Rodriguez-Mateos, A., Spencer, J. P., Tognolini, M., Borges, G. and Crozier, A. 
(2013). Dietary (poly)phenolics in human health: structures, bioavailability, and 
evidence of protective effects against chronic diseases. Antioxidants & Redox 
Signaling, 18 (14): 1818-1892. 
Delgado, R., Martín, P., del Álamo, M. and González, M.-R. (2004). Changes in the phenolic 
composition of grape berries during ripening in relation to vineyard nitrogen and 
potassium fertilisation rates. Journal of the Science of Food and Agriculture, 84 (7): 
623-630. 
Delmas, D., Jannin, B. and Latruffe, N. (2005). Resveratrol: preventing properties against 
vascular alterations and ageing. Molecular Nutrition & Food Research, 49 (5): 377-
395. 
Demrow, H. S., Slane, P. R. and Folts, J. D. (1995). Administration of wine and grape juice 
inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. 
Circulation, 91 (4): 1182-1188. 
Deng, Q., Penner, M. H. and Zhao, Y. (2011). Chemical composition of dietary fiber and 
polyphenols of five different varieties of wine grape pomace skins. Food Research 
International, 44 (9): 2712-2720. 
Déprez, S., Brezillon, C., Rabot, S., Philippe, C., Mila, I., Lapierre, C. and Scalbert, A. 
(2000). Polymeric proanthocyanidins are catabolized by human colonic microflora 
into low-molecular-weight phenolic acids. The Journal of Nutrition, 130 (11): 2733-
2738. 
Desch, S., Schmidt, J., Kobler, D., Sonnabend, M., Eitel, I., Sareban, M., Rahimi, K., 
Schuler, G. and Thiele, H. (2010). Effect of cocoa products on blood pressure: 
systematic review and meta-analysis. American Journal of Hypertension 23 (1): 97-
103. 
Devine, A., Criddle, R. A., Dick, I. M., Kerr, D. A. and Prince, R. L. (1995). A longitudinal 
study of the effect of sodium and calcium intakes on regional bone density in 
postmenopausal women. The American Journal of Clinical Nutrition, 62 (4): 740-745. 
315 
 
Díaz, A. B., Bolívar, J., de Ory, I., Caro, I. and Blandino, A. (2011). Applicability of 
enzymatic extracts obtained by solid state fermentation on grape pomace and orange 
peels mixtures in must clarification. LWT - Food Science and Technology, 44 (4): 
840-846. 
Dickinson, B. D., Havas, S. and et al. (2007). Reducing the population burden of 
cardiovascular disease by reducing sodium intake: A report of the council on science 
and public health. Archives of Internal Medicine, 167 (14): 1460-1468. 
Diebolt, M., Bucher, B. and Andriantsitohaina, R. (2001). Wine polyphenols decrease blood 
pressure, improve NO vasodilatation, and induce gene expression. Hypertension, 38 
(2): 159-165. 
Dietz R., Shomig A. and Rascher, W. (1984). Pathophysiological aspects of genetically-
determined hypertension in rats with special emphasis on stroke prone spontaneously 
hypertensive rats. In Hanbook of Hypertension.  pp. 256-285, Amsterdam, New York, 
Oxford, Elsevier. 
Do, G.-M., Kwon, E.-Y., Kim, H.-J., Jeon, S.-M., Ha, T.-Y., Park, T. and Choi, M.-S. (2008). 
Long-term effects of resveratrol supplementation on suppression of atherogenic lesion 
formation and cholesterol synthesis in apo E-deficient mice. Biochemical and 
Biophysical Research Communications, 374 (1): 55-59. 
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, 
M., Woolf, B., Robison, K., Jeyaseelan, R., Breitbart, R. E. and Acton, S. (2000). A 
Novel angiotensin-converting enzyme related carboxypeptidase (ACE2) converts 
angiotensin I to angiotensin 1-9. Circulation Research, 87 (5): 1-9. 
Donovan, J. L., Bell, J. R., Kasim-Karakas, S., German, J. B., Walzem, R. L., Hansen, R. J. 
and Waterhouse, A. L. (1999). Catechin is present as metabolites in human plasma 
after consumption of red wine. The Journal of Nutrition, 129 (9): 1662-1668. 
Donovan, J. L., Kasim-Karakas, S., German, J. B. and Waterhouse, A. L. (2002a). Urinary 
excretion of catechin metabolites by human subjects after red wine consumption. 
British Journal of Nutrition, 87 (1): 31-37. 
Donovan, J. L., Lee, A., Manach, C., Rios, L., Morand, C., Scalbert, A. and Rémésy, C. 
(2002b). Procyanidins are not bioavailable in rats fed a single meal containing a 
grapeseed extract or the procyanidin dimer B3. British Journal of Nutrition, 87 (04): 
299-306. 
Donovan, J. L., Manach, C., Faulks, R. M. and Kroon, P. A. (2007). Absorption and 
metabolism of dietary plant secondary metabolites. In Plant Secondary Metabolites: 
Occurrence, Structure and Role in the Human Diet.  pp. 303-351, Blackwell 
Publishing Ltd. 
Downey, M. O., Harvey, J. S. and Robinson, S. P. (2004). The effect of bunch shading on 
berry development and flavonoid accumulation in Shiraz grapes. Australian Journal 
of Grape and Wine Research, 10 (1): 55-73. 
Draijer, R., den Hartog, S. and Mulder, T. P. J. (2009). Food composition. US20090186118. 
Dreosti, I. E. (1996). Bioactive ingredients: antioxidants and polyphenols in tea. Nutrition 
Reviews, 54 (11): 51-58. 
Drinkine, J., Lopes, P., Kennedy, J. A., Teissedre, P. L. and Saucier, C. (2007). Analysis of 
ethylidene-bridged flavan-3-ols in wine. Journal of Agricultural and Food Chemistry, 
55 (4): 1109-1116. 
Dröge, W. (2002). Free radicals in the physiological control of cell function. Physiological 
Reviews, 82 (1): 47-95. 
du Cailar, G., Ribstein, J. and Mimran, A. (2002). Dietary sodium and target organ damage in 
essential hypertension. American Journal of Hypertension, 15 (3): 222-229. 
316 
 
Duarte, J., Jiménez, R., Villar, I. C., Pérez-Vizcaíno, F., Jiménez, J. and Tamargo, J. (2001). 
Vasorelaxant effects of the bioflavonoid chrysin in isolated rat aorta. Planta Medica, 
67 (06): 567-569. 
Dudonné, S., Vitrac, X., Coutière, P., Woillez, M. and Mérillon, J. M. (2009). Comparative 
study of antioxidant properties and total phenolic content of 30 plant extracts of 
industrial interest using DPPH, ABTS, FRAP, SOD, and ORAC assays. CORD 
Conference Proceedings, 57 (5): 1768-1774. 
Duffy, S. J., Keaney Jr, J. F., Holbrook, M., Gokce, N., Swerdloff, P. L., Frei, B. and Vita, J. 
A. (2001). Short- and long-term black tea consumption reverses endothelial 
dysfunction in patients with coronary artery disease. Circulation, 104 (2): 151-156. 
Dyer, A. R. and Elliott, P. (1989). The INTERSALT study: relations of body mass index to 
blood pressure. INTERSALT Co-operative Research Group. Journal of Human 
Hypertension, 3 (5): 299-308. 
Echizen, H. and Eichelbaum, M. (1986). Clinical pharmacokinetics of verapamil, nifedipine 
and diltiazem. Clinical Pharmacokinetics, 11 (6): 425-449. 
Egert, M., de Graaf, A. A., Smidt, H., de Vos, W. M. and Venema, K. (2006). Beyond 
diversity: functional microbiomics of the human colon. Trends in Microbiology, 14 
(2): 86-91. 
Eichhorn, T. and Efferth, T. (2012). P-glycoprotein and its inhibition in tumors by 
phytochemicals derived from Chinese herbs. Journal of Ethnopharmacology, 141 (2): 
557-570. 
Endemann, D. H. and Schiffrin, E. L. (2004). Endothelial dysfunction. Journal of the 
American Society of Nephrology, 15 (8): 1983-1992. 
Erlund, I., Koli, R., Alfthan, G., Marniemi, J., Puukka, P., Mustonen, P., Mattila, P. and Jula, 
A. (2008). Favorable effects of berry consumption on platelet function, blood 
pressure, and HDL cholesterol. The American Journal of Clinical Nutrition, 87 (2): 
323-331. 
Erlund, I., Meririnne, E., Alfthan, G. and Aro, A. (2001). Plasma kinetics and urinary 
excretion of the flavanones naringenin and hesperetin in humans after ingestion of 
orange juice and grapefruit juice. The Journal of Nutrition, 131 (2): 235-241. 
Es-Safi, N.-E., Guyot, S. and Ducrot, P.-H. (2006). NMR, ESI/MS, and MALDI-TOF/MS 
analysis of pear juice polymeric proanthocyanidins with potent free radical 
scavenging activity. Journal of Agricultural and Food Chemistry, 54 (19): 6969-6977. 
Fagard, R. H. (2005). Effects of exercise, diet and their combination on blood pressure. 
Journal of Human Hypertension, 19: 20-24. 
Farinella, N. V., Matos, G. D., Lehmann, E. L. and Arruda, M. A. Z. (2008). Grape bagasse 
as an alternative natural adsorbent of cadmium and lead for effluent treatment. 
Journal of Hazardous Materials, 154: 1007-1012. 
Felgines, C., Talavéra, S., Gonthier, M.-P., Texier, O., Scalbert, A., Lamaison, J.-L. and 
Rémésy, C. (2003). Strawberry anthocyanins are recovered in urine as glucuro- and 
sulfoconjugates in humans. The Journal of Nutrition, 133 (5): 1296-1301. 
Felgines, C., Talavera, S., Texier, O., Gil-Izquierdo, A., Lamaison, J.-L. and Remesy, C. 
(2005). Blackberry anthocyanins are mainly recovered from urine as methylated and 
glucuronidated conjugates in humans. Journal of Agricultural and Food Chemistry, 
53 (20): 7721-7727. 
Fernandez de Simon, B., Perez-Ilzarbe, J., Hernandez, T., Gomez-Cordoves, C. and Estrella, 
I. (1992). Importance of phenolic compounds for the characterization of fruit juices. 
Journal of Agricultural and Food Chemistry, 40 (9): 1531-1535. 
317 
 
Ferrara, L., Raimondi, A., d'Episcopo, L., Guida, L., Dello Russo, A. and Marotta, T. (2000). 
Olive oil and reduced need for antihypertensive medications. Archives of Internal 
Medicine, 160 (6): 837-842. 
Ferrario, C. M. and Chappell, M. C. (2004). What’s new in the renin-angiotensin system? 
Cellular and Molecular Life Sciences 61 (21): 2720-2727. 
Fetalvero, K. M., Martin, K. A. and Hwa, J. (2007). Cardioprotective prostacyclin signaling 
in vascular smooth muscle. Prostaglandins & Other Lipid Mediators, 82 (1–4): 109-
118. 
Fiori, L. (2010). Supercritical extraction of grape seed oil at industrial-scale: Plant and 
process design, modeling, economic feasibility. Chemical Engineering and 
Processing: Process Intensification, 49 (8): 866-872. 
Fitzpatrick, D. F., Hirschfield, S. L. and Coffey, R. G. (1993). Endothelium-dependent 
vasorelaxing activity of wine and other grape products. American Journal of 
Physiology - Heart and Circulatory Physiology, 265 (2 34-2): H774-H778. 
Flamini, R. (2013). Recent applications of mass spectrometry in the study of grape and wine 
polyphenols. ISRN Spectroscopy, 2013: 45. 
Flamini, R., Rosso, M., Marchi, F., Dalla Vedova, A., Panighel, A., Gardiman, M., Maoz, I. 
and Bavaresco, L. (2013). An innovative approach to grape metabolomics: stilbene 
profiling by suspect screening analysis. Metabolomics: 1-11. 
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M. and Pastan, I. (1987). 
Expression of a multidrug-resistance gene in human tumors and tissues. Proceedings 
of the National Academy of Sciences, 84 (1): 265-269. 
Folkow, B. (1982). Physiological aspects of primary hypertension. Physiological Reviews, 62 
(2): 347-504. 
Folkow, B. (1993). Early structural changes in hypertension: pathophysiology and clinical 
consequences. Journal of Cardiovascular Pharmacology, 22 (1): 1-6. 
Forester, S. C. and Waterhouse, A. L. (2008). Identification of Cabernet Sauvignon 
anthocyanin gut microflora metabolites. Journal of Agricultural and Food Chemistry, 
56 (19): 9299-9304. 
Forman, J. P., Stampfer, M. J. and Curhan, G. C. (2009). Diet and lifestyle risk factors 
associated with incident hypertension in women. JAMA, 302 (4): 401-411. 
Fornage, M., Amos, C. I., Kardia, S., Sing, C. F., Turner, S. T. and Boerwinkle, E. (1998). 
Variation in the region of the angiotensin-converting enzyme gene influences 
interindividual differences in blood pressure levels in young White malesw. 
Circulation, 97 (18): 1773-1779. 
Förstermann, U. and Münzel, T. (2006). Endothelial nitric oxide synthase in vascular disease: 
from marvel to menace. Circulation, 113 (13): 1708-1714. 
Fournand, D., Vicens, A., Sidhoum, L., Souquet, J.-M., Moutounet, M. and Cheynier, V. 
(2006). Accumulation and extractability of grape skin tannins and anthocyanins at 
different advanced physiological stages. Journal of Agricultural and Food Chemistry, 
54 (19): 7331-7338. 
Frank, T., Netzel, M., Strass, G., Bitsch, R. and Bitsch, I. (2003). Bioavailability of 
anthocyanidin-3-glucosides following consumption of red wine and red grape juice. 
Canadian Journal of Physiology and Pharmacology, 81 (5): 423-435. 
Frankel, E. N., Kanner, J., German, J. B., Parks, E. and Kinsella, J. E. (1993). Inhibition of 
oxidation of human low-density lipoprotein by phenolic substances in red wine. 
Lancet, 341 (8843): 454-457. 
Frankel, E. N., Waterhouse, A. L. and Teissedre, P. L. (1995). Principal phenolic 
phytochemicals in selected California wines and their antioxidant activity in inhibiting 
318 
 
oxidation of human low-density lipoproteins. Journal of Agricultural and Food 
Chemistry, 43 (4): 890-894. 
Frederiksen, H., Mortensen, A., Schrøder, M., Frandsen, H., Bysted, A., Knuthsen, P. and 
Rasmussen, S. E. (2007). Effects of red grape skin and seed extract supplementation 
on atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Molecular Nutrition 
& Food Research, 51 (5): 564-571. 
Freedman, J. E., Parker, C., Li, L., Perlman, J. A., Frei, B., Ivanov, V., Deak, L. R., Iafrati, 
M. D. and Folts, J. D. (2001). Select flavonoids and whole juice from purple grapes 
inhibit platelet function and enhance nitric oxide release. Circulation, 103 (23): 2792-
2798. 
Frei, B. (1995). Cardiovascular disease and nutrient antioxidants: Role of low density 
lipoprotein oxidation. Critical Reviews in Food Science and Nutrition, 35 (1-2): 83-
98. 
Freitas, V. and Mateus, N. (2011). Formation of pyranoanthocyanins in red wines: a new and 
diverse class of anthocyanin derivatives. Analytical and Bioanalytical Chemistry, 401 
(5): 1463-1473. 
Frohlich, E. D. and Varagic, J. (2004). The role of sodium in hypertension is more complex 
than simply elevating arterial pressure. Nature Clinical Practice Cardiovascular 
Medicine, 1 (1): 24-30. 
Fuchs, F. D., Chambless, L. E., Whelton, P. K., Nieto, F. J. and Heiss, G. (2001). Alcohol 
consumption and the incidence of hypertension: the atherosclerosis risk in 
communities study. Hypertension, 37 (5): 1242-1250. 
Fuhr, U. and Kummert, A. L. (1995). The fate of naringin in humans: A key to grapefruit 
juice-drug interactions? Clinical Pharmacology & Therapeutics, 58 (4): 365-373. 
Fuhrman, B. and Aviram, M. (2001). Flavonoids protect LDL from oxidation and attenuate 
atherosclerosis. Curr Opin Lipidol, 12 (1): 41-48. 
Fuhrman, B., Volkova, N., Coleman, R. and Aviram, M. (2005). Grape powder polyphenols 
attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and 
reduce macrophage atherogenicity. The Journal of Nutrition, 135 (4): 722-728. 
Fulcrand, H., Benabdeljalil, C., Rigaud, J., Cheynier, V. and Moutounet, M. (1998). A new 
class of wine pigments generated by reaction between pyruvic acid and grape 
anthocyanins. Phytochemistry, 47 (7): 1401-1407. 
Furie, B. and Furie, B. C. (2008). Mechanisms of thrombus formation. New England Journal 
of Medicine, 359 (9): 938-949. 
Gagné, S., Lacampagne, S., Claisse, O. and Gény, L. (2009). Leucoanthocyanidin reductase 
and anthocyanidin reductase gene expression and activity in flowers, young berries 
and skins of Vitis vinifera L. cv. Cabernet-Sauvignon during development. Plant 
Physiology and Biochemistry, 47 (4): 282-290. 
Galisteo, M., Garcia-Saura, M. F., Jimenez, R., Villar, I. C., Zarzuelo, A., Vargas, F. and 
Duarte, J. (2004). Effects of chronic quercetin treatment on antioxidant defence 
system and oxidative status of deoxycorticosterone acetate-salt-hypertensive rats. 
Molecular and Cellular Biochemistry, 259 (1-2): 91-99. 
García-Beneytez, E., Revilla, E. and Cabello, F. (2002). Anthocyanin pattern of several red 
grape cultivars and wines made from them. European Food Research and 
Technology, 215 (1): 32-37. 
García-Martínez, S., Grau, A., Agulló, E., Bustamante, M. Á., Paredes, C., Moral, R. and 
Ruiz, J. J. (2009). Use of composts derived from winery Wastes in tomato crop. 
Communications in Soil Science and Plant Analysis, 40 (1-6): 445-452. 
García-Ramírez, B., Fernández-Larrea, J., Salvadó, M. J., Ardèvol, A., Arola, L. and Bladé, 
C. (2006). Tetramethylated dimeric procyanidins are detected in rat plasma and liver 
319 
 
early after oral administration of synthetic oligomeric procyanidins. Journal of 
Agricultural and Food Chemistry, 54 (7): 2543-2551. 
Garcia-Viguera, C. and Bridle, P. (1995). Analysis of non-coloured phenolic compounds in 
red wines. A comparison of high-performance liquid chromatography and capillary 
zone electrophoresis. Food Chemistry, 54 (4): 349-352. 
Gawel, R. (1998). Red wine astringency: a review. Australian Journal of Grape and Wine 
Research, 4 (2): 74-95. 
Gee, J. M., DuPont, M. S., Day, A. J., Plumb, G. W., Williamson, G. and Johnson, I. T. 
(2000). Intestinal transport of quercetin glycosides in rats involves both 
deglycosylation and interaction with the hexose transport pathway. The Journal of 
Nutrition, 130 (11): 2765-2771. 
Geleijnse, J. M., Kok, F. J. and Grobbee, D. E. (2003). Blood pressure response to changes in 
sodium and potassium intake: a metaregression analysis of randomised trials. Journal 
of Human Hypertension, 17 (7): 471-480. 
German, J. B. and Walzem, R. L. (2000). The health benefits of wine. Annual Review of 
Nutrition, 20 (1): 561-593. 
Glories, Y. (1984). La couleur des vins rouges. 2ème partie mesure, origine et interpretation. 
Connaissance de la Vigne et du Vin, 18: 253-271. 
Goch, A., Banach, M., Mikhailidis, D. P., Rysz, J. and Goch, J. H. (2009). Endothelial 
dysfunction in patients with noncomplicated and complicated hypertension. Clinical 
and Experimental Hypertension, 31 (1): 20-30. 
Goldberg, D. M., Ng, E., Karumanchiri, A., Yan, J., Diamandis, E. P. and Soleas, G. J. 
(1995). Assay of resveratrol glucosides and isomers in wine by direct-injection high-
performance liquid chromatography. Journal of Chromatography A, 708 (1): 89-98. 
Goldberg, D. M., Yan, J. and Soleas, G. J. (2003). Absorption of three wine-related 
polyphenols in three different matrices by healthy subjects. Clinical Biochemistry, 36 
(1): 79-87. 
Gómez-Cordovés, C., Bartolomé, B. and Jimeno, M. L. (1997). Identification of 2,3-
dihydroxy-1-guaiacylpropan-1-one in brandies. Journal of Agricultural and Food 
Chemistry, 45 (3): 873-876. 
Gonthier, M.-P., Donovan, J. L., Texier, O., Felgines, C., Remesy, C. and Scalbert, A. 
(2003). Metabolism of dietary procyanidins in rats. Free Radical Biology and 
Medicine, 35 (8): 837-844. 
González-Barrio, R., Edwards, C. A. and Crozier, A. (2011). Colonic catabolism of 
ellagitannins, ellagic acid, and raspberry anthocyanins: in vivo andiIn vitro studies. 
Drug Metabolism and Disposition, 39 (9): 1680-1688. 
González-Centeno, M. R., Jourdes, M., Femenia, A., Simal, S., Rosselló, C. and Teissedre, P. 
L. (2012). Proanthocyanidin composition and antioxidant potential of the stem 
winemaking byproducts from 10 different grape varieties (Vitis vinifera L.). Journal 
of Agricultural and Food Chemistry, 60 (48): 11850-11858. 
González-Centeno, M. R., Rosselló, C., Simal, S., Garau, M. C., López, F. and Femenia, A. 
(2010). Physico-chemical properties of cell wall materials obtained from ten grape 
varieties and their byproducts: grape pomaces and stems. LWT - Food Science and 
Technology, 43 (10): 1580-1586. 
González-Paramás, A. M., Esteban-Ruano, S., Santos-Buelga, C., de Pascual-Teresa, S. and 
Rivas-Gonzalo, J. C. (2003). Flavanol content and antioxidant activity in winery 
byproducts. Journal of Agricultural and Food Chemistry, 52 (2): 234-238. 
Gorinstein, S., Caspi, A., Libman, I., Lerner, H. T., Huang, D., Leontowicz, H., Leontowicz, 
M., Tashma, Z., Katrich, E., Feng, S. and Trakhtenberg, S. (2006). Red grapefruit 
positively influences serum triglyceride level in patients suffering from coronary 
320 
 
atherosclerosis: studies in vitro and in humans. Journal of Agricultural and Food 
Chemistry, 54 (5): 1887-1892. 
Gottesman, M. M. and Pastan, I. (1993). Biochemistry of multidrug resistance mediated by 
the multidrug transporter. Annual Review of Biochemistry, 62: 385-427. 
Govers, R. and Rabelink, T. J. (2001). Cellular regulation of endothelial nitric oxide synthase. 
American Journal of Physiology - Renal Physiology, 280 (2): F193-F206. 
Graefe, E. U., Wittig, J., Mueller, S., Riethling, A.-K., Uehleke, B., Drewelow, B., Pforte, H., 
Jacobasch, G., Derendorf, H. and Veit, M. (2001). Pharmacokinetics and 
bioavailability of quercetin glycosides in humans. The Journal of Clinical 
Pharmacology, 41 (5): 492-499. 
Griendling, K. K. and FitzGerald, G. A. (2003). Oxidative stress and cardiovascular injury: 
Part I: basic mechanisms and in vivo monitoring of ROS. Circulation, 108 (16): 1912-
1916. 
Griendling, K. K., Sorescu, D. and Ushio-Fukai, M. (2000). NAD(P)H Oxidase: role in 
cardiovascular biology and disease. Circulation Research, 86 (5): 494-501. 
Groenewoud, G. and Hundt, H. K. L. (1986). The microbial metabolism of condensed (+)-
catechins by rat-caecal microflora. Xenobiotica, 16 (2): 99-107. 
Grossman, E. and Messerli, F. H. (1995). High blood pressure: A side effect of drugs, 
poisons, and food. Archives of Internal Medicine, 155 (5): 450-460. 
Grün, C. H., Van Dorsten, F. A., Jacobs, D. M., Le Belleguic, M., van Velzen, E. J. J., 
Bingham, M. O., Janssen, H.-G. and van Duynhoven, J. P. M. (2008). GC–MS 
methods for metabolic profiling of microbial fermentation products of dietary 
polyphenols in human and in vitro intervention studies. Journal of Chromatography 
B, 871 (2): 212-219. 
Grunfeld, S., Hamilton, C. A., Mesaros, S., McClain, S. W., Dominiczak, A. F., Bohr, D. F. 
and Malinski, T. (1995). Role of superoxide in the depressed nitric oxide production 
by the endothelium of genetically hypertensive rats. Hypertension, 26 (6): 854-857. 
Guebailia, H. A., Chira, K., Richard, T., Mabrouk, T., Furiga, A., Vitrac, X., Monti, J.-P., 
Delaunay, J.-C. and Mérillon, J.-M. (2006). Hopeaphenol: the first resveratrol 
tetramer in wines from North Africa. Journal of Agricultural and Food Chemistry, 54 
(25): 9559-9564. 
Güntert, M., Rapp, A., Takeoka, G. and Jennings, W. (1986). HRGC and HRGC-MS applied 
to wine constituents of lower volatility. European Food Research and Technology 
182 (3): 200-204. 
Guo, G. B. and Abboud, F. M. (1984a). Angiotensin II attenuates baroreflex control of heart 
rate and sympathetic activity. American Journal of Physiology - Heart and 
Circulatory Physiology, 246 (1): 80-89. 
Guo, G. B. and Abboud, F. M. (1984b). Impaired central mediation of the arterial baroreflex 
in chronic renal hypertension. American Journal of Physiology - Heart and 
Circulatory Physiology, 246 (5): H720-H727. 
Guyton, A. C., Coleman, T. G., Cowley, A. W., Scheel, K. W., Manning, R. D. and Norman, 
R. A. (1972). Arterial pressure regulation: Overriding dominance of the kidneys in 
long-term regulation and in hypertension. The American Journal of Medicine, 52 (5): 
584-594. 
Hall, J. E. (2003). The Kidney, hypertension, and obesity. Hypertension, 41 (3): 625-633. 
Hall, J. E., Guyton, A. C. and Mizelle, H. L. (1990). Role of the renin-angiotensin system in 
control of sodium excretion and arterial pressure. Acta physiologica Scandinavica, 
591: 48-62. 
Halliwell, B. (1994). Free radicals, antioxidants, and human disease: curiosity, cause, or 
consequence? The Lancet, 344 (8924): 721-724. 
321 
 
Halliwell, B. (2001). Role of free radicals in the neurodegenerative diseases: therapeutic 
implications for antioxidant treatment. Drugs & Aging, 18 (9): 685-716. 
Hanes, D. S., Weir, M. R. and Sowers, J. R. (1996). Gender considerations in hypertension 
pathophysiology and treatment. The American Journal of Medicine, 101 (3A): 10-21. 
Hanlin, R. L., Kelm, M. A., Wilkinson, K. L. and Downey, M. O. (2011). Detailed 
Characterization of Proanthocyanidins in Skin, Seeds, and Wine of Shiraz and 
Cabernet Sauvignon Wine Grapes (Vitis vinifera). Journal of Agricultural and Food 
Chemistry, 59 (24): 13265-13276. 
Harborne, J. B. and Williams, C. A. (2000). Advances in flavonoid research since 1992. 
Phytochemistry, 55 (6): 481-504. 
Harder, S., Rietbrock, S. and Thurmann, P. (1993). Concentration/effect analysis of 
verapamil: evaluation of different approaches. International journal of clinical 
pharmacology, therapy, and Toxicology, 31 (10): 469-475. 
Hashimoto, M., Kim, S., Eto, M., Iijima, K., Ako, J., Yoshizumi, M., Akishita, M., Kondo, 
K., Itakura, H., Hosoda, K., Toba, K. and Ouchi, Y. (2001). Effect of acute intake of 
red wine on flow-mediated vasodilatation of the brachial artery. The American 
Journal of Cardiology, 88 (12): 1457-1460. 
Hayasaka, Y. and Asenstorfer, R. E. (2002). Screening for potential pigments derived from 
anthocyanins in red wine using nanoelectrospray tandem mass spectrometry. Journal 
of Agricultural and Food Chemistry, 50 (4): 756-761. 
He, F., He, J. J., Pan, Q. H. and Duan, C. Q. (2010). Mass-spectrometry evidence confirming 
the presence of pelargonidin-3-O-glucoside in the berry skins of Cabernet Sauvignon 
and Pinot Noir (Vitis vinifera L.). Australian Journal of Grape and Wine Research, 
16 (3): 464-468. 
He, F. J., Nowson, C. A., Lucas, M. and MacGregor, G. A. (2007). Increased consumption of 
fruit and vegetables is related to a reduced risk of coronary heart disease: meta-
analysis of cohort studies. Journal of Human Hypertension 21 (9): 717-728. 
Heiss, C., Dejam, A., Kleinbongard, P., Schewe, T., Sies, H. and Kelm, M. (2003). Vascular 
effects of cocoa rich in flavan-3-ols. JAMA, 290 (8): 1030-1031. 
Heller, J., Hellerová, S., Dobesková, Z., Kunes, J. and Zicha, J. (1993). The Prague 
hypertensive rat: a new model of genetic hypertension. Clinical and Experimental 
Hypertension, 15 (5): 807-818. 
Hermosin Gutierrez, I. and Garcia-Romero, E. (2004). Anthocyanins of red wine grape 
cultivars grown in the Spanish region of La Mancha: Characteristic cultivar patterns 
of grapes and single cultivar wines, and evolution during the ripening of the berry. 
Alimentaria, 41: 127–139. 
Herrmann, K. (1988). On the occurrence of flavonol and flavone glycosides in vegetables. 
European Food Research and Technology, 186 (1): 1-5. 
Hertog, M. G. L., Hollman, P. C. H. and Katan, M. B. (1992). Content of potentially 
anticarcinogenic flavonoids of 28 vegetables and 9 fruits commonly consumed in the 
Netherlands. Journal of Agricultural and Food Chemistry, 40 (12): 2379-2383. 
Hertog, M. G. L., Hollman, P. C. H., Katan, M. B. and Kromhout, D. (1993a). Intake of 
potentially anticarcinogenic flavonoids and their determinants in adults in the 
Netherlands. Nutrition and Cancer, 20 (1): 21-29. 
Hertog, M. G. L., Hollman, P. C. H. and van de Putte, B. (1993b). Content of potentially 
anticarcinogenic flavonoids of tea infusions, wines, and fruit juices. Journal of 
Agricultural and Food Chemistry, 41 (8): 1242-1246. 
Holbrook, J. T., Patterson, K. Y., Bodner, J. E., Douglas, L. W., Veillon, C., Kelsay, J. L., 
Mertz, W. and Smith, J. C., Jr. (1984). Sodium and potassium intake and balance in 
322 
 
adults consuming self-selected diets. The American Journal of Clinical Nutrition, 40 
(4): 786-793. 
Hollman, P. C., Bijsman, M. N., van Gameren, Y., Cnossen, E. P., de Vries, J. H. and Katan, 
M. B. (1999). The sugar moiety is a major determinant of the absorption of dietary 
flavonoid glycosides in man. Free Radical Research, 31 (6): 569-573. 
Hollman, P. C., de Vries, J. H., van Leeuwen, S. D., Mengelers, M. J. and Katan, M. B. 
(1995). Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy 
volunteers. The American Journal of Clinical Nutrition, 62 (6): 1276-1282. 
Hollman, P. C. H., van Trijp, J. M. P., Buysman, M. N. C. P., v.d. Gaag, M. S., Mengelers, 
M. J. B., de Vries, J. H. M. and Katan, M. B. (1997a). Relative bioavailability of the 
antioxidant flavonoid quercetin from various foods in man. FEBS Letters, 418 (1–2): 
152-156. 
Hollman, P. C. H., van Trijp, J. M. P., Mengelers, M. J. B., de Vries, J. H. M. and Katan, M. 
B. (1997b). Bioavailability of the dietary antioxidant flavonol quercetin in man. 
Cancer Letters, 114 (1–2): 139-140. 
Holt, R. R., Lazarus, S. A., Sullards, M. C., Zhu, Q. Y., Schramm, D. D., Hammerstone, J. F., 
Fraga, C. G., Schmitz, H. H. and Keen, C. L. (2002). Procyanidin dimer B2 
[epicatechin-(4β-8)-epicatechin] in human plasma after the consumption of a 
flavanol-rich cocoa. The American Journal of Clinical Nutrition, 76 (4): 798-804. 
Howard, A. N. (2001). Method of producing high flavonol content polyphenol compositions. 
US6238673  
Hsu, C. H., Yang, C. S., Patel, S. R. and Stevens, M. G. (1987). Calcium and vitamin D 
metabolism in spontaneously hypertensive rats. American Journal of Physiology - 
Cell Physiology, 253 (4): 712-718. 
Hsu, Y.-L., Liang, H.-L., Hung, C.-H. and Kuo, P.-L. (2009). Syringetin, a flavonoid 
derivative in grape and wine, induces human osteoblast differentiation through bone 
morphogenetic protein-2/extracellular signal-regulated kinase 1/2 pathway. Molecular 
Nutrition & Food Research, 53 (11): 1452-1461. 
Huang, D., Ou, B. and Prior, R. L. (2005). The chemistry behind antioxidant capacity assays. 
Journal of Agricultural and Food Chemistry, 53 (6): 1841-1856. 
Hubbard, G. P., Wolffram, S., Lovegrove, J. A. and Gibbins, J. M. (2004). Ingestion of 
quercetin inhibits platelet aggregation and essential components of the collagen-
stimulated platelet activation pathway in humans. Journal of Thrombosis and 
Haemostasis, 2 (12): 2138-2145. 
Hwang, I. S., Ho, H., Hoffman, B. B. and Reaven, G. M. (1987). Fructose-induced insulin 
resistance and hypertension in rats. Hypertension, 10 (5): 512-516. 
Ignat, I., Volf, I. and Popa, V. I. (2011). A critical review of methods for characterisation of 
polyphenolic compounds in fruits and vegetables. Food Chemistry, 126 (4): 1821-
1835. 
Intersalt (1988). Intersalt an international study of electrolyte excretion and blood pressure. 
Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative 
Research Group. BMJ, 297 (6644): 319-328. 
Ishii, K., Furuta, T. and Kasuya, Y. (1999). Mass Spectrometric Identification and High-
Performance Liquid Chromatographic Determination of a Flavonoid Glycoside 
Naringin in Human Urine. Journal of Agricultural and Food Chemistry, 48 (1): 56-
59. 
Jaganath, I. B., Mullen, W., Edwards, C. A. and Crozier, A. (2006). The relative contribution 
of the small and large intestine to the absorption and metabolism of rutin in man. Free 
Radical Research, 40 (10): 1035-1046. 
323 
 
Jagroop, I. A., Clatworthy, I., Lewin, J. and Mikhailidis, D. P. (2000). Shape change in 
human platelets: measurement with a channelyzer and visualisation by electron 
microscopy. Platelets, 11 (1): 28-32. 
Jagroop, I. A., Kakafika, A. I. and Mikhailidis, D. P. (2007). Platelets and vascular risk: an 
option for treatment. Current Pharmaceutical Design, 13 (16): 1669-1683. 
Jandera, P., Skeifikova, V., Rehova, L., Hajek, T., Baldrianova, L., Skopova, G., Kellner, V. 
and Horna, A. (2005). RP-HPLC analysis of phenolic compounds and flavonoids in 
beverages and plant extracts using a CoulArray detector. Journal of Separation 
Science, 28 (9-10): 1005-1022. 
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, 
H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C. and Pezzuto, 
J. M. (1997). Cancer chemopreventive activity of resveratrol, a natural product 
derived from grapes. Science, 275 (5297): 218-220. 
Jeandet, P., Bessis, R. and Gautheron, B. (1991). The production of resveratrol (3,5,4'-
trihydroxystilbene) by grape berries in different developmental stages. American 
Journal of Enology and Viticulture, 42 (1): 41-46. 
Jeandet, P., Bessis, R., Maume, B. F., Meunier, P., Peyron, D. and Trollat, P. (1995a). Effect 
of enological practices on the resveratrol isomer content of wine. Journal of 
Agricultural and Food Chemistry, 43 (2): 316-319. 
Jeandet, P., Bessis, R., Sbaghi, M. and Meunier, P. (1995b). Production of the phytoalexin 
resveratrol by grapes as a response to Botrytis attack under natural conditions. 
Journal of Phytopathology, 143 (3): 135-139. 
Jeffery, D. W., Parker, M. and Smith, P. A. (2008). Flavonol composition of Australian red 
and white wines determined by high-performance liquid chromatography. Australian 
Journal of Grape and Wine Research, 14 (3): 153-161. 
Jennings, L. K. (2009). Mechanisms of platelet activation: need for new strategies to protect 
against platelet-mediated atherothrombosis. Thrombosis and Haemostasis, 102 (2): 
248-257. 
Jensen, J. S., Demiray, S., Egebo, M. and Meyer, A. S. (2008). Prediction of wine color 
attributes from the phenolic profiles of red grapes (Vitis vinifera). Journal of 
Agricultural and Food Chemistry, 56 (3): 1105-1115. 
Jiménez, J. P., Serrano, J., Tabernero, M., Arranz, S., Díaz-Rubio, M. E., García-Diz, L., 
Goñi, I. and Saura-Calixto, F. (2008). Effects of grape antioxidant dietary fiber in 
cardiovascular disease risk factors. Nutrition, 24 (7–8): 646-653. 
Jobin, C., Bradham, C. A., Russo, M. P., Juma, B., Narula, A. S., Brenner, D. A. and Sartor, 
R. B. (1999). Curcumin blocks cytokine-mediated NF-κB activation and 
proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. 
The Journal of Immunology, 163 (6): 3474-3483. 
Jodoin, J., Demeule, M. and Beliveau, R. (2002). Inhibition of the multidrug resistance P-
glycoprotein activity by green tea polyphenols. Biochimica et Biophysica Acta, 30: 1-
3. 
Johnson, M. L., Ely, D. L. and Turner, M. E. (1992). Genetic divergence between the Wistar-
Kyoto rat and the spontaneously hypertensive rat. Hypertension, 19 (5): 425-427. 
Jones, D. W. (2004). Dietary Sodium and Blood Pressure. Hypertension, 43 (5): 932-935. 
Justesen, U., Knuthsen, P. and Leth, T. (1997). Determination of plant polyphenols in danish 
foodstuffs by HPLC-UV and LC-MS detection. Cancer Letters, 114 (1–2): 165-167. 
Kacew, S. and Festing, M. F. (1996). Role of rat strain in the differential sensitivity to 
pharmaceutical agents and naturally occurring substances. Journal of Toxicology and 
Environmental Health, 47 (1): 1-30. 
324 
 
Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E. A., Caldwell, S. D., 
Napper, A., Curtis, R., DiStefano, P. S., Fields, S., Bedalov, A. and Kennedy, B. K. 
(2005). Substrate-specific activation of sirtuins by resveratrol. Journal of Biological 
Chemistry, 280 (17): 17038-17045. 
Kahle, K., Kempf, M., Schreier, P., Scheppach, W., Schrenk, D., Kautenburger, T., Hecker, 
D., Huemmer, W., Ackermann, M. and Richling, E. (2011). Intestinal transit and 
systemic metabolism of apple polyphenols. European Journal of Nutrition, 50 (7): 
507-522. 
Kahle, K., Kraus, M., Scheppach, W. and Richling, E. (2005). Colonic availability of apple 
polyphenols – A study in ileostomy subjects. Molecular Nutrition & Food Research, 
49 (12): 1143-1150. 
Kammerer, D., Claus, A., Carle, R. and Schieber, A. (2004). Polyphenol screening of pomace 
from red and white grape varieties (Vitis vinifera L.) by HPLC-DAD-MS/MS. 
Journal of Agricultural and Food Chemistry, 52 (14): 4360-4367. 
Kanemaru, K., Seya, K., Miki, I., Motomura, S. and Furukawa, K. (2008). Calcification of 
aortic smooth muscle cells isolated from spontaneously hypertensive rats. Journal of 
Pharmacological Sciences, 106 (2): 280-286. 
Kaplan, Z. S. and Jackson, S. P. (2011). The role of platelets in atherothrombosis. ASH 
Education Program Book, 2011 (1): 51-61. 
Karakaya, S. (2004). Bioavailability of phenolic compounds. Critical Reviews in Food 
Science and Nutrition, 44 (6): 453-464. 
Karim, M., McCormick, K. and Kappagoda, C. T. (2000). Effects of cocoa extracts on 
endothelium-dependent relaxation. The Journal of Nutrition, 130 (8): 2105S-2108S. 
Kartner, N., Riordan, J. R. and Ling, V. (1983). Cell surface P-glycoprotein associated with 
multidrug resistance in mammalian cell lines. Science, 221 (4617): 1285-1288. 
Kassirer, J. P. and Harrington, J. T. (1985). Fending off the potassium pushers. New England 
Journal of Medicine, 312 (12): 785-787. 
Katholi, R. E., Naftilan, A. J. and Oparil, S. (1980). Importance of renal sympathetic tone in 
the development of DOCA-salt hypertension in the rat. Hypertension, 2 (3): 266-273. 
Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L. and Gordon, J. I. (2011). Human 
nutrition, the gut microbiome and the immune system. Nature, 474 (7351): 327-336. 
Kauser, K. and Rubanyi, G. M. (1995). Gender difference in endothelial dysfunction in the 
aorta of spontaneously hypertensive rats. Hypertension, 25 (4): 517-523. 
Kawai, K., Tsuno, N. H., Kitayama, J., Okaji, Y., Yazawa, K., Asakage, M., Hori, N., 
Watanabe, T., Takahashi, K. and Nagawa, H. (2004). Epigallocatechin gallate 
attenuates adhesion and migration of CD8+ T cells by binding to CD11b. Journal of 
Allergy and Clinical Immunology, 113 (6): 1211-1217. 
Kawashima, S. and Yokoyama, M. (2004). Dysfunction of endothelial nitric oxide synthase 
and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 24 (6): 998-
1005. 
Keevil, J. G., Osman, H. E., Reed, J. D. and Folts, J. D. (2000). Grape juice, but not orange 
juice or grapefruit juice, inhibits human platelet aggregation. The Journal of Nutrition, 
130 (1): 53-56. 
Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde, A. and Haskell, 
C. F. (2010). Effects of resveratrol on cerebral blood flow variables and cognitive 
performance in humans: a double-blind, placebo-controlled, crossover investigation. 
The American Journal of Clinical Nutrition, 91 (6): 1590-1597. 
Kennedy, J. A. (2008). Grape and wine phenolics: Observations and recent findings. Ciencia 
e investigación agraria, 35: 107-120. 
325 
 
Keppler, K. and Humpf, H. U. (2005). Metabolism of anthocyanins and their phenolic 
degradation products by the intestinal microflora. Bioorganic & Medicinal Chemistry, 
13 (17): 5195-5205. 
Khanal, R. C., Howard, L. R. and Prior, R. L. (2009). Procyanidin content of grape seed and 
pomace, and total anthocyanin content of grape pomace as affected by extrusion 
processing. Journal of Food Science, 74 (6): 174-182. 
Khoo, N. K. H., White, C. R., Pozzo-Miller, L., Zhou, F., Constance, C., Inoue, T., Patel, R. 
P. and Parks, D. A. (2010). Dietary flavonoid quercetin stimulates vasorelaxation in 
aortic vessels. Free Radical Biology and Medicine, 49 (3): 339-347. 
Kitagawa, S. (2006). Inhibitory effects of polyphenols on p-glycoprotein-mediated transport. 
Biological & Pharmaceutical Bulletin, 29 (1): 1-6. 
Klatsky, A. L., Friedman, G. D. and Armstrong, M. A. (1986). The relationships between 
alcoholic beverage use and other traits to blood pressure: a new Kaiser Permanente 
study. Circulation, 73 (4): 628-636. 
Koppenol, W. H., Moreno, J. J., Pryor, W. A., Ischiropoulos, H. and Beckman, J. S. (1992). 
Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chemical 
Research in Toxicology 5(6): 834-842. 
Korhammer, S., Reniero, F. and Mattivi, F. (1995). An oligostilbene from vitis roots. 
Phytochemistry, 38 (6): 1501-1504. 
Korkina, L. G. and Afanas'ev, I. B. (1997). Antioxidant and chelating properties of 
flavonoids. Advances in Pharmacology, 38: 151-163. 
Kottra, G. and Daniel, H. (2007). Flavonoid glycosides are not transported by the human 
Na
+
/Glucose transporter when expressed in Xenopus laevis Oocytes, but effectively 
inhibit electrogenic glucose uptake. Journal of Pharmacology and Experimental 
Therapeutics, 322 (2): 829-835. 
Koundouras, S., Marinos, V., Gkoulioti, A., Kotseridis, Y. and van Leeuwen, C. (2006). 
Influence of vineyard location and vine water status on fruit maturation of 
nonirrigated cv. Agiorgitiko (Vitis vinifera L.). Effects on wine phenolic and aroma 
components. Journal of Agricultural and Food Chemistry, 54 (14): 5077-5086. 
Krinsky, N. I. (1992). Mechanism of Action of Biological Antioxidants. Experimental 
Biology and Medicine, 200 (2): 248-254. 
Kuhnau, J. (1976). The flavonoids. A class of semi-essential food components: their role in 
human nutrition. World Review of Nutrition and Dietetics, 24: 117-191. 
Kuhnle, G., Spencer, J. P. E., Schroeter, H., Shenoy, B., Debnam, E. S., Srai, S. K. S., Rice-
Evans, C. and Hahn, U. (2000). Epicatechin and catechin are O-methylated and 
glucuronidated in the small intestine. Biochemical and Biophysical Research 
Communications, 277 (2): 507-512. 
Kurowska, E. M., Spence, J. D., Jordan, J., Wetmore, S., Freeman, D. J., Piché, L. A. and 
Serratore, P. (2000). HDL-cholesterol-raising effect of orange juice in subjects with 
hypercholesterolemia. The American Journal of Clinical Nutrition, 72 (5): 1095-1100. 
Kurtz, T. W. and Morris, R. C. (1987). Biological variability in Wistar-Kyoto rats. 
Implications for research with the spontaneously hypertensive rat. Hypertension, 10 
(1): 127-131. 
Kwan, C.-Y., Zhang, W.-B., Deyama, T. and Nishibe, S. (2004). Endothelium-dependent 
vascular relaxation induced by Eucommia ulmoides Oliv. bark extract is mediated by 
NO and EDHF in small vessels. Naunyn-Schmiedeberg's Archives of Pharmacology, 
369 (2): 206-211. 
Lambert, J. D., Sang, S. and Yang, C. S. (2007). Biotransformation of green tea polyphenols 
and the biological activities of those metabolites. Molecular Pharmaceutics, 4 (6): 
819-825. 
326 
 
Landrault, N., Larronde, F., Delaunay, J.-C., Castagnino, C., Vercauteren, J., Merillon, J.-M., 
Gasc, F., Cros, G. and Teissedre, P.-L. (2002). Levels of stilbene oligomers and 
astilbin in french varietal wines and in grapes during noble rot development. Journal 
of Agricultural and Food Chemistry, 50 (7): 2046-2052. 
Landrault, N., Poucheret, P., Ravel, P., Gasc, F., Cros, G. and Teissedre, P. L. (2001). 
Antioxidant capacities and phenolics levels of French wines from different varieties 
and vintages. Journal of Agricultural and Food Chemistry, 49 (7): 3341-3348. 
Langcake, P. and Pryce, R. J. (1977). A new class of phytoalexins from grapevines. 
Experientia, 33 (2): 151-152. 
Langheinrich, M., Ae Lee, M., Böhm, M., Pinto, Y. M., Ganten, D. and Paul, M. (1996). The 
hypertensive ren-2 transgenic rat TGR (mREN2) 27 in hypertension research 
characteristics and functional aspects. American Journal of Hypertension, 9 (5): 506-
512. 
Lapidot, T., Harel, S., Granit, R. and Kanner, J. (1998). Bioavailability of red wine 
anthocyanins as detected in human urine. Journal of Agricultural and Food 
Chemistry, 46 (10): 4297-4302. 
Laufenberg, G., Kunz, B. and Nystroem, M. (2003). Transformation of vegetable waste into 
value added products: (A) the upgrading concept; (B) practical implementations. 
Bioresource Technology, 87 (2): 167-198. 
Lee, M. J., Wang, Z. Y., Li, H., Chen, L., Sun, Y., Gobbo, S., Balentine, D. A. and Yang, C. 
S. (1995). Analysis of plasma and urinary tea polyphenols in human subjects. Cancer 
Epidemiology Biomarkers & Prevention, 4 (4): 393-399. 
Lekakis, J., Rallidis, L. S., Andreadou, I., Vamvakou, G., Kazantzoglou, G., Magiatis, P., 
Skaltsounis, A.-L. and Kremastinos, D. T. (2005). Polyphenols compounds from red 
grapes acutely improve endothelial function in patients with coronary heart disease. 
European Journal of Cardiovascular Prevention & Rehabilitation, 12 (6): 596-600. 
Leopoldini, M., Russo, N. and Toscano, M. (2011). The molecular basis of working 
mechanism of natural polyphenolic antioxidants. Food Chemistry, 125 (2): 288-306. 
Ley, R. E., Hamady, M., Lozupone, C., Turnbaugh, P. J., Ramey, R. R., Bircher, J. S., 
Schlegel, M. L., Tucker, T. A., Schrenzel, M. D., Knight, R. and Gordon, J. I. (2008). 
Evolution of mammals and their gut microbes. Science, 320 (5883): 1647-1651. 
Li, C., Lee, M.-J., Sheng, S., Meng, X., Prabhu, S., Winnik, B., Huang, B., Chung, J. Y., 
Yan, S., Ho, C.-T. and Yang, C. S. (2000). Structural identification of two metabolites 
of catechins and their kinetics in human urine and blood after tea ingestion. Chemical 
Research in Toxicology, 13 (3): 177-184. 
Li, Z., Mao, H. Z., Abboud, F. M. and Chapleau, M. W. (1996). Oxygen-derived free radicals 
contribute to baroreceptor dysfunction in atherosclerotic rabbits. Circulation 
Research, 79 (4): 802-811. 
Liang, Z., Wu, B., Fan, P., Yang, C., Duan, W., Zheng, X., Liu, C. and Li, S. (2008). 
Anthocyanin composition and content in grape berry skin in Vitis germplasm. Food 
Chemistry, 111 (4): 837-844. 
Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420 (6917): 868-874. 
Lindberg, M. L. and Amsterdam, E. A. (2008). Alcohol, wine, and cardiovascular health. 
Clinical Cardiology, 31 (8): 347-351. 
Lindpaintner, K., Kreutz, R. and Ganten, D. (1992). Genetic variation in hypertensive and 
'control' strains. What are we controlling for anyway? Hypertension, 19 (5): 428-430. 
Littman, D. R. and Pamer, E. G. (2011). Role of the commensal microbiota in normal and 
pathogenic host immune responses. Cell Host & Microbe, 10 (4): 311-323. 
Liu, Z., Song, Y., Zhang, X., Liu, Z., Zhang, W., Mao, W., Wang, W., Cui, W., Zhang, X., 
Jia, X., Li, N., Han, C. and Liu, C. (2005). Effects of trans-resveratrol on 
327 
 
hypertension-induced cardiac hypertrophy using the partially nephrectomized rat 
model. Clinical and Experimental Pharmacology and Physiology, 32 (12): 1049-
1054. 
Llobera, A. and Cañellas, J. (2007). Dietary fibre content and antioxidant activity of Manto 
Negro red grape (Vitis vinifera): pomace and stem. Food Chemistry, 101 (2): 659-666. 
Llorach, R., Garrido, I., Monagas, M., Urpi-Sarda, M., Tulipani, S., Bartolome, B. and 
Andres-Lacueva, C. (2010). Metabolomics study of human urinary metabolome 
modifications after intake of almond (Prunus dulcis (Mill.) D.A. Webb) skin 
polyphenols. Journal of Proteome Research, 9 (11): 5859-5867. 
Lorenz, M., Wessler, S., Follmann, E., Michaelis, W., Düsterhöft, T., Baumann, G., Stangl, 
K. and Stangl, V. (2004). A Constituent of green tea, epigallocatechin-3-gallate, 
activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, 
cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to 
endothelial-dependent vasorelaxation. Journal of Biological Chemistry, 279 (7): 
6190-6195. 
Lorrain, B., Chira, K. and Teissedre, P. L. (2011). Phenolic composition of Merlot and 
Cabernet-Sauvignon grapes from Bordeaux vineyard for the 2009-vintage: 
comparison to 2006, 2007 and 2008 vintages. Food Chemistry, 126 (4): 1991-1999. 
Louli, V., Ragoussis, N. and Magoulas, K. (2004). Recovery of phenolic antioxidants from 
wine industry by-products. Bioresource Technology, 92 (2): 201-208. 
Lu, Y. and Yeap Foo, L. (1999). The polyphenol constituents of grape pomace. Food 
Chemistry, 65 (1): 1-8. 
Ludwig, A., Lorenz, M., Grimbo, N., Steinle, F., Meiners, S., Bartsch, C., Stangl, K., 
Baumann, G. and Stangl, V. (2004). The tea flavonoid epigallocatechin-3-gallate 
reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial 
cells. Biochemical and Biophysical Research Communications, 316 (3): 659-665. 
Luft, F. C. (1998). Molecular genetics of human hypertension. Journal of Hypertension, 16: 
1871-1878. 
Ma, X., Wu, H., Liu, L., Yao, Q., Wang, S., Zhan, R., Xing, S. and Zhou, Y. (2011). 
Polyphenolic compounds and antioxidant properties in mango fruits. Scientia 
Horticulturae, 129 (1): 102-107. 
Makris, D. P., Boskou, G. and Andrikopoulos, N. K. (2007). Polyphenolic content and in 
vitro antioxidant characteristics of wine industry and other agri-food solid waste 
extracts. Journal of Food Composition and Analysis, 20 (2): 125-132. 
Makris, D. P., Kallithraka, S. and Kefalas, P. (2006). Flavonols in grapes, grape products and 
wines: Burden, profile and influential parameters. Journal of Food Composition and 
Analysis, 19 (5): 396-404. 
Manach, C., Morand, C., Gil-Izquierdo, A., Bouteloup-Demange, C. and Remesy, C. (2003). 
Bioavailability in humans of the flavanones hesperidin and narirutin after the 
ingestion of two doses of orange juice. European Journal of Clinical Nutrition 57 (2): 
235-242. 
Manach, C., Scalbert, A., Morand, C., Rémésy, C. and Jiménez, L. (2004). Polyphenols: food 
sources and bioavailability. The American Journal of Clinical Nutrition, 79 (5): 727-
747. 
Manach, C., Williamson, G., Morand, C., Scalbert, A. and Rémésy, C. (2005). Bioavailability 
and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. The 
American Journal of Clinical Nutrition, 81 (1): 230-242. 
Manna, S. K., Mukhopadhyay, A. and Aggarwal, B. B. (2000). Resveratrol suppresses TNF-
induced activation of nuclear transcription factors NF-κB, activator protein-1, and 
328 
 
apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. The 
Journal of Immunology, 164 (12): 6509-6519. 
Manzano, S. and Williamson, G. (2010). Polyphenols and phenolic acids from strawberry and 
apple decrease glucose uptake and transport by human intestinal Caco-2 cells. 
Molecular Nutrition & Food Research, 54 (12): 1773-1780. 
Mark, A. L. (1996). The sympathetic nervous system in hypertension: a potential long-term 
regulator of arterial pressure. Journal of Hypertension, 14 (5): 159-165. 
Marks, S. C., Mullen, W., Borges, G. and Crozier, A. (2009). Absorption, metabolism, and 
excretion of cider dihydrochalcones in healthy humans and subjects with an 
Ileostomy. Journal of Agricultural and Food Chemistry, 57 (5): 2009-2015. 
Marquez, A., Dueñas, M., Serratosa, M. P. and Merida, J. (2012). Formation of vitisins and 
anthocyanin–flavanol adducts during red grape drying. Journal of Agricultural and 
Food Chemistry, 60 (27): 6866-6874. 
Mateus, N., Silva, A. M. S., Vercauteren, J. and de Freitas, V. (2001). Occurrence of 
anthocyanin-derived pigments in red wines. Journal of Agricultural and Food 
Chemistry, 49 (10): 4836-4840. 
Matsuo, S., Nakamura, Y., Takahashi, M., Ouchi, Y., Hosoda, K., Nozawa, M. and 
Kinoshita, M. (2001). Effect of red wine and ethanol on production of nitric oxide in 
healthy subjects. The American Journal of Cardiology, 87 (8): 1029-1031. 
Mattes, R. D. and Donnelly, D. (1991). Relative contributions of dietary sodium sources. The 
Journal of the American College of Nutrition, 10 (4): 383-393. 
Mattivi, F., Guzzon, R., Vrhovsek, U., Stefanini, M. and Velasco, R. (2006). Metabolite 
profiling of grape: flavonols and anthocyanins. Journal of Agricultural and Food 
Chemistry, 54 (20): 7692-7702. 
Mattivi, F., Vrhovsek, U., Malacarne, G., Masuero, D., Zulini, L., Stefanini, M., Moser, C., 
Velasco, R. and Guella, G. (2011). Profiling of resveratrol oligomers, important stress 
metabolites, accumulating in the leaves of hybrid Vitis vinifera (Merzling x 
Teroldego) genotypes infected with Plasmopara viticola. Journal of Agricultural and 
Food Chemistry, 59 (10): 5364-5375. 
Mazza, G. and Francis, F. J. (1995). Anthocyanins in grapes and grape products. Critical 
Reviews in Food Science and Nutrition, 35: 341-371. 
Meneton, P., Jeunemaitre, X., de Wardener, H. E. and MacGregor, G. A. (2005). Links 
between dietary salt intake, renal salt handling, blood pressure, and cardiovascular 
diseases. Physiological Reviews, 85 (2): 679-715. 
Meng, X., Sang, S., Zhu, N., Lu, H., Sheng, S., Lee, M.-J., Ho, C.-T. and Yang, C. S. (2002). 
Identification and characterization of methylated and ring-fission metabolites of tea 
catechins formed in humans, mice, and rats. Chemical Research in Toxicology, 15 (8): 
1042-1050. 
Mennen, L. I., Sapinho, D., de Bree, A., Arnault, N., Bertrais, S., Galan, P. and Hercberg, S. 
(2004). Consumption of foods rich in flavonoids is related to a decreased 
cardiovascular risk in apparently healthy french women. The Journal of Nutrition, 134 
(4): 923-926. 
Meselhy, M. R., Nakamura, N. and Hattori, M. (1997). Biotransformation of (-)-epicatechin 
3-O-gallate by human intestinal bacteria. Chemical & Pharmaceutical Bulletin, 45 
(5): 888-893. 
Metivier, R. P., Francis, F. J. and Clydesdale, F. M. (1980). Solvent extraction of 
anthocyanins from wine pomace. Journal of Food Science, 45 (4): 1099-1100. 
Milbury, P. E., Vita, J. A. and Blumberg, J. B. (2010). Anthocyanins are bioavailable in 
humans following an acute dose of cranberry juice. The Journal of Nutrition, 140 (6): 
1099-1104. 
329 
 
Miliauskas, G., Venskutonis, P. R. and Van Beek, T. A. (2004). Screening of radical 
scavenging activity of some medicinal and aromatic plant extracts. Food Chemistry, 
85 (2): 231-237. 
Milstien, S. and Katusic, Z. (1999). Oxidation of tetrahydrobiopterin by peroxynitrite: 
implications for vascular endothelial function. Biochemical and Biophysical Research 
Communications, 263 (3): 681-684. 
Mimić-Oka, J., Simić, D. V. and Simić, T. P. (1999). Free radicals in cardiovascular diseases. 
Facta Universitatis Series Medicine and  Biology, 6: 11-22. 
Miyazaki, R., Ichiki, T., Hashimoto, T., Inanaga, K., Imayama, I., Sadoshima, J. and 
Sunagawa, K. (2008). SIRT1, a longevity gene, downregulates angiotensin II type 1 
receptor expression in vascular smooth muscle cells. Arteriosclerosis, Thrombosis, 
and Vascular Biology, 28 (7): 1263-1269. 
Mizugaki, M., Ishizawa, F., Yamazaki, T. and Hishinuma, T. (2000). Epigallocatechin gallate 
increase the prostacyclin production of bovine aortic endothelial cells. Prostaglandins 
& Other Lipid Mediators, 62 (2): 157-164. 
Moco, S., Martin, F.-P. J. and Rezzi, S. (2012). Metabolomics view on gut microbiome 
modulation by polyphenol-rich foods. Journal of Proteome Research, 11 (10): 4781-
4790. 
Molina-Alcaide, E., Moumen, A. and Martín-García, A. I. (2008). By-products from 
viticulture and the wine industry: potential as sources of nutrients for ruminants. 
Journal of the Science of Food and Agriculture, 88 (4): 597-604. 
Monagas, M., Bartolomé, B. and Gomez-Cordovés, C. (2005). Updated knowledge about the 
presence of phenolic compounds in wine. Critical Reviews in Food Science and 
Nutrition, 45 (2): 85-118. 
Monagas, M., Gómez-Cordovés, C., Bartolomé, B., Laureano, O. and Ricardo da Silva, J. M. 
(2003). Monomeric, oligomeric, and polymeric flavan-3-ol composition of wines and 
grapes from Vitis vinifera L. Cv. Graciano, Tempranillo, and Cabernet Sauvignon. 
Journal of Agricultural and Food Chemistry, 51 (22): 6475-6481. 
Mori, K., Goto-Yamamoto, N., Kitayama, M. and Hashizume, K. (2007). Loss of 
anthocyanins in red-wine grape under high temperature. Journal of Experimental 
Botany, 58 (8): 1935-1945. 
Morten, G., Allan, D., Thorkild, I. A. S., Ulrik, B., Peter, S. and Gorm, J. (1995). Mortality 
associated with moderate intakes of wine, beer, or spirits. British Medical Journal, 
310 (6988): 1165-1169. 
Mullen, W., Edwards, C. A., Serafini, M. and Crozier, A. (2008). Bioavailability of 
pelargonidin-3-O-glucoside and its metabolites in humans following the ingestion of 
strawberries with and without cream. Journal of Agricultural and Food Chemistry, 56 
(3): 713-719. 
Mulvany, M. J. and Aalkjaer, C. (1990). Structure and function of small arteries. 
Physiological Reviews, 70 (4): 921-961. 
Murray, C. J. and Lopez, A. D. (1996). Evidence-based health policy-lessons from the global 
burden of disease study. Science, 274 (5288): 740-743. 
Nakamura, Y. and Tonogai, Y. (2003). Metabolism of grape seed polyphenol in the rat. 
Journal of Agricultural and Food Chemistry, 51 (24): 7215-7225. 
Nardini, M., Natella, F. and Scaccini, C. (2007). Role of dietary polyphenols in platelet 
aggregation. A review of the supplementation studies. Platelets, 18 (3): 224-243. 
Natsume, M., Osakabe, N., Oyama, M., Sasaki, M., Baba, S., Nakamura, Y., Osawa, T. and 
Terao, J. (2003). Structures of (-)-epicatechin glucuronide identified from plasma and 
urine after oral ingestion of (-)-epicatechin: differences between human and rat. Free 
Radical Biology & Medicine, 34 (7): 840-849. 
330 
 
Ndiaye, M., Chataigneau, T., Chataigneau, M. and Schini-Kerth, V. B. (2004). Red wine 
polyphenols induce EDHF-mediated relaxations in porcine coronary arteries through 
the redox-sensitive activation of the PI3-kinase/Akt pathway. British Journal of 
Pharmacology, 142 (7): 1131-1136. 
Neter, J. E., Stam, B. E., Kok, F. J., Grobbee, D. E. and Geleijnse, J. M. (2003). Influence of 
weight reduction on blood pressure: a meta-analysis of randomized controlled trials. 
Hypertension, 42 (5): 878-884. 
Neveu, V., Perez-Jiménez, J., Vos, F., Crespy, V., du Chaffaut, L., Mennen, L., Knox, C., 
Eisner, R., Cruz, J., Wishart, D. and Scalbert, A. (2010). Phenol-Explorer: an online 
comprehensive database on polyphenol contents in foods. Database, 2010. 
Nichols, J. and Katiyar, S. (2010). Skin photoprotection by natural polyphenols: anti-
inflammatory, antioxidant and DNA repair mechanisms. Archives of Dermatological 
Research, 302 (2): 71-83. 
Nie, L., Wise, M. L., Peterson, D. M. and Meydani, M. (2006). Avenanthramide, a 
polyphenol from oats, inhibits vascular smooth muscle cell proliferation and enhances 
nitric oxide production. Atherosclerosis, 186 (2): 260-266. 
Núñez, V., Gómez-Cordovés, C., Bartolomé, B., Hong, Y.-J. and Mitchell, A. E. (2006). 
Non-galloylated and galloylated proanthocyanidin oligomers in grape seeds from Vitis 
vinifera L. cv. Graciano, Tempranillo and Cabernet Sauvignon. Journal of the Science 
of Food and Agriculture, 86 (6): 915-921. 
O'Reilly, J. D., Mallet, A. I., McAnlis, G. T., Young, I. S., Halliwell, B., Sanders, T. A. and 
Wiseman, H. (2001). Consumption of flavonoids in onions and black tea: lack of 
effect on F2-isoprostanes and autoantibodies to oxidized LDL in healthy humans. The 
American Journal of Clinical Nutrition, 73 (6): 1040-1044. 
O'Shaughnessy, K. M. and Karet, F. E. (2004). Salt handling and hypertension. The Journal 
of Clinical Investigation, 113 (8): 1075-1081. 
O’Donnell, C. J., Lindpaintner, K., Larson, M. G., Rao, V. S., Ordovas, J. M., Schaefer, E. J., 
Myers, R. H. and Levy, D. (1998). Evidence for association and genetic linkage of the 
angiotensin-converting enzyme locus with hypertension and blood pressure in men 
but not women in the Framingham heart study. Circulation, 97 (18): 1766-1772. 
Obata, J., Nakamura, T., Takano, H., Naito, A., Kimura, H., Yoshida, Y., Shimizu, F., Guo, 
D. F. and Inagami, T. (2000). Increased gene expression of components of the renin-
angiotensin system in glomeruli of genetically hypertensive rats. Journal of  
Hypertension 18 (9): 1247-1255. 
Ogata, J., Fujishima, M., Tamaki, K., Nakatomi, Y., Ishitsuka, T. and Omae, T. (1982). 
Stroke-prone spontaneously hypertensive rats as an experimental model of malignant 
hypertension. Virchows Archiv A, 394 (3): 185-194. 
OIV (2011). World statistics. 9th General Assembly of the OIV Porto 2011: OIV: Paris. 
Olas, B., Wachowicz, B., Tomczak, A., Erler, J., Stochmal, A. and Oleszek, W. (2008). 
Comparative anti-platelet and antioxidant properties of polyphenol-rich extracts from: 
berries of Aronia melanocarpa, seeds of grape and bark of Yucca schidigera in vitro. 
Platelets, 19 (1): 70-77. 
Oliverio, M. I., Best, C. F., Kim, H. S., Arendshorst, W. J., Smithies, O. and Coffman, T. M. 
(1997). Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B 
receptors in blood pressure regulation. American Journal of Physiology - Renal 
Physiology, 272 (4): 515-520. 
Ottaviani, J. I., Kwik-Uribe, C., Keen, C. L. and Schroeter, H. (2012a). Intake of dietary 
procyanidins does not contribute to the pool of circulating flavanols in humans. The 
American Journal of Clinical Nutrition, 95 (4): 851-858. 
331 
 
Ottaviani, J. I., Momma, T. Y., Kuhnle, G. K., Keen, C. L. and Schroeter, H. (2012b). 
Structurally related (-)-epicatechin metabolites in humans: assessment using de novo 
chemically synthesized authentic standards. Free Radical Biology & Medicine, 52 (8): 
1403-1412. 
Ottaviani, J. I., Momma, T. Y., Kuhnle, G. K., Keen, C. L. and Schroeter, H. (2012c). 
Structurally related (−)-epicatechin metabolites in humans: Assessment using de novo 
chemically synthesized authentic standards. Free Radical Biology and Medicine, 52 
(8): 1403-1412. 
Ottesen, J. T. and Olufsen, M. S. (2011). Functionality of the baroreceptor nerves in heart rate 
regulation. Computer Methods and Programs in Biomedicine, 101 (2): 208-219. 
Ou, B., Hampsch-Woodill, M. and Prior, R. L. (2001). Development and validation of an 
improved oxygen radical absorbance capacity assay using fluorescein as the 
fluorescent probe. Journal of Agricultural and Food Chemistry, 49 (10): 4619-4626. 
Pacher, P., Beckman, J. S. and Liaudet, L. (2007). Nitric Oxide and Peroxynitrite in Health 
and Disease. Physiological Reviews, 87 (1): 315-424. 
Paganga, G. and Rice-Evans, C. A. (1997). The identification of flavonoids as glycosides in 
human plasma. FEBS Letters, 401 (1): 78-82. 
Palmer, R. M. J., Ferrige, A. G. and Moncada, S. (1987). Nitric oxide release accounts for the 
biological activity of endothelium-derived relaxing factor. Nature, 327 (6122): 524-
526. 
Panza, J. A., Quyyumi, A. A., Brush, J. E. and Epstein, S. E. (1990). Abnormal endothelium-
dependent vascular relaxation in patients with essential hypertension. New England 
Journal of Medicine, 323 (1): 22-27. 
Paradelo, R., Moldes, A. B. and Barral, M. T. (2009a). Treatment of red wine vinasses with 
non-conventional substrates for removing coloured compounds. Water Science and 
Technology, 59 (8): 1585-1592. 
Paradelo, R., Moldes, A. B., Dominguez, J. M. and Barral, M. a. T. (2009b). Reduction of 
water repellence of hydrophobic plant substrates using biosurfactant produced from 
hydrolyzed grape marc. Journal of Agricultural and Food Chemistry, 57 (11): 4895-
4899. 
Pardo, A., Perona, M. A. and Pardo, J. (2007). Indoor composting of vine by-products to 
produce substrates for mushroom cultivation. Spanish Journal of Agricultural 
Research, 5 (3): 417-424. 
Park, Y. K., Kim, J. S. and Kang, M. H. (2004). Concord grape juice supplementation 
reduces blood pressure in Korean hypertensive men: double-blind, placebo controlled 
intervention trial. Biofactors, 22 (1-4): 145-147. 
Patel, K. R., Scott, E., Brown, V. A., Gescher, A. J., Steward, W. P. and Brown, K. (2011). 
Clinical trials of resveratrol. Annals of the New York Academy of Sciences, 1215 (1): 
161-169. 
Peleg, H., Gacon, K., Schlich, P. and Noble, A. C. (1999). Bitterness and astringency of 
flavan-3-ol monomers, dimers and trimers. Journal of the Science of Food and 
Agriculture, 79 (8): 1123-1128. 
Perestrelo, R., Lu, Y., Santos, S. A. O., Silvestre, A. J. D., Neto, C. P., Câmara, J. S. and 
Rocha, S. M. (2012). Phenolic profile of Sercial and Tinta Negra Vitis vinifera L. 
grape skins by HPLC–DAD–ESI-MSn: Novel phenolic compounds in Vitis vinifera 
L. grape. Food Chemistry, 135 (1): 94-104. 
Pérez-Jiménez, J., Arranz, S. and Saura-Calixto, F. (2009). Proanthocyanidin content in foods 
is largely underestimated in the literature data: An approach to quantification of the 
missing proanthocyanidins. Food Research International, 42 (10): 1381-1388. 
332 
 
Pérez-Jiménez, J. and Saura-Calixto, F. (2008). Grape products and cardiovascular disease 
risk factors. Nutrition Research Reviews, 21 (02): 158-173. 
Pérez-Magariño, S. and González-San José, M. L. (2006). Polyphenols and colour variability 
of red wines made from grapes harvested at different ripeness grade. Food Chemistry, 
96 (2): 197-208. 
Perez-Vizcaino, F., Duarte, J., Jimenez, R., Santos-Buelga, C. and Osuna, A. (2009). 
Antihypertensive effects of the flavonoid quercetin. Pharmacological Reports, 61 (1): 
67-75. 
Perlman, D. and Ramonas, L. (2008). Astringency-compensated polyphenolic antioxidant-
containing comestible composition. US20080044539. 
Perrone, G., Nicoletti, I., Pascale, M., de Rossi, A., de Girolamo, A. and Visconti, A. (2007). 
Positive correlation between high levels of Ochratoxin A and resveratrol-related 
compounds in red wines. Journal of Agricultural and Food Chemistry, 55 (16): 6807-
6812. 
Pescatello, L. S., Franklin, B. A., Fagard, R., Farquhar, W. B., Kelley, G. A. and Ray, C. A. 
(2004). American college of sports medicine position stand. Exercise and 
hypertension. Medicine and Science in Sports and Exercise, 36 (3): 533-553. 
Petretto, E., Sarwar, R., Grieve, I., Lu, H., Kumaran, M. K., Muckett, P. J., Mangion, J., 
Schroen, B., Benson, M., Punjabi, P. P., Prasad, S. K., Pennell, D. J., Kiesewetter, C., 
Tasheva, E. S., Corpuz, L. M., Webb, M. D., Conrad, G. W., Kurtz, T. W., Kren, V., 
Fischer, J., Hubner, N., Pinto, Y. M., Pravenec, M., Aitman, T. J. and Cook, S. A. 
(2008). Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation 
of left ventricular mass. Nature Genetics 40 (5): 546-552. 
Ping, L., Brosse, N., Chrusciel, L., Navarrete, P. and Pizzi, A. (2011). Extraction of 
condensed tannins from grape pomace for use as wood adhesives. Industrial Crops 
and Products, 33 (1): 253-257. 
Pinto, Y. M., Paul, M. and Ganten, D. (1998). Lessons from rat models of hypertension: from 
Goldblatt to genetic engineering. Cardiovascular Research, 39 (1): 77-88. 
Planas, J. M., Alfaras, I., Colom, H. and Juan, M. E. (2012). The bioavailability and 
distribution of trans-resveratrol are constrained by ABC transporters. Archives of 
Biochemistry and Biophysics, 527 (2): 67-73. 
Plumb, G. W., De Pascual-Teresa, S., Santos-Buelga, C., Cheynier, V. and Williamson, G. 
(1998). Antioxidant properties of catechins and proanthocyanidins: effect of 
polymerisation, galloylation and glycosylation. Free radical research, 29 (4): 351-
358. 
Polek, A., Sobiczewski, W. and Matowicka-Karna, J. (2009). P-selectin and its role in some 
diseases. Postepy Hig Med Dosw, 63: 465-470. 
Poquet, L., Clifford, M. N. and Williamson, G. (2008). Transport and metabolism of ferulic 
acid through the colonic epithelium. Drug Metabolism and Disposition, 36 (1): 190-
197. 
Portilla-Rivera, O. M., Torrado, A. M. a., Dom nguez, J. M. and Moldes, A. B. n. (2010). 
Stabilization of kerosene/water emulsions using bioemulsifiers obtained by 
fermentation of hemicellulosic sugars with Lactobacillus pentosus. Journal of 
Agricultural and Food Chemistry, 58 (18): 10162-10168. 
Potschka, H., Fedrowitz, M. and Loscher, W. (2001). P-glycoprotein and multidrug 
resistance-associated protein are involved in the regulation of extracellular levels of 
the major antiepileptic drug carbamazepine in the brain. NeuroReport, 12 (16): 3557-
3560. 
333 
 
Potschka, H., Fedrowitz, M. and Loscher, W. (2002). P-Glycoprotein-mediated efflux of 
phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from 
microdialysis experiments in rats. Neuroscience Letters, 327 (3): 173-176. 
Pozo-Bayón, M. Á., Hernández, M. T., Martín-Álvarez, P. J. and Polo, M. C. (2003). Study 
of low molecular weight phenolic compounds during the aging of sparkling wines 
manufactured with red and white grape varieties. Journal of Agricultural and Food 
Chemistry, 51 (7): 2089-2095. 
Pozo-Bayón, M. Á., Monagas, M., Polo, M. C. and Gómez-Cordovés, C. (2004). Occurrence 
of pyranoanthocyanins in sparkling wines manufactured with red grape varieties. 
Journal of Agricultural and Food Chemistry, 52 (5): 1300-1306. 
Praticò, D. and Dogné, J.-M. (2009). Vascular biology of eicosanoids and atherogenesis. 
Expert Review of Cardiovascular Therapy, 7 (9): 1079-1089. 
Pravenec, M., Churchill, P. C., Churchill, M. C., Viklicky, O., Kazdova, L., Aitman, T. J., 
Petretto, E., Hubner, N., Wallace, C. A., Zimdahl, H., Zidek, V., Landa, V., Dunbar, 
J., Bidani, A., Griffin, K., Qi, N., Maxova, M., Kren, V., Mlejnek, P., Wang, J. and 
Kurtz, T. W. (2008a). Identification of renal Cd36 as a determinant of blood pressure 
and risk for hypertension. Nature Genetics, 40 (8): 952-954. 
Pravenec, M., Kazdova, L., Landa, V., Zidek, V., Mlejnek, P., Simakova, M., Jansa, P., 
Forejt, J., Kren, V., Krenova, D., Qi, N., Wang, J.-M., Chan, D., Aitman, T. J. and 
Kurtz, T. W. (2008b). Identification of mutated srebf1 as a QTL influencing risk for 
hepatic steatosis in the spontaneously hypertensive rat. Hypertension, 51 (1): 148-153. 
Pravenec, M. and Kurtz, T. W. (2007). Molecular genetics of experimental hypertension and 
the metabolic syndrome: from gene pathways to new therapies. Hypertension, 49 (5): 
941-952. 
Price, S. F., Breen, P. J., Valladao, M. and Watson, B. T. (1995). Cluster sun exposure and 
quercetin in Pinot noir grapes and wine. American Journal of Enology and Viticulture, 
46 (2): 187-194. 
Prieur, C., Rigaud, J., Cheynier, V. and Moutounet, M. (1994). Oligomeric and polymeric 
procyanidins from grape seeds. Phytochemistry, 36 (3): 781-784. 
Prior, R. L. and Wu, X. (2006). Anthocyanins: structural characteristics that result in unique 
metabolic patterns and biological activities. Free Radical Research, 40 (10): 1014-
1028. 
Puddey, I. B., Beilin, L. J. and Rakic, V. (1997). Alcohol, hypertension and the 
cardiovascular system: a critical appraisal. Addiction Biology, 2 (2): 159-170. 
Pulido, R., Hernández-García, M. and Saura-Calixto, F. (2003). Contribution of beverages to 
the intake of lipophilic and hydrophilic antioxidants in the Spanish diet. European 
Journal of Clinical Nutrition, 57 (10): 1275-1282. 
Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, 
N., Levenez, F., Yamada, T., Mende, D. R., Li, J., Xu, J., Li, S., Li, D., Cao, J., Wang, 
B., Liang, H., Zheng, H., Xie, Y., Tap, J., Lepage, P., Bertalan, M., Batto, J.-M., 
Hansen, T., Le Paslier, D., Linneberg, A., Nielsen, H. B., Pelletier, E., Renault, P., 
Sicheritz-Ponten, T., Turner, K., Zhu, H., Yu, C., Li, S., Jian, M., Zhou, Y., Li, Y., 
Zhang, X., Li, S., Qin, N., Yang, H., Wang, J., Brunak, S., Dore, J., Guarner, F., 
Kristiansen, K., Pedersen, O., Parkhill, J., Weissenbach, J., Bork, P., Ehrlich, S. D. 
and Wang, J. (2010). A human gut microbial gene catalogue established by 
metagenomic sequencing. Nature, 464 (7285): 59-65. 
Ranaivo, H. R., Diebolt, M. and Andriantsitohaina, R. (2004). Wine polyphenols induce 
hypotension, and decrease cardiac reactivity and infarct size in rats: involvement of 
nitric oxide. British Journal of Pharmacology, 142 (4): 671-678. 
334 
 
Raza, H. and John, A. (2005). Green tea polyphenol epigallocatechin-3-gallate differentially 
modulates oxidative stress in PC12 cell compartments. Toxicology and Applied 
Pharmacology, 207 (3): 212-220. 
Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M. and Rice-Evans, C. (1999). 
Antioxidant activity applying an improved ABTS radical cation decolorization assay. 
Free Radical Biology and Medicine, 26 (9-10): 1231-1237. 
Rein, D., Lotito, S., Holt, R. R., Keen, C. L., Schmitz, H. H. and Fraga, C. G. (2000). 
Epicatechin in human plasma: in vivo determination and effect of chocolate 
consumption on plasma oxidation status. The Journal of Nutrition, 130 (8): 2109-
2114. 
Renaud, S. and de Lorgeril, M. (1992). Wine, alcohol, platelets, and the French paradox for 
coronary heart disease. The Lancet, 339 (8808): 1523-1526. 
Rentzsch, M., Schwarz, M. and Winterhalter, P. (2007). Pyranoanthocyanins – an overview 
on structures, occurrence, and pathways of formation. Trends in Food Science & 
Technology, 18 (10): 526-534. 
Ribéreau-Gayon, P. (1959). Recherches sur les anthocyanes des végétaux. Application au 
genre Vitis. Paris: Librairie Générale d'Enseignement, Paris 
Ribéreau-Gayon, P. (1965). Identification d’esters des acides des acides cinnamiques et 
l’acide tartrique dans les limbes et les baies de Vitis. vinifera. Comptes rendus 
hebdomadaires des seances de l'Academie des sciences, 260: 341-343. 
Ribéreau-Gayon, P., Glories, Y., Maujean, A. and Dubourdieu, D. (2006). Phenolic 
Compounds. In Handbook of Enology. The chemistry of wine. Stabilization and 
treatments.  pp. 141-203, John Wiley & Sons, Ltd. 
Ribéreau Gayon, P. and Stonestreet, E. (1965). Le dosage des anthocyanes dans le vin rouge. 
Bulletin de la Société Chimique de France (9): 2649–2652. 
Rice-Evans, C. A. and Miller, N. J. (1996). Antioxidant activities of flavonoids as bioactive 
components of food. Biochemical Society transactions, 24 (3): 790-795. 
Richelle, M., Pridmore-Merten, S., Bodenstab, S., Enslen, M. and Offord, E. A. (2002). 
Hydrolysis of isoflavone glycosides to aglycones by β-glycosidase does not alter 
plasma and urine isoflavone pharmacokinetics in postmenopausal women. The 
Journal of Nutrition, 132 (9): 2587-2592. 
Rios, L. Y., Bennett, R. N., Lazarus, S. A., Rémésy, C., Scalbert, A. and Williamson, G. 
(2002). Cocoa procyanidins are stable during gastric transit in humans. The American 
Journal of Clinical Nutrition, 76 (5): 1106-1110. 
Rivera, Ó., Torrado, A., Moldes, A. and Domínguez, J. (2009). Minerals and organic nitrogen 
present in grape marc hydrolyzates enhance xylose consumption by Lactobacillus 
pentosus. Applied Biochemistry and Biotechnology, 152 (2): 262-274. 
Rivera, O. M. P., Moldes, A. B., Torrado, A. M. and Domínguez, J. M. (2007). Lactic acid 
and biosurfactants production from hydrolyzed distilled grape marc. Process 
Biochemistry, 42 (6): 1010-1020. 
Robbins, R. J., Leonczak, J., Johnson, J. C., Li, J., Kwik-Uribe, C., Prior, R. L. and Gu, L. 
(2009). Method performance and multi-laboratory assessment of a normal phase high 
pressure liquid chromatography–fluorescence detection method for the quantitation of 
flavanols and procyanidins in cocoa and chocolate containing samples. Journal of 
Chromatography A, 1216 (24): 4831-4840. 
Robichaud, J. L. and Noble, A. C. (1990). Astringency and bitterness of selected phenolics in 
wine. Journal of the Science of Food and Agriculture, 53 (3): 343-353. 
Robinson, G. M. and Robinson, R. (1933). A survey of anthocyanins: Notes on the 
distribution of leuco-anthocyanins. . Biochemical Journal, 27 (1): 206-212. 
335 
 
Roby, G., Harbertson, J. F., Adams, D. A. and Matthews, M. A. (2004). Berry size and vine 
water deficits as factors in winegrape composition: Anthocyanins and tannins. 
Australian Journal of Grape and Wine Research, 10 (2): 100-107. 
Rockenbach, I. I., Gonzaga, L. V., Rizelio, V. M., Gonçalves, A. E. d. S. S., Genovese, M. I. 
and Fett, R. (2011). Phenolic compounds and antioxidant activity of seed and skin 
extracts of red grape (Vitis vinifera and Vitis labrusca) pomace from Brazilian 
winemaking. Food Research International, 44 (4): 897-901. 
Rodríguez, L. A., Toro, M. E., Vazquez, F., Correa-Daneri, M. L., Gouiric, S. C. and Vallejo, 
M. D. (2010). Bioethanol production from grape and sugar beet pomaces by solid-
state fermentation. International Journal of Hydrogen Energy, 35 (11): 5914-5917. 
Roginsky, V. and Lissi, E. A. (2005). Review of methods to determine chain-breaking 
antioxidant activity in food. Food Chemistry, 92 (2): 235-254. 
Romero-Cascales, I., Ortega-Regules, A., López-Roca, J. M., Fernández-Fernández, J. I. and 
Gómez-Plaza, E. (2005). Differences in anthocyanin extractability from grapes to 
wines according to variety. American Journal of Enology and Viticulture, 56 (3): 212-
219. 
Romero-Pérez, A. I., Lamuela-Raventós, R. M., Waterhouse, A. L. and de la Torre-Boronat, 
M. C. (1996). Levels of cis- and trans-resveratrol and their glucosides in white and 
rosé Vitis vinifera wines from Spain. Journal of Agricultural and Food Chemistry, 44 
(8): 2124-2128. 
Romero, M., Jiménez, R., Hurtado, B., Moreno, J. M., Rodríguez-Gómez, I., López-
Sepúlveda, R., Zarzuelo, A., Pérez-Vizcaino, F., Tamargo, J., Vargas, F. and Duarte, 
J. (2010). Lack of beneficial metabolic effects of quercetin in adult spontaneously 
hypertensive rats. European Journal of Pharmacology, 627 (1–3): 242-250. 
Roowi, S., Stalmach, A., Mullen, W., Lean, M. E. J., Edwards, C. A. and Crozier, A. (2010). 
Green tea flavan-3-ols: colonic degradation and urinary excretion of catabolites by 
humans. Journal of Agricultural and Food Chemistry, 58 (2): 1296-1304. 
Rosenblat, M., Volkova, N., Coleman, R. and Aviram, M. (2006). Pomegranate by-product 
administration to apolipoprotein E-deficient mice attenuates atherosclerosis 
development as a result of decreased macrophage oxidative stress and reduced 
cellular uptake of oxidized low-density lipoprotein. Journal of Agricultural and Food 
Chemistry, 54 (5): 1928-1935. 
Ross, R. (1999). Atherosclerosis — an inflammatory disease. New England Journal of 
Medicine, 340 (2): 115-126. 
Rouanet, J. M. and Teissèdre, P. L. (2011). Effects of wine consumption on cardiovascular 
diseases. Journal of Wine Research, 22 (2): 159-163. 
Ruberto, G., Renda, A., Daquino, C., Amico, V., Spatafora, C., Tringali, C. and Tommasi, N. 
D. (2007). Polyphenol constituents and antioxidant activity of grape pomace extracts 
from five Sicilian red grape cultivars. Food Chemistry, 100 (1): 203-210. 
Rush, J. W. E., Quadrilatero, J., Levy, A. S. and Ford, R. J. (2007). Chronic resveratrol 
enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of 
spontaneously hypertensive rats. Experimental Biology and Medicine, 232 (6): 814-
822. 
Sacks, F. M., Obarzanek, E., Windhauser, M. M., Svetkey, L. P., Vollmer, W. M., 
McCullough, M., Karanja, N., Lin, P.-H., Steele, P., Proschan, M. A., Evans, M. A., 
Appel, L. J., Bray, G. A., Vogt, T. M., Moore, T. J. and Investigators, D. (1995). 
Rationale and design of the dietary approaches to stop hypertension trial (DASH): A 
multicenter controlled-feeding study of dietary patterns to lower blood pressure. 
Annals of Epidemiology, 5 (2): 108-118. 
336 
 
Safar, M. E., Temmar, M., Kakou, A., Lacolley, P. and Thornton, S. N. (2009). Sodium 
intake and vascular stiffness in hypertension. Hypertension, 54 (2): 203-209. 
Salagoïty-Auguste, M.-H. and Bertrand, A. (1984). Wine phenolics—analysis of low 
molecular weight components by high performance liquid chromatography. Journal 
of the Science of Food and Agriculture, 35 (11): 1241-1247. 
Sampson, L., Rimm, E., Hollman, P. C. H., de Vries, J. H. M. and Katan, M. B. (2002). 
Flavonol and flavone intakes in US health professionals. Journal of the American 
Dietetic Association, 102 (10): 1414-1420. 
Sang, S., Lee, M. J., Yang, I., Buckley, B. and Yang, C. S. (2008). Human urinary metabolite 
profile of tea polyphenols analyzed by liquid chromatography/electrospray ionization 
tandem mass spectrometry with data-dependent acquisition. Rapid Communications 
in Mass Spectrometry, 22 (10): 1567-1578. 
Sano, A., Uchida, R., Saito, M., Shioya, N., Komori, Y., Tho, Y. and Hashizume, N. (2007). 
Beneficial effects of grape seed extract on malondialdehyde-modified LDL. Journal 
of Nutritional Science and Vitaminology, 53 (2): 174-182. 
Sano, A., Yamakoshi, J., Tokutake, S., Tobe, K., Kubota, Y. and Kikuchi, M. (2003). 
Procyanidin B1 is detected in human serum after intake of proanthocyanidin-rich 
grape seed extract. Bioscience, Biotechnology, and Biochemistry, 67 (5): 1140-1143. 
Sarr, M., Chataigneau, M., Martins, S., Schott, C., El Bedoui, J., Oak, M.-H., Muller, B., 
Chataigneau, T. and Schini-Kerth, V. B. (2006). Red wine polyphenols prevent 
angiotensin II-induced hypertension and endothelial dysfunction in rats: Role of 
NADPH oxidase. Cardiovascular Research, 71 (4): 794-802. 
Sassard, J., Vincent, M., Oréa, V., Privat, P. and Bataillard, A. (1997). Genetics of blood 
pressure and associated phenotypes in the Lyon rat. Clinical and Experimental 
Hypertension, 19 (5-6): 567-575. 
Sato, M., Ramarathnam, N., Suzuki, Y., Ohkubo, T., Takeuchi, M. and Ochi, H. (1996). 
Varietal differences in the phenolic content and superoxide radical scavenging 
potential of wines from different sources. Journal of Agricultural and Food 
Chemistry, 44 (1): 37-41. 
Saura-Calixto, F. (1998). Antioxidant dietary fiber product: a new concept and a potential 
food ingredient. Journal of Agricultural and Food Chemistry, 46 (10): 4303-4306. 
Saura-Calixto, F., Serrano, J. and Goñi, I. (2007). Intake and bioaccessibility of total 
polyphenols in a whole diet. Food Chemistry, 101 (2): 492-501. 
Sáyago-Ayerdi, S. G., Brenes, A., Viveros, A. and Goñi, I. (2009). Antioxidative effect of 
dietary grape pomace concentrate on lipid oxidation of chilled and long-term frozen 
stored chicken patties. Meat Science, 83 (3): 528-533. 
Scalbert, A., Johnson, I. T. and Saltmarsh, M. (2005). Polyphenols: antioxidants and beyond. 
The American Journal of Clinical Nutrition, 81 (1): 215S-217S. 
Scalbert, A. and Williamson, G. (2000). Dietary intake and bioavailability of polyphenols. 
The Journal of Nutrition, 130 (8): 2073-2085. 
Schini-Kerth, V. B., Étienne-Selloum, N., Chataigneau, T. and Auger, C. (2011). Vascular 
protection by natural product-derived polyphenols: in vitro and in vivo evidence. 
Planta Medica 77 (11): 1161-1167. 
Schinkel, A. H. (1999). P-Glycoprotein, a gatekeeper in the blood-brain barrier. Advanced 
Drug Delivery Reviews, 36 (2-3): 179-194. 
Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., 
Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. and et al. 
(1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in 
the blood-brain barrier and to increased sensitivity to drugs. Cell, 77 (4): 491-502. 
337 
 
Schotte, D. E. and Stunkard, A. J. (1990). The effects of weight reduction on blood pressure 
in 301 obese patients. Archives of Internal Medicine, 150 (8): 1701-1704. 
Schwarz, M., Wabnitz, T. C. and Winterhalter, P. (2003). Pathway leading to the formation 
of anthocyanin−vinylphenol adducts and related pigments in red wines. Journal of 
Agricultural and Food Chemistry, 51 (12): 3682-3687. 
Scott O. Galbreath, J. (2001). Method for preparing a grape derived product. US6190716  
Selma, M. a. V., Esp n, J. C. and Tom s-Barber n, F. A. (2009). Interaction between 
phenolics and gut microbiota: role in human health. Journal of Agricultural and Food 
Chemistry, 57 (15): 6485-6501. 
Serra, A., Macià, A., Romero, M.-P., Piñol, C. and Motilva, M.-J. (2011). Rapid methods to 
determine procyanidins, anthocyanins, theobromine and caffeine in rat tissues by 
liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, 
879 (19): 1519-1528. 
Serra, A., Macià, A., Romero, M.-P., Valls, J., Bladé, C., Arola, L. and Motilva, M.-J. (2010). 
Bioavailability of procyanidin dimers and trimers and matrix food effects in in vitro 
and in vivo models. British Journal of Nutrition, 103 (07): 944-952. 
Serra, A., Macià, A., Romero, M. P., Salvado, M. J., Bustos, M., Fernandez-Larrea, J. and 
Motilva, M. J. (2009). Determination of procyanidins and their metabolites in plasma 
samples by improved liquid chromatography-tandem mass spectrometry. Journal of 
Chromatography B, 877 (11-12): 1169-1176. 
Sesink, A. L. A., Arts, I. C. W., Faassen-Peters, M. and Hollman, P. C. H. (2003). Intestinal 
uptake of quercetin-3-glucoside in rats involves hydrolysis by lactase phlorizin 
hydrolase. The Journal of Nutrition, 133 (3): 773-776. 
Sever, P. S. and Poulter, N. R. (1989). A hypothesis for the pathogenesis of essential 
hypertension: the initiating factors. Journal of Hypertension, 7 (1): S9-12. 
Shanmuganayagam, D., Beahm, M. R., Osman, H. E., Krueger, C. G., Reed, J. D. and Folts, 
J. D. (2002). Grape seed and grape skin extracts elicit a greater antiplatelet effect 
when used in combination than when used individually in dogs and humans. The 
Journal of Nutrition, 132 (12): 3592-3598. 
Shibata, H. and Ghishan, F. K. (1990). Intestinal calcium transport in spontaneously 
hypertensive rats (SHR) and their genetically matched WKY rats. Proceedings of the 
Society for Experimental Biology and Medicine, 194 (1): 26-31. 
Shoji, T., Masumoto, S., Moriichi, N., Akiyama, H., Kanda, T., Ohtake, Y. and Goda, Y. 
(2006). Apple procyanidin oligomers absorption in rats after oral administration: 
analysis of procyanidins in plasma using the porter method and high-performance 
liquid chromatography/tandem mass spectrometry. Journal of Agricultural and Food 
Chemistry, 54 (3): 884-892. 
Shrikhande, A. J., Race, E. J., Wightman, J. D. and Sambueso, R. D. (2003). Process for 
extraction, purification and enrichment of polyphenolic substances from whole 
grapes, grape seeds and grape pomace. US6544581. 
Shrikhande, A. J., Wang, H. and Kupina, S. A. (2007). Grape extract, dietary supplement 
thereof, and processes therefor. US7767235  
Shukitt-Hale, B., Carey, A., Simon, L., Mark, D. A. and Joseph, J. A. (2006). Effects of 
Concord grape juice on cognitive and motor deficits in aging. Nutrition, 22 (3): 295-
302. 
Siemann, E. H. and Creasy, L. L. (1992). Concentration of the phytoalexin resveratrol in 
wine. American Journal of Enology and Viticulture, 43 (1): 49-52. 
Silva, M. A., Ky, I., Jourdes, M. and Teissedre, P. L. (2011). Rapid and simple method for 
the quantification of flavan-3-ols in wine. European Food Research and Technology: 
1-5. 
338 
 
Simonetti, P., Gardana, C. and Pietta, P. (2001). Plasma levels of caffeic acid and antioxidant 
status after red wine intake. Journal of Agricultural and Food Chemistry, 49 (12): 
5964-5968. 
Simons, A. L., Renouf, M., Hendrich, S. and Murphy, P. A. (2005). Human gut microbial 
degradation of flavonoids: structure−function relationships. Journal of Agricultural 
and Food Chemistry, 53 (10): 4258-4263. 
Singleton, V. L. and Rossi, J. A. (1965). Colorimetry of total phenolics with 
phosphomolybdic-phosphotungstic acid reagents. American Journal of Enology and 
Viticulture, 16 (3): 144-158. 
Singleton, V. L., Timberlake, C. F. and Lea, A. G. H. (1978). The phenolic cinnamates of 
white grapes and wine. Journal of the Science of Food and Agriculture, 29 (4): 403-
410. 
Skov, K., Nyengaard, J. R., Korsgaard, N. and Mulvany, M. J. (1994). Number and size of 
renal glomeruli in spontaneously hypertensive rats. Journal of Hypertension, 12 (12): 
1373-1376. 
Smirk, F. H. and Hall, W. H. (1958). Inherited Hypertension in Rats. Nature, 182 (4637): 
727-728. 
Smith, T. L. and Hutchins, P. M. (1979). Central hemodynamics in the developmental stage 
of spontaneous hypertension in the unanesthetized rat. Hypertension, 1 (5): 508-517. 
Soares de Moura, R., Viana, F. S. C., Souza, M. A. V., Kovary, K., Guedes, D. C., Oliveira, 
E. P. B., Rubenich, L. M. S., Carvalho, L. C. R. M., Oliveira, R. M., Tano, T. and 
Correia, M. L. G. (2002). Antihypertensive, vasodilator and antioxidant effects of a 
vinifera grape skin extract. Journal of Pharmacy and Pharmacology, 54 (11): 1515-
1520. 
Soleas, G. J., Tomlinson, G., Diamandis, E. P. and Goldberg, D. M. (1997). Relative 
contributions of polyphenolic constituents to the antioxidant status of wines: 
development of a predictive model. Journal of Agricultural and Food Chemistry, 45 
(10): 3995-4003. 
Soleimani, M., Bergman, J. A., Hosford, M. A. and McKinney, T. D. (1990). Potassium 
depletion increases luminal Na+/H+ exchange and basolateral Na+:CO3=:HCO3- 
cotransport in rat renal cortex. The Journal of Clinical Investigation, 86 (4): 1076-
1083. 
Somers, T. C. (1971). The polymeric nature of wine pigments. Phytochemistry, 10 (9): 2175-
2186. 
Somers, T. C., Vérette, E. and Pocock, K. F. (1987). Hydroxycinnamate esters of Vitis 
vinifera: Changes during white vinification, and effects of exogenous enzymic 
hydrolysis. Journal of the Science of Food and Agriculture, 40 (1): 67-78. 
Souquet, J.-M., Cheynier, V., Brossaud, F. and Moutounet, M. (1996). Polymeric 
proanthocyanidins from grape skins. Phytochemistry, 43 (2): 509-512. 
Souquet, J.-M., Labarbe, B., Le Guernevé, C., Cheynier, V. and Moutounet, M. (2000). 
Phenolic composition of grape stems. Journal of Agricultural and Food Chemistry, 48 
(4): 1076-1080. 
Spencer, J. P. E., Chaudry, F., Pannala, A. S., Srai, S. K., Debnam, E. and Rice-Evans, C. 
(2000). Decomposition of cocoa procyanidins in the gastric milieu. Biochemical and 
Biophysical Research Communications, 272 (1): 236-241. 
Spencer, J. P. E., Schroeter, H., Shenoy, B., S. Srai, S. K., Debnam, E. S. and Rice-Evans, C. 
(2001). Epicatechin is the primary bioavailable form of the procyanidin dimers B2 
and B5 after transfer across the small intestine. Biochemical and Biophysical 
Research Communications, 285 (3): 588-593. 
339 
 
Spranger, I., Sun, B., Mateus, A. M., Freitas, V. d. and Ricardo-da-Silva, J. M. (2008). 
Chemical characterization and antioxidant activities of oligomeric and polymeric 
procyanidin fractions from grape seeds. Food Chemistry, 108 (2): 519-532. 
Sriram, G., Surendranath, C. and Sureshkumar, G. K. (1999). Kinetics of anthocyanin 
extraction from fresh and dried grape waste. Separation Science and Technology, 34 
(4): 683-697. 
St Lezin, E., Simonet, L., Pravenec, M. and Kurtz, T. W. (1992). Hypertensive strains and 
normotensive 'control' strains. How closely are they related? Hypertension, 19 (5): 
419-424. 
Staessen, J. A., Kuznetsova, T., Wang, J. G., Emelianov, D., Vlietinck, R. and Fagard, R. 
(1999). M235T angiotensinogen gene polymorphism and cardiovascular renal risk. 
Journal of Hypertension, 17 (1): 9-17. 
Stalmach, A., Edwards, C. A., Wightman, J. D. and Crozier, A. (2013). Colonic catabolism of 
dietary phenolic and polyphenolic compounds from Concord grape juice. Food & 
Function, 4 (1): 52-62. 
Stalmach, A., Troufflard, S., Serafini, M. and Crozier, A. (2009). Absorption, metabolism 
and excretion of Choladi green tea flavan-3-ols by humans. Molecular Nutrition & 
Food Research, 53 (1): 44-S53. 
Stankevicius, E., Kevelaitis, E., Vainorius, E. and Simonsen, U. (2003). [Role of nitric oxide 
and other endothelium-derived factors]. Medicina, 39 (4): 333-341. 
Stein, J. H., Keevil, J. G., Wiebe, D. A., Aeschlimann, S. and Folts, J. D. (1999). Purple 
grape juice improves endothelial function and reduces the susceptibility of LDL 
cholesterol to oxidation in patients with coronary artery disease. Circulation, 100 
(10): 1050-1055. 
Stoclet, J. C., Chataigneau, T., Ndiaye, M., Oak, M. H., El Bedoui, J., Chataigneau, M. and 
Schini-Kerth, V. B. (2004). Vascular protection by dietary polyphenols. European 
Journal of Pharmacology, 500 (1-3 SPEC. ISS.): 299-313. 
Stoupi, S., Williamson, G., Drynan, J. W., Barron, D. and Clifford, M. N. (2010a). A 
comparison of the in vitro biotransformation of (–)-epicatechin and procyanidin B2 by 
human faecal microbiota. Molecular Nutrition & Food Research, 54 (6): 747-759. 
Stoupi, S., Williamson, G., Drynan, J. W., Barron, D. and Clifford, M. N. (2010b). 
Procyanidin B2 catabolism by human fecal microflora: Partial characterization of 
‘dimeric’ intermediates. Archives of Biochemistry and Biophysics, 501 (1): 73-78. 
Stoupi, S., Williamson, G., Viton, F., Barron, D., King, L. J., Brown, J. E. and Clifford, M. 
N. (2010c). In vivo bioavailability, absorption, excretion, and pharmacokinetics of 
[14C]procyanidin B2 in male rats. Drug Metabolism and Disposition, 38 (2): 287-
291. 
Stranges, S., Wu, T., Dorn, J. M., Freudenheim, J. L., Muti, P., Farinaro, E., Russell, M., 
Nochajski, T. H. and Trevisan, M. (2004). Relationship of alcohol drinking pattern to 
risk of hypertension: a population-based study. Hypertension, 44 (6): 813-819. 
Sumner, M. D., Elliott-Eller, M., Weidner, G., Daubenmier, J. J., Chew, M. H., Marlin, R., 
Raisin, C. J. and Ornish, D. (2005). Effects of pomegranate juice consumption on 
myocardial perfusion in patients with coronary heart disease. The American Journal 
of Cardiology, 96 (6): 810-814. 
Takagaki, A. and Nanjo, F. (2013). Catabolism of (+)-catechin and (−)-epicatechin by rat 
intestinal microbiota. Journal of Agricultural and Food Chemistry, 61 (20): 4927-
4935. 
Takano, K., Nakaima, K., Nitta, M., Shibata, F. and Nakagawa, H. (2004). Inhibitory effect 
of (−)-epigallocatechin 3-gallate, a polyphenol of green tea, on neutrophil chemotaxis 
in vitro and in vivo. Journal of Agricultural and Food Chemistry, 52 (14): 4571-4576. 
340 
 
Tarascou, I., Barathieu, K., André, Y., Pianet, I., Dufourc, E. J. and Fouquet, E. (2006). An 
improved synthesis of procyanidin dimers: Regio- and stereocontrol of the interflavan 
bond. European Journal of Organic Chemistry (23): 5367-5377. 
Taubert, D., Roesen, R., Lehmann, C., Jung, N. and Schomig, E. (2007). Effects of low 
habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized 
controlled trial. JAMA, 298 (1): 49-60. 
Teissedre, P.-L. and Landrault, N. (2000). Wine phenolics: contribution to dietary intake and 
bioavailability. Food Research International, 33 (6): 461-467. 
Teissedre, P. L., Frankel, E. N., Waterhouse, A. L., Peleg, H. and Bruce German, J. (1996). 
Inhibition of in vitro human LDL oxidation by phenolic antioxidants from grapes and 
wines. Journal of the Science of Food and Agriculture, 70 (1): 55-61. 
The sixth report of the joint national committee on prevention, d., evaluation, and treatment 
of high blood pressure (1997). Archives of Internal Medicine, 157 (21): 2413-2446. 
Thorngate, J. H. and Singleton, V. L. (1994). Localization of procyanidins in grape seeds. 
American Journal of Enology and Viticulture, 45 (2): 259-262. 
Tikellis, C., Cooper, M. E., Bialkowski, K., Johnston, C. I., Burns, W. C., Lew, R. A., Smith, 
A. I. and Thomas, M. C. (2006). Developmental expression of ACE2 in the SHR 
kidney: A role in hypertension? Kidney International, 70 (1): 34-41. 
Timberlake, C. F. and Bridle, P. (1976). Interactions between anthocyanins, phenolic 
compounds, and acetaldehyde and their significance in red wines. American Journal 
of Enology and Viticulture, 27 (3): 97-105. 
Toba, K., Ohta, M., Kimura, T., Nagano, K., Ito, S. and Ouchi, Y. (1999). Role of brain 
vasopressin in regulation of blood pressure. In Progress in Brain Research. 119 pp. 
337-349. I.J.A. Urban, J. P. H. B. and Wed, D. D., Elsevier. 
TOHP (1997). Trials of Hypertension Prevention Collaborative Research Group. Effects of 
weight loss and sodium reduction intervention on blood pressure and hypertension 
incidence in overweight people with high-normal blood pressure. The Trials of 
Hypertension Prevention, phase II. The Trials of Hypertension Prevention 
Collaborative Research Group. Archives of Internal Medicine, 157 (6): 657-667. 
Touri o, S., Fuguet, E., Vinardell, M. a. P., Cascante, M. and Torres, J. L. s. (2009). Phenolic 
metabolites of grape antioxidant dietary fiber in rat urine. Journal of Agricultural and 
Food Chemistry, 57 (23): 11418-11426. 
Trambas, C. M., Muller, H. K. and Woods, G. M. (1997). P-glycoprotein mediated multidrug 
resistance and its implications for pathology. Pathology, 29 (2): 122-130. 
Trela, B. C. and Waterhouse, A. L. (1996). Resveratrol: isomeric molar absorptivities and 
stability. Journal of Agricultural and Food Chemistry, 44 (5): 1253-1257. 
Tresserra-Rimbau, A., Medina-Remon, A., Perez-Jimenez, J., Martinez-Gonzalez, M. A., 
Covas, M. I., Corella, D., Salas-Salvado, J., Gomez-Gracia, E., Lapetra, J., Aros, F., 
Fiol, M., Ros, E., Serra-Majem, L., Pinto, X., Munoz, M. A., Saez, G. T., Ruiz-
Gutierrez, V., Warnberg, J., Estruch, R. and Lamuela-Raventos, R. M. (2013). Dietary 
intake and major food sources of polyphenols in a Spanish population at high 
cardiovascular risk: The PREDIMED study. Nutrition, Metabolism and 
Cardiovascular Diseases, 16 (12): 00245-00241. 
Trousdale Vernon, L. and Singleton, E. K. (1983). Astilbin engeletin in grapes and wine. 
Phytochemistry, 22 (2): 619-620. 
Tsai Su, C. and Singleton, V. L. (1969). Identification of three flavan-3-ols from grapes. 
Phytochemistry, 8 (8): 1553-1558. 
Tsang, C., Auger, C., Mullen, W., Bornet, A., Rouanet, J.-M., Crozier, A. and Teissedre, P.-
L. (2005a). The absorption, metabolism and excretion of flavan-3-ols and 
341 
 
procyanidins following the ingestion of a grape seed extract by rats. British Journal of 
Nutrition, 94 (2): 170-181. 
Tsang, C., Auger, C., Mullen, W., Bornet, A., Rouanet, J.-M., Crozier, A. and Teissedre, P.-
L. (2005b). The absorption, metabolism and excretion of flavan-3-ols and 
procyanidins following the ingestion of a grape seed extract by rats. British Journal of 
Nutrition, 94 (02): 170-181. 
Tsao, R. and McCallum, J. (2009). Chemistry of Flavonoids. In Fruit and Vegetable 
Phytochemicals.  pp. 131-153. de la Rosa, L. A., Alvarez-Parrilla, E. and González-
Aguilar, G. A., Oxford, UK, Wiley-Blackwell. 
Tzounis, X., Vulevic, J., Kuhnle, G. G., George, T., Leonczak, J., Gibson, G. R., Kwik-Uribe, 
C. and Spencer, J. P. (2008a). Flavanol monomer-induced changes to the human 
faecal microflora. British Journal of Nutrition, 99 (4): 782-792. 
Tzounis, X., Vulevic, J., Kuhnle, G. G. C., George, T., Leonczak, J., Gibson, G. R., Kwik-
Uribe, C. and Spencer, J. P. E. (2008b). Flavanol monomer-induced changes to the 
human faecal microflora. British Journal of Nutrition, 99 (04): 782-792. 
Urpi-Sarda, M., Garrido, I., Monagas, M., Gomez-Cordoves, C., Medina-Remon, A., Andres-
Lacueva, C. and Bartolome, B. (2009a). Profile of plasma and urine metabolites after 
the intake of almond [Prunus dulcis (Mill.) D.A. Webb] polyphenols in humans. 
Journal of Agricultural and Food Chemistry 57 (21): 10134-10142. 
Urpi-Sarda, M., Monagas, M., Khan, N., Lamuela-Raventos, R., Santos-Buelga, C., 
Sacanella, E., Castell, M., Permanyer, J. and Andres-Lacueva, C. (2009b). 
Epicatechin, procyanidins, and phenolic microbial metabolites after cocoa intake in 
humans and rats. Analytical and Bioanalytical Chemistry, 394 (6): 1545-1556. 
Vaidyanathan, J. B. and Walle, T. (2002). Glucuronidation and sulfation of the tea flavonoid 
(−)-epicatechin by the human and rat enzymes. Drug Metabolism and Disposition, 30 
(8): 897-903. 
Vaidyanathan, J. B. and Walle, T. (2003). Cellular uptake and efflux of the tea flavonoid (-
)epicatechin-3-gallate in the human intestinal cell line caco-2. Journal of 
Pharmacology and Experimental Therapeutics, 307 (2): 745-752. 
Valant-Vetschera, K. M. and Wollenweber, E. (2005). Flavones and flavonols. In 
Flavonoids: Chemistry, Biochemistry and Applications.  pp. 617-748. Andersen, O. 
M. and Markham, K. R., Boca Raton, FL, USA, CRC Press/ Taylor & Francis Group. 
van de Wetering, K., Burkon, A., Feddema, W., Bot, A., de Jonge, H., Somoza, V. and Borst, 
P. (2009). Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug 
resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of 
resveratrol. Molecular Pharmacology, 75 (4): 876-885. 
van der Hooft, J. J., de Vos, R. C., Mihaleva, V., Bino, R. J., Ridder, L., de Roo, N., Jacobs, 
D. M., van Duynhoven, J. P. and Vervoort, J. (2012). Structural elucidation and 
quantification of phenolic conjugates present in human urine after tea intake. 
Analytical Chemistry, 84 (16): 7263-7271. 
Vanhoenacker, G., Villiers, A., Lazou, K., Keukeleire, D. and Sandra, P. (2001). Comparison 
of high-performance liquid chromatography — Mass spectroscopy and capillary 
electrophoresis— mass spectroscopy for the analysis of phenolic compounds in 
diethyl ether extracts of red wines. Chromatographia, 54 (5-6): 309-315. 
Vanhoutte, P. M. (2009). Endothelial dysfunction -the first step toward coronary 
arteriosclerosis. Circulation Journal, 73 (4): 595-601. 
Vatai, T., Škerget, M. and Knez, Ž. (2009). Extraction of phenolic compounds from elder 
berry and different grape marc varieties using organic solvents and/or supercritical 
carbon dioxide. Journal of Food Engineering, 90 (2): 246-254. 
342 
 
Vera, R., Sanchez, M., Galisteo, M., Villar, I. C., Jimenez, R., Zarzuelo, A., Perez-Vizcaino, 
F. and Duarte, J. (2007). Chronic administration of genistein improves endothelial 
dysfunction in spontaneously hypertensive rats: involvement of eNOS, caveolin and 
calmodulin expression and NADPH oxidase activity. Clinical Science, 112 (3): 183-
191. 
Vidal, S., Francis, L., Guyot, S., Marnet, N., Kwiatkowski, M., Gawel, R., Cheynier, V. and 
Waters, E. J. (2003). The mouth-feel properties of grape and apple proanthocyanidins 
in a wine-like medium. Journal of the Science of Food and Agriculture, 83 (6): 564-
573. 
Vinson, J. A., Mandarano, M. A., Shuta, D. L., Bagchi, M. and Bagchi, D. (2002). Beneficial 
effects of a novel IH636 grape seed proanthocyanidin extract and a niacin-bound 
chromium in a hamster atherosclerosis model. Molecular and Cellular Biochemistry, 
240 (1-2): 99-103. 
Vita, J. A. and Keaney, J. F. (2002). Endothelial function: a barometer for cardiovascular 
risk? Circulation, 106 (6): 640-642. 
Vitaglione, P., Donnarumma, G., Napolitano, A., Galvano, F., Gallo, A., Scalfi, L. and 
Fogliano, V. (2007). Protocatechuic acid is the major human metabolite of cyanidin-
glucosides. The Journal of Nutrition, 137 (9): 2043-2048. 
Vitrac, X., Bornet, A., Vanderlinde, R., Valls, J., Richard, T., Delaunay, J.-C., Merillon, J.-
M. and Teissedre, P.-L. (2005). Determination of stilbenes (δ-viniferin, trans-
astringin, trans-piceid, cis- and trans-resveratrol, ε-viniferin) in Brazilian Wines. 
Journal of Agricultural and Food Chemistry, 53 (14): 5664-5669. 
Vitrac, X., Castagnino, C., Waffo-Téguo, P., Delaunay, J.-C., Vercauteren, J., Monti, J.-P., 
Deffieux, G. and Mérillon, J.-M. (2001). Polyphenols newly extracted in red wine 
from southwestern France by centrifugal chromatography. Journal of Agricultural 
and Food Chemistry, 49 (12): 5934-5938. 
Vitrac, X., Monti, J.-P., Vercauteren, J., Deffieux, G. and Mérillon, J.-M. (2002). Direct 
liquid chromatographic analysis of resveratrol derivatives and flavanonols in wines 
with absorbance and fluorescence detection. Analytica Chimica Acta, 458 (1): 103-
110. 
Vivar-Quintana, A. M., Santos-Buelga, C., Francia-Aricha, E. and Rivas-Gonzalo, J. C. 
(1999). Formation of anthocyanin-derived pigments in experimental red wines / 
Formación de pigmentos derivados de antocianos en vinos tintos experimentales. 
Food Science and Technology International, 5 (4): 347-352. 
Vivas de Gaulejac, N., Vivas, N., Absalon, C. and Nonier, M. F. (2001). Identification of 
procyanidin A2 in grape and wine of Vitis vinifera L. cv. Merlot Noir and Cabernet 
Sauvignon. Journal International des Sciences de la Vigne et du Vin, 35 (1): 51-56. 
Vogiatzoglou, A., Heuer, T., Mulligan, A., Lentjes, M. H., Luben, R. and Kuhnle, G. C. 
(2013). Estimated dietary intakes and sources of flavanols in the German population 
(German National Nutrition Survey II). European Journal of Nutrition: 1-9. 
Vollmer, W. M., Sacks, F. M., Ard, J., Appel, L. J., Bray, G. A., Simons-Morton, D. G., 
Conlin, P. R., Svetkey, L. P., Erlinger, T. P., Moore, T. J. and Karanja, N. (2001). 
Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-
sodium trial. Annals of Internal Medicine, 135 (12): 1019-1028. 
Wagner, A., Sadoun, A., Dallongeville, J., Ferrières, J., Amouyel, P., Ruidavets, J. B. and 
Arveiler, D. (2011). High blood pressure prevalence and control in a middle-aged 
French population and their associated factors: The MONA LISA study. Journal of 
Hypertension, 29 (1): 43-50. 
Walgren, R. A., Karnaky, K. J., Lindenmayer, G. E. and Walle, T. (2000). Efflux of dietary 
flavonoid quercetin 4′-β-glucoside across human intestinal Caco-2 cell monolayers by 
343 
 
apical multidrug resistance-associated protein-2. Journal of Pharmacology and 
Experimental Therapeutics, 294 (3): 830-836. 
Walle, T. (2011). Bioavailability of resveratrol. Annals of the New York Academy of Sciences, 
1215 (1): 9-15. 
Walle, T., Browning, A. M., Steed, L. L., Reed, S. G. and Walle, U. K. (2005). Flavonoid 
glucosides are hydrolyzed and thus activated in the oral cavity in humans. The 
Journal of Nutrition, 135 (1): 48-52. 
Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E. and Walle, U. K. (2004). High absorption 
but very low bioavailability of oral resveratrol in humans. Drug Metabolism and 
Disposition, 32 (12): 1377-1382. 
Wallerath, T., Poleo, D., Li, H. and Förstermann, U. (2003). Red wine increases the 
expression of human endothelial nitric oxide synthase: a mechanism that may 
contribute to its beneficial cardiovascular effects. Journal of the American College of 
Cardiology, 41 (3): 471-478. 
Wang, J., Xiong, X. and Liu, W. (2013). Yoga for essential hypertension: a systematic 
review. Plos One, 8 (10). 
Ward, N. C., Croft, K. D., Puddey, I. B. and Hodgson, J. M. (2004). Supplementation with 
grape seed polyphenols results in increased urinary excretion of 3-
hydroxyphenylpropionic acid, an important metabolite of proanthocyanidins in 
humans. Journal of Agricultural and Food Chemistry, 52 (17): 5545-5549. 
Watanabe, S., Yamaguchi, M., Sobue, T., Takahashi, Tosei, Miura, T., Arai, Y., Mazur, W., 
Wähälä, K. and Adlercreutz, H. (1998). Pharmacokinetics of soybean isoflavones in 
plasma, urine and feces of men after ingestion of 60 g baked soybean powder 
(Kinako). The Journal of Nutrition, 128 (10): 1710-1715. 
Weisshaar, B. and Jenkins, G. I. (1998). Phenylpropanoid biosynthesis and its regulation. 
Current Opinion in Plant Biology, 1 (3): 251-257. 
Welty, F. K., Lee, K. S., Lew, N. S. and Zhou, J. R. (2007). Effect of soy nuts on blood 
pressure and lipid levels in hypertensive, prehypertensive, and normotensive 
postmenopausal women. Archives of Internal Medicine, 167 (10): 1060-1067. 
Whelton, P. K., Appel, L. J., Espeland, M. A., Applegate, W. B., Ettinger, W. H., Jr., Kostis, 
J. B., Kumanyika, S., Lacy, C. R., Johnson, K. C., Folmar, S. and Cutler, J. A. (1998). 
Sodium reduction and weight loss in the treatment of hypertension in older persons: a 
randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). 
TONE Collaborative Research Group. JAMA, 279 (11): 839-846. 
Whelton, P. K., He, J., Cutler, J. A., Brancati, F. L., Appel, L. J., Follmann, D. and Klag, M. 
J. (1997). Effects of oral potassium on blood pressure. Meta-analysis of randomized 
controlled clinical trials. JAMA, 277 (20): 1624-1632. 
Whitman, W. B., Coleman, D. C. and Wiebe, W. J. (1998). Prokaryotes: The unseen 
majority. Proceedings of the National Academy of Sciences, 95 (12): 6578-6583. 
WHO (2012). The World health statistics 2012 report. 
Wild, H.-P. and Sass, M. (2006). Concentrate comprising green tea, grape skin extract and 
grape extract, the production thereof and use of the same. US7087259. 
Williams, C. A. (2005). Flavone and flavonol O-glycosides. In Flavonoids: Chemistry, 
Biochemistry and Applications.  pp. 749 -856 Andersen, O. M. and Markham, K. R., 
Boca Raton, FL, USA, CRC Press/Taylor & Francis Group. 
Williamson, G. and Holst, B. (2008). Dietary reference intake (DRI) value for dietary 
polyphenols: are we heading in the right direction? British Journal of Nutrition, 99 
(SupplementS3): S55-S58. 
344 
 
Williamson, G. and Manach, C. (2005). Bioavailability and bioefficacy of polyphenols in 
humans. II. Review of 93 intervention studies. The American Journal of Clinical 
Nutrition, 81 (1): 243S-255S. 
Wilson, T., Singh, A. P., Vorsa, N., Goettl, C. D., Kittleson, K. M., Roe, C. M., Kastello, G. 
M. and Ragsdale, F. R. (2008). Human glycemic response and phenolic content of 
unsweetened cranberry juice. Journal of Medicinal Food, 11 (1): 46-54. 
Winkel-Shirley, B. (2002). Biosynthesis of flavonoids and effects of stress. Current Opinion 
in Plant Biology, 5 (3): 218-223. 
Wolf-Maier, K., Cooper, R. S., Kramer, H., Banegas, J. R., Giampaoli, S., Joffres, M. R., 
Poulter, N., Primatesta, P., Stegmayr, B. and Thamm, M. (2004). Hypertension 
treatment and control in five European countries, Canada, and the United States. 
Hypertension, 43 (1): 10-17. 
Wollny, T., Aiello, L., Di Tommaso, D., Bellavia, V., Rotilio, D., Donati, M. B., De Gaetano, 
G. and Iacoviello, L. (1999). Modulation of haemostatic function and prevention of 
experimental thrombosis by red wine in rats: a role for increased nitric oxide 
production. British Journal of Pharmacology, 127 (3): 747-755. 
Wong, B. W., Meredith, A., Lin, D. and McManus, B. M. (2012). The biological role of 
inflammation in atherosclerosis. Canadian Journal of Cardiology, 28 (6): 631-641. 
Woodman, O. L. and Chan, E. C. H. (2004). Vascular and anti-oxidant actions of flavonols 
and flavones. Clinical and Experimental Pharmacology and Physiology, 31 (11): 786-
790. 
Wu, X., Beecher, G. R., Holden, J. M., Haytowitz, D. B., Gebhardt, S. E. and Prior, R. L. 
(2006). Concentrations of anthocyanins in common foods in the United States and 
estimation of normal consumption. Journal of Agricultural and Food Chemistry, 54 
(11): 4069-4075. 
Wu, X., Cao, G. and Prior, R. L. (2002). Absorption and metabolism of anthocyanins in 
elderly women after consumption of elderberry or blueberry. The Journal of 
Nutrition, 132 (7): 1865-1871. 
Xu, J., Mahowald, M. A., Ley, R. E., Lozupone, C. A., Hamady, M., Martens, E. C., 
Henrissat, B., Coutinho, P. M., Minx, P., Latreille, P., Cordum, H., Van Brunt, A., 
Kim, K., Fulton, R. S., Fulton, L. A., Clifton, S. W., Wilson, R. K., Knight, R. D. and 
Gordon, J. I. (2007). Evolution of symbiotic bacteria in the distal human intestine. 
PLoS Biology, 5 (7): 19. 
Yamori, Y., Kitamura, Y., Nara, Y. and Iritani, N. (1981). Mechanism of 
hypercholesterolemia in arteriolipidosis-prone rats (ALR). Japanese circulation 
journal, 45 (9): 1068-1073. 
Yang, B., Arai, K. and Kusu, F. (2000). Determination of catechins in human urine 
subsequent to tea ingestion by high-performance liquid chromatography with 
electrochemical detection. Analytical Biochemistry, 283 (1): 77-82. 
Yang, G., Shu, X. O., Jin, F., Zhang, X., Li, H. L., Li, Q., Gao, Y. T. and Zheng, W. (2005). 
Longitudinal study of soy food intake and blood pressure among middle-aged and 
elderly Chinese women. The American Journal of Clinical Nutrition, 81 (5): 1012-
1017. 
Yang, M., I. Koo, S., O. Song, W. and K. Chun, O. (2011). Food matrix affecting 
anthocyanin bioavailability: review. Current Medicinal Chemistry, 18 (2): 291-300. 
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A. and Mayo, 
M. W. (2004). Modulation of NF-kappaB-dependent transcription and cell survival by 
the SIRT1 deacetylase. The EMBO Journal 23 (12): 2369-2380. 
345 
 
Zalba, G., Beaumont, F. J., José, G. S., Fortuño, A., Fortuño, M. A., Etayo, J. C. and Díez, J. 
(2000). Vascular NADH/NADPH Oxidase Is Involved in Enhanced Superoxide 
Production in Spontaneously Hypertensive Rats. Hypertension, 35 (5): 1055-1061. 
Zamora-Ros, R., Andres-Lacueva, C., Lamuela-Raventós, R. M., Berenguer, T., Jakszyn, P., 
Barricarte, A., Ardanaz, E., Amiano, P., Dorronsoro, M., Larrañaga, N., Martínez, C., 
Sánchez, M. J., Navarro, C., Chirlaque, M. D., Tormo, M. J., Quirós, J. R. and 
González, C. A. (2010). Estimation of dietary sources and flavonoid intake in a 
Spanish adult population (EPIC-Spain). Journal of the American Dietetic Association, 
110 (3): 390-398. 
Zern, T. L. and Fernandez, M. L. (2005). Cardioprotective effects of dietary polyphenols. The 
Journal of Nutrition, 135 (10): 2291-2294. 
Zhang, Y., Hendrich, S. and Murphy, P. A. (2003). Glucuronides are the main isoflavone 
metabolites in women. The Journal of Nutrition, 133 (2): 399-404. 
Zhuo, J. L. and Li, X. C. (2011). New insights and perspectives on intrarenal renin-
angiotensin system: Focus on intracrine/intracellular angiotensin II. Peptides, 32 (7): 
1551-1565. 
Zilkens, R. R., Burke, V., Hodgson, J. M., Barden, A., Beilin, L. J. and Puddey, I. B. (2005). 
Red wine and beer elevate blood pressure in normotensive men. Hypertension, 45 (5): 
874-879. 
 
  
346 
 
Résumé:   CONFIDENTIEL 
Mot-clefs: polyphénols, hypertension, rats SHR, verapamil, biodisponibilité, métabolismes 
phénoliques, HPLC-UV-Fluo-MS
n
, GC-MS 
Cette étude examine les effets bénéfiques des marcs de raisins obtenus après vinification de 
différents cépages caractéristiques de la Vallée du Rhône, de leurs compositions phénoliques à leurs 
effets in vivo. Les raisins et leurs marcs respectifs des cépages Grenache (provenant de deux endroits 
différents [GRE1] et [GRE2]), Syrah (provenant de deux endroits différents [SYR1] et [SYR2]), 
Carignan (CAR), Mourvèdre (MOU), Counoise (COU) et Alicante (ALI) ont été étudiés. 
La comparaison des extraits de raisins et de leurs marcs respectifs montre que les marcs 
représentent une source importante d’antioxydants phénoliques malgré le processus de vinification. 
Les pépins et pellicules de marcs renferment des quantités appréciables de flavan-3-ols et 
anthocyanes. La distribution qualitative et quantitative des polyphenols dans les marcs de raisin 
présentent des différences significatives au travers des variétés et millésimes allant de 15% à 70% de 
polyphénols extraits. Les pépins de Grenache (GRE1), Syrah (SYR1) et les pellicules de Syrah 
(SYR1), Carignan et Alicante sont les fractions les plus intéressantes dues a la présence d’importantes 
quantités de flavan-3-ols (monomères, dimères et trimère) jusqu’à 8.7 mg/g MS et d’anthocyanes 
(glycosylées, acétylées et coumaroylées jusqu’à 17.40 mg/g MS, 1.57 mg/g MS et 2.38 mg/g MS 
respectivement). L’analyse des extraits aqueux (EAQ) et hydro-alcoolique 70% (EA70) indique que 
les pépins de Carignan et Syrah (SYR1) et les pellicules de Carignan et d’Alicante contiennent les 
plus fort taux en composés phénoliques et activités antioxydantes. 
Certains extraits on été afin d’évaluer leur efficacité in vivo sur l’hypertension utilisant un 
modèle de rat SHR. Les extraits de marcs ont administrés à une dose de 21mg/kg/jour de polyphénols 
par jour ce qui équivaut à une consommation de polyphénols contenus dans 500 mL de vin rouge par 
un adulte de 70kg et le vérapamil à une dose de 40 mg/kg/jour. Les résultats des expériences in vivo 
démontrent que certains extraits administrés seuls ou en association avec le vérapamil possèdent un 
effet anti-hypertenseur. Cette capacité a été mise en évidence une fois que les extraits de pépins de 
marcs de GRE1 (EA70) et SYR1 (EA70) et de pellicules de marcs d’ALI (EA70) ont été administrés 
seuls ou lorsque les extraits de pépins de marcs GRE1 (EA70) et SYR1 (EAQ) et les pellicules de 
marcs d’ALI (EA70) et SYR2 (EAQ) ont été administrés en association avec le vérapamil.  
Cette étude met en évidence la biodisponibilité des extraits de pépins et de pellicules de marcs 
des rats SHR incluant à la fois le métabolisme de phase II et de la microflore intestinale. Les extraits 
de marcs administrés seuls et en association au vérapamil sont absorbés en tant que métabolites de 
phase II présent sous forme de dérivé O-methylglucuronidé, sulfaté, O-methylsulfaté d’(épi)catéchine 
dérivant du métabolisme des monomères de flavan-3-ols. La détection de métabolites microbiens 
dérivés de flavan-3-ols, d’hydroxyphényl-γ-valérolactones sous leurs formes glucuronidés et sulfatés 
confirme l'absorption des métabolites dérivés des flavan-3-ols, la fois monomères et polymères des 
extraits de marcs et des conjugaisons supplémentaires dans le foie. De nombreux métabolites issus de 
la dégradation microbienne des hydroxyvalerolactones ont également été détectés. L’excrétion 
urinaire de ces métabolites représente une plus grande proportion de polyphénols ingérés comparé à 
ceux issus de métabolisme de phase II des monomères de flavan-3-ols, indiquant un rôle important 
des bactéries intestinales dans le métabolisme des molécules hautement polymérisées. Ces métabolites 
peuvent avoir exercé leurs effets biologiques lors de leur passage dans la circulation sanguine. 
Cette étude constitue une première étape de valorisation de marcs de raisins après vinification, 
en tant qu’activateur de vérapamil, un médicament couramment utilisé contre l’hypertension. Des 
quantités suffisantes de composés phénoliques subsistent dans les marcs, en particulier en terme de 
flavan-3-ols et d’anthocyanes, pour exercer des effets antihypertenseurs. En effet, selon le type et la 
composition des extraits, il est possible de moduler les effets antihypertenseurs en amplifiant ou en 
diminuant l’absorption des polyphénols et/ou du vérapamil. 
347 
 
Summary:   CONFIDENTIAL 
Keywords: polyphenols, hypertension, SHR rats, verapamil, bioavailability, phenolics metabolism, 
HPLC-UV-Fluo-MS
n
, GC-MS 
This study investigated the beneficial potential effects of grape pomaces obtained after 
winemaking of different Mediterranean grape varieties from crude materials to their in vivo effectiveness. 
Grapes and their respective grape pomaces from six different V. vinifera L. cultivar were studied namely 
Grenache (from two different locations [GRE1 and GRE2]), Syrah (from two different locations [SYR1 
and SYR2]), Carignan (CAR), Mourvèdre (MOU), Counoise (COU) and Alicante (ALI) grape varieties 
from the Rhône Valley.  
The comparison of several wine industry by-products with their respective grapes provided 
evidence that pomace remaining at the end of the winemaking process can be very rich sources of 
antioxidants. The quantitative and qualitative distribution of polyphenols by HPLC-PDA-Fluo-MS in 
grape pomaces showed significant differences through varieties and vintages varying from 15% to 70% of 
polyphenols extracted. Seeds from Grenache (GRE1), Syrah (SYR1) and skins from Syrah (SYR1), 
Carignan and Alicante were of particular interest because of their higher polyphenol contents in terms of 
flavan-3-ols (monomers, dimers and trimers) up to 8.7 mg/g DW and anthocyanins (glycosides, acetylated 
and coumaroylated derivatives up to 17.40, 1.57 and 2.38 mg/g DW, respectively). The investigation of 
aqueous and hydro-alcoholic 70% extracts of seeds from Carignan and Syrah (SYR1) and skins from 
Carignan and Alicante was carried out as they contained high levels of total phenols and antioxidant 
activity. 
Several extracts, were tested in order to evaluate their in vivo biological effects on hypertension 
using a spontaneously hypertensive rat (SHR) model. Grape pomace extracts were administrated at a dose 
of 21 mg/kg/day which in terms of phenolic compounds is equivalent to a 70 kg human consuming of ~0.5 
L of red wine. A series of different grape pomace extracts were tested in association with verapamil. All in 
vivo experiments demonstrated that some grape pomace extracts administrated with or without co-
ingestion with verapamil possessed an anti-hypertensive activity. This was evident with GRE1 (EA70) 
seed pomace extract, SYR1 (EA70) seed pomace extract, ALI (EA70) skin pomace extract administrated 
alone and with GRE1 (EA70) seed pomace extract, SYR1 (EAQ) seed pomace extract, ALI (EA70) skin 
pomace extract and SYR2 (EAQ) skin pomace extract administrated in association with verapamil.  
Grape pomace extracts with or without co-ingestion with verapamil were absorb as phase II 
metabolites mainly including glucuronide, O-methyl glucuronide, sulfate, and O-methyl sulfate derivatives 
of (epi)catechin which arise from the metabolism of monomeric flavan-3-ols. The detection by HPLC-
PDA-Fluo-MS
n
 and GC-MS of microbial-derived metabolites of flavan-3-ols, hydroxyphenyl-γ-
valerolactones in their glucuronide and sulfate forms confirmed the absorption of metabolites derived from 
both monomeric and polymeric flavan-3-ols from grape pomace extracts and subsequent post-absorption 
conjugation. Numerous metabolites derived from further microbial degradation of hydroxyvalerolactones 
were also detected. The urinary excretion of these metabolites accounted for a larger proportion of the total 
polyphenol ingested than phase II metabolites of monomeric flavan-3-ols, indicating the important role of 
intestinal bacteria in the metabolism of polymerized procyanidins. All these metabolites may have exerted 
biological effects during the period in which they circulated in the bloodstream. 
This study constitutes the first step of assessing grape pomace as an enhancer of the verapamil, an 
anti-hypertensive drug. Substantial levels of polyphenols, especially flavan-3-ols, procyanidins and 
anthocyanins, remain in pomace after the winemaking process in quantities sufficient to exert anti-
hypertensive effects. In addition, according to the extract used and its composition, it is feasible to 
modulate anti-hypertensive effects by amplifying or decreasing polyphenols and/or verapamil absorption. 
